




EUROPEAN
HEMATOLOGY
ASSOCIATION



MADRID
22ND CONGRESS
JUNE 22 - 25 | 2017

European Hematology Association

FINAL PROGRAM



Now Enrolling: Copanlisib^a Clinical Trials in Indolent Non-Hodgkin's Lymphoma (iNHL)




^aCopanlisib is an investigational agent currently in clinical trials and is not approved by the FDA, EMA, or other health authorities. The efficacy and safety of copanlisib have not been established, and this information is being provided only for the purpose of providing an overview of clinical trials for recruitment.

LEARN ABOUT THESE ONGOING STUDIES INVESTIGATING COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY iNHL

CHRONOS-3: Now enrolling¹

A phase III, randomized study of copanlisib in combination with rituximab in patients with iNHL who have relapsed after ≥1 prior line of rituximab-containing therapy. **The primary endpoint of the study is progression-free survival (PFS).**




¹To see full patient inclusion and exclusion criteria, visit <https://clinicaltrials.gov/ct2/show/NCT02367040>.

Selected inclusion criteria^a:
Patients ≥18 years with iNHL (FL Grade 1-3a, SLL, LPL/WM, MZL); relapsed after ≥1 prior lines of therapy, including R; ECOG performance status ≤2; ≥12 months after completion of the last R-containing treatment or be considered unfit to receive chemotherapy.

Selected exclusion criteria^b:
FL Grade 3b, disease transformation, or CLL; resistance to prior treatment with idelalisib or other PI3K inhibitors.

CHRONOS-4: Now enrolling²

A phase III, randomized study of copanlisib in combination with standard immunochemotherapy in patients with iNHL who have relapsed after ≥1 prior line of therapy, including rituximab and alkylating agents. **The primary endpoint of the study is PFS.**



²To see full patient inclusion and exclusion criteria, visit <https://clinicaltrials.gov/ct2/show/NCT02626455>.

Selected inclusion criteria^a:
Patients ≥18 years with iNHL (FL Grade 1-3a, SLL, LPL/WM, MZL); relapsed after ≥1 prior line of therapy, including R and alkylating agents; ECOG performance status ≤2.

Selected exclusion criteria^b:
FL Grade 3b, transformed disease, or CLL; R resistance at any line of therapy; type I or II diabetes mellitus with HbA1c >8.5% or fasting plasma glucose >160 mg/dL at screening; uncontrolled hypertension.

1L=first-line; 2L=second-line; C=copanlisib; CHOP=a combination of cyclophosphamide, hydroxydaunomycin, Oncovin, prednisone; CLL=chronic lymphocytic leukemia; CR=complete response; DOR=duration of response; ECOG=the Eastern Cooperative Oncology Group; FL=follicular lymphoma; IV=intravenous; LPL=lymphoplasmacytic lymphoma; MZL=marginal zone lymphoma; ORR=objective response rate; OS=overall survival; PD=progressive disease; PI3K=phosphatidylinositol 3-kinase; QOL=quality of life; QW=once weekly; R=rituximab; RB=rituximab and bendamustine; RCHOP=rituximab and chemotherapy; SLL=small lymphocytic lymphoma; TTP=time to progression; WM=Waldenström macroglobulinemia.

Learn about the complete trial information at www.chronotrials.com

Copanlisib is a reversible pan-class I phosphatidylinositol 3-kinase pathway inhibitor with predominant activity against the alpha and delta isoforms.¹⁻³

Contact us for more information on clinical trials 1-844-229-3710 (US and Canada only)

References: 1. Bayer. Copanlisib and rituximab in relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) (CHRONOS-3): NCT02367040. <https://clinicaltrials.gov/ct2/show/NCT02367040>. Accessed October 12, 2016. 2. Bayer. Study of copanlisib in combination with standard immunochemotherapy in relapsed indolent non-Hodgkin's lymphoma (iNHL) (CHRONOS-4): NCT02626455. <https://clinicaltrials.gov/ct2/show/NCT02626455>. Accessed October 12, 2016. 3. Liu N, et al. *Mol Cancer Ther*. 2013;12(11):2319-2330.

Bayer (Schweiz) AG, Grubenstrasse 6, 8045 Zurich, Switzerland

Bayer@emergingmed.com



© 2017 Bayer. All rights reserved. BAYER and the Bayer Cross are registered trademarks of Bayer. Apr 2017

TABLE OF CONTENTS

WORDS OF WELCOME	5
SPONSORS	
Corporate Sponsors	7
Congress Sponsors & Exhibitors	9
EHA	
About EHA	13
EHA Committees and Units	14
Future EHA congresses & meetings	16
CONGRESS ORGANIZATION	
Scientific Program Committee & Advisory Board	19
Abstract reviewers	20
Educational Updates in Hematology Book reviewers	23
Organizers	23
AWARDS	
Travel grant winners	27
YoungEHA Best Abstract Awards	28
José Carreras Award	28
Jean Bernard Lifetime Achievement Award	29
Research grant winners	29
KEY INFORMATION	
Congress information	33
Scientific information	34
General information	37
Transportation in Madrid	39
PROGRAM OVERVIEW	
Program-at-a-glance	42
About the congress program	43
What's new this year?	43
How to navigate the congress program?	44
CME accreditation	45
Program overview per day	46
Advocacy track	54
Early career track	54
CONGRESS PROGRAM	
Thursday, June 22	57
Friday, June 23	77
Saturday, June 24	121
Sunday, June 25	165
E-POSTERS	181
INDEX	
Speaker & disclosure index	235
Abstract authors index	247
FLOOR PLANS	
Congress center	318
Exhibition	320

HIGHLIGHTED SESSIONS

FRIDAY, JUNE 23

- **Opening Ceremony**
13:00 – 14:15, Hall A
- **EHA-EBMT Joint Symposium**
09:45 – 11:15, Hall E
- **EHA-JSH Joint Symposium**
14:30 – 15:30, Hall D
- **EHA-HST Joint Symposium**
14:30 – 15:30, Room N105
- **Presidential Symposium**
15:45 – 17:00, Hall A

SATURDAY, JUNE 24

- **EHA-ISEH Joint Symposium**
08:30 – 09:30, Room N104
- **EHA-ASH Joint Symposium**
10:15 – 11:15, Hall D
- **Plenary Session I**
13:15 – 14:30, Hall A
- **EHA-ESH Joint Symposium**
14:45 – 15:45, Room N109
- **EHA-CSH Joint Symposium**
14:45 – 15:45, Room N103

SUNDAY, JUNE 25

- **EHA-ISTH Joint Symposium**
09:30 – 10:30, Room N105
- **Late Breaking Oral Session**
11:15 – 12:45, Hall A
- **Plenary Session II**
13:00 – 14:30, Hall A



WORDS OF WELCOME

Welcome to the 22nd Congress of the European Hematology Association (EHA) and to Madrid. This is the first congress we are organizing in the capital of Spain, a cosmopolitan city with a large cultural and artistic heritage.


This year, the Scientific Program Committee and the Advisory Board have compiled an exciting educational and scientific program, creating a testament to EHA's spirit of unity in diversity. It brings together and bridges gaps between research and clinical practice, benign and malignant disorders, and national and international societies.

A clear example are the many joint symposia in this year's program. We present you with topical symposia organized in collaboration with the European Group for Bone and Marrow Transplantation (EBMT), the European School of Haematology (ESH), the International Society of Experimental Hematology (ISEH), the International Society of Thrombosis and Haemostasis (ISTH), the International Society of Laboratory Hematology (ISLH) as well as the American Society of Hematology (ASH), the Chinese Society of Hematology (CSH), the Hematology Society of Taiwan (HST), and the Japanese Society of Hematology (JSH). Each symposium has its own merits and adds a unique perspective to a program that celebrates diversity.


Top experts are ready to share their knowledge with you during the plenary and parallel sessions. Furthermore, the quality and number of submitted abstracts clearly indicates that research and progress in laboratory diagnostics, as well as basic, translational and clinical research, are moving at high speed with many innovative findings to be presented to you here in Madrid.

A selection of interesting sessions is listed on the left page and summarized on the tab of each day in this program book. The full program is of course also available in the EHA App. With the app you can compile a personalized program that fits your particular needs and interests. EHA is also active on social media – feel free to share your congress experiences and photos with us by using our social media tags: #EHA #EHA22 #EHACongress.

We hope that by bringing together attendees from all continents the congress contributes to further uniting the hematology community. Together, let's make this congress one to remember!



Tony Green
EHA President



Shai Izraeli
Chair Scientific Program Committee



Celgene Committed to Research, committed to improving the lives of patients



Celgene consistently invests **more than 30%** of its revenues back into Research and Development* ⁽¹⁾

Almost **double** of industry average ^(1,3)

Sponsoring >100 clinical trials ⁽²⁾

Committed to support independent academic research: > 500 IIT's (Investigator Initiated Trials) ⁽²⁾

Since 2010, R&D investment more than **tripled** ⁽¹⁾



* Data available since 2005

References

- 1. Celgene Annual Report 2015, 2012, 2009, 2007
- 2. <http://www.celgene.com/research-development/clinical-trials/> consulted on April 12th 2017
- 3. Scrip Pharma Intelligence, <https://scrip.pharmamedtechbi.com/SC097769/Scrip-100-RampD-Paths-Of-Top-50-Pharma>, consulted on April 10th 2017

CORPORATE SPONSORS 2017

The European Hematology Association wishes to express its gratitude to the following corporate sponsors:

PLATINUM



GOLD



SILVER



BRONZE



CONTRIBUTOR



Novartis Oncology

Changing the practice of medicine

At Novartis, we use science-based innovation to address some of society's most challenging health care issues. We are passionate about discovering new ways to improve and extend people's lives.

As a leader in oncology, Novartis offers a portfolio of more than 20 approved therapies and approximately 30 compounds in development.



SPONSORS & EXHIBITORS 22ND CONGRESS OF EHA (as of May 16)

The European Hematology Association wishes to express its gratitude to the following sponsors and exhibitors:

- Abbvie
- Adaptive Biotechnologies Corporation
- Agios Pharmaceuticals
- Alexion Pharma GmbH
- American Society of Hematology
- Amgen
- ArcherDX
- Argentinean Society of Hematology
- AROG Pharmaceuticals
- Astellas Pharma Europe
- Bayer
- BD
- Binding Site
- Bio-Rad
- Biotype Diagnostic GmbH
- Bristol-Myers Squibb
- Celgene
- Celltrion Healthcare
- Cepheid
- CLL Advocates Network
- CML Advocates Network
- Cytognos SL
- Daiichi Sankyo Europe GmbH
- Erytech Pharma
- ESLHO foundation
- EuroBloodNet
- European School of Haematology
- EWMn European Waldenstroem Network
- F. Hoffmann-La Roche Ltd
- Gilead Sciences
- Global Academy for Medical Education
- Haematology Nurses & Healthcare Professionals Group
- Harmony Alliance
- Hematology Specialist Association
- Illumina
- Incyte Biosciences International Sàrl
- Invivoscribe® Technologies, Inc.
- International Society for Laboratory Hematology
- ITP Support Association
- Janssen Pharmaceutica
- Japanese Society of Hematology
- Jazz Pharmaceuticals
- Karyopharm Therapeutics
- Leukemia Patient Advocates Foundation
- Lipomed AG
- Lymphoma Coalition
- Maco Pharma
- MDS Alliance
- MDS Foundation, Inc
- MediCom Oncology
- MorphoSys AG
- MPN Advocates Network
- MSD
- Myeloma Patients Europe
- NeoGenomics
- Nordmedica
- Novartis
- Omeros Corporation
- Otsuka Pharmaceutical Europe Ltd.
- Oxford Gene Technology
- Pfizer Oncology
- Pfizer Pharma
- Pharmacyclics, an AbbVie Company
- PIVOTAL
- prIME Oncology
- PROFILE
- Prothena Corporation
- QIAGEN
- Resonance Health
- Sandoz
- Sanofi Genzyme
- Seattle Genetics
- SEI healthcare
- SERVIER INTERNATIONAL
- Shire
- SkylineDx B.V.
- Sunesis Pharmaceuticals, Inc.
- Takeda Oncology
- Teva Pharmaceuticals Europe
- Turkish Society of Hematology
- UniQure biopharma
- Verastem, Inc.
- VIVIA BIOTECH
- Wisepress Medical Bookshop
- 37th World Congress of the International Society of Hematology (ISH 2018)

Bristol-Myers Squibb

At the Forefront of Immuno-Oncology

ADVANCING HEMATOLOGY RESEARCH



Bringing the
science of
Immuno-Oncology
into hematologic
malignancies

FOR MORE INFORMATION,
PLEASE VISIT THE I-O SECTION OF BOOTH 930





ABOUT EHA



Become an EHA member

Support our mission to promote excellence in patient care, research and education in hematology.

Join your fellow EHA members worldwide and enjoy membership benefits for both professional and personal development within the field of hematology.

BECOME A MEMBER!

- Full Membership € 155/year
- Junior Membership € 20/year
- Health Care Affiliated Professional Membership € 90/year
- Emeritus Membership € 90/year



ENJOY OUR MEMBERSHIP BENEFITS ALL-YEAR ROUND



ALREADY A MEMBER? RENEW YOUR MEMBERSHIP NOW!

ehaweb.org/eha-membership

ABOUT EHA

The European Hematology Association (EHA) is a non-profit scientific association that represents European medical professionals with an active interest in hematology. The Annual Congress, organized in a major European city, offers the opportunity to learn about new data from basic, translational and clinical research and gives access to knowledge that directly impacts clinical practice. The scope of the congress has increased over the years and education and career development programs broadened.

Your educational needs are the focus of our continuing medical education program. We fulfill these needs through live events, but also through the EHA Learning Center, our online learning platform. EHA supports high quality science. We encourage research by strengthening networks and sharing knowledge.

EHA offers education, training and supports the career of hematologists in Europe through its career development program. Various research grants are available for basic, translational and clinical researchers both in their early or advanced career.

As the largest organization of hematologists in Europe, EHA has taken it upon itself to serve and further the interests of hematologists. We advocate for more research funding, improved research environment and better access to hematology care at the European level.

Information about all the initiatives of the association can be found on www.ehaweb.org.



EHA COMMITTEES AND UNITS

EXECUTIVE BOARD

AR Green, *United Kingdom* (President)
P Sonneveld, *the Netherlands* (President Elect)
C Chomienne, *France* (Past President)
M Muckenthaler, *Germany* (Secretary)
A Engert, *Germany* (Treasurer)

COUNCILORS

S Fröhling, *Germany*
G Gaidano, *Italy*
J Gribben, *United Kingdom*
S Izraeli, *Israel*
E Macintyre, *France*
MV Mateos, *Spain*
HA Papadaki, *Greece*
K Porkka, *Finland*
F Rodeghiero, *Italy*
V Sexl, *Austria*

COMMUNICATION COMMITTEE

A Hagenbeek, *the Netherlands* (Chair)
J Cools, *Belgium*
S Fröhling, *Germany*
E Macintyre, *France*
S McCann, *Ireland*
I Roberts, *United Kingdom*
M de Montalembert, *France*

CURRICULUM COMMITTEE

A Almeida, *Portugal* (Chair)
CH Toh, *United Kingdom*
M Cem Ar, *Turkey*
M Guenova, *Bulgaria*
E Hellström Lindberg, *Sweden* (ex-officio)
M Liljeholm, *Sweden*
JT Navarro Ferrando, *Spain*
G Ossenkoppele, *the Netherlands*
M Wondergem, *the Netherlands*

CRTH COMMITTEE

P Sonneveld, *the Netherlands*
A Engert, *Germany*
MV Mateos, *Spain*
A Hagenbeek, *the Netherlands*

EARLY CAREER COMMITTEE

V Gaidzik, *Germany* (Chair)
H Becker, *Germany*
AK Eisfeld, *USA*
M Gruber, *USA*
F McClanahan, *USA*
M Mraz, *Czech Republic*
C Scharenberg, *Sweden*

EDUCATION COMMITTEE

R Foà, *Italy* (Chair)
H Akan, *Turkey*
OW Bjerrum, *Denmark*

C Chomienne, *France*
J Delgado, *Spain*
C Dufour, *Italy*
A Ganser, *Germany*
AR Green, *United Kingdom*
S Modok, *Hungary*
G Ossenkoppele, *the Netherlands*
A Tichelli, *Switzerland*
A Almeida, *Portugal*
G Gaidano, *Italy*

EHA LEARNING CENTER EDITORIAL BOARD

G Ossenkoppele, *the Netherlands* (Chair)
MC Béné, *France*
D Bron, *Belgium*
S Eichinger, *Denmark*
G Gaidano, *Italy*
N Kröger, *Germany*
J Palmblad, *Sweden*
K Porkka, *Finland*
D Prati, *Italy*

EUROPEAN AFFAIRS COMMITTEE

U Jäger, *Austria* (Chair)
C Chomienne, *France*
A Hagenbeek, *the Netherlands*
P Sonneveld, *the Netherlands*
A Engert, *Germany*
E Macintyre, *France*
J Geissler, *Germany*
R Hehlmann, *Germany*

EUROPEAN BOARD FOR ACCREDITATION IN HEMATOLOGY

A Tichelli, *Switzerland* (Chair)
H Akan, *Turkey*
M Guenova, *Bulgaria*
H Schouten, *the Netherlands*
M Vilarmau, *Spain*
M Mohty, *France*
M Lozano, *Spain*
A Falanga, *Italy*

FELLOWSHIPS AND GRANTS COMMITTEE

M Muckenthaler, *Germany* (Chair)
JP Bourquin, *Switzerland*
M Alberich Jorda, *Czech Republic*
R Delwel, *the Netherlands*
J Eikenboom, *the Netherlands*
S Fröhling, *Germany*
R Handgretinger, *Germany*
T Holyoake, *United Kingdom*
K Stamatopoulos, *Greece*
C Thieblemont, *France*

FUNDRAISING & SPONSOR COMMITTEE

J Gribben, *United Kingdom* (Chair)
P Sonneveld, *the Netherlands*
R Foà, *Italy*

K Porkka, *Finland*
 MV Mateos, *Spain*
 G Ossenkuppele, *the Netherlands*

GOOD GOVERNANCE COMMITTEE

W Fibbe, *the Netherlands* (Chair)
 T Barbui, *Italy*
 L Degos, *France*
 M Guenova, *Bulgaria*
 L Malcovati, *Italy*

MEMBERSHIP COMMITTEE

S Fröhling, *Germany* (Chair)
 J Cools, *Belgium*
 V Sexl, *Austria*

NOMINATION COMMITTEE

E Hellström Lindberg, *Sweden* (Chair)
 C Camaschella, *Italy*
 H Döhner, *Germany*
 W Fibbe, *the Netherlands*
 J San Miguel, *Spain*

ONLINE & CASE UNIT

S Modok, *Hungary* (Chair)
 B Bain, *United Kingdom*
 J Burthem, *United Kingdom*
 S McCann, *Ireland*
 MF McMullin, *Ireland*
 C McNamara, *United Kingdom*
 M Cem Ar, *Turkey*

RESEARCH COMMITTEE

AR Green, *United Kingdom* (Chair)
 W Fibbe, *the Netherlands* (Co-Chair)
 C Bonini, *Italy*
 J Cools, *Belgium*
 R Delwel, *the Netherlands*
 S Izraeli, *Israel*
 U Jäger, *Austria*
 MV Mateos, *Spain*
 M Muckenthaler, *Germany*
 B Porse, *Denmark*
 I Roberts, *United Kingdom*
 T Schroeder, *Switzerland*
 P Sonneveld, *the Netherlands*
 S Stilgenbauer, *Germany*

SCIENTIFIC PROGRAM COMMITTEE 22ND CONGRESS

S Izraeli, *Israel* (Chair)
 S Eichinger, *Austria*
 A Engert, *Germany*
 A Fielding, *United Kingdom*
 S Fröhling, *Germany*
 K Grønbaek, *Denmark*
 J Jansen, *the Netherlands*
 JJ Kiladjan, *France*
 N Kröger, *Germany*
 H Ludwig, *Austria*
 C Moreno, *Spain*
 M Muckenthaler, *Germany*

G Ossenkuppele, *the Netherlands*
 JA Pérez-Simón, *Spain*
 D Rees, *United Kingdom*
 A Reiter, *Germany*
 F Rodeghiero, *Italy*
 S Soverini, *Italy*
 S Stanworth, *United Kingdom*
 CH Toh, *United Kingdom*
 MM van den Heuvel-Eibrink, *the Netherlands*

LOCAL REPRESENTATIVE 22ND CONGRESS

A Alegre, *Spain*

SCIENTIFIC PROGRAM COMMITTEE ADVISORY BOARD 22ND CONGRESS

I Aurer, *Croatia*
 H Avet-Loiseau, *France*
 C Bonini, *Italy*
 JP Bourquin, *Switzerland*
 M Delforge, *Belgium*
 B Eichhorst, *Germany*
 N Gökbüget, *Germany*
 JB Hansen, *Norway*
 H Hasle, *Denmark*
 H Hasselbalch, *Denmark*
 T Holyoake, *United Kingdom*
 M Hutchings, *Denmark*
 A Iolascon, *Italy*
 PA Kyrle, *Austria*
 T Lapidot, *Israel*
 JI Martin-Subero, *Spain*
 A Nagler, *Israel*
 M Olsson, *Sweden*
 RA Padua, *France*
 D Pospíšilová, *Czech Republic*
 D Prati, *Italy*
 S Saußebe, *Germany*
 H Tamary, *Israel*
 A Undas, *Poland*

SWG UNIT

P Sonneveld, *the Netherlands* (Chair)
 MC Béné, *France*
 M Dreyling, *Germany*
 C Dufour, *Italy*
 R Foà, *Italy*
 S Fröhling, *Germany*
 A Iolascon, *Italy*
 L Malcovati, *Italy*
 G Ossenkuppele, *the Netherlands*

TRTH JOINT OVERSIGHT COMMITTEE

R Delwel, *the Netherlands*
 J Licht, *USA*
 A Fielding, *United Kingdom*
 L Kean, *USA*
 M Dinauer, *USA*
 S Izraeli, *Israel*
 D Neuberg, *USA* (Advisor)



FUTURE EHA CONGRESSES & MEETINGS 2017 - 2018

SEPTEMBER 2017

HIGHLIGHTS OF PAST EHA (HOPE) CAIRO 2017

Dates: September 14-16, 2017

Location: Cairo, Egypt

PTHIT ANNUAL CONGRESS - EHA JOINT SYMPOSIUM

Dates: 21-23 September, 2017

Location: Warsaw, Poland

OCTOBER 2017

EHA SCIENTIFIC MEETING ON CHALLENGES IN THE DIAGNOSIS AND MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMS

Chairs: JJ Kiladjian & C Harrison

Dates: October 12-14, 2017

Location: Budapest, Hungary

LEBANESE SOCIETY OF HEMATOLOGY ANNUAL MEETING - EHA JOINT PROGRAM

Dates: October 12-14, 2017

Location: Beirut, Lebanon

EHA-AHA TUTORIAL ON BIOLOGY AND MANAGEMENT OF MYELOID MALIGNANCIES

Chairs: S Daghbashyan, JJ Kiladjian & P Fenaux

Dates: October 20-21, 2017

Location: Yerevan, Armenia

RUSSIAN ONCO-HEMATOLOGY SOCIETY'S CONFERENCE ON MALIGNANT LYMPHOMA - JOINT PROGRAM

Dates: October 25-26, 2017

Location: Moscow, Russian Federation

NOVEMBER 2017

TURKISH SOCIETY OF HEMATOLOGY - EHA JOINT PROGRAM

Dates: November 1-4, 2017

Location: Antalya, Turkey

INDIAN SOCIETY OF HAEMATOLOGY AND BLOOD TRANSFUSION - EHA JOINT PROGRAM

Dates: November 2-5, 2017

Location: Guwahati, Assam, India

ARGENTINIAN SOCIETY OF HEMATOLOGY - EHA JOINT EDUCATION DAY

Dates: November 17-18, 2017

Location: Mar del Plata, Argentina

EHA SCIENTIFIC MEETING ON SHAPING THE FUTURE OF MESENCHYMAL STROMAL CELLS THERAPY

Chair: W Fibbe

Dates: November 23-25, 2017

Location: Amsterdam, the Netherlands

FEBRUARY 2018

EHA SCIENTIFIC MEETING ON INTEGRATED DIAGNOSIS STRATEGIES IN ONCOHEMATOLOGY FOR THE MANAGEMENT OF CYTOPENIAS AND LEUKOCYTOSIS

Chairs: MC Béné & G Zini

Dates: February 8-10, 2018

EHA-ISHBT TUTORIAL ON LYMPHOPROLIFERATIVE AND PLASMA CELL DISORDERS

Dates: February 16-18, 2018

Location: Lucknow, India

APRIL 2018

EHA SCIENTIFIC MEETING ON NEW MOLECULAR INSIGHTS AND INNOVATIVE MANAGEMENT APPROACHES FOR ACUTE LYMPHOBLASTIC LEUKEMIA

Chair: N Gökbüget

Dates: April 12-14, 2018

RUSSIAN HEMATOLOGY SOCIETY CONGRESS - EHA JOINT PROGRAM

Dates: April 12-14, 2018

Location: Moscow, Russian Federation

JULY 2018

EHA-RHS-ROHS TUTORIAL ON REAL WORLD CHALLENGES AND OPPORTUNITIES IN THE MANAGEMENT OF ONCO-HEMATOLOGICAL PATIENTS TODAY

Dates: July 5-7, 2018

Location: Moscow, Russian Federation

CONGRESS ORGANIZATION



A photograph of a silver laptop with a blue screen, positioned as if it is an open book. The pages of the book are fanned out. Above the laptop, several circular icons in various colors (red, blue, yellow, green) float in the air. These icons represent various medical and educational concepts: a microscope, a graduation cap, a beaker, a globe, a brain, a book, a computer monitor, a gear, and a network of nodes.

EHA MEDICAL EDUCATION PROGRAM

Benefit directly from EHA's education opportunities



EHA is one of the largest international, independent providers of peer-reviewed hematological knowledge. As a knowledge platform, the association offers a comprehensive and integral curriculum

which forms the basis of the Medical Education Program. This enables professionals to improve their hematology knowledge through the EHA Learning Center, the Master Class and live events.

Online opportunities

- EHA Learning Center: EHA's official learning platform.
- Master Class: online program that allows hematologists to study real patient cases, in groups, together with colleagues from all over the world.
- Curriculum Passport: online tool to monitor progress in the European Hematology Curriculum.

Live opportunities

- Educational events, including Hematology Tutorials, Highlights of Past EHA and Outreach
- Scientific events
- European Hematology Exam

CONGRESS ORGANIZATION

SCIENTIFIC PROGRAM COMMITTEE 22ND CONGRESS

S Izraeli, *Israel (Chair)*
 S Eichinger, *Austria*
 A Engert, *Germany*
 A Fielding, *United Kingdom*
 S Fröhling, *Germany*
 K Grønbaek, *Denmark*
 J Jansen, *the Netherlands*
 JJ Kiladjian, *France*
 N Kröger, *Germany*
 H Ludwig, *Austria*
 C Moreno, *Spain*
 M Muckenthaler, *Germany*
 G Ossenkoppele, *the Netherlands*
 JA Pérez-Simón, *Spain*
 D Rees, *United Kingdom*
 A Reiter, *Germany*
 F Rodeghiero, *Italy*
 S Soverini, *Italy*
 S Stanworth, *United Kingdom*
 CH Toh, *United Kingdom*
 MM van den Heuvel-Eibrink, *the Netherlands*

LOCAL REPRESENTATIVE 22ND CONGRESS

A Alegre, *Spain*

SCIENTIFIC PROGRAM COMMITTEE ADVISORY BOARD 22ND CONGRESS

I Aurer, *Croatia*
 H Avet-Loiseau, *France*
 C Bonini, *Italy*
 JP Bourquin, *Switzerland*
 M Delforge, *Belgium*
 B Eichhorst, *Germany*
 N Gökbüget, *Germany*
 JB Hansen, *Norway*
 H Hasle, *Denmark*
 H Hasselbalch, *Denmark*
 T Holyoake, *United Kingdom*
 M Hutchings, *Denmark*
 A Iolascon, *Italy*
 P Kyrle, *Austria*
 T Lapidot, *Israel*
 JI Martin-Subero, *Spain*
 A Nagler, *Israel*
 M Olsson, *Sweden*
 RA Padua, *France*
 D Pospíšilová, *Czech Republic*
 D Prati, *Italy*
 S Saußebe, *Germany*
 H Tamary, *Israel*
 A Undas, *Poland*



ABSTRACT REVIEWERS

EHA would like to thank the following experts for their time and efforts reviewing abstracts for this Congress.

Abdel-Wahab O, *USA*
Abdul-Kadir R, *United Kingdom*
Abken H, *Germany*
Adès L, *France*
Alegre A, *Spain*
Alessi MC, *France*
Almeida A, *Portugal*
Almeida J, *Spain*
Alvarez-Larrán A, *Spain*
André M, *Belgium*
Asp J, *Sweden*
Aurer I, *Croatia*
Avet-Loiseau H, *France*
Barcellini W, *Italy*
Bartels M, *the Netherlands*
Beilhack A, *Germany*
Berntorp E, *Sweden*
Bhatia R, *USA*
Bierings M, *the Netherlands*
Bocchia M, *Italy*
Bodó I, *Hungary*
Boelens JJ, *the Netherlands*
Bolli N, *Italy*
Bondanza A, *Italy*
Bonifazi F, *Italy*
Bonini C, *Italy*
Bonnet D, *United Kingdom*
Bonnetain F, *France*
Bornhauser B, *Switzerland*
Bosch F, *Spain*
Bourquin JP, *Switzerland*
Bouscary D, *France*
Brækkan SK, *Norway*
Brander DM, *United Kingdom*
Breems D, *Belgium*
Burnett A, *United Kingdom*
Caballero D, *Spain*
Calado D, *United Kingdom*
Camaschella C, *Italy*
Canaani J, *USA*
Cazzola M, *Italy*
Chakraverty R, *United Kingdom*
Chalandon Y, *Switzerland*
Chiapella A, *Italy*
Chiaretti S, *Italy*
Chng WJ, *Singapore*
Ciceri F, *Italy*

Clappier E, *France*
Colombatti R, *Italy*
Colomer D, *Spain*
Copland M, *United Kingdom*
Craddock C, *United Kingdom*
Curti A, *Italy*
Da Costa L, *France*
Damm F, *Germany*
Davies A, *United Kingdom*
De Bont E, *the Netherlands*
de Botton S, *France*
de la Fuente A, *Spain*
de la Rubia J, *Spain*
De Moerloose B, *Belgium*
de Montalembert M, *France*
Delforge M, *Belgium*
den Boer M, *the Netherlands*
Devos T, *Belgium*
Dokal I, *United Kingdom*
Dolstra H, *the Netherlands*
Dreyling M, *Germany*
Dührsen U, *Germany*
Eaves C, *Canada*
Edgren G, *Sweden*
Eichhorst B, *Germany*
Eichinger S, *Austria*
Elitzur S, *Israel*
Engelhardt M, *Germany*
Engert A, *Germany*
Facon T, *France*
Federico M, *Italy*
Fibbe W, *the Netherlands*
Fielding A, *United Kingdom*
Fröhling S, *Germany*
Ganser A, *Germany*
Garcia-Marco J, *Spain*
Ginzburg Y, *USA*
Giralt S, *USA*
Giri N, *USA*
Gisselbrecht C, *France*
Gökbuget N, *Germany*
Goldschmidt H, *Germany*
Gomes da Silva M, *Portugal*
Goudemand J, *France*
Grebien F, *Austria*
Greinix H, *Austria*
Grønbaek K, *Denmark*

Gröschel S, *Germany*
Gutierrez N, *Spain*
Hagenbeek A, *the Netherlands*
Hansen JB, *Norway*
Harrison C, *United Kingdom*
Hasle H, *Denmark*
Hasselbalch H, *Denmark*
Heemskerk JWM, *the Netherlands*
Hermans C, *Belgium*
Hermouet S, *France*
Heß G, *Germany*
Heyman M, *Sweden*
Holte H, *Norway*
Horvathova M, *Czech Republic*
Hough T, *United Kingdom*
Huls G, *the Netherlands*
Hunault-Berger M, *France*
Hutchings M, *Denmark*
Iolascon A, *Italy*
Ionova T, *Russia*
Izraeli S, *Israel*
Jansen J, *the Netherlands*
Janssen J, *the Netherlands*
Jeremias I, *Germany*
Jerkeman M, *Sweden*
Johnson P, *United Kingdom*
Jurczak W, *Poland*
Karlsson S, *Sweden*
Kaspers GJ, *the Netherlands*
Kater AP, *the Netherlands*
Kattamis A, *Greece*
Kiladjian JJ, *France*
Krause D, *Germany*
Kristinsson S, *Sweden*
Kröger N, *Germany*
Krüger W, *Germany*
Kühn M, *Germany*
Kyrle PA, *Austria*
Lamy T, *France*
Lane S, *Australia*
Laperche S, *France*
Lapidot T, *Israel*
Leblanc T, *France*
Lehmann S, *Sweden*
Lippert E, *France*
Ljungman P, *Sweden*
Lo Celso C, *United Kingdom*

Lucas C, *United Kingdom*
 Ludwig H, *Austria*
 Luminari S, *Italy*
 Macintyre E, *France*
 Maertens J, *Belgium*
 Maguer-Satta V, *France*
 Manz M, *Switzerland*
 Martin-Subero JI, *Spain*
 Mayer J, *Czech Republic*
 McMahon C, *Ireland*
 Medyouf H, *Germany*
 Méndez-Ferrer S, *United Kingdom*
 Mercher T, *France*
 Mesa R, *USA*
 Michallet M, *France*
 Michaux L, *Belgium*
 Moccia A, *Switzerland*
 Montoto S, *United Kingdom*
 Moreno C, *Spain*
 Muckenthaler M, *Germany*
 Müller-Tidow C, *Germany*
 Mulligan S, *Australia*
 Munshi N, *USA*
 Muus P, *the Netherlands*
 Nagler A, *Israel*
 Nicolini F, *France*
 Niemann C, *Denmark*
 Nomdedéu J, *Spain*
 Nurden A, *France*
 Oakes C, *USA*
 Olavarria E, *United Kingdom*
 Oliva E, *Italy*
 Olsson M, *Sweden*
 Oriol A, *Spain*
 Ossenkoppele G, *the Netherlands*
 Padua R, *France*
 Papaemmanuil E, *USA*
 Pellagatti A, *United Kingdom*
 Perez-Simon JA, *Spain*
 Petrucci MT, *Italy*
 Plesner TH, *Denmark*
 Porkka K, *Finland*
 Porto G, *Portugal*
 Pospíšilová D, *Czech Republic*
 Pott C, *Germany*
 Prati D, *Italy*
 Premawardhena A, *Sri Lanka*

Preudhomme C, *France*
 Puissant A, *France*
 Raaijmakers M, *the Netherlands*
 Racil Z, *Czech Republic*
 Raemaekers J, *the Netherlands*
 Raje N, *USA*
 Ramenghi U, *Italy*
 Ravandi F, *USA*
 Rees D, *United Kingdom*
 Reiter A, *Germany*
 Renella R, *Switzerland*
 Risitano A, *Italy*
 Riva N, *Italy*
 Roberts I, *United Kingdom*
 Rodeghiero F, *Italy*
 Rosendaal FR, *the Netherlands*
 Rosenquist R, *Sweden*
 Rosiñol L, *Spain*
 Rovó A, *Switzerland*
 Rowe J, *Israel*
 Ruutu T, *Finland*
 Salles G, *France*
 San Miguel J, *Spain*
 Sanchez M, *Spain*
 Sander B, *Sweden*
 Santini V, *Italy*
 Sanz G, *Spain*
 Saußebe S, *Germany*
 Savage K, *Canada*
 Schneider R, *the Netherlands*
 Schrezenmeier H, *Germany*
 Schuh A, *United Kingdom*
 Sekeres M, *USA*
 Selleslag D, *Belgium*
 Shpilberg O, *Israel*
 Skov V, *Denmark*
 Socie G, *France*
 Sonneveld P, *the Netherlands*
 Soverini S, *Italy*
 Spina M, *Italy*
 Stanworth S, *United Kingdom*
 Steele A, *United Kingdom*
 Suttorp M, *Germany*
 Tadmor T, *Israel*
 Taher A, *Lebanon*
 Tamarly H, *Israel*
 te Boekhorst P, *the Netherlands*

Teshima T, *Japan*
 Thompson A, *United Kingdom*
 Toh CH, *United Kingdom*
 Tothova Z, *USA*
 Trka J, *Czech Republic*
 Trümper L, *Germany*
 Ugo V, *France*
 Undas A, *Poland*
 Uyl-de Groot C, *the Netherlands*
 Vago L, *Italy*
 van den Heuvel-Eibrink MM,
the Netherlands
 van der Velde V, *the Netherlands*
 van Duin M, *the Netherlands*
 van Tendeloo V, *Belgium*
 Venditti A, *Italy*
 Verma A, *USA*
 von Lilienfeld-Toal M, *Germany*
 Watała C, *Poland*
 Windyga J, *Poland*
 Wlodarski M, *Germany*
 Yacobovich J, *Israel*
 Yerushalmi R, *Israel*
 Zenz T, *Germany*



A medical educational resource provided by Takeda Oncology for UK healthcare professionals treating patients with multiple myeloma



EXPERT
INSIGHTS



DOWNLOADABLE
RESOURCES



PODCASTS



www.myelomahub.co.uk

Developed by



ONCOLOGY

REVIEWERS EDUCATIONAL UPDATES IN HEMATOLOGY BOOK

EHA would like to thank the following experts for their time and efforts reviewing the articles for the Educational Updates in Hematology Book of this Congress.

Anderson R, *United Kingdom*
 Ariens R, *United Kingdom*
 Armand PA, *USA*
 Baruchel A, *France*
 Becattini C, *Italy*
 Besses C, *Spain*
 Blaise D, *France*
 Brousse V, *France*
 Bueren J, *Spain*
 Cosmi B, *Italy*
 Cymbalista F, *France*
 Döhner K, *Germany*
 Enblad G, *Sweden*
 Fielding A, *United Kingdom*
 Gribben J, *United Kingdom*
 Grønbaek K, *Denmark*

Hellström-Lindberg E, *Sweden*
 Jacoby E, *Israel*
 Jilma B, *Austria*
 Kaiser M, *United Kingdom*
 Koschmieder S, *Germany*
 Ludwig H, *Austria*
 Makris M, *United Kingdom*
 Malcovati L, *Italy*
 Massey E, *United Kingdom*
 Moreau P, *France*
 Müller M, *Germany*
 Muller-Tidow C, *Germany*
 Nemeth E, *USA*
 Niemann C, *Denmark*
 Pane F, *Italy*
 Pasqualucci L, *USA*

Platzbecker U, *Germany*
 Porter J, *United Kingdom*
 Rachmilewitz E, *Israel*
 Rambaldi A, *Italy*
 Rosenwald A, *Germany*
 Saglio G, *Italy*
 Salles G, *France*
 Schlatt S, *Germany*
 Schlenk R, *Germany*
 Stanworth S, *United Kingdom*
 Stevenson F, *United Kingdom*
 Tamary H, *Israel*
 Tausch E, *Germany*
 Valk P, *the Netherlands*
 Weiss G, *Austria*
 Zucca E, *Switzerland*

The Educational Updates in Hematology are freely available on the EHA Learning Center, learningcenter.ehaweb.org.

ORGANIZERS

European Hematology Association

EHA Executive Office
 Koninginnegracht 12b
 2514 AA The Hague
 The Netherlands
 Tel: +31 (0)70 3455 563
 Fax: +31 (0)70 3923 663
 E-mail: info@ehaweb.org

Congress Logistics

MCI Amsterdam
 Schipluidenlaan 4
 1062 HE Amsterdam
 The Netherlands
 Tel: +31 (0)20 570 96 00
 E-mail: eha@mci-group.com

Hotel Accommodation

MCI Amsterdam
 Schipluidenlaan 4
 1062 HE Amsterdam
 The Netherlands
 Tel: +31 (0)20 570 96 00
 E-mail: ehagroups@mci-group.com



Hall C

Chaired by Francesc Bosch, who will be joined by Florence Cymbalista, Paolo Ghia, and Peter Hillmen

RELAPSED/ REFRACTORY CLL: HOW FAR HAVE WE COME, AND WHERE WILL WE GO NEXT

AbbVie-sponsored symposia at the 22nd Congress of the European Hematology Association

THURSDAY JUNE 22 2017
16:15-18:15



EMERGING NOVEL AGENTS FOR AML: ARE WE ON THE THRESHOLD OF A TRANSFORMATION IN THERAPY?

Room N103

Chaired by Hagop Kantarjian, who will be joined by Lionel Adès, Hartmut Döhner, and Gail Roboz

Date of Preparation: April 2017
ES/VEN/0417/0524
Copyright © 2017 AbbVie Inc.
North Chicago, Illinois, U.S.A.

abbvie

AWARDS

Biosimilars for Haematologic Malignancies: The Path to Sustainable Care

Friday, 23 June 2017

Room: N103 (first floor)

IFEMA – Feria de Madrid

17:15 – 18:45 U-i-H Symposium

Expert perspectives from:



Moderator
**Paul Cornes, BA, BM BCH,
MA, MRCP, FRCR**
Comparative Outcomes Group
Bristol, United Kingdom



Faculty
**Arnold G. Vulto, PharmD,
PhD, FCP**
Erasmus University Medical Center
Rotterdam, The Netherlands



Faculty
**Wojciech Jurczak,
MD, PhD**
Jagiellonian University
Krakow, Poland

AGENDA

Welcome & Introduction

- Paul Cornes, BA, BM BCH, MA, MRCP, FRCR

The role of biosimilars in promoting sustainability of care

- Presentation by Paul Cornes, BA, BM BCH, MA, MRCP, FRCR, and panel discussion

A look at biosimilars development

- Presentation by Arnold G. Vulto, PharmD, PhD, FCP, and panel discussion led by Paul Cornes, BA, BM BCH, MA, MRCP, FRCR

The role of new molecule innovation in the sustainability of treatment for haematologic malignancies

- Presentation by Wojciech Jurczak, MD, PhD, and panel discussion led by Paul Cornes, BA, BM BCH, MA, MRCP, FRCR

“Ask the Faculty” and Take-Home Messages

- Entire panel

www.peercme.com/biosimilars-update

Official Sponsored Update-in-Hematology Session at the 22nd Congress of the European Hematology Association.

This educational activity is supported by Sandoz.

This CME activity is jointly provided by Oakstone Publishing, LLC and PeerVoice.

Please contact webmaster@peercme.com for more information.

© 2012-2017, PeerCME

TRAVEL GRANT WINNERS

For this Congress 140 travel grants have been awarded to junior members of EHA, based on the mean score of their abstracts.

EHA congratulates the following persons with their travel grants:

Agrawal M, *Germany*
 Anagnostou T, *USA*
 Arriazu E, *Spain*
 Barcia Duran JG, *USA*
 Beekman R, *Spain*
 Bhoi S, *Sweden*
 Binder M, *USA*
 Birgisdóttir AM, *Iceland*
 Blunt M, *United Kingdom*
 Botthof J, *United Kingdom*
 Bouillon AS, *Belgium*
 Bröckelmann P, *Germany*
 Buffiere A, *France*
 Burney C, *United Kingdom*
 Cabal-Hierro L, *USA*
 Caraffini V, *Austria*
 Casado Izquierdo P, *United Kingdom*
 Cerchione C, *Italy*
 Chaudhry G, *India*
 Chitre S, *United Kingdom*
 Cleyrat C, *USA*
 De Bie J, *Belgium*
 de la Morena-Barrio ME, *Spain*
 De Paepe K, *United Kingdom*
 De Rosa G, *Italy*
 Di Marcantonio D, *USA*
 Dinmohamed A, *the Netherlands*
 Dominguez Rodriguez M, *Spain*
 Duran-Ferrer M, *Spain*
 Eisfeld AK, *USA*
 Escribà Garcia L, *Spain*
 Eskelund C, *Denmark*
 Fancello L, *Belgium*
 Farina F, *Italy*
 Fattizzo B, *Italy*
 Fernandez MC, *Spain*
 Ferrero S, *Italy*
 Figueroa R, *Spain*
 Flasiniski M, *Germany*
 Gabelli M, *Italy*
 Ganuza Fernandez M, *USA*
 García Ramírez P, *Spain*

Geelen I, *the Netherlands*
 Giannoni L, *Italy*
 Gugliotta G, *Italy*
 Hansen J, *Denmark*
 Hasibeder A, *Germany*
 Healey M, *United Kingdom*
 Hermetet F, *France*
 Herrmann O, *Germany*
 Hu B, *USA*
 Iskander D, *United Kingdom*
 Jaafar S, *United Kingdom*
 Jentzsch M, *Germany*
 Jetani H, *Germany*
 Kampen K, *Belgium*
 Karamitros D, *United Kingdom*
 Kardosova M, *Czech Republic*
 Karjalainen R, *Finland*
 Karsa M, *Australia*
 Kim JC, *Republic of Korea*
 Kim T, *Canada*
 Koning MT, *the Netherlands*
 Larrea de Orte E, *Spain*
 Li X, *China*
 Lippert L, *Germany*
 Machnicki MM, *Poland*
 Maekawa T, *Japan*
 Manier S, *France*
 Mannion N, *United Kingdom*
 Manta L, *Germany*
 Marchesini M, *Italy*
 McKerrell T, *United Kingdom*
 McPherson S, *United Kingdom*
 Medrano Domínguez M, *Spain*
 Meyer-Pannwitt, V, *Germany*
 Milani P, *Italy*
 Miller K, *USA*
 Mitchell RJ, *United Kingdom*
 Mora B, *Italy*
 Morales Hernandez A, *USA*
 Morita K, *Japan*
 Nadeu F, *Spain*
 Nasso D, *Italy*

Norfo R, *United Kingdom*
 O'Byrne S, *United Kingdom*
 Okasha D, *Egypt*
 Ordoñez R, *Spain*
 Papaioannou D, *USA*
 Passaro D, *United Kingdom*
 Pawlyn C, *United Kingdom*
 Pei X, *China*
 Peric Z, *Croatia*
 Plevova K, *Czech Republic*
 Pozzo F, *Italy*
 Prassek VV, *Germany*
 Pugliese N, *Italy*
 Rencz F, *Hungary*
 Ribeiro D, *Portugal*
 Rotolo A, *United Kingdom*
 Saeed BRM, *Germany*
 Sala E, *Italy*
 Schmidt L, *Austria*
 Schwartzman O, *Israel*
 Seyfried F, *Germany*
 Short N, *USA*
 Smith J, *United Kingdom*
 Song Y, *China*
 Stamatopoulos B, *Belgium*
 Stege C, *the Netherlands*
 Stieglitz E, *USA*
 Sud A, *United Kingdom*
 Suksangpleng T, *Thailand*
 Sulima S, *Belgium*
 Suzuki K, *Japan*
 Svaton M, *Czech Republic*
 Sverrisdottir IS, *Iceland*
 Talati C, *USA*
 Theis F, *Germany*
 Thivakaran A, *Germany*
 Thompson P, *USA*
 Thorsteinsdottir S, *Iceland*
 Tissino E, *Italy*
 Toda J, *Japan*
 Unnikrishnan A, *Australia*
 Uras I, *Austria*



Van de Wyngaert Z, *France*
Van den Bergh M, *USA*
van Dooijeweert B, *the Netherlands*
van Straaten S, *the Netherlands*
Vermaat J, *the Netherlands*
Versluis J, *the Netherlands*
Vinas I, *Spain*
Vinchi F, *Germany*
Viswanathan GK, *India*
Wannez A, *Belgium*
Weigl A, *Germany*
Wiggers C, *the Netherlands*
Zaninetti C, *Italy*

Travel Grant Supported By
Giuseppe Bigi Association
Salvatore D, *Italy*

YOUNGEHA BEST ABSTRACT AWARDS

One of the primary missions of the European Hematology Association is to support young hematology clinicians and researchers. This year we are proud to announce the launching of the YoungEHA Best Abstract Awards. These will be awarded to the highest ranking abstracts in the following four categories: Clinicians or medical students training for a PhD degree, PhD research students, postdoctoral fellows and clinical hematology trainees. We are honored these outstanding YoungEHA trainees will be presenting during the EHA congress – they are the future of Hematology!

CLINICAL TRAINEE AWARD

■ C Pawlyn, *United Kingdom*

MD-PHD AWARD

■ O Schwartzman, *Israel*

PHD RESEARCH STUDENT AWARD

■ JG Barcia Duran, *USA*

POSTDOCTORAL RESEARCH TRAINEE AWARD

■ F Vinchi, *Italy*

JOSÉ CARRERAS LECTURE & AWARD

The José Carreras Award was established by EHA in order to honor leaders in hematological research and is presented each year to an established and active investigator who has made an important contribution to hematology. This honor has been bestowed on internationally recognized specialists for their invaluable contribution to the field of hematology.

EHA congratulates the winner of the 2017 José Carreras Lecture and Award, Professor Ruud Delwel (Erasmus MC, Rotterdam, the Netherlands), for his outstanding contributions to the research of acute myeloid leukemia. Professor Delwel was one of the first to describe the heterogeneity of acute myeloid leukemias. Utilizing modern genomic and gene editing tools he recently uncovered the regulatory mechanisms modulating the expression of leukemia causing genes.

During the Opening Ceremony, Professor Delwel will present the José Carreras Honorary Lecture. This lecture takes place on Friday, June 23 at 13:30 – 14:15 in Hall A.

The previous winners are:

2016 E Hellström Lindberg, *Sweden*
2015 H de Thé, *France*
2014 H Döhner, *Germany*
2013 K Rajewsky, *Germany*
2012 J San Miguel, *Spain*
2011 D Higgs, *United Kingdom*
2010 B Falini, *Italy*
2009 W Vainchenker, *France*
2008 J Goldman, *United Kingdom*
2007 R Bertina, *the Netherlands*
2006 E Gluckman, *France*
2005 H Waldmann, *United Kingdom*
2004 V Diehl, *Germany*
2003 C Verfaillie, *Belgium*
2002 L Luzzatto, *Italy*
2001 M Greaves, *United Kingdom*
2000 D Collen, *Belgium*
1999 C Rozman, *Spain*

JEAN BERNARD LIFETIME ACHIEVEMENT AWARD

The Jean Bernard Lifetime Achievement Award was established in 2008 to honor outstanding physicians and scientists for their lifetime contribution to the advancement of hematology. EHA is proud to posthumously grant the 2017 Jean Bernard Lifetime Achievement Award to Professor David Grimwade (King's College London School of Medicine, London, United Kingdom), for his significant contribution to the translational research to improve therapy of acute myeloid leukemia. His major contributions were in studying the molecular interactions between leukemia genetics and response to therapy. The molecular tools that he developed for determining minimal residual disease have been widely adopted for personalized adjustment of therapy of acute myeloid leukemia. In addition to his research achievements Professor Grimwade had a specific passion for educating innumerable hematologists around the world.

The award will be presented to Frances Hildreth, David Grimwade's wife, during Plenary Session I on Saturday, June 24 at 13:15 – 14:30 in Hall A.

The previous winners of the award are:

2016	C Camaschella, <i>Italy</i>
2015	V Diehl, <i>Germany</i>
2014	F Stevenson, <i>United Kingdom</i>
2013	T Barbui, <i>Italy</i>
2012	L Degos, <i>France</i>
2011	B Löwenberg, <i>the Netherlands</i>
2010	E Montserrat, <i>Spain</i>
2009	P Mannuccio Mannucci, <i>Italy</i>
2008	D Hoelzer, <i>Germany</i>

TALENT ACCELERATOR PROGRAMS

By investing in promising early careers, EHA fosters the next generation of leaders in hematology research. Talented researchers can apply for either funding or research training programs.

RESEARCH GRANTS

The winners of the 2016 and 2017 rounds will be acknowledged during the Opening Ceremony on Friday, June 23.

2016 WINNERS:

JOHN GOLDMAN CLINICAL RESEARCH GRANT

- R Schneider, Erasmus Medical Center, Rotterdam, the Netherlands

CLINICAL RESEARCH GRANT

- E Gavrilaki, George Papanicolaou Hospital, Thessaloniki, Greece

NON-CLINICAL ADVANCED RESEARCH GRANTS

- A Puissant, IUH - St Louis Hospital – Paris, France
- J Nangalia, Wellcome Trust Sanger Institute, United Kingdom

JOSÉ CARRERAS NON-CLINICAL JUNIOR RESEARCH GRANT

- S Sulima, KU Leuven, Belgium

NON-CLINICAL JUNIOR RESEARCH GRANT

- S Dertschnig, University College London, United Kingdom

SHORT TERM COLLABORATION AWARD

- J Thaler, University of Vienna, Austria

2017 WINNERS:

The winners were announced after the book was printed. Please check the EHA website for the list of winners.

If you are interested in applying for a research grant, please check the EHA website or drop by the EHA booth.



RESEARCH TRAINING IN HEMATOLOGY

By learning from the best in your field and getting in-depth comprehensive feedback, translational and clinical researchers are improving their skills and knowledge. Both training programs are intense and customized to fit each participant's professional development.



EHA CLINICAL RESEARCH TRAINING IN HEMATOLOGY (CRTH)

CRTH 2016-2017 WINNERS:

A Brioli, *Germany*
A Broijl, *the Netherlands*
A Bukauskas, *Lithuania*
M Cabrero, *Spain*
V Gaidzik, *Germany*
K van Galen, *the Netherlands*
M Griffin, *United Kingdom*
E Hatzimichael, *Greece*
L López-Anglada Fernández, *Spain*
J Krawczyk, *Ireland*
C McNamara, *Canada*
K Metzeler, *Germany*
L Scarfò, *Italy*
F Thol, *Germany*
M Tobiasson, *Sweden*
C Tomuleasa, *Romania*
C Vitale, *Italy*



TRANSLATIONAL RESEARCH
TRAINING IN HEMATOLOGY

EHA-ASH TRANSLATIONAL RESEARCH TRAINING IN HEMATOLOGY (TRTH)

TRTH 2017 WINNERS:

F Asmar, *Denmark*
G Bianchi, *USA*
L Brunetti, *USA*
D Duarte, *United Kingdom*
P Gallipoli, *United Kingdom*
A Giustacchini, *United Kingdom*
D Herranz, *USA*
T Itkin, *USA*
G Lee, *USA*
A Mottok, *Canada*
S Ng, *USA*
A Pastore, *USA*
F Pastore, *USA*
L Quek, *United Kingdom*
N Rao Tata, *Switzerland*
K Rouault-Pierre, *United Kingdom*
L Smeenk, *the Netherlands*
C Thirant, *France*
D Wiseman, *United Kingdom*
K-R Yu, *USA*

If you are interested in applying for TRTH or CRTH, please attend the bite-size CRTH or TRTH on Saturday, June 24 at 16:00 – 17:15 or drop by the EHA booth.

KEY INFORMATION



OPENING HOURS

Please find below all opening hours of the different areas and information desks:

	Wednesday, June 21	Thursday, June 22	Friday, June 23	Saturday, June 24	Sunday, June 25
Cloakroom					
Registration area, Hall 5	x	07:00-21:30	07:00-19:30	07:00-19:30	07:00-16:00
CME Booth					
Hall 9	x	07:30-19:30	07:30-17:30	07:30-17:30	07:30-14:30
EHA Booth					
Hall 9	x	07:30-19:30	07:30-17:30	07:30-17:30	07:30-14:30
Congress Run Registration Desk					
Hall 5	x	x	09:00-17:00	x	x
Exhibition					
Hall 7	x	09:00-16:30	09:00-16:30	09:00-16:30	09:00 -13:30
Poster Desk					
Hall 7	x	x	09:30-19:00	09:30-19:30	09:30-11:00
Press Center					
First floor, above Hall 5	x	07:30-18:00	07:30-18:00	07:30-18:00	07:30-14:00
Business center					
First floor, above Hall 5	x	07:30-18:00	07:30-18:00	07:30-18:00	07:30-14:00
Registration Area					
Hall 5	13:30-17:30	07:00-19:30	07:00-17:30	07:30-17:30	07:30-15:00
Speaker Service Center					
Hall 9	13:30-17:30	07:00-19:30	07:00-17:30	07:30-17:30	07:30-13:00
Madrid & Public Transport Information					
Hall 5	13:30-17:30	07:00-21:30	07:00-19:15	07:30-19:30	07:30-15:00

SERVICES PROVIDED DURING CONGRESS

Service	Name	Location
Abstract Book	Book Desk	Registration Area
Cash withdrawal	Cash dispenser	Outside Hall 5
City and excursion information	Madrid Information Desk	Registration Area
Cloakroom and luggage	Cloakroom	Registration Area
Email and internet	Internet Corners	Hall 7 and 9
Exhibition information	Exhibitor desk	Registration Area
First Aid	First Aid	First floor, between Hall 7 and 9
Hotel Information	Hotel Information Desk	Registration Area
Lost and found	Registration Services Desk	Registration Area
EHA Congress Run registration	EHA Congress Run desk	Registration Area
EHA Grooves Tickets	EHA Grooves Desk	Registration Area
Poster Information	Poster Desk	Poster Area, Hall 7
Restaurant Information	Madrid Information Desk	Registration Area
Presentation check-in	Speaker Service Center	Hall 9
WiFi	Wireless Internet	Throughout the venue

CONGRESS INFORMATION

VENUE

IFEMA – Feria de Madrid, South Entrance, Av. Partenón, 5, 28042 Madrid, Spain.

REGISTRATION HOURS

The registration area is located in Hall 5 and will be open during the following hours:

Wednesday, June 21	13:30-17:30
Thursday, June 22	07:00-19:30
Friday, June 23	07:00-17:30
Saturday, June 24	07:30-17:30
Sunday, June 25	07:30-15:00

EXHIBITION

The exhibition will be open during the following hours:

Thursday, June 22	09:00-16:30
Friday, June 23	09:00-16:30
Saturday, June 24	09:00-16:30
Sunday, June 25	09:00-13:30

EHA BOOTH

The EHA Booth is located in Hall 9. Please come and visit us to collect your EBAH Credit Points, get information on membership, the EHA Learning Center and to find out what more EHA can do for you!

BADGES

All participants will receive a personal badge upon registration. You are kindly requested to wear this badge when attending any scientific session or congress related event. Only participants who are wearing their name badge will be admitted to the meeting rooms, the exhibition area, satellite symposia and updates-in-hematology.

Name badges have been color-coded as follows:

RED	EHA members
ORANGE	EHA junior members
GREEN	delegates
YELLOW	junior delegates
BLUE	exhibitors
PURPLE	press

The charge for replacement of lost badges will be € 30 per badge.

SOCIAL MEDIA

EHA is active on various social media platforms. Follow us on the networks below and get real-time hematology updates:

Facebook: European Hematology Association

Linkedin: EHA

Twitter: @EHA_hematology

#EHA #EHA22 #YoungEHA #EHACongress

PRESS CENTER

The Press Center is located on the first floor, above hall 5. Press inquiries prior to and after the annual congress should be directed to communication@ehaweb.org or +31 (0)70 3020 099.

The Press Center will be open during the following hours:

Thursday, June 22	07:30 – 18:00
Friday, June 23	07:30 – 18:00
Saturday, June 24	07:30 – 18:00
Sunday, June 25	07:30 – 14:00

CERTIFICATES OF ATTENDANCE

See page 37.

BUSINESS CENTER

General printing services as well as photocopying will be available at the Business Center managed by the IFEMA. A minimum payment will be required per page.

INTERNET

WiFi is available in all areas. The network name is: EHA. There is no password required. A number of internet corners with computers can be found in the Exhibition Hall and in the seating area of Hall 9, see the floor plan on page 318.

CLOAKROOM AND LUGGAGE

In the cloakroom you can leave your belongings free of charge. The cloakroom is located at the Registration area in Hall 5 (see floor plan, page 318) and will be open during the following hours:

Thursday, June 22	07:00 – 21:30
Friday, June 23	07:00 – 19:30
Saturday, June 24	07:00 – 19:30
Sunday, June 25	07:00 – 16:00

LOST AND FOUND

Items that are found by the IFEMA and EHA staff will be brought to the Registration Services Desk (Registration area). Should you have lost any of your personal belongings, we kindly ask you to visit this desk to report it or to pick up items.

INSURANCE

In registering for the 22nd Congress of EHA, participants agree that neither EHA, the organizing committee nor the congress organizers assume any liability whatsoever. Participants are requested to make their own arrangements with respect to health and travel insurance.

PRAYING ROOM

A praying room is available on the first floor, room A10.09 (see floor plan, page 319)

LUNCH & REFRESHMENTS

Lunch is included in the registration fee from Friday until Sunday. Lunch tickets are attached to the participants' badge sheet. These tickets are valid on Friday, June 23, Saturday, June 24 and Sunday, June 25. Lunch and coffee (Thursday 22nd only) will be provided in the Catering Area (located next to the Exhibition in Hall 7).

EHA CONGRESS RUN

The congress run (5km) will take place on Saturday, June 24, 06:45 – 08:00 at Juan Carlos I Park - Hamburgo roundabout, close to Partenon Avenue, and 12c Pavillion at IFEMA Madrid. The start is located at the corner of Av Partenon/ Calle via Dublin. Based on availability you can register on-site on Friday, June 23, 09:00 - 17:00. Join this healthy start of the day!

SCIENTIFIC INFORMATION

CONGRESS MATERIALS ON THE EHA LEARNING CENTER

Find all congress materials on the EHA Learning Center - EHA's official learning platform. Materials become available prior, during and shortly after the congress. Watch, download, read and browse through the abstracts, webcasts of congress sessions, E-posters, interviews with leading experts and the Educational Updates in Hematology Book and articles. Visit the EHA Learning Center online via learningcenter.ehaweb.org or come by the EHA Booth to find out more about how to get access!

HARD COPY ABSTRACT BOOK

If you have pre-registered for the hard copy of the Abstract Book, a voucher will be attached to your badge sheet. With this voucher you can pick up your book at the Book Desk. If you would like to buy a hard copy on-site, please go to the Book Desk in the Registration Area.



EDUCATIONAL UPDATES IN HEMATOLOGY BOOK

This year, the "Educational Updates in Hematology" book is available online via the EHA Learning Center. The book will not be available in hard copy.

EHA CONGRESS RECORDINGS AND BROADCASTS – COME AND VISIT THE LIVE RECORDINGS IN THE EHA STUDIO

A selection of semi-live reports and interviews with the leaders in the field of this moment, are recorded and broadcast during the congress. Recordings take place every day during the congress in the EHA Studio in Hall 9.

ON DEMAND; watch the materials after the congress via the mobile app, the EHA website and EHA's official learning platform, the EHA Learning Center.

The materials are available for everyone, including those not attending the congress.

SPEAKER SERVICE CENTER

Equipment to enable a final check of your PowerPoint presentation is available in the Speaker Service Center located in Hall 9 (see floor plan, page 318).

The Speaker Service Center will be open during the following hours::

Wednesday, June 21	13:30 - 17:30
Thursday, June 22	07:00 - 19:30
Friday, June 23	07:00 - 17:30
Saturday, June 24	07:30 - 17:30
Sunday, June 25	07:30 - 13:00

Only PowerPoint presentations will be accepted. To ensure that the presentations are well prepared, we strongly advise you to bring your presentation AT LEAST 3 HOURS before the start of your presentation to the Speaker Service Center.

You can bring your presentation on a USB memory stick. You may bring your own laptop (exclusively for copying your presentation onto the network). The use of your own laptop during your presentation is strictly prohibited.

EHA MOBILE APP

A special mobile app has been developed for this congress in which you can find the entire program in detail. Use the app to find sessions of interest, create your own program, find and read all the abstracts and locate the meeting rooms. Download the app from the Apple App store or Google Play.

MEET-THE-EXPERT SESSIONS – FIRST COME FIRST SERVE

In total 12 small scale Meet-the-Expert sessions are organized on Friday and Saturday, during the following timeslots:

Friday, June 23	11:30 - 12:30 & 14:30 - 15:30
Saturday, June 24	11:30 - 12:30 & 14:45 - 15:45

The number of participants is limited to 50 persons per session in order to guarantee the opportunity of intensive interaction with leading experts in the field. The session details can be found in the program pages.

WEBSITE

Up-to-date information regarding the congress program, including all abstracts, is available at the congress section of www.ehaweb.org.

POSTER SESSION

The main goal of the Poster Session is to gain a maximum benefit from the scientific work presented and to create a lively interaction between poster authors, moderators (senior experts in the field) and interested congress participants. The Poster Session consists of two parts: the Poster Walk and Poster Browsing Time. This setup guarantees sufficient time for all posters that have been selected for a presentation. The first hour of the Poster Walk is moderated and then followed by the Poster Browsing Time, where the rest of the posters can be browsed on the e-poster screens available in the poster area.

Poster walks will be organized during the poster sessions on Friday, June 23 at 17:15 – 18:45 and Saturday, June 24 at 17:30 - 19:00. Poster authors and moderators are requested to be present at the first poster in their poster session, at the beginning of the presentation time (Friday at 17:15 and Saturday at 17:30).

Poster Browsing Time will be organized after the Poster Walk, on Friday, June 23, 18:15 – 18:45 and Saturday, June 24, 18:30 – 19:00.

POSTER PITCHES

Poster pitches are an exciting new opportunity to promote basic science and research, and to attract delegates to the poster walks. During selected oral sessions, 5-8 presenters will have the opportunity to pitch their abstract/poster to the attendees of the session. The following simultaneous sessions contain a poster pitch:

- **AML Biology I: Towards molecular therapies**
Friday, June 23, 11:30 - 12:45, Room N103
- **Hematopoiesis, stem cells and microenvironment**
Friday, June 23, 11:30 - 12:45, Room N104
- **Lymphoma biology**
Friday, June 23, 11:30 - 12:45, Room N101
- **New insights into chronic lymphocytic leukemia biology**
Friday, June 23, 11:30 - 12:45, Hall D
- **AML Biology II: Epigenetic targets**
Saturday, June 24, 11:30 - 12:45, Hall E



POSTER AREA AND (E-)POSTER DESK

Poster sessions will take place in the Poster Area (Hall 7).

The Poster Area and (E-)Poster Desk will be open on:

Friday, June 23	09:30 – 19:00
Saturday, June 24	09:30 – 19:30
Sunday, June 25	09:30 – 11:00

FREE POSTER PRINTING SERVICE

Poster presenters that have submitted their posters online (before May 25) to the poster printing service offered by Pfizer, can collect their posters at the Poster Desk in the Poster Area (Hall 7).

POSTER MOUNTING

Posters should be mounted during the indicated set-up time (see below), using double sided tape or Velcro tape. Assistance will be available at the Poster Desk.

POSTER VIEWING AND PRESENTATION

Posters will be on display in the Poster Area for two days and will be open for viewing on Friday and Saturday during registration hours. Poster authors are requested to be present at their poster during the entire presentation time (see below) to attend the Poster walks. During these walks, an expert in the field will discuss posters in the same poster session, together with interested congress participants.

REMOVING YOUR POSTER MATERIAL

All posters should be removed after Poster Session II (Saturday, June 24 as of 19:00).

If posters are not removed before 11:00 on Sunday, June 25, they will be removed and disposed of.

DISCLOSURES

As part of the European Board for Accreditation in Hematology (EBAH) accreditation procedures, all speakers and chairs are obliged to provide disclosures of relevant financial relations. The disclosures of all invited speakers and chairs of the 22nd Congress have been included in the disclosure index on page 235. On the first slide of every presentation the disclosure must be presented for at least 10 seconds.

PROGRAM CHANGES

Program updates will be available through the mobile app as well as on a printed flyer available at the registration desk.

Poster Session I - Friday, June 23

Set-up	Friday, June 23, 09:30 - 12:00
Viewing	Friday, June 23, 09:30 - Saturday, June 24, 19:00
Presentation during Poster Walk	Friday, June 23, 17:15 - 18:15
Poster Browsing time	Friday, June 23, 18:15 - 18:45
Dismantling	Saturday, June 24, 19:00 - Sunday, June 25, 11:00

Poster Session II - Saturday, June 24

Set-up	Friday, June 23, 09:30 - 12:00
Viewing	Friday, June 23, 09:30 - Saturday, June 24, 19:00
Presentation during Poster Walk	Saturday, June 24, 17:30 - 19:00
Poster Browsing time	Saturday, June 24, 18:30 - 19:00
Dismantling	Saturday, June 24, 19:00 - Sunday, June 25, 11:00

The Poster Area is open during the above mentioned hours. Unauthorized access outside these opening hours is in violation of the registration terms and conditions and can result in permanent expulsion from the congress and the congress grounds.

A GREENER EHA CONGRESS

CERTIFICATE OF ATTENDANCE: THIS YEAR DIGITAL ONLY

The EHA Certificate of Attendance will be sent to your personal e-mail address after the congress, saving a large amount of paper. Please pass by the designated stations in the Registration Area in order to make sure we have correct e-mail address in our database. You can do this from Friday, June 23 (12:00) to Sunday, June 25 (15:00).

FSC CERTIFIED PAPER

All paper used for our congress badges, final program books, pocket programs and related congress materials is fully FSC certified. The Forest Stewardship Council (FSC) is an international non-profit, multi-stakeholder organization established in 1993 to promote responsible management of the world's forests. The FSC does this by setting standards on forest products, along with certifying and labeling them as eco-friendly.



CONGRESS BAGS FROM RECYCLED PET MATERIAL

Recycled PET is the most common practice of saving energy when producing plastic and reducing pollution in mass production. That's why the congress bags this year are made of this eco-friendly material.

TAILOR MADE CONGRESS LUNCH

Food and paper waste are reduced by allowing each participant to assemble his or her own lunch. Help us reduce waste, think twice and pick your favorite items only. Enjoy your lunch!

PUBLIC TRANSPORT TICKETS OFFERED

Madrid public transportation is clean, fast, safe, extensive and efficient. EHA offers each delegate a public transport ticket in order to reduce CO2 emissions on their daily commute to the congress center.

GENERAL INFORMATION

LANGUAGE

The official language during the congress is English, therefore, all presentations will be given in English.

CLIMATE

The average temperature is around 25-30 degrees. June is the beginning of summer and from this month on Madrid sees much more sun and you can enjoy the warm weather. Make sure you protect yourself against the sun and keep hydrated.

ELECTRICITY SUPPLY

In Madrid the alternating current is 220 volt. Plugs and sockets follow European standard with two round pins.

BANKING SERVICE

The official currency in Madrid is the Euro (€). Foreign currencies can be exchanged at banks, which are usually open from Monday to Friday from 10:00 to 16:00. ATM Cash dispensers (Cajero automático) are located throughout the congress venue, at the airport and railway stations.

CURRENCY FOR CONGRESS RELATED PAYMENTS

All payments related to your congress registration should be made in Euro (€).

INFORMATION

For practical information about the city please visit the Madrid & Public Transport Information Desk. This desk is located in Hall 5 and will be open during the following hours:

Wednesday, June 21	13:30 - 17:30
Thursday, June 22	07:00 - 21:30
Friday, June 23	07:00 - 19:15
Saturday, June 24	07:30 - 19:30
Sunday, June 25	07:30 - 15:00

HOTEL INFORMATION DESK

For hotel information and reservations please visit the Hotel Information Desk. This desk is located in the Registration Area and will be open during the following hours:

Wednesday, June 21	13:30 - 17:30
Thursday, June 22	07:00 - 19:30
Friday, June 23	07:00 - 17:30
Saturday, June 24	07:30 - 17:30
Sunday, June 25	07:30 - 15:00

DINING OUT IN MADRID & TIPPING

Restaurants in Madrid usually serve lunch from 13:30 until 15:00. Dinner service usually starts at 20:30 with busiest hours between 20:30 - 22:30. Dinner bookings are recommended.

It is also recommended to leave a gratuity of 10% of the bill if the service was satisfying.

PUBLIC TRANSPORT

Metro Lines

- 1 PINAR DE CHAMARTÍN / VALDECARROS
- 2 LAS ROSAS / CUATRO CAMINOS
- 3 VILLAVEDE ALTO / MONCLOA
- 4 ARGÜELLES / PINAR DE CHAMARTÍN
- 5 ALAMEDA DE OSUNA / CASA DE CAMPO
- 6 CIRCULAR
- 7 HOSPITAL DEL HENARES / PITIS
- 8 NUEVOS MINISTERIOS / AEROPUERTO
- 9 MIRASIERRA / ARGANDA DEL REY
- 10 HOSPITAL INFANTA SOFÍA / PUERTA DEL SUR
- 11 PLAZA ELÍPTICA / LA FORTUNA
- 12 METROSUR
- R ÓPERA / PRÍNCIPE PID

Keys

- Metro Interchange station
- Interchange station with long walking distance
- Station with restricted opening times
- Change of trains
- Madrid-Barajas Airport
- Airport extra charge
- Renfe suburban railway station
- Travel information centre
- Public Transport Card Office
- Parking
- Suburban bus station
- Interregional bus station
- Terminal night bus line
- Railway station
- Transfer Terminal
- Light Rail
- Change of fare

Light Rail

- 1 PINAR DE CHAMARTÍN / LAS TABLAS
- 2 COLONIA JARDÍN / ESTACIÓN DE ARAVACA
- 3 COLONIA JARDÍN / PUERTA DE BOADILLA



TRANSPORTATION IN MADRID

PUBLIC TRANSPORT IS INCLUDED IN YOUR REGISTRATION!

Every delegate will receive a Public Transport Ticket voucher attached to their congress badge. This voucher can be exchanged for the physical ticket at the Public Transport desk at the Registration Area, Hall 5.

The public transport ticket is valid for 5 consecutive days on Madrid's extensive travel network.

The ticket covers all Metro lines, metropolitan bus lines and the light rail system (Cercanías) within the metropolitan area, which covers downtown Madrid, the financial district, the shopping areas, the IFEMA area and the airport – Metro line 8 (pink) and light rail connection to terminal T4. It also covers the airport supplement, which is usually added to one-way metro or Cercanías tickets.

Please follow strictly the instructions on the ticket itself in order to avoid any fines around the city.

HOW TO REACH THE IFEMA CONGRESS VENUE FROM THE AIRPORT

The IFEMA congress venue is only a few kilometres away from Madrid Barajas International Airport (MAD) and can be reached by using one of the following means of transport.

BY METRO

From Madrid Barajas International Airport (MAD) it is only a short metro ride to IFEMA. Take metro line 8 from Aeropuerto T1-T2-T3-T4 (direction to Nuevos Ministerios) to Campo de las Naciones. From Campo de las Naciones station it is a 5 minute walk to the entrance of IFEMA.

BY BUS

A number of bus lines including number 112 and 122 stop outside the IFEMA congress venue. Bus timetables can be found on the following website: www.crtm.es

BY TAXI

A taxi from Madrid Barajas International Airport (MAD) to IFEMA costs around € 20. All terminals have clearly marked taxi ranks outside the arrivals area. Official taxis are white with a red stripe and have the Madrid City Council coat-of-arms on their doors.

To call a taxi please dial:

+34 911 76 00 81
+34 622 465 365

Address: IFEMA – Feria de Madrid, Avda. del Partenón, 5

Please advise your taxi driver to take you to the South entrance.

Growing Today's Clinical Expertise Improving Tomorrow's Clinical Decisions

THURSDAY, JUNE 22

08.00 - 10.00 Hall D

Navigating the Complex Waters in Relapsed/Refractory Multiple Myeloma

This educational activity is supported by Celgene,
Karyopharm Therapeutics, and PharmaMar.

Webcast available July 2017



08.00 - 10.00 Room N103

Fine-Tuning Therapeutic Strategies in Acute Myeloid Leukemia

Chair: Miguel Sanz, MD, Valencia, Spain

This educational activity is supported by a
grant from Celgene and Helsinn Healthcare SA.

Webcast available July 2017




19.00 - 21.00 Room N103

Current State-of-the-Art and Future Strategies in Acute Lymphoblastic Leukemia

Chair: Dieter Hoelzer, MD, PhD, Frankfurt, Germany

This educational activity is supported by a grant from Shire.

Webcast available July 2017



FOR MORE INFO AND ACCESS TO WEBCASTS:
www.prIMEoncology.org/madrid-2017-heme-symposia

Find the insights you need...

Join our program today!


www.prIMEoncology.org



PROGRAM OVERVIEW



PROGRAM-AT-A-GLANCE



SESSION TYPES

- Education Sessions
- Scientific Working Groups
- Basic-Science-in-Focus
- Simultaneous Sessions
- Meet-the-Experts
- Hematology-in-Focus
- Clinical Debates
- Early Career Sessions
- Advocacy Sessions
- Poster Sessions
- Satellite Symposia
- Updates-in-Hematology
- Joint Symposia
- Plenary Sessions
- Workshops

ABOUT THE CONGRESS PROGRAM

OBJECTIVES OF THE EHA CONGRESS

The EHA Annual Congress provides a forum for presenting new data from clinical trials and basic research and sharing ideas for hematological innovation as well as disseminating evidence-based knowledge of primary clinical relevance.

Hematologists and affiliated professionals attending the EHA Congress will be able to:

- Enhance their knowledge of evidence-based approaches on diagnosis and treatment of hematologic diseases.
- Access the latest results on clinical and translational research in hematologic disorders.
- Be updated on emerging innovative techniques, diagnostic tools and risk-assessment strategies in hematology and its subspecialties.
- Communicate, collaborate and network with representatives of a large international audience – medical professionals, national hematology societies, patient groups, medical industry and the media.

These general goals for the Congress will be further refined with learning goals for all presentations of the invited speaker program.

On the following pages you will find information about the congress program, new sessions and program changes.

WHAT'S NEW THIS YEAR?

The congress program is in constant development to meet the needs of attendees and to keep up with developments in the field. This year, the Thursday program has been expanded with an extra timeslot for satellite symposia, to provide pharmaceutical companies with a platform to share their research results. The programs are available in this program book and in the EHA App.

The well-appreciated Meet-the-Expert sessions have now been divided over four timeslots, two on Friday and two on Saturday. This means you have more opportunities to meet and interact with experts in the field.

Another important change is related to the Laboratory Diagnosis Workshop, which is organized on Saturday morning and constitutes a full morning program focused on a variety of topics related to diagnosis and the 2016 WHO classification. The workshop is now co-organized by EHA and the International Society of Laboratory Hematology.

Like every year, EHA has sought the collaboration of a number of societies to bring different views and expertises to the program via the joint symposia. The following societies are contributing to the program with a joint session:

- **European Group for Bone and Marrow Transplantation (EBMT)**
60 years of allogeneic stem cell transplantation
Friday, June 23, 09:45 - 10:45
- **Hematology Society of Taiwan (HST)**
Acute myeloid leukemia
Friday, June 23, 14:30 - 15:30
- **International Society of Experimental Research (ISEH)**
Hematopoietic stem cells and their niche
Saturday, June 24, 08:30 - 09:30
- **Chinese Society of Hematology (CSH)**
Stem cell transplantation for relapsed leukemia
Saturday, June 24, 14:45 - 15:45
- **International Society of Thrombosis and Haemostasis (ISTH)**
Anticoagulation in difficult patients
Sunday, June 25, 09:30 - 10:30

HOW TO NAVIGATE THE CONGRESS PROGRAM?

1 DOWNLOAD THE EHA APP

The EHA app is your high-tech gateway to access all the content of the congress all from the palm of your hand. You can view the program by day, track or session type.

2 SELECT SESSIONS OF INTEREST BY USING THE TRACKS AND THE SESSION DESCRIPTIONS

Tracks in Hematology

The sections of the Hematology Curriculum form the basis for the 'tracks of hematology' that make navigating the congress program a bit easier. Please find below an overview of the tracks and their subdivisions:

- 1 Clinical hematology: Benign
 - 2 Clinical hematology: Myeloid malignancies
 - 3 Clinical hematology: Lymphoid malignancies and plasma cell disorders
 - 4 Clinical hematology: Stem cell transplantation and special therapy
 - 5 Laboratory diagnosis
 - 6 Thrombosis and hemostasis
 - 7 Transfusion medicine
 - 8 General skills
 - 9 Pediatric hematology
 - 10 Personalized medicine
- B** Biology
- T** Translational
- C** Clinical

SESSION DESCRIPTIONS

Below you can find descriptions of the various session types offered in the congress program.

PLENARY SESSIONS

Focus: Outstanding speakers within basic science or clinical hematology on a topic of general interest.

Format: Plenary lectures by 2 or 3 speakers and 2 chairs.

EDUCATION SESSIONS

Format: Education sessions concentrate on one topic and follow a common principle. The first speaker gives information on basic principles and mechanisms, the second speaker on translational research and the third on clinical aspects. This format has been chosen with the hope to attract both basic researchers and clinicians to the same session.

Format: 90 minutes, 3 speakers and 1 chair, sessions are repeated once.

HEMATOLOGY-IN-FOCUS

Focus: The Hematology-in-Focus sessions concentrate on a hot scientific or clinical topic in any field of hematology. These sessions are designed to look at one topic in-depth, rather than the broader overview provided in Education sessions.

Format: 60 minutes, 2 or 3 speakers and 1 chair.

BASIC-SCIENCE-IN-FOCUS

Focus: Basic-Science-in-Focus sessions zoom in on very specific topics in basic research and are intended mainly for basic and translational researchers.

Format: 60 minutes, 2 or 3 speakers and 1 chair.

MEET-THE-EXPERTS

Focus: Meet-the-Expert sessions focus on one topic in depth with an expert in the field.

Format: The session is hosted by one speaker who will discuss questions from the audience. In some cases the speaker presents a few slides to introduce the topic.

CLINICAL DEBATES

Focus: These clinical or diagnostic debates all relate to a controversial topic in the field of hematology.

Format: 60 minutes, 2 debaters and 1 chair.

EARLY CAREER SESSIONS

Focus: The Early Career Sessions address topics of interest for scientists and clinicians in the early stages of their careers.

Format: 60 minutes, 2 or 3 speakers and 1 or 2 chairs.

JOINT SYMPOSIA

Focus: The joint symposia demonstrate EHA's connections with well-known societies in- and outside of Europe. The topic of the symposium can be scientific or educational, but also political or any other aspect important to the professional and medical development of hematologists.

Format: 60 minutes, number of speakers and chairs varies.

SCIENTIFIC WORKING GROUP SESSIONS

Focus: The SWG Sessions are organized by the EHA Scientific Working Groups, which are active networks of researchers and clinicians. The sessions highlight research coming out of each working group.

Format: 60 minutes, number of speakers varies.

SIMULTANEOUS SESSIONS

Focus: The simultaneous sessions are the core of the abstract program compiled from the abstracts submitted for presentation at the congress.

Format: 75 minutes, abstract-based presentations by 5 speakers and 2 chairs.

POSTER SESSIONS

Focus: The poster session is a collection of poster walks, each poster walk includes up to 10 poster presentations selected from the abstracts submitted for presentation at the congress.

Format: 90 minutes, abstract-based posters by a maximum of 10 speakers and 1 Poster Walk moderator.

EBAH CME ACCREDITATION

Participants of the 22nd Congress of EHA are eligible to receive Continuing Medical Education (CME) Credit Points from the European Board for Accreditation in Hematology (EBAH). CME is widely accepted as a means to encourage individual practitioners to maintain and develop professional knowledge and skills. This accreditation system has been implemented as a service to hematologists in response to this need. It facilitates identification and registration of CME activities, which have been submitted to a peer-review process and respond to pre-established quality standards. Attendants of the 22nd Congress of EHA are eligible to receive one Credit Point for every hour of accredited activity.

CME Credit Points will be awarded for the scientific and educational sessions including Plenary Sessions, Education Sessions, Meet-the-Experts, Clinical Debates, Hematology-in-Focus, Basic-Science-in-Focus, EHA-ISLH Laboratory Diagnosis Workshop, Simultaneous Sessions, the workshops, EHA Scientific Working Groups Meetings and the Joint Symposia with ASH, ESH, ISEH, ISTH, EBMT, JSH, CSH and HST.

HOW TO CLAIM YOUR CREDIT POINTS

You need to have an account on the EBAH platform so the Credit Points can be added to your online CME portfolio, this is free of charge. In case you have already provided the email connected to your EBAH account upon your registration for the Congress, this will be used to add your Credit Points. If you failed to do so or do not have an account yet, you are welcome to create one, and then we kindly invite you to visit the EBAH CME booth, where staff will be happy to assist you to make sure your points are added. At the booth you can also check the status of your current EBAH account and update your contact details. A sufficient number of computers are made available to register an account with the EBAH system.

STEPS TO FOLLOW FOR YOUR CME CREDIT POINTS

- Step 1: Visit the EBAH website: www.ebah.org
- Step 2: If you have an account in this system which you already submitted upon your registration for Congress, you may log in.
In case you do not have an account yet, you may create an account by clicking "Create CME account" and let us know you did so at the EBAH CME booth.
- Step 3: Your EBAH CME Credit Points Certificate will be available in your personal account in PDF format for downloading, saving and printing.

For further assistance or more information on CME accreditation we kindly invite you to visit the EBAH booth or contact: info@ebah.org T +31 (0)70 302 00 99.



PROGRAM OVERVIEW PER DAY

	Hall A	Hall B	Hall C	Hall D	Hall E
08:00 →			MSD Anti-PD1 in Lymphomas and Multiple Myeloma P.59	prIME Oncology Navigating the Complex Waters in Relapsed/Refractory Multiple Myeloma P.59	Invivoscribe NGS-based Clinical Assessment of B- and T-Cell Clonality and MRD Determination P.60
10:00 →					
10:45 →	Celgene The evolving art of treating multiple myeloma P.62	Janssen The when, why and how of managing your CLL patients: clarity in a changing environment P.63	Novartis Recent Advances in MPNs P.63	Bristol-Myers Squibb A look ahead: the next chapter of immuno-oncology research in hematologic malignancies P.64	
12:45 →					
13:30 →		Janssen Multiple Myeloma: Changing the present, creating the future P.66	Novartis Emerging Trends in Chronic Myeloid Leukemia and Acute Myeloid Leukemia P.66	Celgene Innovation today, treatments tomorrow: tailoring treatment strategies for myeloid malignancies P.67	
15:30 →					
16:15 →			Abbvie Relapsed/refractory CLL: How far have we come, and where will we go next P.69	Celgene Shifting treatment paradigms in non-Hodgkin lymphoma P.70	Amgen Navigating the treatment continuum in multiple myeloma P.70
18:15 →					
19:00 →				AROG Pharmaceuticals Targeting the FLT-3 pathway in AML: Evolution of next generation tyrosine kinase inhibitors P.73	Global Academy for Medical Education New Horizons in the Treatment of Acute Myeloid Leukemia P.73
21:00 →					

Room N101	Room N105	Room N103	Room N104	
<p>Pfizer Targeting AML: recent advances and clinical perspectives</p> <p>P.60</p>	<p>Sanofi Genzyme The Sherlock Holmes approach to diagnosis and treatment: Thrombocytopenia in rare haematological diseases</p> <p>P.61</p>	<p>prIME Oncology Fine tuning therapeutic strategies in acute myeloid leukemia in 2017 and beyond</p> <p>P.61</p>	<p>MorphoSys AG Diffuse large b-cell lymphoma management: exploring novel treatment strategies</p> <p>P.62</p>	<p>← 08:00</p> <p>← 10:00</p>
<p>Novartis Managing safety of investigational CAR T-cell therapies in leukemias and lymphomas</p> <p>P.64</p>	<p>Takeda Oncology Continuous therapy in multiple myeloma: on target with proteasome inhibition</p> <p>P.65</p>	<p>Jazz Pharmaceuticals Raising the bar: New management and treatment in Acute Leukemias</p> <p>P.65</p>		<p>← 10:45</p> <p>← 12:45</p>
<p>Novartis Leading towards optimizing the treatment of ITP and new treatment strategies in SAA and MDS</p> <p>P.67</p>	<p>Takeda Oncology Unmet need in the management of advanced-stage hodgkin lymphoma: where do we go from here?</p> <p>P.68</p>	<p>Amgen Aiming higher in adult ALL: novel therapies and treatment strategies</p> <p>P.68</p>	<p>Gilead Defining treatment strategies for CLL and FL in the era of targeted therapies: evidence and experience</p> <p>P.69</p>	<p>← 13:30</p> <p>← 15:30</p>
<p>Gilead Expert Guides in AML: Exploring Current Challenges and Future Directions to Optimise Patient Outcomes</p> <p>P.71</p>	<p>Incyte Patients in focus: What's relevant for CML and PH+ALL?</p> <p>P.71</p>	<p>Abbvie Emerging novel agents for AML: Are we on the threshold of a transformation in therapy?</p> <p>P.72</p>	<p>Alexion Thrombosis in complement-mediated diseases</p> <p>P.72</p>	<p>← 16:15</p> <p>← 18:15</p>
<p>Pfizer GETTING PERSONAL: Individualising Therapy in CML</p> <p>P.74</p>	<p>Shire A new practical tool to help identify Gaucher disease: Accelerating diagnosis and improving long-term outcomes for patients</p> <p>P.74</p>	<p>prIME Oncology Current state-of-the-art and future strategies in acute lymphoblastic leukemia</p> <p>P.75</p>	<p>Celltrion The 1st biosimilar rituximab based on clinical evidence</p> <p>P.75</p>	<p>← 19:00</p> <p>← 21:00</p>



PROGRAM OVERVIEW PER DAY

	Hall A	Hall B	Hall C	Hall D	Hall E	Room N101	Room N105	Room N103
08:00 →								
08:30 →	Education Session Indolent lymphoma T C P.79	Education Session Myeloproliferative neoplasms T C P.79	SWG Session Novel developments in myeloma and related diseases T C P.79	Education Session Acute lymphoblastic leukemia: The worst and the best T C P.80	Education Session Stem cell transplantation - GvHD B T C P.80	Molecular Hemopoiesis Workshop B T P.81	Education Session Thrombosis B T C P.82	Education Session Hereditary hematological disorders T C P.82
09:30 →								
09:45 →	Education Session Immunotherapy lymphoma B T C P.85	Education Session Myeloproliferative neoplasms T C P.85	Education Session Chronic myeloid leukemia T C P.86	Education Session Acute lymphoblastic leukemia: The worst and the best T C P.86	EHA-EBMT Joint Symposium 60 years of allogeneic stem cell transplantation T C P.86		Education Session Bleeding disorders B T C P.87	Education Session Hereditary hematological disorders T C P.87
10:45 →								
11:15 →								
11:30 →	Simultaneous Session New advances in plasma cell disorders and implications for therapy T C P.90	Simultaneous Session Aggressive Non-Hodgkin lymphoma - 1st line C P.90	Simultaneous Session MRD directed treatment in AML B T C P.90	Simultaneous Session New insights into chronic lymphocytic leukemia biology B T P.91	Simultaneous Session Pathogenesis of MDS B T P.92	Simultaneous Session Lymphoma biology B T P.92	Simultaneous Session Thalassemia B T C P.93	Simultaneous Session AML Biology I: Towards molecular therapies B T P.93
12:45 →								
13:00 →	Opening Ceremony Research Grant Winners José Carreras Lecture P.96							
14:15 →								
14:30 →	Hematology-in-Focus News in WHO 2016 classification of hematopoietic malignancies C P.96	Clinical Debate Should low risk MDS be transplanted? C P.96	Hematology-in-Focus Waldenström's disease B T C P.96	EHA-JSH Joint Symposium Next generation sequencing B T P.97	Clinical Debate Reversal of direct oral anticoagulants (DOAC): Do we really need an antidote? C P.97	Hematology-in-Focus Leukemias with mixed phenotypes T C P.97	EHA-HST Joint Symposium Acute myeloid leukemia T C P.98	Clinical Debate Do new studies support a preferential indication of plasma-derived vs. recombinant concentrates for the treatment of new patients with severe hemophilia A? C P.98
15:30 →								
15:45 →	Presidential Symposium B T C P.100							
17:00 →								
17:15 →	POSTER SESSION I - Hall 7						Updates-in-Hematology Celgene CAR-T cell therapy: Progress and Prospects P.100	Updates-in-Hematology PeerVoice Biosimilars for Hematologic Malignancies: The Path to Sustainable Care P.101
18:45 →								

Room N104	Room N109	Room N111	Room N113	Room N115	Room N107	Room N108	Room N117	
SWG Session New insights in neutropenias B T C P.83	SWG Session Minimal residual disease in leukemia C P.83	Basic-Science-in-Focus Myeloid derived suppressor cells B T P.84	Basic-Science-in-Focus Microbiome B T C P.84	Basic-Science-in-Focus Focus on iron B P.84				← 08:00 ← 08:30
SWG Session Aging and hematology: New challenges C P.88	SWG Session Present and future of quality of life and symptom assessment in daily clinical practice in hematological malignancies C P.88	Basic-Science-in-Focus Role of NK cells in myeloid malignancies and SCT B T C P.88	Basic-Science-in-Focus Aging and hematopoiesis B T P.89	SWG Session Red cell & iron: RBC hydration defects B T C P.89				← 09:30 ← 09:45
Simultaneous Session Hematopoiesis, stem cells and microenvironment B T P.94	Simultaneous Session Gene therapy, cellular immunotherapy and vaccination 1 B T C P.95				Meet-the-Expert Approach to iron overload in MDS and after BMT C P.96	Meet-the-Expert ALL in adolescence and young adults case studies C P.96	Meet-the-Expert Amyloidois treatment C P.96	← 11:30 ← 10:45 ← 11:15
Hematology-in-Focus Chronic myelomonocytic leukemia (CMML) B T C P.98	Early Career Session EHA Fellowship and TRTH Awardees B T C P.98	Hematology-in-Focus Erythropoiesis and rare anemias T C P.99	Hematology-in-Focus How to diagnose and manage cytopenias in children and young adults? T C P.99		Meet-the-Expert Management of Von Willebrand disease C P.99	Meet-the-Expert CLL in the era in targeted therapies C P.99	Meet-the-Expert Treatment of GvHD C P.99	← 12:30 ← 12:45 ← 13:00
								← 14:15 ← 14:30
								← 15:30 ← 15:45
								← 17:00 ← 17:15
								← 18:45

Updates-in-Hematology Prothema
AL amyloidosis, don't miss it!
P.102

TRACKS		SUBDIVISIONS/TRACKS	
1 Clinical hematology: Benign	6 Thrombosis and hemostasis	B Biology	
2 Clinical hematology: Myeloid malignancies	7 Transfusion medicine	T Translational	
3 Clinical hematology: Lymphoid malignancies and plasma cell disorders	8 General skills	C Clinical	← 17:00
4 Clinical hematology: Stem cell transplantation and special therapy	9 Pediatric hematology	🎓 Early Career Hematologist	← 17:15
5 Laboratory diagnosis	10 Personalized medicine	🎓 Early Career Scientist	



PROGRAM OVERVIEW PER DAY

	Hall A	Hall B	Hall C	Hall D	Hall E	Room N101	Room N105	Room N103
08:00 →								
08:30 →	Education Session Immunotherapy in lymphoma B T C P.123	Education Session Multiple myeloma T C P.123	SWG Session Lymphomas: Diagnosis and follow-up of lymphoma T C P.123	Education Session Chronic myeloid leukemia T C P.124	EHA-ISLH Laboratory Diagnosis Workshop B T C P.124	Education Session Stem cell transplantation - GVHD B T C P.125	Basic-Science-in-Focus Genomics and epigenomics of CLL B T P.126	SWG Session MDS and the role of the immune system in pathophysiology and therapy T C P.126
09:30 →								
09:45 →								
10:15 →	Education Session Indolent lymphoma T C P.128	Education Session Chronic lymphocytic leukemia B T C P.128	Education Session Acute myeloid leukemia T C P.129	EHA-ASH Joint Symposium The future of genome editing for hematology/CRISPR B T C P.129	EHA-ISLH Laboratory Diagnosis Workshop B T C P.124	Education Session Fertility preservation in patients with hematological malignancies T C P.130	SWG Session Adult ALL first line therapy: Major results and future approaches of national ALL study groups C P.130	SWG Session Mantle cell lymphoma: The PROs and CONs in the treatment of MCL patients C P.130
10:45 →								
11:15 →								
11:30 →	Simultaneous Session Front-line combinations in multiple myeloma and amyloidosis C P.133	Simultaneous Session Hodgkin and indolent lymphoma - Clinical C P.133	Simultaneous Session Biology of MPN: JAK2 and beyond B T P.133	Simultaneous Session Clinical trials including treatment discontinuation in CML C P.134	Simultaneous Session AML Biology II: Epigenetic targets B T P.134	Simultaneous Session Acquired and inherited platelet disorders T C P.135	Simultaneous Session Acute lymphoblastic leukemia - Biology B T P.136	Simultaneous Session Thrombotic disorders T C P.136
12:45 →								
13:15 →	Jean Bernard Lifetime Achievement Award B T P.138							
13:30 →	Plenary Session 1 B T P.138							
14:30 →								
14:45 →	Clinical Debate News in WHO 2016 Treatment should be started in every patient with high risk smoldering multiple myeloma C P.138	Hematology-in-Focus Richter transformation in CLL T C P.138	Hematology-in-Focus Rare lymphoma subtypes C P.138	Hematology-in-Focus New strategies in cellular therapy to prevent relapse of acute leukemia B T C P.139	Clinical Debate All children with sickle cell anemia and an HLA identical sibling should be offered hematopoietic stem cell transplantation C P.139	Hematology-in-Focus Novel approaches for treatment of hemophilia C P.139	Hematology-in-Focus Pediatric hematology: New drugs for children C P.139	EHA-CSH Joint Symposium Stem cell transplantation for relapsed leukemia C P.140
15:45 →								
16:00 →	Simultaneous Session New drugs for rescue in relapsed/refractory multiple myeloma T C P.141	Simultaneous Session Improving prognostication and front-line therapy in chronic lymphocytic leukemia T C P.142	Simultaneous Session Aggressive Non-Hodgkin lymphoma-Relapsed/refractory C P.142	Simultaneous Session Targeted treatment of AML T C P.142	Simultaneous Session Immunotherapy in ALL T C P.143	Simultaneous Session Biology and disease monitoring in CML T C P.143	Simultaneous Session Prognostic markers and new treatment in MDS T C P.144	Simultaneous Session Stem cell transplantation - Clinical 1 C P.144
17:15 →								
17:30 →	POSTER SESSION II - Hall 7						Updates-in-Hematology Pfizer Broadening our horizons in relapsed/refractory ALL P.146	
19:00 →								

Room N104	Room N109	Room N111	Room N113	Room N115	Room N107	Room N108	Room N117	
EHA-ISEH Joint Symposium Hematopoietic stem cells and their niche B P.126	Education Session Update on hemoglobinopathies B T C P.127	Education Session Bleeding disorders B T C P.127	SWG Session Treatment of difficult to treat thrombocytopenias C P.127	Patient Advocacy Session Innovative clinical trial designs, adaptive pathways (MAPPs) and patient involvement in R&D C P.128				← 08:00 ← 08:30
								← 09:30
SWG Session New tools for MPN patients management C P.131	Education Session Update on hemoglobinopathies B T C P.131	Education Session Thrombosis B T C P.132	SWG Session Stem cells: Metabolic regulation of stem cell B T P.132	SWG Session Mesenchymal stem cells: The immunology of tissue repair B T P.132				← 09:45
								← 10:45 ← 11:15
Simultaneous Session Stem cell transplantation - Experimental B T C P.136	Simultaneous Session Sickle cell disease, enzymes B T P.137			Patient Advocacy Session Pregnancy during and after treatment: Myths and reality C P.137	Meet-the-Expert How I treat elderly AML C P.138	Meet-the-Expert Aplastic anemia or MDS in a child - How to distinguish? C P.138	Meet-the-Expert Treatment of advanced systemic mastocytosis C P.138	← 11:30 ← 12:30 ← 12:45 ← 13:15
								← 14:30 ← 14:45
	EHA-ESH Joint Symposium Doctor-patient communication regarding bad news and future prospects C P.140	Early Career Session Biologic, translational and clinical hematology: What is beyond? B T C P.140		EU Funded Projects in Hematology HARMONY P.141	Meet-the-Expert Stop of TKI in CML C P.141	Meet-the-Expert Eosinophilia C P.141	Meet-the-Expert How I plan and run a hospital patient blood management programme? C P.141	← 15:45
								← 16:00
Simultaneous Session Bone marrow failure and PNH B T C P.144	Simultaneous Session Quality of life, palliative care, ethics and health economics C P.145	Early Career Session Bite-size CRTH C P.145	Early Career Session Bite-size TRTH T P.146	EHA Advocacy Session New drugs in hematology: Fair pricing & access C P.146				← 17:15

TRACKS		SUBDIVISIONS/TRACKS	
1	Clinical hematology: Benign	6	Thrombosis and hemostasis
2	Clinical hematology: Myeloid malignancies	7	Transfusion medicine
3	Clinical hematology: Lymphoid malignancies and plasma cell disorders	8	General skills
4	Clinical hematology: Stem cell transplantation and special therapy	9	Pediatric hematology
5	Laboratory diagnosis	10	Personalized medicine
B	Biology	B	Biology
T	Translational	T	Translational
C	Clinical	C	Clinical
	Early Career Hematologist		Early Career Hematologist
	Early Career Scientist		Early Career Scientist



PROGRAM OVERVIEW PER DAY

	Hall A	Hall C	Hall D	Hall E	Room N101	Room N105
08:00 →	Simultaneous Session Targeted therapies in relapsed in chronic lymphocytic leukemia	Simultaneous Session Follicular lymphoma - Clinical	Simultaneous Session Changing the strategy of therapy in multiple myeloma	Simultaneous Session Old and new drugs in MPN	Simultaneous Session Childhood and more intensive treatment of AML	Simultaneous Session Stem cell transplantation - Clinical 2
09:15 →	T C P.167	C P.167	C P.167	T C P.168	T C P.168	C P.169
09:30 →	Education Session Chronic lymphocytic leukemia	Education Session Aggressive lymphoma	SWG Session ELN-EHA-SWG on CML	Education Session Myelodysplastic syndromes	Education Session Acute myeloid leukemia	EHA-ISTH Joint Symposium Anticoagulation in difficult patients
10:30 →	B T C P.171	B T C P.171	B T C P.172	B T C P.172	T C P.173	T C P.173
11:00 →						
11:15 →	Late Breaking Oral Session	Education Session Aggressive lymphoma	Education Session Multiple myeloma	Education Session Myelodysplastic syndromes	Education Session Fertility preservation in patients with hematological malignancies	SWG Session A roadmap for CLL treatment: What to choose and why
11:45 →		B T C P.176	T C P.176	B T C P.176	T C P.177	C P.177
12:45 →	P.175					
13:00 →	Plenary Session 2					
14:30 →	B T C P.180					
14:30 →	Business Meeting					
15:00 →	P.180					

Room N103	Room N104	Room N109	Room N111	Room N113	Room N115	
Simultaneous Session Biomarkers in ALL B T C P.169	Simultaneous Session Infectious diseases, supportive care C P.170	Simultaneous Session Iron: Deficiency and overload B T C P.170	Simultaneous Session Gene therapy, cellular immunotherapy and vaccination 2 B T P.170			← 08:00
						← 09:15
Basic-Science-in-Focus Hematopoietic stem cells and the microenvironment B T P.173	Basic-Science-in-Focus Vaccines & antibodies B T C P.174	Education Session Blood transfusion B T C P.174	Education Session Acquired problems in red cells B T C P.174	SWG Session EuroFlow: High throughput flowcytometry in Hemato-Oncology C P.175	Basic-Science-in-Focus Metabolomics and leukemia B T P.175	← 09:30 ← 10:30 ← 11:00
						← 11:15 ← 11:45
SWG Session Acute myeloid leukemia B T C P.178	SWG Session Bleeding and thrombosis: Acquired bleeding disorder emergencies C P.178	Education Session Blood transfusion B T C P.178	Education Session Acquired problems in red cells B T C P.179	Basic-Science-in-Focus Methylation and epigenetics B T P.179	Basic-Science-in-Focus Mouse models of acute leukemia B T P.179	← 12:45 ← 13:00

TRACKS

- | | |
|---|------------------------------------|
| 1 Clinical hematology: Benign | 6 Thrombosis and hemostasis |
| 2 Clinical hematology: Myeloid malignancies | 7 Transfusion medicine |
| 3 Clinical hematology: Lymphoid malignancies and plasma cell disorders | 8 General skills |
| 4 Clinical hematology: Stem cell transplantation and special therapy | 9 Pediatric hematology |
| 5 Laboratory diagnosis | 10 Personalized medicine |

SUBDIVISIONS/TRACKS

- | |
|---------------------------|
| B Biology |
| T Translational |
| C Clinical |
| Early Career Hematologist |
| Early Career Scientist |



VISIT EHA'S ADVOCACY TRACK!

EHA's advocacy track puts the spotlight on high-impact patient and policy issues.

Two of the advocacy track's main sessions are organized by patient advocates. The first Patient Advocacy Session will focus on the cumulative impact of new clinical trial designs, the EMA's new 'Adaptive Pathways' (MAPPS) licensing scheme and the new EU Clinical Trials Regulation. What opportunities do they offer to patients and clinicians? Will they help accelerate research and access to new therapies in areas of high unmet medical need, without compromising the gathering of solid evidence?

The second Patient Advocacy Session will focus on fertility and pregnancy during and after treatment, a major concern for many cancer patients. The speakers will discuss existing hurdles and potential approaches and address some persisting myths about what is and should be possible or even allowed, from various viewpoints – patient, clinical, research, legal and bioethical.

The third major element of this track is the EHA Advocacy Session, which will highlight an issue of great importance to hematologists and patients: the pricing of innovative medicines. At a time when rising prices increasingly threaten the availability and affordability of innovative pharmaceutical care, there is an urgent need for a new, more transparent economic model that will deliver innovative medicines at fair prices. Speakers will present the economic, public health and patient perspectives, followed by discussion with an industry panel.

EARLY CAREER TRACK

As a young researcher or hematologist, it's important to enlarge your network and to stay up-to-date in order to enrich your professional life.

Sessions that are marked 'Early Career' will help you accomplish these goals.

Talk to recipients and reviewers of EHA Career Development programs to learn how to apply successfully at the Early Career Reception on Thursday, June 22, 18:00.

Learn the interesting results from research supported by EHA Research Grants at the Early Career session on Friday, June 23, 14:30 – 15:30.

Get a head start on becoming an independent researcher in clinical or translational research at the mini-CRTH or mini-TRTH sessions on Saturday, June 24, 16:00 – 17:15.

Get Groovy with EHA on Saturday, June 24, 19:30.

Learn which EHA programs will help your professional development at the EHA Booth

INSIDER TIPS ON NAVIGATING THE CONGRESS PROGRAM

To successfully approach the massive conference program of the 22nd Congress, it is certainly good to get a first feeling for the different session types: What is offered, and how can I get the best balance out of everything? Regardless of whether you are an early career hematologist at the beginning of your clinical training, or a basic scientist, some of the sessions are a "must see" for every attendee. These include the "Big 3" (the Presidential Symposium on Friday featuring the highest scoring abstracts, the Plenary Sessions on Saturday and Sunday, and the block of Late breaking Abstracts on Sunday morning), the two consecutive blocks of Education sessions at the start of every day, and of course the oral and poster sessions of the presented abstracts. The latter are not only important from a scientific perspective, but even more for the goal of a successful EHA attendance: meeting people and exchanging ideas in an open, collaborative environment. In addition, this year features a new exciting addition to the program: The Early Career sessions on Saturday afternoon. While the first session is lead by "rising stars" of hematology who are presenting their research, the second and third sessions provide insights into the EHA-ASH TRTH and CRTH classes.

In addition to those sessions which are of interest for all early career hematologists, there are several program items which may be more important for either clinicians or others with a more basic science focus. As a clinician, the Hematology-in-Focus and Meet-the-Expert sessions contain a multitude of exciting presentations and make it hard to choose what to attend. The Meet-the-Expert session on clinical trial design may be of special importance for clinicians who are already more advanced in their clinical training. The SWG sessions at the start of every day provide a great overview of broad topics, and are also highly recommended.

For early career translational researchers and PhDs, Sessions in the morning on Friday, Saturday and Sunday should be considered: The Basic Science-in-Focus sessions on Saturday and Sunday, as well as some of the SWG sessions and the EHA-ASH symposium provide great insight into advancing topics with high yield.

For certain patients with chronic ITP and other cytopenias

MAKE REVOLADE (eltrombopag) YOUR FIRST CHOICE¹



Step inside Booth #940 at the 22nd Congress of the European Hematology Association to learn more



Paediatric
Chronic ITP



Adult
Chronic ITP



Severe Aplastic
Anaemia



Chronic Hepatitis C
Virus-Associated
Thrombocytopenia

REVOLADE (eltrombopag) is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year and above who are refractory to other treatments (e.g. corticosteroids, immunoglobulins); in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation; and in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.^{1*}

*The information on indication has been abbreviated and reworded compared with the SmPC.

Reference: 1. REVOLADE Summary of Product Characteristics. November 2016.

Please see Important Safety Information for REVOLADE in the back of the publication.

 **NOVARTIS**

Novartis Pharma AG
CH-4002 Basel Switzerland

© Novartis 2017

April 2017

G-REV-1160583

Once daily oral therapy
REVOLADE™
(eltrombopag olamine)

IMPORTANT SAFETY INFORMATION

REVOLADE® / PROMACTA™

Important note: Before prescribing, consult full prescribing information.

Presentation: • Film-coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg, or 100 mg of eltrombopag free acid. • Powder for oral suspension containing eltrombopag olamine equivalent to 25 mg of eltrombopag free acid per sachet.

Indications: • Eltrombopag is indicated for the treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura (ITP) to increase platelet counts and reduce or prevent bleeding. • Eltrombopag is indicated in patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia to enable the initiation of interferon based therapy/ to optimize interferon based therapy. • Eltrombopag is indicated for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy.

Dosage and administration: • Dosing regimens must be individualized based on the patient's platelet counts. • Dose regimen: Starting dose between 25 to 50 mg once daily. Monitoring and individual dose adjustment. Maintenance doses with maximum daily doses between 75 to 150 mg depending on patient population and indication.

Special populations: • Pediatric age group: safety and efficacy not established in patients with chronic HCV or SAA. • Elderly: No clinically significant differences in safety. • Renal impairment: Caution and close monitoring recommended. • Hepatic impairment: Caution and close monitoring, starting dose 25 mg once daily.

Contraindications: • None.

Warnings and precautions: • Hepatotoxicity: Eltrombopag administration can cause hepatobiliary laboratory abnormalities, severe hepatotoxicity and potentially fatal liver injury. • Hepatic decompensation (use with interferon): Chronic HCV patients with cirrhosis may be at risk for hepatic decompensation, some with fatal outcomes, when receiving alpha interferon therapy. Close monitoring for signs and symptoms of hepatic decompensation. • Thrombotic/thromboembolic complications: Use with caution in patients with known risk factors for thromboembolism. Monitoring of platelet counts and potentially dose reduction or discontinuation. • Increased risk for bleeding after discontinuation of treatment. Monitoring weekly for 4 weeks following discontinuation. • Risk for malignancies and progression of malignancies. • Patient with cataracts: Routine monitoring.

Women of child-bearing potential, pregnancy: • Should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.

Breast-feeding: • Not recommended unless the expected benefit justifies the potential risk to the infant.

Adverse drug reactions (by highest reporting frequency):

ITP study population: • **Very common (≥10%):** Nausea, diarrhoea. • **Common (1 to 10%):** Pharyngitis, urinary tract infection, dry mouth, vomiting, increased aspartate aminotransferase, increased alanine aminotransferase, alopecia, rash, back pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, cataract.

Uncommon (0.1 to 1%): Drug-induced liver injury.

ITP pediatric study population (1 to 17 years of age) – Additional ADRs: • **Very common (≥10%):** Nasopharyngitis, upper respiratory tract infection. • **Common (1 to 10%):** Rhinitis, abdominal pain, toothache, cough, oropharyngeal pain, rhinorrhoea, pyrexia.

HCV study population: • **Very common (≥10%):** Anaemia, decreased appetite, insomnia, headache, cough, nausea, diarrhoea, pruritus, alopecia, myalgia, fatigue, pyrexia, chills, asthenia, oedema peripheral, influenza like illness. • **Common (1 to 10%):** Hyperbilirubinaemia, drug-induced liver injury, rash, cataract.

SAA study population: • **Very common (≥10%):** Headache, cough, dyspnoea, oropharyngeal pain, rhinorrhoea, abdominal pain, diarrhoea, nausea, transaminases increased, ecchymosis, arthralgia, muscle spasms, pain in extremity, dizziness, fatigue, febrile neutropenia, pyrexia. • **Common (1 to 10%):** Rash, cataract.

Adverse reaction from spontaneous reports: Rare (0.01 to 0.1%): Thrombotic microangiopathy with acute renal failure. • **Not known:** skin discolouration.

For a complete list of ADRs, consult full prescribing information.

Interactions: • Rosuvastatin: Dose reduction and monitoring. Other OATP1B1 and BCRP substrates to be used with caution. • Cyclosporine (BCRP inhibitor): monitoring weekly for 2 to 3 weeks, eltrombopag dose may need to be increased. • Polyvalent cations (chelation): staggered administration. • Food interactions. • Lopinavir/ritonavir: Caution and monitoring of platelet count weekly for 2 to 3 weeks.

Packs and prices: Country-specific.

Legal classification: Country-specific.

THURSDAY, JUNE 22



SPECIAL SESSIONS OF THE DAY

We would like to draw your attention to the following sessions:

SATELLITE SYMPOSIA →

Page 59 - Page 75

EXHIBITION

DON'T FORGET TO VISIT THE EXHIBITION IN HALL 7

The exhibition will be open on the following days
and times:

Thursday, June 22	09:00-16:30
Friday, June 23	09:00-16:30
Saturday, June 24	09:00-16:30
Sunday, June 25	09:00-13:30



→ SATELLITE SYMPOSIUM

08:00 – 10:00, Hall C

ANTI-PD1 IN LYMPHOMAS AND MULTIPLE MYELOMA

Chair: PL Zinzani, Bologna University, Department of Hematology,
A.O.U. Policlinico Sant'Orsola Malpighi, Italy

PROGRAM

- **Introduction and welcome**
PL Zinzani, Bologna University, Department of Hematology,
A.O.U. Policlinico Sant'Orsola Malpighi, Italy
- **Understanding the Rationale For Immunotherapy in Hematologic Malignancies**
PL Zinzani, Bologna University, Department of Hematology,
A.O.U. Policlinico Sant'Orsola Malpighi, Italy
- **Clinical Updates for Hodgkin Lymphoma**
R Chen, Department of Hematology & Hematopoietic Cell
Transplantation, City of Hope, Duarte, CA, United States
- **Q&A**
Faculty
- **Pursuing Immunotherapy in Non-Hodgkin Lymphoma**
S Neelapu, Department of Lymphoma/Myeloma, Division of
Cancer Medicine, The University of Texas MD Anderson Cancer
Center, Houston, TX, United States
- **Navigating the Multiple Myeloma Landscape**
SZ Usmani, Levine Cancer Institute/Carolinas Healthcare System,
Charlotte, NC, United States
- **Q&A / Closing Remarks**
Faculty
PL Zinzani, Bologna University, Department of Hematology,
A.O.U. Policlinico Sant'Orsola Malpighi, Italy



→ SATELLITE SYMPOSIUM

08:00 - 10:00, Hall D

This independent educational activity is industry supported.

**NAVIGATING THE COMPLEX WATERS IN RELAPSED/
REFRACTORY MULTIPLE MYELOMA**

Chair: M Dimopoulos, University of Athens, Athens, Greece

PROGRAM

- **Welcome, introduction, and pop quiz**
M Dimopoulos, University of Athens, Athens, Greece
- **Looking back to shore: How did we get to relapsed/refractory (RR) multiple myeloma (MM)?**
P Moreau, University of Nantes, Nantes, France
- **Wind in our sails: Next generation therapeutic options in R/R MM**
M Dimopoulos, University of Athens, Athens, Greece
- **What's on the near horizon? New targets in R/R MM**
S Lonial, Emory University, Atlanta, United States
- **Avoiding treacherous waters: Balancing efficacy with adversity**
E Ocio, University of Salamanca, Salamanca, Spain
- **Conclusion and key points**
M Dimopoulos, University of Athens, Athens, Greece



→ SATELLITE SYMPOSIUM

08:00 - 10:00, Hall E

NGS-BASED CLINICAL ASSESSMENT OF B- AND T-CELL CLONALITY AND MRD DETERMINATION

Chair: M Arcila, Memorial Sloan Kettering Cancer Center, Molecular Diagnostic Service, New York, United States

PROGRAM

- **Minimal Residual Disease in Multiple Myeloma by NGS: A Comparison with Flow Cytometry and ASO-PCR**
R Garcia Sanz, University Hospital of Salamanca, Hematology Department, Salamanca, Spain
- **IGHV Somatic Hypermutation Analysis by NGS in CLL Routine Diagnostics**
R Bomben, Oncology Reference Center (CRO) Aviano - Clinical and Experimental Onco-Hematology Unit, Aviano, Italy
- **Minimal Residual Disease Detection of Lymphoid and Plasma Cell Neoplasms Using a Next-Generation Sequencing (NGS)-Based Assay**
M Arcila, Memorial Sloan Kettering Cancer Center, Molecular Diagnostic Service, New York, United States
- **Deep sequencing reveals clinically relevant subclonal IGHV rearrangements in CLL**
B. Stamatopoulos, University of Brussels (ULB), Laboratory of Clinical Cell Therapy, Brussels, Belgium



→ SATELLITE SYMPOSIUM

08:00 - 10:00, Room N101

TARGETING AML: RECENT ADVANCES AND CLINICAL PERSPECTIVES

Chair: O Ottmann, Cardiff University, Cardiff, United Kingdom

PROGRAM

- **Welcome and introduction**
O Ottmann, Cardiff University, Cardiff, United Kingdom
- **Advances in the molecular characterisation of AML**
P Paschka, University Hospital Ulm, Ulm Germany
- **Challenges and emerging opportunities for elderly unfit patients with AML**
J Cortes, Md Anderson cancer center, Houston, United States
- **Innovative therapeutic approaches for fit patients with AML**
O Ottmann, Cardiff University, Cardiff, United Kingdom
- **Debate: The relevance of MRD in AML clinical practice - For MRD**
A Venditti, University of Rome tor Vergata, Rome, Italy
- **Debate: The relevance of MRD in AML clinical practice - Against MRD**
R Schlenk, National Center for Tumor Diseases, Heidelberg, Germany
- **Closing remarks**
O Ottmann, Cardiff University, Cardiff, United Kingdom



→ SATELLITE SYMPOSIUM

08:00 - 10:00, Room N105

THE SHERLOCK HOLMES APPROACH TO DIAGNOSIS AND TREATMENT: THROMBOCYTOPENIA IN RARE HAEMATOLOGICAL DISEASES

Chair: MD Cappellini, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

PROGRAM

- **Welcome and introduction**
MD Cappellini, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- **Holmes unmasks an accidental villain**
M Machaczka, Karolinska University Hospital Huddinge, Stockholm, Sweden
- **Watson is lured by a seductive melody**
G Massenkeil, Klinikum Gütersloh gGmbH, Gütersloh, Germany
- **The curious case of Ludwig the tailor**
J Villarubia, Hospital Universitario Ramón y Cajal, Madrid, Spain
- **Holmes and Watson are baffled by a blinding blizzard**
M Machaczka, Karolinska University Hospital Huddinge, Stockholm, Sweden
- **Holmes turns as white as a ghost**
G Massenkeil, Klinikum Gütersloh gGmbH, Gütersloh, Germany
- **Suspicious circumstances make trouble for Holmes**
J Villarubia, Hospital Universitario Ramón y Cajal, Madrid, Spain
- **Concluding remarks**
MD Cappellini, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy



→ SATELLITE SYMPOSIUM

08:00 - 10:00, Room N103

This educational activity is supported by a grant from Celgene and Helsinn Healthcare SA.

FINE TUNING THERAPEUTIC STRATEGIES IN ACUTE MYELOID LEUKEMIA IN 2017 AND BEYOND

Chair: M Sanz, Valencia University Medical School, University Hospital La Fe, Valencia, Spain

PROGRAM

- **Welcome, introduction, and quiz questions**
M Sanz, Valencia University Medical School, University Hospital La Fe, Valencia, Spain
- **Examining genetics and genomics in acute myeloid leukemia (AML) in 2017**
E Papaemmanuil, Memorial Sloan Kettering Cancer Center, New York, United States
- **Personalizing initial therapy in AML**
F Lo Coco, University Tor Vergata Rome, Italy
- **What's on the horizon for relapsed/refractory AML?**
L Pleyer, Salzberg Cancer Research Institute, Salzburg, Germany
- **A deeper dive into AML subgroups**
M Sanz, Valencia University Medical School, University Hospital La Fe, Valencia, Spain
- **Key points**
M Sanz, Valencia University Medical School, University Hospital La Fe, Valencia, Spain



→ SATELLITE SYMPOSIUM

08:00 - 10:00, Room N104

**DIFFUSE LARGE B-CELL LYMPHOMA MANAGEMENT:
EXPLORING NOVEL TREATMENT STRATEGIES**

Chair: B Coiffier, Centre Hospitalier Lyon Sud, Pierre-Benite, France

PROGRAM

- **Welcome and Introduction**
B Coiffier, Centre Hospitalier Lyon Sud, Pierre-Benite, France
- **DLBCL upfront treatments – What have we learned from recent trials**
G Nowakowski, Mayo Clinic, Rochester, United States
- **Progressive disease - Treatment standards and goals**
G Hess, Johannes Gutenberg University, Mainz, Germany
- **Changing treatment landscape in R/R DLBCL – Novel targets and new strategies**
W Jurczak, Jagiellonian University, Krakow, Poland



→ SATELLITE SYMPOSIUM

10:45 - 12:45, Hall A

THE EVOLVING ART OF TREATING MULTIPLE MYELOMA

Chair 1: M Attal, L'Université Toulouse Capitole, Toulouse, France

Chair 2: F Davies, UAMS Myeloma Institute, Little Rock, United States

PROGRAM

- **Welcome and introduction**
M Attal, L'Université Toulouse Capitole, Toulouse, France
F Davies, UAMS Myeloma Institute, Little Rock, United States
- **Depicting the nature of long remissions**
B Paiva, Universidad de Navarra, Pamplona, Spain
- **The renaissance of maintenance after transplant**
M Attal, L'Université Toulouse Capitole, Toulouse, France
- **The modern art of treating patients when transplant is not an option**
G Jackson, Newcastle University, Newcastle, United Kingdom
- **"But is it art?" A post-modern approach to managing relapse**
F Davies, UAMS Myeloma Institute, Little Rock, United States
- **Closing remarks**
M Attal, L'Université Toulouse Capitole, Toulouse, France
F Davies, UAMS Myeloma Institute, Little Rock, United States



→ SATELLITE SYMPOSIUM

10:45 - 12:45, Hall B

THE WHEN, WHY AND HOW OF MANAGING YOUR CLL PATIENTS: CLARITY IN A CHANGING ENVIRONMENT

Chair: F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain

PROGRAM

- **Welcome & Introduction**

F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain

- **Patient assessment: Optimising the stratification of patients with CLL**

P Ghia, Università Vita-Salute San Raffaele, Milano, Italy

- **Optimizing outcomes: Options for previously untreated CLL**

S Coutre, Stanford University School of Medicine, Stanford, CA, United States

- **Optimizing outcomes: Selecting our strategy for patients with relapsed CLL**

P Hillmen, St James's University Hospital, Leeds, United Kingdom

- **Practical management considerations in the era of novel agents**

G Follows, Cambridge University Hospital NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom

- **Summary and Close**

F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain



→ SATELLITE SYMPOSIUM

10:45 - 12:45, Hall C

RECENT ADVANCES IN MPNS

Chair: F Cervantes, Hospital Clínic IDIBAPS, Barcelona, Spain

PROGRAM

- **Welcome**

F Cervantes, Hospital Clínic IDIBAPS, Barcelona, Spain

- **Recent Updates in the Diagnosis and Prognosis of MPNs**

H Kvasnicka, Senckenberg Institute of Pathology, University of Frankfurt, Frankfurt, Germany

- **Current Treatment Landscape in Myelofibrosis**

F Passamonti, University of Insubria, Varese, Italy

- **Recent Updates in the Treatment of Polycythemia Vera**

S Verstovsek, The University of Texas MD Anderson Cancer Center, Houston, United States

- **JAK Inhibitors in the Transplant Setting**

P Laneuville, McGill University Health Centre and Research Institute, Montreal, Canada

- **Summary and Q&A**

F Cervantes, Hospital Clínic IDIBAPS, Barcelona, Spain

- **Closing Remarks**

F Cervantes, Hospital Clínic IDIBAPS, Barcelona, Spain



Bristol-Myers Squibb

→ SATELLITE SYMPOSIUM

10:45 - 12:45, Hall D

A LOOK AHEAD: THE NEXT CHAPTER OF IMMUNO-ONCOLOGY RESEARCH IN HEMATOLOGIC MALIGNANCIES

Chair: I Borrello, Johns Hopkins School of Medicine, Baltimore, Maryland, United States

PROGRAM

- **Welcoming Remarks**
I Borrello, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
- **Behind the Science: A Primer on Immuno-Oncology in Hematology**
I Borrello, Johns Hopkins School of Medicine, Baltimore, Maryland, United States
- **Current Perspectives and Future Possibilities of Immuno-Oncology in Multiple Myeloma**
N Van De Donk, VU University Medical Center, Amsterdam, the Netherlands
- **Immuno-Oncology as a Treatment Option for Lymphoma**
P Borchmann, University Hospital of Cologne, Cologne, Germany
- **Making Headway with Immuno-Oncology Research in Acute Myeloid Leukemia**
N Daver, MD Anderson Cancer Center, Houston, Texas, United States
- **Open Discussion with the Experts and Closing Remarks**
I Borrello, Johns Hopkins School of Medicine, Baltimore, MD, United States



NOVARTIS

→ SATELLITE SYMPOSIUM

10:45 - 12:45, Room N101

MANAGING SAFETY OF INVESTIGATIONAL CAR T-CELL THERAPIES IN LEUKEMIAS AND LYMPHOMAS

Chair: U Jäger, Medical University of Vienna, Vienna, Austria

PROGRAM

- **Opening remarks**
U Jäger, Medical University of Vienna, Vienna, Austria
- **Safety and efficacy of anti-CD19 therapies: Acute lymphoblastic leukemia**
S Rives, Hospital Sant Joan de Déu, Madrid, Spain
- **Safety and efficacy of anti-CD19 therapies: Non-Hodgkin lymphoma**
P Corradini, University of Milano, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- **Differences in safety management algorithms**
S Maude, Children's Hospital of Philadelphia, Philadelphia, United States
- **Biomarkers for the prediction of safety profiles**
S Maude, Children's Hospital of Philadelphia, Philadelphia, United States
- **Long term patient management after investigational CAR therapy**
U Jäger, Medical University of Vienna, Vienna, Austria
- **Panel discussion**
- **Closing remarks**
U Jäger, Medical University of Vienna, Vienna, Austria



→ SATELLITE SYMPOSIUM
10:45 - 12:45, Room N105

CONTINUOUS THERAPY IN MULTIPLE MYELOMA: ON TARGET WITH PROTEASOME INHIBITION

Chair: P Richardson, Dana-Farber Cancer Institute, Boston, MA, United States

PROGRAM

- **Chair's Welcome and Introduction**
P Richardson, Dana-Farber Cancer Institute, Boston, MA, United States
- **Targeting the plasma cell: rationale for proteasome inhibition in multiple myeloma**
S Lonial, Winship Cancer Institute, Atlanta, GA, United States
- **Continuous therapy as a treatment paradigm**
E Terpos, University of Athens School of Medicine, Athens, Greece
- **TOURMALINE-MM1: the role of ixazomib in relapsed/refractory multiple myeloma**
P Moreau, University Hospital Hôtel Dieu, Nantes, France
- **Clinical decision making in relapsed/refractory multiple myeloma**
P Richardson, Dana-Farber Cancer Institute, Boston, MA, United States
- **Panel discussion and Q&A**
All
- **Summary and close**
P Richardson, Dana-Farber Cancer Institute, Boston, MA, United States



→ SATELLITE SYMPOSIUM
10:45 - 12:45, Room N103

RAISING THE BAR: NEW MANAGEMENT AND TREATMENT IN ACUTE LEUKEMIAS

Chair: H Döhner, University Hospital Ulm, Ulm, Germany

PROGRAM

- **Welcome**
H Döhner, University Hospital Ulm, Ulm, Germany
- **The latest movement: What's new in the management and treatment of Acute Lymphoblastic Leukemia?**
N Boissel, Assistance Publique – Hôpitaux de Paris, France
- **New players in the treatment of Acute Myeloid Leukemia: Are we improving treatment?**
N Russell, University of Nottingham, Nottingham, United Kingdom
- **Setting the tone: Managing challenging patients with Acute Myeloid Leukemia – case study overview**
G Roboz, Weill Medical College of Cornell University, New York, United States
H Döhner, University Hospital Ulm, Ulm, Germany
- **Close**
H Döhner, University Hospital Ulm, Ulm, Germany



→ SATELLITE SYMPOSIUM

13:30 - 15:30, Hall B

MULTIPLE MYELOMA: CHANGING THE PRESENT, CREATING THE FUTURE

Chair 1: P Moreau, University Hospital of Nantes, Nantes, France

Chair 2: X De La Rubia, University Hospital Doctor Peset, Valencia, Spain

PROGRAM

- **Welcome & Introduction**
X De La Rubia, University Hospital Doctor Peset, Valencia, Spain
- **Current considerations for transplant eligible patients and possible impact of immunotherapy in patient management**
M Cavo, University School of Medicine, Bologna, Italy
- **Current and future considerations for transplant ineligible newly-diagnosed myeloma**
S Zweegman, VU University Medical Center, Amsterdam, the Netherlands
- **A revolution in therapy for patients with relapsed refractory MM ? A focus on CD38 monoclonal antibodies**
M Dimopoulos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
- **When advancements in science meet patients**
A Aguarón, Madrid, Spain
- **Translating evidence into tomorrow's practice**
P Moreau, University Hospital of Nantes, Nantes, France



→ SATELLITE SYMPOSIUM

13:30 - 15:30, Hall C

EMERGING TRENDS IN CHRONIC MYELOID LEUKEMIA AND ACUTE MYELOID LEUKEMIA

Chair 1: H Döhner, Universitätsklinikum Ulm, Ulm, Germany

Chair 2: G Saglio, University of Turin, Orbassano, Italy

PROGRAM

- **Welcome and Opening Remarks**
G Saglio, University of Turin, Orbassano, Italy
- **TFR and the Future of CML Treatment**
G Saglio, University of Turin, Orbassano, Italy
- **Molecular Monitoring in the Setting of Deep Molecular Response and TFR**
S Branford, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia
- **From Diagnosis to Remission: The Patient Journey**
R Christensen, Lyle – Patientorganization for lymphoma, leukemia and MDS, Zealand, Denmark
- **CML Panel Discussion & Audience Questions**
G Saglio, University of Turin, Orbassano, Italy
- **Current Recommendations for Genetic Testing in AML**
H Döhner, Universitätsklinikum Ulm, Ulm, Germany
- **The Role of Genomics and Identifying Co-Mutations in Predicting Outcomes in AML**
E Papaemmanuil, Memorial Sloan Kettering Cancer Center, New York, United States
- **AML Panel Discussion & Audience Questions**
H Döhner, Universitätsklinikum Ulm, Ulm, Germany
- **Closing Remarks**
H Döhner, Universitätsklinikum Ulm, Ulm, Germany



→ SATELLITE SYMPOSIUM

13:30 - 15:30, Hall D

This scientific symposium has been organised and funded by Celgene

INNOVATION TODAY, TREATMENTS TOMORROW: TAILORING TREATMENT STRATEGIES FOR MYELOID MALIGNANCIES

Chair: G Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain

PROGRAM

- Welcome and introduction

G Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain

- A genomic portrait of lower-risk MDS by the European MDS Registry

A de Graaf, Radboud University Medical Centre, Nijmegen, the Netherlands

- Linking progress in our understanding of MDS to an innovative treatment approach

A Giagounidis, Marien Hospital Düsseldorf, Düsseldorf, Germany

- Can the mutational landscape of AML inform targeted treatment?

C Craddock, Queen Elizabeth Hospital, Birmingham, United Kingdom

- A review of existing and emerging treatments for older patients with AML

A Schuh, Princess Margaret Cancer Centre, Toronto, Canada

- Closing remarks

G Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain

Job Bag: UK-CELG170059j

Job Bag: INT-CELG170027

Date of preparation: April 2017



→ SATELLITE SYMPOSIUM

13:30 - 15:30, Room N101

LEADING TOWARDS OPTIMIZING THE TREATMENT OF ITP AND NEW TREATMENT STRATEGIES IN SAA AND MDS

Chair: J Bussel, Weill Cornell Medical College, New York, United States

PROGRAM

- Welcome and introduction from the Chair

J Bussel, Weill Cornell Medical College, New York, United States

- Where we are now: Current treatment strategies for patients with ITP

J Bussel, Weill Cornell Medical College, New York, United States

- The road ahead: Considerations for long-term treatment of ITP patients with TPO-R agonists

J Bussel, Weill Cornell Medical College, New York, United States

- Striding towards the future: Recent advances in the treatment of patients with SAA

P Scheinberg, Division of Clinical Hematology, Antônio Ermírio de Moraes Cancer Center, Hospital A Beneficência Portuguesa de São Paulo, São Paulo, Brazil

- Stop, start, continue? Practical guidance on the use of TPO-R agonists in patients with SAA

P Scheinberg, Division of Clinical Hematology, Antônio Ermírio de Moraes Cancer Center, Hospital A Beneficência Portuguesa de São Paulo, São Paulo, Brazil

- Taking the next step: Addressing unmet supportive care needs in patients with MDS

M Mittelman, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

- Panel discussion/Q&A

J Bussel, Weill Cornell Medical College, New York, United States

- Summary and close from Chair

J Bussel, Weill Cornell Medical College, New York, United States



→ SATELLITE SYMPOSIUM
13:30 - 15:30, Room N105

UNMET NEED IN THE MANAGEMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA: WHERE DO WE GO FROM HERE?

Chair: J Radford, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

PROGRAM

- **Welcome and introductions**
Problem statement: What are the key issues in treating advanced-stage Hodgkin lymphoma?
J Radford, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
- **Current treatment landscape: A focus on ABVD**
P Brice, Hôpital Saint-Louis, Paris, France
- **Current treatment landscape: A focus on BEACOPP**
P Borchmann, University Hospital of Cologne, Cologne, Germany
- **Managing risk in advanced-stage Hodgkin lymphoma**
C Moskowitz, Memorial Sloan-Kettering Cancer Center, New York, United States
- **Future prospects: Where do we go from here?**
J Radford, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
- **Panel discussion and Q&A session:**
Beyond the current treatment paradigm: What does the future hold for advanced-stage Hodgkin lymphoma?
All
- **Conclusions and meeting close**
J Radford, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom



→ SATELLITE SYMPOSIUM
13:30 - 15:30, Room N103

AIMING HIGHER IN ADULT ALL: NOVEL THERAPIES AND TREATMENT STRATEGIES

Chair: J M Hernández, Universidad de Salamanca-CSIC, Salamanca, Spain

PROGRAM

- **Welcome and introduction**
J M Hernández, Universidad de Salamanca-CSIC, Salamanca, Spain
- **Modern approaches to frontline management of adult ALL**
N Boissel, Saint-Louis Hospital, Paris, France
- **Novel therapies for the treatment of adult patients with relapsed/refractory B-ALL**
A Rambaldi, University of Milan, Bergamo, Italy
- **Improving survival and quality of life in adult relapsed/refractory B-ALL**
M Topp, University of Wurzburg, Wurzburg, Germany
- **Ongoing challenges and future perspectives**
D Hoelzer, Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany



→ SATELLITE SYMPOSIUM
 13:30 - 15:30, Room N104

DEFINING TREATMENT STRATEGIES FOR CLL AND FL IN THE ERA OF TARGETED THERAPIES: EVIDENCE AND EXPERIENCE

Chair 1: U Jäger, Medical University of Vienna, Vienna, Austria
 Chair 2: F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain

PROGRAM

- **Welcome, introduction and overview of agenda**
 U Jäger, Medical University of Vienna, Vienna, Austria
 F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain
- **Treatment choice in CLL: What does the evidence tell us?**
 F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain
- **Treatment choice in FL: What does the evidence tell us?**
 W Hiddemann, Ludwig-Maximilians University, Munich, Germany
- **How do we achieve optimal sequencing of therapies in CLL?**
 L Ysebaert, The Cancer University Institute of Toulouse, Toulouse, France
- **How does our understanding of signaling pathways inform treatment decisions?**
 P Ghia, San Raffaele Scientific Institute, Milan, Italy
- **Real-world patient management: Case studies in double-refractory FL**
 A Isidori, Marche Nord Hospital, Pesaro, Italy
- **Real-world patient management: Case studies in CLL**
 T Munir, St. James's University Hospital, Leeds, United Kingdom
- **How I manage patients in my practice**
 U Jäger, Medical University of Vienna, Vienna, Austria
- **Conclusions and close**
 U Jäger, Medical University of Vienna, Vienna, Austria
 F Bosch, University Hospital Vall d'Hebron, Barcelona, Spain



→ SATELLITE SYMPOSIUM
 16:15 - 18:15, Hall C

RELAPSED/REFRACTORY CLL: HOW FAR HAVE WE COME, AND WHERE WILL WE GO NEXT

Chair: F Bosch, University hospital Vall d'Hebron, Barcelona, Spain

PROGRAM

- **Welcome and introduction**
 F Bosch, University hospital Vall d'Hebron, Barcelona, Spain
- **Here and now: Current approaches with targeted agents in relapsed/refractory CLL**
 F Bosch, University hospital Vall d'Hebron, Barcelona, Spain
- **Treatment in practice: Sequencing of targeted therapy**
 F Cymbalista, Hôpital Avicenne, Bobigny, France
- **Roundtable discussion: Implementing the new targeted treatment paradigm**
 F Bosch, University hospital Vall d'Hebron, Barcelona, Spain
- **Evolution of therapy for relapsed/refractory CLL: Emerging regimens and agents**
 P Hillmen, St James's University Hospital, Leeds, United Kingdom
- **Future goals of treatment: Finite duration as a desirable goal**
 P Ghia, Università Vita, Milan, Italy
- **Roundtable discussion: What does the future hold for patients with relapsed/refractory CLL?**
 F Bosch, University hospital Vall d'Hebron, Barcelona, Spain
- **Q&A**
- **Closing comments**
 F Bosch, University hospital Vall d'Hebron, Barcelona, Spain



→ SATELLITE SYMPOSIUM

16:15 - 18:15, Hall D

SHIFTING TREATMENT PARADIGMS IN NON-HODGKIN LYMPHOMA

Chair: D Caballero, University Hospital, Salamanca, Spain

PROGRAM

- **Welcome and introduction**
D Caballero, University Hospital, Salamanca, Spain
- **Follicular lymphoma: strategies in the era of new targeted therapies**
D Caballero, University Hospital, Salamanca, Spain
- **Shaping treatment approaches in DLBCL using molecular subtyping**
U Vitolo, University Hospital, Turin, Italy
- **Mantle cell lymphoma: evolving treatment strategies**
M Dreyling, University Hospital Grosshadern, Munich, Germany
- **The emerging role of checkpoint inhibitors in NHL**
R Houot, University Hospital, Rennes, France
- **Closing remarks**
D Caballero, University Hospital, Salamanca, Spain

→ SATELLITE SYMPOSIUM

16:15 - 18:15, Hall E

NAVIGATING THE TREATMENT CONTINUUM IN MULTIPLE MYELOMA

Chair: A Oriol, Hospital German Trias i Pujol, Barcelona, Spain

PROGRAM

- **Putting the patient first – Optimised treatment strategies**
N Raje, Massachusetts General Hospital, Boston, United States
- **Facing disease relapse – Tailored treatment options**
K Yong, University College London, London, United Kingdom
- **Holistic patient care with impact on treatment outcome**
E Terpos, University of Athens, Athens, Greece
- **Interactive panel discussion**
All faculty
- **Conclusion and closing**
A Oriol, Hospital German Trias i Pujol, Barcelona, Spain



→ SATELLITE SYMPOSIUM

16:15 - 18:15, Room N101

EXPERT GUIDES IN AML: EXPLORING CURRENT CHALLENGES AND FUTURE DIRECTIONS TO OPTIMISE PATIENT OUTCOMES

Chair: W Hiddemann, Ludwig-Maximilians University, Munich, Germany

PROGRAM

- **Welcome and introduction**
W Hiddemann, Ludwig-Maximilians University, Munich, Germany
- **The Journey So Far: The Research Pathway to Our Current Standard of Care**
W Hiddemann, Ludwig-Maximilians University, Munich, Germany
- **Challenges in Our Way: Novel Prognostic Markers in AML**
J Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- **Choosing a Path: How to Guide Treatment in AML**
A Venditti, Tor Vergata University, Rome, Italy
- **Identifying New Routes: Molecular Characterisation of AML to Inform Future Research**
H Serve, University Hospital Frankfurt, Germany
- **Panel discussion and close**
W Hiddemann, Ludwig-Maximilians University, Munich, Germany
All



→ SATELLITE SYMPOSIUM

16:15 - 18:15, Room N105

PATIENTS IN FOCUS: WHAT'S RELEVANT FOR CML AND PH+ALL?

Chair 1: MB Bacarani, University of Bologna, Bologna, Italy

Chair 2: EO Olavarria, Imperial College, London, United Kingdom

PROGRAM

- **The evolving role of molecular monitoring**
HDL De Lavallade, King's College Hospital, London, United Kingdom
- **Factors affecting clinical decision making in refractory and relapsed CP-CML patients**
DR Rea, Hôpital Saint-Louis, Paris, France
- **Current Challenges, New Insights and Future Directions in Ph+ALL**
GM Martinelli, University of Bologna, Bologna, Italy
- **Closure**
EO Olavarria, Imperial College London, London, United Kingdom



→ SATELLITE SYMPOSIUM

16:15 – 18:15, Room N103

EMERGING NOVEL AGENTS FOR AML: ARE WE ON THE THRESHOLD OF A TRANSFORMATION IN THERAPY?

Chair: H Kantarjian, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

PROGRAM

- **Chair's welcome**

H Kantarjian, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

- **Improving the efficacy and safety of AML therapy**

H Döhner, University Hospital of Ulm, Ulm, Germany

- **Molecular biology of AML and implications for therapy**

G Roboz, Weill Medical College of Cornell University, New York, New York, United States

- **Emerging novel agents for AML therapy**

H Kantarjian, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

- **Treating the AML patient with less intensive therapy**

- **evolving options**

L Adès, St Louis Hospital, University of Paris, Paris, France

- **Panel discussion and Q&A**

All

- **Chair's summary and close**

H Kantarjian, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States



→ SATELLITE SYMPOSIUM

16:15 - 18:15, Room N104

THROMBOSIS IN COMPLEMENT-MEDIATED DISEASES

Chair: B Kemkes-Matthes, University of Giessen, Giessen, Germany

PROGRAM

- **Welcome and Introduction: Overview of Thrombosis in complement-mediated disease**

B Kemkes-Matthes, University of Giessen, Giessen, Germany

- **The Path to Thrombosis through Complement**

C Schmidt, University of Ulm, Ulm, Germany

- **Complement-Mediated Diseases in Hematology**

S Zeerleder, University of Amsterdam, Amsterdam, the Netherlands

- **Paroxysmal Nocturnal Hemoglobinuria: – “The Most Vicious Thrombophilic State*”**

A Hill, University of Leeds, Leeds, United Kingdom

- **Conclusion and Q&A**

B Kemkes-Matthes, University of Giessen, Giessen, Germany

(*Luzzatto L, et al. Haematologica 2010)



→ SATELLITE SYMPOSIUM

19:00 – 21:00, Hall D

TARGETING THE FLT-3 PATHWAY IN AML: EVOLUTION OF NEXT GENERATION TYROSINE KINASE INHIBITORS

Chair: H Döhner, University Hospital of Ulm, Germany

PROGRAM

- **Welcome**

H Döhner, University Hospital of Ulm, Ulm, Germany

- **Biology of FLT-3, FLT-3 mutations and the mutational spectrum**

S Meshinchi, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

- **Clinical spectrum of FLT-3 positive AML**

R Schlenk, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany

- **Activity of single-agent crenolanib in FLT-3 positive AML**

J Cortes, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

- **Activity of crenolanib with induction chemotherapy in FLT-3 positive AML**

E Wang, Roswell Park Cancer Institute, Buffalo, New York, United States

- **Activity of crenolanib with salvage chemotherapy in relapsed/refractory FLT-3 positive AML**

R Stone, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

- **Conclusion and wrap up**

H Döhner, University Hospital of Ulm, Ulm, Germany



**Global Academy for
Medical Education**

→ SATELLITE SYMPOSIUM

19:00 - 21:00, Hall E

NEW HORIZONS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA

JM Rowe, Shaare Zedek Medical Center, Jerusalem, Israel

PROGRAM

- **Welcome**

JM Rowe, Shaare Zedek Medical Center, Jerusalem, Israel

- **Introduction: Recent Developments in the Treatment of AML**

JM Rowe, Shaare Zedek Medical Center, Jerusalem, Israel

- **Q&A**

- **Defining key targets for therapy in AML: Lessons from gene expression and molecular pathway activation patterns**

F Lo Coco, University Tor Vergata Rome, Italy

- **Q&A**

- **How tyrosine kinase inhibitors may affect primary AML blasts: outcomes in R/R AML**

M Sanz, Universitario y Politécnico La Fe Valencia, Valencia, Spain

- **Q&A**

- **Panel discussion**

Moderator: JM Rowe, Shaare Zedek Medical Center, Jerusalem, Israel

- **Wrap-up & Adjourn**

JM Rowe, Shaare Zedek Medical Center, Jerusalem, Israel



→ SATELLITE SYMPOSIUM

19:00 - 21:00, Room N101

GETTING PERSONAL; INDIVIDUALISING THERAPY IN CML

Chair: G Rosti, Department of Hematology and Oncology. St Orsola University Hospital, Bologna, Italy

PROGRAM

- **Improving long-term outcomes; Maximizing efficacy in second line and beyond**

G Rosti, Department of Hematology and Oncology. St Orsola University Hospital, Bologna, Italy

- **Choosing the right TKI for patients; Treatment options focusing on an optimal QOL**

T Brümmendorf, Euregionales Comprehensive Cancer Center Aachen, Aachen, Germany

- **Treatment outcomes; Data from the real world**

J Apperley, Hammersmith Hospital, London, United Kingdom

- **Future perspectives; Is there an unmet need in CML?**

LF Casado, Hospital Virgen De La Salud, Toledo, Spain



→ SATELLITE SYMPOSIUM

19:00 - 21:00, Room N105

A NEW PRACTICAL TOOL TO HELP IDENTIFY GAUCHER DISEASE: ACCELERATING DIAGNOSIS AND IMPROVING LONG-TERM OUTCOMES FOR PATIENTS

Chair 1: A Mehta, Royal Free Hospital, London, United Kingdom

Chair 2: D Kuter, Center for Hematology, Massachusetts General Hospital, Boston, United States

PROGRAM

- **A rare heterogeneous disease: What do I need to know?**

A Mehta, Royal Free Hospital, London, United Kingdom

- **The many faces of Gaucher: Challenging case studies**

A Mehta, Royal Free Hospital, London, United Kingdom

D Kuter, Center for Hematology, Massachusetts General Hospital, Boston, United States

- **A new diagnostic tool for clinical practice**

A Mehta, Royal Free Hospital, London, United Kingdom

D Kuter, Center for Hematology, Massachusetts General Hospital, Boston, United States



→ SATELLITE SYMPOSIUM

19:00 - 21:00, Room N103

This educational activity is supported by a grant from Shire.

CURRENT STATE-OF-THE-ART AND FUTURE STRATEGIES IN ACUTE LYMPHOBLASTIC LEUKEMIA

Chair: D Hoelzer, Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany

PROGRAM

- **Welcome, introduction, and quiz questions**
D Hoelzer, Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany
- **Diagnosis and risk assessment of acute lymphoblastic leukemia in 2017**
D I Marks, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
- **Making the most of induction therapy in ALL**
D Hoelzer, Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany
- **MRD and risk-adapted post-remission therapy**
R Foà, University of Rome, Rome, Italy
- **New strategies for relapsed/refractory ALL**
M Topp, University of Würzburg, Würzburg, Germany
- **Conclusion and key points**
D Hoelzer, Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany



→ SATELLITE SYMPOSIUM

19:00 - 21:00, Room N104

THE 1ST BIOSIMILAR RITUXIMAB BASED ON CLINICAL EVIDENCE

Chair: B Coiffier, University of Lyon-1, Hospicos Civils de Lyon, Lyon, France

PROGRAM

- **Welcome and introduction: perceptual evolution on biosimilar**
B Coiffier, University of Lyon-1, Hospicos Civils de Lyon, Lyon, France
- **Reducing budgets, increasing access**
L Gulácsi, Corvinus University of Budapest, Budapest, Hungary
- **The rationale of biosimilarity**
J Gonçalves, University of Lisboa, Lisboa, Portugal
- **Clinical evidence of biosimilar rituximab**
C Buske, University of Ulm, Ulm, Germany
- **Biosimilar in oncology: yesterday, today and a look ahead**
Moderator: B Coiffier, University of Lyon-1, Hospicos Civils de Lyon, Lyon, France

WE ASPIRE TO CURE CANCER.



At **TAKEDA ONCOLOGY**, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.

This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.

We've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though we've made great strides in our fight against cancer, we are determined to do more – to work harder and to reach higher. We continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that we are today.

We know that our mission is not a quick or simple one, but we are up for the task:
we aspire to cure cancer.



JOIN US IN BOOTH #630

Make a wish to make a difference for cancer patients.



To learn more, visit us at takedaoncology.com.

 [@TakedaOncology](https://twitter.com/TakedaOncology)

Takeda Oncology is a trademark of Takeda Pharmaceutical Company Limited.
Millennium Pharmaceuticals, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
©2017 Millennium Pharmaceuticals, Inc.

FRIDAY, JUNE 23

SPECIAL SESSIONS OF THE DAY

Next to the high quality scientific and education sessions of the day we would like to draw your attention to the following interesting sessions:

OPENING CEREMONY →	Page 96
JOSÉ CARRERAS LECTURE →	Page 96
JAPANESE SOCIETY OF HEMATOLOGY JOINT SYMPOSIUM →	Page 97
HEMATOLOGY SOCIETY OF TAIWAN JOINT SYMPOSIUM →	Page 98
EARLY CAREER SESSION →	Page 98
PRESIDENTIAL SYMPOSIUM →	Page 100
UPDATES-IN-HEMATOLOGY →	Page 100

Download the EHA app

Keep yourself up-to-date
with sessions especially
designed for you.

Download the EHA app
and carry the congress
in your pocket.



→ EDUCATION SESSION 3 5 T C
 08:00 - 09:30, Hall A
 Repeat Session:
 Saturday, June 24, 09:45 - 11:15, Hall A

NEW APPROACHES TO INDOLENT LYMPHOMA

Chair: P Brice (Hopital Saint Louis, Paris, France)

- **Molecular profiling of indolent lymphoma**
 S Pileri (European Institute of Oncology, Milan, Italy)
- **Update on follicular lymphoma: Time beyond chemotherapy?**
 K Hübel (University of Cologne, Germany)
- **Treatment of extranodal marginal zone B-cell lymphomas**
 M Raderer (Medical University Vienna, Austria)

LEARNING GOALS

S Pileri

After attending this lecture, the participant will be able to

- Describe the molecular characteristics of the main varieties of indolent lymphoma.
- Discuss how they can impact on the prognosis and therapy in the present era of precision medicine.

K Hübel

After attending this lecture, the participant will be able to

- Understand requirements for a chemotherapy-free approach in Follicular Lymphoma.
- Recognize the potential of existing and emerging therapeutics in the management of Follicular Lymphoma.
- Assess critically the benefits and risks of common cytotoxic regimens versus targeted therapies in different lines of treatment.

M Raderer

After attending this lecture, the participant will be able to

- Eradication of Helicobacter pylori remains the preferred first-line therapy in patients with gastric MALT lymphoma.
- Also patients with HP-negative gastric MALT lymphoma may also be managed with (clarithromycin-based) antibiotic therapy.
- Antibiotic therapy can also be given in patients with ocular adnexal MALT-lymphomas as sole initial management.
- Both systemic treatment as well as radiotherapy appear to have curative potential in localised disease.

→ EDUCATION SESSION 2 5 T C
 08:00 - 09:30, Hall B
 Repeat Session:
 Friday, June 23, 09:45 - 11:15, Hall B

MYELOPROLIFERATIVE NEOPLASMS

Chair: J Samuelsson (Karolińska Institute, Stockholm, Sweden)

- **Molecular genetics in MPN**
 AM Vannucchi (University of Florence, Italy)
- **Targeting specific mutations in MPN**
 A Mullally (Brigham and Women's Hospital, Boston, USA)

- **Emerging treatments for classical myeloproliferative neoplasms**
 C Harrison (Guys and St Thomas' NHS Foundation Trust, London, United Kingdom)

LEARNING GOALS

AM Vannucchi

After attending this lecture, the participant will be able to

- Describe current status of mutation landscape in patients with myeloproliferative neoplasms (MPN).
- Describe the key role of driver mutations in the revised 2016 WHO diagnostic criteria of MPN.
- Discuss the prognostic relevance of driver and non-driver mutations for patients with myelofibrosis.

A Mullally

After attending this lecture, the participant will be able to

- Summarize the key molecular driver mutations in MPN.
- Describe the development and use of JAK2 inhibitors in MPN.
- Describe investigational approaches focused on enhancing the clonal selectivity of MPN therapies.

C Harrison

After attending this lecture, the participant will be able to

- Appreciate the importance of an accurate diagnosis of specific MPN.
- Select an appropriate prognostic score for their patient and understand how these may be changing during the coming years.
- Discuss pros and cons of conventional treatment options for MPN patients in particular the emerging story with regard to HU and IFN.
- Understand the different efficacies of JAK inhibitors and the potential other emerging therapies for MPN patients.

→ SCIENTIFIC WORKING GROUPS 3 5 10 T C
 08:30 - 09:30, Hall C

MULTIPLE MYELOMA: NOVEL DEVELOPMENTS IN MYELOMA AND RELATED DISEASES

Chair: M Kaiser (The Institute of Cancer Research & Royal Marsden Hospital, London, United Kingdom)

- **Treatment and sequence in relapsed and refractory multiple myeloma**
 X Leleu (CHU La Milétrie, Poitiers, France)
- **Should imaging be part of MRD?**
 E Zamagni (Seragnoli Institute of Hematology, Bologna, Italy)
- **Novel approaches in AL-Amyloidosis**
 G Palladini (University of Pavia, Italy)
- **Is NGS of value for clinical practice?**
 KM Kortüm (University Hospital, Würzburg, Germany)

LEARNING GOALS

X Leleu

After attending this lecture, the participant will be able to

- Describe current and emerging therapies for RRM.

- Describe objectives and concepts of treatment in the RRMM setting.
- Understand early versus late relapse.
- Understand relapsed versus relapsed refractory, versus primary refractory.
- Understand high risk versus standard risk.

E Zamagni

After attending this lecture, the participant will be able to

- Be aware of the new response criteria for multiple myeloma as stated by the international myeloma working group.
- Understand the different methods for minimal residual disease evaluation after treatment, both inside and outside the bone marrow, with a particular focus on imaging techniques.
- Discuss pros and cons of each methods, timing and availability.

G Palladini

After attending this lecture, the participant will be able to

- Describe current and emerging therapy for patients with AL amyloidosis.
- Select appropriate upfront therapy based upon risk stratification.
- Monitor response to treatment with clonal and organ markers.

KM Kortüm

After attending this lecture, the participant will be able to

- Identify patients that might benefit from NGS testing.
- Understand the limits and chances of current clinically oriented NGS testing in MM.

→ EDUCATION SESSION

3 9 10 T C

08:00 - 09:30, Hall D

Repeat Session:

Friday, June 23, 09:45 - 11:15, Hall D

ACUTE LYMPHOBLASTIC LEUKEMIA: THE WORST AND THE BEST

Chair: R Pieters (Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands)

- **Balancing efficacy and toxicity in the treatment of childhood ALL**
A Vora (Great Ormond Street Hospital, London, United Kingdom)
- **Immunotherapy for ALL: From biology to the clinic and back**
T Fry (Pediatric Oncology Branch, CCR, NCI, NIH, Bethesda, USA)
- **Novel approaches with recently licensed drugs or recently studied in relapsed ALL**
JM Ribera (ICO-Hospital Germans Trias i Pujol, Badalona, Spain)

LEARNING GOALS

A Vora

After attending this lecture, the participant will be able to

- Describe the burden of toxicity of treatment for childhood ALL.
- Discuss risk stratification for childhood ALL.
- Select treatment that provides optimal efficacy with minimal toxicity based on leukaemia phenotype, genotype and treatment response.

T Fry

After attending this lecture, the participant will be able to

- Describe the clinical activity and limitations of CD19-targeted chimeric antigen receptor (CD19 CAR) T cells in pediatric malignancies.
- Differentiate between and explain the patterns of failure following CD19 CAR T cells.
- List possible approaches to improve durability of remission following CAR T cell therapy for acute lymphoblastic leukemia.

JM Ribera

After attending this lecture, the participant will be able to

- Although ALL is highly curable with conventional chemotherapy, novel therapeutic approaches are still needed to improve outcomes for high-risk or relapsed ALL, especially in adults.
- Immunotherapeutic approaches have significantly improved the outcome of R/R ALL patients and are currently tested in early phases of the disease.
- Targeted therapy combined with conventional chemotherapy and/or immunotherapy can provide promising results in some specific subtypes of ALL.

→ EDUCATION SESSION

4 B T C

08:00 - 09:30, Hall E

Repeat Session:

Saturday, June 24, 08:00 - 09:30, Room N101

STEM CELL TRANSPLANTATION - GVHD

Chair: N Kröger (University Medical Center Hamburg-Eppendorf, Germany)

- **The role of the intestinal microbiota in graft-versus-host disease**
R Zeiser (Freiburg University Medical Center, Germany)
- **The role of intestinal flora in patients undergoing allogeneic hematopoietic stem cell transplantation**
M van den Brink (Memorial Sloan Kettering Cancer Center, New York, USA)
- **Balancing Graft versus Leukemia and Graft versus Host responses**
JHF Falkenburg (Leiden University Medical Center, the Netherlands)

LEARNING GOALS

R Zeiser

After attending this lecture, the participant will be able to

- Describe emerging molecular therapies for steroid refractory GVHD.
- Discuss novel concepts on the role of neutrophils in GVHD.
- Understand the basic principles of GVHD biology.

M van den Brink

After attending this lecture, the participant will be able to

- Describe the major changes observed in the intestinal microbiota of patients undergoing that are associated with graft-vs-host disease and transplant-related mortality.
- Recapitulate the impact of antibiotic therapy, broad- vs narrow-spectrum antibiotic, on clinical outcomes in allogeneic

- hematopoietic stem cell transplantation (allo-HSCT) patients.
- Discuss current and putative future options for gut microbiota interventions to increase survival and gastrointestinal health in patients undergoing allo-HSCT.

JHF Falkenburg

After attending this lecture, the participant will be able to

- Understand the different nature of allo-immune T cell responses following HLA matched and HLA mismatched stem cell transplantation.
- Estimate the likelihood of developing selective GVL responses after allogeneic stem cell transplantation.
- Understand how post-transplant circumstances and interventions influence the balance between GVL and GVHD.

→ MOLECULAR HEMOPOIESIS WORKSHOP

08:00 - 11:15, Room N101

Organizer: S Fröhling (National Center for Tumor Diseases, Heidelberg, Germany)

PART 1: SIGNALLING

2 B

Chair: V Sexl (Pharmacology and Toxicology, Vienna, Austria)

- **JAK-STAT signaling in myeloproliferative neoplasms**
A Mullally (Brigham and Women's Hospital, Boston, USA)
- **Inflammatory cell death in AML**
P Jost (TU München, Germany)
- **Molecular signaling in CLL**
M Hallek (University Hospital of Cologne, Germany)
- **Exploring and exploiting aberrant cell fate programs in leukemia**
J Zuber (Research Institute of Molecular Pathology (IMP), Vienna, Austria)

LEARNING GOALS

A Mullally

After attending this lecture, the participant will be able to

- Understand the mechanism by which mutant calreticulin is oncogenic.
- Understand the aberrant signal transduction pathway activation that occurs as a result of mutations in calreticulin in MPN.

P Jost

After attending this lecture, the participant will be able to

- Understand the relevance of inflammatory cell death for AML blast cell survival.
- Describe the role of TNF signaling in FLT3-ITD AML.
- Define the expression levels of RIPK3 in primary de novo FLT3-ITD AML.

M Hallek

An up-to-date program is available via the mobile app.

J Zuber

After attending this lecture, the participant will have learned

- How genetically engineered AML mouse models, in-vivo transcrip-

- tomics and focused genetic screens can aid drug target discovery.
- How common gene regulatory programs maintain aberrant LSC self-renewal downstream of disease-defining mutations in AML.
- How genome-wide CRISPR/Cas9-screens can be used to decipher synthetic-lethal dependencies.

PART 2: HEMATOPOIETIC STEM CELLS & THEIR NICHE

2 3 5 B T

Chair: J Schwaller (University Children's Hospital Basel, Switzerland)

- **Single cell functional and transcriptional analysis of normal primary human lympho-myeloid progenitors**
P Vyas (Weatherall Institute of Molecular Medicine, Oxford, United Kingdom)
- **DNMT3A mutations enhance CpG mutagenesis through deregulation of the active DNA demethylation pathway**
M Sanders (Erasmus Medical Center, Rotterdam, the Netherlands)
- **Maintenance of tissue resident macrophages during tissue repair and aging**
E Gomez Perdiguero (Institut Pasteur, Paris, France)
- **Multicolor quantitative imaging cytometry of bone and marrow**
T Schroeder (ETH Zurich, Basel, Switzerland)

LEARNING GOALS

P Vyas

After attending this lecture, the participant will be able to

- How are normal haemopoietic progenitors purified?
- What are the assays of haemopoietic progenitor function?
- How are transcriptional signatures identified and how do they correlate with function?

M Sanders

After attending this lecture, the participant will be able to

- Describe the elements involved in active DNA demethylation and understand their dynamic interplay.
- Describe which genetic lesions, commonly observed in clonal hematopoiesis and myeloid malignancies, impact this pathway and their repercussion on DNA methylation dynamics.
- Discuss the etiology of these preleukemic mutations and their significance for leukemic development.

E Gomez Perdiguero

After attending this lecture, the participant will be able to

- Understand current challenges when studying tissue macrophages
- Understand different methods available for characterising the developmental origin of myeloid cells.
- Discuss potential implication of ontogeny into macrophage functions.

T Schroeder

After attending this lecture, the participant will be able to

- Current state of the art and remaining challenges in quantitative 3D bone marrow imaging.
- Update on latest insights into hematopoietic stem and progenitor cell bone marrow niche.

PART 3: TRANSCRIPTIONAL AND EPIGENETIC REGULATION

1 2 3 5 10 **B T**

Chair: O Abdel-Wahab (Memorial Sloan Kettering Cancer Center, New York, USA)

- Discovery and functional characterization of long non-coding RNAs in acute myeloid leukemia
C Lobry (Institut Gustave Roussy / INSERM, Villejuif, France)
- Hedgehog-Gli signaling in bone marrow fibrosis
R Schneider (Erasmus MC, Rotterdam, the Netherlands)
- Insights into hematopoiesis using single-cell transcriptomics
O Kilpivaara (University of Helsinki, Finland)
- Delineating and targeting cancer-specific chromatin vulnerabilities in T cell leukemia
P Ntziachristos (Feinberg School of Medicine, Northwestern University, Chicago, USA)

LEARNING GOALS

C Lobry

After attending this lecture, the participant will be able to

- Understand basic biology of long non-coding RNA.
- Understand usage of CRISPRi and CRISPRa technologies to modulate lncRNA expression.
- Understand how lncRNA can regulate oncogenes in acute leukemia.
- Discuss potential usage of targeting lncRNA for leukemia treatment.

R Schneider

After attending this lecture, the participant will be able to

- Describe the contribution of Gli1+ cells in bone marrow fibrosis.
- Describe the cellular and molecular mechanisms in the fibrotic transformation of stromal cells in bone marrow fibrosis.
- Discuss the therapeutic strategy of targeting Gli proteins in bone marrow fibrosis.

O Kilpivaara

After attending this lecture, the participant will be able to

- Describe the single-cell transcriptome analysis principle.
- Discuss the value of using single-cell vs. "bulk" RNA-sequencing.

P Ntziachristos

After attending this lecture, the participant will be able to

- Describe major clinical and molecular characteristics of T cell acute lymphoblastic leukemia (ALL).
- Describe the roles of ubiquitin specific peptidases (USPs) in sustaining oncogenic activity and transcriptional response.
- Discuss the molecular and phenotypic effect of therapeutic inhibition of USPs in preclinical models of T-ALL using small molecule inhibitors.
- Discuss how information gained from recent molecular studies could lend rationale towards targeted therapies, exploiting cancer vulnerabilities.

→ **EDUCATION SESSION**

5 6 **B T C**

08:00 - 09:30, Room N105

Repeat Session:

Saturday, June 24, 09:45 - 11:15, Room N111

THROMBOSIS

Chair: W Ageno (University of Insubria, Varese, Italy)

- Cross-talk between coagulation and inflammation
T Renné (University Medical Center Hamburg, Germany & Karolinska Institutet, Stockholm, Sweden)
- Novel aspects in the diagnostic management of deep vein thrombosis and pulmonary embolism
M Huisman (Leiden University Medical Center, the Netherlands)
- Controversies in treating small clots in the leg and in the lung
S Schellong (Städtisches Klinikum Dresden, Germany)

LEARNING GOALS

T Renné

After attending this lecture, the participant will be able to

- Understand the novel concept of Safe Anticoagulants that do not increase bleedings.
- Get insight in the crosstalk of coagulation and inflammation.
- Learn about the plasma contact system.

M Huisman

After attending this lecture, the participant will be able to

- Describe current and emerging diagnostic algorithms for patients with clinically suspected venous thromboembolism.
- Select appropriate diagnostic algorithms for selected populations including older patients, pregnant patients, and patients with suspected recurrent venous thromboembolism.

S Schellong

After attending this lecture, the participant will be able to

- Acknowledge the new situation that for DVT as well as for PE the current standard diagnostic imaging detects clots in the leg and the lung which might be clinically insignificant and do not require standard treatment.
- Define a subgroup of patients with isolated distal DVT which represents a very low risk group for proximal extension and PE.
- Discuss the risk difference of two different patient groups with subsegmental PE: cancer patients with incidental PE versus symptomatic patients without cancer.

→ **EDUCATION SESSION**

1 2 3 6 9 **T C**

08:00 - 09:30, Room N103

Repeat Session:

Friday, June 23, 09:45 - 11:15, Room N103

HEREDITARY HEMATOLOGICAL DISORDERS

Chair: J Sevilla (Hospital Infantil Universitario Niño Jesús, Madrid, Spain)

- Syndromes predisposing to hematological malignancies
C Kratz (Hannover Medical School, Germany)

- **Diagnosis of inherited bone marrow failure and myelodysplastic syndromes**

A Shimamura (Dana-Farber/Boston Children's Cancer and Blood Disorders Center, USA)

- **The 100.000 genomes project**

WH Ouwehand (Wellcome Trust Sanger Institute, University of Cambridge, NHS Blood & Transplant, United Kingdom)

LEARNING GOALS

C Kratz

After attending this lecture, the participant will be able to

- Know the genetic syndromes associated with a range of hematologic neoplasms.
- Know the different clinical features and cancer risks associated with these conditions.
- Know why the identification of such syndromes is highly relevant clinically.

A Shimamura

After attending this lecture, the participant will be able to

- Diagnosis of inherited bone marrow failure (BMF) and inherited myelodysplastic syndromes (MDS) informs surveillance strategies and treatment decisions.
- Classical clinical stigmata of these inherited syndromes may be absent.
- Understand the indications and caveats of genetic screening strategies for the diagnosis of patients with bone marrow failure.

WH Ouwehand

After attending this lecture, the participant will be able to

- New approaches to gene discovery for inherited haematological diseases of unknown molecular aetiology by whole genome sequencing.
- Review of newly identified inherited haematological disorders since the introduction of high throughput sequencing in 2009.
- The application of high throughput sequencing platforms for the comprehensive molecular diagnosis of inherited haematological diseases caused by DNA variants in known genes.
- The need for sharing of genotype and phenotype data via 'safe-haven' models.

→ **SCIENTIFIC WORKING GROUPS**

08:30 - 09:30, Room N104

1 2 9 **B T C**

GRANULOCYTE AND MONOCYTE DISORDERS: NEW INSIGHTS IN NEUTROPENIAS

Chair: C Dufour (G Gaslini Children's Hospital, Genova, Italy)

- **Drivers of leukemogenesis in congenital neutropenias**
K Welte (University Children's Hospital, Tuebingen, Germany)
- **Neutrophil extra cellular traps (NET)**
J Donadieu (Hôpital Trousseau, Paris, France)
- **PEG Filgrastim in SCN**
F Fioredda (Istituto Giannina Gaslini, Genoa, Italy)

LEARNING GOALS

K Welte

After attending this lecture, the participant will be able to

- Have an overview on the germ-line mutations causing congenital neutropenias.
- Have an overview on the available treatment for congenital neutropenias.
- Be more aware about the leukemia risk of patients with congenital neutropenias.
- Know that acquired mutations in the CSF3R and RUNX1 are major drivers of leukemogenesis.

J Donadieu

After attending this lecture, the participant will be able to

- What is NET?
- How to study NET and what is a pertinent to understand pathology?
- Do NET and the pathophysiology of diseases?

F Fioredda

After attending this lecture, the participant will be able to

- Have an overview on the available treatments for severe congenital neutropenia.
- Be more aware about the use of Pegfilgrastim in severe congenital neutropenia.

→ **SCIENTIFIC WORKING GROUPS**

08:30 - 09:30, Room N109

2 3 5 9 **C**

LEUKEMIA DIAGNOSIS: MORPHOLOGY AND FLOW CYTOMETRY: MINIMAL RESIDUAL DISEASE IN LEUKEMIA

Chair: MC Bene (Nantes University Hospital, France)

- **The challenge of morphological remission**
A Tichelli (University Hospital, Basel, Switzerland)
- **Flow cytometry for MRD detection in ALL**
G Basso (University of Padova, Italy)
- **Flow cytometry for MRD detection in AML**
GJ Schuurhuis (VU University Medical Center, Amsterdam, the Netherlands)

LEARNING GOALS

A Tichelli

After attending this lecture, the participant will be able to

- Know the criteria of morphological response and morphological remission in AML, MDS, CML and BCR-ABL1 negative MPN.
- Recognize possible pitfalls in morphological interpretation of remission.
- Understand the clinical relevance of morphology in monitoring response to treatment.

G Basso

After attending this lecture, the participant will be able to

- Discuss the main strengths and pitfalls of Flow Cytometry in Minimal Residual Disease detection in children affected by Acute Lymphoblastic Leukemia (ALL).

- Describe the clinical impact of Flow Cytometry Minimal Residual Disease in childhood ALL in patients stratification and in follow-up.

GJ Schuurhuis

After attending this lecture, the participant will be able to

- MRD is extra prognostic factor to be used for risk stratification and adaptation of consolidation therapy.
- Incorporation of post-diagnosis stem cell load improves MRD based prognostic impact and with that may lead to further adaptation of therapy.
- Prognostic impact, and with that the clinical consequences, of incorporation of MRD and stem cells mean different things in different classically-defined cytogenetic sub-groups.
- MRD urgently needs further standardization to enable further implementation in clinical studies.

→ BASIC-SCIENCE-IN-FOCUS 1 2 B T
08:30 - 09:30, Room N111

MYELOID DERIVED SUPPRESSOR CELLS

Chair: AA van de Loosdrecht (VU University Medical Center, Amsterdam, the Netherlands)

- **A clinical and biological perspective of human myeloid-derived suppressor cells in cancer**
G Pawelec (University of Tuebingen, Germany)
- **Myeloid-derived suppressor cells: Critical cells driving immune suppression in the tumor microenvironment**
S Ostrand-Rosenberg (University of Maryland Baltimore County, United States)

LEARNING GOALS

G Pawelec

After attending this lecture, the participant will be able to

- Consolidate their knowledge about human myeloid-derived suppressor cells and distinguish their characteristics from murine MDSCs.
- Recognize that MDSC levels are altered in cancer patients in association with patient survival.
- Be aware of the different mechanisms employed by MDSCs to exert immune suppression.
- Acquire knowledge of possible therapeutic agents that can be used to target MDSCs and reduce immune suppression.

S Ostrand-Rosenberg

After attending this lecture, the participant will be able to

- Appreciate the immune suppressive role that myeloid cells play in promoting the progression of primary and metastatic cancer.
- Describe how the low grade pro-inflammatory environment prevalent in obesity mechanistically leads to immune suppression and tumor growth.
- Explain how high fat diet-induced immune suppressive myeloid cells protect against the metabolic dysfunction associated with obesity.

→ BASIC-SCIENCE-IN-FOCUS 2 3 4 B T C
08:30 - 09:30, Room N113

MICROBIOME

Chair: M van den Brink (Memorial Sloan Kettering Cancer Center, New York, USA)

- **Modifying the microbiome in allogeneic stem cell transplantation**
A Bhatt (Stanford University, Palo Alto, USA)
- **Role of molecular tools for discrimination of fungal infections in cancer**
T Lion (Children's Cancer Research Institute, Vienna, Austria)

LEARNING GOALS

A Bhatt

After attending this lecture, the participant will be able to

- Provide a basis to select candidate patients based on both disease and patient-related factors.
- Provide a basis to define optimal timing of transplantation in individual patient.
- Discuss the use of hypomethylating agents as part of a comprehensive strategy to prevent relapse after transplantation in high risk patients.
- Discuss the clinical utility of somatic mutations in MDS transplantation decision-making.

T Lion

After attending this lecture, the participant will be able to

- Describe the current place of molecular diagnostic approaches in the detection of invasive fungal infections.
- Discuss the advantages and limitations of molecular diagnostics in relation to established standards.
- Discuss future directions in optimized fungal diagnostics in immunocompromised patients.

→ BASIC-SCIENCE-IN-FOCUS 1 B
08:30 - 09:30, Room N115

FOCUS ON IRON

Chair: M Muckenthaler (University of Heidelberg, Germany)

- **Iron and macrophages**
I Theurl (Medical University of Innsbruck, Austria)
- **Iron storage and release**
F Carlomagno (DMMBM, University Federico II, Naples, Italy)
- **Role of TFR2 in erythropoiesis**
A Nai (Ospedale San Raffaele - San Raffaele Scientific Institute, Milan, Italy)

LEARNING GOALS

I Theurl

After attending this lecture, the participant will be able to

- Understand the basics of macrophage iron metabolism.
- Discuss the interaction of innate immunity and iron metabolism.

- Conceive treatment options for diseases in which an altered macrophage iron metabolism plays a central role in disease pathology.

F Carlomagno

After attending this lecture, the participant will be able to

- Understand the role of ferritinophagy in maintaining iron homeostasis.
- Know how NCOA4 functions in controlling ferritinophagy.
- Envisage how ferritinophagy is connected to cell cycle control.

A Nai

After attending this lecture, the participant will be able to

- Dissect the hepatic and erythroid functions of Transferrin Receptor 2.
- Understand the beneficial effect of deleting erythroid Transferrin Receptor 2 in ineffective erythropoiesis.

→ EDUCATION SESSION

3 4 B T C

09:45 - 11:15, Hall A

Repeat Session:

Saturday, June 24, 08:00 - 09:30, Hall A

IMMUNOTHERAPY IN LYMPHOMA

Chair: A Engert (University Hospital of Cologne, Germany)

- The role of the microenvironment in the pathogenesis of B-cell lymphomas

G Lenz (Translational Oncology, Münster, Germany)

- Immune checkpoint inhibitors

A Younes (Memorial Sloan Kettering Cancer Center, New York, USA)

- Is transplantation in lymphoma still needed in the era of immunotherapy?

A Sureda (Institut Català d'Oncologia - Hospital Duran i Reynalds, Barcelona, Spain)

LEARNING GOALS

G Lenz

After attending this lecture, the participant will be able to

- Describe the role of the microenvironment in the biology of different B-cell lymphomas.
- Discuss important components of the microenvironment of different B-cell malignancies.
- Appreciate the interaction between bystander and malignant cells in B-cell lymphomas.

A Younes

An up-to-date program is available via the mobile app.

A Sureda

After attending this lecture, the participant will be able to

- Understand how the introduction of check point inhibitors will potentially modify the profile of Hodgkin's lymphoma patients undergoing allogeneic hematopoietic stem cell transplantation.

- Describe transplant related toxicities and long term outcome of patients with Hodgkin's lymphoma that have been previously treated with check point inhibitors.
- Learn how to use check point inhibitors in those patients that relapse after the allogeneic procedure.

→ EDUCATION SESSION

2 5 T C

09:45 - 11:15, Hall B

Repeated from:

Friday, June 23, 08:00 - 09:30, Hall B

MYELOPROLIFERATIVE NEOPLASMS

Chair: J Samuelsson (Karolinska Institute, Stockholm, Sweden)

- Molecular genetics in MPN

AM Vannucchi (University of Florence, Italy)

- Targeting specific mutations in MPN

A Mullally (Brigham and Women's Hospital, Boston, USA)

- Emerging treatments for classical myeloproliferative neoplasms

C Harrison (Guys and St Thomas' NHS Foundation Trust, London, United Kingdom)

LEARNING GOALS

AM Vannucchi

After attending this lecture, the participant will be able to

- Describe current status of mutation landscape in patients with myeloproliferative neoplasms (MPN).
- Describe the key role of driver mutations in the revised 2016 WHO diagnostic criteria of MPN.
- Discuss the prognostic relevance of driver and non-driver mutations for patients with myelofibrosis.

A Mullally

After attending this lecture, the participant will be able to

- Summarize the key molecular driver mutations in MPN.
- Describe the development and use of JAK2 inhibitors in MPN.
- Describe investigational approaches focused on enhancing the clonal selectivity of MPN therapies.

C Harrison

After attending this lecture, the participant will be able to

- Appreciate the importance of an accurate diagnosis of specific MPN.
- Select an appropriate prognostic score for their patient and understand how these may be changing during the coming years.
- Discuss pros and cons of conventional treatment options for MPN patients in particular the emerging story with regard to HU and IFN.
- Understand the different efficacies of JAK inhibitors and the potential other emerging therapies for MPN patients.

→ EDUCATION SESSION 2 5 10 T C
09:45 - 11:15, Hall C
Repeat Session:
Saturday, June 24, 08:00 - 09:30, Hall D

CHRONIC MYELOID LEUKEMIA

Chair: S Soverini (University of Bologna, Italy)

- Novel approaches to eradicate CML stem cells
M Copland (University of Glasgow, United Kingdom)
- Molecular work up and monitoring of CML patients
N Cross (University of Southampton, United Kingdom)
- How to treat CML in 2017
A Hochhaus (UK Jena, Germany)

LEARNING GOALS

M Copland

- After attending this lecture, the participant will be able to
- Describe the different potential mechanisms of CML stem cell resistance to tyrosine kinase inhibitors.
 - Discuss potential therapeutic strategies, in preclinical development or early phase clinical trials, which may improve eradication of CML stem cells.

N Cross

- After attending this lecture, the participant will be able to
- Describe the essential elements for the diagnostic work of CML patients.
 - Discuss factors associated with heterogeneous response to TKI therapy.
 - Understand the role of molecular monitoring for personalised treatment, and how this process is standardised.

A Hochhaus

- After attending this lecture, the participant will be able to
- Describe current and emerging therapies for newly diagnosed patients with CML.
 - Select appropriate upfront therapy based upon patients treatment goals and preferences, considering efficacy, safety and costs of various options.
 - Describe recommended monitoring strategies and clinical consequences from monitoring.
 - Describe the selection of second line therapies according to biological and clinical parameters.
 - Understand which patients may be eligible for treatment free remission.

→ EDUCATION SESSION 3 9 10 T C
09:45 - 11:15, Hall D
Repeated from:
Friday, June 23, 08:00 - 09:30, Hall D

ACUTE LYMPHOBLASTIC LEUKEMIA: THE WORST AND THE BEST

Chair: R Pieters (Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands)

- Balancing efficacy and toxicity in the treatment of childhood ALL
A Vora (Great Ormond Street Hospital, London, United Kingdom)
- Immunotherapy for ALL: From biology to the clinic and back
T Fry (Pediatric Oncology Branch, CCR, NCI, NIH, Bethesda, USA)
- Novel approaches with recently licensed drugs or recently studied in relapsed ALL
JM Ribera (ICO-Hospital Germans Trias i Pujol, Badalona, Spain)

LEARNING GOALS

A Vora

- After attending this lecture, the participant will be able to
- Describe the burden of toxicity of treatment for childhood ALL.
 - Discuss risk stratification for childhood ALL.
 - Select treatment that provides optimal efficacy with minimal toxicity based on leukaemia phenotype, genotype and treatment response.

T Fry

- After attending this lecture, the participant will be able to
- Describe the clinical activity and limitations of CD19-targeted chimeric antigen receptor (CD19 CAR) T cells in pediatric malignancies.
 - Differentiate between and explain the patterns of failure following CD19 CAR T cells.
 - List possible approaches to improve durability of remission following CAR T cell therapy for acute lymphoblastic leukemia.

JM Ribera

- After attending this lecture, the participant will be able to
- Although ALL is highly curable with conventional chemotherapy, novel therapeutic approaches are still needed to improve outcomes for high-risk or relapsed ALL, especially in adults.
 - Immunotherapeutic approaches have significantly improved the outcome of R/R ALL patients and are currently tested in early phases of the disease.
 - Targeted therapy combined with conventional chemotherapy and/or immunotherapy can provide promising results in some specific subtypes of ALL.

→ EHA - EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION JOINT SYMPOSIUM 4 T C
09:45 - 10:45, Hall E

60 YEARS OF ALLOGENEIC STEM CELL TRANSPLANTATION

Chairs: M Mohty (Hôpital Saint-Antoine, Paris, France)

- AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)
- From dogs to humans... The 60 year long road of allogeneic stem cell transplantation
R Storb (Fred Hutchinson Cancer Research Center, Seattle, USA)
- The long journey of donor search: From sibling to MUD to cord and haplo transplantation
E Gluckman (Hôpital Saint Louis, Paris, France)

- **Harnessing T-cell mediated anti-leukemic effect: From unmanipulated donor T-cells to tumor-specific and genetically modified T-cells**

HJ Kolb (Kolb Consulting UG, Munich, Germany)

LEARNING GOALS

R Storb

After attending this lecture, the participant will be able to

- The history and underlying principles of blood and marrow stem cell transplantation.
- The sources of stem cell grafts.
- The importance of tissue antigens.
- Graft-vs.-host disease and graft-vs.-tumor effects.
- The diseases for which transplantation can be curative.
- The concept of "minimal intensity" transplantation for older patients and those with comorbid conditions.
- Targeted radioimmunotherapy.
- Myeloablative vs. nonmyeloablative conditioning regimens.

E Gluckman

After attending this lecture, the participant will be able to

- Development of bone marrow registries.
- Development of cord blood banks.
- Interaction between donor registries and patients outcome data.
- Role of HLA for donor choice.
- Criteria of donor choice.
- Outcome of alternative donor transplants.

HJ Kolb

After attending this lecture, the participant will be able to

- The efficacy of donor lymphocytes in different diseases.
- The pathophysiology of the sustained GVL effect in chronic myeloid leukemia.
- The different effects of prophylactic/preemptive and therapeutic donor lymphocyte transfusions.
- The stimulation of GVL by leukemia derived dendritic cells and direct antigen presentation.

→ EDUCATION SESSION

09:45 - 11:15, Room N105

Repeat Session:

Saturday, June 24, 08:00 - 09:30, Room N111

5 6 9 **B T C**

BLEEDING DISORDERS

Chair: F Peyvandi (Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy)

- **Biological and clinical relevance of fibrin clot structure**

N Mutch (University of Aberdeen, United Kingdom)

- **Diagnosis and management of DIC and primary hyperfibrinolysis**

A Squizzato (Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese, Italy)

- **Diagnosis and management of rare bleeding disorders**

G Kenet (Sheba Medical Center, Tel Hashomer, Israel)

LEARNING GOALS

N Mutch

After attending this lecture, the participant will be able to

- Discuss conditions in which abnormal clot structure is observed and the downstream impact on clot stability.
- Describe how the fibrin network is degraded by the fibrinolytic system and how this can be monitored.
- Explain the factors that may influence clot structure in different areas of the vasculature.

A Squizzato

After attending this lecture, the participant will be able to

- Describe four main clinical phenotypes of patients with DIC.
- Promptly diagnose DIC and rapidly identify underlying disorders of DIC.
- Provide the best supportive therapy to prevent or treat main clinical manifestations of DIC.

G Kenet

After attending this lecture, the participant will be able to

- Describe the epidemiology, symptoms and diagnosis of patients with rare bleeding disorders.
- Discuss current and emerging treatment options, including non-replacement therapy.

→ EDUCATION SESSION

09:45 - 11:15, Room N103

Repeated from:

Friday, June 23, 08:00 - 09:30, Room N103

1 2 3 6 9 **T C**

HEREDITARY HEMATOLOGICAL DISORDERS

Chair: J Sevilla (Hospital Infantil Universitario Niño Jesús, Madrid, Spain)

- **Syndromes predisposing to hematological malignancies**

C Kratz (Hannover Medical School, Germany)

- **Diagnosis of inherited bone marrow failure and myelodysplastic syndromes**

A Shimamura (Dana-Farber/Boston Children's Cancer and Blood Disorders Center, USA)

- **The 100.000 genomes project**

WH Ouwehand (Wellcome Trust Sanger Institute, University of Cambridge, NHS Blood & Transplant, United Kingdom)

LEARNING GOALS

C Kratz

After attending this lecture, the participant will be able to

- Know the genetic syndromes associated with a range of hematologic neoplasms.
- Know the different clinical features and cancer risks associated with these conditions.
- Know why the identification of such syndromes is highly relevant clinically.

A Shimamura

After attending this lecture, the participant will be able to

- Diagnosis of inherited bone marrow failure (BMF) and inherited myelodysplastic syndromes (MDS) informs surveillance strategies and treatment decisions.
- Classical clinical stigmata of these inherited syndromes may be absent.
- Understand the indications and caveats of genetic screening strategies for the diagnosis of patients with bone marrow failure.

WH Ouwehand

After attending this lecture, the participant will be able to

- New approaches to gene discovery for inherited haematological diseases of unknown molecular aetiology by whole genome sequencing.
- Review of newly identified inherited haematological disorders since the introduction of high throughput sequencing in 2009.
- The application of high throughput sequencing platforms for the comprehensive molecular diagnosis of inherited haematological diseases caused by DNA variants in known genes.
- The need for sharing of genotype and phenotype data via 'safe-haven' models.

→ SCIENTIFIC WORKING GROUPS

2 3 8 C

09:45 - 10:45, Room N104

ELDERLY TASK FORCE IN HEMATOLOGY: AGING AND HEMATOLOGY: NEW CHALLENGES

Chair: D Bron (Institut Jules Bordet, Brussels, Belgium)

- **Introduction: Unmet needs in the supportive care of older patients with malignant hemopathies?**
D Bron (Institut Jules Bordet, Brussels, Belgium)
- **Immunosenescence or why are older patients more sensitive to malignancies?**
T Fulop (Université de Sherbrooke, Research Center on Aging, Canada)
- **Immunosenescence: When and how to vaccinate older patients with malignant hemopathies?**
R Solana (IMIBIC, Cordoba, Spain)

LEARNING GOALS

T Fulop

After attending this lecture, the participant will be able to

- Understand immune changes with aging: Immunosenescence.
- Assess the specific alterations contributing to the increased sensitivity to malignancies.
- Discuss the eventual impact of immunosenescence on the treatment of malignancies in the elderly.

R Solana

After attending this lecture, the participant will be able to

- Understand the basis of age-associated alterations of the immune response.
- Discuss the possible use and limitations of vaccination therapies in elderly AML patients.

→ SCIENTIFIC WORKING GROUPS

2 3 8 C

09:45 - 10:45, Room N109

QUALITY OF LIFE AND SYMPTOMS: PRESENT AND FUTURE OF QUALITY OF LIFE AND SYMPTOM ASSESSMENT IN DAILY CLINICAL PRACTICE IN HAEMATOLOGICAL MALIGNANCIES

Chair: T Ionova (Multinational Center for QoL Research, St Petersburg, Russia)

- **The value of PRO measures in clinical trials versus daily practice**
E Oliva (Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy)
- **Barriers and solutions in assessing PROs in daily practice**
A Fielding (UCL, London, United Kingdom)
- **Hematological malignancies: The patient's voice**
A Waldmann (LHRM e.V., Ruesselsheim, Germany)
- **A novel PRO tool for patients with hematological malignancies in clinical practice**
S Salek (University of Hertfordshire, Hatfield, United Kingdom)

LEARNING GOALS

E Oliva

After attending this lecture, the participant will be able to

- Discuss advantages of PRO measures in clinical practice.
- Describe current PRO measures for patients with haematological malignancies and their applicability in clinical trials and in daily practice.
- Select available PRO measures based upon patient and disease characteristics.

A Fielding

An up-to-date program is available via the mobile app.

A Waldmann

An up-to-date program is available via the mobile app.

S Salek

After attending this lecture, the participant will be able to

- List the disease and treatment related Quality of life issues important to patients with haematological malignancy.
- Discuss the need for a new measure of HRQoL and Symptoms for the management of patients with HM in routine clinical practice
- Describe the new haematological malignancy specific patient-reported outcome measure, the HM-PRO.

→ BASIC-SCIENCE-IN-FOCUS

2 4 B T C

09:45 - 10:45, Room N111

ROLE OF NK CELLS IN MYELOID MALIGNANCIES AND SCT

Chair: U Koehl (Institute of Cellular Therapeutics, Hannover Medical School, Germany)

- **Functional diversification of human NK cells**
K Malmberg (University of Oslo, Norway)

- **Engineering NK cells for the treatment of hematologic malignancies**

K Rezvani (The University of Texas MD Anderson Cancer Center, Houston, USA)

LEARNING GOALS

K Malmberg

- After attending this lecture, the participant will be able to
- Understand the basic principle behind the functional regulation of natural killer cells.
 - Appreciate the phenotypic and functional diversity within the NK cell repertoire.
 - Discuss the use of NK cells in cancer immunotherapy across HLA-barriers.

K Rezvani

After attending this lecture, the participant will be able to

- Describe current and emerging strategies for the next generation of cell immunotherapies using natural killer cells.
- Discuss strategies for the manufacture of effective cancer immunotherapies by redirecting NK cell specificity using chimeric antigen receptors (CAR) and by making them less susceptible to the tumor microenvironment.

→ **BASIC-SCIENCE-IN-FOCUS**

09:45 - 10:45, Room N113

1 2 **B T**

AGING AND HEMATOPOIESIS

Chair: G Vassiliou (Wellcome Trust Sanger Institute, Cambridge, United Kingdom)

- **Limited regenerative capacity of the HSC compartment as a cause of aged hematopoiesis**

M Milsom (HI-STEM & DKFZ, Heidelberg, Germany)

- **Aging, clonal hematopoiesis and pre-leukemia**

L Shlush (The Weizmann Institute of Science, Rehovot, Israel)

LEARNING GOALS

M Milsom

After attending this lecture, the participant will be able to

- Understand the likely role of hematopoietic stem cell (HSC) attrition in driving age-associated pathologies of the hematopoietic system.
- Appreciate key differences between animal models of hematopoietic ageing and aged human hematopoiesis, along with the likely reasons for these differences.
- Recognise the link between environmental stress agonists, HSC division history and hematologic ageing.

L Shlush

An up-to-date program is available via the mobile app.

→ **SCIENTIFIC WORKING GROUPS**

09:45 - 10:45, Room N115

1 **B T C**

RED CELL AND IRON: RBC HYDRATION DEFECTS

Chair: A Iolascon (University Federico II Naples, Italy)

- **RBC membrane transport in health and disease**

G Bosman (Radboud University Medical Center, Nijmegen, the Netherlands)

- **Stomatocytosis and allied disorders**

I Andolfo (University of Naples, Italy)

- **RBC hydration defects**

C Brugnara (Boston Children's Hospital, USA)

LEARNING GOALS

G Bosman

After attending this lecture, the participant will be able to

- Interpret pathological red blood cell shape and function based on disturbed membrane transport characteristics.
- Apply the most informative diagnostic tools to identify the most likely molecular pathophysiological mechanism underlying disturbed red blood cell homeostasis.
- Identify putative connections between biomarkers of disturbed systemic metabolism and red blood cell structure and function.

I Andolfo

After attending this lecture, the participant will be able to

- Identify clinical parameters to suspect an hereditary anemias due to altered permeability of red blood cell membrane.
- Explain differential diagnosis of the patients with altered permeability of red blood cell membrane.
- Understand the molecular genetics of hereditary anemias associated with altered permeability of red blood cell membrane comprising targeted-NGS approach.

C Brugnara

After attending this lecture, the participant will be able to

- Describe the major pathways capable of producing erythrocyte dehydration in hemoglobinopathies.
- Be familiar with diagnostic and clinical implication of the presence of dense, dehydrated cells.
- Discuss potential therapeutic strategies aimed at reducing red cell dehydration in hemoglobinopathies.

→ SIMULTANEOUS SESSIONS

3 T C

11:30 – 12:45, Hall A

**NEW ADVANCES IN PLASMA CELL
DISORDERS AND IMPLICATIONS FOR THERAPY**

Chairs: H Avet-Loiseau (IUC-Oncopole, Toulouse, France)
H Goldschmidt (Medizinische Klinik V, Universitätsklinikum
Heidelberg, Germany)

11:30 – 11:45

S100 **NEXT GENERATION SEQUENCING (NGS) METHODOLOGY
FOR DETERMINING CYTOGENETIC RISK STATUS IN THE
DARATUMUMAB PHASE 3 CASTOR AND POLLUX STUDIES IN
RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)**
C Chiu¹ (¹Janssen Research & Development, LLC, Spring
House, PA, United States)

11:45 – 12:00

S101 **EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMU-
MAB IN COMBINATION WITH LENALIDOMIDE AND DEXA-
METHASONE OR BORTEZOMIB AND DEXAMETHASONE IN
RELAPSED OR REFRACTORY MULTIPLE MYELOMA**
J San-Miguel¹ (¹Clínica Universidad de Navarra-CIMA,
IDISNA, Pamplona, Spain)

12:00 – 12:15

S102 **MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAME-
TER FLOW CYTOMETRY (MFC) IN TRANSPLANT ELIGIBLE
PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
(MM): RESULTS FROM THE EMN02/H095 PHASE 3 TRIAL**
S Oliva¹ (¹Myeloma Unit, Division of Hematology, University of
Torino, Torino, Italy)

12:15 – 12:30

S103 **PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC AN-
TIGEN RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/
REFRACTORY MULTIPLE MYELOMA**
W Zhang¹ (¹Second Affiliated Hospital of Xi'an Jiaotong
University, Xi'an, China)

12:30 – 12:45

S104 **PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS TREATED WITH
NEOD001 ACHIEVE RAPID ORGAN RESPONSES THAT ARE
INDEPENDENT OF PREVIOUS PLASMA CELL-DIRECTED
THERAPIES**
MA Gertz¹ (¹Mayo Clinic, Rochester, United States)

→ SIMULTANEOUS SESSIONS

3 C

11:30 – 12:45, Hall B

AGGRESSIVE NON-HODGKIN LYMPHOMA - 1ST LINE

Chairs: M Dreyling (Klinikum der Universitaet Muenchen, Germany)
A la Fuente Burguera (MD Anderson Cancer Center, Madrid,
Spain)

11:30 – 11:45

S105 **RITUXIMAB MAINTENANCE AFTER AUTOLOGOUS TEM CELL
TRANSPLANTATION PROLONGS SURVIVAL IN YOUNGER
PATIENTS WITH MANTLE CELL LYMPHOMA: FINAL RESULTS
OF THE LYMA TRIAL OF THE LYSA/GOELAMS GROUP**
S Le Gouill¹ (¹Nantes Medical University, nantes, France)

11:45 – 12:00

S106 **POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RI-
TUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISO-
NE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE
LARGE B-CELL LYMPHOMA**
H Tilly¹ (¹University of Rouen, Rouen, France)

12:00 – 12:15

S107 **RITUXIMAB SC AND IV PLUS CHOP SHOW SIMILAR EFFICACY
AND SAFETY IN THE RANDOMIZED MABEASE STUDY IN
FIRST-LINE DLBCL**
P Lugtenburg¹ (¹Erasmus MC Cancer Institute, Rotterdam,
the Netherlands)

12:15 – 12:30

S108 **ANALYSIS AND CHARACTERIZATION OF HEMATOLOGIC CAN-
CERS USING A COMPREHENSIVE NGS PANEL COMPRISED OF
DNA AND RNA BAITS TARGETING 704 GENES**
AR Carson¹ (¹Inivoscribe, San Diego, United States)

12:30 – 12:45

S109 **TP53 MUTATIONS, BUT NOT DELETION OF TP53 AND CDK-
N2A, HAVE INDEPENDENT PROGNOSTIC VALUE IN MANTLE
CELL LYMPHOMA TREATED BY THE NORDIC (MCL2 AND
MCL3) REGIMEN**
CW Eskelund¹ (¹University Hospital of Copenhagen,
Copenhagen, Denmark)

→ SIMULTANEOUS SESSIONS

2 5 9 10 B T C

11:30 – 12:45, Hall C

MRD DIRECTED TREATMENT IN AML

Chairs: G Ossenkoppelle (VU University Medical Center, Amster-
dam, the Netherlands)
A Venditti (Università di Roma "Tor Vergata", Italy)

11:30 – 11:45

S110 **DEEP MOLECULAR RESPONSE TO GILTERITINIB IMPROVES
SURVIVAL IN FLT3 MUTATION-POSITIVE RELAPSED/RE-
FRACTORY ACUTE MYELOID LEUKEMIA**
A Jessica¹ (¹Robert H. Lurie Comprehensive Cancer Center of
Northwestern University, Chicago, United States)

11:45 – 12:00

S111 **RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG
ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEU-
KEMIA: RESULTS OF THE AML1310 TRIAL OF THE GIMEMA
GROUP**
A Venditti¹ (¹Hematology, University Tor Vergata, Roma, Italy)

12:00 – 12:15
S112 **GRAFT VERSUS LEUKEMIA EFFECT OF ALLOGENEIC STEM CELL TRANSPLANTATION AND MINIMAL RESIDUAL DISEASE IN PATIENTS WITH AML IN FIRST COMPLETE REMISSION.**
J Versluis¹ (Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands)

12:15 – 12:30
S113 **LEUKEMIC STEM CELL FREQUENCY COMBINED WITH MRD IS AN IMPORTANT BIOMARKER TO PREDICT RELAPSE IN ACUTE MYELOID LEUKEMIA. RESULTS FROM A PROSPECTIVE H102 STUDY**
W Zeijlemaker¹ (VU University Medical Center, Amsterdam, the Netherlands)

12:30 – 12:45
S114 **DEFINITION OF PARTIAL RESPONSE IN YOUNGER AML PATIENTS AFTER FIRST INDUCTION COURSE MAY BE EXTENDED BY INCLUSION OF IMMUNOPHENOTYPIC DETECTION OF MEASURABLE RESIDUAL DISEASE IN CR**
S Freeman¹ (University of Birmingham, Birmingham, United Kingdom)

→ SIMULTANEOUS SESSIONS 3 5 B T
11:30 – 12:45, Hall D

NEW INSIGHTS INTO CHRONIC LYMPHOCYTTIC LEUKEMIA BIOLOGY

Chairs: A Steele (Leukemia and Lymphoma Molecular Mechanisms and Therapy Group, Southampton, United Kingdom)
JI Martin-Subero (IDIBAPS, Barcelona, Spain)

11:30 – 11:45
S115 **CLINICAL IMPACT OF THE SUBCLONAL ARCHITECTURE AND MUTATIONAL COMPLEXITY IN CHRONIC LYMPHOCYTTIC LEUKEMIA**
F Nadeu¹, ² (IDIBAPS, Barcelona, Spain, ²CIBERONC, Madrid, Spain)

11:45 – 12:00
S116 **FBXW7 MUTATIONS LEAD TO ACCUMULATION OF NOTCH1, HIF1- α AND C-MYC IN CLL CELLS**
V Meyer-Pannwitt¹, ² (Department of Molecular Genetics (B061), Cooperation Unit "Mechanisms of Leukemogenesis", DKFZ, Heidelberg, Germany, ²Internal Medicine III, Ulm University, Ulm, Germany)

12:00 – 12:15
Poster Pitches
P236 **GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTTIC LEUKEMIA**
J Brown
Full Poster presentation: Friday, June 23 – Poster Walk: "Chronic lymphocytic leukemia and related disorders - Biology 1". More information on page 109

P244 **DNA METHYLATION PROFILING IN CHRONIC LYMPHOCYTTIC LEUKEMIA PATIENTS CARRYING STEREOTYPED B-CELL RECEPTORS: A DIFFERENT CELLULAR ORIGIN FOR SUBSET #2?**
S Bhoi
Full Poster presentation: Friday, June 23 – Poster Walk: "Chronic lymphocytic leukemia and related disorders - Biology 1". More information on page 109

P583 **NOTCH1 MUTATED CHRONIC LYMPHOCYTTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS**
F Pozzo
Full Poster presentation: Saturday, June 24 – Poster Walk: "Chronic lymphocytic leukemia and related disorders - Biology 2". More information on page 152

P588 **INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE**
E Tissino
Full Poster presentation: Saturday, June 24 – Poster Walk: "Chronic lymphocytic leukemia and related disorders - Biology 2". More information on page 152

P586 **MICROENVIRONMENT REGULATION OF PROGRAMMED DEATH-1 (PD1) RECEPTOR AND ITS LIGANDS PDL1 AND PDL2 IN CHRONIC LYMPHOCYTTIC LEUKEMIA (CLL)**
F Morabito
Full Poster presentation: Saturday, June 24 – Poster Walk: "Chronic lymphocytic leukemia and related disorders - Biology 2". More information on page 152

P589 **IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLE STUDY**
F Yates
Full Poster presentation: Saturday, June 24 – Poster Walk: "Chronic lymphocytic leukemia and related disorders - Biology 2". More information on page 152

12:15 – 12:30
S117 **INTEGRATIVE ANALYSIS OF THE GENOME, EPIGENOME, TRANSCRIPTOME AND THREE-DIMENSIONAL CHROMATIN STRUCTURE IN CHRONIC LYMPHOCYTTIC LEUKEMIA**
R Beekman¹ (IDIBAPS, Barcelona, Spain)

12:30 – 12:45
S118 **THERAPEUTIC DISRUPTION OF THE BAFF- B-CELL RECEPTOR (BCR) CROSS-TALK IN CHRONIC LYMPHOCYTTIC LEUKEMIA (CLL) CELLS**
A Danilov¹ (Oregon Health and Science University, Portland, United States)

→ SIMULTANEOUS SESSIONS

2 5 B T

11:30 – 12:45, Hall E

PATHOGENESIS OF MDS

Chairs: M Cazzola (University of Pavia, Italy)
D Nowak (University Hospital Mannheim, Germany)

11:30 – 11:45

S119 **LOW MYBL2 EXPRESSION OBSERVED IN MYELOYDYSPLASTIC SYNDROME PATIENTS WITH WORSE PROGNOSIS IS ASSOCIATED WITH ALTERED DNA REPAIR MECHANISMS IN HAEMATOPOIETIC STEM CELLS**
P Garcia¹ (¹University of Birmingham, Birmingham, United Kingdom)

11:45 – 12:00

S120 **A NOVEL GENETIC AND MORPHOLOGIC PHENOTYPE OF ARID2-MEDIATED MYELOYDYSPLASTIC SYNDROMES.**
H Makishima^{1, 5} (¹Cleveland Clinic, Cleveland, United States, ⁵Kyoto University, Kyoto, Japan)

12:00 – 12:15

S121 **THE VALUE OF NGS PANEL SEQUENCING TO MOLECULARLY DEFINE MYELOID MALIGNANCIES AND CLARIFY BORDERLINE CASES: A STUDY ON 39 GENES IN 1143 PATIENTS**
C Baer¹ (1MLL Munich Leukemia Laboratory, Munich, Germany)

12:15 – 12:30

S122 **IDENTIFICATION OF ABERRANTLY SPLICED GENES AND DEREGULATED PATHWAYS/GENE ONTOLOGY THEMES IN MYELOYDYSPLASTIC SYNDROME PATIENTS WITH SPLICING FACTOR GENE MUTATIONS**
A Pellagatti¹ (¹University of Oxford, Oxford, United Kingdom)

12:30 – 12:45

S123 **TRANSCRIPTOME SEQUENCING REVEALS DISTINCT SUBTYPES OF MYELOYDYSPLASIA WITH PROGNOSTIC SIGNIFICANCE**
S Ogawa¹ (¹Kyoto University, Kyoto, Japan)

→ SIMULTANEOUS SESSIONS

3 5 B T

11:30 – 12:45, Room N101

LYMPHOMA BIOLOGY

Chairs: E Macintyre (Université Sorbonne Paris Cité (Descartes) / Hôpital Necker Enfants Malades, Paris, France)
K Grønbaek (Rigshospitalet, Copenhagen Ø, Denmark)

11:30 – 11:45

S124 **GENETIC ALTERATIONS INVOLVING PROGRAMMED DEATH LIGANDS IN EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOMAS**
K Kataoka¹ (¹Kyoto University, Kyoto, Japan)

11:45 – 12:00

S125 **FOXO1 CONTROL CD20 EXPRESSION AND INFLUENCE B-CELL LYMPHOMA RESPONSE TO RITUXIMAB-BASED IMMUNOTHERAPY**
M Dwojak¹ (¹Medical University of Warsaw, Warsaw, Poland)

12:00 – 12:15

Poster Pitches

P295 **GENOME-WIDE ASSOCIATION STUDY OF HODGKIN LYMPHOMA IDENTIFIES HISTOLOGY-SPECIFIC ASSOCIATIONS AND TRANSCRIPTIONAL REGULATORS OF DISEASE SUSCEPTIBILITY**
A Sud
Full Poster presentation: Friday, June 23 – Poster Walk: “Lymphoma biology”. More information on page 112

P296

SOX11 PROMOTES TUMOR PROTECTIVE MICROENVIRONMENT INTERACTIONS IN MANTLE CELL LYMPHOMA
P Balsas
Full Poster presentation: Friday, June 23 – Poster Walk: “Lymphoma biology”. More information on page 112

P297

AICDA DRIVES EPIGENETIC HETEROGENEITY IN GERMINAL CENTER-DERIVED LYMPHOMAS AND ACCELERATES LYMPHOMAGENESIS
M Dominguez Rodriguez
Full Poster presentation: Friday, June 23 – Poster Walk: “Lymphoma biology”. More information on page 112

P298

XPO1 INHIBITION SYNERGIZES WITH BCR INHIBITION, BLOCKS TUMOR GROWTH AND PROLONGS SURVIVAL IN A BIOLUMINESCENT ANIMAL MODEL OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
M Crespo
Full Poster presentation: Friday, June 23 – Poster Walk: “Lymphoma biology”. More information on page 112

P299

MOLECULAR HETEROGENEITY IN PERIPHERAL T-CELL LYMPHOMA NOT OTHERWISE SPECIFIED REVEALED BY COMPREHENSIVE MUTATIONAL PROFILING.
Y Watatani
Full Poster presentation: Friday, June 23 – Poster Walk: “Lymphoma biology”. More information on page 112

P300

A COMPREHENSIVE PORTRAIT OF THE DNA METHYLOME OF 866 SAMPLES FROM DIFFERENT B CELL NEOPLASMS: BIOLOGICAL INSIGHTS AND CLINICAL APPLICATIONS
M Duran-Ferrer
Full Poster presentation: Friday, June 23 – Poster Walk: “Lymphoma biology”. More information on page 113

P301

ACTIVATION OF RHOA-VAV1 SIGNALING AXIS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
M Fujisawa
Full Poster presentation: Friday, June 23 – Poster Walk: “Lymphoma biology”. More information on page 113

P302 **STAT3 IS CONSTITUTIVELY ACTIVATED AND CAN BE A THERAPEUTIC TARGET OF JAK INHIBITORS IN CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION**

A Arai

Full Poster presentation: Friday, June 23 – Poster Walk: “Lymphoma biology”. More information on page 113

12:15 – 12:30

S126 **ALPHA-KETOGLUTURATE EXPOSES METABOLIC VULNERABILITIES IN B-CELL LYMPHOMAS**

R Aguiar¹ (University of Texas Health Science Center, San Antonio, United States)

12:30 – 12:45

S127 **DELETION OF THE F-BOX PROTEIN NIPA (NUCLEAR INTERACTION PARTNER OF ALK) IMPAIRS NPM-ALK DRIVEN TRANSFORMATION**

LJ Lippert¹ (University of Freiburg Medical Center, Freiburg, Germany)

→ SIMULTANEOUS SESSIONS

1 4 5 9 B T

11:30 – 12:45, Room N105

THALASSEMIA

Chairs: GL Forni (European Reference Networks for Rare Diseases ERN-EuroBloodNet / Ospedale Galliera, Genova, Italy)
C McMahon (Our Lady’s Children’s Hospital, Crumlin, Dublin, Ireland)

11:30 – 11:45

S128 **GENE THERAPY FOR BETA THALASSEMIA: INITIAL RESULTS FROM THE PHASE I/II TIGET-BTHAL TRIAL OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS GENETICALLY MODIFIED WITH GLOBE LENTIVIRAL VECTOR**

S Markteli¹ (San Raffaele Scientific Institute, Milano, Italy)

11:45 – 12:00

S129 **LUSPATERCEPT INCREASES HEMOGLOBIN AND DECREASES TRANSFUSION BURDEN IN ADULTS WITH β -THALASSEMIA**

A Piga¹ (Turin University, Turin, Italy)

12:00 – 12:15

S130 **DENOSUMAB INCREASES BONE MINERAL DENSITY IN PATIENTS WITH THALASSEMIA MAJOR AND OSTEOPOROSIS: RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND, PHASE 2B CLINICAL TRIAL**

E Voskaridou¹ (“Laiko” General Hospital, Athens, Greece)

12:15 – 12:30

S131 **LONG-TERM HEALTH STATUS AFTER HSC TRANSPLANTATION FOR THALASSEMIA: THE FRENCH EXPERIENCE**

I Thuret¹ (Hopital de la Timone, Assistance publique-hôpitaux de Marseille, Marseille, France)

12:30 – 12:45

S132 **CD34+ AND HUMAN INDUCED PLURIPOTENT STEM CELL (IPSC) DIFFERENTIATION TO TRANSFUSION READY RED BLOOD CELLS**

MJ Claessen^{1, 2} (1AMC Amsterdam, Amsterdam, the Netherlands, 2Sanquin Research, Amsterdam, the Netherlands)

→ SIMULTANEOUS SESSIONS

2 5 9 10 B T

11:30 – 12:45, Room N103

AML BIOLOGY I: TOWARDS MOLECULAR THERAPIES

Chairs: A Thompson (Centre for Biomolecular Sciences, Nottingham, United Kingdom)
M Kühn (University Medical Center, Johannes Gutenberg-Universität Mainz, Germany)

11:30 – 11:45

S133 **FUNCTIONAL PROTEOMICS IDENTIFIES SETD2 AS A CRITICAL EFFECTOR OF MLL FUSION PROTEINS TO SAFEGUARD GENOMIC INTEGRITY.**

A Skucha¹ (CeMM - Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria)

11:45 – 12:00

S134 **CEBPA-MUTANT ACUTE MYELOID LEUKEMIA IS SENSITIVE TO SMALL-MOLECULE-MEDIATED INHIBITION OF THE MEN-IN-MLL INTERACTION**

L Schmidt¹ (Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria)

12:00 – 12:15

Poster Pitches

P171 **RECURRENT MYB REARRANGEMENT IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM**

K Suzuki

Full Poster presentation: Friday, June 23 – Poster Walk: “Acute myeloid leukemia - Biology 1”. More information on page 105

P172 **BRANCHED CHAIN AMINO ACID METABOLISM REGULATES ALPHA-KETOGLUTARATE HOMEOSTASIS RESEMBLING MUTANT-IDH DRIVEN DNA HYPERMETHYLATION IN AML**

S Raffel

Full Poster presentation: Friday, June 23 – Poster Walk: “Acute myeloid leukemia - Biology 1”. More information on page 105

P173 **NUCLEAR RE-LOCALIZATION OF NPM1C+ INDUCES DIFFERENTIATION AND CELL GROWTH ARREST**

L Brunetti

Full Poster presentation: Friday, June 23 – Poster Walk: “Acute myeloid leukemia - Biology 1”. More information on page 105

P174 **THE LONG NON-CODING RNA HOXB-AS3 REGULATES RIBOSOMAL BIOGENESIS IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA**

D Papaioannou

Full Poster presentation: Friday, June 23 – Poster Walk:
“Acute myeloid leukemia - Biology 1”. More information on page 105

P175 **A DUAL BH3-MIMETIC APPROACH TARGETING BOTH BCL-2 AND MCL1 IS HIGHLY EFFICACIOUS AND WELL-TOLERATED IN ACUTE MYELOID LEUKEMIA**

D Moujalled

Full Poster presentation: Friday, June 23 – Poster Walk:
“Acute myeloid leukemia - Biology 1”. More information on page 105

P176 **THE PMLC62A/C65A KNOCK-IN MOUSE MODEL PROVIDES EVIDENCE FOR THE ROLE OF NUCLEAR BODY DISRUPTION IN THE PATHOGENESIS OF ACUTE PROMYELOCYTIC LEUKEMIA**

E Voisset

Full Poster presentation: Friday, June 23 – Poster Walk:
“Acute myeloid leukemia - Biology 1”. More information on page 105

P177 **DECIPHERING THE ONCOGENIC NETWORK OF PRC2 LOSS GUIDED LEUKEMOGENESIS**

D Heckl

Full Poster presentation: Friday, June 23 – Poster Walk:
“Acute myeloid leukemia - Biology 1”. More information on page 105

12:15 – 12:30

S135 **INHIBITION OF THE MYELOID MASTER REGULATOR PU.1 AS A THERAPEUTIC STRATEGY IN ACUTE MYELOID LEUKEMIA**

I Antony-Debre¹, ² (1Gustave Roussy, Villejuif, France, 2Albert Einstein College of Medicine, New York, United States)

12:30 – 12:45

S136 **METABOLIC ADAPTATIONS TO TARGETED THERAPY IN FLT3 MUTATED ACUTE MYELOID LEUKAEMIA (AML)**

P Gallipoli¹ (1UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

→ SIMULTANEOUS SESSIONS

1 4 5 9 B T

11:30 – 12:45, Room N104

HEMATOPOIESIS, STEM CELLS AND MICROENVIRONMENT

Chairs: W Fibbe (Leiden University Medical Center, the Netherlands)
S Karlsson (Lund University, Sweden)

11:30 – 11:45

S137 **STEP-WISE REPROGRAMMING OF ENDOTHELIAL CELLS INTO IMMUNE-COMPETENT HEMATOPOIETIC STEM CELLS**

JG Barcia Duran¹ (1Weill Cornell Graduate School of Medical Sciences, New York, United States)

11:45 – 12:00

S138 **MARROW MESENCHYMAL STEM CELLS RESCUE BONE MARROW ENDOTHELIAL CELLS SUFFERING CHEMOTHERAPY STRESS BY TRANSFERRING MITOCHONDRIA THROUGH NANOTUBES**

Y Feng¹ (1Institute of Hematology, Beijing, China)

12:00 – 12:15

Poster Pitches

P268 **TARGETING THE CASPASE / NOX2 AXIS TO MODULATE MACROPHAGE POLARIZATION**

S Solier

Full Poster presentation: Friday, June 23 – Poster Walk:
“Hematopoiesis, stem cells and microenvironment”. More information on page 111

P264 **ACUTE MYELOID LEUKEMIA ALTERS THE PERMEABILITY OF THE BONE MARROW VASCULAR MICROENVIRONMENT, FOSTERING DISEASE PROGRESSION AND DRUG RESISTANCE**

D Passaro

Full Poster presentation: Friday, June 23 – Poster Walk:
“Hematopoiesis, stem cells and microenvironment”. More information on page 110

P265 **BUILDING HUMAN BONE MARROW-LIKE MODELS TO STUDY NICHE INTERACTIONS**

R Groen

Full Poster presentation: Friday, June 23 – Poster Walk:
“Hematopoiesis, stem cells and microenvironment”. More information on page 110

P266 **MULTISCALE IMAGE-BASED QUANTITATIVE ANALYSIS OF BONE MARROW STROMAL NETWORK TOPOLOGY REVEALS STRICT SPATIAL CONSTRAINTS FOR HEMATOPOIETIC-STROMAL CELLULAR INTERACTIONS**

C Nombela Arrieta

Full Poster presentation: Friday, June 23 – Poster Walk:
“Hematopoiesis, stem cells and microenvironment”. More information on page 111

P267 TEMPLATED V(D)J INSERTIONS ARE A NOVEL BIOLOGIC MECHANISM FOR B-CELL RECEPTOR REPERTOIRE DIVERSIFICATION

M Koning

Full Poster presentation: Friday, June 23 – Poster Walk: “Hematopoiesis, stem cells and microenvironment”. More information on page 111

P269 MULTIPLE MYELOMA-POLARIZED M2C MACROPHAGES PROMOTE A TUMOR-SUPPORTIVE OSTEOLYTIC MICROENVIRONMENT VIA CXCL13

K Beider

Full Poster presentation: Friday, June 23 – Poster Walk: “Hematopoiesis, stem cells and microenvironment”. More information on page 111

P270 RE-ORDERING THE B CELL DEVELOPMENT HIERARCHY IN HUMAN FETAL BONE MARROW: CHARACTERISATION OF A NOVEL HUMAN FETAL B PROGENITOR

S OByrne

Full Poster presentation: Friday, June 23 – Poster Walk: “Hematopoiesis, stem cells and microenvironment”. More information on page 111

P271 HUNDREDS OF EMBRYONIC HEMATOPOIETIC PRECURSORS CONTRIBUTE TO LIFE-LONG HEMATOPOIESIS

M Ganuza Fernandez

Full Poster presentation: Friday, June 23 – Poster Walk: “Hematopoiesis, stem cells and microenvironment”. More information on page 111

12:15 – 12:30

S139 SHORT-TERM FEEDING OF A HIGH-FAT DIET DISTURBS LIPID RAFT/TGF- β SIGNALING-MEDIATED QUIESCENCE OF HEMATOPOIETIC STEM CELLS IN C57BL/6J MOUSE BONE MARROW

F Hermetet^{1, 2} (¹UMR1231 Inserm / Université Bourgogne Franche-Comté / AgroSup, Dijon, France, ²LabEx LipSTIC, Dijon, France)

12:30 – 12:45

S140 A NOVEL MODEL OF HUMAN LYMPHO-MYELOID PROGENITOR HIERARCHY BASED ON SINGLE CELL FUNCTIONAL AND TRANSCRIPTIONAL ANALYSIS

D Karamitros^{1, 2} (¹Oxford Biomedical Research Centre, Oxford, United Kingdom, ²WIMM/NDCLS University of Oxford, Oxford, United Kingdom)

→ SIMULTANEOUS SESSIONS

1 4 5 9 10 B T C

11:30 – 12:45, Room N109

GENE THERAPY, CELLULAR IMMUNOTHERAPY AND VACCINATION 1

Chairs: Z Berneman (Antwerp University Hospital, Edegem, Belgium)

T Haas (III. Medizinische Klinik, Technische Universität München, Germany)

11:30 – 11:45

S141 WILMS' TUMOR 1 (WT1) RNA-ELECTROPORATED DENDRITIC CELL VACCINATION AS POST-REMISSION TREATMENT TO PREVENT OR DELAY RELAPSE IN ACUTE MYELOID LEUKEMIA: FINAL RESULTS OF A PHASE II STUDY IN 30 PATIENTS

Z Berneman¹ (¹ANTWERP UNIVERSITY HOSPITAL, Edegem, Belgium)

11:45 – 12:00

S142 FIRST-IN-HUMAN MULTICENTER STUDY OF BB2121 ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS

Y Lin¹ (¹Mayo Clinic, Rochester, MN, United States)

12:00 – 12:15

S143 BASELINE AND EARLY POST-TREATMENT CLINICAL AND LABORATORY FACTORS ASSOCIATED WITH SEVERE NEUROTOXICITY FOLLOWING 19-28Z CAR T CELLS IN ADULT PATIENTS WITH RELAPSED B-ALL

J Park¹ (¹MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, United States)

12:15 – 12:30

S144 FIRST EVIDENCE DEMONSTRATING ENGRAFTMENT AND REPOPULATION ADVANTAGE OF GENE-CORRECTED HEMATOPOIETIC REPOPULATING CELLS IN NON-CONDITIONED FANCONI ANEMIA PATIENTS

J Sevilla¹ (¹Hospital Infantil Universitario Niño Jesús. FIB HIUNJ. CIBERER, Madrid, Spain)

12:30 – 12:45

S145 TARGETING FLT3 WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS CONFERS POTENT REACTIVITY AGAINST ACUTE MYELOID LEUKEMIA (AML)

H Jetani¹ (¹University Hospital Würzburg, Würzburg, Germany)

→ MEET-THE EXPERT 1 2 4 C
11:30 - 12:30, Room N107
Availability on first come first serve basis

AN APPROACH TO IRON OVERLOAD IN MDS AND EITHER IN BMT OR BEFORE, DURING AND AFTER BMT

Speaker: E Rachmilewitz (Edith Wolfson Medical center, Holon, Israel)

→ MEET-THE EXPERT 3 9 C
11:30 - 12:30, Room N108
Availability on first come first serve basis

ALL IN ADOLESCENCE AND YOUNG ADULTS CASE STUDIES

Speaker: JM Ribera (ICO-Hospital Germans Trias i Pujol, Badalona, Spain)

→ MEET-THE EXPERT 3 C
11:30 - 12:30, Room N117
Availability on first come first serve basis

AMYLOIDOSIS TREATMENT

Speaker: GP Merlini (Scientific Institute Policlinico San Matteo and University of Pavia, Italy)

→ SPECIAL SESSION
13:00 - 14:15, Hall A

OPENING CEREMONY

Chairs: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)
S Izraeli, Chair Scientific Program Committee (Sheba Medical Center, Ramat Gan, Israel)

- **Opening address**
AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)
- **Presentation EHA – José Carreras young investigator award & EHA research grants**
M Muckenthaler, Chair Fellowships & Grants Committee (University of Heidelberg, Germany)
- **Introduction José Carreras Award & Lecture**
S Izraeli, Chair Scientific Program Committee (Sheba Medical Center, Ramat Gan, Israel)
- **José Carreras Lecture:**
AML: The Evil side of gene regulation
R Delwel (Erasmus MC, Rotterdam, the Netherlands)

→ HEMATOLOGY-IN-FOCUS 2 3 5 C
14:30 - 15:30, Hall A

NEWS IN WHO 2016 CLASSIFICATION OF HEMATOLOGIC MALIGNANCIES

Chair: U Jäger (Medical University of Vienna, Austria)

- **Lymphoid malignancies**
SH Swerdlow (University of Pittsburgh School of Medicine, USA)
- **Myeloid malignancies**
M Cazzola (University of Pavia, Italy)

LEARNING GOALS

SH Swerdlow

After attending this lecture, the participant will be able to

- Explain the process by which the WHO lymphoma classification was developed.
- Discuss the major changes introduced in the 2016 revised WHO lymphoma classification & upcoming monograph.
- Apply the practice-changing elements of the revised classification & diagnostic criteria in their clinical work.

M Cazzola

After attending this lecture, the participant will be able to

- Describe the most important modifications of the 2016 revision of the WHO classification of myeloid malignancies.
- Describe the many novel molecular findings with diagnostic and/or prognostic importance that have been incorporated into the 2016 revision.
- Discuss the different levels of integration of genetic data into the clinicopathological classification of myeloid malignancies.

→ CLINICAL DEBATE 2 4 C
14:30 - 15:30, Hall B

SHOULD LOW RISK MDS BE TRANSPLANTED?

Chair: JA Pérez Simón (University Hospital Virgen del Rocío, Seville, Spain)

- **Yes**
N Kröger (University Medical Center Hamburg-Eppendorf, Germany)
- **No**
P Fenaux (Hôpital St Louis, Paris, France)

→ HEMATOLOGY-IN-FOCUS 3 B T C
14:30 - 15:30, Hall C

WALDENSTRÖM'S DISEASE

Chair: MV Mateos (University Hospital of Salamanca, Spain)

- **Molecular biology of Waldenström's disease**
S Treon (Harvard Medical School, Boston, USA)
- **Novel treatment strategies in Waldenström's macroglobulinemia**
E Kastiris (National and Kapodistrian University of Athens, Greece)

LEARNING GOALS

S Treon

After attending this lecture, the participant will be able to

- Understand current and novel therapeutic options for WM.
- Understand the role of MYD88 and CXCR4 mutations in treatment choices in WM.
- Role of maintenance therapy in WM.

E Kastritis

After attending this lecture, the participant will be able to

- Indications for treatment in patients with Waldenström's Macroglobulinemia and definitions of symptomatic disease.
- Available treatment options for patients with symptomatic Waldenström's Macroglobulinemia.
- Risk assessment in patients with WM and risk adapted/ symptom oriented choice of therapy.
- Management of special populations of patients with WM (elderly, transplant candidates, IgM-related complications, IgM amyloidosis).
- Management of rare complications of WM.
- Management of relapsed / refractory disease.

→ EHA - JAPANESE SOCIETY OF HEMATOLOGY JOINT SYMPOSIUM 2 3 5 B T
14:30 - 15:30, Hall D

NEXT GENERATION SEQUENCING OF HEMATOLOGICAL MALIGNANCIES

Chairs: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)
K Akashi, President of JSH (Kyushu University, Fukuoka, Japan)

- NGS discovering cancer immune evasion through disruption of PD-L1 3'-UTR sequence
S Ogawa (Kyoto University, Japan)
- Interrogating the architecture of cancer genomes
P Campbell (The Wellcome Trust Sanger Inst, Hinxton, United Kingdom)

LEARNING GOALS

S Ogawa

After attending this lecture, the participant will be able to

- Describe how cancer cells evade host immune system using checkpoints.
- Describe how PD-L1 expression is regulated via its 3'-UTR sequences.
- Describe how the mechanism is deregulated in cancer cells via disruption of the 3'-UTR sequences, leading to abnormally high expression of PD-L1 and promoting cancer immune evasion.
- Describe how PD-L1 3'-UTR disruption could be exploited as a potential biomarkers to predict the response to anti-PD-1/PD-L1 antibodies.

P Campbell

After attending this lecture, the participant will be able to

- Understand patterns of somatic mutation in normal blood cells.
- Use somatic mutations as read-outs of clonal structure.

→ CLINICAL DEBATE 6 C
14:30 - 15:30, Hall E

REVERSAL OF DIRECT ORAL ANTICOAGULANTS (DOAC): DO WE REALLY NEED AN ANTIDOTE?

Chair: PA Kyrle (Medical University of Vienna, Austria)

- Yes
M Levi (Academic Medical Center, University of Amsterdam, the Netherlands)
- No
W Ageno (University of Insubria, Varese, Italy)

→ HEMATOLOGY-IN-FOCUS 2 3 5 9 T C
14:30 - 15:30, Room N101

LEUKEMIAS WITH MIXED PHENOTYPES

Chair: J Martinez-Lopez (Hospital Universitario 12 de Octubre, Madrid, Spain)

- What is ambiguous: Shrinking the zone of uncertainty between ALL and AML
O Hrusak (CLIP Childhood Leukaemia Investigation Prague, Czech Republic)
- Genomics and clinical characteristics of mixed phenotype acute leukemia
H Inaba (St. Jude Children's Research Hospital, Memphis, USA)

LEARNING GOALS

O Hrusak

After attending this lecture, the participant will be able to

- Distinguish 4 categories of ambiguous lineage leukemias while being aware of overlaps among them.
- Relate current knowledge and history of the ambiguous lineage leukemia definitions.
- Describe the molecular genetic heterogeneity of ambiguous lineage leukemias.
- Understand the criteria for selecting the upfront ALL or AML type of therapy.
- Know the options in treatment failure including transplant and change of treatment type.
- Describe the nature of on-treatment lineage switches, and when to react to them therapeutically.

H Inaba

After attending this lecture, the participant will be able to

- Describe the results of an international collaborative genomic study of pediatric mixed-phenotype acute leukemia.
- Discuss the possible pathophysiology of pediatric mixed-phenotype acute leukemia.
- Discuss the treatment options for pediatric mixed-phenotype acute leukemia based on genetic findings.

→ EHA - HEMATOLOGY SOCIETY OF TAIWAN JOINT SYMPOSIUM 2 5 T C
14:30 - 15:30, Room N105

ACUTE MYELOID LEUKEMIA

Chairs: DT Lin (The Hematology Society of Taiwan, Taipei, Taiwan)
C Chomienne (Hôpital Saint-Louis, Paris, France)

- Clinical implications of gene alterations in risk-adapted treatment of AML

HF Tien (National Taiwan University Hospital, Taipei, Taiwan)

- Emerging therapeutic strategies in AML

S Knapper (Cardiff University, United Kingdom)

LEARNING GOALS

HF Tien

After attending this lecture, the participant will be able to

- Understand the landscape of gene mutations in AML.
- Know the implications of gene mutations in classification, risk stratification, and personalized treatment of AML.

S Knapper

After attending this lecture, the participant will be able to

- Describe emerging treatment strategies for adults with newly diagnosed and relapsed / refractory AML.
- Understand the expanding options for targeted intervention in different genetic sub-groups and disease scenarios.
- Appreciate some of the challenges in designing and coordinating clinical trials in this rapidly expanding field.

→ CLINICAL DEBATE 6 9 C
14:30 - 15:30, Room N103

DO NEW STUDIES SUPPORT A PREFERENTIAL INDICATION OF PLASMA-DERIVED VS. RECOMBINANT CONCENTRATES FOR THE TREATMENT OF NEW PATIENTS WITH SEVERE HEMOPHILIA A?

Chairs: D Di Michele (National Institutes of Health, USA)

F Rodeghiero (Hematology Project Foundation /
Fondazione Progetto Ematologia, Vicenza, Italy)

• Yes

PM Mannucci (IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation, Milan, Italy)

• No

F Pignatti (European Medicines Agency, London,
United Kingdom)

→ HEMATOLOGY-IN-FOCUS 2 10 B T C
14:30 - 15:30, Room N104

CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

Chair: F Onida (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - University of Milan, Italy)

- From genetics to epigenetics in CMML

E Solary (Gustave Roussy, Inserm, Villejuif, France)

- Risk adapted treatment of CMML

E Padron (H. Lee Moffitt Cancer Center, Tampa, USA)

LEARNING GOALS

E Solary

After attending this lecture, the participant will be able to

- Combine appropriate tools to rapidly distinguish a chronic myelomonocytic leukemia from a reactive monocytosis.
- Summarize current understanding of chronic myelomonocytic leukemia pathogenesis.
- Identify the main prognostic factors identified so far in this disease.
- Discuss current therapeutic options and emerging therapeutic strategies.

E Padron

After attending this lecture, the participant will be able to

- Describe state of the art diagnostic criteria for Chronic Myelomonocytic Leukemia (CMML).
- Describe current standard of care and emerging therapies in CMML.
- Describe preclinical challenges and opportunities for future translational research in CMML.

→ EARLY CAREER SESSION 1 2 3 B T C
14:30 - 15:30, Room N109

EHA FELLOWSHIP AND TRTH AWARDEES

Chair: AK Eisfeld (The Ohio State University, Columbus, USA)

- Clonal heterogeneity and clonal evolution in AML during chemotherapy-understanding a dynamic disease

K Metzeler (Laboratory for Leukemia Diagnostics, University of Munich, Germany)

- Molecular regulation of exit from quiescence in human hematopoietic stem cells

E Laurenti (Wellcome Trust MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom)

- Macrophage iron recycling or dietary iron uptake: What causes iron overload in hemochromatosis?

S Altamura (University of Heidelberg, Germany)

LEARNING GOALS

K Metzeler

After attending this lecture, the participant will be able to

- Describe the spectrum of conditions characterized by somatic mutations in hematopoietic stem/precursor cell clones, from clonal hematopoiesis of indeterminate potential (CHIP) to myeloid neoplasms.
- Discuss the relevance of clonal hematopoiesis as a risk factor for spontaneous and therapy-induced myeloid neoplasia.
- Summarize our current knowledge on pre-leukemic clones in AML, their persistence after induction chemotherapy, and their clinical relevance.

E Laurenti

After attending this lecture, the participant will be able to

- The human hematopoietic stem cell (HSC) compartment contains functionally and molecularly distinct HSC subsets.
- The transcriptional status of HSC subsets is highly dependent on the cell cycle state.
- The quiescent state (G0) masks transcriptional differences between human HSC subsets.

S Altamura

An up-to-date program is available via the mobile app.

→ HEMATOLOGY-IN-FOCUS 1 5 9 T C
14:30 - 15:30, Room N111

ERYTHROPOIESIS AND RARE ANEMIAS

Chair: A Iolascon (University Federico II Naples, Italy)

- **Genetic studies of human erythropoiesis**
V Sankaran (Boston Children's Hospital/ Broad Institute, USA)
- **Gene targeted NGS to improve diagnosis of rare anemia**
B Clark (King's College Hospital, London, United Kingdom)

LEARNING GOALS

V Sankaran

After attending this lecture, the participant will be able to

- Describe our current understanding of human erythropoiesis and hemoglobin gene regulation
- Discuss the current understanding of how rare and common genetic variation can influence human erythropoiesis.
- Describe how genetic insight is suggesting new treatments for sickle cell disease, thalassemia, and Diamond-Blackfan anemia.

B Clark

After attending this lecture, the participant will be able to

- Understand what targeted next generation sequencing is.
- Understand the diagnostic utility of next generation sequencing for red cell disorders.

→ HEMATOLOGY-IN-FOCUS 1 2 9 T C
14:30 - 15:30, Room N113

HOW TO DIAGNOSE AND MANAGE CYTOPENIAS IN CHILDREN AND YOUNG ADULTS?

Chair: A Shimamura (Dana-Farber/Boston Children's Cancer and Blood Disorders Center, USA)

- **Immune mediated cytopenia**
D Teachey (Children's Hospital of Philadelphia, USA)
- **Myelodysplastic syndrome**
C Niemeyer (University Children's Hospital, Freiburg, Germany)

LEARNING GOALS

D Teachey

After attending this lecture, the participant will be able to

- Describe current treatment approaches and targeted therapeutic options for patients with autoimmune cytopenias.
- Discuss recently described syndromes that can present with chronic or multi-lineage autoimmune cytopenias and define populations who should undergo additional diagnostic testing.

C Niemeyer

After attending this lecture, the participant will be able to

- Recognize the genetic disorders presenting with cytopenia in young individuals.
- Plan diagnostic procedures for each patient in a rational and cost-effective manner.
- Critically discuss therapy options including immunosuppressive therapy and stem cell transplantation.

→ MEET-THE EXPERT 6 C
14:30 - 15:30, Room N107
Availability on first come first serve basis

MANAGEMENT OF VON WILLEBRAND DISEASE

Speaker: G Castaman (Center for Bleeding Disorders, Careggi University Hospital, Florence, Italy)

→ MEET-THE EXPERT 3 10 C
14:30 - 15:30, Room N108
Availability on first come first serve basis

CLL IN THE ERA IN TARGETED THERAPIES

Speaker: C Moreno (Hospital Santa Creu I Sant Pau, Barcelona, Spain)

→ MEET-THE EXPERT 4 C
14:30 - 15:30, Room N117
Availability on first come first serve basis

TREATMENT OF GVHD

Speaker: T Ruutu (Clinical Research Institute, Helsinki University Hospital, Finland)

→ SPECIAL SESSION 1 2 3 4 6 7 8 9 10 **B T C**

15:45 – 17:00, Hall A

PRESIDENTIAL SYMPOSIUM

Chairs: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)
S Izraeli, Chair Scientific Program Committee (Sheba Medical Center, Ramat Gan, Israel)

YOUNG EHA AWARDS**- Introduction**

S Izraeli, Chair Scientific Program Committee (Sheba Medical Center, Ramat Gan, Israel)

15:45 – 16:00

S146 **BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS**
M Algeri¹ (Ospedale Pediatrico Bambino Gesù, Rome, Italy)

16:00 – 16:15

S147 **RE-CREATING HEREDITARY PERSISTENCE OF FETAL HEMOGLOBIN (HPFH) WITH CRISPR/CAS9 TO TREAT SICKLE CELL DISEASE (SCD) AND BETA-THALASSEMIA (BETA-THAL)**
A Lundberg¹ (CRISPR Therapeutics, Cambridge, United States)

16:15 – 16:30

S148 **EXPOSURE TO INFECTION TRIGGERS PAX5 AND ETV6-RUNX1 CHILDHOOD BCP-ALL**
J Hauer² (Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany)

16:30 – 16:45

S149 **REVERSIBLE PHARMACOLOGICAL TARGETING OF RHOA ALLOWS IMPROVED STORAGE, SURVIVAL AND HEMOSTATIC ACTIVITY OF PLATELETS IN VITRO AND IN VIVO, IN MICE AND IN PRIMATES.**
S Hegde^{1, 2} (Cincinnati Children's Hospital Medical Center, Cincinnati, United States, ²University of Cincinnati College of Medicine, Cincinnati, United States)

16:45 – 17:00

S150 **TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP**
P Borchmann¹ (University Hospital of Cologne, Cologne, Germany)



→ UPDATES-IN-HEMATOLOGY

17:15 - 18:45, Room N105

CAR-T CELL THERAPY: PROGRESS AND PROSPECTS

Chair: M Hudecek, Universitätsklinikum Würzburg, Würzburg, Germany

This Update in Hematology session features experts in the field of CAR-T cell therapy and will cover three topics. The session will be introduced by the meeting chair and then begin with a review of the efficacy data available to date across different indications and target antigens. Results of combinations of CAR-T cells with other agents will be discussed and assessed in the context of designing future clinical trials. Particular attention will be paid to the CAR-T production processes that may impact efficacy and safety. The next topic of the session will cover the discussion on safety aspects focusing on cytokine release syndrome and CNS toxicity. Efforts aimed at the use of predictive clinical features and biomarkers for these adverse events will be reviewed. Practical approaches to patient management for minimizing the risks and impact of adverse events will be discussed. The session will be concluded with a look into the future of adoptive T-cell therapies. Novel constructs for the next generation of CARs will be described, as well as new antigen targets and the characteristics which make them appealing and discuss rational CAR-T combination approaches to improve safety and outcomes.

- Understand the current efficacy of CAR-T cell therapy and approaches for optimisation
- Understand the safety aspects of CAR-T cell therapy and approaches to minimize the incidence and impact of adverse events
- Gain insights into the future of CAR-T cell technology and novel approaches to improve safety and outcomes

PROGRAM**- Introduction**

M Hudecek, Universitätsklinikum Würzburg, Würzburg, Germany

- Data update: efficacy review across indications and antigen targets

J Abramson, Massachusetts General Hospital, Boston, MA, United States

- Data update: safety and patient management

S Grupp, Abramson Cancer Center, Philadelphia, United States

- Scientific developments: targets, constructs, combinations

M Sadelain, Memorial Sloan Kettering Cancer Center, New York, United States



→ **UPDATES-IN-HEMATOLOGY**

17:15 - 18:45, Room N103

BIOSIMILARS FOR HEMATOLOGIC MALIGNANCIES: THE PATH TO SUSTAINABLE CARE

Chair: P Cornes, Comparative Outcomes Group, Bristol, United Kingdom

Biologic therapies for hematologic malignancies represent a much needed treatment advance; however, the associated financial burden and potentially long duration of therapy present a challenge to the sustainability of care. During this interactive Update in Haematology session, the expert faculty will explore how the advent of biosimilar agents may impact the sustainability of treatment for hematologic malignancies. In the first presentation, Dr. Paul Cornes will review the current economic burden of cancer care, and the panel will discuss how biosimilars may alleviate this financial burden and expand access to care. Panellists will evaluate the critical role of both physicians and pharmacists in driving sustainability of care, and explore how to overcome perceived obstacles to incorporating biosimilars into treatment plans. In the second presentation, Dr. Arnold Vulto will review the development process for biosimilars, and the panel will evaluate biosimilars as alternative options to originator molecules in light of the current regulatory environment. In the final presentation, Dr. Wojciech Jurczak will review how monoclonal antibodies have changed the landscape of treatment for hematologic malignancies and evaluate opportunities for these agents to further advance treatment strategies. The panel will go on to discuss the potential role of biosimilars and where these may fit into future treatment paradigms for the management of hematologic malignancies. The audience will have the opportunity to ask questions of the expert faculty and participate in this interactive programme through an audience response system.

- Recognise the similarities and differences between biosimilars and originators
- Discuss the role of biosimilars in sustainability of treatment for hematologic malignancies
- Evaluate the data on monoclonal antibodies for the treatment of hematologic malignancies and the role of biosimilar monoclonal antibodies to address some lingering gaps in care

PROGRAM

- **Introduction and welcome**

P Cornes, Comparative Outcomes Group, Bristol, United Kingdom

- **The role of biosimilars in promoting sustainability of care [presentation and panel discussion]**

P Cornes, Comparative Outcomes Group, Bristol, United Kingdom

- **A look at biosimilars development [presentation and panel discussion]**

AG Vulto, Erasmus University Medical Center, Rotterdam, the Netherlands

- **The role of new molecule innovation in the sustainability of treatment for hematologic malignancies [presentation and panel discussion]**

W Jurczak, Jagiellonian University, Kopernika, Poland

- **Ask the faculty**

P Cornes, Comparative Outcomes Group, Bristol, United Kingdom



→ UPDATES-IN-HEMATOLOGY
17:15 - 18:45, Room N104

AL AMYLOIDOSIS, DON'T MISS IT!

Chair: M Gertz, Mayo Clinic College of Medicine, Rochester, United States

Amyloid light chain (AL) amyloidosis is a rare and often fatal disease caused by clonal plasma cells that create misfolded light chains, which form soluble toxic aggregates and deposited fibrils (amyloid). Amyloid can lead to progressive failure of critical organs and systems (eg, heart, kidneys, nervous system) causing significant morbidity and mortality. The most common presenting symptoms such as fatigue, edema, dyspnea are nonspecific and are often confused with those of other more common diseases; heterogeneous symptoms cause delays in suspicion and diagnosis, or missed diagnoses. AL amyloidosis is associated with a high disease burden, which negatively impacts patients' physical and mental well-being. There is a substantial need to increase disease awareness and early diagnosis to improve outcomes. At this symposium we will discuss the key to making a diagnosis, the use of biomarkers to manage patients' disease and the importance of organ response in patients' quality of life and survival.

1. To educate on the diagnosis of AL amyloidosis and increase clinical suspicion
2. To inform on the importance of biomarkers for diagnosis and prognosis
3. To discuss disease management and the importance of organ responses

PROGRAM

– **Welcome and introduction**

M Gertz, Mayo Clinic College of Medicine, Rochester, United States

– **Early diagnosis can change the outcomes: clinical case (part I)**

M Liedtke, Stanford University School of Medicine, Stanford, United States

– **Early diagnosis can change the outcomes: presentation**

A Wechalekar, National Amyloidosis Centre, University College London (Royal Free Campus), London, United Kingdom

– **Incorporating biomarkers in the management of patients' disease: case study (part II)**

M Liedtke, Stanford University School of Medicine, Stanford, United States

– **Incorporating biomarkers in the management of patients' disease: presentation**

D Mohty, National Amyloidosis Center and Hematology unit, CHU Limoges, Limoges, France

– **Organ response: the ultimate goal of therapy: case study (part III)**

M Liedtke, Stanford University School of Medicine, Stanford, United States

– **Organ response: the ultimate goal of therapy: presentation**

S Schoenland, Universitätsklinikum Heidelberg, Heidelberg, Germany

– **Closing and remarks**

M Gertz, Mayo Clinic College of Medicine, Rochester, United States

POSTER SESSION I

The main goal of the Poster Session is to gain a maximum benefit from the scientific work presented and to create a lively interaction between poster authors, moderators (senior experts in the field) and interested congress participants. The Poster Session consists of two parts: the Poster Walk and Poster Browsing Time. This setup guarantees sufficient time for all posters that have been selected for a presentation. The first hour of the Poster Walk is moderated and then followed by the Poster Browsing Time, where the rest of the posters can be browsed on the e-poster screens available in the poster area.

Poster walks will be organized during the poster sessions on Friday, June 23 at 17:15 – 18:45 and Saturday, June 24 at 17:30 - 19:00. Poster authors and moderators are requested to be present at the first poster in their poster session, at the beginning of the presentation time (Friday at 17:15 and Saturday at 17:30).

Poster Browsing Time will be organized after the Poster Walk, on Friday, June 23 18:15 – 18:45 and Saturday, June 24 at 18:30 – 19:00.

Poster Walk Title	From	To	Page
■ Acute lymphoblastic leukemia - Biology 1	P151	P159	104
■ Acute lymphoblastic leukemia - Clinical 1	P160	P170	104
■ Acute myeloid leukemia - Biology 1	P171	P180	105
■ Acute myeloid leukemia - Biology 2	P181	P190	105
■ Acute myeloid leukemia - Clinical 1	P191	P199	106
■ Acute myeloid leukemia - Clinical 2	P200	P207	106
■ Acute myeloid leukemia - Clinical 3	P208	P215	107
■ Aggressive Non-Hodgkin lymphoma - 1st line	P216	P225	107
■ Bone marrow failure syndromes incl. PNH - Biology	P226	P235	108
■ Chronic lymphocytic leukemia and related disorders - Biology 1	P236	P244	109
■ Chronic lymphocytic leukemia and related disorders - Clinical	P245	P254	109
■ Chronic myeloid leukemia - Clinical 1	P255	P263	110
■ Hematopoiesis, stem cells and microenvironment	P264	P274	110
■ Hodgkin lymphoma	P275	P283	111
■ Iron metabolism, deficiency and overload	P284	P294	112
■ Lymphoma biology	P295	P304	112
■ Multifaced aspects of bleeding disorders	P305	P312	113
■ Myelodysplastic syndromes – Clinical 1	P313	P319	113
■ Myeloma and other monoclonal gammopathies - Biology	P320	P329	114
■ Myeloma and other monoclonal gammopathies - Clinical 1	P330	P339	114
■ Myeloma and other monoclonal gammopathies - Clinical 2	P340	P349	115
■ Myeloproliferative neoplasms - Clinical 1	P350	P359	115
■ Platelet disorders: Basic	P360	P368	116
■ Quality of life, palliative care, ethics and health economics 1	P369	P378	117
■ Stem cell transplantation - Clinical 1	P379	P390	117
■ Thalassemia	P391	P400	118
■ Transfusion medicine	P401	P406	119

17:15 – 18:45, Poster area

ACUTE LYMPHOBLASTIC LEUKEMIA - BIOLOGY 1

Moderator: J Soulier (INSERM U944/CNRS UMR7212 Hôpital Saint-Louis & University Paris Diderot UP7, France)

- P151 **TARGETED SINGLE CELL SEQUENCING TO IDENTIFY MUTATIONAL HIERARCHY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
J De Bie¹ (¹KU Leuven, Leuven, Belgium)
- P152 **BCL-2 INHIBITION AS NEW THERAPEUTIC OPPORTUNITY FOR RPL10 R98S MUTANT PEDIATRIC T-ALL**
K Kampen¹ (¹KU Leuven, LKI Leuven Cancer Institute, Leuven, Belgium)
- P153 **TRANSLATOME ANALYSIS OF THE T-ALL ASSOCIATED RIBOSOMAL PROTEIN L10 R98S MUTATION REVEALS ALTERED SERINE METABOLISM**
L Fancello¹ (¹KU Leuven - University of Leuven, Leuven, Belgium)
- P154 **REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS: OXIDATIVE STRESS AS A TARGET FOR HIGH-RISK LEUKAEMIA IN CHILDREN**
M Karsa¹ (¹Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia)
- P155 **TP53 MUTATIONS DISRUPTING DNA BINDING LEAD TO CHEMOTHERAPY RESISTANCE IN ACUTE LYMPHOBLASTIC LEUKEMIA**
M Pogodzinski¹ (¹Charité - Universitaetsmedizin Berlin, Berlin, Germany)
- P156 **GENETIC ACTIVATION AND THERAPEUTIC TARGETING OF PIM1 IN T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA**
R De Smedt¹ (¹Ghent University, Gent, Belgium)
- P157 **IL-7 FLEXIBLY REGULATES AUTOPHAGY-DEPENDENT VIABILITY OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELLS**
D Ribeiro¹ (¹Instituto de Medicina Molecular, Lisbon, Portugal)
- P158 **PRECLINICAL ACTIVITY OF ENTOSPLETINIB IN CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
S Tasian², ³(²Children's Hospital of Philadelphia, Philadelphia, United States, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, United States)
- P159 **PHARMACOLOGICAL ACTIVITY OF CB-103 – AN ORAL PANTH NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION**
R Lehal¹ (¹Cellestia Biotech AG, Basel, Switzerland)

17:15 – 18:45, Poster area

ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL 1

Moderator: S Chiaretti (Sapienza University of Rome, Italy)

- P160 **IKZF1Δ4-7 CAN BE EASILY SCREENED BY PCR BUT DOES NOT PREDICT OUTCOME IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA; DATA FROM 490 PATIENTS ENROLLED ON THE UKALL14 TRIAL.**
R Mitchell¹ (¹UCL Cancer Institute, London, United Kingdom)
- P161 **PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE DETECTED BY MLL FUSION GENE TRANSCRIPTS IN INFANT ACUTE LYMPHOBLASTIC LEUKEMIA. UPDATED RESULTS OF 76 PATIENTS ENROLLED INTO MLL-BABY STUDY**
G Tsaour¹ (¹Regional Children Hospital #1, Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation)
- P162 **PRO-T CELL ALL/LBL: AN ULTRA-HIGH RISK CD2-NEGATIVE DISEASE SUBTYPE IN ADULTS DEFINED BY FLOW CYTOMETRY**
B Ostrowska¹ (¹The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland, Warszawa, Poland)
- P163 **CLINICAL SIGNIFICANCE OF END OF INDUCTION MINIMAL RESIDUAL DISEASE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMPLETE REMISSION AFTER A SINGLE CHEMOTHERAPY COURSE**
R Bassan¹ (¹Ospedale dell'Angelo, Mestre Venezia, Italy)
- P164 **RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA**
N Morley¹ (¹Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom)
- P165 **CLINICAL OUTCOMES OF ELDERLY ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA – A SINGLE INSTITUTION EXPERIENCE**
K Miller¹ (¹Mayo Clinic, Rochester, United States)
- P166 **MANAGEMENT AND OUTCOME OF ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED AT THE "SAPIENZA" UNIVERSITY BETWEEN 1996 AND 2016**
S Chiaretti¹ (¹Sapienza University of Rome, Rome, Italy)
- P167 **THE TETRASPANIN CD9 IS A PROGNOSTIC MARKER FOR PREDICTING SURVIVAL OUTCOMES OF PEDIATRIC B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA**
K Leung¹ (¹The Chinese University of Hong Kong, Shatin, Hong Kong)
- P168 **PEDIATRIC MLL ACUTE LEUKEMIA PATIENTS SHOW DIFFERENTIAL HDAC EXPRESSION**
N Vega-Garcia¹ (¹Institut de Recerca Pediàtrica Hospital Sant Joan de Deu, Barcelona, Spain)

- P169 **MINIMAL DISSEMINATED DISEASE DETECTION BY FLOW-CYTOMETRIC IMMUNOPHENOTYPING IN T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA**
G Viswanathan¹ (¹Advanced Centre for Treatment, Research and Education in Cancer (Actrec) - Tata Memorial Centre (TMC), MUMBAI, India)
- P170 **INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AS FRONTLINE THERAPY FOR OLDER PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE I/II TRIAL**
N Short¹ (¹The University of Texas MD Anderson Cancer Center, Houston, United States)
- 17:15 – 18:45, Poster area
ACUTE MYELOID LEUKEMIA - BIOLOGY 1
Moderator: S Gröschel (DKFZ Heidelberg / University Hospital Heidelberg, Germany)
- P171 **RECURRENT MYB REARRANGEMENT IN BLASTIC PLASMA-CYTOID DENDRITIC CELL NEOPLASM**
K Suzuki¹ (¹Nagoya University Graduate School of Medicine, Nagoya, Japan)
- P172 **BRANCHED CHAIN AMINO ACID METABOLISM REGULATES ALPHA-KETOGLUTARATE HOMEOSTASIS RESEMBLING MUTANT-IDH DRIVEN DNA HYPERMETHYLATION IN AML**
S Raffel^{1, 2, 3} (¹German Cancer Research Center, Heidelberg, Germany, ²Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany, ³Heidelberg University, Heidelberg, Germany)
- P173 **NUCLEAR RE-LOCALIZATION OF NPM1C+ INDUCES DIFFERENTIATION AND CELL GROWTH ARREST**
L Brunetti¹ (¹Baylor College of Medicine, Houston, United States)
- P174 **THE LONG NON-CODING RNA HOXB-AS3 REGULATES RIBOSOMAL BIOGENESIS IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA**
D Papaioannou¹ (¹The Ohio State University, Columbus, United States)
- P175 **A DUAL BH3-MIMETIC APPROACH TARGETING BOTH BCL-2 AND MCL1 IS HIGHLY EFFICACIOUS AND WELL-TOLERATED IN ACUTE MYELOID LEUKEMIA**
D Moujalled^{1, 2} (¹Monash University, Melbourne, Australia, ²The Alfred Hospital, Melbourne, Australia)
- P176 **THE PMLC62A/C65A KNOCK-IN MOUSE MODEL PROVIDES EVIDENCE FOR THE ROLE OF NUCLEAR BODY DISRUPTION IN THE PATHOGENESIS OF ACUTE PROMYELOCYTIC LEUKEMIA**
E Voisset¹ (¹King's College London, London, United Kingdom)
- P177 **DECIPHERING THE ONCOGENIC NETWORK OF PRC2 LOSS GUIDED LEUKEMOGENESIS**
D Heckl¹ (¹Hannover Medical School, Hannover, Germany)
- P179 **ACUTE MYELOID LEUKEMIA EVOLUTION CAN BE RECONSTRUCTED BY ANALYSIS OF NON-LEUKEMIC CELLULAR SUBCOMPARTMENTS AND MULTI-LINEAGE ENGRAFTED MICE**
B Saeed¹ (¹Heidelberg University Hospital, Heidelberg, Germany)
- P180 **THE ESSENTIAL ROLE OF THE ENHANCERS OF POLYCOMB EPC1 AND EPC2 IN MLL-AF9 ACUTE MYELOID LEUKAEMIA IS A 'COMPLEX' STORY**
N Mannion¹ (¹Institute of Cancer Sciences, MVLS, University of Glasgow, Glasgow, United Kingdom)
- 17:15 – 18:45, Poster area
ACUTE MYELOID LEUKEMIA - BIOLOGY 2
Moderator: A Puissant (INSERM U944, Institute of Hematology, St Louis Hospital, Paris, France)
- P181 **STROMA-DERIVED FACTORS STIMULATE JAK/STAT SIGNALING IN AML CELLS RESULTING IN RESISTANCE TO BCL2 INHIBITOR VENETOCLAX**
R Karjalainen¹ (¹Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland)
- P182 **IDENTIFICATION OF NOVEL GENE FUSIONS IN ACUTE MYELOID LEUKEMIA WITH COMPLEX KARYOTYPE BY TRANSCRIPTOME ANALYSIS USING RNA SEQUENCING**
F Rucker¹ (¹University Hospital of Ulm, Ulm, Germany)
- P183 **H3K27ME3 LEVEL ON THE HIST1 CLUSTER: A POWERFUL EPIGENETIC BIOMARKER THAT STRATIFIES TWO GROUPS OF NPM1-MUTATED AML DIFFERING IN THEIR OUTCOME AND EXPRESSION PROFILE**
S Garcia^{1, 2, 3} (¹Paoli-Calmettes Institute, Marseille, France, ²Cancer research center, Marseille, France, ³Aix-Marseille University, Marseille, France)
- P184 **FUNCTIONAL ASSESSMENT OF NOVEL DIAGNOSTIC FLT3 MUTATIONS AND INHIBITION BY KINASE INHIBITORS**
K Tarlock^{1, 2} (¹Seattle Children's Hospital, Seattle, United States, ²Fred Hutchinson Cancer Research Center, Seattle, United States)
- P186 **THE BCL-2 INHIBITOR VENETOCLAX INHIBITS NRF2 ANTIOXIDANT PATHWAY ACTIVATION INDUCED BY HYPOMETHYLATING AGENTS IN ACUTE MYELOID LEUKEMIA**
L Nguyen¹ (¹City of Hope Medical Center, Duarte, United States)
- P187 **UNRAVELING EPIGENOMIC REGULATION IN THE EVOLUTION OF RELAPSING PEDIATRIC AML**
C Wiggers^{1, 2} (¹University Medical Center Utrecht, Utrecht, the Netherlands, ²Hubrecht Institute, Utrecht, the Netherlands)



P188 **MECHANISTICALLY INFORMED COMBINATIONS OF SY-1425, A POTENT AND SELECTIVE RAR β AGONIST, WITH HYPOMETHYLATING OR ANTI-CD38 TARGETED AGENTS IN AML AND MDS**
M Mckeown¹ (¹Syros Pharmaceuticals, Cambridge, United States)

P189 **FLT3 INHIBITION OVERCOMES RESISTANCE TO THE BCL-2 SELECTIVE ANTAGONIST, VENETOCLAX, IN FLT3-ITD MUTANT AML MODELS**
D Sampath¹ (¹Genentech, South San Francisco, United States)

P190 **SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA STEM CELLS BY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7**
L Smit¹ (¹VU University Medical Center, Amsterdam, the Netherlands)

17:15 – 18:45, Poster area

ACUTE MYELOID LEUKEMIA - CLINICAL 1

Moderator: S Freeman (University of Birmingham, United Kingdom)

P191 **ONGOING PHASE 2 CLINICAL TRIAL OF SL-401 IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN): STAGE 1 AND STAGE 2 RESULTS**
N Pemmaraju¹ (¹MD Anderson Cancer Center, Houston, TX, United States)

P192 **PROGNOSTIC IMPACT OF SOMATIC MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**
K Takahashi¹ (¹UT MD ANDERSON CANCER CENTER, Houston, United States)

P193 **DO EDUCATION AND INCOME AFFECT TREATMENT AND OUTCOME IN ACUTE MYELOID LEUKEMIA IN A TAX-SUPPORTED HEALTH CARE SYSTEM? A DANISH NATIONAL POPULATION-BASED COHORT STUDY**
L Østgård¹, ² (¹Aarhus University Hospital, Aarhus, Denmark, ²Aarhus University Hospital, Aarhus, Denmark)

P194 **IDENTIFICATION OF PATTERNS IN CO-OCCURRING MUTATIONS IN AML PATIENTS WITH GERMLINE AND SOMATIC RUNX1 MUTATIONS**
U Borate¹ (¹Oregon Health & Science University, Portland, United States)

P195 **MUTATIONAL LOAD OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE – IMPACT OF AZACITIDINE TREATMENT LINE**
L Pleyer¹, ², ³ (¹Paracelsus Medical University, Salzburg, Austria, ²Center for Clinical Cancer and Immunology Trials, Salzburg, Austria, ³Cancer Cluster, Salzburg, Austria)

P196 **MULTIPLE LEUKEMIC STEM CELL MARKER EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN DE NOVO ACUTE MYELOID LEUKEMIA**
T Yabushita¹ (¹Kobe City Medical Center General Hospital, Kobe City, Japan)

P197 **NEXT GENERATION SEQUENCING TARGETED PANEL FOR MINIMAL RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA**
V McClain¹ (¹Inivoscribe, San Diego, United States)

P198 **IS IT POSSIBLE TO RELIABLY DETECT CLINICALLY-RELEVANT BIALLELIC CEBPA GENE MUTATIONS USING NGS PANELS?**
M Fernandez-Mercado¹, ², ³ (¹School of Engineering, University of Navarra, San Sebastian, Spain, ²Biodonostia HRI, Donostia University Hospital, San Sebastian, Spain, ³CIMA LAB Diagnostics, University of Navarra, Pamplona, Spain)

P199 **EXPERIENCE WITH MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN AML WITH RUNX1-RUNX1T1: A STUDY ON 186 PATIENTS**
A Hoellein¹ (¹Munich Leukemia Laboratory, Munich, Germany)

17:15 – 18:45, Poster area

ACUTE MYELOID LEUKEMIA - CLINICAL 2

Moderator: D Breems (Ziekenhuis Netwerk Antwerpen, Belgium)

P200 **NUMBER OF TP53 ABNORMALITIES AND THEIR CLINICAL RELEVANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES**
G Montalban-Bravo¹ (¹The University of Texas MD Anderson Cancer Center, Houston, United States)

P201 **VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS (HMA): A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)**
F Ravandi¹ (¹MD Anderson, Houston, United States)

P202 **ACUTE MYELOID LEUKEMIA WITH INTERMEDIATE-RISK CYTOGENETICS AND A FAVORABLE GENOTYPE: PROGNOSTIC FACTORS AND RESULTS IN PATIENTS TREATED ACCORDING TO THE SPANISH CETLAM PROTOCOLS.**
J Sierra¹ (¹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

P203 **GMI-1271, A POTENT E-SELECTIN ANTAGONIST, COMBINED WITH INDUCTION CHEMOTHERAPY IN ELDERLY PATIENTS WITH UNTREATED AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE**
D DeAngelo¹ (¹Dana-Farber Cancer Institute, Boston, United States)

- P204 **A PHASE 2 STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)**
 J Cortes¹ (¹University of Texas, MD Anderson Cancer Center, Houston, TX, United States)
- P205 **CM942 IS A NEW SMALL MOLECULE THAT TARGETS SET-PP2A INTERACTION AND INHIBITS GROWTH OF ACUTE MYELOID LEUKEMIA CELLS**
 P García-Ramírez¹ (¹Complejo Hospitalario de Navarra, Pamplona, Spain)
- P206 **CLONAL HETEROGENEITY IN LEUKEMIC STEM CELLS FROM PATIENTS WITH ACUTE MYELOID LEUKEMIA**
 L Manta¹ (¹University of Heidelberg, Heidelberg, Germany)
- P207 **TREATMENT OF PRACINOSTAT AND AZACITIDINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): CORRELATION BETWEEN MUTATION CLEARANCE AND CLINICAL RESPONSE**
 K Takahashi¹ (¹University of Texas MD Anderson Cancer Center, Houston, United States)

17:15 – 18:45, Poster area

ACUTE MYELOID LEUKEMIA - CLINICAL 3

Moderator: C Muller-Tidow (University Hospital Heidelberg, Germany)

- P208 **STABLE DISEASE WITH HEMATOLOGIC IMPROVEMENT IS CLINICALLY MEANINGFUL FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE**
 A Schuh¹ (¹Princess Margaret Cancer Centre/University Health Network, Toronto, Canada)
- P209 **A RANDOMIZED PHASE II STUDY OF IDARUBICIN AND CYTARABINE WITH EITHER CLOFARABINE (CIA) OR FLUDARABINE (FIA) IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA**
 N Short¹ (¹The University of Texas MD Anderson Cancer Center, Houston, United States)
- P210 **OVERALL SURVIVAL AND TRANSPLANTATION IN PATIENTS WITH FLT3 MUTATIONS: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE MYELOID LEUKEMIA**
 B Medeiros¹ (¹Stanford University School of Medicine, Stanford, CA, United States)
- P211 **NIVOLUMAB MAINTENANCE THERAPY FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML) IN REMISSION**
 T Kadia¹ (¹MD Anderson Cancer Center, Houston, United States)

- P212 **HIGHER EXPRESSION OF LONG NON-CODING RNA KIAA0125 IS ASSOCIATED WITH CHARACTERISTIC CLINICAL AND BIOLOGICAL FEATURES AND IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA**
 SY Hung¹ (¹National Taiwan University Hospital, Taipei City, Taiwan, Republic of China)
- P213 **LEUKEMIC STEM CELLS CAN BE DETECTED IN A CONSIDERABLE PERCENTAGE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AT DIAGNOSIS AND IS A SIGNIFICANT PROGNOSTIC FACTOR**
 O Pérez-López¹ (¹Virgen del Rocío University Hospital, Sevilla, Spain)
- P214 **POST-REMISSIONAL AND PRE-TRANSPLANT ROLE OF MINIMAL RESIDUAL DISEASE DETECTED BY WT1 IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COHORT STUDY**
 C Frairia¹ (¹University-Hospital Città della Salute e della Scienza, Torino, Italy, Torino, Italy)
- P215 **DIFFERENTIATION SYNDROME ASSOCIATED WITH ENASIDENIB (AG-221), A SELECTIVE INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE 2 (MIDH2)**
 A Fathi¹, ² (¹Massachusetts General Hospital Cancer Center, Boston, United States, ²Harvard Medical School, Boston, United States)

17:15 – 18:45, Poster area

AGGRESSIVE NON-HODGKIN LYMPHOMA - 1ST LINE

Moderator: To be announced

- P216 **RADIOTHERAPY TO PET-NEGATIVE BULKY DISEASE CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF A PLANNED INTERIM ANALYSIS OF 187 PATIENTS WITH BULKY DISEASE OF THE OPTIMAL→60 STUDY OF THE DSH-NHL**
 M Pfreundschuh¹ (¹Saarland University Medical School, Homburg, Germany)
- P217 **OUTCOME OF PATIENTS WITH INTRAVASCULAR B-CELL LYMPHOMA, A RETROSPECTIVE STUDY CONDUCTED ON BEHALF OF THE LYMPHOMA STUDY ASSOCIATION (LYSA) GROUP**
 A Bonnet¹ (¹University Hospital Hôtel-Dieu, Nantes, France)
- P218 **OUTCOME OF ELDERLY DLBCL PATIENTS (≥ 80 YEARS) TREATED WITH ANTHRACYCLINE BASED CHEMOTHERAPY; R-CHOP DOSE REDUCTION IS NOT NECESSARY FOR EVERYBODY**
 M Trněný¹ (¹Charles University General Hospital, Prague, Czech Republic)

- P219 **IMPROVED SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) UP TO AGE 70 ONLY: A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL IN THE NETHERLANDS, 1989-2015**
A Dinmohamed^{1, 2, 3} (¹Erasmus MC Cancer Institute, Rotterdam, the Netherlands, ²Erasmus University Medical Center, Rotterdam, the Netherlands, ³the Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands)
- P220 **CLINICAL CHARACTERISTICS AND LONG-TERM RESULTS OF TREATMENT OF DIFFUSE LARGE HEPATITIS C - ASSOCIATED NON-HODGKIN LYMPHOMA (DLBCL + C).**
S Lepkov¹ (¹Russian National Research Medical University named after N.I. Pirogov, Moscow, Russian Federation)
- P221 **MAGNETIC RESONANCE IMAGING FOR EARLY DETECTION OF ANTHRACYCLINE CARDIOTOXICITY IN MALIGNANT LYMPHOMA**
A Laursen¹ (¹Rigshospitalet, Copenhagen, Denmark)
- P222 **ANTI-INFECTIVE PROPHYLAXIS WITH ACICLOVIR AND COTRIMOXAZOLE SIGNIFICANTLY REDUCES THE RATE OF INFECTIONS AND THERAPY-ASSOCIATED DEATHS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH R-CHOP**
M Pfreundschuh¹ (¹Saarland University Medical School, Homburg, Germany)
- P223 **RELAPSE CHARACTERISTICS AND THE ROLE OF SURVEILLANCE COMPUTED TOMOGRAPHY IN AGGRESSIVE NON-HODGKIN LYMPHOMA**
KW Kang¹ (¹Korea University School of Medicine, Seoul, Korea, Republic Of)
- P224 **A MULTI-CENTER STUDY OF GLIDE CHEMOTHERAPY CONSOLIDATED WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED STAGE IV AND RELAPSED EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA PATIENTS**
J Ji¹ (¹West China Hospital of Sichuan University, Chengdu, China)
- P225 **LONG TERM FOLLOW-UP OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS TREATED WITH IFOSFAMIDE, ETOPOSIDE, EPIRUBICIN / INTERMEDIATE METHOTREXATE AND AUTOLOGOUS STEM CELL TRANSPLANTATION**
M Sieniawski¹ (¹Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, United Kingdom)
- 17:15 – 18:45, Poster area
BONE MARROW FAILURE SYNDROMES INCL. PNH - BIOLOGY
Moderator: M Bartels (Wilhelmina Kinderziekenhuis, Utrecht, the Netherlands)
- P226 **IDENTIFICATION OF A NOVEL GERMLINE MECOM / EVI1 VARIANT THAT RUNS IN A PEDIGREE WITH RADIOULNAR SYNOSTOSIS AND AMEGAKARYOCYTIC THROMBOCYTOPENIA AND PREDISPOSES TO ADULT ONSET MYELOID MALIGNANCY**
T Ripperger¹ (¹Hannover Medical School, Hannover, Germany)
- P227 **LOSS OF THE HOMOLOGOUS RECOMBINATION GENE RAD51 LEADS TO FANCONI ANEMIA-LIKE SYMPTOMS IN ZEBRAFISH**
J Botthof^{1, 2, 3} (¹University of Cambridge, Cambridge, United Kingdom, ²Wellcome Trust Sanger Institute, Cambridge, United Kingdom, ³University of Cambridge, Cambridge, United Kingdom)
- P228 **A NOVEL TELOMERASE RNA COMPONENT (TERC) VARIANT IN A FAMILY WITH MACROCYTOSIS AND MILD VARIABLE CYTOPENIAS**
C Burney¹ (¹University Hospitals Bristol NHS Trust, Bristol, United Kingdom)
- P229 **GENERATION OF X-LINKED DYSKERATOSIS CONGENITA-LIKE HUMAN HEMATOPOIETIC STEM CELLS**
G Guenechea^{1, 2} (¹Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT) and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD/UAM), Madrid, Spain, ²Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain)
- P230 **STUDY OF EXTRACELLULAR VESICLES ROLES IN THE PATHOPHYSIOLOGY OF THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS DURING ECULIZUMAB TREATMENT: A PILOT PROSPECTIVE LONGITUDINAL CLINICAL STUDY**
A Wannez^{1, 2} (¹University of Namur, Namur, Belgium, ²Université catholique de Louvain, Yvoir, Belgium)
- P231 **TELOMERE LENGTH SCREENING TRIGGERED BY CLINICAL SUSPICION FOR CLASSICAL AND/OR CRYPTIC DYSKERATOSIS CONGENITA –PROSPECTIVE RESULTS FROM THE AACHEN TELOMEROPATHY REGISTRY**
F Beier¹ (¹Medical Faculty, RWTH Aachen University, Aachen, Germany)
- P232 **TRANSPLANTATION IN PATIENTS WITH ACQUIRED APLASTIC ANEMIA OVER THE AGE OF 40: MORTALITY HAS NOT BEEN REDUCED IN 2010-2015.**
S Giammarco¹ (¹Università Cattolica del Sacro Cuore, Rome, Italy)

- P233 **CLINICAL AND GENETIC DIVERSITY IN DIAMOND-BLACKFAN ANAEMIA: AN UPDATE FROM THE UNITED KINGDOM**
D Iskander¹ (¹Imperial College London, London, United Kingdom)
- P234 **BONE MARROW FAILURE SECONDARY TO NOVEL/KNOWN PRIMARY IMMUNODEFICIENCY-RELATED MUTATIONS. A SINGLE CENTER ANALYSIS**
M Miano¹ (¹IRCCS Istituto Giannina Gaslini, Genova, Italy)
- P235 **COVERSIN, A NOVEL C5 COMPLEMENT INHIBITOR, FOR THE TREATMENT OF PNH: RESULTS OF A PHASE 2 CLINICAL TRIAL**
A Hill¹ (¹Leeds Teaching Hospitals, LEEDS, United Kingdom)
- 17:15 – 18:45, Poster area
CHRONIC LYMPHOCYTTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY 1
Moderator: D Colomer (Unitat d'Hematopatologia, Barcelona, Spain)
- P236 **GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTTIC LEUKEMIA**
J Brown^{1, 2, 3} (¹Broad Institute of MIT and Harvard, Cambridge, United States, ²Dana-Farber Cancer Institute, Boston, United States, ³Brigham and Women's Hospital, Boston, United States)
- P237 **DIFFERENTIAL ENHANCER TRANSCRIPTION ASSOCIATED WITH RISK ALLELE GENOTYPE IN CLL**
J Brown^{1, 2} (¹Dana Farber Cancer Institute, Boston, United States, ²Harvard Medical School, Boston, United States)
- P238 **BIALLELIC TP53 GENE MUTATIONS DUE TO COPY-NEUTRAL LOSS OF HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF 17P DELETION OCCUR IN CLL WITH COMPAREABLE FREQUENCY**
K Plevova^{1, 2} (¹University Hospital Brno, Brno, Czech Republic, ²Masaryk University, Brno, Czech Republic)
- P239 **INTERGRATED OLIGO/SNP ARRAY- AND NEXT GENERATION SEQUENCING BASED ANALYSIS IS REQUIRED TO DETERMINE TP53/17P STATUS IN CLL PATIENTS**
M Stevens-Kroef¹ (¹Radboud university medical center, Nijmegen, the Netherlands)
- P240 **CYTOGENETIC CLONAL EVOLUTION OCCURS AT THE TIME OF DISEASE PROGRESSION DURING IBRUTINIB THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL.**
P Thompson¹ (¹MD Anderson Cancer Center, Houston, United States)
- P241 **LANDSCAPE OF SOMATIC MUTATIONS AND THEIR IMPACT ON RESPONSE AND OUTCOMES FROM LENALIDOMIDE-BASED THERAPIES IN PATIENTS WITH CHRONIC LYMPHOCYTTIC LEUKEMIA (CLL)**
B Hu¹ (¹MD Anderson Cancer Center, Houston, Texas, United States)
- P242 **HIGH THROUGHPUT IMMUNOPROFILING OF CHRONIC LYMPHOCYTTIC LEUKEMIA PATIENTS ASSIGNED TO STEREOTYPED SUBSET #4: NOVEL INSIGHTS INTO THE DEPTH, DIVERSITY AND TEMPORAL DYNAMICS OF CLONAL EVOLUTION**
L Sutton^{3, 4} (²Uppsala University, Uppsala, Sweden, ³Karolinska Institutet, Stockholm, Sweden)
- P243 **FAILED HYDROXYMETHYLATION CONTRIBUTES TO A CHRONIC LYMPHOCYTTIC LEUKEMIA SPECIFIC EPIGENOTYPE**
K Szarc Vel Szic¹ (¹University Freiburg Medical Center, Freiburg, Germany)
- P244 **DNA METHYLATION PROFILING IN CHRONIC LYMPHOCYTTIC LEUKEMIA PATIENTS CARRYING STEREOTYPED B-CELL RECEPTORS: A DIFFERENT CELLULAR ORIGIN FOR SUBSET #2?**
S Bhoi¹ (¹Uppsala University, Uppsala, Sweden)
- 17:15 – 18:45, Poster area
CHRONIC LYMPHOCYTTIC LEUKEMIA AND RELATED DISORDERS - CLINICAL
Moderator: To be announced
- P245 **ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLE EXTENSION STUDY**
A Rawstron¹ (¹HMDS, St. James's Institute of Oncology, Leeds, United Kingdom)
- P246 **CHRONIC LYMPHOCYTTIC LEUKEMIA PATIENTS EXPRESSING THE LIGHT CHAIN IGLV3-21 HAVE A POOR PROGNOSIS INDEPENDENTLY OF HEAVY CHAIN IGHV3-21 OR THE IGHV MUTATIONAL STATUS**
B Stamatoopoulos¹ (¹J. Bordet Institute, University of Brussels, Brussels, Belgium)
- P247 **DURABILITY OF RESPONSES ON CONTINUOUS THERAPY AND FOLLOWING DRUG CESSATION IN DEEP RESPONDERS WITH VENETOCLAX AND RITUXIMAB**
M Anderson¹ (¹Royal Melbourne Hospital and Walter and Eliza Hall Institute of Medical Research, Cancer and Hematology Division, Melbourne, Australia)
- P248 **PREDICTIVE AND PROGNOSTIC IMPACT OF GENE MUTATIONS IN THE CONTEXT OF FLUDARABINE AND CYCLOPHOSPHAMIDE (FC) WITH OR WITHOUT OFATUMUMAB TREATMENT IN PATIENTS WITH REL/REF CLL**
E Tausch¹ (¹Ulm University, Ulm, Germany)
- P249 **RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTTIC LEUKEMIA (CLL)**
A Danilov¹ (¹Oregon Health and Science University, Portland, United States)

P250 **RELATIVE SURVIVAL REACHES A PLATEAU IN HAIRY CELL LEUKEMIA (HCL): A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL AMONG 1,427 PATIENTS DIAGNOSED IN THE NETHERLANDS, 1989-2014**
A Dinmohamed^{1, 2, 3} (the Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands, ²Erasmus University Medical Center, Utrecht, the Netherlands, ³Erasmus MC Cancer Institute, Rotterdam, the Netherlands)

P251 **CUMULATIVE ILLNESS RATING SCALE (CIRS) PROVIDES PROGNOSTIC INFORMATION BEYOND THE INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI): AN ACROSS-TRIAL ANALYSIS BY THE GCLLSG**
V Goede^{1, 2} (University Hospital Cologne, Cologne, Germany, ²St. Marien Hospital, Cologne, Germany)

P252 **A PHASE II RANDOMISED STUDY INVESTIGATING THE EFFICACY OF STANDARD OR HIGH-DOSE OFATUMUMAB IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA**
D Allsup^{1, 2} (Hull and East Yorkshire NHS Trust, Hull, United Kingdom, ²Hull York Medical School, Hull, United Kingdom)

P253 **FINAL RESULTS OF THE PHASE IB GALTON TRIAL IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): DURABLE REMISSIONS WITH FRONTLINE OBINUTUZUMAB (G) PLUS FLUDARABINE/ CYCLOPHOSPHAMIDE (G-FC) OR BENDAMUSTINE (G-B)**
J Brown¹ (Dana-Farber Cancer Institute (CLL Research Consortium), Boston, United States)

P254 **THE PROGNOSTIC SIGNIFICANCE OF CLL-IPI AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANT IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE MAYO CLINIC EXPERIENCE**
T Anagnostou¹ (Mayo Clinic, Rochester, United States)

17:15 – 18:45, Poster area

CHRONIC MYELOID LEUKEMIA - CLINICAL 1

Moderator: J Mayer (Masaryk University Hospital, Brno, Czech Republic)

P255 **IMPACT OF ABCG2, OCT1 AND ABCB1 (MDR1) ON TREATMENT FREE REMISSION IN AN EUROSKI SUBTRIAL**
S Rinaldetti¹ (Universitätsmedizin Mannheim, Mannheim, Germany)

P256 **HLA-G MOLECULES AND CLINICAL OUTCOME IN CHRONIC MYELOID LEUKEMIA**
G Caocci¹ (University of Cagliari, Cagliari, Italy)

P257 **DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE Nilotinib (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE**
T Hughes¹ (SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia)

P258 **NILOTINIB-INDUCED METABOLIC DYSFUNCTION: INSIGHTS FROM A TRANSLATIONAL PILOT STUDY USING IN VITRO ADIPOCYTE MODELS AND PATIENT COHORTS**
S Pushpakom¹ (University of Liverpool, Liverpool, United Kingdom)

P259 **EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA**
S Jung^{3, 4} (Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea, Republic Of, ⁴College of Pharmacy, Seoul National University, Seoul, Korea, Republic Of)

P261 **A HIGH SENSITIVITY HIGH SPECIFICITY DIGITAL PCR ASSAY FOR BCR-ABL**
GN Franke¹ (Universitätsklinikum Leipzig AöR, Leipzig, Germany)

P262 **VALIDATION OF THE EUTOS LONG TERM SURVIVAL (ELTS) SCORE IN DUTCH CML-PATIENTS**
I Geelen¹ (Albert Schweitzer Hospital, Dordrecht, the Netherlands)

P263 **FINAL STUDY RESULTS OF DISCONTINUATION OF DASATINIB IN PATIENTS WITH CML WHO MAINTAINED DEEP MOLECULAR RESPONSE FOR LONGER THAN ONE YEAR (DADI TRIAL) AFTER THREE YEARS OF FOLLOW-UP**
H Nakamae¹ (Graduate School of Medicine, Osaka City University, Osaka, Japan)

17:15 – 18:45, Poster area

HEMATOPOIESIS, STEM CELLS AND MICROENVIRONMENT

Moderator: T Itkin (Weill Cornell Medicine, New York)

P264 **ACUTE MYELOID LEUKEMIA ALTERS THE PERMEABILITY OF THE BONE MARROW VASCULAR MICROENVIRONMENT, FOSTERING DISEASE PROGRESSION AND DRUG RESISTANCE**
D Passaro¹ (The Francis Crick Institute, London, United Kingdom)

P265 **BUILDING HUMAN BONE MARROW-LIKE MODELS TO STUDY NICHE INTERACTIONS**
R Groen¹ (VU University Medical Center, Amsterdam, the Netherlands)

- P266 **MULTISCALE IMAGE-BASED QUANTITATIVE ANALYSIS OF BONE MARROW STROMAL NETWORK TOPOLOGY REVEALS STRICT SPATIAL CONSTRAINTS FOR HEMATOPOIETIC-STROMAL CELLULAR INTERACTIONS**
C Nombela Arrieta¹ (¹University and Universit Hospital Zurich, Zurich, Switzerland)
- P267 **TEMPLATED V(D)J INSERTIONS ARE A NOVEL BIOLOGIC MECHANISM FOR B-CELL RECEPTOR REPERTOIRE DIVERSIFICATION**
M Koning¹ (¹Leiden University Medical Center, Leiden, the Netherlands)
- P268 **TARGETING THE CASPASE / NOX2 AXIS TO MODULATE MACROPHAGE POLARIZATION**
S Solier¹ (¹Gustave Roussy, VILLEJUIF, France)
- P269 **MULTIPLE MYELOMA-POLARIZED M2C MACROPHAGES PROMOTE A TUMOR-SUPPORTIVE OSTEOLYTIC MICROENVIRONMENT VIA CXCL13**
K Beider¹ (¹SHEBA MEDICAL CENTER, Ramat-Gan, Israel)
- P270 **RE-ORDERING THE B CELL DEVELOPMENT HIERARCHY IN HUMAN FETAL BONE MARROW: CHARACTERISATION OF A NOVEL HUMAN FETAL B PROGENITOR**
S O'Byrne¹ (¹University of Oxford, Oxford, United Kingdom)
- P271 **HUNDREDS OF EMBRYONIC HEMATOPOIETIC PRECURSORS CONTRIBUTE TO LIFE-LONG HEMATOPOIESIS**
M Ganuza Fernandez¹ (¹St. Jude Children's Research Hospital, Memphis, United States)
- P272 **A20 RESTRAINS THYMIC REGULATORY T CELL DEVELOPMENT**
T Haas¹ (¹Klinikum rechts der Isar, TU München, München, Germany)
- P273 **THE TRANSCRIPTION FACTOR C/EBPG REGULATES MAST CELL DEVELOPMENT AND FUNCTION**
M Kardosova¹ (¹Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic)
- P274 **TRANSCRIPTIONAL DIVERSITY AND DEVELOPMENTAL POTENTIAL OF EARLY HEMATOPOIETIC PROGENITORS REVEALED BY CELLULAR BARCODING AND TRANSCRIPTOME-WIDE PROFILING**
D Tronik-Le Roux¹ (¹CEA, Paris, France)
- 17:15 – 18:45, Poster area
HODGKIN LYMPHOMA
Moderator: A Sureda (Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain)
- P275 **LONG-TERM OUTCOME OF PATIENTS WITH NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL) TREATED WITHIN THE RANDOMIZED HD7-HD15 TRIALS: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP (GHSg)**
D Eichenauer¹ (¹University Hospital Cologne, Cologne, Germany)
- P276 **ADVANCED HODGKIN LYMPHOMA IN THE EAST OF ENGLAND CANCER NETWORK: A 10-YEAR COMPARATIVE ANALYSIS OF OUTCOMES FOR ABVD AND ESCALATED-BEACOPP TREATED PATIENTS AGED 16-59**
J Russell¹ (¹Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom)
- P277 **IMPACT ON SURVIVAL OF EARLY DETECTION OF RECURRENCE IN THE FOLLOW-UP OF HIGH RISK HODGKIN LYMPHOMA IN FIRST COMPLETE REMISSION**
N Pugliese¹ (¹University of Naples Federico II, Naples, Italy)
- P278 **LATER LINE DRUG TREATMENT PATTERNS OF CLASSICAL HODGKIN'S LYMPHOMA (CHL) PATIENTS IN CANADA, FRANCE, GERMANY AND THE UNITED KINGDOM**
K Byrne¹ (¹Adelphi Real World, Bollington, United Kingdom)
- P279 **CHEMOTHERAPY AND RADIATION IMPROVE SURVIVAL IN EARLY STAGE CLASSICAL HODGKIN LYMPHOMA, A STATEWIDE CANCER REGISTRY ANALYSIS.**
H Saeed¹ (¹University of Kentucky- Markey Cancer Center, Lexington, United States)
- P280 **THE IMPACT OF TREATMENT WITH BRENTUXIMAB VEDOTIN ON OVERALL SURVIVAL OF PATIENTS WITH HODGKIN LYMPHOMA RELAPSED AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. A NATIONWIDE POPULATION BASED ANALYSIS**
P Tsigotis¹ (¹National and Kapodistrian University of Athens, Athens, Greece)
- P281 **NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY**
B Ferhanoglu^{1, 2} (¹Koc University School of Medicine, Istanbul, Turkey, ²V.K.V. American Hospital, Istanbul, Turkey)
- P282 **GENOTYPING OF HODGKIN LYMPHOMA ON THE LIQUID BIOPSY**
V Spina¹ (¹Institute of Oncology Research, Bellinzona, Switzerland)

P283 **FDG PET-CT MAYBE A USEFUL TOOL TO IDENTIFY DOXORUBICIN INDUCED CARDIOTOXICITY IN HODGKIN LYMPHOMA**
G Sambuceti¹ (¹IRCCS San Martino - IST, Genova, Italy)

17:15 – 18:45, Poster area

IRON METABOLISM, DEFICIENCY AND OVERLOAD

Moderator: A Kattamis (University of Athens, 'Aghia Sofia' Children's Hospital, Greece)

P284 **ELEVATED SYSTEMIC HEME AND IRON LEVELS AS RISK FACTORS FOR VASCULAR DYSFUNCTION AND ATHEROSCLEROSIS: EVIDENCE FROM B-THALASSEMIA AND HEMOCHROMATOSIS COHORT STUDIES**
F Vinchi¹ (¹University of Heidelberg & EMBL, Heidelberg, Germany)

P285 **REAL-WORLD ADHERENCE TO IRON CHELATION THERAPY: COMPARING A FILM-COATED TABLET VERSUS DISPERSIBLE TABLET OF DEFERASIROX**
Q Said³ (³Novartis Pharmaceuticals, East Hanover, United States)

P286 **MEDIATION BY PATIENT-REPORTED OUTCOMES ON THE ASSOCIATION BETWEEN FILM-COATED VERSUS DISPERSIBLE FORMULATIONS OF DEFERASIROX AND SERUM FERRITIN REDUCTION: A POST HOC ANALYSIS OF THE ECLIPSE TRIAL**
A Taher¹ (¹American University of Beirut Medical Center, Beirut, Lebanon)

P287 **ASSESSMENT OF THE PERFORMANCE OF A WIDELY AVAILABLE T2*/R2* LIVER IRON CONCENTRATION METHOD USED IN CLINICAL PRACTICE IN A POPULATION OF THALASSEMIA PATIENTS**
T St Pierre⁴ (⁴The University of Western Australia, Crawley, Australia)

P288 **SIMILAR TRENDS IN RENAL FUNCTION AS MEASURED BY SERUM CREATININE DURING LONG-TERM IRON CHELATION TREATMENT WITH OR WITHOUT DEFERASIROX IN PATIENTS WITH TRANSFUSIONAL HEMOSIDEROSIS**
R Origa¹ (¹Ospedale Pediatrico Microcitamico 'A Cao', University of Cagliari, Cagliari, Italy)

P289 **WHEN IRON LEADS TO RED CELLS (AND VICE VERSA): A COMPREHENSIVE PHENOTYPE -TOWARDS NGS/WES PATHWAY FOR THE DIAGNOSIS OF RED CELL AND IRON DISORDERS**
P Aguilar Martinez¹ (¹HOPITAL SAINT ELOI, MONTEPELLIER CEDEX 5, France)

P290 **CHANGES IN LIVER IRON CONCENTRATION R2 MRI MEASUREMENT ACROSS DIFFERENT CHELATION REGIMENS IN PATIENTS WITH HEMATOLOGICAL DISORDERS: REAL-LIFE EXPERIENCE FROM LICNET**
A Maggio¹ (¹Campus of Hematology Franco and Piera Cutino, AOOR Villa Sofia-V. Cervello, Palermo, Italy)

P291 **IN UTERO IRON STATUS AND AUDITORY NEURAL MATURATION IN FULL TERM INFANTS BORN TO MOTHERS WITH IRON DEFICIENCY ANEMIA**
R El-Farrash¹ (¹Faculty of Medicine-Ain Shams University, Cairo, Egypt)

P292 **THE RELATIONSHIP BETWEEN SERUM FERRITIN AND LIVER IRON CONCENTRATION IN PEDIATRIC CANCER SURVIVORS**
T St. Pierre¹, ² (¹Resonance Health, Claremont, Australia, ²The University of Western Australia, Crawley, Australia)

P293 **DECREASED MCP-1 LEVELS IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA: A CYTOKINE SIGNATURE OF IRON DEFICIENCY**
G Porto¹ (¹I3S, Instituto de Investigação e Inovação em Saúde, Porto, Portugal)

P294 **FERRIC CARBOXYMALTOSIDE VERSUS IRON SUCROSE COMPLEX IN WOMEN WITH IRON DEFICIENCY ANEMIA - A RANDOMISED CONTROLLED TRIAL**
G Chaudhry¹ (¹SBAMI, New Delhi, India)

17:15 – 18:45, Poster area

LYMPHOMA BIOLOGY

Moderator: F Asmar (Rigshospitalet, Copenhagen, Denmark)

P295 **GENOME-WIDE ASSOCIATION STUDY OF HODGKIN LYMPHOMA IDENTIFIES HISTOLOGY-SPECIFIC ASSOCIATIONS AND TRANSCRIPTIONAL REGULATORS OF DISEASE SUSCEPTIBILITY**
A Sud¹ (¹The Institute of Cancer Research, London, United Kingdom)

P296 **SOX11 PROMOTES TUMOR PROTECTIVE MICROENVIRONMENT INTERACTIONS IN MANTLE CELL LYMPHOMA**
P Balsas¹ (¹Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain)

P297 **AICDA DRIVES EPIGENETIC HETEROGENEITY IN GERMINAL CENTER-DERIVED LYMPHOMAS AND ACCELERATES LYMPHOMAGENESIS**
P Dominguez¹ (¹Weill Cornell Medicine, New York, United States)

P298 **XPO1 INHIBITION SYNERGIZES WITH BCR INHIBITION, BLOCKS TUMOR GROWTH AND PROLONGS SURVIVAL IN A BIOLUMINESCENT ANIMAL MODEL OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA**
M Crespo¹ (¹Vall d'Hebron Institute of Oncology, Barcelona, Spain)

P299 **MOLECULAR HETEROGENEITY IN PERIPHERAL T-CELL LYMPHOMA NOT OTHERWISE SPECIFIED REVEALED BY COMPREHENSIVE MUTATIONAL PROFILING.**
Y Watatani¹ (¹Kyoto university, Kyoto, Japan)

- P300 **A COMPREHENSIVE PORTRAIT OF THE DNA METHYLOME OF 866 SAMPLES FROM DIFFERENT B CELL NEOPLASMS: BIOLOGICAL INSIGHTS AND CLINICAL APPLICATIONS**
M Duran-Ferrer¹ (¹UB, Barcelona, Spain)
- P301 **ACTIVATION OF RHOA-VAV1 SIGNALING AXIS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA**
M Fujisawa¹ (¹University of Tsukuba, Tsukuba city, Japan)
- P302 **STAT3 IS CONSTITUTIVELY ACTIVATED AND CAN BE A THERAPEUTIC TARGET OF JAK INHIBITORS IN CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION**
E Onozawa^{1, 2} (¹Tokyo Medical and Dental University, Tokyo, Japan, ²Tokyo Medical and Dental University, Tokyo, Japan)
- P303 **RECURRENT MUTATIONS IN MICRO-RNA BINDING SITES MAY BE POTENTIALLY RELEVANT IN FOLLICULAR LYMPHOMA**
E Larrea¹ (¹Biodonostia, Donostia/San Sebastian, Spain)
- P304 **CLINICAL IMPACT OF TP53 AND KMT2D MUTATIONS IN MCL RECEIVING HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: UPDATED RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL**
S Ferrero¹ (¹Università di Torino, Torino, Italy)
- 17:15 – 18:45, Poster area
MULTIFACED ASPECTS OF BLEEDING DISORDERS
Moderator: I Bodó (Emory University School of Medicine, Atlanta, USA)
- P305 **A LOOKBACK AT VWD TYPE 2A AND 2M CLASSIFICATION IN A LARGE COMPREHENSIVE HAEMOPHILIA CENTRE.**
S Jaafar^{1, 2} (¹Royal Free Hospital /NHS, London, United Kingdom, ²katharine dormandy haemophilia centre/royal free hospital, London, United Kingdom)
- P306 **RETROSPECTIVE EVALUATION OF PHENOTYPE AND MANAGEMENT OF DYSFIBRINOGENEMIA AND HYPODYSFIBRINOGENEMIA IN A COHORT OF ITALIAN PATIENTS.**
C Santoro¹ (¹HEMATOLOGY SAPIENZA UNIVERSITY, Rome, Italy)
- P307 **OSTEOPOROSIS IN PATIENTS WITH HEMOPHILIA**
V Zorenko¹ (¹National Research Center for Hematology, Moscow, Russian Federation)
- P308 **PREVALENCE OF GENETIC MARKERS OF OXIDATIVE STRESS IN PATIENTS WITH SEVERE HEMOPHILIA FROM NORTH-WESTERN RUSSIA**
S Kapustin¹ (¹Russian Research Institute Of Haematology And Transfusiology, Saint-Petersburg, Russian Federation)
- P309 **THE ROLE OF DNA METHYLATION AND EXPRESSION OF MMP-2 AND MMP-9 IN PATHOGENESIS OF INTRACEREBRAL HEMORRHAGE IN CONGENITAL FACTOR XIII DEFICIENCY**
A Noroozi-Aghideh¹ (¹AJA UNIVERSITY OF MEDICAL SCIENCES, Tehran, Iran, Islamic Republic Of)
- P310 **GENETIC CONFIRMATION AND FINDING NOVEL MUTATIONS IN GLANZMANN THROMBASTHENIA AND VON WILLEBRAND DISEASE FAMILIES BY DIAGNOSTIC EXOME SEQUENCING**
Y Shim¹ (¹Keimyung University School of Medicine and Dongsan Medical Center, Daegu, Korea, Republic Of)
- P311 **HPA-3A/3A GENOTYPE IS A POSSIBLE RISK FACTOR OF SEVERE HEMORRHAGIC SYNDROME IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA**
Z Irina¹ (¹Russian Research Institute of hematology, Saint-Petersburg, Russian Federation)
- P312 **AN ALGORITHM TO IDENTIFY CASES OF SEVERE HEMORRHAGE IN ROUTINELY COLLECTED HEALTHCARE DATA**
A Kreuger^{1, 2} (¹Sanquin Research, Leiden, the Netherlands, ²LUMC, Leiden, the Netherlands)
- 17:15 – 18:45, Poster area
MYELODYSPLASTIC SYNDROMES – CLINICAL 1
Moderator: L Pleyer (Paracelsus Medical University, Salzburg, Austria)
- P313 **MOLECULAR MECHANISMS AND CLINICAL SIGNIFICANCE OF REDUCED PTPN1 EXPRESSION IN MYELODYSPLASTIC SYNDROMES**
M Shiseki¹ (¹Tokyo Women's Medical University, Tokyo, Japan)
- P314 **MOLECULAR MARKERS PREDICTING RESPONSE TO AZACITIDINE TREATMENT FOR MYELODYSPLASTIC SYNDROMES.**
Y Nannya¹ (¹Kyoto University, Kyoto, Japan)
- P315 **UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA**
G Montalban-Bravo¹ (¹MD Anderson Cancer Center, Houston, United States)
- P316 **AZACITIDINE IMPROVES OUTCOME IN HIGH RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES: RETROSPECTIVE COMPARISON OF GESMD AND GFM REGISTRIES.**
M Díez Campelo¹ (¹GESMD, Valencia, Spain)
- P317 **UN UPDATE OF A PHASE II EXPLORATORY STUDY OF OPN-305, A TOLL-LIKE RECEPTOR 2 (TLR-2) ANTIBODY, IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH PRIOR HYPOMETHYLATING AGENT (HMA) THERAPY**
G Garcia-Manero¹ (¹The University of Texas MD Anderson Cancer Center, Houston, United States)
- P318 **IN PATIENTS UNDEGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MDS DEVELOPMENT OF CHRONIC GVHD COULD AMELIORATE THE ADVERSE IMPACT OF SPECIFIC SOMATIC MUTATIONS**
J Caballero Berrocal¹ (¹University Hospital of Salamanca, Salamanca, Spain)

P319 **VOSAROXIN PLUS AZACITIDINE TREATMENT FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS): A PHASE 1/ COHORT EXPANSION STUDY**
M Jacoby¹ (¹Washington University Medical School, St. Louis, United States)

17:15 – 18:45, Poster area

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - BIOLOGY

Moderator: WJ Chng (National University Cancer Institute, Singapore)

P320 **ADVANCED STAGE MYELOMA IS CHARACTERIZED BY A SIGNIFICANT INCREASE OF MUTATIONS IN GENES ASSOCIATED WITH DRUG RESPONSE**
S Barrio¹ (¹Würzburg University Hospital, Würzburg, Germany)

P321 **ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA**
M Marchesini¹ (¹MDAnderson Cancer Center, Houston, United States)

P322 **PROGNOSTIC IMPLICATION OF SOMATIC MUTATIONS BY NEXT GENERATION SEQUENCING: AN ANALYSIS FROM THE MMRF COMPASS STUDY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.**
M D'agostino¹ (¹Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy)

P323 **TARGETING GENE DEPENDENCY OF 1Q AMPLIFICATION IN MULTIPLE MYELOMA**
S Manier^{1, 2} (¹Dana-Farber Cancer Institute, Boston, United States, ²Lille Hospital, Lille, France)

P324 **DUAL INHIBITION OF DNMT1 AND EZH2 CAN EFFECTIVELY OVERCOME BOTH INTRINSIC AND ACQUIRED RESISTANCE OF MYELOMA CELLS TO IMiDS**
K Dimopoulos¹ (¹Rigshospitalet, Copenhagen, Denmark)

P325 **MULTILAYER EPIGENOMIC ANALYSES REVEAL OF NEW CANDIDATE ONCOGENES INVOLVED IN THE PATHOGENESIS OF MULTIPLE MYELOMA**
R Ordoñez¹ (¹Center for Applied Medical Research (CIMA), Pamplona, Spain)

P326 **CLINICAL IMPLICATIONS OF CLONAL CD34+ CELLS IN STEM CELL HARVEST FROM PATIENTS WITH PLASMA CELL DYS-CRASIAS**
S Chitre¹ (¹KINGS COLLEGE LONDON, London, United Kingdom)

P327 **PATHOPHYSIOLOGICAL FUNCTIONS AND CLINICAL IMPACT OF THE NEW IMMUNORECEPTOR SLAMF3 IN MULTIPLE MYELOMA**
M Ishibashi¹ (¹Nippon Medical School, Tokyo, Japan)

P328 **TARGETING CD74 IN MULTIPLE MYELOMA WITH A NOVEL ANTIBODY DRUG CONJUGATE (ADC), STRO-001**
A Molina¹ (¹Sutro Biopharma, South San Francisco, United States)

P329 **GENOTYPE CHARACTERIZATION OF LIGHT CHAIN AMYLOIDOSIS BY WHOLE EXOME SEQUENCING**
I Cuenca¹ (¹Hospital 12 de Octubre, Madrid, Spain)

17:15 – 18:45, Poster area

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL 1

Moderator: N Bolli (Università degli Studi di Milano, Italy)

P330 **IMPROVED SURVIVAL IN 21,465 MULTIPLE MYELOMA PATIENTS: RESULTS FROM A POPULATION-BASED STUDY**
S Thorsteinsdottir¹ (¹Landspítali - The National University Hospital of Iceland, Reykjavik, Iceland)

P331 **PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA**
M Binder¹ (¹Mayo Clinic, Rochester, United States)

P332 **LENALIDOMIDE MAINTENANCE VS PLACEBO AFTER STEM CELL TRANSPLANT FOR PATIENTS WITH MULTIPLE MYELOMA: OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AFTER ADJUSTING FOR TREATMENT CROSSOVER IN CALGB**
P McCarthy¹ (¹Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY, United States)

P333 **UPDATED RESULTS FROM ASPIRE AND ENDEAVOR, RANDOMISED, OPEN-LABEL, MULTICENTRE PHASE 3 STUDIES OF CARFILZOMIB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)**
D Siegel¹ (¹Hackensack University Medical Center, Hackensack, United States)

P334 **EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF POLLUX**
M Dimopoulos¹ (¹National and Kapodistrian University of Athen, Athens, Greece)

P335 **DARATUMUMAB-BASED COMBINATION REGIMENS IN ELDERLY (≥75 YEARS) PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUBGROUP ANALYSIS OF THE PHASE 3 CASTOR AND POLLUX STUDIES**
MV Mateos¹ (¹University Hospital of Salamanca/IBSAL, Salamanca, Spain)

- P336 **ALL ORAL COMBINATION OF IXAZOMIB PLUS THALIDOMIDE AND DEXAMETHASONE FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA: INTERIM DATA OF AN ONGOING PHASE II TRIAL**
H Ludwig¹ (¹Wilhelminen Cancer Research Institute, Vienna, Austria)
- P337 **EVALUATION OF GROWTH DIFFERENTIATION FACTOR-1 (GDF15) AS A NEW BIOMARKER FOR RENAL OUTCOMES IN DIFFERENT COHORTS OF PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS**
E Kastritis¹ (¹National and Kapodistrian University of Athens, Athens, Greece)
- P338 **AN OPEN-LABEL, PHASE 2 STUDY TO EVALUATE THE ORAL COMBINATION OF IXAZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ICD) IN TRANSPLANT-INELIGIBLE PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)**
M Dimopoulos¹ (¹National and Kapodistrian University of Athens School of Medicine, Athens, Greece)
- P339 **THE ORAL PROTEASOME INHIBITOR IXAZOMIB IN COMBINATION WITH MELPHALAN-PREDNISONE (MP) FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 1/2 DOSE-ESCALATION STUDY (NCT01335685)**
J San Miguel¹ (¹Clinica Universidad de Navarra, Centro Investigación Medica Aplicada (CIMA) Hospital Universitario Virgen del Rocío, Pamplona, Spain)
- 17:15 – 18:45, Poster area
MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL 2
Moderator: J de la Rubia (University Hospital Dr. Peset, Valencia, Spain)
- P340 **FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN – PREDNISONE – BORTEZOMIB (MPV) IN PATIENTS ≥ 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY**
S Zweegman¹ (¹VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands)
- P341 **THE EUROPEAN MYELOMA NETWORK EMN09 STUDY: CARFILZOMIB, BENDAMUSTINE, AND DEXAMETHASONE (CBD) IS EFFICIENT AND SAFE IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA**
M Gramatzki¹ (¹Division of Stem Cell Transplantation and Immunotherapy, University of Kiel, Kiel, Germany)
- P342 **CHEMOTHERAPY BEFORE AND AFTER HEART TRANSPLANTATION FOR PATIENTS WITH ADVANCED CARDIAC AL AMYLOIDOSIS, SINGLE CENTER RESULTS WITH LONG-TERM FOLLOW-UP**
U Hegenbart¹ (¹University Hospital, Heidelberg, Germany)
- P343 **MM-013 PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE (POM) PLUS LOW-DOSE DEXAMETHASONE (LODEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI)**
P Sonneveld¹ (¹Erasmus MC Cancer Institute, Rotterdam, the Netherlands)
- P344 **PEMBROLIZUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B KEYNOTE-013 STUDY**
V Ribrag¹ (¹Institut Gustave Roussy, Villejuif, France)
- P345 **ASSESSMENT OF MOBILIZATION COST FOR MULTIPLE MYELOMA USING 2 DIFFERENT STRATEGIES: HIGH-DOSE CYCLOPHOSPHAMIDE VERSUS PLERIXAFOR. ON BEHALF OF IFM.**
Z Van De Wyngaert¹ (¹CHRU Lille, Lille, France)
- P346 **SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF INDUCTION TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS**
JC Kim¹ (¹Inha University Hospital, Incheon, Korea, Republic Of)
- P347 **A STUDY OF UTILITY OR FUTILITY OF PERFORMING SKELETAL SURVEYS IN PARAPROTEINAEMIA: A MULTICENTER EXPERIENCE FROM UK**
O gamage¹ (¹Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom)
- P348 **SERUM FLC MEASUREMENTS COMPLEMENT BONE MARROW ASSESSMENT TO DETERMINE PROGNOSIS IN MYELOMA PATIENTS ACHIEVING DEEP RESPONSES**
T Dejoie¹ (¹Centre Hospitalier Universitaire-Nantes, Nantes, France)
- P349 **THE CONNECT MM REGISTRY: IMPACT OF THE CYTOGENETIC ABNORMALITY T(11;14) ON SURVIVAL OUTCOMES IN AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA**
C Gasparetto¹ (¹Duke University Medical Center, Durham, United States)
- 17:15 – 18:45, Poster area
MYELOPROLIFERATIVE NEOPLASMS - CLINICAL 1
Moderator: A Almeida (Instituto Português de Oncologia de Lisboa (IPO Lisboa), Portugal)
- P350 **RAS-PATHWAY MUTATION PATTERNS DEFINE EPIGENETIC SUBCLASSES IN JUVENILE MYELOMONOCYTIC LEUKEMIA**
D Lipka^{1, 2} (¹German Cancer Research Center (DKFZ), Heidelberg, Germany, ²German Cancer Research Center (DKFZ), Heidelberg, Germany)

- P351 **CYTOGENETIC ABNORMALITIES IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: CORRELATIONS WITH GENOTYPE AND PHENOTYPE IN THE MYSEC STUDY**
B Mora¹ (¹Ospedale di Circolo, ASST Sette Laghi, Varese, Italy)
- P352 **MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM - UNCLASSIFIABLE (MDS/MPN-U)**
P Bose¹ (¹University of Texas MD Anderson Cancer Center, Houston, United States)
- P353 **GENOME WIDE DNA METHYLATION PROFILING IS PREDICTIVE OF OUTCOME IN JUVENILE MYELOMONOCYTIC LEUKEMIA**
E Stieglitz¹, ² (¹UCSF Benioff Children's Hospital, San Francisco, United States, ²University of California, San Francisco, San Francisco, United States)
- P354 **LEUKEMIC TRANSFORMATION OF MYELOPROLIFERATIVE NEOPLASMS: IS NGS PROFILE THE BEST PROGNOSTIC BIOMARKER?**
V Geoffroy¹ (¹Institut Paoli Calmettes, Marseille, France)
- P355 **INCIDENCE AND OUTCOME OF SECONDARY NON HEMATOLOGICAL CANCERS IN ADULT PATIENTS WITH MASTOCYTOSIS**
M Bonifacio¹, ² (¹University of Verona, Verona, Italy, ²Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy)
- P356 **HIGH WBC COUNT WAS THE RISK FACTOR FOR SURVIVAL IN PATIENTS WITH CSF3R- MUTATED CHRONIC NEUTROPHILIC LEUKEMIA**
Q Jiang¹ (¹Peking University Institute of Hematology, Beijing, China)
- P357 **CLINICAL PHENOTYPE AND OUTCOME OF ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC MYELOFIBROSIS DIAGNOSED ACCORDING TO THE REVISED 2016 WHO DIAGNOSTIC CRITERIA**
E Rumi¹, ² (¹Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ²Department of Molecular Medicine, University of Pavia, Pavia, Italy)
- P358 **VALIDATION OF THE REVISED IPSET-THROMBOSIS SCORE IN 734 PATIENTS WITH WHO 2016-DEFINED ESSENTIAL THROMBOCYTHEMIA. REPORT OF THE REGISTRO ITALIANO TROMBOCITEMIE (RIT)**
L Gugliotta¹ (¹Policlinico S.Orsola-Malpighi, Bologna, Italy)
- P359 **CORRELATIONS BETWEEN INFLAMMATORY BIOMARKERS AND INDIVIDUAL SYMPTOMS EXPRESSED BY MYELOFIBROSIS PATIENTS IN THE COMFORT-I TRIAL: ANALYSIS OF BASELINE ASSOCIATIONS AND CHANGES OVER TIME**
H Geyer¹ (¹Mayo Clinic, Phoenix, AZ, United States)
- 17:15 – 18:45, Poster area
PLATELET DISORDERS: BASIC
Moderator: To be announced
- P360 **NOVEL HETEROZYGOUS IT6B3.P.T746DEL MUTATION INDUCING SPONTANEOUS ACTIVATION OF INTEGRIN α IIb β 3 CAUSES AUTOSOMAL DOMINANT MACROTHROMBOCYTOPE-NIA WITH ABNORMAL α IIb β 3 LOCALIZATION**
N Miyashita¹ (¹Hokkaido University Graduate School of Medicine, Sapporo, Japan)
- P361 **CHANGES IN THE GENE EXPRESSION PROFILE OF IMMUNE THROMBOCYTOPENIA PATIENTS TREATED WITH ELTROMBOPAG**
J Bastida¹ (¹Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain)
- P362 **DEFECTIVE PTEN REGULATION CONTRIBUTES TO B CELL HYPERRESPONSIVENESS IN CHRONIC IMMUNE THROMBOCYTOPENIA**
S Wang¹ (¹State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin, China)
- P363 **A DECREASED INTRACELLULAR S1P LEVEL AND S1P RECEPTORS EXPRESSED ON MEGAKARYOCYTES POSSIBLY CONTRIBUTE TO DEFECTIVE PROPLATELETS FORMATION IN IMMUNE THROMBOCYTOPENIA**
X Zhang¹ (¹Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China)
- P364 **ANTIBODY MEDIATED GLYCAN MODIFICATION: A POTENTIAL ROLE IN PLATELET DESTRUCTION IN AUTOIMMUNE THROMBOCYTOPENIA**
I Marini¹ (¹University Hospital of Tübingen , Tübingen, Germany)
- P365 **NOVEL RUNX1 MUTATIONS IN FAMILIES WITH INHERITED THROMBOCYTOPENIA**
P Noris¹ (¹IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy)
- P366 **TNF- α BLOCKADE CORRECTED THE IMPAIRED BALANCE OF MONOCYTE/MACROPHAGE SUBSETS IN PRIMARY IMMUNE THROMBOCYTOPENIA**
Y Zhao¹ (¹Qilu Hospital, Jinan, China)
- P367 **A SINGLE-ARM, OPEN-LABEL, LONG-TERM EFFICACY AND SAFETY STUDY OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)**
J Grainger¹ (¹University of Manchester, Manchester, United Kingdom)

P368 NOVEL THIENOPYRIDINES AS POTENT PLATELET INHIBITORS: FUTURE TREATMENTS FOR PLATELET HYPERACTIVITY DISORDERS?

N Binsaleh¹ (¹Manchester Metropolitan University, Manchester, United Kingdom)

17:15 – 18:45, Poster area

QUALITY OF LIFE, PALLIATIVE CARE, ETHICS AND HEALTH ECONOMICS 1

Moderator: K Weisel (University Hospital of Tuebingen, Germany)

P369 PATIENT-REPORTED OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION BEFORE AND DURING TREATMENT WITH ECLIZUMAB: RESULTS FROM THE INTERNATIONAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA REGISTRY
 P Muus¹ (¹Radboud University Medical Center, Nijmegen, the Netherlands)

P370 ECONOMIC IMPACT OF INTRODUCING AGE-ADJUSTED D-DIMER CUT-OFF LEVELS IN THE DIAGNOSIS STRATEGY OF VENOUS THROMBOEMBOLISM
 P Toulon¹ (¹Pasteur University Hospital, Nice, France)

P371 IMPACT OF CELLULAR THERAPY ON THE ECONOMIC BURDEN AND SURVIVAL FOLLOWING RELAPSE AFTER HLA IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME.
 S Lachance¹ (¹Université de Montréal, Hôpital Maisonneuve-Rosemont, Montréal, Canada)

P372 ACUTE MYELOID LEUKEMIA (AML) TREATMENT PRACTICE PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS IN A US COMMERCIALY-INSURED POPULATION
 M Hagiwara¹ (¹Policy Analysis Inc., Brookline, MA, United States)

P373 HEALTH-RELATED QUALITY OF LIFE IN AL AMYLOIDOSIS PATIENTS WITH NERVOUS SYSTEM INVOLVEMENT
 K McCausland¹ (¹Optum, Lincoln, United States)

P374 ACCESS TO COMMUNITY CHEMOTHERAPY IMPROVES PATIENT QUALITY OF LIFE
 R Iredale¹ (¹University of South Wales, Pontypridd, United Kingdom)

P375 THE BUDGET IMPACT OF TREATMENT-FREE REMISSION FOR FIRST-LINE NILOTINIB OR GENERIC IMATINIB IN TREATING CHRONIC PHASE PHILADELPHIA-POSITIVE CHRONIC MYELOID LEUKEMIA
 P Brandt² (²Novartis Pharmaceuticals Corporation, East Hanover, United States)

P376 GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (→65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES
 J de la Rubia¹⁷ (¹⁷H.U. Doctor Peset, Valencia, Spain)

P377 NUTRITIONAL NEEDS AND PREFERENCES OF MYELOPROLIFERATIVE NEOPLASM PATIENTS: PHASE IA OF THE NUTRIENT STUDY

R Scherber^{1, 2} (¹Mayo Clinic, Scottsdale, United States, ²Oregon Health and Science University, Portland, United States)

P378 DO PHYSICIANS NEED HELP TO ADEQUATELY INFORM AND SUPPORT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA? RESULTS FROM A QUALITATIVE STUDY IN GREECE
 C Karamanidou¹ (¹CERTH, Thessaloniki, Greece)

17:15 – 18:45, Poster area

STEM CELL TRANSPLANTATION - CLINICAL 1

Moderator: C Solano (Hospital Clínico Universitario-INCLIVA Institute of Research, University of Valencia, Spain)

P379 OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE LEUKEMIA ABOVE 70 YEARS OF AGE: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
 A Nagler⁶ (⁶Chaim Sheba Medical Center, Tel-Hashomer, Israel)

P380 BLOOD BAALC AND MN1 COPY NUMBER ASSESSMENT BY DIGITAL DROPLET PCR PRIOR TO ALLOGENEIC TRANSPLANTATION PREDICTS RELAPSE IN ACUTE MYELOID LEUKEMIA PATIENTS
 M Jentsch¹ (¹UNIVERSITÄTSKLINIKUM LEIPZIG, Leipzig, Germany)

P381 THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS
 A Bertaina¹ (¹Ospedale Pediatrico Bambino Gesù, Rome, Italy)

P382 EXCELLENT RESPONSE, LOW TRM AND GOOD SURVIVAL IN PATIENTS WITH THERAPY-REFRACTORY AGVHD AFTER TREATMENT WITH EQUIPOTENT MSCS OF A SERUM-FREE MSC-BANK GENERATED FROM POOLED BM-MNCS OF MULTIPLE DONORS
 S Kuci¹ (¹Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany)

P383 HIGHER PEAK TACROLIMUS CONCENTRATIONS AFTER ALLOGENEIC TRANSPLANTATION INCREASE THE RISK OF ENDOTHELIAL CELL DAMAGE COMPLICATIONS
 T Morishita¹ (¹Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan)

P384 IMPACT OF CONDITIONING REGIMEN ON OUTCOMES OF T-REPLETE HAPLO-IDENTICAL TRANSPLANTATION FOR PATIENTS OVER 45 YEARS-OLD WITH AML: A STUDY ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT

D Nasso^{1, 2} (¹"Tor Vergata" University of Rome, Rome, Italy, ²Hôpital Saint Antoine, Paris, France)

P385 ROLE OF UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE ADULT T-CELL LEUKEMIA-LYMPHOMA: A DECISION ANALYSIS

S Fuji¹ (¹National Cancer Center Hospital, Tokyo, Japan)

P386 OUTCOMES OF THIOTEPA BASED REDUCED-INTENSITY CONDITIONING VERSUS STANDARD REDUCED-INTENSITY CONDITIONING IN ADULT PATIENTS UNDERGOING DOUBLE-UNIT CORD-BLOOD HEMATOPOIETIC STEM CELL TRANSPLANT.

P Sharma¹ (¹University of Colorado, Denver, United States)

P387 INTERFERON- β IS EFFECTIVE FOR TREATMENT OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

XD Mo¹ (¹Institute of Hematology, Beijing, China)

P388 COMPARABLE LONG-TERM OUTCOME AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR OLDER PATIENTS (AGE \geq 50 YEARS) WITH AML FROM SIBLING AND MATCHED UNRELATED DONORS. A REPORT ON BEHALF OF THE ALWP OF EBMT.

A Shimoni¹ (¹CHAIM SHEBA MEDICAL CENTER, Tel-Hashomer, Israel)

P389 IMPACT OF AZACITIDINE PRETREATMENT ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROME

J Aoki¹ (¹Kanagawa Cancer Center, Yokohama, Japan)

P390 LOW-DOSE DECITABINE IMPROVES PLATELET RECOVERY IN PATIENTS WITH ISOLATED THROMBOCYTOPENIA AFTER HSCT

Y Han^{1, 2} (¹Soochow University, Suzhou, China, ²The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China)

17:15 – 18:45, Poster area

THALASSEMIA

Moderator: A Taher (American University of Beirut Medical Center (AUBMC), Lebanon)

P391 QUANTITATIVE PROTEOMICS OF PLASMA EXTRACELLULAR VESICLES TO IDENTIFY NOVEL BIOMARKERS OF CLINICAL SEVERITY FOR HBE/ δ -THALASSEMIC PATIENTS

J Kittivorapart^{1, 2, 3} (¹NHS Blood and Transplant, Bristol, United Kingdom, ²University of Bristol, Bristol, United Kingdom, ³Faculty of Medicine Siriraj Hospital, Bangkok, Thailand)

P392 A SELECTIVE ORAL GLYT1 INHIBITOR IMPROVES ANEMIA IN A MOUSE MODEL OF BETA-THALASSEMIA

L De Franceschi¹ (¹University of Verona, Verona, Italy)

P393 MAY MUTATIONS IN THE KLF1 GENE HAVE WORSENING EFFECTS ON THE BETA THALASSEMIA PHENOTYPE?

M Grosso¹ (¹University of Naples Federico II, Naples, Italy)

P394 SECONDARY SOLID TUMORS FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR THALASSEMIA MAJOR

A Meloni¹ (¹Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy)

P395 VALIDATING A NOVEL CAPILLARY ELECTROPHORESIS: THE MOST SUITABLE PLATFORM FOR THE NATIONAL NEWBORN SCREENING PROGRAM IN A REGION WITH HIGH PREVALENCE OF THALASSEMIA AND HEMOGLOBINOPATHIES

T Suksangpleng¹ (¹Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand)

P396 TRANSIENT ELASTOGRAPHY IN NON TRANSFUSION DEPENDENT THALASSEMIA: A SUCCESSFUL TOOL TO ASSESS AND MONITORING LIVER FIBROSIS

A Marcon¹ (¹Foundation IRCCS "Ca' Granda" Ospedale Maggiore Policlinico, Milan, Italy)

P397 INCREASING INCIDENCE OF MALIGNACIES IN AGING THALASSEMIC PATIENTS: A SINGLE INSTITUTION'S LONGITUDINAL EXPERIENCE

E Repousi¹ (¹National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, Athens, Greece)

P398 SAFETY AND EFFICACY OF EARLY START WITH SUBOPTIMAL DOSE OF DEFERIPRONE IN MINIMALLY TRANSFUSED INFANTS WITH TRANSFUSION DEPENDENT THALASSEMIA: A RANDOMIZED TRIAL

M Elalfy¹ (¹AinShams university, Cairo, Egypt)

P399 LONGITUDINAL PROSPECTIVE MRI STUDY IN PEDIATRIC PATIENTS WITH THALASSEMIA MAJOR

M Casale¹ (¹AORN A. Cardarelli, Napoli, Italy)

P400 LONG TERM FOLLOW-UP OF A COHORT OF WELL TREATED β -THALASSEMIA MAJOR PATIENTS BY MULTI-ORGAN R2* MAGNETIC RESONANCE IMAGING

G Forni¹ (¹Ospedale Galliera Genova, Genova, Italy)

17:15 – 18:45, Poster area

TRANSFUSION MEDICINE

Moderators: S Stanworth (NHS Blood and Transplant / Oxford University Hospitals NHS Trust, United Kingdom)
D Prati (Ospedale Alessandro Manzoni, Lecco, Italy)

P401 DEVELOPMENT OF HTLV-1 HYPERIMMUNE GLOBULINS AGAINST HTLV-1 INFECTION

T Mizukami¹ (¹National Institute of Infectious Diseases, Tokyo, Japan)

P402 THE CONTAMINATION OF TUMOR CELLS IN THE APHERESIS MATERIAL DOES NOT PREDICT THE RESPONSE OF MULTIPLE MYELOMA PATIENTS TO AUTOLOGOUS TRANSPLANTATION

M Lozano¹ (¹IMIB-Arrixaca, CB15/00055-CIBERER, Murcia, Spain)

P403 EVALUATION OF THERAPEUTIC PLASMA EXCHANGE AT A TERTIARY LONDON HOSPITAL

R Moll¹ (¹Royal Free Hospital, London, United Kingdom)

P404 A COMPREHENSIVE PROTEOMICS STUDY ON PLATELET CONCENTRATES: PLATELET PROTEOME, STORAGE TIME AND MIRASOL PATHOGEN REDUCTION TECHNOLOGY

L Gutierrez⁴ (⁴IdISSC, Madrid, Spain)

P405 USE OF A SURVEY TO ASSESS AND IMPROVE ADHERENCE TO UK BLOOD TRANSFUSION GUIDELINES IN A HOSPITAL SETTING

D Warcel¹ (¹Royal Free Hospital, London, United Kingdom)

P406 SCREENING OF TRANSFUSION PRODUCTS FOR PRION DISEASES USING APTAMERS AND TUNABLE RESISTIVE PULSE SENSING

M Healey¹ (¹Loughborough University, Loughborough, United Kingdom)

EHA-SWG SCIENTIFIC MEETING

Challenges in the diagnosis and management of myeloproliferative neoplasms



Dates: October 12-14, 2017

Location: Budapest, Hungary

Organized by:

EHA Scientific Working Group on Myeloproliferative Neoplasms

Chairs:

C Harrison, JJ Kiladjian

Topics:

- Molecular pathogenesis and diagnosis
- State of the art: Novel therapies for MPNs
- Indolent MPN
- What's new in myelofibrosis?
- Use of interferon in MPN
- Mechanisms of resistance to JAK inhibitors
- Patient advocacy in EU
- Prognostic scores in MPN
- Advances in systemic mastocytosis
- Advances in diagnosis and management of CMML
- State of the art: investigation and management of erythrocytosis

SATURDAY, JUNE 24



SPECIAL SESSIONS OF THE DAY

Next to the high quality scientific and education sessions of the day we would like to draw your attention to the following interesting sessions:

INTERNATIONAL SOCIETY FOR EXPERIMENTAL HEMATOLOGY JOINT SYMPOSIUM →	Page 126
AMERICAN SOCIETY OF HEMATOLOGY JOINT SYMPOSIUM →	Page 129
PLENARY SESSION I →	Page 138
JEAN BERNARD LIFETIME ACHIEVEMENT AWARD →	Page 138
CHINESE SOCIETY OF HEMATOLOGY JOINT SYMPOSIUM →	Page 140
EUROPEAN SCHOOL OF HAEMATOLOGY JOINT SYMPOSIUM →	Page 140
EARLY CAREER SESSION →	Page 140
UPDATES-IN-HEMATOLOGY →	Page 146

ADVOCACY TRACK

INTERESTED IN ADVOCACY & LOBBYING?

EHA Advocacy Track offers interesting sessions for you on Saturday:

PATIENT ADVOCACY SESSIONS →	Page 128 and 137
EU-FUNDED PROJECTS IN HEMATOLOGY - HARMONY →	Page 141
EHA ADVOCACY SESSION →	Page 146

→ EDUCATION SESSION 3 4 B T C

08:00 - 09:30, Hall A

Repeated from:

Friday, June 23, 09:45 - 11:15, Hall A

IMMUNOTHERAPY IN LYMPHOMA

Chair: A Engert (University Hospital of Cologne, Germany)

- The role of the microenvironment in the pathogenesis of B-cell lymphomas

G Lenz (Translational Oncology, Münster, Germany)

- Immune checkpoint inhibitors

A Younes (Memorial Sloan Kettering Cancer Center, New York, USA)

- Is transplantation in lymphoma still needed in the era of immunotherapy?

A Sureda (Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain)

LEARNING GOALS

G Lenz

After attending this lecture, the participant will be able to

- Describe the role of the microenvironment in the biology of different B-cell lymphomas.
- Discuss important components of the microenvironment of different B-cell malignancies.
- Appreciate the interaction between bystander and malignant cells in B-cell lymphomas.

A Younes

An up-to-date program is available via the mobile app.

A Sureda

After attending this lecture, the participant will be able to

- Understand how the introduction of check point inhibitors will potentially modify the profile of Hodgkin's lymphoma patients undergoing allogeneic hematopoietic stem cell transplantation.
- Describe transplant related toxicities and long term outcome of patients with Hodgkin's lymphoma that have been previously treated with check point inhibitors.
- Learn how to use check point inhibitors in those patients that relapse after the allogeneic procedure.

→ EDUCATION SESSION 3 5 10 T C

08:00 - 09:30, Hall B

Repeat Session:

Sunday, June 25, 11:15 - 12:45, Hall D

MULTIPLE MYELOMA

Chair: A Alegre (Hospital Universitario de La Princesa, Madrid, Spain)

- Immunopathology of MM

N Munshi (Dana-Farber Cancer Institute, Boston, USA)

- Genetic classification of myeloma for prognostication and treatment selection

H Avet-Loiseau (IUC-Oncopole, Toulouse, France)

- New treatment approaches in myeloma in 2017

JF San-Miguel (Universidad de Navarra, Pamplona, Spain)

LEARNING GOALS

N Munshi

After attending this lecture, the participant will be able to

- Describe the immune status in multiple myeloma.
- Discuss the impact of immune dysfunction on myeloma cell growth and survival.
- Elucidate various methods and mechanisms to augment immune function for potential therapeutic application.

H Avet-Loiseau

After attending this lecture, the participant will be able to

- Understand the genetic heterogeneity in myeloma.
- Know what main prognostic parameters are.
- Understand how these factors may influence treatment choices.

JF San-Miguel

After attending this lecture, the participant will be able to

- Better tools for diagnosis and monitoring treatment efficacy are being implemented.
- Early treatment and the use of more efficient drugs upfront prolong survival.
- The treatment goal is to find the best possible balance between efficacy, toxicity and cost, particularly at the time of relapse.

→ SCIENTIFIC WORKING GROUPS 3 5 T C

08:30 - 09:30, Hall C

LYMPHOMAS: DIAGNOSIS AND FOLLOW-UP OF LYMPHOMA

Chair: MJ Kersten (Academic Medical Center, Amsterdam, the Netherlands)

- Introduction EHA LyG

MJ Kersten (Academic Medical Center, Amsterdam, the Netherlands)

- Do we still need bone marrow biopsies?

TC El-Galaly (Aalborg University Hospital, Denmark)

- Interim-PET as a valid biomarker for early response in malignant lymphoma; when to perform and how to assess
- J Zijlstra (VU University medical center, Amsterdam, the Netherlands)

- Circulating tumor DNA in Non-Hodgkin lymphoma: Clinical and future research applications

M Roschewski (National Cancer Institute, NIH, Bethesda, USA)

LEARNING GOALS

TC El-Galaly

After attending this lecture, the participant will be able to

- Learn about the diagnostic value of routine bone marrow biopsy in different lymphoma subtypes.
- Be informed about the Lugano Classification recommendations for routine bone marrow biopsy.
- Be informed about the controversies related to prognostic value of imaging-ascertained bone marrow involve.

J Zijlstra

After attending this lecture, the participant will be able to

- Describe the role of interim-PET in Hodgkin lymphoma.
- Discuss the assessment of PET-CT and the aetiology of false-positive/ false-negative PET-CT.
- Describe the difficulties in using interim-PET in DLBCL trials.

M Roschewski

After attending this lecture, the participant will be able to

- Describe how circulating tumor DNA assays compare to medical imaging as a surveillance tool in diffuse large B-cell lymphoma.
- Understand the potential advantages of circulating tumor DNA assays over tissue biopsies.
- Discuss future potential applications of circulating tumor DNA assays across the spectrum of non-Hodgkin lymphomas.

→ EDUCATION SESSION

2 5 10 T C

08:00 - 09:30, Hall D

Repeated from:

Friday, June 23, 09:45 - 11:15, Hall C

CHRONIC MYELOID LEUKEMIA

Chair: S Soverini (University of Bologna, Italy)

- **Novel approaches to eradicate CML stem cells**
M Copland (University of Glasgow, United Kingdom)
- **Molecular work up and monitoring of CML patients**
N Cross (University of Southampton, United Kingdom)
- **How to treat CML in 2017**
A Hochhaus (UK Jena, Germany)

LEARNING GOALS

M Copland

After attending this lecture, the participant will be able to

- Describe the different potential mechanisms of CML stem cell resistance to tyrosine kinase inhibitors.
- Discuss potential therapeutic strategies, in preclinical development or early phase clinical trials, which may improve eradication of CML stem cells.

N Cross

After attending this lecture, the participant will be able to

- Describe the essential elements for the diagnostic work of CML patients.
- Discuss factors associated with heterogeneous response to TKI therapy.
- Understand the role of molecular monitoring for personalised treatment, and how this process is standardised.

A Hochhaus

After attending this lecture, the participant will be able to

- Describe current and emerging therapies for newly diagnosed patients with CML.
- Select appropriate upfront therapy based upon patients treatment goals and preferences, considering efficacy, safety and costs of various options.
- Describe recommended monitoring strategies and clinical

consequences from monitoring.

- Describe the selection of second line therapies according to biological and clinical parameters.
- Understand which patients may be eligible for treatment free remission.

→ EHA - INTERNATIONAL SOCIETY OF LABORATORY HEMATOLOGY (ISLH) - LABORATORY DIAGNOSIS WORKSHOP

08:00 - 11:15, Hall E

Organizers: JJM van Dongen (Leiden University Medical Center (LUMC), the Netherlands)

A Orfao (University of Salamanca, Spain)

B-CELL MALIGNANCIES

3 5 9 10 T C

Chairs: JJM van Dongen (Leiden University Medical Center (LUMC), the Netherlands)

G Zini (Catholic University Fondazione Policlinico Gemelli, Rome, Italy)

- **Pathogenic mechanisms in mantle cell lymphoma: Impact on the heterogeneity and WHO-2016 subclassification of the disease**
P Jares (Hospital Clinic Barcelona, University of Barcelona, Spain)
- **How many subtypes of diffuse large B-cell lymphoma can be defined?**
J Cabeçadas (Instituto Português de Oncologia, Lisbon, Portugal)
- **Is the WHO-2016 sufficient for the diagnosis and classification of plasma cell neoplasias?**
B Durie (Cedars Sinai Medical Center, USA)

LEARNING GOALS

P Jares

After attending this lecture, the participant will be able to

- Understand the molecular pathogenesis in the development and progression of major subtypes of MCL.
- Recognize the different MCL variants, including the two indolent variants: Leukemic nonnodal MCL and in situ mantle cell neoplasia (ISMCN).

J Cabeçadas

After attending this lecture, the participant will be able to

- Identify the most important subtypes of DLBC according to the new (2017) WHO classification of lymphoid tumors.
- Understand the strategies for subtyping of DLBCL, NOS.
- Use the information in the pathology report to stratify patients and select possible therapeutic options.

B Durie

An up-to-date program is available via the mobile app.

T-CELL AND NK-CELL MALIGNANCIES 3 5 T C

Chairs: T George (University of New Mexico, Albuquerque, USA)

J Cabeçadas (Instituto Português de Oncologia, Lisbon, Portugal)

- **Current classification of T/NK cell lymphomas: Controversies and questions**
S Pileri (European Institute of Oncology, Milan, Italy)
- **T-cell malignancies of the skin: Separate disease entities?**
J Goodlad (HMDS, Leeds, United Kingdom)
- **The role of molecular genetics in the classification of peripheral T cell malignancies?**
P Gaulard (Hôpital Henri Mondor, Créteil, France)

LEARNING GOALS

S Pileri

After attending this lecture, the participant will be able to

- Discussion of the main changes introduced by the revised WHO Classification.
- Identification of the new diagnostic and prognostic algorithms applied to peripheral T/NK-cell lymphomas.
- Difficulties encountered by peripheral Hospitals in the application of such algorithms and need for inter-institutional networks.

J Goodlad

An up-to-date program is available via the mobile app.

P Gaulard

After attending this lecture, the participant will be able to

- Describe recurrent gene mutations in epigenetic modifiers (TET2, IDH2, DNMT3) in T-cell lymphomas of Follicular Helper T-cells (TFH) origin and their potential clinical implications.
- Recognize the genetic heterogeneity of anaplastic large cell lymphomas and the diagnostic importance and clinical relevance of the genetic alterations.
- Recognize that activating mutations in genes of the JAK-STAT pathway are common to several cytotoxic PTCL entities.

MYELOID MALIGNANCIES 2 5 C

Chairs: A Orfao (University of Salamanca, Spain)

MC Bene (Nantes University Hospital, France)

- **The WHO 2016 classification of myelodysplastic/myeloproliferative neoplasms**
A Orazi (Weill Cornell Medical College, New York, USA)
- **What is new in the WHO-2016 classification of MDS**
L Malcovati (University of Pavia, Italy)

LEARNING GOALS

A Orazi

After attending this lecture, the participant will be able to

- Update the participants on the WHO 2016 diagnostic criteria for myelodysplastic/myeloproliferative neoplasms.
- Describe how a proper diagnosis can be achieved by careful integration of clinical, morphologic and biologic data (e.g. cytogenetics and molecular genetics).
- Discuss strategies useful to achieve a reproducible differential

diagnosis with other myeloid neoplasms.

L Malcovati

After attending this lecture, the participant will be able to

- Describe definitions and diagnostic criteria introduced by the 2016 revision of the WHO classification of Myelodysplastic Syndromes/Neoplasms.
- Discuss the role of cytogenetic abnormalities and somatic mutations in the diagnosis and classification of Myelodysplastic Syndromes/Neoplasms.
- Discuss the limitations of current classification of Myelodysplastic Syndromes/Neoplasms and identify the areas of diagnostic uncertainty.

→ EDUCATION SESSION

4 B T C

08:00 - 09:30, Room N101

Repeated from:

Friday, June 23, 08:00 - 09:30, Hall E

STEM CELL TRANSPLANTATION - GVHD

Chair: N Kröger (University Medical Center Hamburg-Eppendorf, Germany)

- **GVHD prophylaxis and treatment, new modalities**
R Zeiser (Freiburg University Medical Center, Germany)
- **The role of the intestinal microbiota in graft-versus-host disease**
M van den Brink (Memorial Sloan Kettering Cancer Center, New York, USA)
- **Balancing Graft versus Leukemia and Graft versus Host responses**
JHF Falkenburg (Leiden University Medical Center, the Netherlands)

LEARNING GOALS

R Zeiser

After attending this lecture, the participant will be able to

- Describe emerging molecular therapies for steroid refractory GVHD.
- Discuss novel concepts on the role of neutrophils in GVHD.
- Understand the basic principles of GVHD biology.

M van den Brink

After attending this lecture, the participant will be able to

- Describe the major changes observed in the intestinal microbiota of patients undergoing that are associated with graft-vs-host disease and transplant-related mortality.
- Recapitulate the impact of antibiotic therapy, broad- vs narrow-spectrum antibiotic, on clinical outcomes in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients.
- Discuss current and putative future options for gut microbiota interventions to increase survival and gastrointestinal health in patients undergoing allo-HSCT.

JHF Falkenburg

After attending this lecture, the participant will be able to

- Understand the different nature of allo-immune T cell responses

following HLA matched and HLA mismatched stem cell transplantation.

- Estimate the likelihood of developing selective GVL responses after allogeneic stem cell transplantation.
- Understand how post-transplant circumstances and interventions influence the balance between GVL and GVHD.

→ BASIC-SCIENCE-IN-FOCUS
08:30 - 09:30, Room N105

3 B T

GENOMICS AND EPIGENOMICS OF CLL

Chair: D Rossi (Oncology Institute of Southern Switzerland, Bellinzona, Italy)

- **Genetics and epigenetics of CLL evolution**
D Landau (Weill Cornell Medicine, New York, USA)
- **Epigenetics of CLL - The Blueprint project**
Jl Martin-Subero (IDIBAPS, Barcelona, Spain)

LEARNING GOALS

D Landau

After attending this lecture, the participant will be able to

- Describe current and emerging concepts in CLL genomics.
- Describe epigenetic contribution to CLL evolution.
- Describe the relationship between CLL therapy and CLL evolution.

Jl Martin-Subero

After attending this lecture, the participant will be able to

- Describe different epigenetic marks and their impact on genome function.
- Be aware that the DNA methylation profile is widely modulated during B-cell differentiation and that epigenetic imprints from normal B cells at different maturation stages are useful to classify CLLs into 3 different clinico-biological groups.
- Know that an integrative analysis of different epigenetic marks is important to understand oncogenic deregulation in CLL.

→ SCIENTIFIC WORKING GROUPS
08:30 - 09:30, Room N103

2 T C

MYELODYSPLASTIC SYNDROMES (MDS): MDS AND THE ROLE OF THE IMMUNE SYSTEM IN PATHOPHYSIOLOGY AND THERAPY

Chair: U Platzbecker (Uni Dresden, Germany)

- **Coexistence of MDS and immune disorders**
O Fain (Hôpital Saint Antoine (AP-HP), Paris, France)
- **Modification of immune signalling by epigenetic therapy in MDS**
K Gronbaek (Rigshospitalet, Copenhagen Ø, Denmark)
- **Immunotherapeutic approaches in MDS and overlap diseases**
A Ganser (Medizinische Hochschule Hannover, Germany)

LEARNING GOALS

O Fain

After attending this lecture, the participant will be able to

- Describe the autoimmune and autoinflammatory disorders associated with MDS.

- Discuss the links between immune disorders and MDS.
- Discuss treatment of these associated manifestations in MDS patients according to the type of immune disorders and the type of MDS.

K Gronbaek

After attending this lecture, the participant will be able to

- How epigenetic therapy modulate the innate and adaptive immune system in MDS.
- How epigenetic therapy may have "side effects" on healthy immune cells in MDS.
- Why combinations of hypomethylating agents, vitamin C and immune check point inhibitors may improve the outcome of treatment in MDS.

A Ganser

After attending this lecture, the participant will be able to

- Understand the pathophysiological basis for immunotherapy in patients with MDS.
- Use the selection criteria for immunosuppressive therapy with special emphasis on ATG/cyclosporin A.
- Understand the rationale for the clinical studies with checkpoint inhibitors in MDS.

→ EHA - INTERNATIONAL SOCIETY FOR
EXPERIMENTAL HEMATOLOGY JOINT SYMPOSIUM
08:30 - 09:30, Room N104

1 4 9 B

HEMATOPOIETIC STEM CELLS AND THEIR NICHE

Chairs: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)

- **Developmental specification of hematopoietic stem cells**
D Traver (UCSD, La Jolla, USA)
- **Long-term single cell quantification: New tools for old questions in hematopoiesis research**
T Schroeder (ETH Zurich, Basel, Switzerland)

LEARNING GOALS

D Traver

After attending this lecture, the participant will be able to

- Describe the current understanding of HSC emergence during embryogenesis.
- Understand the importance of the Notch pathway in HSC specification.
- Discuss how study of HSC generation in vivo informs the instruction of HSC fate in vitro from human pluripotent precursors.

T Schroeder

After attending this lecture, the participant will be able to

- Understand the importance of quantifying single-cell dynamics.
- Current state of the art and remaining challenges in long-term bioimaging.
- Latest approaches and conclusions in analyzing molecular mechanisms of hematopoietic stem and progenitor cell fate control.

→ EDUCATION SESSION **1 9 B T C**

08:00 - 09:30, Room N109

Repeat Session:

Saturday, June 24, 09:45 - 11:15, Room N109

UPDATE ON HEMOGLOBINOPATHIES

Chair: MD Cappellini (University of Milan-Foundation IRCCS

Policlinico Hospital, Italy)

- **Genome editing in hemoglobinopathies**
M Weiss (St Jude Children's Research Hospital, Memphis, USA)
- **Iron chelation in hemoglobinopathies**
V Viprakasit (Siriraj Hospital, Mahidol University, Bangkok, Thailand)
- **Neurological complications of sickle cell disease**
F Kirkham (UCL Great Ormond Street Institute of Child health, London, United Kingdom)

LEARNING GOALS

M Weiss

After attending this lecture, the participant will be able to

- Understand the genetics of common hemoglobinopathies: sickle cell disease and beta thalassemia.
- Understand the tools of genome editing and how they can be applied to treating hemoglobinopathies.
- Understand potential barriers for using genome editing to treat hemoglobinopathies.

V Viprakasit

After attending this lecture, the participant will be able to

- Describe current and latest mechanism of iron overload and its clinical significance in thalassemia and hemoglobinopathies.
- Select appropriate iron overload monitoring based upon availability and accessibility.
- Discuss iron chelation options for thalassemia patients with iron overload as a monotherapy or a combination of different iron chelators.

F Kirkham

After attending this lecture, the participant will be able to

- Understand the causes of acute neurological events, including stroke, in sickle cell disease.
- Manage acute stroke in sickle cell disease in collaboration with emergency, intensive care and stroke unit physicians and neurologists.
- Follow the guidelines for primary and secondary prevention of stroke in children and adults with sickle cell disease.

→ EDUCATION SESSION **5 6 9 B T C**

08:00 - 09:30, Room N111

Repeated from:

Friday, June 23, 09:45 - 11:15, Room N105

BLEEDING DISORDERS

Chair: F Peyvandi (Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy)

Biological and clinical relevance of fibrin clot structure

N Mutch (University of Aberdeen, United Kingdom)

Diagnosis and management of DIC and primary hyperfibrinolysis

A Squizzato (Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese, Italy)

Diagnosis and management of rare bleeding disorders

G Kenet (Sheba Medical Center, Tel Hashomer, Israel)

LEARNING GOALS

N Mutch

After attending this lecture, the participant will be able to

- Discuss conditions in which abnormal clot structure is observed and the downstream impact on clot stability.
- Describe how the fibrin network is degraded by the fibrinolytic system and how this can be monitored.
- Explain the factors that may influence clot structure in different areas of the vasculature.

A Squizzato

After attending this lecture, the participant will be able to

- Describe four main clinical phenotypes of patients with DIC.
- Promptly diagnose DIC and rapidly identify underlying disorders of DIC.
- Provide the best supportive therapy to prevent or treat main clinical manifestations of DIC.

G Kenet

After attending this lecture, the participant will be able to

- Describe the epidemiology, symptoms and diagnosis of patients with rare bleeding disorders.
- Discuss current and emerging treatment options, including non- replacement therapy.

→ SCIENTIFIC WORKING GROUPS **6 9 C**

08:30 - 09:30, Room N113

THROMBOCYTOPENIAS AND PLATELET FUNCTION DISORDERS: TREATMENT OF DIFFICULT TO TREAT THROMBOCYTOPENIAS

Chair: CL Balduini (University of Pavia-IRCCS Policlinico San Matteo Foundation, Italy)

- **Thrombocytopenia in the critically ill**
NP Juffermans (Academic Medical Center, Amsterdam, the Netherlands)
- **Acute management of thrombotic microangiopathies**
JA Kremer Hovinga (Inselspital, Bern University Hospital, Switzerland)
- **Is it possible to increase platelet count in inherited thrombocytopenias without giving platelet transfusions?**
A Pecci (IRCCS Policlinico San Matteo Foundation - University of Pavia, Italy)

LEARNING GOALS

NP Juffermans

After attending this lecture, the participant will be able to

- Describe mechanisms and effects of thrombocytopenia in the critically ill.
- Select indications for prophylactic platelet transfusion (prior to invasive procedures).
- Management of platelet transfusions not resulting in platelet count increment.

JA Kremer Hovinga

An up-to-date program is available via the mobile app.

A Pecci

After attending this lecture, the participant will be able to

- Critically evaluate the current and emerging therapeutic options to increase platelet count in patients with inherited thrombocytopenias.

→ PATIENT ADVOCACY SESSION 1 1 2 3 8 10 C
08:00 - 09:30, Room N115

INNOVATIVE CLINICAL TRIAL DESIGNS, ADAPTIVE PATHWAYS (MAPPS) AND PATIENT INVOLVEMENT IN R&D

Chairs: S Wintrich (MDS UK Patient Support Group, London, United Kingdom)

S Liptrott (European Institute of Oncology, Milan, Italy)

- Patient perspective on new trial design, regulation and patient involvement

G Spurrier-Bernard (Melanoma Patients Network Europe & MelanomeFrance, Teillet, France)

- Adaptive pathways and other approaches to promote timely access to medicines

F Pignatti (European Medicines Agency, London, United Kingdom)

- Designing innovative clinical trials: Methodology and practice

EH Estey (University of Washington, Seattle, USA)

- How will the new EU Clinical Trials Regulation foster innovation in clinical trials?

B Woermann (Charité University Medicine, Berlin, Germany)

LEARNING GOALS

G Spurrier-Bernard

An up-to-date program is available via the mobile app.

F Pignatti

An up-to-date program is available via the mobile app.

EH Estey

After attending this lecture, the participant will be able to

- Appreciate the conflict between the scientific need to randomize patients between a new and an older, often unsatisfactory, therapy and the wish of patients not to be randomized to the older therapy.
- Become familiar with “adaptive” randomization as a means to address this dilemma.
- Understand the value of designs that adaptively monitor several outcomes (e.g. response and toxicity) rather than only a single outcome (toxicity in phase 1 and response in phase 2).
- Understand the importance of any design’s “operating characteristics”.

B Woermann

An up-to-date program is available via the mobile app.

→ EDUCATION SESSION 3 5 T C

09:45 - 11:15, Hall A

Repeated from:

Friday, June 23, 08:00 - 09:30, Hall A

NEW APPROACHES TO INDOLENT LYMPHOMA

Chair: P Brice (Hôpital Saint Louis, Paris, France)

- Molecular profiling of indolent lymphoma

S Pileri (European Institute of Oncology, Milan, Italy)

- Update on follicular lymphoma: Time beyond chemotherapy?

K Hübel (University of Cologne, Germany)

- Treatment of extranodal marginal zone B-cell lymphomas

M Raderer (Medical University Vienna, Austria)

LEARNING GOALS

S Pileri

After attending this lecture, the participant will be able to

- Describe the molecular characteristics of the main varieties of indolent lymphoma.
- Discuss how they can impact on the prognosis and therapy in the present era of precision medicine.

K Hübel

After attending this lecture, the participant will be able to

- Understand requirements for a chemotherapy-free approach in Follicular Lymphoma.
- Recognize the potential of existing and emerging therapeutics in the management of Follicular Lymphoma.
- Assess critically the benefits and risks of common cytotoxic regimens versus targeted therapies in different lines of treatment.

M Raderer

After attending this lecture, the participant will be able to

- Eradication of *Helicobacter pylori* remains the preferred first-line therapy in patients with gastric MALT lymphoma.
- Also patients with HP-negative gastric MALT lymphoma may also be managed with (clarithromycin-based) antibiotic therapy.
- Antibiotic therapy can also be given in patients with ocular adnexal MALT-lymphomas as sole initial management.
- Both systemic treatment as well as radiotherapy appear to have curative potential in localised disease.

→ EDUCATION SESSION 3 10 B T C

09:45 - 11:15, Hall B

Repeat Session:

Sunday, June 25, 09:30 - 11:00, Hall A

CHRONIC LYMPHOCYTIC LEUKEMIA

Chair: B Eichhorst (University Clinic of Cologne, Germany)

- Relevance of microenvironment in CLL

F Caligaris-Cappio (Italian Association for Cancer Research, Milan, Italy)

- **Prognostic factors in CLL: When, which and how?**
S Pospisilova (Masaryk University and University Hospital Brno, Czech Republic)
- **Prioritisation therapies in CLL**
C Wendtner (Klinikum Schwabing, Munich, Germany)

LEARNING GOALS

F Caligaris-Cappio

After attending this lecture, the participant will be able to

- Describe how malignant CLL cells entail a bi-directional dialogue with a host of non-malignant elements within the microenvironment.
- Describe the key cellular elements in the microenvironment.
- Describe how cell-cell interactions favour malignant cell growth, survival and prevent anti-tumour response.

S Pospisilova

After attending this lecture, the participant will be able to

- Describe the biological and clinical factors applicable in CLL prognostication.
- Define the predictive markers currently used for therapy response assessment in CLL patients.
- Indicate the timepoints when the prognostic and predictive factors should be analyzed during the disease course.

C Wendtner

After attending this lecture, the participant will be able to

- For CLL patients we have to prioritize treatment options based on clinical and novel molecular markers.
- Chemoimmunotherapy remains the standard-of-care for the majority of CLL patients in the frontline setting.
- Novel drugs like ibrutinib, idelalisib and venetoclax are nowadays treatment standards for CLL patients with relapsed/refractory disease.

→ EDUCATION SESSION

2 5 9 10 T C

09:45 - 11:15, Hall C

Repeat Session:

Sunday, June 25, 09:30 - 11:00, Room N101

ACUTE MYELOID LEUKEMIA

Chair: G Ossenkoppele (VU University Medical Center, Amsterdam, the Netherlands)

- **Molecular diagnostics in AML**
L Bullinger (University Hospital of Ulm, Germany)
- **Targeting mutated FLT3 in AML**
M Levis (Johns Hopkins University, Phoenix, USA)
- **3+7 and beyond**
N Vey (Institut Paoli Calmettes, Marseille, France)

LEARNING GOALS

L Bullinger

After attending this lecture, the participant will be able to

- There is a growing need to implement novel next-generation-sequencing (NGS) based gene panel diagnostic tools to rapidly capture inter- and intra-individual disease heterogeneity.

- Future technological developments will enable genome-wide comprehensive genomic, epigenomic and transcriptomic characterization of the disease (at single cell level), but for now these approaches are reserved for research questions.
- Molecular genomics have started to inform patient care with regard to improved disease classification and risk prediction (knowledge databases), MRD monitoring and guiding targeted therapeutic approaches.

M Levis

After attending this lecture, the participant will be able to

- Identify the subsets of AML patients that might benefit from FLT3 inhibition
- Describe the different points in AML therapy where FLT3 inhibitors are likely to be incorporated.
- Discuss the different potential roles for selective versus non-selective FLT3 inhibitors.

N Vey

After attending this lecture, the participant will be able to

- Describe current and emerging therapies for patients with AML.
- Describe the main mechanisms of action of current new drugs and the rationale for their combination.
- Discuss how emerging therapies might be combined to or replace 3+7.

→ EHA - AMERICAN SOCIETY OF HEMATOLOGY JOINT SYMPOSIUM

1 4 9 10 B T C

10:15 - 11:15, Hall D

THE FUTURE OF HEMATOLOGY: GENOME EDITING/CRISPR

Chairs: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)

K Anderson, President of ASH (Dana-Farber /Harvard Cancer Center, Boston, USA)

- **CRISPR/Cas9 Genome Editing, from Mechanism to Therapy**
J Corn (Innovative Genomics Institute, Berkeley, USA)
- **Towards clinical translation of targeted gene editing in human hematopoietic stem cells**
L Naldini (San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy)

LEARNING GOALS

J Corn

After attending this lecture, the participant will be able to

- Describe how CRISPR-Cas9 gene editing works.
- Determine whether gene editing may be appropriate to address a given patient disease.
- Develop a rough timeline for clinical application of gene editing.

L Naldini

After attending this lecture, the participant will be able to understand the:

- Advanced stage of clinical testing reached by HSC gene therapy using conventional gene replacement with lentiviral vectors.
- Potential advantages and current limitations of targeted gene

editing vs. gene replacement strategies for the correction of genetic deficiencies in HSC.

- Solutions being developed to overcome the constraints to safe and successful gene editing of HSC.

→ EDUCATION SESSION 2 3 4 8 9 T C

09:45 - 11:15, Room N101

Repeat Session:

Sunday, June 25, 11:15 - 12:45, Room N101

FERTILITY PRESERVATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Chair: D Meirou (Sheba Medical Center, Tel Hashomer, Israel)

- **The effects of chemotherapy and radiotherapy on reproduction**
WH Wallace (University of Edinburgh, United Kingdom)
- **What patients expect from hematologists**
A Plate (Myeloma Patients Europe, Munich, Germany)
- **Fertility preservation in female patients**
MM Dolmans (Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Gynécologie, Brussels, Belgium)
- **Fertility preservation in pre-pubertal and adult males**
R Mitchell (University of Edinburgh, United Kingdom)

LEARNING GOALS

WH Wallace

After attending this lecture, the participant will be able to

- More high quality research is required to provide the evidence for impaired testicular and ovarian function after chemotherapy and radiation.
- Conditioning treatments for BMT that include chemotherapy and or radiotherapy are likely to impair gonadal function irrespective of the age of the patient at treatment.
- Radiotherapy to a field that includes the pelvis in females may impair uterine function with increased risk of miscarriage and preterm delivery.

MM Dolmans

After attending this lecture, the participant will be able to

- Cite and outline currently available fertility preservation options.
- Select the most appropriate course of action according to disease type and treatment, as well as patient age.
- Describe recent advances and successes in oocyte and ovarian tissue cryopreservation.

R Mitchell

After attending this lecture, the participant will be able to

- Understand the key differences between the prepubertal and adult testis.
- Describe how cancer treatments can damage the prepubertal testis.
- Discuss the options available for fertility preservation in prepubertal and adolescent males.
- Describe the experimental approaches that are currently under investigation for young males at risk of infertility.

→ SCIENTIFIC WORKING GROUPS 2 C

09:45 - 10:45, Room N105

EUROPEAN WORKING GROUP ON ALL (EWALL): ADULT ALL FIRST LINE THERAPY: MAJOR RESULTS AND FUTURE APPROACHES OF NATIONAL ALL STUDY GROUPS

Chair: N Gökbuget (University Hospital, Goethe University, Frankfurt, Germany)

- **Major results and future approaches of Italian ALL study groups**
S Chiaretti (Sapienza University of Rome, Italy)
- **France-Belgium-Switzerland: The GRAALL Intergroup**
H Dombret (University Hospital Saint-Louis, Paris, France)
- **The role of allogeneic transplant in U.K. trials for adult ALL**
A Fielding (UCL, London, United Kingdom)
- **Strategies of the GMALL Group**
N Gökbuget (University Hospital, Goethe University, Frankfurt, Germany)

LEARNING GOALS

S Chiaretti

After attending this lecture, the participant will be able to

- Describe the gold standard management of adults and adolescents with Ph-negative ALL in first-line treatment.
- Describe the gold standard management of Ph-positive ALL in first-line treatment.
- Describe the introduction of novel compounds in the current/forth coming trials for both Ph-negative and Ph-positive in first-line treatment.

H Dombret

An up-to-date program is available via the mobile app.

A Fielding

An up-to-date program is available via the mobile app.

N Gökbuget

After attending this lecture, the participant will be able to

- Describe the major strategies of the German Multicenter ALL Study Group.
- Discuss options for MRD based treatment intensification.
- Explain different strategies for younger and older patients.

→ SCIENTIFIC WORKING GROUPS 3 C

09:45 - 10:45, Room N103

EUROPEAN MANTLE CELL LYMPHOMA NETWORK: THE PROS AND CONS IN THE TREATMENT OF MCL PATIENTS

Chair: M Dreyling (Klinikum der Universität München, Germany)

- **Pro: Uniform standard treatment in all elderly patients**
S Rule (Plymouth University Peninsula Schools of Medicine and Dentistry, United Kingdom)
- **Con: Standard treatment has to be individual in elderly patients**
C Visco (San Bortolo Hospital, Vicenza, Italy)

- Immunological approaches in MCL
S Ansell (Mayo Clinic, Rochester, USA)

LEARNING GOALS

S Rule

- After attending this lecture, the participant will be able to
- Understand the current treatment algorithms for elderly patients with mantle cell lymphoma.
 - Understand risk stratification for this group of patients.
 - The difficulties in individualising therapy based on the limited treatment options and lack of targeted therapy.

C Visco

- After attending this lecture, the participant will be able to
- Describe current and emerging therapies for older patients with Mantle Cell Lymphoma.
 - Select appropriate upfront therapy based upon patient and disease characteristics.
 - Discuss treatment options for older patients who may or may not be candidates for standard chemotherapy.

S Ansell

- After attending this lecture, the participant will be able to
- Describe the immunological barriers to an effective anti-tumor response in mantle cell lymphoma (MCL).
 - Discuss immunological treatment approaches to MCL.

→ SCIENTIFIC WORKING GROUPS

09:45 - 10:45, Room N104

2 8 C

EUROPEAN WORKING GROUP FOR PHILADELPHIA-NEGATIVE MPN: NEW TOOLS FOR MPN PATIENTS MANAGEMENT

Chair: JJ Kiladjian (Hôpital Saint-Louis, Paris, France)

- Social media: Impact on research and management of MPNs
R Mesa (Mayo Clinic, Phoenix, USA)
- Are MPN patients and doctors ready for e-medicine?
P Jourdain (CH R Dubos, Pontoise, France)
- What have we learned from MPN registries
M Hultcrantz (Karolinska Institute, Stockholm, Sweden)

LEARNING GOALS

R Mesa

- After attending this lecture, the participant will be able to
- Understand the functionality and parameters of the most common social media platforms and how they can be used in academic hematology.
 - Understand the role of social media for patient engagement in research, increasing clinical trial accrual and survey research.
 - Understand use of social media to assist in clinical management of myeloproliferative neoplasms.

P Jourdain

- After attending this lecture, the participant will be able to
- Characterize a telemedicine or E health project.
 - Analyze the main component of a telemedicine project from definition to evaluation.

M Hultcrantz

- After attending this lecture, the participant will be able to
- Describe the epidemiology, prognosis and survival of MPN patients in relation to the general population estimated using various statistical methods.
 - Have knowledge of the spectrum of complications as well as treatment-related effects associated with MPNs.
 - Understand the benefits, possibilities, and limitations of population-based register research.

→ EDUCATION SESSION

09:45 - 11:15, Room N109

Repeated from:

Saturday, June 24, 08:00 - 09:30, Room N109

1 9 B T C

UPDATE ON HEMOGLOBINOPATHIES

Chair: MD Cappellini (University of Milan-Foundation IRCCS Policlinico Hospital, Italy)

- Genome editing in hemoglobinopathies
M Weiss (St Jude Children's Research Hospital, Memphis, USA)
- Iron chelation in hemoglobinopathies
V Viprakasit (Siriraj Hospital, Mahidol University, Bangkok, Thailand)
- Neurological complications of sickle cell disease
F Kirkham (UCL Great Ormond Street Institute of Child health, London, United Kingdom)

LEARNING GOALS

M Weiss

- After attending this lecture, the participant will be able to
- Understand the genetics of common hemoglobinopathies: sickle cell disease and beta thalassemia.
 - Understand the tools of genome editing and how they can be applied to treating hemoglobinopathies.
 - Understand potential barriers for using genome editing to treat hemoglobinopathies.

V Viprakasit

- After attending this lecture, the participant will be able to
- Describe current and latest mechanism of iron overload and its clinical significance in thalassemia and hemoglobinopathies.
 - Select appropriate iron overload monitoring based upon availability and accessibility.
 - Discuss iron chelation options for thalassemia patients with iron overload as a monotherapy or a combination of different iron chelators.

F Kirkham

- After attending this lecture, the participant will be able to
- Understand the causes of acute neurological events, including stroke, in sickle cell disease.
 - Manage acute stroke in sickle cell disease in collaboration with emergency, intensive care and stroke unit physicians and neurologists.
 - Follow the guidelines for primary and secondary prevention of stroke in children and adults with sickle cell disease.

→ EDUCATION SESSION **5 6 B T C**
09:45 - 11:15, Room N111
Repeated from:
Friday, June 23, 08:00 - 09:30, Room N105

THROMBOSIS

Chair: W Ageno (University of Insubria, Varese, Italy)

- **Cross-talk between coagulation and inflammation**
T Renné (University Medical Center Hamburg, Germany & Karolinska Institutet, Stockholm, Sweden)
- **Novel aspects in the diagnostic management of deep vein thrombosis and pulmonary embolism**
M Huisman (Leiden University Medical Center, the Netherlands)
- **Controversies in treating small clots in the leg and in the lung**
S Schellong (Städtisches Klinikum Dresden, Germany)

LEARNING GOALS

T Renné

- After attending this lecture, the participant will be able to
- Understand the novel concept of Safe Anticoagulants that do not increase bleedings.
 - Get insight in the crosstalk of coagulation and inflammation.
 - Learn about the plasma contact system.

M Huisman

- After attending this lecture, the participant will be able to
- Describe current and emerging diagnostic algorithms for patients with clinically suspected venous thromboembolism.
 - Select appropriate diagnostic algorithms for selected populations including older patients, pregnant patients, and patients with suspected recurrent venous thromboembolism.

S Schellong

- After attending this lecture, the participant will be able to
- Acknowledge the new situation that for DVT as well as for PE the current standard diagnostic imaging detects clots in the leg and the lung which might be clinically insignificant and do not require standard treatment.
 - Define a subgroup of patients with isolated distal DVT which represents a very low risk group for proximal extension and PE.
 - Discuss the risk difference of two different patient groups with subsegmental PE: cancer patients with incidental PE versus symptomatic patients without cancer.

→ SCIENTIFIC WORKING GROUPS **1 4 B T**
09:45 - 10:45, Room N113

EUROPEAN WORKING GROUP FOR STEM CELLS: METABOLIC REGULATION OF STEM CELL

Chair: D Bonnet (The Francis Crick Institute, London, United Kingdom)

- **Mitochondrial regulation of hematopoietic stem cells**
HW Snoeck (Columbia University, New York, USA)
- **Nutrient fueling of hematopoietic stem cell lineage specification**

- N Taylor (Institut de Genetique Moleculaire de Montpellier, France)
- **P38 α protects hematopoietic stem/progenitor cells in acute and aging stresses**
K Takubo (National Center for Global Health and Medicine, Tokyo, Japan)

LEARNING GOALS

HW Snoeck

- After attending this lecture, the participant will be able to
- Understand mitochondrial biology and its relation to stem cell function.
 - Understand approaches to investigate mitochondrial function and calcium homeostasis in hematopoietic stem cells function.

N Taylor

- After attending this lecture, the participant will be able to
- Recount the different nutrients that are used to fuel hematopoietic stem cell maintenance and differentiation.
 - Discuss alterations in metabolite utilization during hematopoietic stem cell differentiation.
 - Describe nutrient pathway utilization that may result in pathological HSC differentiation.

K Takubo

- After attending this lecture, the participant will be able to
- Describe functional roles of metabolic programs in hematopoietic stem cell homeostasis.
 - Describe molecules that govern metabolic programs in hematopoietic stem/progenitor cells.

→ SCIENTIFIC WORKING GROUPS **1 4 B T**
09:45 - 10:45, Room N115

MESENCHYMAL STEM CELLS: THE IMMUNOLOGY OF TISSUE REPAIR

Chair: W Fibbe (Leiden University Medical Center, the Netherlands)

- **The immune challenges of pluripotent stem cell based therapy**
Y Xu (University of California, San Diego, La Jolla, USA)
- **Neural stem cell-mediated immune regulation and brain repair**
S Pluchino (Wellcome Trust-Medical Research Council Stem Cell Institute, Cambridge, United Kingdom)

LEARNING GOALS

Y Xu

- After attending this lecture, the participant will be able to
- Understand the mechanism underlying the immunogenicity of pluripotent stem cells and their derivatives.
 - Learn new strategies to induce immune tolerance of pluripotent stem cell derived cells.
 - Learn new technologies to study human immune responses in model system.

S Pluchino

- After attending this lecture, the participant will be able to

- Understand the state of the art non-hematopoietic stem cell treatments for inflammatory neurological diseases.
- Understand the main immune regulatory effects of neural stem cell-based therapeutics.

→ SIMULTANEOUS SESSIONS **3 C**
11:30 – 12:45, Hall A

FRONT-LINE COMBINATIONS IN MULTIPLE MYELOMA AND AMYLOIDOSIS

Chairs: P Sonneveld (Erasmus MC, Rotterdam, the Netherlands)
P Moreau (University Hospital, Nantes, France)

11:30 – 11:45

S407 **QUADRUPLET VS SEQUENTIAL TRIPLET INDUCTION THERAPY FOR MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY.**
C Pawlyn¹ (¹The Institute of Cancer Research, London, United Kingdom)

11:45 – 12:00

S408 **DEEP AND DURABLE RESPONSES WITH WEEKLY IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS WHO DID NOT UNDERGO SCT**
S Kumar¹ (¹Mayo Clinic, Rochester, United States)

12:00 – 12:15

S409 **DEPTH OF RESPONSE AS SURROGATE MARKER FOR PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH VMP AND RD: GEM2010MAS65**
MV Mateos¹ (¹University Hospital of Salamanca, Salamanca, Spain)

12:15 – 12:30

S410 **CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION: PLANNED INTERIM ANALYSIS OF THE RANDOMIZED FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA**
F Gay¹ (¹Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy)

12:30 – 12:45

S411 **HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS**
M Minnema¹ (¹UMC UTRECHT, Utrecht, the Netherlands)

→ SIMULTANEOUS SESSIONS **3 9 C**
11:30 – 12:45, Hall B

HODGKIN AND INDOLENT LYMPHOMA – CLINICAL

Chairs: A Engert (University Hospital of Cologne, Germany)
A Hagenbeek (University of Amsterdam, the Netherlands)

11:30 – 11:45

S412 **NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL**
A Engert¹ (¹University Hospital of Cologne, Cologne, Germany)

11:45 – 12:00

S413 **EARLY CHEMOTHERAPY INTENSIFICATION WITH ESCALATED BEACOPP IN ADVANCED-STAGE HODGKIN LYMPHOMA WITH A POSITIVE INTERIM PET-CT AFTER 2 ABVD CYCLES: LONG-TERM RESULTS OF THE GITIL/FIL HD 0607 TRIAL**
A Gallamini¹ (¹Centre A. Lacassagne, Nice, France)

12:00 – 12:15

S414 **DISEASE CHARACTERISTICS AND SURVIVAL AFTER 3RD RECURRENCE OF CLASSICAL HODGKIN LYMPHOMA: AN ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP**
PJ Bröckelmann¹ (¹University Hospital of Cologne, Cologne, Germany)

12:15 – 12:30

S415 **A REVISED STAGING SYSTEM FOR WALDENSTRÖM'S MACROGLOBULINEMIA**
E Kastiris¹ (¹Greek Myeloma Study Group, Athens, Greece)

12:30 – 12:45

S416 **SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) TREATED WITH RITUXIMAB (R) MONOTHERAPY: A LONG TERM FOLLOW-UP STUDY ON 104 PATIENTS**
C Kalpadakis¹ (¹University Hospital, University of Crete, Heraklion, Greece)

→ SIMULTANEOUS SESSIONS **2 5 B T**
11:30 – 12:45, Hall C

BIOLOGY OF MPN: JAK2 AND BEYOND

Chairs: H Hasselbalch (Zealand University Hospital, Roskilde, Denmark)
S Hermouet (Inserm U1232 - CRCINA, Université de Nantes, France)

11:30 – 11:45

S417 **YOU DON'T KNOW JAK: A PROGRAMMED RIBOSOMAL FRAMESHIFTING DEFECT POTENTIATES THE TRANSFORMING ACTIVITY OF THE JAK2-V617F MUTATION**
S Sulima¹ (¹KU Leuven, Leuven, Belgium)

11:45 – 12:00

S418 EFFECTIVENESS OF LSD1 INHIBITION FOR THE TREATMENT OF MPN

JS Jutzi¹ (¹University Medical Center, Freiburg, Germany)

12:00 – 12:15

S419 LOSS OF RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN MYELOMONOCYTIC LINEAGE COMMITMENT AND AGGRAVATES THE DEVELOPMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN A MURINE IN-VIVO MODEL

V Caraffini¹ (¹Medical University of Graz, Graz, Austria)

12:15 – 12:30

S420 JAK2 V617F HAEMATOPOIETIC CLONES WITH DIFFERENT EXPANSION KINETICS ARE DETECTABLE SEVERAL YEARS PRIOR TO MPN DIAGNOSIS

T Mckerrell¹, ² (¹University of Cambridge, Cambridge, United Kingdom, ²Wellcome Trust Sanger Institute, Cambridge, United Kingdom)

12:30 – 12:45

S421 DISRUPTION OF HAEMATOPOIETIC STEM CELL HETEROGENEITY IN A MOUSE MODEL OF MYELOPROLIFERATIVE NEOPLASM

R Norfo¹ (¹MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom)

→ SIMULTANEOUS SESSIONS

2 C

11:30 – 12:45, Hall D

CLINICAL TRIALS INCLUDING TREATMENT DISCONTINUATION IN CML

Chairs: M Suttorp (Univ. Hospital "Carl Gustav Carus", Dresden, Germany)

M Bocchia (Azienda Ospedaliera Universitaria Senese, Siena, Italy)

11:30 – 11:45

S422 DASATINIB IN CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM A PHASE 2 TRIAL

CM Zwaan¹ (¹Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands)

11:45 – 12:00

S423 INITIAL REDUCTION OF THERAPY BEFORE COMPLETE WITHDRAWAL IMPROVES THE CHANCE OF SUCCESSFUL TREATMENT DISCONTINUATION IN CHRONIC MYELOID LEUKAEMIA (CML): YEAR 2 RESULTS IN THE BRITISH DESTINY STUDY

R Clark¹ (¹Royal Liverpool University Hospital, Liverpool, United Kingdom)

12:00 – 12:15

S424 ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10 -YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV

R Hehlmann¹ (¹Ruprecht Karls University Heidelberg, Mannheim, Germany)

12:15 – 12:30

S425 BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: INITIAL RESULTS FROM THE BFORE TRIAL

TH Brümmendorf¹ (¹Universitätsklinikum der RWTH Aachen, Aachen, Germany)

12:30 – 12:45

S426 CHRONIC MYELOID LEUKEMIA PATIENTS WERE NOT DIFFERENT IN MOLECULAR RELAPSE AFTER STOPPING IMATINIB IN MR4 WHETHER RESIDUAL DISEASE WAS DETECTED OR NOT - WHEN ADJUSTING FOR NUMBER OF CONTROL TRANSCRIPTS

M Pfirrmann¹ (¹LMU München, München, Germany)

→ SIMULTANEOUS SESSIONS

2 5 9 10 B T

11:30 – 12:45, Hall E

AML BIOLOGY II: EPIGENETIC TARGETS

Chairs: R Schneider (Erasmus MC, Rotterdam, the Netherlands)

F Grebien (Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria)

11:30 – 11:45

S427 ETO2-GLIS2 RECRUITS ETO2/ERG COMPLEX AT SUPER-ENHANCERS TO CONTROL TRANSCRIPTION AND DRIVE LEUKEMIC PROPERTIES IN PEDIATRIC ACUTE MEGAKARYOBLASTIC LEUKEMIA

C Thirant¹, ² (¹INSERM U1170, Villejuif, France, ²Gustave Roussy, Villejuif, France)

11:45 – 12:00

S428 NUCLEOSOME BINDING PROTEIN HMGN1 BLOCKS MYELOID DIFFERENTIATION AND PROMOTES CLONAL DOMINANCE VIA ABERRANT HISTONE ACETYLATION

L Cabal-Hierro¹, ² (¹Broad Institute, Cambridge, United States, ²Dana Farber Cancer Institute/ Harvard Medical School, Boston, United States)

Poster Pitches

P526 DESIGNING THE NEXT GENERATION CD33-TARGETING ADC: IMGN779, SELECTED FOR POTENCY, NOVEL MECHANISM AND PRECLINICAL TOLERABILITY, WITH HIGH ACTIVITY IN DISSEMINATED AML MODELS AND MULTI-DOSE REGIMENS

S Adams
Full Poster presentation: Saturday, June 24 – Poster Walk: "Acute myeloid leukemia - Biology 3". More information on page 149

P527 THE MIXED LINEAGE LEUKEMIA FUSION PARTNER ENL RECRUITS PAF1 TO CLEAR POLYCOMB-INDUCED TRANSCRIPTIONAL REPRESSION

R Slany

Full Poster presentation: Saturday, June 24 – Poster Walk: “Acute myeloid leukemia - Biology 3”. More information on page 149

P528 PKC EPSILON SUPPORTS ACUTE MYELOID LEUKEMIA BY MAINTAINING MITOCHONDRIAL REDOX HOMEOSTASIS.

D Di Marcantonio

Full Poster presentation: Saturday, June 24 – Poster Walk: “Acute myeloid leukemia - Biology 3”. More information on page 149

P537 GENETIC LANDSCAPE OF ACUTE ERYTHROID LEUKEMIA

J Takeda

Full Poster presentation: Saturday, June 24 – Poster Walk: “Acute myeloid leukemia - Biology 4”. More information on page 149

P538 THE MOLECULAR LANDSCAPE OF MLL-PTD AML: SPECIFIC CONCURRENT MUTATIONS, CLINICAL OUTCOME AND GENE EXPRESSION SIGNATURES

A Al Hinai

Full Poster presentation: Saturday, June 24 – Poster Walk: “Acute myeloid leukemia - Biology 4”. More information on page 149

P539 EXPLORING THE IMPACT OF LOSS OF FUNCTION STAG2 MUTATIONS ON CHROMATIN ARCHITECTURE IN MDS/AML

J Smith

Full Poster presentation: Saturday, June 24 – Poster Walk: “Acute myeloid leukemia - Biology 4”. More information on page 149

P540 NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKEMIA

IJ Lau

Full Poster presentation: Saturday, June 24 – Poster Walk: “Acute myeloid leukemia - Biology 4”. More information on page 150

12:15 – 12:30

S429 PIWIL4 ACTS AS A PIRNA BINDING, EPIGENETICALLY ACTIVE AND GROWTH REGULATORY PROTEIN IN HUMAN ACUTE MYELOID LEUKEMIA

S Bamezai¹ (Institute for Experimental Cancer Research, Ulm, Germany)

12:30 – 12:45

S430 METTL3 CONTROLS TRANSLATION OF TARGET MRNAS BY N6 METHYLATION OF ADENOSINE RESIDUES IN THEIR CODING SEQUENCE AND CONSTITUTES A NOVEL THERAPEUTIC VULNERABILITY OF ACUTE MYELOID LEUKAEMIA

K Tzelepis¹ (Wellcome Trust Sanger Institute, Cambridge, United Kingdom)

→ SIMULTANEOUS SESSIONS

6 9 T C

11:30 – 12:45, Room N101

ACQUIRED AND INHERITED PLATELET DISORDERS

Chairs: CH Toh (University of Liverpool, United Kingdom)
 To be announced

11:30 – 11:45

S431 THE COMBINATION OF ORAL ALL-TRANS RETINOIC ACID AND DANAZOL VS DANAZOL AS SECOND-LINE TREATMENT IN ADULT IMMUNE THROMBOCYTOPENIA: A MULTICENTRE, RANDOMIZED, OPEN-LABEL TRIAL

XH Zhang^{1, 2, 3} (Collaborative Innovation Center of Hematology, Peking University, Beijing, China, ²Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, ³Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China)

11:45 – 12:00

S432 NOVEL PERSPECTIVES IN GENOTYPE-PHENOTYPE CORRELATIONS IN MYH9-RELATED DISEASE: NO LONGER JUST A MATTER OF HEAD OR TAIL

C Zaninetti¹ (IRCCS Policlinico San Matteo Foundation, and University of Pavia, Pavia, Italy)

12:00 – 12:15

S433 A MONOALLELIC LOSS-OF-FUNCTION MUTATION IN THE THROMBOPOIETIN (THPO) GENE IS RESPONSIBLE FOR A NEW FORM OF INHERITED THROMBOCYTOPENIA (IT)

P Noris¹ (IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy)

12:15 – 12:30

S434 POSITION OF THE GF11B ZINC FINGER MUTATION DECOUPLES CD34 EXPRESSION FROM ALPHA-GRANULE DEFICIENCY IN GF11B-RELATED PLATELET DISORDERS

W Stevenson¹ (UNIVERSITY OF SYDNEY, Sydney, Australia)

12:30 – 12:45

S435 TREATMENT OF PRIMARY ADULT CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) WITH FOSTAMATINIB, AN ORAL SYK INHIBITOR: RESULTS OF TWO RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES

J Bussel¹ (Weill Cornell Medicine, New York, NY, United States)

→ SIMULTANEOUS SESSIONS

3 5 9 T C

11:30 – 12:45, Room N105

ACUTE LYMPHOBLASTIC LEUKEMIA – BIOLOGY

Chairs: E Clappier (Saint-Louis Hospital, Paris, France)

B Bornhauser (University Children's Hospital Zurich, Switzerland)

11:30 – 11:45

S436 THE YING AND YANG OF JAK SIGNALING : LOSS OF USP9X BUFFERS JAK SIGNALING AND ENHANCES SURVIVAL OF CRLF2- JAK- STAT EXPRESSING B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA.O Schwartzman^{1, 2} (¹Sackler medical school, Tel Aviv University, Tel Aviv, Israel, ²The Gene Development and Environment Pediatric Research Institute, Pediatric Hemato-Oncology, Edmond and Lily Safra Children Hospital, Sheba Medical Center, Ramat Gan, Israel)

11:45 – 12:00

S437 TNF RECEPTOR 2 IS REQUIRED FOR RIP1-DEPENDENT CELL DEATH IN LEUKEMIAJ Agudé-Gorgorio¹ (¹University Children's Hospital Zurich, Zurich, Switzerland)

12:00 – 12:15

S438 THERAPEUTIC TARGETING OF ONCOGENIC MYB ACTIVITY IN T-ALLT Pieters¹ (¹Center for Medical Genetics, Ghent University, Ghent, Belgium)

12:15 – 12:30

S439 THE T-CELL LEUKEMIA ASSOCIATED RIBOSOMAL RPL10 R98S MUTATION ENHANCES JAK-STAT SIGNALINGS Vereecke¹ (¹Department of Oncology, LKI, KU Leuven, Leuven, Belgium)

12:30 – 12:45

S440 NFATC3-PLA2G15 IS A NOVEL INTERGENICALLY SPLICED CHIMERA THAT IS ASSOCIATED WITH AGGRESSIVE T-ACUTE LYMPHOBLASTIC LEUKAEMIA BIOLOGY.J Bond^{1, 2} (¹Laboratory of Onco-Haematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker Enfants-Malades, Paris, France, ²Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut national de recherche médicale (INSERM) U1151, Paris, France)

→ SIMULTANEOUS SESSIONS

6 T C

11:30 – 12:45, Room N103

THROMBOTIC DISORDERS

Chairs: S Eichinger (Medical University of Vienna, Austria)

To be announced

11:30 – 11:45

S441 ASSESSING THE RISK-BENEFIT OF ANTICOAGULANTS IN ELDERLY PATIENTS WITH CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM: A POPULATION BASED STUDYA Lazo-Langner^{1, 2} (¹Western University, London, Canada, ²Western University, London, Canada)

11:45 – 12:00

S442 RISK OF THROMBOSIS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA: A POPULATION-BASED COHORT STUDYAM Birgisdóttir¹ (¹Faculty of Medicine, University of Iceland and Landspítali University Hospital, Reykjavik, Iceland)

12:00 – 12:15

S443 COMPARATIVE ANALYSIS OF PREDICTIVE MODELS FOR THROMBOEMBOLIC EVENTS IN LYMPHOMA PATIENTSD Antic¹ (¹Clinical Center of Serbia, Belgrade, Serbia)

12:15 – 12:30

S444 IMPACT OF A NEW ELECTRONIC ALERT SYSTEM (V2.0) FOR VENOUS THROMBOEMBOLISM PREVENTION IN HOSPITALIZED CANCER PATIENTS.R Figueroa¹ (¹Clínica universidad de Navarra, Pamplona (Navarra), Spain)

12:30 – 12:45

S445 IDENTIFICATION OF A NEW AND RELATIVELY FREQUENT SERPINC1 GENE DEFECT CAUSING ANTITHROMBIN DEFICIENCY HARDLY DETECTED BY CURRENT MOLECULAR METHODS: DUPLICATION OF EXON 6.ME De La Morena-Barrio^{1, 2} (¹Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Murcia, Spain, ²Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain)

→ SIMULTANEOUS SESSIONS

1 2 3 4 9 10 B T C

11:30 – 12:45, Room N104

STEM CELL TRANSPLANTATION – EXPERIMENTAL

Chairs: C Bonini (Fondazione San Raffaele Del Monte Tabor, Milan, Italy)

N Kröger (University Medical Center Hamburg-Eppendorf, Germany)

11:30 – 11:45

S446 CYTOSOLIC NUCLEIC ACID SENSORS PROMOTE INTESTINAL EPITHELIAL INTEGRITY DURING ACUTE TISSUE DAMAGE AND PROTECT FROM GRAFT-VERSUS-HOST DISEASEH Poeckl¹ (¹Technische Universität München, München, Germany)

11:45 – 12:00

S447 CD4 T CELLS RECOGNIZING MISMATCHED HLA-DP AFTER ALLOGENEIC STEM CELL TRANSPLANTATION SHOW TISSUE SPECIFIC REACTIVITIES

P van Balen¹ (¹LEIDEN UNIVERSITY MEDICAL CENTER, Leiden, the Netherlands)

12:00 – 12:15

S448 MESENCHYMAL STROMAL CELLS STIMULATE THE PROLIFERATION AND IL-22 PRODUCTION BY TYPE 3 INNATE LYMPHOID CELLS

V Van Hoven¹, ² (¹Academic Medical Center Amsterdam, Amsterdam, the Netherlands, ²Academic Medical Center Amsterdam, Amsterdam, the Netherlands)

12:15 – 12:30

S449 ABERRANT T CELL RESPONSES IN THE BONE MARROW MICROENVIRONMENT OF PATIENTS WITH POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Y Kong¹ (¹Peking University Institute of Hematology, Beijing, China)

12:30 – 12:45

S450 HIGHER FREQUENCY OF SWITCHED MEMORY B CELLS PREDICTS THE INCIDENCE OF CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

RM Saliba¹ (¹The University of Texas MD Anderson Cancer Center, Houston, United States)

→ **SIMULTANEOUS SESSIONS**

11:30 – 12:45, Room N109

1 9 **B T**

SICKLE CELL DISEASE, ENZYMES

Chairs: R Colombatti (Azienda Ospedaliera-Università di Padova, Italy)

V Brousse (Hopital Necker Enfants Malades, APHP & Inserm S -1134, Institut National de Transfusion Sanguine, Paris, France)

11:30 – 11:45

S451 EFFECTS OF AG-348, A PYRUVATE KINASE ACTIVATOR, IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY: UPDATED RESULTS FROM THE DRIVE PK STUDY

RF Grace¹ (¹Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, United States)

11:45 – 12:00

S452 STEM CELL TRANSPLANTATION IN PYRUVATE KINASE DEFICIENCY

S Van Straaten¹, ² (¹UMC Utrecht, Utrecht, the Netherlands, ²UMC Utrecht, Utrecht, the Netherlands)

12:00 – 12:15

S453 HEREDITARY XEROCYTOSIS: CLINICAL AND BIOLOGICAL PRESENTATION AT DIAGNOSIS IN A RETROSPECTIVE SERIES OF 103 PATIENTS

L Garçon¹⁹ (¹⁹CHU Amiens, Amiens CEDEX1, France)

12:15 – 12:30

S454 CRIZANLIZUMAB, A P-SELECTIN INHIBITOR, INCREASES THE LIKELIHOOD OF NOT EXPERIENCING A SICKLE CELL-RELATED PAIN CRISIS WHILE ON TREATMENT: RESULTS FROM THE PHASE II SUSTAIN STUDY

A Kutlar¹ (¹Medical College of Georgia, Augusta University, Augusta, United States)

12:30 – 12:45

S455 FREE IRON IN SERA OF PATIENTS WITH SICKLE CELL DISEASE CONTRIBUTES TO THE RELEASE OF NEUTROPHIL EXTRACELLULAR TRAPS

K Van Avondt¹ (¹Sanquin Research, and Landsteiner Laboratory, AMC, University of Amsterdam, Amsterdam, the Netherlands)

→ **PATIENT ADVOCACY SESSION II**

2 3 4 8 10 C

11:30 - 12:45, Room N115

PREGNANCY DURING AND AFTER TREATMENT: MYTHS AND REALITY

Chairs: D Turner (King's College Hospital, Ipswich, United Kingdom)
J Geissler (Leukemia Patient Advocates Foundation, Munich, Germany)

- Hematologist perspective: The trade-off between treatment and real life
J Apperley (Imperial College, London, United Kingdom)
- Patient perspective on myths, reality and appropriate patient information
A Plate (Myeloma Patients Europe, Munich, Germany)
- Overcoming infertility after cancer treatment: IVF and egg/sperm donation
A Guillén (IVI Madrid, Spain)

LEARNING GOALS

J Apperley

An up-to-date program is available via the mobile app.

A Plate

An up-to-date program is available via the mobile app.

A Guillén

After attending this lecture, the participant will be able to

- Describe the state of the art in ovarian stimulation and the new improvements in IVF techniques.
- Describe selection and matching in sperm and oocyte donation.
- Discuss treatment options in different countries and legislations.

→ MEET-THE EXPERT 2 C
11:30 - 12:30, Room N107
Availability on first come first serve basis

HOW I TREAT ELDERLY AML

Speakers: H Dombret (University Hospital Saint-Louis, Paris, France)

→ MEET-THE EXPERT 1 2 5 9 C
11:30 - 12:30, Room N108
Availability on first come first serve basis

APLASTIC ANEMIA OR MDS IN A CHILD - HOW TO DISTINGUISH?

Speaker: MM van den Heuvel-Eibrink (Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands)

→ MEET-THE EXPERT 1 2 8 C
11:30 - 12:30, Room N117
Availability on first come first serve basis

TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS

Speaker: JR Gotlib (USA)

→ SPECIAL SESSION 2 3 9 B T
13:15 - 14:30, Hall A

JEAN BERNARD LIFETIME ACHIEVEMENT AWARD

- Introduction

AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)

PLENARY SESSION I

Chairs: S Izraeli (Sheba Medical Center, Ramat Gan, Israel)
J Sierra (Hospital de la Santa Creu i Sant Pau Autonomous University of Barcelona, Spain)

- Heterogeneity in the making of blood

D Scadden (Harvard University / Mass General Hospital, Boston, USA)

- From stem cells and stem cell niche to acute lymphoblastic leukemia

T Enver (UCL Cancer Institute, London, United Kingdom)

LEARNING GOALS

D Scadden

After attending this lecture, the participant will be able to

- Understand experimental approaches to overcoming differentiation blockade in acute myeloid leukemia.
- Define specific metabolic processes that represent vulnerabilities of AML cells.

T Enver

An up-to-date program is available via the mobile app.

→ CLINICAL DEBATE 3 C
14:45 - 15:45, Hall A

TREATMENT SHOULD BE STARTED IN EVERY PATIENT WITH HIGH RISK SMOLDERING MULTIPLE MYELOMA

Chair: H Ludwig (Wilhelminen Cancer Research Institute, Vienna, Austria)

- Yes

MV Mateos (University Hospital of Salamanca, Spain)

- No

S Kristinsson (University of Iceland, Reykjavik, Iceland)

→ HEMATOLOGY-IN-FOCUS 3 T C
14:45 - 15:45, Hall B

RICHTER TRANSFORMATION IN CLL

Chair: C Moreno (Hospital Santa Creu i Sant Pau, Barcelona, Spain)

- Molecular pathogenesis of Richter syndrome

G Gaidano (University of Eastern Piedmont, Novara, Italy)

- New developments in Richter syndrome

N Jain (MD Anderson Cancer Center, Houston, USA)

LEARNING GOALS

G Gaidano

After attending this lecture, the participant will be able to

- Describe the risk factors for Richter's syndrome development.
- Understand the molecular genetics of Richter's syndrome.
- Discuss the clinical implications of the genetic profile of Richter's syndrome.

N Jain

After attending this lecture, the participant will be able to

- Describe current and emerging therapies for patients with Richter transformation of CLL.
- Select appropriate therapies based upon patient and disease characteristics.

→ HEMATOLOGY-IN-FOCUS 3 C
14:45 - 15:45, Hall C

RARE LYMPHOMA SUBTYPES

Chair: A Engert (University Hospital of Cologne, Germany)

- "Double hit" lymphomas

ME Chamuleau (VU University Medical Center, Amsterdam, the Netherlands)

- NLPHL - A forgotten entity?

A Engert (University Hospital of Cologne, Germany)

LEARNING GOALS

ME Chamuleau

After attending this lecture, the participant will be able to

- Describe biological and clinical features of patients with double-hit and double-expressor lymphoma.
- Discuss the current knowledge on heterogeneity of these

lymphomas (double-hit vs double-expressor, double-hit vs single-hit, MYC-IG translocation partner vs MYC-non-Ig translocation partner).

- Discuss different treatment schedules, outcome and new therapeutic strategies.

A Engert

After attending this lecture, the participant will be able to

- Discuss the diagnostics for NPLHL and differences between NPLHL and cHL.
- Describe current and emerging therapies and outcomes for patients with newly diagnosed NPLHL.
- Discuss treatment options for relapsing patients.

→ HEMATOLOGY-IN-FOCUS

2 4 B T C

14:45 - 15:45, Hall D

NEW STRATEGIES IN CELLULAR THERAPY TO PREVENT RELAPSE OF ACUTE LEUKEMIA

Chair: T Fry (Pediatric Oncology Branch, CCR, NCI, NIH, Bethesda, USA)

- **CAR-T cells in AML**

A Bondanza (San Raffaele University Hospital and Scientific Institute, Milan, Italy)

- **T cell subsets for preventing relapse**

J Kuball (University Medical Center Utrecht, the Netherlands)

LEARNING GOALS

A Bondanza

After attending this lecture, the participant will be able to

- Discuss target-antigen choice for CAR-T cells against AML.
- Describe the options for maximising CAR-T cell efficacy in AML, while minimising toxicity.
- Position CAR-T cell therapy of AML in the context of hematopoietic stem cell transplantation.

J Kuball

An up-to-date program is available via the mobile app.

→ CLINICAL DEBATE

1 4 9 C

14:45 - 15:45, Hall E

ALL CHILDREN WITH SICKLE CELL ANEMIA AND AN HLA IDENTICAL SIBLING SHOULD BE OFFERED HEMATOPOIETIC STEM CELL TRANSPLANTATION

Chair: R Colombatti (Azienda Ospedaliera-Università di Padova, Italy)

- **Yes**

L Krishnamurti (Children's Healthcare of Atlanta, Emory University, USA)

- **No**

M de Montalembert (Hôpital Necker, Paris, France)

→ HEMATOLOGY-IN-FOCUS

6 9 C

14:45 - 15:45, Room N101

NOVEL APPROACHES FOR TREATMENT OF HEMOPHILIA

Chair: J Windyga (Institute of Hematology and Transfusion Medicine, Warsaw, Poland)

- **Factor VIII based**

F Peyvandi (Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy)

- **Non substitutive therapies for hemophilia**

M Makris (University of Sheffield, United Kingdom)

LEARNING GOALS

F Peyvandi

After attending this lecture, the participant will be able to

- Describe current treatment landscape and its limits for hemophilia A patients
- Illustrate the evolution of emerging therapies obtained by bioengineering technologies as PEGylation and fusion proteins
- Report data on efficacy in prophylactic treatment and safety of these innovative drugs
- Discuss new treatment options and requirement of a systematic approach for their marketing surveillance

M Makris

After attending this lecture, the participant will be able to

- Appreciate the limitations of the current haemophilia treatments that are based on substitution of the missing clotting factor as a concentrate.
- Describe the new disruptive technologies undergoing clinical trials and targeting antithrombin, TFPI and factors IX/X.
- Describe the current status of gene therapy for haemophilia A and B.

→ HEMATOLOGY-IN-FOCUS

9 C

14:45 - 15:45, Room N105

PEDIATRIC HEMATOLOGY: NEW DRUGS FOR CHILDREN

Chair: A Baruchel (France)

- **How to introduce new drugs for children with hematological malignancies? The US perspective**

P Adamson (The Children's Hospital of Philadelphia, USA)

- **Early phase clinical trials in children: The European perspective**

CM Zwaan (Erasmus MC Sophia Children's Hospital & Princess Máxima Center, Rotterdam, the Netherlands)

LEARNING GOALS

P Adamson

An up-to-date program is available via the mobile app.

CM Zwaan

After attending this lecture, the participant will be able to

- Describe the medical need in pediatric leukemia and have an

overview of the drugs currently in development in Europe.

- Understand the role of the European Pediatric Regulation including discussion points raised in the 10-year report after its implementation.
- Discuss the design and minimal dataset required for pediatric leukemia studies.

→ EHA - CHINESE SOCIETY OF HEMATOLOGY 2 3 4 C
JOINT SYMPOSIUM
14:45 - 15:45, Room N103

STEM CELL TRANSPLANTATION FOR RELAPSED LEUKEMIA

Chairs: J Wang (Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, China)
S Izraeli (Sheba Medical Center, Ramat Gan, Israel)

- **SCT for relapsed leukemia - The Chinese perspective**
X Huang (Peking University Institute of Hematology, China)
- **SCT for relapsed leukemia - The European perspective**
A Nagler (Chaim Sheba Medical Center, Tel Hashomer, Israel)

LEARNING GOALS

X Huang

After attending this lecture, the participant will be able to

- Review the poor prognosis of relapse acute leukemia, and review the outcomes of HSCT for relapsed leukemia.
- Present the current strategies to improve the outcome of HSCT for relapse leukemia adopted by Chinese physicians, including optimizing the conditioning regimen, modified donor lymphocyte infusion, selection of optimal donor and MRD-guided strategies.
- Evaluate potential benefits of using haploidentical donor, including stronger GVL effect and shorter waiting time led to increased chance to receive transplant.

A Nagler

After attending this lecture, the participant will be able to

- Discuss prognostic factors for AML relapse.
- Delineate therapeutic options for relapsed AML.
- Evaluate the role of allogeneic transplantation for relapsed AML.
- Present potential strategies to prevent relapse post allogeneic transplantation for AML.

→ EHA - EUROPEAN SCHOOL OF HEMATOLOGY JOINT SYMPOSIUM 1 2 3 4 8 9 C
14:45 - 15:45, Room N109

DOCTOR-PATIENT COMMUNICATION REGARDING BAD NEWS AND FUTURE PROSPECTS

Chairs: S Johnson (ESH, South Petherton, United Kingdom)
E Hellström Lindberg (EHA, Karolinska Institutet, Stockholm, Sweden)

- **Introduction, session overview, intro consultation and communication issues**
S Johnson (ESH, South Petherton, United Kingdom)
E Hellström Lindberg (EHA, Karolinska Institutet, Stockholm, Sweden)

Consultation role play

B Kennedy (Leicester Royal Infirmary, United Kingdom)

Actors:

- D Manship (RoleCall, United Kingdom)
- C Webber (RoleCall, United Kingdom)

CLINICAL SCENARIO

Patient is a 62 year old man who has a relapsed Hodgkin Lymphoma. Initial chemotherapy about a year earlier had failed despite early intensification and six months ago an autologous stem cell transplant was performed. The patient tolerated this well but seems to have had a rather slow general recovery. More recently there was evidence of active lymphoma once more. He is now undergoing a programme of salvage therapy with a view to allogeneic transplant. Both patient and wife have come to the consultation. The patient, his wife and the hematologist are expecting to discuss the recent FDG-PET Scan and to confirm plans regarding the transplant. The patient is very anxious for the future and feels the transplant is in his best interest. However, during the consultation it will become apparent to the clinician that a transplant is no longer viable. He will need to break this news and manage the couple's expectations of the future.

Summary and conclusions

- S Johnson (ESH, South Petherton, United Kingdom)
- E Hellström Lindberg (Karolinska Institutet, Stockholm, Sweden)

→ EARLY CAREER SESSION 8 B T C
14:45 - 15:45, Room N111

BIOLOGIC, TRANSLATIONAL AND CLINICAL HEMATOLOGY: WHAT IS BEYOND?

Chair: M Gruber (Center for Molecular Medicine, Vienna, Austria)

- **Introduction: Early Career Committee, Overview on Early Career Session 2 and the two Bite-size classes**
V Gaidzik (University Hospital of Ulm, Germany)
- **How to present and how to get published: Personal perspective from the Blood Editor-in-chief**
B Lowenberg (Erasmus University Medical Center, Rotterdam, the Netherlands)

LEARNING GOALS

V Gaidzik

After attending this lecture, the participant will be able to

- Know about the Early Career Committee of EHA.
- Describe current EHA career development opportunities and how to apply for them.

B Lowenberg

After attending this lecture, the participant will be able to

- Understand the biomedical publication processes.
- Identify and avoid common pitfalls in manuscript preparation and submission.

→ **EU FUNDED PROJECTS**
 14:45 - 15:45, Room N115

HARMONY: ENABLING BETTER AND FASTER TREATMENT FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Chairs: R Hehlmann (Medizinische Fakultät Mannheim Universität Heidelberg, Mannheim, Germany)
 P Bacon (Celgene, Switzerland)

- **HARMONY: Bench to Bed Projects**
 JM Hernández (IECSCYL-IBSAL, Spain)
 P van Dijck (Novartis, Switzerland)
- **HARMONY research projects: AML, MDS, CLL.**
 L Bullinger (University Hospital of Ulm, Germany)
 P Fenaux (Hôpital St Louis, Paris, France)
 LA Ann Sutton (Uppsala Universitet, Sweden)
 A Vasconcelos (Celgene, Switzerland)
 C Löfgren (Janssen-Cilag, Sweden)
- **Multi stakeholder involvement**
 J Geissler (Leukemia Patient Advocates Foundation, Munich, Germany)
 H Chevrou-Séverac (Celgene, Switzerland)
- **Q&A**
- **Conclusion: join the HARMONY journey: invitation to "informal meeting", booth, website**
 G Sanz (HULAFE, Spain)

→ **MEET-THE-EXPERT** 2 C
 14:45 - 15:45, Room N107
Availability on first come first serve basis

STOP OF TKI IN CML

Speaker: JL Steegmann (Hospital de la Princesa & IIS-IP, Madrid, Spain)

→ **MEET-THE EXPERT** 1 2 C
 14:45 - 15:45, Room N108
Availability on first come first serve basis

EOSINOPHILIA

Speaker: A Reiter (University Medical Centre Mannheim, Germany)

→ **MEET-THE-EXPERT** 7 8 C
 14:45 - 15:45, Room N117
Availability on first come first serve basis

HOW I PLAN AND RUN A HOSPITAL PATIENT BLOOD MANAGEMENT PROGRAM?

Speaker: K Pendry (NHS Blood and Transplant and Central Manchester University Hospitals NHS Foundation Trust, United Kingdom)

→ **SIMULTANEOUS SESSIONS** 3 10 T C
 16:00 - 17:15, Hall A

NEW DRUGS FOR RESCUE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

Chairs: S Giral (Memorial Sloan Kettering Cancer Center, New York, USA)
 A Alegre (Hospital Universitario de La Princesa, Madrid, Spain)

16:00 - 16:15
 S456 **PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA**
 MA Dimopoulos¹ (¹National and Kapodistrian University of Athens School of Medicine, Athens, Greece)

16:15 - 16:30
 S457 **A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)**
 J Mikhael¹ (¹Mayo Clinic, Pheonix, United States)

16:30 - 16:45
 S458 **OVERALL SURVIVAL OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TREATED WITH CARFILZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN THE RANDOMIZED PHASE 3 ENDEAVOR TRIAL**
 M Dimopoulos¹ (¹National and Kapodistrian University of Athens, Athens, Greece)

16:45 - 17:00
 S459 **EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF CASTOR**
 K Weisel¹ (¹Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tuebingen, Germany)

17:00 - 17:15
 S460 **A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**
 P Moreau¹ (¹CHU de Nantes, Hotel Dieu-HME, Nantes, France)

→ SIMULTANEOUS SESSIONS 3 5 10 T C
16:00 – 17:15, Hall B

IMPROVING PROGNOSTICATION AND FRONT-LINE THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA

Chairs: A Tedeschi (Niguarda Cancer Center, Niguarda Hospital, Milan, Italy)
S Mulligan (Royal North Shore Hospital, Sydney, Australia)

16:00 – 16:15

S461 **CYTOGENETIC COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA: DEFINITIONS, ASSOCIATIONS WITH OTHER BIOMARKERS AND CLINICAL IMPACT; A RETROSPECTIVE STUDY ON BEHALF OF ERIC**
P Baliakas¹ (¹Uppsala University, Uppsala, Sweden)

16:15 – 16:30

S462 **IS FCR THE TREATMENT OF CHOICE FOR IGHV MUTATED CLL WITHOUT POOR FISH CYTOGENETICS?**
C Cuéllar-García¹ (¹Hospital Santa Creu i Sant Pau, Barcelona, Spain)

16:30 – 16:45

S463 **IBRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (GA101) (IFCG) FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH MUTATED IGHV AND NON-DEL(17P)**
N Jain¹ (¹MD Anderson Cancer Center, Houston, United States)

16:45 – 17:00

S464 **BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)**
P Cramer¹ (¹University Hospital Cologne, Cologne, Germany)

17:00 – 17:15

S465 **SAFETY RESULTS OF TERMINATED PHASE 2 STUDY OF IDE-LALISIB PLUS RITUXIMAB IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH DEL(17P)**
P Hillmen¹ (¹The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom)

→ SIMULTANEOUS SESSIONS 3 C
16:00 – 17:15, Hall C

AGGRESSIVE NON-HODGKIN LYMPHOMA - RELAPSED/REFRACTORY

Chairs: D Caballero (University Hospital, Salamanca, Spain)
M Hutchings (Rigshospitalet, Copenhagen University Hospital, Denmark)

16:00 – 16:15

S466 **CLINICAL AND BIOLOGIC COVARIATES OF OUTCOMES IN ZUMA-1: A PIVOTAL TRIAL OF AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL)**
Y Lin¹⁰ (¹⁰Mayo Clinic, Rochester, United States)

16:15 – 16:30

S467 **CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): PHASE IB STUDY IN RELAPSED OR REFRACTORY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA, OR MARGINAL ZONE LYMPHOMA**
R Bouabdallah¹ (¹Institut Paoli-Calmettes, Marseille, France)

16:30 – 16:45

S468 **POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY**
M Matasar¹ (¹Memorial Sloan Kettering Cancer Center, New York, United States)

16:45 – 17:00

S469 **SINGLE AGENT ORAL SELINEXOR EXHIBITS DURABLE RESPONSES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF BOTH GCB AND NON-GCB SUBTYPES: THE PHASE 2B SADAL STUDY**
M Maerevoet¹ (¹Institute Jules Bordet, Brussels, Belgium)

17:00 – 17:15

S470 **L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) – A SINGLE-ARM PHASE II STUDY**
K Maddocks¹ (¹The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States)

→ SIMULTANEOUS SESSIONS 2 5 9 10 T C
16:00 – 17:15, Hall D

TARGETED TREATMENT OF AML

Chairs: A Ganser (Medizinische Hochschule Hannover, Germany)
F Ravandi (University of Texas, M. D. Anderson Cancer Center, Houston, USA)

16:00 – 16:15

S471 **ENASIDENIB (AG-221) IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE-ESCALATION AND EXPANSION STUDY**
EM Stein^{1, 2} (¹Memorial Sloan Kettering Cancer Center, New York, United States, ²Weill Cornell Medical College, New York, United States)

16:15 – 16:30

- S472 **SAFETY AND EFFICACY OF VENETOCLAX (VEN) IN COMBINATION WITH DECITABINE OR AZACITIDINE IN TREATMENT-NAIVE, ELDERLY PATIENTS (≥ 65 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML)**
K Pratz¹ (¹Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States)

16:30 – 16:45

- S473 **UPDATED SAFETY AND EFFICACY RESULTS OF PHASE 1/2 STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE IN TREATMENT-NAIVE ACUTE MYELOID LEUKEMIA PATIENTS AGED ≥ 65 YEARS AND UNFIT FOR STANDARD INDUCTION THERAPY**
AH Wei¹ (¹The Alfred Hospital and Monash University, Melbourne, Australia)

16:45 – 17:00

- S474 **PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH AZACYTIDINE (AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)**
N Daver¹ (¹University of Texas MD Anderson Cancer Center, Houston, United States)

17:00 – 17:15

- S475 **QUIZARTINIB AND BRIDGE TO TRANSPLANT IN FLT3-ITD AML PATIENTS AFTER FAILURE OF SALVAGE CHEMOTHERAPY: A HISTORICAL COMPARISON WITH UK NATIONAL CANCER RESEARCH INSTITUTE (NCRI) DATA**
R Hills¹ (¹Cardiff University, Cardiff, United Kingdom)

→ SIMULTANEOUS SESSIONS

16:00 – 17:15, Hall E

3 4 5 9 10 T C

IMMUNOTHERAPY IN ALL

Chairs: A Fielding (UCL, London, United Kingdom)
K Porkka (Helsinki University Hospital Comprehensive Cancer Center, Finland)

16:00 – 16:15

- S476 **GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE INTERIM ANALYSIS**
J Buechner¹ (¹Oslo University Hospital Rikshospitalet, Oslo, Norway)

16:15 – 16:30

- S477 **CTL019 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS IN PEDIATRIC PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)**
K Thudium Mueller¹ (¹Novartis Pharmaceuticals Corporation, East Hanover, United States)

16:30 – 16:45

- S478 **BLINATUMOMAB VS SOC CHEMOTHERAPY IN FIRST SALVAGE COMPARED WITH SECOND OR GREATER SALVAGE IN A PHASE 3 STUDY**
H Dombret¹ (¹Hôpital Saint-Louis, Paris, France)

16:45 – 17:00

- S479 **DURABLE LONG-TERM SURVIVAL OF ADULT PATIENTS WITH B-ALL AFTER CD19 CAR (19-28Z) T CELL THERAPY**
J Park¹ (¹MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, United States)

17:00 – 17:15

- S480 **STANDARD-RISK RANDOMIZATION OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN TRIAL AIEOP-BFM ALL 2000 INDICATES EQUAL OUTCOME WITH REDUCED-INTENSITY DELAYED INTENSIFICATION IN ETV6-RUNX1-POSITIVE PATIENTS**
K Bleckmann¹ (¹University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany)

→ SIMULTANEOUS SESSIONS

16:00 – 17:15, Room N101

2 5 10 T C

BIOLOGY AND DISEASE MONITORING IN CML

Chairs: D Krause (Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany)
J Janssen (VU University Medical Center, Amsterdam, the Netherlands)

16:00 – 16:15

- S481 **A SECOND GENERATION LYSOSOMOTROPIC AGENT DRIVES LEUKAEMIC STEM CELL DIFFERENTIATION AND SENSITIZES THEM TO TYROSINE KINASE INHIBITOR TREATMENT IN VITRO AND IN VIVO**
P Baquero¹ (¹University of Glasgow, Glasgow, United Kingdom)

16:15 – 16:30

- S482 **FC GAMMA RECEPTOR 2B IS CRITICAL FOR BCR-ABL MEDIATED LEUKEMOGENESIS**
O Herrmann¹ (¹Faculty of Medicine, University Hospital RWTH Aachen, Aachen, Germany)

16:30 – 16:45

- S483 **MYC-DEPENDENT REPRESSION MECHANISM OF THE MIR-150 TRANSCRIPTIONAL REGULATION IN CHRONIC MYELOID LEUKEMIA.**
N Čučíř^{1, 2} (¹Institute of Hematology and Blood Transfusion, Prague, Czech Republic, ²Institute of Pathological Physiology, 1st Medical faculty, Charles University in Prague, Prague, Czech Republic)

16:45 – 17:00

- S484 **COMPARISON OF GENOMIC DNA AND REVERSE TRANSCRIPTASE Q-PCR FOR THE MONITORING OF FIRST-LINE IMATINIB TREATMENT: AN ALLG CML9 SUB-STUDY**
DM Ross⁴ (⁴Royal Adelaide Hospital and SA Pathology, Adelaide, Australia)

17:00 – 17:15

- S485 **ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY**
S Soverini¹ (¹Hematology/Oncology "L. e A. Seràgnoli", Bologna, Italy)

→ SIMULTANEOUS SESSIONS

3 5 10 T C

16:00 – 17:15, Room N105

PROGNOSTIC MARKERS AND NEW TREATMENT IN MDS

- Chairs: L Adès (¹Hôpital Saint Louis, Paris, France)
V Santini (¹AOU Careggi, University of Florence, Italy)

16:00 – 16:15

- S486 **PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE SHOW SIMILAR SURVIVAL PATTERNS AS LOW RISK MDS PATIENTS.**
JW Hansen¹ (¹Rigshospitalet, University of Copenhagen, Copenhagen, Denmark)

16:15 – 16:30

- S487 **AN UPDATE OF A PHASE II STUDY OF NIVOLUMAB (NIVO) OR IPILIMUMAB (IPI) WITH AZACITIDINE IN PTS WITH PREVIOUSLY TREATED OR UNTREATED MYELODYSPLASTIC SYNDROMES (MDS)**
G Garcia-Manero¹ (¹The University of Texas MD Anderson Cancer Center, Houston, United States)

16:30 – 16:45

- S488 **ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS): EFFECTS IN TREATMENT NAÏVE AND RELAPSED/REFRACTORY PATIENTS**
S Navada¹ (¹Icahn School of Medicine at Mount Sinai, New York, United States)

16:45 – 17:00

- S489 **IMPACT OF THE MUTATIONAL PROFILE AT THE TIME OF DIAGNOSIS IN RESPONSE OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS**
G Montalban-Bravo¹ (¹The University of Texas MD Anderson Cancer Center, Houston, United States)

17:00 – 17:15

- S490 **STUDY OF THE EFFECT OF MIRNAS TARGETING RPS14 ON CELLULAR BIOLOGICAL BEHAVIOR OF MYELODYSPLASTIC SYNDROMES**
Y Nie¹ (¹Zhongnan Hospital of Wuhan University, Wuhan, China)

→ SIMULTANEOUS SESSIONS

4 9 C

16:00 – 17:15, Room N103

STEM CELL TRANSPLANTATION - CLINICAL 1

- Chairs: H Einsele (¹University Hospital Wuerzburg, Germany)
E Olavarria (¹Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom)

16:00 – 16:15

- S491 **SERIAL SEQUENCING REVEALS CLONAL ORIGINS AND STRATEGIES FOR EARLY DETECTION OF POST-ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)**
T Kim^{1, 2} (¹University of Toronto, Toronto, Canada, ²University of Toronto, Toronto, Canada)

16:15 – 16:30

- S492 **IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER FAILURE OF FRONTLINE CORTICOSTEROIDS: RESULTS OF A MULTICENTER OPEN-LABEL PHASE 2 STUDY**
I Pusic¹ (¹Washington University School of Medicine, St. Louis, United States)

16:30 – 16:45

- S493 **OUTCOMES OF NON T CELL-DEPLETED HAPLOIDENTICAL HSCT VERSUS HSCT FROM MATCHED SIBLING DONORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION, AN ALWP-EBMT STUDY**
D Salvatore¹ (¹Federico II, Naples, Italy)

16:45 – 17:00

- S494 **INDIVIDUAL OUTCOME PREDICTION FOR MDS AND SECONDARY AML AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION BASED ON GENETIC, PATIENT- AND TRANSPLANTATION-ASSOCIATED RISK FACTORS**
M Heuser¹ (¹Hannover Medical School, Hannover, Germany)

17:00 – 17:15

- S495 **IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE (BPX-501 CELLS) ON CHILDREN WITH LEUKEMIA GIVEN ALPHA-BETA T-CELL DEPLETED HAPLO-HSCT**
P Merli¹ (¹Ospedale Pediatrico Bambino Gesù, Rome, Italy)

→ **SIMULTANEOUS SESSIONS** 1 9 B T C
16:00 – 17:15, Room N104

BONE MARROW FAILURE AND PNH

Chairs: H Hasle (Aarhus University Hospital, Denmark)
MM van den Heuvel-Eibrink (Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands)

16:00 – 16:15

S496 **HEREDITARY HEMATOLOGIC MALIGNANCIES: GENETIC COUNSELING IMPLEMENTATION IN A LARGE LEUKEMIA CENTER**
C Dinardo¹ (¹The University of Texas MD Andesron Cancer Center, Houston, United States)

16:15 – 16:30

S497 **SECONDARY LEUKEMIAS IN GENETIC SUBTYPES OF CONGENITAL NEUTROPENIA (ELANE, HAX1, WASP, G6PC3, ETC.): A LONG-TERM ANALYSIS OF THE SCNIR EUROPE**
C Zeidler¹ (¹Medical School Hannover, Hannover, Germany)

16:30 – 16:45

S498 **EFFECT OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS WITH OR WITHOUT HIGH DISEASE ACTIVITY: RESULTS FROM THE INTERNATIONAL PNH REGISTRY**
B Höchsmann¹ (¹Institute for Clinical Transfusion Medicine and Immunogenetics, University Hospital Ulm, Ulm, Germany)

16:45 – 17:00

S499 **CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA: FUNCTIONAL RESCUE OF A NOVEL MPL MUTANT IN PRIMARY HEMATOPOIETIC CELLS USING CRISPR-CAS9**
C Cleyrat¹ (¹University of New Mexico Cancer Center, Albuquerque, United States)

17:00 – 17:15

S500 **DISCOVERY OF ORALLY BIOAVAILABLE SMALL MOLECULES FOR INHIBITION OF COMPLEMENT C5**
A Ricardo¹ (¹Ra Pharmaceuticals, Inc., CAMBRIDGE, United States)

→ **SIMULTANEOUS SESSIONS** 1 8 C
16:00 – 17:15, Room N109

QUALITY OF LIFE, PALLIATIVE CARE, ETHICS AND HEALTH ECONOMICS

Chairs: M Delforge (UZ Leuven, Belgium)
JL Harrousseau (Groupe Confluent, Nantes, France)

16:00 – 16:15

S501 **QUALITY OF LIFE WITH MELPHALAN/PREDNISONE PLUS EITHER THALIDOMIDE (MPT-T) OR LENALIDOMIDE (MPR-R) IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE HOVON87/NMSG18 STUDY**
C Stege¹ (¹VU University Medical Center, Amsterdam, the Netherlands)

16:15 – 16:30

S502 **HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE PHASE III GALLIUM STUDY OF OBINUTUZUMAB-BASED AND RITUXIMAB-BASED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED INDOLENT NON-HODGKIN LYMPHOMA**
A Davies¹ (¹Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom)

16:30 – 16:45

S503 **EFFECTIVE KEY WORKERS REDUCE THE NEED FOR CANCER SUPPORT GROUPS: RESULTS OF A POPULATION BASED SURVEY FROM GREATER MANCHESTER CANCER PATHWAY BOARD (GMCBP)**
J Tomlins¹ (¹The Christie NHS Foundation Trust, Manchester, United Kingdom)

16:45 – 17:00

S504 **FRONT-LINE VASCULAR ACCESS DEVICES IN ACUTE LEUKEMIAS – PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) VERSUS TRADITIONAL CENTRAL VENOUS CATHETER (CVC): A PHASE IV RANDOMIZED TRIAL (NCT02405728)**
C Cerchione¹ (¹Ematologia e trapianto/au federico ii, Napoli, Italy)

17:00 – 17:15

S505 **THE SIMM STUDY: SURVEY OF INTEGRATIVE MEDICINE IN MYELOPROLIFERATIVE NEOPLASMS**
K Gowin¹ (¹Mayo Clinic Arizona, Phoenix, United States)

→ **EARLY CAREER SESSION** 8 C
16:00 – 17:15, Room N111

BITE-SIZE CRTH

Chair: H Becker (University of Freiburg - Medical Center, Germany)

- Pitfalls in the design of clinical trials
R Hills (Cardiff University, United Kingdom)
- Execution of clinical trials: How to do it right?
M Hutchings (Rigshospitalet, Copenhagen University Hospital, Denmark)

LEARNING GOALS

R Hills

After attending this lecture, the participant will be able to

- Describe and evaluate traditional trial designs in hematology.
- Understand the shortcomings of many traditional designs.
- Describe the advantages of more modern trial designs.

M Hutchings

An up-to-date program is available via the mobile app.

→ **EARLY CAREER SESSION**
16:00 - 17:15, Room N113

8 T

BITE-SIZE TRTH

Chair: C Scharenberg (Karolinska Institute, Stockholm, Sweden)

- Pitfalls in biostatistics
D Neuberger (Dana-Farber Cancer Institute, Boston, USA)
- Personal journey through a career in translational hematology
J Gribben (Queen Mary University of London, United Kingdom)

LEARNING GOALS

D Neuberger

After attending this lecture, the participant will be able to

- Appreciate the importance of statistical advice in planning, executing, and reporting a study.
- Have a clear understanding of the role of variability in study design and analysis.
- Realize improved ability to manage both inherent and induced variability in research.

J Gribben

An up-to-date program is available via the mobile app.

→ **EHA ADVOCACY SESSION**
16:00 - 17:15, Room N115

1 2 3 4 8 9 10 C

NEW DRUGS IN HEMATOLOGY: FAIR PRICING & ACCESS

Chair: A Hagenbeek (University of Amsterdam, the Netherlands)

- A new economic model for medicine pricing in hemato-oncology
R Sullivan (Kings College London, United Kingdom)
- Fixing the fundamental flaws in medicine pricing: what can regulators and public health authorities do?
S Garner (World Health Organization (WHO), Geneva, Switzerland)
- The patient perspective
P Kapitein (Inspire2Live, Amsterdam, the Netherlands)
- Panel discussion

LEARNING GOALS

R Sullivan

An up-to-date program is available via the mobile app.

S Garner

An up-to-date program is available via the mobile app.

P Kapitein

After attending this lecture, the participant will be able to

- Realize that a lower price is blocked by industry, politics and government.
- Experience that this blocking is not caused by bad intention but by The Medical Industrial Complex that we created and therefore can change.
- Be shocked that we in healthcare are distracted from our essence: the patient.
- Contribute to the solution by working with patients and put them in the centre of healthcare again. Where they belong.



→ **UPDATES-IN-HEMATOLOGY**
17:30 - 19:00, Room N105

BROADENING OUR HORIZONS IN RELAPSED/REFRACTORY ALL

Chair: D Marks, University of Bristol, Bristol, United Kingdom

Acute lymphoblastic leukaemia (ALL) is a heterogeneous disease associated with low response rates and high toxicity in the salvage setting following standard chemotherapy. Therefore, there remains an unmet need for improved treatment options for patients with relapsed/refractory ALL. In this meeting, we will explore the latest understanding around prognostic tools which help predict outcomes and stratify treatment selection for patients with ALL. We will also discuss the latest clinical data surrounding innovative antibody-targeted approaches at the forefront of the evolving treatment paradigm in the relapsed/refractory setting. Finally, interactive case studies will be used to demonstrate how novel antibody-targeted therapies are transforming the lives of patients with relapsed/refractory ALL.

- To explore how prognostic tools can help predict patient outcomes and facilitate treatment decisions in ALL
- To discuss innovative antibody-targeted approaches in the treatment of relapsed/refractory ALL, and their potential to change the treatment paradigm
- To discuss the use of emerging antibody-targeted therapies in clinical practice through interactive case-based presentations

PROGRAM

- Prognostic tools to optimise outcomes in ALL: What do we know?
M Brüggemann, University Schleswig Holstein in the City Hospital, Kiel, Germany
- A new era in the treatment of relapsed/refractory ALL
E Jabbour, University of Texas M. D. Anderson Cancer Center Houston, Houston, Texas, United States
- Advancing the treatment of relapsed/refractory ALL: A case-based discussion
D Marks, University of Bristol, Bristol, United Kingdom

POSTER SESSION II

The main goal of the Poster Session is to gain a maximum benefit from the scientific work presented and to create a lively interaction between poster authors, moderators (senior experts in the field) and interested congress participants. The Poster Session consists of two parts: the Poster Walk and Poster Browsing Time. This setup guarantees sufficient time for all posters that have been selected for a presentation. The first hour of the Poster Walk is moderated and then followed by the Poster Browsing Time, where the rest of the posters can be browsed on the e-poster screens available in the poster area.

Poster walks will be organized during the poster sessions on Friday, June 23 at 17:15 – 18:45 and Saturday, June 24 at 17:30 - 19:00. Poster authors and moderators are requested to be present at the first poster in their poster session, at the beginning of the presentation time (Friday at 17:15 and Saturday at 17:30).

Poster Browsing Time will be organized after the Poster Walk, on Friday, June 23 18:15 – 18:45 and Saturday, June 24 at 18:30 – 19:00.

Poster Walk Title	From	To	Page
■ Acute lymphoblastic leukemia - Biology 2	P506	P514	148
■ Acute lymphoblastic leukemia - Clinical 2	P515	P525	148
■ Acute myeloid leukemia - Biology 3	P526	P535	149
■ Acute myeloid leukemia - Biology 4	P536	P544	149
■ Acute myeloid leukemia - Clinical 4	P546	P553	150
■ Acute myeloid leukemia - Clinical 5	P554	P562	150
■ Aggressive Non-Hodgkin lymphoma - Relapsed/refractory	P563	P572	151
■ Bone marrow failure syndromes incl. PNH - Clinical	P573	P582	152
■ Chronic lymphocytic leukemia and related disorders - Biology 2	P583	P590	152
■ Chronic myeloid leukemia - Biology	P591	P600	153
■ Chronic myeloid leukemia - Clinical 2	P601	P611	153
■ Enzymes and sickle cell disease	P612	P620	154
■ Gene therapy, cellular immunotherapy and vaccination	P621	P631	154
■ Indolent Non-Hodgkin lymphoma - Clinical	P632	P641	155
■ Infectious diseases, supportive care	P642	P651	155
■ Myelodysplastic syndromes - Biology	P652	P661	156
■ Myelodysplastic syndromes - Clinical 2	P662	P668	157
■ Myeloma and other monoclonal gammopathies - Clinical 3	P669	P678	157
■ Myeloma and other monoclonal gammopathies - Clinical 4	P679	P688	158
■ Myeloproliferative neoplasms - Biology	P689	P698	158
■ Myeloproliferative neoplasms - Clinical 2	P699	P708	159
■ Other Non-malignant hematopoietic disorders	P709	P718	159
■ Platelet disorders: Clinical	P719	P727	160
■ Quality of life, palliative care, ethics and health economics 2	P728	P737	161
■ Stem cell transplantation - Clinical 2	P738	P748	161
■ Stem cell transplantation - Experimental	P749	P758	162
■ Thrombotic disorders	P759	P768	163

→ POSTER SESSION

17:30 – 19:00, Poster area

ACUTE LYMPHOBLASTIC LEUKEMIA - BIOLOGY 2

Moderator: C Baldus (Charité, Berlin, Germany)

- P506 **T CELL EXHAUSTION CHARACTERIZED BY COMPROMISED MHC CLASS I AND II RESTRICTED CYTOTOXIC ACTIVITY ASSOCIATES WITH ACUTE B LYMPHOBLASTIC LEUKEMIA RELAPSE AFTER ALLO-HSCT**
L Liu¹ (Peking University People's Hospital & Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China)
- P507 **RUXOLITINIB/NILOTINIB COTREATMENT BETTER INHIBITS LEUKEMIA-PROPAGATING CELLS IN PHILADELPHIA CHROMOSOME-POSITIVE ALL**
Y Kong¹ (Peking University Institute of Hematology, Beijing, China)
- P508 **PREDICTING ANTI-LEUKEMIA ACTIVITY OF THE BCL-2-SELECTIVE INHIBITOR ABT-199 IN BCP-ALL BY FUNCTIONAL ASSESSMENT OF APOPTOSIS SIGNALING**
F Seyfried¹ (UlM University Medical Center, Ulm, Germany)
- P509 **CD45RA- MEMORY T CELLS EXPRESSING AN NKG2D-CAR TARGET PEDIATRIC ACUTE LEUKEMIA**
L Fernandez¹ (CNIO, Madrid, Spain)
- P510 **A BILINEAL ACUTE LYMPHOBLASTIC LEUKEMIA ORIGINATING AT A COMMON LYMPHOID PROGENITOR**
A Gonzalez-Murillo¹ (HOSPITAL UNIVERSITARIO NIÑO JESUS, MADRID, Spain)
- P511 **CYSTEINE AND GLYCINE-RICH PROTEIN 2 (CSPR2) TRANSCRIPT LEVELS CORRELATE WITH LEUKEMIA RELAPSE AND LEUKEMIA-FREE SURVIVAL IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH NORMAL CYTOGENETICS**
SJ Wang¹ (Peking University Peoples Hospital and Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China)
- P512 **THERAPEUTIC TARGETING OF PRE-B CELL RECEPTOR SIGNALING IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA**
A Alhammer^{1, 2} (Northern Institute for Cancer research, Newcastle upon Tyne, United Kingdom, ²Biotechnology research Center, Baghdad, Iraq)
- P513 **BMP-4 LEVELS IN CHILDHOOD B-ALL OF LOW-/INTERMEDIATE-RISK GROUPS IDENTIFY CHILDREN WITH POOR OUTCOME**
L Fernández-Sevilla¹ (Universidad Complutense, Madrid, Spain)

- P514 **TARGETING LOCALIZATION OF THE IL-7 RECEPTOR WITHIN LIPID RAFTS AS A THERAPEUTIC STRATEGY FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**

A Buffière¹ (UMR1231 Inserm, Université Bourgogne Franche-Comté, AgroSup, Dijon, France)

17:30 – 19:00, Poster area

ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL 2

Moderator: To be announced

- P515 **SYSTEMATIC MRI SCREENING IDENTIFIES EXTENSIVE ASYMPTOMATIC OSTEONECROTIC LESIONS IN ADOLESCENTS WITH ALL - FIRST INTERIM FINDINGS OF THE OPAL TRIAL**
M Kuhlen¹ (Medical Faculty, Heinrich Heine University, Duesseldorf, Germany)
- P516 **FINAL ANALYSIS OF A RANDOMIZED STUDY COMPARING PROPHYLACTIC AND MRD-TRIGGERED, PRE-EMPTIVE IMATINIB AFTER HSCT FOR PH+/BCR-ABL1 POSITIVE ALL: LONG-TERM PATIENT OUTCOME AND IMPLICATIONS OF MRD ANALYSIS**
D Lang¹ (Klinikum der Goethe Universität, Frankfurt, Germany)
- P517 **ANALYSIS OF SAFETY DATA FROM 2 MULTICENTER TRIALS OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)**
S Maude^{1, 2} (Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States, ²Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, United States)
- P518 **UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA**
N Short¹ (The University of Texas MD Anderson Cancer Center, Houston, United States)
- P519 **PROGNOSTIC IMPLICATIONS OF PRETREATMENT CYTOGENETICS IN ADULTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN**
E Jabbour¹ (MD Anderson Cancer Center, Houston, United States)
- P520 **A PHASE II STUDY WITH A SEQUENTIAL CLOFARABINE-CYCLOPHOSPHAMIDE COMBINATION SCHEDULE AS SALVAGE THERAPY FOR REFRACTORY AND RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) IN ADULT PATIENTS**
R Bassan¹ (Ospedale dell'Angelo, Mestre Venezia, Italy)

P521 **BLINATUMOMAB USE IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM AN OPEN-LABEL, MULTICENTER, EXPANDED ACCESS STUDY**
 F Locatelli¹, ² (¹Bambino Gesù Children's Hospital, Rome, Italy, ²University of Pavia, Pavia, Italy)

P522 **PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI-CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI-CEL)**
 F Locke¹ (¹H. Lee Moffitt Cancer Center, Tampa, United States)

P523 **KTE-C19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN ADULTS WITH HIGH-BURDEN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL): UPDATED RESULTS FROM PHASE 1/2 OF ZUMA-3**
 B Shah¹ (¹H. Lee Moffitt Cancer Center, Tampa, United States)

P524 **EXPOSURE-ADJUSTED ADVERSE EVENTS COMPARING BLINATUMOMAB WITH STANDARD OF CARE CHEMOTHERAPY IN ADULTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM A RANDOMIZED PHASE 3 STUDY**
 M Topp¹ (¹Universitätsklinikum Würzburg, Würzburg, Germany)

P525 **FACTORS ASSOCIATED WITH STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN VERSUS CONVENTIONAL CHEMOTHERAPY**
 M Stelljes¹ (¹University of Münster, Münster, Germany)

17:30 – 19:00, Poster area

ACUTE MYELOID LEUKEMIA - BIOLOGY 3

Moderator: O Abdel-Wahab (Memorial Sloan Kettering Cancer Center, New York, USA)

P526 **DESIGNING THE NEXT GENERATION CD33-TARGETING ADC: IMGN779, SELECTED FOR POTENCY, NOVEL MECHANISM AND PRECLINICAL TOLERABILITY, WITH HIGH ACTIVITY IN DISSEMINATED AML MODELS AND MULTI-DOSE REGIMENS**
 S Adams¹ (¹ImmunoGen, Waltham, United States)

P527 **THE MIXED LINEAGE LEUKEMIA FUSION PARTNER ENL RECRUITS PAF1 TO CLEAR POLYCOMB-INDUCED TRANSCRIPTIONAL REPRESSION**
 R Slany¹ (¹Friedrich Alexander University Erlangen-Nürnberg, Erlangen, Germany)

P528 **PKC EPSILON SUPPORTS ACUTE MYELOID LEUKEMIA BY MAINTAINING MITOCHONDRIAL REDOX HOMEOSTASIS.**
 D Di Marcantonio¹ (¹Fox Chase Cancer Center, Philadelphia, United States)

P530 **ROLE OF SHP2 IN A MOUSE MODEL OF AML CARRYING FLT3-ITD ALONG WITH LOSS OF TET2**
 R Pandey¹ (¹Indiana University School of Medicine, Indianapolis, United States)

P531 **CLUSTER REGULATION OF RUNX FAMILY BY "GENE SWITCH" TRIGGERS A PROFOUND TUMOR REGRESSION OF DIVERSE ORIGINS.**
 K Morita¹ (¹Graduate School of Medicine, Kyoto University, Kyoto, Japan)

P532 **PHOSPHOPROTEOMICS AND MASS CYTOMETRY SIGNATURES OF PRIMARY AML CELL DIFFERENTIATION ARE ASSOCIATED WITH SENSITIVITY TO KINASE INHIBITORS**
 P Casado-Izquierdo¹ (¹Barts Cancer Institute, London, United Kingdom)

P533 **CLINICAL IMPACT OF TET2 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS HARBORING CEBPA MUTATIONS: A STUDY OF THE AML STUDY GROUP (AMLSG)**
 F Theis¹ (¹University Hospital of Ulm, Ulm, Germany)

P534 **GFI1B – A NOVEL ONCOSUPPRESSOR WHICH RESTRICTS NUMBER OF LEUKEMIC STEM CELLS**
 A Thivakaran¹ (¹University Hospital of Essen, Essen, Germany)

P535 **VARIANT ALLELE FREQUENCY KINETICS OF TYROSINE KINASE GENE MUTATIONS IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA (CBF-AML) UNDER TREATMENT WITH AND WITHOUT DASATINIB**
 M Agrawal¹ (¹Universitätsklinikum Ulm, Ulm, Germany)

17:30 – 19:00, Poster area

ACUTE MYELOID LEUKEMIA - BIOLOGY 4

Moderator: T Mercher (INSERM U1170, Gustave Roussy institute, Villejuif, France)

P536 **P38 β MAPK INTERACTS WITH SET REGULATING ITS INHIBITORY EFFECT ON PP2A ACTIVITY IN ACUTE MYELOID LEUKEMIA**
 E Arriazu¹ (¹Center for applied medical research University of Navarre, Pamplona, Spain)

P537 **GENETIC LANDSCAPE OF ACUTE ERYTHROID LEUKEMIA**
 J Takeda¹ (¹Kyoto University, Kyoto, Japan)

P538 **THE MOLECULAR LANDSCAPE OF MLL-PTD AML: SPECIFIC CONCURRENT MUTATIONS, CLINICAL OUTCOME AND GENE EXPRESSION SIGNATURES**
 A Al Hinai¹, ² (¹Erasmus University Medical Center, Rotterdam, the Netherlands, ²National Genetic Centre, Muscat, Oman)

P539 **EXPLORING THE IMPACT OF LOSS OF FUNCTION STAG2 MUTATIONS ON CHROMATIN ARCHITECTURE IN MDS/AML**
 J Smith¹ (¹Queens University Belfast, Belfast, United Kingdom)

- P540 **NEXT GENERATION SEQUENCING TECHNIQUES REVEAL MOLECULAR MECHANISMS OF MYB REGULATION AND FUNCTION IN MLL-AF9 LEUKEMIA**
I J Lau¹ (¹Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom)
- P541 **CD123-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN ACUTE MYELOID LEUKAEMIA**
S Chitre¹ (¹KINGS COLLEGE LONDON, London, United Kingdom)
- P542 **TARGETED COMBINATION THERAPY WITH CDK4/6 INHIBITOR PALBOCICLIB IN AML**
I Uras¹ (¹University of Veterinary Medicine, Vienna, Vienna, Austria)
- P543 **CANNABINOIDS DERIVATIVES MODIFY THE PATTERN OF SPHINGOLIPIDS IN ACUTE MYELOID LEUKEMIA CELLS AND PRODUCE A POTENT ANTI-LEUKEMIC EFFECT.**
M Medrano¹ (¹Instituto de Biomedicina de Sevilla, Seville, Spain)
- P544 **PROFILING THE MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA AT RELAPSE AFTER CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.**
E Sala^{1, 2} (¹San Raffaele Scientific Institute, Milano, Italy, ²San Raffaele Scientific Institute, Milano, Italy)

17:30 – 19:00, Poster area

ACUTE MYELOID LEUKEMIA - CLINICAL 4

Moderator: B Gjertsen (University of Bergen, Norway)

- P546 **AML PATIENTS AGED ≥75 YEARS ENROLLED INTO AMLCG TRIALS: DO GENETIC ALTERATIONS IMPACT CLINICAL OUTCOME IN VERY OLD, INTENSIVELY TREATED PATIENTS?**
V Prassek¹ (¹University of Munich, Munich, Germany)
- P547 **GMI-1271, A POTENT E-SELECTIN ANTAGONIST, IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED/REFRACTORY AML: A NOVEL, WELL-TOLERATED REGIMEN WITH A HIGH REMISSION RATE**
D DeAngelo¹ (¹Dana-Farber Cancer Institute, Boston, United States)
- P548 **BST 236, A NOVEL CYTARABINE PRO-DRUG ALLOW, FOR THE FIRST TIME, THE DELIVERY OF HIGH CYTARABINE DOSES FOR OLDER OR UNFIT PATIENTS WITH ACUTE LEUKEMIA. RESULTS OF AN ONGOING PHASE I/IIA STUDY**
T Zuckerman^{1, 2} (¹Technion, Haifa, Israel, ²Rambam Health Care Campus, Haifa, Israel)

- P549 **FEASIBILITY AND BENEFIT OF TARGETED RNA SEQUENCING FOR THE DETECTION OF RECURRENT FUSION TRANSCRIPTS AND THE IDENTIFICATION OF NOVEL FUSION TRANSCRIPTS IN MYELOID MALIGNANCIES**
C Haferlach¹ (¹MLL Munich Leukemia Laboratory, Munich, Germany)
- P550 **COMPREHENSIVE MOLECULAR ANALYSIS OF ADULT MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)**
K Morita^{1, 2} (¹The University of Texas MD Anderson Cancer Center, Texas, United States, ²The University of Tokyo, Tokyo, Japan)
- P551 **THE EFFECTS OF EARLY INTENSIFIED INDUCTION CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA COMPARED TO STANDARD ANTHRACYCLINE PLUS CYTARABINE 3+7 CHEMOTHERAPY**
DH Kwak¹ (¹Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic Of)
- P552 **VARIANT FLT3 MUTATIONS CAN BE ERADICATED BY CYTARABINE/ANTHRACYCLINE/CRENOLANIB INDUCTION IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3 (ITD/TKD) MUTANT AML**
E Wang¹ (¹Roswell Park Cancer Institute, Buffalo, United States)
- P553 **PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO HAVE MUTATIONS IN IDH1 OR IDH2 RESPOND WELL TO INDUCTION CHEMOTHERAPY WITH "7+3" DESPITE THE PRESENCE OF COMPLEX KARYOTYPE OR FLT3-ITD**
D Gupta¹ (¹Mount Sinai Hospital, New York, United States)

17:30 – 19:00, Poster area

ACUTE MYELOID LEUKEMIA - CLINICAL 5

Moderator: J Esteve (University of Barcelona, Spain)

- P554 **VALIDATION OF PRECISION MEDICINE TEST FOR ACUTE MYELOID LEUKEMIA IN AN OBSERVATIONAL CLINICAL TRIAL.**
J Ballesteros² (²Vivia Biotech, Tres Cantos, Spain)
- P555 **RESPONSE-ADAPTED AZACITIDINE AND INDUCTION CHEMOTHERAPY IN PATIENTS → 60 YEARS OLD WITH NEWLY DIAGNOSED AML ELIGIBLE FOR CHEMOTHERAPY: RESULTS OF THE DRKS00004519 STUDY OF THE EAST GERMAN STUDY GROUP**
N Jaekel¹ (¹University Hospital of Leipzig, Leipzig, Germany)
- P556 **OVERALL SURVIVAL WITH CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA: SUBGROUP ANALYSIS OF A PHASE 3 STUDY**
J Lancet¹ (¹H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States)

- P557 HYPERFERRITINEMIA IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA**
 S Bertoli^{1, 2, 3} (¹Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France, ²Université Toulouse III Paul Sabatier, Toulouse, France, ³Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294 CNRS, Toulouse, France)
- P558 NGS ANALYSIS OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE - IMPACT OF AGE ON MUTATIONAL LOAD**
 L Pleyer^{1, 2, 3} (¹Paracelsus Medical University, Salzburg, Austria, ²Center for Clinical Cancer and Immunology Trials, Salzburg, Austria, ³Cancer Cluster, Salzburg, Austria)
- P559 PROGNOSTIC VALUE OF EARLY WT 1 RESPONSE IN AML PATIENTS UNDERGOING INTENSIVE CHEMOTHERAPY**
 S Machherndl-Spandl¹ (¹Ordensklinikum Elisabethinen Linz, Linz, Austria)
- P560 EVALUATION OF THE IMPACT OF SIGNAL RATIO ON OVERALL SURVIVAL IN FLT3-MUTATION-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA FOLLOWING ONCE-DAILY TREATMENT WITH GILTERITINIB**
 M Lewis¹ (¹John Hopkins University, Baltimore, United States)
- P561 CLINICAL OUTCOME OF HYPOCELLULAR AML AND AML WITH MYELODYSPLASIA-RELATED CHANGE (MRC) COMPARED TO DE NOVO ADULT AML WITH NORMAL CELLULARITY AFTER HEMATOPOIETIC CELL TRANSPLANTATION**
 DH Kwak¹ (¹Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic Of)
- P562 INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML**
 J Cortes¹ (¹MD Anderson Cancer Center, Houston, United States)
- 17:30 – 19:00, Poster area
AGGRESSIVE NON-HODGKIN LYMPHOMA - RELAPSED/REFRACTORY
 Moderator: To be announced
- P563 COMBINATION OF TGR-1202, UBLITUXIMAB, AND BEN-DAMUSTINE IS SAFE AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED DLBCL AND FOLLICULAR LYMPHOMA**
 M Lunning¹ (¹University of Nebraska Medical Center, Omaha, NE, United States)
- P564 VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)**
 M Davids¹ (¹Dana-Farber Cancer Institute, Boston, United States)
- P565 WHOLE BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IS A GOOD PREDICTOR OF TREATMENT OUTCOME AFTER ONE CYCLE OF IMMUNOCHEMOTHERAPY IN AGGRESSIVE LYMPHOMA**
 K De Paepe¹ (¹University Hospitals Leuven, Leuven, Belgium)
- P566 CLINICAL OUTCOMES OF DIFFUSE LARGE B CELL LYMPHOMA, FOLLICULAR LYMPHOMA AND RICHTER'S TRANSFORMATION PATIENTS TREATED WITH IBRUTINIB: A REAL-WORLD EXPERIENCE OF OFF LABEL, IBRUTINIB USE.**
 K Isaac¹ (¹Lankenau Medical Center, Wynnewood, United States)
- P567 PREVALENCE AND PROGNOSTIC VALUE OF MYD88 AND CD79B MUTATIONS IN IMMUNE-PRIVILEGED SITE AND (EXTRA)NODAL DLBCLS.**
 J Vermaat¹ (¹Leiden University Medical Center, Leiden, the Netherlands)
- P568 HIV-INFECTED PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA (NHL) OR HODGKIN LYMPHOMA (HL): RESULTS FROM THE GERMAN HIV-RELATED LYMPHOMA COHORT STUDY**
 M Hentrich² (²Rotkreuzklinikum München GmbH, München, Germany)
- P569 RISK STRATIFICATION BASED ON NCCN-IPi AT THE TIME OF DIAGNOSIS IN COMBINATION WITH POST-TREATMENT PET-CT SCAN FOR THE TREATMENT OF NODAL PERIPHERAL T-CELL LYMPHOMA**
 DH Yang¹ (¹Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic Of)
- P570 LONG-TERM EFFICACY AND SAFETY OF CRIZOTINIB IN RELAPSED ALK POSITIVE LYMPHOMA PATIENTS: CLINICAL AND BIOLOGICAL CORRELATES.**
 F Farina^{1, 2, 3} (¹Milano Bicocca University, Monza, Italy, ²San Gerardo Hospital, Monza, Italy, ³San Raffaele Scientific Institute, Milano, Italy)
- P571 PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA.**
 T Witzig¹ (¹Mayo Clinic, Rochester, United States)
- P572 BAM CONDITIONING BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA: A RETROSPECTIVE STUDY ON BEHALF OF THE FRANCOPHONE SOCIETY OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY (SFGM-TC).**
 J Cornillon¹ (¹Institut de Cancérologie de la Loire, Saint-Etienne, France)

17:30 – 19:00, Poster area

BONE MARROW FAILURE SYNDROMES INCL. PNH - CLINICAL

Moderator: H Tamary (Schneider Children's Medical Center of Israel, Petah Tikva, Israel)

- P573 **ANALYSIS OF MICRORNAOME, PROTEOME AND METABOLOME OF EXOSOMES FROM PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA**
I Martínez¹, ² (¹Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain, ²Instituto de Salud Carlos III (ISCIII), Madrid, Spain)
- P575 **SEVERE CHRONIC NEUTROPENIA: THE ROLE OF PRIMARY IMMUNODEFICIENCY AS CAUSATIVE AGENTS . A SINGLE CENTER DATA**
F Fioredda¹ (¹IRCCS Istituto Giannina Gaslini, Genova, Italy)
- P576 **TREATMENT WITH HORSE-DERIVED ANTI-THYMOCYTE GLOBULIN LEADS TO ENDURING HEMATOLOGICAL RESPONSES AND A 1.5-YEAR SURVIVAL PROBABILITY OF 87% IN ADULT ACQUIRED APLASTIC ANEMIA PATIENTS IN THE NETHERLANDS**
S Halkes¹ (¹LUMC, Leiden, the Netherlands)
- P577 **IMMUNE RECONSTITUTION IN PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION**
X Pei¹ (¹Peking University People's Hospital, Beijing, China)
- P578 **DEVELOPMENT OF A SCREENING AND DIAGNOSTIC ALGORITHM FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA USING A MODIFIED DELPHI PANEL METHODOLOGY**
A Röth¹ (¹University Hospital Essen, Essen, Germany)
- P579 **DIAMOND-BLACKFAN ANEMIA IN THE NETHERLANDS: AN OVERVIEW OF CLINICAL CHARACTERISTICS AND UNDERLYING MOLECULAR DEFECTS.**
B Van Dooijeweert¹ (¹Wilhemina Children's Hospital, Utrecht, the Netherlands)
- P580 **NEXT GENERATION SEQUENCING IN BONE MARROW FAILURE SYNDROMES**
E Galvez¹ (¹Hospital Infantil Niño Jesus, Madrid, Spain)
- P581 **APLASTIC ANEMIA PATIENTS WITH MONOCYTE-DOMINANT PNH CLONES HAVE A UNIQUE PRESENTATION AND ARE LESS RESPONSIVE TO IMMUNOSUPPRESSIVE THERAPY**
E Nevill¹ (¹Vancouver General Hospital, Vancouver, Canada)
- P582 **RESPONSE TO ANTI-THYMOCYTE GLOBULIN (ATG) IN PATIENTS WITH APLASTIC ANEMIA (AA): A SINGLE-CENTRE EXPERIENCE OVER THE LAST 28 YEARS**
M Oelmüller¹ (¹University Hospital Essen, Essen, Germany)

17:30 – 19:00, Poster area

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY 2

Moderator: JA Garcia-Marco (Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain)

- P583 **NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS**
F Pozzo¹ (¹Centro di Riferimento Oncologico, Aviano, Italy)
- P584 **CLL-LIKE B-CELL CLONES FROM MBLLO INDIVIDUALS PERSIST AT INCREASED COUNTS AFTER SEVEN YEARS OF FOLLOW-UP.**
I Criado¹ (¹Center for Cancer Research, Salamanca, Spain)
- P585 **NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES**
A Braunx¹ (¹Queen Mary University of London, London, United Kingdom)
- P586 **MICROENVIRONMENT REGULATION OF PROGRAMMED DEATH-1 (PD1) RECEPTOR AND ITS LIGANDS PDL1 AND PDL2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)**
F Morabito¹, ²¹ (¹Azienda Sanitaria Provinciale di Cosenza, Aprigliano (CS), Italy, ²¹Annunziata Hospital of Cosenza, Cosenza, Italy)
- P587 **IL-4 INCREASES EXPRESSION OF POSITIVE REGULATORS OF BCR SIGNALING IN CLL WHICH CAN BE OVERCOME BY CERDULATINIB**
M Blunt¹ (¹University of Southampton, Southampton, United Kingdom)
- P588 **INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE**
E Tissino¹ (¹Centro di Riferimento Oncologico, Aviano, Italy)
- P589 **IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLE STUDY**
T Munir¹ (¹St. James's Institute of Oncology, Leeds, United Kingdom)
- P590 **EVALUATION OF COMBINATIONAL THERAPIES FOR RELAPSED/REFRACTORY CLL WITH MUTATED P53**
S Post¹ (¹MD Anderson, Houston, United States)

17:30 – 19:00, Poster area

CHRONIC MYELOID LEUKEMIA - BIOLOGY

Moderator: To be announced

- P591 **THE DNA REPLICATION PATHWAY HAS POTENTIAL PREDICTIVE VALUE FOR TKI RESPONSE AND THERAPEUTIC INTERVENTION IN CHRONIC MYELOID LEUKAEMIA**
 M Copland¹ (¹Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom)
- P592 **SIGNAL TRANSDUCING ADAPTOR PROTEIN-1 (STAP-1) MAINTAINS CHRONIC MYELOID LEUKEMIC STEM CELLS**
 J Toda¹ (¹Osaka University Graduate School of Medicine, Osaka, Japan)
- P593 **TELOMERE SHORTENING IN CD34+38- BCR-ABL POSITIVE BONE MARROW CELLS FROM NEWLY DIAGNOSED PATIENTS WITH CML CORRELATES WITH THE CLONE SIZE OF THE LEUKEMIC STEM CELL COMPARTMENT**
 AS Bouillon¹ (¹Medical Faculty, Uniklinik RWTH Aachen, Aachen, Germany)
- P594 **GENOMIC CHARACTERIZATION OF CML AT DIAGNOSIS REVEALS PREEEXISTING SOMATIC MUTATIONS THAT MAY PREDICT PROGRESSION TO BLASTIC PHASE INDEPENDENTLY OF BCR-ABL1 MUTATIONS**
 M Machnicki¹, ² (¹Medical University of Warsaw, Warsaw, Poland, ²Medical University of Warsaw, Warsaw, Poland)
- P595 **INCREASED INDOLEAMINE 2,3-DIOXYGENASE (IDO1) ACTIVITY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) IS REDUCED BY NILOTINIB THERAPY AND PREDICTS MOLECULAR RESPONSE**
 S Sopper¹ (¹Medizinische Universität Innsbruck, Innsbruck, Austria)
- P596 **BCR-ABL1 COMPOUND MUTANTS DISPLAY DIFFERENTIAL AND DOSE-DEPENDENT RESPONSES TO PONATINIB**
 K Byrgazov¹ (¹Children's Cancer Research Institute, Vienna, Austria)
- P597 **IS THERE EFFECTIVE IMMUNE SURVEILLANCE AGAINST CHRONIC MYELOID LEUKAEMIA? NO.**
 R Gale¹ (¹Imperial College London, London, United Kingdom)
- P598 **MUTATIONAL ANALYSIS IN BCR-ABL1 POSITIVE LEUKEMIA BY DEEP SEQUENCING BASED ON NANOPORE MINION TECHNOLOGY**
 F Albano¹ (¹Hematology - University of Bari, Bari, Italy)
- P599 **THE AUTOMATED MOLECULAR TECHNIQUE "ULTRA" ALLOWS A SENSITIVE AND ACCURATE BCR-ABL1 QUANTIFICATION IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA.**
 S Galimberti¹ (¹Clinical and Experimental Medicine, University of Pisa, Hematology, Italy, Pisa, Italy)

- P600 **ROLE OF THE AURORA KINASE A/PLK 1 AXIS INHIBITION IN RESTORATION OF CELL GROWTH CONTROL OF CHRONIC MYELOID LEUKEMIA PROGENITORS**

M Mancini¹ (¹Istituto di Ematologia Seràgnoli-DIMES, Bologna, Italy)

17:30 – 19:00, Poster area

CHRONIC MYELOID LEUKEMIA - CLINICAL 2

Moderator: FE Nicolini (Centre Hospitalier Lyon Sud, France)

- P601 **DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE**
 D Ross¹ (¹SA Pathology, Adelaide, Australia)
- P602 **RESPONSE DIFFERENCES IN THE BCR-ABL1 E13A2 AND E14A2 VARIANTS MAY BE A TECHNICAL QPCR ARTIFACT**
 L Kjaer¹ (¹Zealand University Hospital, Roskilde, Roskilde, Denmark)
- P603 **5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)**
 J Cortes¹ (¹The University of Texas MD Anderson Cancer Center, Houston, TX, United States)
- P604 **LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE**
 I Capodanno³⁹ (³⁹Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Italy)
- P605 **IMPACT OF ARTERIAL THROMBOTIC EVENTS ON THE LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: AN ANALYSIS OF THE GIMEMA CML WORKING PARTY**
 G Gugliotta¹ (¹University of Bologna, Bologna, Italy)
- P606 **ASSESSMENT OF CHRONIC RENAL INJURY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE RECEIVING TYROSINE KINASE INHIBITORS**
 Q Jiang¹ (¹Peking University Institute of Hematology, Beijing, China)
- P607 **COMPARATIVE MONITORING OF MINIMAL RESIDUAL DISEASE (MRD) BY QPCR AND DIGITAL-PCR (DPCR) IN CHRONIC MYELOID LEUKEMIA PATIENTS ACHIEVING MAJOR OR DEEP MOLECULAR RESPONSE WITH TIROSIN-KINASE INHIBITORS**
 S Bernardi¹, ² (¹University of Brescia, Brescia, Italy, ²AO Spedali Civili of Brescia, Brescia, Italy)

P608 **OUTCOME OF BLAST PHASE CHRONIC MYELOID LEUKEMIA (CML-BP) IN THE TYROSINE KINASE INHIBITOR ERA**
C Talati¹ (¹University of South Florida/Moffitt Cancer Center, Tampa, United States)

P609 **EFFICACY OF SWITCHING TO DASATINIB IN CHRONIC MYELOID PATIENTS WITH LATE WARNING RESPONSES TO IMATINIB. STUDY OF THE ASSOCIATION OF RESPONSE TO DASATINIB TO IMMUNOLOGIC STATUS**
J Steegmann¹ (¹Hospital Universitario de la Princesa/ IIS-IP Madrid, Madrid, Spain)

P610 **GENETIC PREDICTION OF INSULIN RESISTANCE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH Nilotinib**
G Caocci¹ (¹University of Cagliari, Cagliari, Italy)

P611 **THE EUROPE AGAINST CANCER PROTOCOL FOR BCR-ABL P210 TRANSCRIPT MEASUREMENT MAY OVERESTIMATE RESULTS FOR E13A2 VARIANT**
M Gniot¹ (¹Poznan University of Medical Sciences, Poznań, Poland)

17:30 – 19:00, Poster area

ENZYMES AND SICKLE CELL DISEASE

Moderator: M de Montalembert (Hopital Necker, Paris, France)

P612 **ESTABLISHMENT OF IN VIVO AND IN VITRO MODEL OF X-LINKED SIDEROBLASTIC ANEMIA**
K Saito¹ (¹Tohoku University Graduate School of Medicine, Sendai, Japan)

P613 **BENDAMUSTINE AND RITUXIMAB COMBINATION THERAPY FOR COLD AGGLUTININ DISEASE: RESULTS OF A PROSPECTIVE NORDIC TRIAL.**
S Berentsen¹ (¹HAUGESUND HOSPITAL, Haugesund, Norway)

P614 **EX VIVO TREATMENT OF RED BLOOD CELLS FROM 15 PYRUVATE KINASE (PK)-DEFICIENT PATIENTS WITH AG-348, AN ALLOSTERIC ACTIVATOR OF PK-R, INCREASES ENZYMATIC ACTIVITY, PROTEIN STABILITY AND ATP LEVELS.**
R van Wijk¹ (¹University Medical Center Utrecht, Utrecht, the Netherlands)

P615 **IDENTIFICATION OF NEW PATHOGENIC MUTATIONS IN PATIENTS WITH RED BLOOD CELL MEMBRANE DISORDERS USING NEXT-GENERATION SEQUENCING**
M Mañu Pereira¹ (¹JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE, BARCELONA, Spain)

P616 **CLINICAL FOLLOW-UP OF 378 PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA: PROGNOSTIC IMPACT OF HEMOGLOBIN LEVELS, AUTOANTIBODY CLASS, AND RETICULOCYTOPENIA AT ONSET ON THE RELAPSE RISK AND OUTCOME**
B Fattizzo¹ (¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy)

P617 **HEME BINDS ANNEXIN-A5 DURING HEMOLYSIS AND PREVENTS ITS INTERACTION WITH CELL MEMBRANE PHOSPHATIDYL SERINE DURING SICKLE CELL DISEASE**
O Blanc-Brude¹ (¹INSERM, Paris, France)

P618 **USE OF PEGYLATED-CARBOXYHEMOGLOBIN BOVINE FOR THE TREATMENT OF SICKLE CELL DISEASE ASSOCIATED LEG ULCERS: RESULTS FROM A PHASE 2 SAFETY STUDY**
H Misra¹ (¹Prolong Pharmaceuticals, South Plainfield, United States)

P619 **NON-RENAL DETERMINANTS OF ENDOGENOUS ERYTHROPOIETIN LEVELS IN SICKLE CELL DISEASE**
K Gardner^{1, 2} (¹King's College Hospital, London, United Kingdom, ²King's College London, London, United Kingdom)

P620 **THE PHARMACOKINETICS (PK) OF GBT440 ARE SIMILAR IN ADOLESCENTS AND ADULTS WITH SICKLE CELL DISEASE (SCD)**
C Washington¹ (¹Global Blood Therapeutics, South San Francisco, United States)

17:30 – 19:00, Poster area

GENE THERAPY, CELLULAR IMMUNOTHERAPY AND VACCINATION

Moderator: Z Berneman (Antwerp University Hospital, Edegem, Belgium)

P621 **DEVELOPMENT OF TAX-REDIRECTED T-CELL IMMUNOTHERAPY FOR ADULT T CELL LEUKEMIA**
K Kawamura¹ (¹Saitama Medical Center, Jichi Medical University, Saitama, Japan)

P623 **NHEJ-BASED GENE EDITING: A NOVEL GENE THERAPY APPROACH IN FANCONI ANEMIA HEMATOPOIETIC STEM AND PROGENITOR CELLS**
F Roman-Rodriguez^{1, 2} (¹CIEMAT/CIBERER, Madrid, Spain, ²IIS-Fundacion Jimenez Diaz (IIS-FJD, UAM), Madrid, Spain)

P624 **NOVEL, ENHANCED AND DUAL TARGETING CAR INVARIANT NKT CELL-BASED IMMUNOTHERAPY FOR CD1D+ B CELL MALIGNANCIES**
A Rotolo¹ (¹Imperial College London, London, UK, United Kingdom)

P625 **A NOVEL CHIMERIC ANTIGEN RECEPTOR ENDOWS T CELLS WITH NK CELL-LIKE SPECIFICITY AND ATTACKS A WIDE RANGE OF HEMATOLOGICAL MALIGNANCIES AND CANCERS**
Y Kasahara¹ (¹Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan)

P626 **NKP30-CAR REDIRECTED HUMAN T LYMPHOCYTES INDUCE POTENT ANTITUMOR IMMUNITY TO LEUKEMIA CELL LINES AND PATIENT-DERIVED ACUTE MYELOID LEUKEMIA IN NSG XENOGRAFT MODELS**
U Hartwig¹ (¹University Medical Center Mainz, Mainz, Germany)

- P627 **PRECLINICAL TESTING OF ADOPTIVE T-CELL RECEPTOR GENE TRANSFER IN COMBINATION WITH CHECKPOINT INHIBITORS AS A NOVEL THERAPY FOR MULTIPLE MYELOMA**
H Echchannaoui⁰, ² (¹University Medical Center Mainz, Mainz, Germany, ²German Cancer Consortium (DKTK), partner site Frankfurt / Mainz, German Cancer Research Center (DKFZ), Heidelberg, Germany)
- P628 **ENGINEERED T CELLS TOWARDS BAFF RECEPTOR: A NOVEL STRATEGY TO EFFICIENTLY TARGET B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
N Turazzi¹ (¹M. Tettamanti Reserach Center, Department of pediatrics, University of Milano Bicocca S.Gerardo Hospital/ Fondazione MBBM, Monza, Italy)
- P629 **EXPLORING HUMAN TCR- AND CAR-REDIRECTED INKT CELLS FOR ADOPTIVE CELLULAR THERAPY**
U Hartwig¹ (¹University Medical Center Mainz, Mainz, Germany)
- P630 **SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA BY THE USE OF ENGINEERED CIK (CYTOKINE-INDUCED KILLER) CELLS EXPRESSING THE ANTI-CD33 CHIMERIC ANTIGEN RECEPTOR (CAR).**
M Rotiroti¹ (¹Tettamanti Research Center, Monza, Italy)
- P631 **UPDATE ON THE FIRST PATIENTS WITH SEVERE HEMOGLOBINOPATHIES TREATED WITH LENTIGLOBIN GENE THERAPY**
M Cavazzana¹ (¹Necker Hospital, Paris, France)
- 17:30 – 19:00, Poster area
INDOLENT NON-HODGKIN LYMPHOMA - CLINICAL
Moderator: A Davies (Southampton General Hospital, United Kingdom)
- P632 **A SINGLE INSTITUTIONAL EXPERIENCE OF 261 PATIENTS WITH LARGE GRANULAR LYMPHOCYTTIC LEUKEMIA**
M Van den Bergh¹ (¹H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States)
- P633 **ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3K-DELTA INHIBITOR, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (CITADEL-101)**
A Forero-Torres¹ (¹University of Alabama Birmingham, Birmingham, AL, United States)
- P634 **PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS**
J Burke¹, ² (¹Rocky Mountain Cancer Centers, Aurora, CO, United States, ²The US Oncology Network, The Woodlands, TX, United States)
- P635 **A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO INNOVATOR RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA**
M Ogura¹ (¹Department of Hematology, Tokai Central Hospital, Gifu, Japan)
- P636 **DURABLE DISEASE CONTROL OF EARLY MYCOSIS FUNGOIDES PATIENTS TREATED WITH LOW-DOSE INTERFERON-ALPHA2B AND PUVA**
S Rupoli¹, ¹ (¹Ospedali Riuniti Umberto I- Salesi-Lancisi di Ancona, ancona, Italy, ¹Ospedali Riuniti Umberto I- Salesi-Lancisi di Ancona, ancona, Italy)
- P637 **PHASE 3 ALCANZA STUDY OF BRENTUXIMAB VEDOTIN (BV) OR PHYSICIAN'S CHOICE (PC) OF METHOTREXATE (MTX) OR BEXAROTENE (BEX) IN CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA (CTCL):NUMBER NEEDED TO TREAT ANALYSIS**
M Dalal¹ (¹Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States)
- P638 **PRIMARY OCULAR ADNEXAL LYMPHOMA OF ALL HISTOLOGIC SUBTYPES: SURVIVAL OUTCOMES AND RISK FACTORS IN LARGE COHORT OF PATIENTS AND LONG-TERM FOLLOW-UP**
YW Jeon¹ (¹ST.MARY HOSPITAL,SEOUL, CATHOLIC MEDICAL CENTER, SEOUL, Korea, Republic Of)
- P639 **CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): A PROSPECTIVE REGISTRATIONAL STUDY ON 96 CASES**
C Kalpadakis¹ (¹University Hospital, University of Crete, Heraklion, Greece)
- P640 **SAFETY OF SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB DURING THE FIRST-LINE TREATMENT OF PATIENTS WITH NON-HODGKIN LYMPHOMA: THE MABELLA STUDY**
C Panizo¹ (¹Clínica Universidad de Navarra, Pamplona, Spain)
- P641 **REAL-WORLD EXPERIENCE WITH RITUXIMAB-FLUDARABINE (RF) AND DEXAMETHASONE, RITUXIMAB, CYCLOPHOSPHAMIDE (DRC) IN WALDENSTROM MACROGLOBULINEMIA : A RETROSPECTIVE STUDY FROM 163 PATIENTS**
C Protin¹ (¹IUC Toulouse-Oncopole, Toulouse, France)
- 17:30 – 19:00, Poster area
INFECTIOUS DISEASES, SUPPORTIVE CARE
Moderator: A Bondanza (San Raffaele University Hospital and Scientific Institute, Milan, Italy)
- P642 **MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR EMPIRICAL ANTIFUNGAL THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED TRIAL**
T Oyake¹ (¹Iwate Medical University School of Medicine, Morioka, Japan)

P643 ANTIFUNGAL DRUGS INFLUENCE NEUTROPHIL EFFECTOR FUNCTIONS IN VITRO AND MODULATE PULMONARY DAMAGE IN INVASIVE ASPERGILLOSIS

D Teschner¹ (¹University Medical Center of the Johannes Gutenberg University, Mainz, Germany)

P644 CHARACTERISTICS AND OUTCOME OF PULMONARY INFILTRATES IN ACUTE LEUKEMIA CLASSIFIED ACCORDING TO EORTC/MSG CRITERIA OF INVASIVE FUNGAL INFECTION: A PROSPECTIVE STUDY BY THE RETE EMATOLOGICA LOMBARDA

C Cattaneo¹ (¹Hematology, Spedali Civili, Brescia, Italy)

P645 ANTIFUNGAL PROPHYLAXIS WITH CD101 IN IMMUNOSUPPRESSED MOUSE MODELS OF CANDIDIASIS, ASPERGILLOSIS, AND PNEUMOCYSTIS PNEUMONIA (PCP)

V Ong¹ (¹Cidara Therapeutics, Inc., San Diego, United States)

P646 SURGICAL MANAGEMENT OF INVASIVE FUNGAL INFECTIONS IN ADULT LEUKAEMIA PATIENTS – EXPERIENCE FROM A LARGE TERTIARY CENTRE IN SOUTH-EAST ASIA

C Nagarajan¹ (¹Singapore General Hospital, Singapore, Singapore)

P647 INFECTIONS IN MULTIPLE MYELOMA ARE FREQUENT AND PREDOMINANTLY CAUSED BY BACTERIA: RESULTS OF A 12-YEAR SURVEY FROM A SINGLE CENTER

M Von Lilienfeld-Toal¹ (¹Universitätsklinikum Jena, Jena, Germany)

P648 HUMAN L-FICOLIN POLYMORPHISMS CONTRIBUTE TO SUSCEPTIBILITY TO INFECTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

U Schnetzke¹ (¹Universitätsklinikum Jena, Jena, Germany)

P649 PREDICTIVE FACTORS OF RESPONSE TO EPOETIN THETA IN CHEMOTHERAPY-INDUCED ANEMIA: A FRENCH MULTICENTER OBSERVATIONAL STUDY (PIVOINE).

P Rodon¹ (¹Ch De Périgueux, Périgueux, France)

P650 TIMING OF DEFIBROTIDE INITIATION POST-DIAGNOSIS OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER PRIMARY CHEMOTHERAPY: EXPLORATORY ANALYSIS OF AN EXPANDED-ACCESS PROTOCOL

P Richardson² (²Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States)

P651 ADAMTS-13 REGULATES NEUTROPHIL RECRUITMENT IN A MOUSE MODEL OF INVASIVE PULMONARY ASPERGILLOSIS

A Hasibeder¹ (¹Johannes Gutenberg-University Medical Center, Mainz, Germany)

17:30 – 19:00, Poster area

MYELODYSPLASTIC SYNDROMES - BIOLOGY

Moderator: A Pellagatti (University of Oxford, United Kingdom)

P652 IDENTIFICATION OF THE SPECIFIC HEMATOPOIETIC STEM CELL POPULATIONS RESPONSIBLE FOR FAILURE TO HYPO-METHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES

I Gañán-Gómez¹ (¹The University of Texas MD Anderson Cancer Center, Houston, United States)

P653 FUNCTIONAL STUDY ON THE COOPERATION OF ASXL1 AND RUNX1 MUTATIONS FOR LEUKEMIC TRANSFORMATION

R Bera¹ (¹Chang Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China)

P654 A NOVEL MASS SPECTROMETRY METHOD REVEALS THE INTRACELLULAR PHARMACOKINETICS OF AZACYTIDINE THERAPY IN VIVO

A Unnikrishnan¹ (¹UNSW Sydney, Sydney, Australia)

P655 CLONAL EVOLUTION OF STAG2 AND NRAS DURING PROGRESSION FROM MDS TO SAML ASSESSED BY WHOLE-EXOME AND TARGETED-DEEP SEQUENCING

M Martín-Izquierdo¹ (¹IBMCC-Centro de Investigación del Cáncer (USAL-CSIC), Salamanca, Spain)

P656 PROGRESSION OF MDS TO AML FEATURES GAIN OF SINGLE DRIVER MUTATIONS WITH CONSEQUENT CHANGES IN CLONAL COMPOSITION AND OCCURRENCE OF MULTIPLE CLONES WITH MUTATIONS IN IDENTICAL GENES

J Stosch¹ (¹Medical Center - University of Freiburg, Freiburg, Germany)

P657 PRECLINICAL MODELING OF MYELODYSPLASTIC SYNDROMES

K Rouault-Pierre¹ (¹The Francis Crick Institute, London, United Kingdom)

P658 MYELODYSPLASTIC SYNDROMES WITH IRON OVERLOAD ARE CHARACTERIZED BY A SWITCH FROM OXIDATIVE PHOSPHORYLATION TO GLYCOLYSIS AND THIS DEFECT IS PARTIALLY RESTORED BY IRON CHELATION. A FISM STUDY

D Cilloni¹ (¹University of Turin, Orbassano, Italy)

P659 V-SET AND IMMUNOGLOBULIN DOMAIN-CONTAINING 4 (VSIG4) EXPRESSED ON MONOCYTES INCLUDING TUMOR-ASSOCIATED MACROPHAGES SUPPRESSED ANTI-TUMOR IMMUNE RESPONSES IN MYELODYSPLASTIC SYNDROMES

Y Kuribayashi-Hamada¹ (¹Nippon Medical School, Japan, Sendagi, Bunkyo-ku, Tokyo, Japan)

P660 TRANSCRIPTOME ASSESSMENT OF DNA REPAIR GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA: SYNTHETIC LETHALITY TARGETS

A Hurtado López¹ (¹IMIB, Murcia, Spain)

- P661 **DIFFERENTIAL DIAGNOSIS BETWEEN MYELODYSPLASTIC SYNDROMES AND NON-CLONAL CYTOPENIAS BY FLOW CYTOMETRY ANALYSIS USING A MYELOID MATURATION DATABASE**
M Cedena¹ (H. 12 Octubre, Madrid, Spain)

17:30 – 19:00, Poster area

MYELODYSPLASTIC SYNDROMES - CLINICAL 2

Moderator: T Braun (Hôpital Avicenne-APHP-Université Paris XIII, France)

- P662 **A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB ALONE AND IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES**
A Gerdts¹ (Cleveland Clinic, Cleveland, United States)
- P663 **EPIGENETIC DRUG TREATMENT GLOBALLY INDUCES CRYPTIC TRANSCRIPTION START SITES ENCODED IN LONG TERMINAL REPEATS (LTRS)**
M Daskalakis¹ (German Cancer Research Center, Heidelberg, Germany)
- P664 **LYMPHOPENIA IS AN INDEPENDENT RISK-FACTOR IN PATIENTS WITH LOW-RISK MDS ACCORDING TO THE IPSS-R**
T Silzle¹ (Cantonal Hospital St. Gallen, St. Gallen, Switzerland)
- P665 **IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS**
A Alfonso Pierola¹ (MD Anderson Cancer Center, Houston, United States)
- P666 **LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY**
A Giagounidis¹ (Marien Hospital Düsseldorf, Düsseldorf, Germany)
- P667 **RATE AND CAUSES OF 5-AZACYTIDINE DISCONTINUATION AND SUBSEQUENT THERAPEUTIC OPTIONS IN 418 MDS PATIENTS FROM THE ITALIAN MDS REGISTRY OF FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE (FISM)**
M Clavio¹, ² (IRCCS AOU San Martino-IST, Genova, Italy, ²(FISM), Alessandria, Italy)
- P668 **COMBINATION OF DEEP PHENOTYPING AND TARGETED NEXT GENERATION SEQUENCING AS A DIAGNOSTIC TOOL IN CHILDREN WITH SUSPECTED MDS**
E Louka¹ (Weatherall Institute of Molecular Medicine University of Oxford, Oxford, United Kingdom)

17:30 – 19:00, Poster area

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL 3

Moderator: S Kristinsson (University of Iceland, Reykjavik, Iceland)

- P669 **OUTCOMES IN PATIENTS ALLOCATED TO NO-ASCT BASED ON DEPTH OF RESPONSE: INITIAL RESULTS OF A PHASE 2 TRIAL ASSESSING THE IMPACT OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DEFERRED ASCT (PADI-MAC)**
K Yong¹ (University College London, London, United Kingdom)
- P670 **PROPORTION AND COMPOSITION OF BONE MARROW LYMPHOCYTE POOL AT BASELINE CORRELATES WITH OUTCOME IN MM PATIENTS AFTER RVD AND ASCT**
S Luoma¹, ² (Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland, ²University of Helsinki, Helsinki, Finland)
- P671 **VALUE OF THE 18F-FDG PET-CT IN THE IDENTIFYING BONE INVOLVEMENT EITHER AT DIAGNOSIS OR DURING FOLLOW-UP OF PATIENTS AFFECTED BY MULTIPLE MYELOMA.**
S Galimberti¹ (hematology, Pisa, Italy)
- P672 **INITIAL PHASE 2 RESULTS OF IBRUTINIB COMBINED WITH BORTEZOMIB/DEXAMETHASONE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA**
R Hájek¹, ² (University Hospital in Ostrava, Ostrava, Czech Republic, ²University of Ostrava, Ostrava, Czech Republic)
- P673 **PROGNOSTIC SIGNIFICANCE OF CLONAL CIRCULATING PLASMA CELLS BY MULTI-PARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION**
S Sidana¹ (Mayo Clinic, Rochester, United States)
- P674 **RENAL IMPAIRMENT IN MYELOMA - PATIENT CHARACTERISTICS, TREATMENT MODALITIES, STEM CELL TRANSPLANT & OUTCOMES FROM THE AUSTRALIAN AND NEW ZEALAND MYELOMA REGISTRY**
P Ho¹ (Royal Prince Alfred Hospital, Sydney, Australia)
- P675 **VENETOCLAX AS TARGETED THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA**
S Kumar¹ (Mayo Clinic, Rochester, United States)
- P676 **AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)**
S Usmani¹ (Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC, United States)

P677 **GENE EXPRESSION CLASSIFIER EMC92/SKY92 AND REVISED ISS ROBUSTLY IDENTIFY HIGH-RISK MULTIPLE MYELOMA IN ELDERLY PATIENTS OF THE HOVON-87/NMSG-18 STUDY**
R Kuiper¹ (¹Skylindex, Rotterdam, the Netherlands)

P678 **MULTIPLE MYELOMA AND COMORBIDITY: A POPULATION-BASED STUDY**
I Sverrisdottir¹, ² (¹Landspítali, Reykjavik, Iceland, ²University of Iceland, Reykjavik, Iceland)

17:30 – 19:00, Poster area

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL 4

Moderator: B Aguado Bueno (Hospital Universitario de La Princesa, Madrid, Spain)

P679 **DETECTION OF NEW EMERGING CLONES DURING TREATMENT BY NGS ALLOWS A BETTER RISK PREDICTION ON MULTIPLE MYELOMA PATIENTS**
B Sanchez-Vega¹ (¹Hospital 12 de Octubre, Madrid, Spain)

P680 **FINAL RESULTS OF PHASE (PH) 1/2 STUDY OF CARFILZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (KPD) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A MULTI-CENTER MMRC STUDY**
A Jakubowiak¹ (¹University of Chicago, Chicago, IL, United States)

P681 **PANOBINOSTAT INDUCES CD38 UPREGULATION AND AUGMENTS THE ANTI-MYELOMA EFFICACY OF DARATUMUMAB**
E Garcia-Guerrero¹ (¹Universitätsklinikum Würzburg, Würzburg, Germany)

P682 **BCL2 EXPRESSION IS A POTENTIAL PREDICTIVE BIOMARKER OF RESPONSE TO VENETOCLAX IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA**
J Ross¹ (¹AbbVie, Inc., North Chicago, United States)

P683 **THE IMPACT OF THE INTRODUCTION OF BORTEZOMIB ON DIALYSIS INDEPENDENCE IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE: A NATIONWIDE DUTCH POPULATION-BASED STUDY**
B Oortgiesen¹ (¹Medical Centre Leeuwarden, Leeuwarden, the Netherlands)

P684 **TREATMENT WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND LIGHT CHAIN (AL) AMYLOIDOSIS**
P Milani¹ (¹Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy)

P685 **MYOCARDIAL UPTAKE OF 99mTc-DPD IN PATIENTS WITH AL AMYLOIDOSIS**
C De Miguel¹ (¹Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain)

P686 **WHEN PERFORMANCE OF CYTOGENETICS MATTERS: A POPULATION-BASED STUDY IN THE NETHERLANDS ON NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS**
M Brink¹ (¹Comprehensive Cancer Center the Netherlands, Utrecht, the Netherlands)

P687 **AN UPDATED ADJUSTED COMPARISON SUGGESTS DARATUMUMAB IS ASSOCIATED WITH PROLONGED SURVIVAL COMPARED WITH STANDARD OF CARE THERAPIES IN HEAVILY PRE-TREATED AND HIGH REFRACTORY MULTIPLE MYELOMA PATIENTS**
S Kumar¹ (¹Division of Hematology, Mayo Clinic, Rochester, MN, United States)

P688 **PREDICTORS OF EARLY DEATH RELATED TO ACTIVE MULTIPLE MYELOMA IN ELDERLY PATIENTS RECEIVING OPTIMIZED FRONTLINE TREATMENT COMBINATIONS**
P Rodriguez Otero¹ (¹Clinica Universidad de Navarra, Pamplona, Spain)

17:30 – 19:00, Poster area

MYELOPROLIFERATIVE NEOPLASMS - BIOLOGY

Moderator: N Pallisgaard (Sjællands Universitetshospital, Roskilde, Denmark)

P689 **MPL ACTIVATION DIRECTLY INDUCES FIBROCYTE DIFFERENTIATION TO CAUSE MYELOFIBROSIS**
T Maekawa¹ (¹National Defense Medical College, Tokorozawa, Saitama, Japan)

P690 **ENGRAFTMENT OF PRIMARY MYELOFIBROSIS BONE MARROW-DERIVED CD14+ MONOCYTES IN NOD-SCID-g MICE**
T Manshouri¹ (¹The University of Texas/ MD. Anderson Cancer Center, Houston, United States)

P691 **ESTABLISHMENT OF AN IN VITRO MODEL FOR THE SKEWED MEGAKARYOPOIESIS BY CALRETICULIN MUTATION IN HUMAN CELLS**
H Takei¹ (¹Juntendo University Graduate School of Medicine, Tokyo, Japan)

P692 **QUANTITATIVE PROTEOME HETEROGENEITY IN MYELOPROLIFERATIVE NEOPLASM SUBTYPES AND ASSOCIATION WITH JAK2 MUTATION STATUS**
N Socoro Yuste¹ (¹TIMC-IMAG Laboratory - TheREx team, GRENoble, France)

P693 **THE NOVEL SWITCH CONTROL INHIBITOR DCC-2618 COUNTERACTS GROWTH AND SURVIVAL OF VARIOUS NEOPLASTIC CELLS, INCLUDING MAST CELLS, EOSINOPHILS, AND MONOCYTES, IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS**
M Schneeweiss¹, ² (¹Medical University of Vienna, Vienna, Austria, ²Medical University of Vienna, Vienna, Austria)

- P694 **DISTRIBUTION OF MUTATIONS IN DRIVER AND NON-DRIVER GENES ACCORDING TO CLONAL HEMATOPOIESIS IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA**
A Senín^{1, 2} (¹Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain, ²IMIM, Barcelona, Spain)
- P695 **RUXOLITINIB/NILOTINIB/PREDNISOLONE COMBINATION: A PROMISING NOVEL TREATMENT FOR MYELOFIBROSIS**
J Martínez-López¹ (¹Hospital 12 de Octubre, Madrid, Spain)
- P696 **INTERLABORATORY ASSESSMENT OF MUTATION DETECTION IN MYELOID MALIGNANCIES BY TARGETED NEXT-GENERATION SEQUENCING**
C Fernández-Rodríguez¹ (¹Hospital del Mar, Barcelona, Spain)
- P697 **METHYLATION AGE IN MPN PATIENTS AS A CORRELATE FOR DISEASE STATUS, ALLELE BURDEN AND THERAPEUTIC RESPONSE**
S McPherson¹ (¹Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast, United Kingdom)
- P698 **ELUCIDATING THE AGE INDUCED HEMATOPOIETIC CELL-INTRINSIC AND EXTRINSIC MECHANISMS IN MYELOPROLIFERATIVE NEOPLASM INITIATION AND PROGRESSION**
N Tata¹ (¹University Hospital Basel, Basel, Switzerland)
- 17:30 – 19:00, Poster area
MYELOPROLIFERATIVE NEOPLASMS - CLINICAL 2
Moderator: T Devos (UZ Leuven, Belgium)
- P699 **PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL**
M Talpaz¹ (¹University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, United States)
- P700 **COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110)**
F Stegelmann¹ (¹University Hospital of Ulm, Ulm, Germany)
- P701 **PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), IN PATIENTS WITH MYELOFIBROSIS (MF) AND BASELINE (BL) THROMBOCYTOPENIA: FOCUS ON RUXOLITINIB (RUX)-TREATED PATIENTS IN THE PHASE 3 PERSIST-2 TRIAL**
C Harrison¹ (¹Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom)
- P702 **SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN ELDERLY PATIENTS (\geq 75 YEARS) WITH MYELOFIBROSIS (MF): AN ANALYSIS FROM THE PHASE 3B, EXPANDED-ACCESS JUMP STUDY**
P Raanani¹ (¹Rabin Medical Center, Petah Tikva, Israel)
- P703 **PROGNOSTIC RISK MODELS FOR TRANSPLANT DECISION-MAKING IN MYELOFIBROSIS**
J Hernández-Boluda¹ (¹Hospital Clínico Universitario, Valencia, Spain)
- P704 **LEUKEMIC TRANSFORMATION AND SECOND CANCERS IN 3649 HIGH RISK ET PATIENTS IN THE EXELS STUDY**
G Birgegård¹ (¹Uppsala University, Uppsala, Sweden)
- P705 **EPIDEMIOLOGY, OUTCOME AND RISK FACTORS FOR INFECTIOUS COMPLICATIONS IN MF PATIENTS RECEIVING RUXOLITINIB. A MULTICENTER STUDY ON 373 PATIENTS**
N Polverelli¹ (¹ASST Spedali Civili di Brescia, Brescia, Italy)
- P706 **TREATMENT AND MANAGEMENT OF PATIENTS WITH MPNS—FINDINGS FROM THE INTERNATIONAL MPN LAND-MARK SURVEY**
S Koschmieder¹ (¹RWTH Aachen University, Aachen, Germany)
- P707 **SUCCESSFUL LONG-TERM MAINTENANCE OF PV PATIENTS WITH A MONTHLY SCHEDULE OF ROPEGINTERFERON ALFA-2B – AN UPDATE FROM THE PEGINVERA STUDY**
H Gisslinger⁸ (⁸Medical University Vienna, Vienna, Austria)
- P708 **NO IMPROVEMENT IN SURVIVAL OVER TIME FOR PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASM PATIENTS WHO TRANSFORM TO ACCELERATED OR BLAST PHASE**
C Mcnamara¹ (¹Princess Margaret Cancer Centre, Toronto, Canada)
- 17:30 – 19:00, Poster area
OTHER NON-MALIGNANT HEMATOPOIETIC DISORDERS
Moderator: W Barcellini (Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy)
- P709 **MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 STUDY**
O Hermine^{1, 2, 3} (¹University of Paris Descartes, Institut Imagine INSERM U1163, Paris, France, ²CNRS ERL8654, Centre de Reference des Mastocytoses, Paris, France, ³AB Science, Paris, France)
- P710 **THERAPY RESPONSE AND LONG-TERM OUTCOME OF 71 ADULT PATIENTS WITH HEMATOLOGICAL MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SINGLE INSTITUTION EXPERIENCE**
M Machaczka^{1, 2} (¹KAROLINSKA UNIVERSITY HOSPITAL HUDDINGE, Stockholm, Sweden, ²University of Rzeszow, Rzeszow, Poland)

- P711 **WHOLE-EXOME SEQUENCING IN CHILDREN WITH IMMUNE CYTOPENIA: THE APPLICABILITY AND CLINICAL IMPACT**
M Svatoň¹ (¹Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic)
- P712 **SEQUENCING OF THE HYPOXIA PATHWAY GENES IN PATIENTS WITH CONGENITAL ERYTHROCYTOSES BY NEXT GENERATION SEQUENCING**
F Girodon¹, ² (¹PLATEAU TECHNIQUE DE BIOLOGIE, DIJON CEDEX, France, ²Faculté médecine, Dijon, France)
- P713 **CHARACTERIZATION OF CD34+ HEMATOPOIETIC PRECURSORS IN INDOLENT SYSTEMIC MASTOCYTOSIS AND THEIR POTENTIAL ROLE IN EARLY DISSEMINATION OF THE DISEASE.**
A Mayado¹ (¹University of Salamanca, Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain)
- P714 **MONOALLELIC VARIANTS IN GENES RELATED TO FAMILIAL HEMOPHAGOCYTTIC LYMPHOHISTIOCYTOSIS: REPORT FROM THE ITALIAN REGISTRY**
L Vinas¹, ² (¹Vall d'Hebron University Hospital, Barcelona, Spain, ²A. Meyer Children's University Hospital, Florence, Italy)
- P715 **PRIMARY AND CONGENITAL ERYTHROCYTOSIS IN PEDIATRICS: THE EXPERIENCE OF ITALIAN CENTERS**
G Geranio¹ (¹Haematology-Oncology, University of Padua, Padua, Italy)
- P716 **NEUROLOGICAL INVOLVEMENT IN EVANS SYNDROME AND CHRONIC HEMOLYTIC AUTOIMMUNE ANEMIA OF CHILDREN: DESCRIPTION, EVOLUTION AND GENETICS**
T Pincez¹ (¹APHP - Hôpital Trousseau, Paris, France)
- P717 **AUTOIMMUNE NEUTROPENIA OF CHILDHOOD SECONDARY TO OTHER AUTOIMMUNE DISORDERS: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY**
P Farruggia¹ (¹Pediatric Hematology and Oncology Unit, Oncology Department, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, Palermo, Italy)
- P718 **PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT DURING PREGNANCY**
M Vinogradova¹ (¹Federal Scientific Center for Obstetrics, Gynecology and Perinatology, Moscow, Russian Federation)
- 17:30 – 19:00, Poster area
PLATELET DISORDERS: CLINICAL
Moderator: To be announced
- P719 **LONG-TERM RESPONSE TO ORAL ELIGLUSTAT IN TREATMENT-NAÏVE ADULTS WITH GAUCHER DISEASE TYPE 1: FINAL EFFICACY AND SAFETY RESULTS FROM A PHASE 2 CLINICAL TRIAL AFTER 8 YEARS OF TREATMENT**
E Lukina¹ (¹National Research Center for Hematology, Moscow, Russian Federation)
- P720 **REAL WORLD EVIDENCE ON DRUG UTILIZATION PATTERNS OF ELTROMBOPAG IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA: REVIEU (REVOLADE™ [ELTROMBOPAG]) IN SELECTED COUNTRIES IN THE EUROPEAN UNION) STUDY**
E Gutiérrez¹ (¹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain)
- P721 **BIOLOGICAL CHARACTERIZATION OF ITP PATIENTS THAT ARE NON-RESPONDERS TO TRADITIONAL THERAPIES**
N Revilla¹ (¹Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arraxaca, Murcia, Spain)
- P722 **SEQUENTIAL USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN ADULT PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE COLLABORATIVE SURVEY FROM ITALIAN HEMATOLOGY CENTERS**
S Cantonì² (²Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy)
- P723 **THROMBOEMBOLIC EVENT MANAGEMENT AND OUTCOMES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ELTROMBOPAG (EPAG): RESULTS FROM THE EXTEND STUDY**
M Saleh¹ (¹Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, United States)
- P724 **SEVERE BLEEDING IN THE ELDERLY WITH PRIMARY IMMUNE THROMBOCYTOPENIA: CHARACTERISTICS, RESPONSE TO THERAPY AND LONG-TERM OUTCOME**
M Lyu¹, ² (¹Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences And Peking Union Medical College, Tianjin, China, ²Affiliated Suzhou Hospital of Nanjing Medical University (Suzhou Municipal Hospital), Suzhou, China)
- P725 **ATORVASTATIN IMPROVE THE PROGNOSIS OF ADULT PATIENTS WITH CORTICOSTEROID-RESISTANT IMMUNE THROMBOCYTOPENIA VIA ENHANCING BONE MARROW ENDOTHELIAL CELL FUNCTION**
XN Cao¹ (¹Peking University Institute of Hematology, Beijing, China)
- P726 **PLATELET DESIALYLATION IS A NOVEL MECHANISM AND A THERAPEUTIC TARGET IN THROMBOCYTOPENIA DURING SEPSIS: AN OPEN-LABEL, MULTICENTER, RANDOMIZED CONTROLLED TRIAL**
X Li¹ (¹Qilu Hospital, Shandong University, Jinan, China, Jinan, China)
- P727 **SAFETY AND EFFICACY OF LONG-TERM OPEN-LABEL DOSING OF SUBCUTANEOUS (SC) ROMIPLOSTIM IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA (ITP)**
J Bussel¹ (¹Weill Cornell Medicine, New York, United States)

17:30 – 19:00, Poster area

QUALITY OF LIFE, PALLIATIVE CARE, ETHICS AND HEALTH ECONOMICS 2

Moderator: MT Petrucci (Italy)

- P728 **IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF CLL PATIENTS RELAPSED/REFRACTORY TO B-CELL RECEPTOR (BCR) SIGNALING PATHWAY INHIBITOR TREATMENT**
W Wierda¹ (¹The University of Texas MD Anderson Cancer Center, Houston, United States)
- P729 **THE ROLE OF PSYCHOLOGICAL VARIABLES FOR TYROSINE KINASE INHIBITORS (TKI) DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: IMPLICATION FOR MEDICAL DECISION MAKING PRACTICE**
S Riva¹ (¹University of Milan, Milan, Italy)
- P730 **BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB (CT-P10) FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE 28 EU MEMBER STATES**
F Rencz¹, ² (¹Corvinus University of Budapest, Budapest, Hungary, ²HTA Consulting Budapest, Budapest, Hungary)
- P731 **AN INVESTIGATION INTO THE NEEDS AND PRIORITIES OF PATIENTS WITH MULTIPLE MYELOMA DURING REMISSION – IMPLICATIONS FOR RE-DESIGNING PATIENT-CENTRED HEALTHCARE SYSTEMS.**
D De-Silva¹ (¹University College London, London, United Kingdom)
- P732 **COST-EFFECTIVENESS OF RITUXIMAB IN ADDITION TO STANDARD OF CARE CHEMOTHERAPY FOR ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA**
M Seftel³, ⁴ (³CancerCare Manitoba, Winnipeg, Canada, ⁴University of Manitoba, Winnipeg, Canada)
- P733 **THE THERAPEUTIC UTILITY OF A SYSTEMATIC PROTOCOL FOR GERIATRIC ASSESMENT IN ONCOHEMATOLOGIC PATIENTS**
C Terán¹ (¹Fundacion Jimenez Diaz, Madrid, Spain)
- P734 **RADIATION EXPOSURE FROM CT IMAGING AND CHILDHOOD LEUKEMIA: A NATIONWIDE CASE-CONTROL STUDY**
A Nikkilä¹ (¹University of Tampere, Tampere, Finland)
- P735 **HEALTHCARE RESOURCE UTILIZATION WITH IXAZOMIB OR PLACEBO PLUS LENALIDOMIDE-DEXAMETHASONE IN THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 TOURMALINE-MM1 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)**
P Hari¹ (¹Medical College of Wisconsin, Milwaukee, United States)
- P736 **MANAGEMENT, ECONOMIC AND SOCIAL IMPACT OF SUB-CUTANEOUS RITUXIMAB ADMINISTRATION IN LYMPHOPROLIFERATIVE MALIGNANCIES**
O Annibali¹ (¹university Campus Biomedico, Rome, Italy)

- P737 **EFFECT OF IMPROVEMENTS OF SURVIVAL, POPULATION AGING AND IMWG '14 CRITERIA ON INCIDENCE AND PREVALENCE OF MULTIPLE MYELOMA**

V Martínez-Robles¹ (¹Complejo Asistencial Universitario de León, LEON, Spain)

17:30 – 19:00, Poster area

STEM CELL TRANSPLANTATION - CLINICAL 2

Moderator: To be announced

- P738 **HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ISOLATED EXTRAMEDULLARY RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN**
M Gabelli¹ (¹Università di Padova, Padova, Italy)
- P739 **PREDICTIVE FACTORS FOR DEVELOPING VENO-OCCLUSIVE DISEASE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH INOTUZUMAB OZOGAMICIN FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**
P Kebriaei¹ (¹University of Texas M.D. Anderson Cancer Center, Houston, United States)
- P740 **DEFIBROTIDE EFFICACY AND SAFETY IN PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSED AFTER DAY 21: ANALYSIS OF FINAL DATA FROM AN EXPANDED-ACCESS PROGRAM**
P Richardson¹ (¹Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States)
- P741 **ALLO-HCT FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA – 12 YEARS OF EXPERIENCE**
M Markiewicz¹ (¹MEDICAL UNIVERSITY OF SILESIA, Katowice, Poland)
- P742 **A COMPARISON OF CLINICAL OUTCOMES BETWEEN MATCHED SIBLING DONOR (MSD) AND UNRELATED DONOR (URD) STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA**
S Shin¹ (¹Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic Of)
- P743 **HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANT IN SEVERE THALASSEMIA PATIENTS**
S Hongeng¹ (¹Ramathibodi hospital, Mahidol University, Bangkok, Thailand)
- P744 **AUGMENTATION OF FLUDARABINE AND BUSULFAN-BASED MYELOABLATIVE REGIMEN WITH THIOTEPA IMPROVES OUTCOMES WITH NO ADDED TOXICITY IN ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA**
V Sheth¹ (¹HADASSAH, Jerusalem, Israel)

- P745 **PROGNOSTIC TOOLS CAN PROVIDE PERSONALIZED OUTCOMES PREDICTION AFTER ALLOGENEIC HCT IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES**
C Cho¹ (¹Memorial Sloan Kettering Cancer Center, New York, NY, United States)
- P746 **THROMBOTIC MICROANGIOPATHY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: IS THERE A PROTECTIVE ROLE FOR URSODEOXYCHOLIC ACID?**
R Parody^{1, 2} (¹H.Universitario Virgen del Rocío, Seville, Spain, ²ICO-Duran i Reynals, Barcelona, Spain)
- P747 **FACTORS PREDICTING GRAFT VERSUS HOST DISEASE-FREE, RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION. COMPARISON ATTENDING TO TWO DIFFERENT DEFINITIONS AND BENEFIT OF HAPLOIDENTICAL DONOR.**
E Pérez López¹ (¹Hospital Universitario de Salamanca, Salamanca, Spain)
- P748 **EFFICACY AND SAFETY OF DEFIBROTIDE IN THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL SUBGROUP RESULTS**
P Richardson¹ (¹Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States)

17:30 – 19:00, Poster area

STEM CELL TRANSPLANTATION - EXPERIMENTAL

Moderator: L Vago (San Raffaele Scientific Institute, Milan, Italy)

- P749 **GENERATION OF IMMORTAL MURINE HEMATOPOIETIC STEM/PROGENITOR CELL LINES FROM TRANSGENIC MICE**
E Doma¹ (¹Veterinärmedizinische Universität Wien, Wien, Austria)
- P750 **INHIBITING BCL2 AND NK CELLS IMPROVES STEM CELL TRANSPLANT OUTCOMES.**
J Davis^{1, 2} (¹The Royal Melbourne Hospital, Melbourne, Australia, ²The University of Melbourne, Melbourne, Australia)
- P751 **MESENCHYMAL STROMAL CELL IRRADIATION INTERFERES WITH THE ADIPOGENIC/OSTEOGENIC DIFFERENTIATION BALANCE IMPROVING THEIR HEMATOPOIETIC-SUPPORTING ABILITY**
S Preciado Pérez¹ (¹IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain)

- P752 **DYSFUNCTION OF BONE MARROW MESENCHYMAL STEM CELLS FROM PATIENTS WITH PROLONGED ISOLATED THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN BE IMPROVED BY N-ACETYL-L-CYSTEINE**
Y Song^{1, 2} (¹Peking University People's hospital, Beijing, China, ²Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China)
- P753 **INHIBITORS OF APOPTOSIS PROTEINS (IAPS) MODULATE GASTROINTESTINAL GVHD IN MURINE EXPERIMENTAL BMT MODELS**
T Toubai^{1, 2} (¹Yamagata University Faculty of Medicine, Yamagata, Japan, ²University of Michigan, Ann Arbor, United States)
- P754 **GRAFT-VERSUS HOST DISEASE (GVHD) DEVELOPMENT AFTER BONE MARROW TRANSPLANTATION IS NOT INFLUENCED BY TH9 CELLS**
G Strauss¹ (¹University Medical Center Ulm, Ulm, Germany)
- P755 **IMPROVED HSC ENGRAFTMENT IN A MOUSE MODEL OF HEMATOPOIETIC STEM CELL GENE THERAPY MEDIATED BY MSCS**
M Fernandez-Garcia^{1, 2} (¹Centro de Investigaciones Energéticas Medioambientales y Tecnológicas/Centro de Investigación Biomédica en Red de Enfermedades Raras (CIEMAT/CIBERER), Madrid, Spain, ²Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain)
- P756 **EFFECT OF POMALIDOMIDE ON T CELL POLARIZATION IS MEDIATED THROUGH EPIGENETIC MODIFICATIONS.**
I Alvarez Laderas¹ (¹Instituto de Biomedicina de Sevilla, Seville, Spain)
- P757 **MESENCHYMAL STEM CELLS (MSCS) ATTENUATE CUTANEOUS SCLERODERMATOUS GRAFT-VERSUS-HOST DISEASE (SCL-GVHD) THROUGH INHIBITION OF IMMUNE CELL INFILTRATION IN A MOUSE MODEL**
JY Lim¹ (¹Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic Of)
- P758 **C57BL/6 SUBSTRAINS SHOW DIFFERENCES IN HEMATOPOIETIC REPOPULATION**
A Morales Hernandez¹ (¹St Jude Children's Research Hospital, Memphis, United States)

17:30 – 19:00, Poster area

THROMBOTIC DISORDERS

Moderator: JB Hansen (UiT, The Arctic University of Norway, Tromsø, Norway)

- P759 **GWAS RESULTS IN RED BLOOD CELL PHENOTYPES AND THEIR RELATIONSHIP WITH THROMBOSIS**
R Angel F.³ (Hospital de Sant Pau, Barcelona, Spain)
- P760 **ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTS SHOW AN INCREASED THROMBUS FORMATION IN A DYNAMIC MODEL OF PLATELET ADHESION**
A Vignoli¹ (Hospital Papa Giovanni XXIII, Bergamo, Italy)
- P761 **DOAC ASSOCIATED MAJOR GASTROINTESTINAL BLEEDING: REAL LIFE EXPERIENCE FROM A UNIVERSITY TEACHING HOSPITAL, UK**
B Badugama¹ (Royal Stoke University Hospital, Stoke on Trent, United Kingdom)
- P763 **INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING LOWER LIMB SURGICAL REVASCUARIZATION: IS THROMBOPROPHYLAXIS WARRANTED?**
P Smith¹ (MacNeal Hospital, Berwyn, United States)
- P764 **THE ROLE OF INFLAMMATION IN THROMBOEMBOLISM IN RESECTABLE RENAL CELL CARCINOMA PATIENTS**
H Park¹ (Seoul National University Hospital, Seoul, Korea, Republic Of)
- P765 **GENETIC AND ENVIRONMENTAL RELATIONSHIP BETWEEN VITAMIN B12, FOLATE AND HOMOCYSTEINE AND SUSCEPTIBILITY TO THROMBOSIS IN THE GAIT 2 PROJECT. RESULTS OF A GWAS ANALYSIS.**
R Angel F.¹ (Hospital de Sant Pau, Barcelona, Spain)
- P766 **CELLULAR ORIGIN OF CIRCULATING MICROPARTICLES (MP) ACCORDING TO SOMATIC MUTATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPN)**
C Tartari¹ (Hospital Papa Giovanni XXIII, Bergamo, Italy)
- P767 **ARE WE TESTING APPROPRIATELY FOR THE LUPUS ANTI-COAGULANT?**
J Sharif¹ (Central Manchester University Hospitals, Manchester, United Kingdom)
- P768 **RESULTS OF USING BRIDGING THERAPY WITH SODIUM BEMIPARIN AT THERAPEUTIC-DOSE**
M García Ruiz¹ (Complejo Hospitalario Universitario de Granada, Granada, Spain)

EHA-SWG SCIENTIFIC MEETING

Shaping the future of mesenchymal stromal cells therapy



Dates: November 23-25, 2017

Location: Amsterdam,
The Netherlands

Organized by:

EHA Scientific Working Group on
Mesenchymal Stromal Cells

Chair:

WE Fibbe

Co-chairs:

F Dazzi, K Le Blanc

Topics:

- Basic developmental biology of MSC and their role in immune regulation
- Mechanisms of MSC immune regulation
- Potency assay design
- Technological development
- Clinical trial results with MSC
- Clinical issues
- Regulatory and ethical aspects of clinical trials using MSC

SUNDAY, JUNE 25

SPECIAL SESSIONS OF THE DAY

Next to the high quality scientific and education sessions of the day we would like to draw your attention to the following interesting sessions::

INTERNATIONAL SOCIETY OF THROMBOSIS AND HEMOSTASIS

JOINT SYMPOSIUM →

Page 173

LATE BREAKING ORAL SESSION →

Page 175

PLENARY SESSION II →

Page 180

BUSINESS MEETING →

Page 180

Download the EHA app

Keep yourself up-to-date
with sessions especially
designed for you.

Download the EHA app
and carry the congress
in your pocket.



→ SIMULTANEOUS SESSIONS 3 10 B T
08:00 – 09:15, Hall A

TARGETED THERAPIES IN RELAPSED IN CHRONIC LYMPHO-CYTIC LEUKEMIA

Chairs: To be announced
A Kater (Lymphoma and Myeloma Center, Academic Medical Center Amsterdam, University of Amsterdam, the Netherlands)

08:00 – 08:15
S769 **IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHO-CYTIC LEUKEMIA: UPDATED EFFICACY AND SAFETY OF THE RESONATE STUDY WITH UP TO FOUR YEARS OF FOLLOW-UP**
C Moreno¹ (¹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

08:15 – 08:30
S770 **THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY**
P Hillmen¹ (¹University of Leeds, Leeds, United Kingdom)

08:30 – 08:45
S771 **VENETOCLAX IN RELAPSED/REFRACTORY CHRONIC LYMPHO-CYTIC LEUKEMIA (CLL) WITH 17P DELETION: OUTCOME AND MINIMAL RESIDUAL DISEASE FROM THE FULL POPULATION OF THE PIVOTAL M13-982 TRIAL**
S Stilgenbauer¹ (¹University of Ulm, Ulm, Germany)

08:45 – 09:00
S772 **CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL**
L Nastoupil¹ (¹MD Anderson Cancer Center, Houston, United States)

09:00 – 09:15
S773 **THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES COMPLETE INHIBITION OF SYK AND JAK AND RAPID TUMOR RESPONSES IN A PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES**
P Hamlin¹ (¹Memorial Sloan Kettering Cancer Center, New York, United States)

→ SIMULTANEOUS SESSIONS 3 C
08:00 – 09:15, Hall C

FOLLICULAR LYMPHOMA – CLINICAL

Chairs: D Caballero (University Hospital, Salamanca, Spain)
I Aurer (University Hospital Centre Zagreb, Croatia)

08:00 – 08:15
S774 **COMPARISON OF CONTRAST-ENHANCED CT-BASED RESPONSE WITH PET ASSESSMENT AFTER FIRST-LINE THERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY**
J Trotman¹ (¹Concord Repatriation General Hospital, University of Sydney, Sydney, Australia)

08:15 – 08:30
S775 **IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL) IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN**
W Hiddemann¹ (¹Ludwig-Maximilians-University Munich, Munich, Germany)

08:30 – 08:45
S776 **EFFICACY AND SAFETY OF COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE CHRONOS-1 STUDY**
PL Zinzani¹ (¹Institute of Hematology “L. e A. Seràgnoli”- University of Bologna, Bologna, Italy)

08:45 – 09:00
S777 **DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY FOLLICULAR LYMPHOMA**
PL Zinzani¹ (¹University of Bologna, Bologna, Italy)

09:00 – 09:15
S778 **13-YR FOLLOW UP OF MULTICENTER RANDOMIZED CHOP-R VS R-HDS TRIAL IN HIGH RISK FOLLICULAR LYMPHOMA PATIENTS: PROLONGED SURVIVAL AND HIGH RATE OF LONG-TERM DISEASE FREE SURVIVORS**
C Tarella^{26,29} (²⁶University of Milan, Milano, Italy, ²⁹European oncology Institute, Milano, Italy)

→ SIMULTANEOUS SESSIONS 3 C
08:00 – 09:15, Hall D

CHANGING THE STRATEGY OF THERAPY IN MULTIPLE MYELOMA

Chairs: JF San-Miguel (Universidad de Navarra, Pamplona, Spain)
H Ludwig (Wilhelminen Cancer Research Institute, Vienna, Austria)

08:00 – 08:15
S779 **PHASE II TRIAL OF COMBINATION OF ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA**
I Ghobrial¹ (¹Dana-Farber Cancer Institute, Boston, United States)

08:15 – 08:30

- S780 **TWICE-WEEKLY IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP DATA FOR PATIENTS WHO DID NOT UNDERGO STEM CELL TRANSPLANTATION (SCT)**
P Richardson¹ (¹Dana-Farber Cancer Institute, Boston, United States)

08:30 – 08:45

- S781 **LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY**
C Pawlyn¹ (¹The Institute of Cancer Research, London, United Kingdom)

08:45 – 09:00

- S782 **COMPARISON OF DENOSUMAB (DMB) WITH ZOLEDRONIC ACID (ZA) FOR THE TREATMENT OF BONE DISEASE IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; AN INTERNATIONAL, RANDOMIZED, DOUBLE BLIND TRIAL**
E Terpos¹ (¹National and Kapodistrian University of Athens, School of Medicine, Athens, Greece)

09:00 – 09:15

- S783 **PEMBROLIZUMAB PLUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY AND BIOMARKER RESULTS FROM THE PHASE 1 KEYNOTE-023 STUDY**
P Rodriguez Otero¹ (¹Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, IDISNA, CIBERONC, Pamplona, Spain)

→ SIMULTANEOUS SESSIONS

2 10 T C

08:00 – 09:15, Hall E

OLD AND NEW DRUGS IN MPN

- Chairs: E Gottlieb (Technion, Israel Institute Of Technology, Haifa, Israel)
M Griesshammer (Johannes Wesling Medical Center Minden, UKRUB, University of Bochum, Minden, Germany)

08:00 – 08:15

- S784 **RUXOLITINIB FOR THE TREATMENT OF INADEQUATELY CONTROLLED POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY: 80-WEEK FOLLOW-UP FROM THE RESPONSE-2 TRIAL**
M Greisshammer¹ (¹Johannes Wesling Clinic, Minden, Germany)

08:15 – 08:30

- S785 **PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY**
JR Gotlib¹ (¹Stanford University Medical Center, Stanford, United States)

08:30 – 08:45

- S786 **PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY**
C Harrison¹ (¹Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom)

08:45 – 09:00

- S787 **MOLECULAR RESPONSE TO HYDROXYUREA AND ROPEGINTERFERON ALFA-2B IN THE PROUD-PV RANDOMIZED PHASE 3 TRIAL**
JJ Kiladjian^{1, 2, 3} (¹Hopital Saint-Louis, Paris, France, ²INSERM UMRS-1131, Paris, France, ³Paris Diderot University, Paris, France)

09:00 – 09:15

- S788 **POOLED SURVIVAL ANALYSIS OF MIDOSTAURIN CLINICAL STUDY DATA (D2201 + A2213) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM) COMPARED WITH HISTORICAL CONTROLS**
A Reiter¹ (¹University Medical Centre Mannheim, Mannheim, Germany)

→ SIMULTANEOUS SESSIONS

2 4 9 10 T C

08:00 – 09:15, Room N101

CHILDHOOD AND MORE INTENSIVE TREATMENT OF AML

- Chairs: C Craddock (Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom)
J Sierra (Hospital de la Santa Creu i Sant Pau Autonomous University of Barcelona, Spain)

08:00 – 08:15

- S789 **LOW-DOSE CYTARABINE TREATMENT IN CHILDREN WITH DOWN SYNDROME AND TRANSIENT MYELOPROLIFERATIVE DISORDER TO PREVENT ML-DS: AML-BFM TMD PREVENTION 2007 STUDY**
M Flasiński¹ (¹Hannover Medical School, Hannover, Germany)

08:15 – 08:30

- S790 **FINAL RESULTS OF THE CETLAM LAM-2003 TRIAL FOR THE TREATMENT OF PRIMARY AML UP TO THE AGE OF 70**
A Garrido¹ (¹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

08:30 – 08:45

- S791 **MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY**
C Craddock¹ (¹University of Birmingham, Birmingham, United Kingdom)

08:45 – 09:00

- S792 **SORAFENIB MAINTENANCE IN FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANT**
B Oran¹ (¹UNIVERSITY OF TEXAS, MD ANDERSON CANCER CENTER, Houston, United States)

09:00 – 09:15

- S793 **A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)**
MY Levy¹ (¹Baylor University Medical Center, Dallas, TX, United States)

→ SIMULTANEOUS SESSIONS

4 9 C

08:00 – 09:15, Room N105

STEM CELL TRANSPLANTATION - CLINICAL 2

Chairs: T Ruutu (Clinical Research Institute, Helsinki University Hospital, Finland)
To be announced

08:00 – 08:15

- S794 **21-COLOR FLOW CYTOMETRY REVEALS IMMUNOPHENOTYPES ASSOCIATED WITH RESPONSE IN ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) PATIENTS TREATED WITH THE JANUS KINASE (JAK) INHIBITOR INCB039110 (ITACITINIB)**
K Staser¹ (¹Washington University in Saint Louis, Saint Louis, United States)

08:15 – 08:30

- S795 **GUT COLONIZATION BY MULTI-DRUG RESISTANT BACTERIA IS AN INDEPENDENT RISK FACTOR FOR DEVELOPMENT OF INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE**
Z Peric¹, ² (¹University Hospital Centre Zagreb, Zagreb, Croatia, ²School of Medicine, University of Zagreb, Zagreb, Croatia)

08:30 – 08:45

- S796 **IMPACT OF HLA DISPARITY ON OUTCOME IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION FOLLOWED BY HIGH DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE**
L Giannoni¹ (¹IRCCS AOU San Martino IST, Genoa, Italy)

08:45 – 09:00

- S797 **CYCLOPHOSPHAMIDE VERSUS ETOPOSIDE IN COMBINATION WITH TOTAL BODY IRRADIATION AS CONDITIONING FOR ADULTS WITH PH(-) ALL UNDERGOING ALLO-HCT. A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT**
S Giebel¹ (¹Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland)

09:00 – 09:15

- S798 **ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH DELETION 5Q OR MONOSOMY 5: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY (ALWP) OF THE EBMT**
X Poiré¹ (¹Cliniques Universitaires St-Luc, Brussels, Belgium)

→ SIMULTANEOUS SESSIONS

3 5 9 10 B T

08:00 – 09:15, Room N103

BIOMARKERS IN ALL

Chairs: J Trka (CLIP - Childhood Leukaemia Investigation Prague, Second Faculty of Medicine, Charles University, Prague, Czech Republic)
JP Bourquin (University Children's Hospital, Zurich, Switzerland)

08:00 – 08:15

- S799 **IDENTIFICATIONS OF NOVEL RECURRENT PU.1 FUSIONS WITH HIGHLY AGGRESSIVE PHENOTYPE IN PEDIATRIC T CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
M Seki¹ (¹The University of Tokyo Hospital, Tokyo, Japan)

08:15 – 08:30

- S800 **PROGNOSTIC IMPACT OF ADDITIONAL MOLECULAR LESIONS IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)**
S Chiaretti¹ (¹Sapienza University, Rome, Italy)

08:30 – 08:45

- S801 **MULTI-CENTER VALIDATION OF STANDARDIZED NGS ASSAYS FOR REARRANGED IG / TR MARKER DETECTION IN ACUTE LYMPHOBLASTIC LEUKEMIA - A REPORT OF THE EUROCLONALITY-NGS CONSORTIUM**
M Brüggemann¹ (¹University Hospital Schleswig-Holstein, Kiel, Germany)

08:45 – 09:00

- S802 **POST-INDUCTION MRD PREDICTS HIGH RELAPSE RISK FOLLOWING REDUCED INTENSITY CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION: A PROSPECTIVE STUDY OF ADULT ALL (UKALL14, ISRCTN 66541317)**
D Okasha¹, ² (¹Cancer Institute, UCL, London, United Kingdom, ²Faculty of Medicine, Alexandria University, Alexandria, Egypt)

09:00 – 09:15

- S803 **T-CELL RECEPTOR δ (TRB) REPERTOIRE CHARACTERISTICS IN RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) ON BLINATU-MOMAB TREATMENT.**
M Kotrova¹, ² (¹contributed equally, Kiel, Germany, ²Laboratory for Hematological Diagnostics, University Hospital Schleswig-Holstein, Kiel, Germany)

→ SIMULTANEOUS SESSIONS

1 2 3 4 8 C

08:00 – 09:15, Room N104

INFECTIOUS DISEASES, SUPPORTIVE CARE

Chairs: M von Lilienfeld-Toal (Universitätsklinikum Jena, Germany)
J Canaani (Chaim Sheba Medical Center, Tel Hashomer, Israel)

08:00 – 08:15

S804 **DISCONTINUING ANTIBACTERIAL THERAPY AFTER APYREXIA AND CLINICAL STABILITY REGARDLESS OF NEUTROPHIL COUNT IN FEBRIL NEUTROPENIA IS SAFE AND REDUCES EXPOSITION TO ANTIBIOTICS (HOWLONG RANDOMIZED TRIAL)**

I Espigado¹ (Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain)

08:15 – 08:30

S805 **CONJUGATED PNEUMOCOCCAL VACCINE TRIGGERS A BETTER IMMUNE RESPONSE THAN POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA A RANDOMIZED STUDY BY THE SWEDISH CLL GROUP**

T Svensson¹ (Institution of Medical Sciences, Uppsala, Sweden)

08:30 – 08:45

S806 **INFECTION-RELATED MORTALITY (IRM) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AGE, CMV AND PRE-TRANSPLANT LEVELS OF IGA/IGM PREDICT IRM IN A NEW CLINICO-BIOLOGICAL SCORING SYSTEM**

A Forcina¹ (IRCCS San Raffaele Scientific Institute, Milan, Italy)

08:45 – 09:00

S807 **LETTERMOVIR (LET) FOR PREVENTION OF CYTOMEGALOVIRUS (CMV) INFECTION IN ADULT CMV-SEROPOSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)**

R Duarte¹ (Hospital Universitario Puerta de Hierro, Barcelona, Spain)

09:00 – 09:15

S808 **EFFICACY AND SAFETY OF DEFIBROTIDE TO TREAT HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) POST-CHEMOTHERAPY: A POST HOC ANALYSIS OF FINAL DATA OF AN EXPANDED-ACCESS PROTOCOL**

P Richardson² (Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States)

→ SIMULTANEOUS SESSIONS

1 7 8 B T C

08:00 – 09:15, Room N109

IRON: DEFICIENCY AND OVERLOAD

Chairs: A Iolascon (University of Naples Federico II, Italy)
C Camaschella (Vita-Salute San Raffaele University, Milan, Italy)

08:00 – 08:15

S809 **LACK OF THE FERROPTOSIS INHIBITOR GPX4 IN ERYTHROID CELLS CAUSES A BLOCK IN RETICULOCYTE MATURATION AND A HYPOXIC SIGNATURE WITH IMPAIRED HEPCLDIN REGULATION.**

S Altamura^{1, 2} (MMPU - Molecular Medicine Partnership Unit, Heidelberg, Germany, ²University of Heidelberg, Heidelberg, Germany)

08:15 – 08:30

S810 **IDENTIFICATION OF GUANOSINE 5D-DIPHOSPHATE AS POTENTIAL IRON MOBILIZER: PREVENTING THE HEPCLDIN-FERROPORTIN INTERACTION AND MODULATING THE INTERLEUKIN-6/STAT-3 PATHWAY**

S Angmo¹ (National Agri Food Biotechnology, Mohali, India)

08:30 – 08:45

S811 **UNRAVELING THE MOLECULAR PATHOGENESIS OF INEFFECTIVE ERYTHROPOIESIS IN CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE II: IN VITRO EVALUATION OF RAP-011 TREATMENT**

G De Rosa¹ (CEINGE - Biotecnologie Avanzate, Naples, Italy)

08:45 – 09:00

S812 **INTRAVENOUS IRON VERSUS ORAL IRON VERSUS NO IRON WITH OR WITHOUT ERYTHROPOIESISSTIMULATING AGENTS (ESA) FOR CANCER PATIENTS WITH ANAEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS**

A Weigl¹ (University Hospital Cologne, Cologne, Germany)

09:00 – 09:15

S813 **DIFFERENT IRON SOURCES AND ACQUISITION PATHWAYS SHAPE MACROPHAGES TOWARDS OPPOSING FUNCTIONAL PHENOTYPES**

F Vinchi¹ (University of Heidelberg & EMBL, Heidelberg, Germany)

→ SIMULTANEOUS SESSIONS

2 3 4 5 9 10 C

08:00 – 09:15, Room N111

GENE THERAPY, CELLULAR IMMUNOTHERAPY AND VACCINATION 2

Chairs: H Dolstra (Radboudumc, Nijmegen, the Netherlands)
JM Almeida (University of Salamanca, Spain)

08:00 – 08:15

S814 A PHASE 3 STUDY TO EVALUATE SAFETY AND EFFICACY OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT β -THALASSEMIA IN PATIENTS WITH NON- β 0/ β 0 GENOTYPES: THE NORTHSTAR-2 (HGB-207) TRIAL

M Walters¹ (¹UCSF Benioff Children's Hospital and Research Center, Oakland, United States)

08:15 – 08:30

S815 CIS IS A POTENT CHECKPOINT IN NK CELL ANTI-LEUKEMIA IMMUNITY

N Huntington¹ (¹Walter and Eliza Hall, Parkville, Australia)

08:30 – 08:45

S816 GENERATION OF MEMORY STEM T CELLS (TSCM) MODIFIED WITH A NOVEL OPTIMIZED CD30-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) FOR THE TREATMENT OF CD30+ T-CELL MALIGNANCIES

L Escribà-Garcia¹ (¹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

08:45 – 09:00

S817 MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF STEROID-RESISTANT ACUTE GRAFT VERSUS HOST DISEASE: FACTORS INFLUENCING CLINICAL RESPONSES

A Galleu¹ (¹King's College London, London, United Kingdom)

09:00 – 09:15

S818 CARD9 CONTROLS DECTIN-1-INDUCED T-CELL CYTOTOXICITY AND TUMOR GROWTH IN MICE

T Haas¹ (¹Klinikum rechts der Isar, TU München, München, Germany)

→ EDUCATION SESSION

3 10 **B T C**

09:30 - 11:00, Hall A

Repeated from:

Saturday, June 24, 09:45 - 11:15, Hall B

CHRONIC LYMPHOCYTIC LEUKEMIA

Chair: B Eichhorst (University Clinic of Cologne, Germany)

- **Relevance of microenvironment in CLL**

F Caligaris-Cappio (Italian Association for Cancer Research, Milan, Italy)

- **Prognostic factors in CLL: When, which and how?**

S Pospisilova (Masaryk University and University Hospital Brno, Czech Republic)

- **Prioritisation therapies in CLL**

C Wendtner (Klinikum Schwabing, Munich, Germany)

LEARNING GOALS

F Caligaris-Cappio

After attending this lecture, the participant will be able to

- Describe how malignant CLL cells entail a bi-directional dialogue with a host of non-malignant elements within the microenvironment.
- Describe the key cellular elements in the microenvironment.

- Describe how cell-cell interactions favour malignant cell growth, survival and prevent anti-tumour response.

S Pospisilova

After attending this lecture, the participant will be able to

- Describe the biological and clinical factors applicable in CLL prognostication.
- Define the predictive markers currently used for therapy response assessment in CLL patients.
- Indicate the timepoints when the prognostic and predictive factors should be analyzed during the disease course.

C Wendtner

After attending this lecture, the participant will be able to

- For CLL patients we have to prioritize treatment options based on clinical and novel molecular markers.
- Chemotherapy remains the standard-of-care for the majority of CLL patients in the frontline setting.
- Novel drugs like ibrutinib, idelalisib and venetoclax are nowadays treatment standards for CLL patients with relapsed/refractory disease.

→ EDUCATION SESSION

3 **B T C**

09:30 - 11:00, Hall C

Repeat Session:

Sunday, June 25, 11:15 - 12:45, Hall C

AGGRESSIVE LYMPHOMA

Chair: S Rule (Plymouth University Peninsula Schools of Medicine and Dentistry, United Kingdom)

- **The biological basis of aggressive lymphoma**

E Campo (Hospital Clínic, Barcelona, Spain)

- **Relapsed aggressive lymphoma: Can we optimize the therapy**

G Salles (Hospices Civils de Lyon - Université Claude Bernard, Pierre Benite, France)

- **Treatment of aggressive lymphomas focused on elderly patients**

M Pfreundschuh (Saarland University Medical School, Homburg (Saar), Germany)

LEARNING GOALS

E Campo

After attending this lecture, the participant will be able to

- Understand the biological heterogeneity of aggressive mature B-cell lymphomas and recognize its clinical impact.
- Describe the main molecular features that may be of clinical interest in aggressive mature B-cell lymphomas.

G Salles

After attending this lecture, the participant will be able to

- Describe the population heterogeneity and prognostic factors of patient with relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
- Discuss the current management strategies of patients with R/R DLBCL, their indications, their results and their limitations.
- Describe the different developments of innovative approaches in

R/R DLBCL, including targeted therapies, new antibodies, and CAR-T cells.

M Pfreundschuh

After attending this lecture, the participant will be able to

- Describe the biological and clinical peculiarities of elderly patients with aggressive lymphomas.
- Discuss treatment options for elderly patients who may or may not be candidates for standard treatment.
- Select the appropriate treatment based upon patient's individual characteristics, comorbidities and the specific biology of his/her aggressive lymphoma.
- Provide specific supportive measures that increase the patient's tolerability for the treatment.

→ SCIENTIFIC WORKING GROUPS

2 4 B T C

09:30 - 10:30, Hall D

CHRONIC MYELOID LEUKEMIA: ELN-EHA-SWG ON CML

Chair: R Hehlmann (Medizinische Fakultät Mannheim Universität Heidelberg, Mannheim, Germany)

- **Prognostic indicators of successful TKI-discontinuation**
FX Mahon (France)
- **HSCT for CML: The fine tuned balance between transplantation and disease risks**
A Gratwohl (University of Basel, Switzerland)
- **The role of the bone marrow microenvironment in CML**
D Krause (Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany)
- **The CML 'omics of initiation, progression, and response**
J Radich (Fred Hutchinson Cancer Research Center, Seattle, USA)

LEARNING GOALS

FX Mahon

An up-to-date program is available via the mobile app.

A Gratwohl

After attending this lecture, the participant will be able to

- Describe the specific disease, patient, donor and environment related risks of HSCT.
- As patient: know the conditions, when HSCT is an optimal treatment option, when not.
- As physician: recognize the trigger points to initiate/continue the HSCT process.
- As health care organization: improve the deficiencies in the longitudinal treatment path for CML patients who qualify for HSCT.

D Krause

After attending this lecture, the participant will be able to

- Describe the physiology of the bone marrow microenvironment in health and disease.
- Describe the pathophysiology of the bone marrow microenvironment in chronic myeloid leukemia.
- Describe strategies to target the bone marrow microenvironment in chronic myeloid leukemia.

J Radich

After attending this lecture, the participant will be able to

- Understand the genetic differences between chronic and blast phase chronic myeloid leukemia.
- Appreciate the similarities and differences between treatment resistance and disease progression.

→ EDUCATION SESSION

2 4 B T C

09:30 - 11:00, Hall E

Repeat Session:

Sunday, June 25, 11:15 - 12:45, Hall E

MYELOYDYSPLASTIC SYNDROMES

Chair: P Fenaux (Hôpital St Louis, Paris, France)

- **Clonal evolution in MDS**
J Jansen (Radboud UMC, Nijmegen, the Netherlands)
- **The role of immune response in MDS pathophysiology**
G Mufti (Kings College, London, United Kingdom)
- **Indications for transplantation in MDS**
MG Della Porta (Cancer Center - Humanitas Research Hospital & Humanitas University, Milan, Italy)

LEARNING GOALS

J Jansen

After attending this lecture, the participant will be able to

- Describe the concept of linear and branched evolution of subclones in MDS.
- Understand the effect of disease modifying therapy on clonal evolution and resistance to therapy in MDS.
- Discuss the significance of clonal hematopoiesis of indeterminate potential (CHIP).

G Mufti

After attending this lecture, the participant will be able to

- The role of immune system in MDS pathophysiology and genomic instability.
- The importance of immune-signature "switch" in disease progression.

MG Della Porta

After attending this lecture, the participant will be able to

- Provide a basis to select candidate patients based on both disease and patient-related factors.
- Provide a basis to define optimal timing of transplantation in individual patient.
- Discuss the use of hypomethylating agents as part of a comprehensive strategy to prevent relapse after transplantation in high risk patients.
- Discuss the clinical utility of somatic mutations in MDS transplantation decision-making.

→ EDUCATION SESSION 2 5 9 10 T C

09:30 - 11:00, Room N101

Repeated from:

Saturday, June 24, 09:45 - 11:15, Hall C

ACUTE MYELOID LEUKEMIA

Chair: G Ossenkopppe (VU University Medical Center, Amsterdam, the Netherlands)

- **Molecular diagnostics in AML**
L Bullinger (University Hospital of Ulm, Germany)
- **Targeting mutated FLT3 in AML**
M Levis (Johns Hopkins University, Phoenix, USA)
- **3+7 and beyond**
N Vey (Institut Paoli Calmettes, Marseille, France)

LEARNING GOALS

L Bullinger

After attending this lecture, the participant will be able to

- There is a growing need to implement novel next-generation-sequencing (NGS) based gene panel diagnostic tools to rapidly capture inter- and intra-individual disease heterogeneity.
- Future technological developments will enable genome-wide comprehensive genomic, epigenomic and transcriptomic characterization of the disease (at single cell level), but for now these approaches are reserved for research questions.
- Molecular genomics have started to inform patient care with regard to improved disease classification and risk prediction (knowledge databases), MRD monitoring and guiding targeted therapeutic approaches.

M Levis

After attending this lecture, the participant will be able to

- Identify the subsets of AML patients that might benefit from FLT3 inhibition
- Describe the different points in AML therapy where FLT3 inhibitors are likely to be incorporated.
- Discuss the different potential roles for selective versus non-selective FLT3 inhibitors.

N Vey

After attending this lecture, the participant will be able to

- Describe current and emerging therapies for patients with AML.
- Describe the main mechanisms of action of current new drugs and the rationale for their combination.
- Discuss how emerging therapies might be combined to or replace 3+7.

→ EHA - INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS JOINT SYMPOSIUM 1 6 T C

09:30 - 10:30, Room N105

ANTICOAGULATION IN DIFFICULT PATIENTS

Chairs: W Ageno (University of Insubria, Varese, Italy)
S Eichinger (Medical University of Vienna, Austria)

Introduction

F Rodeghiero (Hematology Project Foundation / Fondazione Progetto Ematologia, Vicenza, Italy)

Anticoagulation in the frail patient

PW Kamphuisen (Tergooi Hospital, Hilversum, the Netherlands)

Epidemiology and management of venous thrombosis in unusual sites

W Ageno (University of Insubria, Varese, Italy)

LEARNING GOALS

PW Kamphuisen

After attending this lecture, the participant will be able to

- Describe current and newer anticoagulant therapies for older patients.
- Discuss risk factors for bleeding in frail patients.
- Select appropriate dose and type of therapy based upon patient characteristics and comorbidity.

W Ageno

After attending this lecture, the participant will be able to

- Identify the most prevalent and clinically relevant risk factors for thrombosis in unusual sites.
- Select appropriate treatment strategies for the management of patients with acute thrombosis in unusual sites.
- Decide appropriate treatment durations and long-term management strategies.

→ BASIC-SCIENCE-IN-FOCUS 1 2 B T

09:30 - 10:30, Room N103

HEMATOPOIETIC STEM CELLS AND THE MICROENVIRONMENT

Chair: N Taylor (Institut de Genetique Moleculaire de Montpellier, France)

Manipulating dormancy of HSC

M Essers (HI-STEM gGmbH / DKFZ, Heidelberg, Germany)

Leukemic stem cell interactions with their microenvironment in AML

D Bonnet (The Francis Crick Institute, London, United Kingdom)

LEARNING GOALS

M Essers

After attending this lecture, the participant will be able to

- Inflammation induces emergency megakaryopoiesis through the activation of haematopoietic stem cell-like megakaryocyte progenitors (SL-MkPs).
- Lineage commitment of haematopoietic stem cells is a continuous process.
- The bone marrow niche plays an important role in stress-induced activation of HSCs in vivo.

D Bonnet

After attending this lecture, the participant will be able to

- Define HSC niche and discuss the complexity of the niche.
- Describe the potential roles niche might play in leukemia development.

- Discuss potential avenues to target leukemia via interfering with niche components.

→ BASIC-SCIENCE-IN-FOCUS 3 B T C
09:30 - 10:30, Room N104

VACCINES & ANTIBODIES

Chair: M Subklewe (LMU-University Hospital Munich, Germany)

- **The use of antibodies to redirect T-cells in the treatment of leukemia and lymphoma**

D Maloney (Fred Hutchinson Cancer Research Center, Seattle, USA)

- **Immunotherapy of hematological malignancies using dendritic cell vaccines**

H Dolstra (Radboud UMC, Nijmegen, the Netherlands)

LEARNING GOALS

D Maloney

After attending this lecture, the participant will be able to

- Describe the structures critical for the development of chimeric antigen receptors.
- Understand the relationship between T-cell proliferation on efficacy and toxicity.

H Dolstra

After attending this lecture, the participant will be able to

- Describe current dendritic cell vaccine therapies for patients with myeloid malignancies.
- Discuss novel and innovative developments to improve dendritic cell vaccines.
- Discuss results of dendritic cell based therapies to boost immunity against hematological malignancies.

→ EDUCATION SESSION 5 7 10 B T C
09:30 - 11:00, Room N109
Repeat Session:
Sunday, June 25, 11:15 - 12:45, Room N109

CHALLENGES IN BLOOD TRANSFUSION

Chair: A Brand (Leiden University Medical Centre & Sanquin blood supply, the Netherlands)

- **Cell-derived microvesicles and microparticles in blood components: Consequences for transfusion recipients**
- T Burnouf (Taipei Medical University, Taiwan)
- **Challenges in typing and matching strategies in patients with hematological malignancies in the era of immunotherapy**

KMK de Vooght (University Medical Center Utrecht, the Netherlands)

- **Red blood cell transfusion: When to transfuse in patients with hematological malignancies?**

M Lozano (University Clinic Hospital, Barcelona, Spain)

LEARNING GOALS

T Burnouf

Participants should be able to realize that

- Extracellular vesicles (EVs) are present in abundance in collected blood since they are released in the circulation by platelets, red and white cells as well as from the endothelium upon activation or as a result of apoptosis.
- The amount of EVs is also largely dependent on the component preparation and storage methods and that the impact of pathogen inactivation methods should be studied with respect to EV content and types.
- EVs play a controversial role in transfusion and often exhibit potent pro-thrombotic and inflammatory potentials.
- Pre-clinical and clinical studies should objectively delineate EV role and possible pathological implications.

KMK de Vooght

After attending this lecture, the participant will be able to

- Describe the impact of CD38 monoclonal antibodies on blood bank serologic testing.
- Discuss strategies to mitigate the impact of these antibodies on serologic testing.
- Evaluate options to provide optimal transfusion support for patients on anti-CD38 therapy.

M Lozano

After attending this lecture, the participant will be able to

- Describe the current evidence to indicate red blood cell transfusion in different patient populations.
- Discuss the particular challenges that the patients with hematological malignancies pose when indicating a red blood cell transfusion.
- Select the hemoglobin threshold for red blood cell transfusion for patients with hematological malignancies based on the available evidence.

→ EDUCATION SESSION 1 4 7 B T C
09:30 - 11:00, Room N111
Repeat Session:
Sunday, June 25, 11:15 - 12:45, Room N111

ACQUIRED PROBLEMS IN RED CELLS

Chair: S Menzel (King's College London, United Kingdom)

- **Transferrin and TfR1 in co-regulation of erythropoiesis and iron metabolism**

Y Ginzburg (Icahn School of Medicine at Mount Sinai, New York, USA)

- **Iron overload before, during and after bone marrow transplantation**

E Angelucci (Ospedale Oncologico di Riferimento Regionale "A. Businco", Cagliari, Italy)

- **Heat Shock Protein 70 (HSP70), one of the major key factors in Diamond-Blackfan anemia**

L Da Costa (France)

LEARNING GOALS

Y Ginzburg

After attending this lecture, the participant will be able to

- Identify disease characteristics commonly found in β -thalassemia.

- Describe the mechanisms regulating iron availability for and utilization during erythropoiesis in physiologic and pathologic conditions.
- Understand the compensatory role of exogenous transferrin and effects on TfR1 in ineffective erythropoiesis.

E Angelucci

After attending this lecture, the participant will be able to

- Recognize principal iron toxicity mechanisms.
- Make a correct diagnosis of iron overload and identify patients at risk of iron toxicity before and during hemopoietic cell transplantation.
- Minimize iron toxicity in the setting of hemopoietic cell transplantation.
- Diagnosis and treat iron overload after hemopoietic cell transplantation.

L Da Costa

An up-to-date program is available via the mobile app.

→ SCIENTIFIC WORKING GROUPS

3 5 9 C

09:30 - 10:30, Room N113

ESLHO-EUOMRD AND ESLHO-EUROFLOW: EUROFLOW: HIGH THROUGHPUT FLOWCYTOMETRY IN HEMATO-ONCOLOGY

Chair: JJM van Dongen (Leiden University Medical Center (LUMC), the Netherlands)

- **Introduction: EuroFlow strategies for high throughput flowcytometry**
JJM van Dongen (Leiden University Medical Center (LUMC), the Netherlands)
- **Reference data bases for automated gating strategies in flowcytometric diagnosis and monitoring of hematological malignancies**
A Orfao (University of Salamanca, Spain)
- **Rapid flowcytometric diagnosis of acute leukemias: application of the EuroFlow ALOT data base**
L Lhermitte (France)
- **Fast, sensitive and standardized flowcytometric monitoring of multiple myeloma**
JA Flores-Montero (University of Salamanca, Cancer Research Center, Spain)

LEARNING GOALS

A Orfao

After attending this lecture, the participant will be able to

- Understand the way flow cytometric data bases for automated gating are constructed and used in routine laboratory diagnostics in onco-hematology.
- Recognize the need for full standardization of the flow cytometric procedures and how to reach it.
- Select specific data bases for the diagnosis and monitoring of distinct hematologic malignancies.

L Lhermitte

An up-to-date program is available via the mobile app.

JA Flores-Montero

After attending this lecture, the participant will be able to

- Understand the strengths of the EuroFlow flowcytometric approach for monitoring of multiple myeloma and identify the comparative advantages of this methodology over conventional flow cytometry and current molecular methods
- Discuss how the approach satisfies current requirements for the efficient follow-up of myeloma patient after treatment.

→ BASIC-SCIENCE-IN-FOCUS

1 2 3 B T

09:30 - 10:30, Room N115

METABOLOMICS AND LEUKEMIA

Chair: V Sexl (Pharmacology and Toxicology, Vienna, Austria)

- **Metabolic dependencies of leukemic stem cells**
E Gottlieb (Technion, Israel Institute Of Technology, Haifa, Israel)
- **Metabolomics and macrophages**
M Müschen (Beckman Research Institute, Pasadena, USA)

LEARNING GOALS

E Gottlieb

After attending this lecture, the participant will be able to

- Have a general understanding of the role of metabolic alterations in supporting tumorigenesis.
- Appreciate metabolic traits that are associated with leukemic stem cells.
- Realize potential therapeutic approaches that capitalize on metabolic vulnerabilities of cancer.

M Müschen

After attending this lecture, the participant will be able to

- Understand the role of transcription factors in B cell vs myeloid lineage commitment and differentiation.
- Describe how B-lymphoid and myeloid transcription factors regulate glucose uptake and energy metabolism in opposite directions.
- Understand the mechanistic basis of why glucocorticoids only work in B-lymphoid but not myeloid malignancies.
- Appreciate the role of B-lymphoid transcription factors as metabolic gatekeepers by restricting the amount of energy available.

→ LATE BREAKING ORAL SESSION

11:15 - 12:45, Hall A

The best abstracts selected from the late breaking abstract submission are presented during this oral session.

A complete session overview is available via the mobile app or the online program at ehaweb.org

→ EDUCATION SESSION **3 B T C**
11:15 - 12:45, Hall C
Repeated from:
Sunday, June 25, 09:30 - 11:00, Hall C

AGGRESSIVE LYMPHOMA

Chair: S Rule (Plymouth University Peninsula Schools of Medicine and Dentistry, United Kingdom)

- **The biological basis of aggressive lymphoma**
E Campo (Hospital Clinic, Barcelona, Spain)
- **Relapsed aggressive lymphoma: Can we optimize the therapy**
G Salles (Hospices Civils de Lyon - Université Claude Bernard, Pierre Benite, France)
- **Treatment of aggressive lymphomas focused on elderly patients**
M Pfreundschuh (Saarland University Medical School, Homburg (Saar), Germany)

LEARNING GOALS

E Campo

After attending this lecture, the participant will be able to

- Understand the biological heterogeneity of aggressive mature B-cell lymphomas and recognize its clinical impact.
- Describe the main molecular features that may be of clinical interest in aggressive mature B-cell lymphomas.

G Salles

After attending this lecture, the participant will be able to

- Describe the population heterogeneity and prognostic factors of patient with relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
- Discuss the current management strategies of patients with R/R DLBCL, their indications, their results and their limitations.
- Describe the different developments of innovative approaches in R/R DLBCL, including targeted therapies, new antibodies, and CAR-T cells.

M Pfreundschuh

After attending this lecture, the participant will be able to

- Describe the biological and clinical peculiarities of elderly patients with aggressive lymphomas.
- Discuss treatment options for elderly patients who may or may not be candidates for standard treatment.
- Select the appropriate treatment based upon patient's individual characteristics, comorbidities and the specific biology of his/her aggressive lymphoma.
- Provide specific supportive measures that increase the patient's tolerability for the treatment.

→ EDUCATION SESSION **3 5 10 T C**
11:15 - 12:45, Hall D
Repeated from:
Saturday, June 24, 08:00 - 09:30, Hall B

MULTIPLE MYELOMA

Chair: A Alegre (Hospital Universitario de La Princesa, Madrid, Spain)

- **Immunopathology of MM**
N Munshi (Dana-Farber Cancer Institute, Boston, USA)
- **Genetic classification of myeloma for prognostication and treatment selection**
H Avet-Loiseau (IUC-Oncopole, Toulouse, France)
- **New treatment approaches in myeloma in 2017**
JF San-Miguel (Universidad de Navarra, Pamplona, Spain)

LEARNING GOALS

N Munshi

After attending this lecture, the participant will be able to

- Describe the immune status in multiple myeloma.
- Discuss the impact of immune dysfunction on myeloma cell growth and survival.
- Elucidate various methods and mechanisms to augment immune function for potential therapeutic application.

H Avet-Loiseau

After attending this lecture, the participant will be able to

- Understand the genetic heterogeneity in myeloma.
- Know what main prognostic parameters are.
- Understand how these factors may influence treatment choices.

JF San-Miguel

After attending this lecture, the participant will be able to

- Better tools for diagnosis and monitoring treatment efficacy are being implemented.
- Early treatment and the use of more efficient drugs upfront prolong survival.
- The treatment goal is to find the best possible balance between efficacy, toxicity and cost, particularly at the time of relapse.

→ EDUCATION SESSION **2 4 B T C**
11:15 - 12:45, Hall E
Repeated from:
Sunday, June 25, 09:30 - 11:00, Hall E

MYELODYSPLASTIC SYNDROMES

Chair: P Fenaux (Hôpital Saint Louis, Paris, France)

- **Clonal evolution in MDS**
J Jansen (Radboud UMC, Nijmegen, the Netherlands)
- **The role of immune response in MDS pathophysiology**
G Mufti (Kings College, London, United Kingdom)
- **Indications for transplantation in MDS**
MG Della Porta (Cancer Center - Humanitas Research Hospital & Humanitas University, Milan, Italy)

LEARNING GOALS

J Jansen

After attending this lecture, the participant will be able to

- Describe the concept of linear and branched evolution of subclones in MDS.
- Understand the effect of disease modifying therapy on clonal evolution and resistance to therapy in MDS.
- Discuss the significance of clonal hematopoiesis of indeterminate potential (CHIP).

G Mufti

After attending this lecture, the participant will be able to

- The role of immune system in MDS pathophysiology and genomic instability.
- The importance of immune-signature “switch” in disease progression.

MG Della Porta

After attending this lecture, the participant will be able to

- Provide a basis to select candidate patients based on both disease and patient-related factors.
- Provide a basis to define optimal timing of transplantation in individual patient.
- Discuss the use of hypomethylating agents as part of a comprehensive strategy to prevent relapse after transplantation in high risk patients.
- Discuss the clinical utility of somatic mutations in MDS transplantation decision-making.

→ EDUCATION SESSION

11:15 - 12:45, Room N101

Repeated from:

Saturday, June 24, 09:45 - 11:15, Room N101

2 3 4 8 9 T C

FERTILITY PRESERVATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Chair: D Meirou (Sheba Medical Center, Tel Hashomer, Israel)

- The effects of chemotherapy and radiotherapy on reproduction
WH Wallace (University of Edinburgh, United Kingdom)
- What patients expect from hematologists
A Plate (Myeloma Patients Europe, Munich, Germany)
- Fertility preservation in female patients
CA Amorim (Université catholique de Louvain, Belgium)
- Fertility preservation in pre-pubertal and adult males
R Mitchell (University of Edinburgh, United Kingdom)

LEARNING GOALS

WH Wallace

After attending this lecture, the participant will be able to

- More high quality research is required to provide the evidence for impaired testicular and ovarian function after chemotherapy and radiation.
- Conditioning treatments for BMT that include chemotherapy and or radiotherapy are likely to impair gonadal function irrespective of the age of the patient at treatment.

- Radiotherapy to a field that includes the pelvis in females may impair uterine function with increased risk of miscarriage and preterm delivery.

A Plate

An up-to-date program is available via the mobile app.

CA Amorim

After attending this lecture, the participant will be able to

- Cite and outline currently available fertility preservation options.
- Select the most appropriate course of action according to disease type and treatment, as well as patient age.
- Describe recent advances and successes in oocyte and ovarian tissue cryopreservation.

R Mitchell

After attending this lecture, the participant will be able to

- Understand the key differences between the prepubertal and adult testis.
- Describe how cancer treatments can damage the prepubertal testis.
- Discuss the options available for fertility preservation in prepubertal and adolescent males.
- Describe the experimental approaches that are currently under investigation for young males at risk of infertility.

→ SCIENTIFIC WORKING GROUPS

11:45 - 12:45, Room N105

3 C

EUROPEAN RESEARCH INITIATIVE ON CHRONIC LYMPHOCYTIC LEUKEMIA (ERIC): A ROADMAP FOR CLL TREATMENT: WHAT TO CHOOSE AND WHY

Chair: M Doubek (University Hospital, Brno, Czech Republic)

- First-line therapy for CLL in 2017
A Tedeschi (Niguarda Cancer Center, Niguarda Hospital, Milan, Italy)
- New drugs for old? What is the role of B-cell receptor pathway inhibition in the front line therapy of CLL in 2017?
S Devereux (King's College Hospital, London, United Kingdom)
- Managing CLL patients after BCR inhibitor failure
JA Jones (The Ohio State University, Columbus, USA)

LEARNING GOALS

A Tedeschi

After attending this lecture, the participant will be able to

- Describe current clinical data and emerging therapies relating to management of treatment naive CLL.
- Select appropriate upfront therapy based upon biological features.
- Identify patients clinical characteristics that may influence treatment choice.

S Devereux

After attending this lecture, the participant will be able to

- Describe the currently available therapies for the front line therapy of CLL.
- Discuss the patient and disease related factors that influence the

selection of front line therapy for patients with CLL.

JA Jones

After attending this lecture, the participant will be able to

- Discuss the mechanisms and patterns of relapse among CLL patients progressing after BCR inhibitor treatment.
- Select appropriate relapse therapy based upon emerging clinical data.
- Describe investigational strategies for managing CLL patients after BCR inhibitor failure.

→ SCIENTIFIC WORKING GROUPS

2 4 B T C

11:45 - 12:45, Room N103

ACUTE MYELOID LEUKEMIA

Chair: G Ossenkoppele (VU University Medical Center, Amsterdam, the Netherlands)

- **Role of enhancers in the pathogenesis of AML**
R Delwel (Erasmus MC, Rotterdam, the Netherlands)

- **Harnessing T cells for immunotherapy of AML**
M Subklewe (LMU-University Hospital Munich, Germany)

LEARNING GOALS

R Delwel

- After attending this lecture, the participant will be able to
- Acute myeloid leukemia is a heterogeneous disease with distinct genetic defects associated with various responses to therapy.
 - AML with 3q26 aberrations overexpress the EVI1 oncogene and are among the cases with the worst outcome.
 - In 3q26 AMLs myeloid specific enhancers are reallocated near EVI1 causing its overexpression.

M Subklewe

- After attending this lecture, the participant will be able to
- Gain an overview of current concepts with bispecific antibodies for AML and the challenges in the clinical translation of these therapeutic strategies.

→ SCIENTIFIC WORKING GROUPS

5 6 C

11:45 - 12:45, Room N104

BLEEDING AND THROMBOSIS: ACQUIRED BLEEDING DISORDER EMERGENCIES

Chair: A Falanga (Hospital Papa Giovanni XXIII - Bergamo, Italy)

- **Hyperfibrinolysis in trauma induced coagulopathy**
C Longstaff (National Institute for Biological Standards and Control, South Mimms, United Kingdom)
- **Perioperative and emergency management of patients on direct oral anticoagulants (DOACs)**
H ten Cate (Maastricht University Medical Center, the Netherlands)
- **The coagulopathy of APL: Still a challenge?**
A Falanga (Hospital Papa Giovanni XXIII - Bergamo, Italy)

LEARNING GOALS

C Longstaff

After attending this lecture, the participant will be able to

- Understand what is meant by the terms fibrinolysis and hyperfibrinolysis.
- Appreciate the current thinking on how hyperfibrinolysis develops after trauma and how it is assessed.
- Better understand treatment options and their current limitations.

H ten Cate

After attending this lecture, the participant will be able to

- Understand the principles of peri-operative continuation or cessation of DOACs.
- Now when and how to apply laboratory testing for DOACs.
- Consider the need for antidotes.

A Falanga

After attending this lecture, the participant will be able to

- Learn about the pathogenesis and management of hyperfibrinolysis in trauma-induced coagulopathy.
- Learn about the perioperative and emergency management of patients on anticoagulant treatments with DOACs.
- Acquire the most recent insights in APL-associated coagulopathy epidemiology and treatment.

→ EDUCATION SESSION

5 7 10 B T C

11:15 - 12:45, Room N109

Repeated from:

Sunday, June 25, 09:30 - 11:00, Room N109

CHALLENGES IN BLOOD TRANSFUSION

Chair: A Brand (Leiden University Medical Centre & Sanquin blood supply, the Netherlands)

- **Cell-derived microvesicles and microparticles in blood components: Consequences for transfusion recipients**
T Burnouf (Taipei Medical University, Taiwan)
- **Challenges in typing and matching strategies in patients with hematological malignancies in the era of immunotherapy**
KMK de Vooght (University Medical Center Utrecht, the Netherlands)
- **Red blood cell transfusion: When to transfuse in patients with hematological malignancies?**
M Lozano (University Clinic Hospital, Barcelona, Spain)

LEARNING GOALS

T Burnouf

Participants should be able to realize that

- Extracellular vesicles (EVs) are present in abundance in collected blood since they are released in the circulation by platelets, red and white cells as well as from the endothelium upon activation or as a result of apoptosis.
- The amount of EVs is also largely dependent on the component preparation and storage methods and that the impact of pathogen inactivation methods should be studied with respect to EV content and types.

- EVs play a controversial role in transfusion and often exhibit potent pro-thrombotic and inflammatory potentials.
- Pre-clinical and clinical studies should objectively delineate EV role and possible pathological implications.

KMK de Vooght

After attending this lecture, the participant will be able to

- Describe the impact of CD38 monoclonal antibodies on blood bank serologic testing.
- Discuss strategies to mitigate the impact of these antibodies on serologic testing.
- Evaluate options to provide optimal transfusion support for patients on anti-CD38 therapy.

M Lozano

After attending this lecture, the participant will be able to

- Describe the current evidence to indicate red blood cell transfusion in different patient populations.
- Discuss the particular challenges that the patients with hematological malignancies pose when indicating a red blood cell transfusion.
- Select the hemoglobin threshold for red blood cell transfusion for patients with hematological malignancies based on the available evidence.

→ EDUCATION SESSION

1 4 7 **B T C**

11:15 - 12:45, Room N111

Repeated from:

Sunday, June 25, 09:30 - 11:00, Room N111

ACQUIRED PROBLEMS IN RED CELLS

Chair: S Menzel (King's College London, United Kingdom)

- **Transferrin and TfR1 in co-regulation of erythropoiesis and iron metabolism**
Y Ginzburg (Icahn School of Medicine at Mount Sinai, New York, USA)
- **Iron overload before, during and after bone marrow transplantation**
E Angelucci (Ospedale Oncologico di Riferimento Regionale "A. Businco", Cagliari, Italy)
- **Heat Shock Protein 70 (HSP70), one of the major key factors in Diamond-Blackfan anemia**
L Da Costa (France)

LEARNING GOALS

Y Ginzburg

After attending this lecture, the participant will be able to

- Identify disease characteristics commonly found in β -thalassemia.
- Describe the mechanisms regulating iron availability for and utilization during erythropoiesis in physiologic and pathologic conditions.
- Understand the compensatory role of exogenous transferrin and effects on TfR1 in ineffective erythropoiesis.

E Angelucci

After attending this lecture, the participant will be able to

- Recognize principal iron toxicity mechanisms.
- Make a correct diagnosis of iron overload and identify patients at risk of iron toxicity before and during hemopoietic cell transplantation.
- Minimize iron toxicity in the setting of hemopoietic cell transplantation.
- Diagnose and treat iron overload after hemopoietic cell transplantation.

L Da Costa

An up-to-date program is available via the mobile app.

→ BASIC-SCIENCE-IN-FOCUS

2 **B T**

11:45 - 12:45, Room N113

METHYLATION AND EPIGENETICS

Chair: K Gronbaek (Rigshospitalet, Copenhagen Ø, Denmark)

- **DNA methyltransferase 3A in normal and malignant hematopoiesis**
P Goodell (Baylor College of Medicine, Houston, USA)
- **Activating the immune system by DNA hypomethylating agents**
D De Carvalho (Princess Margaret Cancer Centre, Toronto, Canada)

LEARNING GOALS

P Goodell

After attending this lecture, the participant will be able to

- Understand how mutations in DNMT3A impact DNA methylation patterns in the genome.
- Understand some of the molecular mechanisms behind DNMT3A function that account for its mutation prevalence in hematologic malignancies.

D De Carvalho

An up-to-date program is available via the mobile app.

→ BASIC-SCIENCE-IN-FOCUS

2 3 9 **B T**

11:45 - 12:45, Room N115

MOUSE MODELS OF ACUTE LEUKEMIA

Chair: J Barata (Instituto de Medicina Molecular, Universidade de Lisboa, Portugal)

- **Infections as predisposing for childhood ALL - Lessons from mouse models**
A Borkhardt (Pediatric Oncology, -Haematology and Clinical Immunology, Düsseldorf, Germany)
- **Modeling the cellular origin of AML**
J Schwaller (University Children's Hospital Basel, Switzerland)

LEARNING GOALS

A Borkhardt

After attending this lecture, the participant will be able to

- Infectious theory of childhood acute lymphoblastic leukemia (ALL).
- Susceptibility to childhood ALL due to germline variations.
- Mouse models to study the complex interplay between inherited germline risk and postnatal infection.
- Infection-dependent versus infection-independent mouse models of ALL.

J Schwaller

After attending this lecture, the participant will be able to

- Functional cooperation of genetic alteration leading to AML.
- Possibilities and limitations of different AML mouse models.
- The role of the cellular origin for the biology of AML.

**→ SPECIAL SESSION**

13:00 - 14:30, Hall A

1 2 3 9 **B T C****PLENARY SESSION II**

Chair: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)

P Sonneveld, President Elect of EHA (Erasmus Medical Center, Rotterdam, the Netherlands)

- **What's new in myeloproliferative neoplasms?**

R Skoda (University Hospital Basel, Switzerland)

- **Hemophilia treatment: Navigating speed bumps on the innovation highway**

D Di Michele (National Institutes of Health, USA)

- **From biology to targeted therapies in chronic lymphocytic leukemia**

S Stilgenbauer (Ulm University, Germany)

LEARNING GOALS

R Skoda

After attending this lecture, the participant will be able to

- Understand the role of early molecular events in the initiation of myeloproliferative neoplasms.

D Di Michele

After attending this lecture, the participant will be able to

- Describe recent advances in knowledge and therapeutics that inform state of art approaches to the prevention of hemorrhagic complications associated with hemophilia A and B of all severities, and incorporate these strategies into their clinical practices.
- Understand the science behind our current understanding of how and why neutralizing antibodies to factor VIII (FVIII inhibitors) develop, as well as the new NIH research initiatives intended to generate a more complete and actionable understanding of FVIII immunogenicity.
- Discuss the disruptive technologies that currently drive the novel therapeutic pipeline for the treatment of individuals with FVIII inhibitors.

- Describe the resurgence of gene therapy and the progress toward a cure for hemophilia B.

S Stilgenbauer

After attending this lecture, the participant will be able to

- Understand biology underlying pathogenesis and progression of CLL.
- Describe current and emerging prognostic and predictive factors.
- Select appropriate therapy based on patient and disease characteristics.
- Discuss mechanisms conferring resistance to various treatment options.

**→ SPECIAL SESSION**

14:30 – 15:00, Hall A

BUSINESS MEETING

Chair: AR Green, President of EHA (Cambridge Institute for Medical Research, United Kingdom)

All EHA members are invited to the yearly EHA Business Meeting, where the EHA Board presents the highlights of the past year and looks ahead to EHA's future. Furthermore, the results of the nomination and ballot are presented and new Board members are installed in their positions.

E-POSTERS

E-POSTERS

On the next pages you can find the overview of E-posters. They have been categorized by abstract topic to allow for easy navigation. The E-posters can be viewed in the Poster Area on the E-poster screens as of Friday, June 23, 09:30 until Saturday, June 24, 19:00. All posters will be available on the EHA Learning Center. Delegates will have complimentary access after the Congress.

E-Poster Topics	From	To	Page
■ Acute lymphoblastic leukemia - Biology	E819	E834	183
■ Acute lymphoblastic leukemia - Clinical	E835	E863	183
■ Acute myeloid leukemia - Biology	E864	E905	185
■ Acute myeloid leukemia - Clinical	E906	E950	188
■ Aggressive Non-Hodgkin lymphoma - Clinical	E951	E973	191
■ Bleeding disorders (congenital and acquired)	E974	E979	192
■ Bone marrow failure syndromes incl. PNH - Clinical	E981	E988	193
■ Chronic lymphocytic leukemia and related disorders - Biology	E989	E1015	193
■ Chronic lymphocytic leukemia and related disorders - Clinical	E1016	E1040	195
■ Chronic myeloid leukemia - Biology	E1041	E1050	197
■ Chronic myeloid leukemia - Clinical	E1051	E1073	197
■ Enzymopathies, membranopathies and other anemias	E1074	E1082	199
■ Gene therapy, cellular immunotherapy and vaccination	E1083	E1098	199
■ Hematopoiesis, stem cells and microenvironment	E1099	E1118	200
■ Hodgkin lymphoma - Clinical	E1119	E1127	202
■ Indolent Non-Hodgkin lymphoma - Clinical	E1129	E1142	202
■ Infectious diseases, supportive care	E1143	E1153	203
■ Iron metabolism, deficiency and overload	E1154	E1165	204
■ Myelodysplastic syndromes - Biology	E1166	E1178	204
■ Myelodysplastic syndromes - Clinical	E1179	E1199	205
■ Myeloma and other monoclonal gammopathies - Biology	E1200	E1238	207
■ Myeloma and other monoclonal gammopathies - Clinical	E1239	E1306	209
■ Myeloproliferative neoplasms - Biology	E1307	E1319	213
■ Myeloproliferative neoplasms - Clinical	E1320	E1352	214
■ Non-Hodgkin & Hodgkin lymphoma - Biology	E1353	E1409	216
■ Other Non-malignant hematopoietic disorders	E1410	E1429	220
■ Platelets disorders	E1430	E1456	221
■ Quality of life, palliative care, ethics and health economics	E1457	E1480	223
■ Sickle cell disease	E1481	E1495	224
■ Stem cell transplantation - Clinical	E1496	E1565	225
■ Stem cell transplantation - Experimental	E1566	E1569	229
■ Thalassemias	E1570	E1589	230
■ Thrombosis and vascular biology	E1590	E1604	231
■ Transfusion medicine	E1605	E1610	232

ACUTE LYMPHOBLASTIC LEUKEMIA - BIOLOGY

- E819 **PRECLINICAL COMBINATION OF A NOVEL IRE1 RNASE INHIBITOR MKC-8866 AND TYROSINE KINASE INHIBITION ACTS SYNERGISTIC IN ACUTE LYMPHOBLASTIC LEUKEMIA.**
M Vieri¹ (¹Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany)
- E820 **HIGH-THROUGHPUT COPY NUMBER PROFILING IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA USING MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION IN COMBINATION WITH NEXT-GENERATION SEQUENCING**
D Alpar¹ (¹MTA-SE Lendulet Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary)
- E821 **CRITICAL ROLE FOR NOTCH SIGNALLING IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) DRUG RESPONSE.**
P Takam Kamga¹ (¹Medicine, University of Verona, Verona, Italy)
- E822 **REGULATION OF NOTCH AND WNT SIGNALING PATHWAYS BY NRARP IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
R Frago¹ (¹JBarata Lab, Instituto de Medicina Molecular, Lisboa, Portugal)
- E823 **ETV6/RUNX1-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA: A NOVEL B-CELL PRECURSOR LEUKEMIA SUBTYPE IDENTIFIED BY THE CD27/CD44 IMMUNOPHENOTYPE**
M Vaskova^{1, 2, 3} (¹Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic, ²CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic)
- E825 **GENETIC ALTERATIONS IN CHILDREN WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN TAIWAN**
DC Liang¹ (¹Mackay Children's Hospital and Mackay Medical College, Taipei, Taiwan, Republic of China)
- E826 **COMPUTATIONAL METHODS TO FIND NEW THERAPEUTIC TARGETS IN ALL, SYSTEMATICAL IDENTIFICATION OF ESSENTIAL GENES**
L Ekdahl¹ (¹Division of Hematology and Transfusion Medicine, Lund University, Lund, Sweden)
- E827 **TARGETING ANTIOXIDANT ENZYMES FOR THE TREATMENT OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
K Fidy¹ (¹Department of Immunology, Medical University of Warsaw, Warsaw, Poland)

- E828 **RNA-BINDING PROTEIN IGF2BP1 PROMOTES SURVIVAL OF ETV6/RUNX1 LEUKEMIA CELLS**
M Stoškus¹ (¹ Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariškių Klinikos, Vilnius, Lithuania)
- E829 **6-MERCAPTOPURINE PROMOTES ENERGETIC FAILURE IN LEUKEMIC T-CELL LINE JURKAT**
AA Fernandez Ramos^{1, 2} (¹Université Paris Descartes, Paris, France, ²INSERM UMRS-1147, Paris, France)
- E830 **GENETIC ABERRATIONS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA AND THEIR IMPACT ON CLINICAL OUTCOME**
K Takahashi¹ (¹Leukemia, UT MD ANDERSON CANCER CENTER, Houston, United States)
- E831 **PROFILING OF RECURRENT COPY NUMBER ALTERATIONS IN RELAPSED ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA**
J Ribera^{1, 2} (¹Josep Carreras Leukemia Research Institute, Badalona, Spain, ²Universitat Autònoma de Barcelona, Badalona, Spain)
- E832 **IGF1R/IRS PHARMACOLOGICAL INHIBITION REDUCES CELL PROLIFERATION AND MIGRATION IN ACUTE LYMPHOBLASTIC LEUKEMIA CELLS**
APN Rodrigues Alves¹ (¹Internal Medicine, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil)
- E833 **LEUKEMIA-PROPAGATING CELLS DEMONSTRATED DISTINCTIVE GENE EXPRESSION PROFILES COMPARED WITH THE OTHER CELL FRACTIONS IN PATIENTS WITH DE NOVO PHILADELPHIA CHROMOSOME-POSITIVE ALL**
HY Zhao¹ (¹Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China)
- E834 **T-CELL LEUKEMIA SENSITIVITY TO FARNESYL TRANSFERASE INHIBITION USING TIPIFARNIB**
R Mondejar¹ (¹Cancer Genomics Lab, IDIVAL, Santander, Spain)

ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL

- E835 **HOSPITALIZATION FOR PATIENTS IN THE U.S. AND EU TREATED WITH INOTUZUMAB OZOGAMICIN VS STANDARD OF CARE FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN A GLOBAL PHASE 3 TRIAL**
Y Su¹ (¹Pfizer Inc, New York, United States)

- E836 NON-INTENSIVE BUT NON-INTERRUPTIVE TREATMENT WITH FEWER ALLO-HSCT IS EFFECTIVE STRATEGY FOR ADULT PH-NEGATIVE B-CELL PRECURSOR (BCP-) ALL: OUTCOME OF THE RUSSIAN PROSPECTIVE MULTICENTER ALL-2009 STUDY**
E Parovichnikova¹ (¹BMT department, National Research Center for Hematology, Moscow, Russian Federation)
- E837 POST-INDUCTION MINIMAL RESIDUAL DISEASE RESPONSE DETERMINED BY MULTICOLOR FLOW CYTOMETRY IS A POWERFUL INDICATOR OF EVENT-FREE-SURVIVAL IN THE CHILDHOOD T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA**
P Tembhare¹ (¹Hematopathology Laboratory, Tata Memorial Centre, Mumbai, Navi Mumbai, India)
- E838 SMAC MIMETICS - A NOVEL THERAPEUTIC APPROACH IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA**
M Meyer¹ (¹Department of Pediatrics and Adolescent Medicine, University Medical Center, Ulm, Germany)
- E839 SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): A SINGLE-ARM PHASE II STUDY**
R Klisovic¹ (¹Department of Internal Medicine, Division of Hematology & Oncology, The Ohio State University, Columbus, OH, United States)
- E840 UPDATED RESULTS FROM ZUMA-4: A PHASE 1/2 STUDY OF KTE-C19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA**
DW Lee¹ (¹Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, United States)
- E841 COMPARISON OF 8-COLOR FLOW CYTOMETRY AND PCR-BASED METHODS IN MEASUREMENT OF MINIMAL RESIDUAL DISEASE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA.**
S Hrabovsky^{1,2} (¹Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic, ²Faculty of Medicine, Masaryk University, Brno, Czech Republic)
- E842 QUALITY-ADJUSTED LIFE YEARS (QALY) FOR INOTUZUMAB OZOGAMICIN VS STANDARD OF CARE FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL)**
I van Oostrum¹ (¹Ingress-health the Netherlands, Rotterdam, the Netherlands)
- E843 A COST-EFFECTIVE, HIGH SENSITIVITY 10-COLOR SINGLE TUBE FLOW-CYTOMETRY BASED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA MINIMAL RESIDUAL DISEASE (MRD) ASSAY WITH STUDY OF ARTIFACTS AND MIMICS**
G Chatterjee¹ (¹Hematopathology, Tata Memorial Hospital, Mumbai, Mumbai, India)
- E844 SPECKLE TRACKING ECHOCARDIOGRAPHY IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY STUDY**
M Belloni¹ (¹Clinic of Pediatric Hemato-Oncology - Department of Woman and Child Health, University of Padua, Padova, Italy)
- E845 NUDT15 VARIANT CAUSING HEMATOPOIETIC TOXICITY WITH LOW 6-TGN LEVEL IN KOREAN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA**
HH Koo¹ (¹Pediatrics, Sungkyunkwan Univ School of Medicine, Samsung Medical Center, Seoul, Korea, Republic Of)
- E846 USING NEXT GENERATION SEQUENCING TO DETECT CLONAL TRG AND TRB GENE REARRANGEMENTS**
P Shah¹ (¹Inivoscribe Technologies, Inc., San Diego, United States)
- E847 DETECTION OF CLONALITY IN CLINICAL SPECIMENS FROM SUSPECTED B-CELL MALIGNANCIES USING COMPREHENSIVE IGH LYMPHOTRACK® MISEQ® AND PGM® ASSAYS**
Y Huang¹ (¹Inivoscribe Technologies, San Diego, United States)
- E848 CORRELATION BETWEEN A 10-COLOR FLOW CYTOMETRIC MINIMAL RESIDUAL DISEASE (MRD) ANALYSIS AND MOLECULAR MRD IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA**
J Singh¹ (¹Laboratory Haematology, Alfred Pathology, Melbourne, Australia)
- E849 HYPOGLYCEMIC EVENTS DURING TREATMENT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: OBSERVATIONS FROM TRIAL AIEOP-BFM ALL 2009**
K Bleckmann¹ (¹Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany)
- E850 NUDT15 VARIANT IN KOREAN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA**
JM Lee¹ (¹Pediatrics, Yeungnam University, College of Medicine, Daegu, Korea, Republic Of)

- E851 SURVIVAL OUTCOMES OF ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH MODIFIED BFM90 AND ALTERNATE ALL PROTOCOLS IN RESOURCE LIMITED SETTINGS: A 10 YEAR PROSPECTIVE STUDY**
 A Jandial¹ (¹INTERNAL MEDICINE, PGIMER Chandigarh, CHANDIGARH, India)
- E852 TREATMENT OUTCOME OF ACUTE LYMPHOBLASTIC LEUKEMIA IN KOREAN ADOLESCENTS AND YOUNG ADULTS**
 HJ Park¹ (¹Center for Pediatric Oncology, National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic Of)
- E853 AUTOLOGOUS TRANSPLANTATION AS TIME-DEPENDENT FACTOR FOR SURVIVAL OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: STUDY DATA AND SIMULATION MODEL**
 S Kulikov¹ (¹Biostatistics, National Research Center for Hematology, Moscow, Russian Federation)
- E854 INDUCTION WITH TYROSINE KINASE INHIBITORS, CONSOLIDATION WITH FLUDARABINE, ARA-C AND DAUNOXOME FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANT IS AN EFFECTIVE AND FEASIBLE STRATEGY FOR PH+ ALL PATIENTS.**
 N Di Felice¹ (¹Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST, Genova, Italy)
- E855 BONE MARROW MRD EVALUATION ON DAY 7 OF STEROID TREATMENT OF MODIFIED ST JUDE TOTAL XV THERAPY IN STANDART/LOW RISK PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA**
 S Aytac¹ (¹Pediatric Hematology, Hacettepe University, Ankara, Turkey)
- E856 PONATINIB (PON) IN PHILADELPHIA CHROMOSOME (PH)-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PRELIMINARY REPORT OF THE OPAL OBSERVATORY.**
 S Tavitian¹ (¹Hematology, IUCT-O, TOULOUSE, France)
- E857 J11 ANTIGEN EXPRESSION OF LEUKEMIC CELLS IN CHILDHOOD ACUTE LEUKEMIA**
 E You¹ (¹Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic Of)
- E858 SERUM LEVELS OF CYTOKINES AND ADHESION MOLECULES AND THEIR ASSOCIATION WITH PROGNOSTIC FACTORS IN NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**
 JM Horacek^{1, 2} (¹ 4th Department of Internal Medicine - Hematology, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic, ²Department of Military Internal Medicine and Hygiene, University of Defence, Faculty of Military Health Sciences (FMHS), Hradec Kralove, Czech Republic)
- E859 IMATINIB VS. DASATINIB FOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH PH+ ACUTE LYMPHOBLASTIC LEUKEMIA.**
 A Shigematsu¹ (¹Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan)
- E860 IS OLDER AGE AN EXCLUSION CRITERION FOR ALLOGENEIC HEMOPOIETIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA?**
 O Gavrilina¹ (¹Chemotherapy and BMT, National Research Center for Hematology, Moscow, Russian Federation)
- E861 TARGETABLE BLINATUMOMAB + TYROSINE KINASE INHIBITORS TREATMENT IN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS: CLINICAL EFFECTIVENESS AND PERIPHERAL LYMPHOCYTES SUBPOPULATIONS KINETICS.**
 A Sokolov¹ (¹National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation)
- E862 VERY VERY LATE RELAPSES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA, A CASE SERIES**
 M NIKITA¹ (¹Pediatric Oncology Department, P.&A. Kyriakou, ATHENS, Greece)
- E863 NOVEL CRLF2 MUTATIONS AND CLINICAL SIGNIFICANCE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA**
 C Song^{2, 4} (²International Cooperative Leukemia Group and International Cooperative Laboratory of Hematology, Zhongda Hospital, Southeast University Medical School, Nanjing, China, ⁴Pediatrics Department, Penn State University College of Medicine, Hershey, United States)

ACUTE MYELOID LEUKEMIA - BIOLOGY

- E864 THE MUTATIONAL SPECTRUM OF T(8;21)(Q22;Q22) POSITIVE ACUTE MYELOID LEUKEMIA DETERMINED BY HIGH-THROUGHPUT TARGETED SEQUENCING**
 N Jahn¹ (¹Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany)

- E865 NFKB PATHWAY PROMOTES TUMOR PROGRESSION THROUGH BRUTON'S TYROSINE KINASE IN MLL+ ACUTE MYELOID LEUKEMIA**
SC Nimmagadda¹ (¹Department for Hematology and Oncology, University Clinic of Magdeburg, Magdeburg, Germany)
- E866 A PRECISION MEDICINE PLATFORM FOR ACUTE MYELOID LEUKEMIA TO HELP UNRAVELING THE MOLECULAR ADDICTIONS OF FLT3-ITD-DRIVEN AML**
P Ayuda-Durán¹ (¹Department of Molecular Cell biology - Institute for Cancer Research, Oslo University Hospital - Radiumhospitalet, Oslo, Norway)
- E867 SECRETION OF SOLUBLE FACTORS BY AML CELLS INFLUENCE CD33/CD3 BITE® ANTIBODY MEDIATED CYTOTOXICITY AND T-CELL PROLIFERATION**
M Costanzi^{1, 2} (¹Department of Internal Medicine III, Hospital of the Ludwig-Maximilians-University (LMU) Munich, Munich, Germany, ²Laboratory for Translational Cancer Immunology - Gene Center, Munich, Germany)
- E868 CLONAL EVOLUTION OF FLT3-ITD POSITIVE AML AT DIAGNOSIS AND RELAPSE IN PATIENTS TREATED WITHIN THE CALGB 10603 (RATIFY) AND AMLSG 16-10 TRIALS**
LK Schmalbrock¹ (¹Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany)
- E869 MICROENVIRONMENT SECRETED PROTEINS MEDIATE RESISTANCE TO TARGETED THERAPY IN PRIMARY AML CELLS**
A Dokal¹ (¹Haemato-Oncology, Barts Cancer Institute, London, United Kingdom)
- E870 CHARACTERIZATION OF FLT3 MUTATIONS AT DIAGNOSIS, REFRACTORY DISEASE OR RELAPSE IN AML PATIENTS TREATED WITH MIDOSTAURIN WITHIN THE CALGB 10603 (RATIFY) AND AMLSG 16-10 TRIALS**
LK Schmalbrock¹ (¹Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany)
- E871 A NOVEL PML-RARG FUSION IN ACUTE PROMYELOCYTIC LEUKEMIA**
JS Ha¹ (¹Keimyung University School of Medicine, Daegu, Korea, Republic Of)
- E872 COOPERATION OF MLL-PTD WITH DNMT3A OR RUNX1 MUTATIONS IN AML LEUKEMOGENESIS**
HW Kao¹ (¹Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan, Republic of China)
- E873 AML BLASTS INDUCE A SENESCENT PHENOTYPE IN THE BM-MSC THROUGH THE UPREGULATION OF P21**
E Forde¹ (¹Norwich Medical School, University of East Anglia, Norwich, United Kingdom)
- E874 HYPOXIA DRIVES AML PROLIFERATION IN THE TUMOR MICROENVIRONMENT THROUGH HIF1 α /MIF SIGNALLING**
A Abdul-Aziz¹ (¹Norwich Medical School, University of East Anglia, Norwich, United Kingdom)
- E875 BONE MARROW ECOLOGICAL COLLAPSE IN ACUTE MYELOID LEUKEMIA IS MEDIATED BY REMODELING OF ENDOSTEAL VESSELS**
D Duarte^{1, 2} (¹Department of Life Sciences, Imperial College London, London, United Kingdom, ²The Francis Crick Institute, London, United Kingdom)
- E876 CLONAL HETEROGENEITY IN PATIENT-DERIVED XENOGRAFT OF ADULT ACUTE MYELOID LEUKAEMIA**
F Gonzales^{1, 2} (¹UMR-S 1172, Inserm, Lille, France, ²Service d'hématologie pédiatrique, CHU Lille, Lille, France)
- E877 COSTIMULATION INCREASES INTRACELLULAR SIGNALLING IN BITE® ANTIBODY CONSTRUCT MEDIATED T-CELL ACTIVATION**
L Pachzelt^{1, 2} (¹Department of Internal Medicine III, Klinikum der Universität München, Munich, Germany, ²Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Germany)
- E878 ESTABLISHING SINGLE CELL WHOLE EXOME SEQUENCING ANALYSIS AS A DISCOVERY TOOL IN NPM1/FLT3 POSITIVE PEDIATRIC ACUTE MYELOID LEUKEMIA**
C Walter¹ (¹Department of Pediatrics III, University Children's Hospital Essen, Essen, Germany)
- E879 RAF KINASE INHIBITOR PROTEIN IS INVOLVED IN THE DEVELOPMENT OF MYELOID SARCOMA**
V Caraffini¹ (¹Division of Hematology, Medical University of Graz, Graz, Austria)
- E880 INHIBITING MIR-10A OVERCOMES CYTARABINE-RESISTANCE IN ACUTE MYELOID LEUKAEMIA**
TT Vu¹ (¹Haematology, St Vincent's Hospital, Sydney, Australia)
- E881 BY AN MCL-1-DEPENDENT MECHANISM, ALVOCIDIB POTENTIATES THE ACTIVITY OF CYTARABINE AND MITOXANTRONE WHEN ADMINISTERED IN A TIME SEQUENTIAL REGIMEN IN AML**
S Warner¹ (¹Discovery Biology, Tolero Pharmaceuticals, Inc., LEHI, United States)
- E882 DYSREGULATION IN KEY REGULATOR GENES OF AUTOPHAGY AS A MECHANISM OF THERAPY RESISTANCE AND POOR PROGNOSIS IN ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM MICROARRAY ANALYSIS ON 148 PATIENTS**
MC Fontana¹ (¹Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy)

- E883 NO EVIDENCE FOR MICROSATELLITE INSTABILITY (MSI) IN 1,394 PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML)**
 C Walker¹ (¹The Ohio State University, Columbus, United States)
- E884 SY-1425, A POTENT AND SELECTIVE RAR β AGONIST, REPROGRAMS AML CELLS FOR DIFFERENTIATION ALONG DISTINCT LINEAGES, UNCOVERING PD MARKERS FOR CLINICAL STUDIES**
 M Mckeown¹ (¹Translational Medicine, Syros Pharmaceuticals, Cambridge, United States)
- E885 GENETIC CHARACTERIZATION OF A LARGE GROUP OF CEBPA MUTATED AML PATIENTS AND THE EFFECT OF TET2 AND GATA2 MUTATIONS ON OUTCOME**
 NP Konstandin¹ (¹Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-Universität, Munich, Germany)
- E886 MECHANISMS OF SYK-MEDIATED SUPPRESSION OF DIFFERENTIATION AND APOPTOSIS IN ACUTE MYELOID LEUKEMIA (AML)**
 A Polak¹ (¹Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warszawa, Poland)
- E887 MUTATIONAL PROFILE OF RELAPSE-RISK GROUPS IN ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS**
 M Prieto-Conde¹ (¹Hematology Department, University Hospital of Salamanca-IBSAL, SALAMANCA, Spain)
- E888 ANALYSIS OF THE PD-1/PD-L1 AXIS POINTS TO ASSOCIATION OF UNFAVORABLE RECURRENT MUTATIONS WITH PD-L1 EXPRESSION IN AML**
 K Giannopoulos^{1, 2} (¹Department of Hematology, St. John's Cancer Center, Lublin, Poland, ²Experimental Hematology Department, Medical University of Lublin, Lublin, Poland)
- E889 DISSECTING THE DYNAMICS OF SINGLE-TUMOR-CELL-LINEAGES THAT UNDERPIN RELAPSE OF AML**
 H Norell^{1, 2} (¹Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal)
- E891 MRD ANALYSIS BY NEXT-GENERATION SEQUENCING APPROACH FOR ACUTE MYELOID LEUKEMIA FOLLOW-UP**
 E Onecha De La Fuente^{1, 2} (¹Hematología traslacional, Hospital 12 de Octubre, Madrid, Spain, ²Haematological Malignancies Clinical Research Unit, CNIO, Madrid, Spain)
- E892 THE ROLE OF MYELOID-DERIVED SUPPRESSOR CELLS-LIKE BLASTS WHICH SUPPRESS T CELL PROLIFERATION IN LEUKEMIC CELL GROWTH**
 SY Hyun¹ (¹Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic Of)
- E893 GENERATION OF NEW CELLULAR MODELS FOR THE STUDY OF PEDIATRIC NON DOWN SYNDROME ACUTE MEGAKARYOBLASTIC LEUKEMIA BASED ON HUMAN PLURIPOTENT STEM CELLS**
 J Domingo-Reinés¹ (¹Genyo, Granada, Spain)
- E894 CHARACTERIZATION OF HEMATOLOGIC MALIGNANCIES WITH ANCHORED MULTIPLEX PCR AND NEXT-GENERATION SEQUENCING**
 D Fugere¹ (¹ArcherDX, Boulder, CO, United States)
- E895 ASXL1 MUTATIONS IN AML ARE ASSOCIATED WITH SPECIFIC CLINICAL AND CYTOGENETIC CHARACTERISTICS**
 K Manola¹ (¹Laboratory of Health Physics, Radiobiology & Cytogenetics, NCSR "Demokritos", ATHENS, Greece)
- E896 ENTOSPLETINIB, A POTENT AND SELECTIVE SYK INHIBITOR, BLOCKS CONSTITUTIVE AND FCGR ACTIVATED SIGNALING IN FLT3-ITD CELL LINES**
 K Keegan¹ (¹Oncology, Gilead Sciences Inc, Foster City, United States)
- E897 A COMPREHENSIVE DNA TEST FOR THE DETECTION OF TRANSLOCATIONS IN ACUTE LEUKEMIA**
 E Van Den Berg-De Ruyter¹ (¹Genetics, UMCG, Groningen, the Netherlands)
- E898 ALTERATIONS IN NECROPTOSIS PATHWAY AFFECT PROGNOSIS OF PATIENTS WITH ACUTE MYELOID LEUKEMIA**
 S Lo Monaco¹ (¹University of Bologna, Bologna, Italy)
- E899 NGS ANALYSIS AND IMPACT OF VARIANT ALLELIC FREQUENCY AT RELAPSE AND REFRACTORINESS STATUS IN AML PATIENTS**
 E Onecha De La Fuente^{1, 2} (¹Haematological Malignancies Clinical Research Unit, CNIO, Madrid, Spain, ²Hematología traslacional, Hospital 12 de Octubre, Madrid, Spain)
- E900 PRECLINICAL EVIDENCE THAT TRAMETINIB ENHANCES THE RESPONSE TO TYROSINE KINASE INHIBITORS IN ACUTE MYELOID LEUKEMIA**
 ML Morales¹ (¹Servicio de Hematología, Hospital Universitario 12 de Octubre, Madrid, Spain)

- E901 IDENTIFICATION OF NOVEL THERAPEUTIC DRUGS IN DISTINCT PEDIATRIC AML SUBTYPES BY TARGETING EPIGENETIC REGULATORS**
C Wiggers^{1, 2} (¹Pediatrics, University Medical Center Utrecht, Utrecht, the Netherlands, ²Hubrecht Institute, Utrecht, the Netherlands)
- E902 ALVICODIB SYNERGIZES WITH CYTARABINE AND DAUNORUBICIN (7+3) IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA**
C Whatcott¹ (¹Discovery Biology, Tolero Pharmaceuticals, Inc., LEHI, United States)
- E903 COMBINATION OF INTERFERON-ALPHA AND VAL-PROIC ACID IN ACUTE MYELOID LEUKEMIA CELLS IN VITRO AND IN VIVO**
BT Gjertsen^{1, 3} (¹Centre for Cancer Biomarkers (CCBIO), University of Bergen, Bergen, Norway, ³Department of Internal Medicine, Haematology Section, Haukeland University Hospital, Bergen, Norway)
- E904 KEVETRIN: PRECLINICAL STUDY OF A NEW COMPOUND IN ACUTE MYELOID LEUKEMIA**
R Napolitano¹ (¹Bioscience Laboratory, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy)
- E905 CLEARANCE OF 'DRIVER-COSMIC' MUTATIONS POST CR1 WITH PERSISTING RUNX1_L56S IS UNLIKELY TO CONTRIBUTE TOWARDS DISEASE PROGRESSION IN AML**
L Rai¹ (¹Onco-Cytogenomics, HSL Analytics LLP, LONDON, United Kingdom)

ACUTE MYELOID LEUKEMIA - CLINICAL

- E906 PROGNOSTIC SIGNIFICANCE OF FLT3 STATUS, CYTOGENETIC, ECOG AND 50% BLAST DECREASE IN PRIMARY REFRACTORY OR EARLY RELAPSED AML PATIENTS BEFORE SALVAGE THERAPY.**
E Paubelle¹ (¹Hematology, Chu Lyon Sud, Pierre Benite, France)
- E907 PRELIMINARY RESULTS FROM A PHASE 1 STUDY EXAMINING THE NOVEL BCL-2 INHIBITOR S55746/ BCL201 AS SINGLE AGENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC SYNDROME**
A Wei¹ (¹Department of Clinical Haematology, The Alfred Hospital and Monash University, Melbourne, Australia)

- E908 DISSECTING THE CLINICAL HETEROGENEITY OF NUCLEOPHOSMIN-1 (NPM1) MUTATED ADULT ACUTE MYELOID LEUKEMIA : THE CONTRIBUTION OF FLOW-CYTOMETRIC DETERMINATION OF MINIMAL RESIDUAL DISEASE**
F Buccisano¹ (¹Biomedicine and Prevention, University Tor Vergata of Rome, Rome, Italy)
- E909 EXPRESSION OF IMMUNE CHECKPOINT MOLECULES (PD-1, PD-L1, AND PD-L2) ON BONE MARROW T CELLS IN ACUTE MYELOID LEUKEMIA**
E You¹ (¹Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic Of)
- E910 ACUTE LEUKEMIA IN HIV PATIENTS : EPIDEMIOLOGY, THERAPEUTIC STRATEGY AND PROGNOSIS**
F Rabian¹ (¹ St Louis Hospital, Paris, France)
- E911 TEN-DAY DECITABINE AS INDUCTION THERAPY FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA FIT FOR INTENSIVE CHEMOTHERAPY**
J Wang¹ (¹Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China)
- E912 INDOXIMOD IN COMBINATION WITH IDARUBICIN AND CYTARABINE FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): PHASE 1 REPORT**
A Emadi^{1, 2, 3} (¹University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, United States, ²Medicine, University of Maryland, Baltimore, United States, ³Pharmacology, University of Maryland, Baltimore, United States)
- E913 PHASE I/II STUDY OF MEK INHIBITOR (MEK-162; BINIMETINIB) IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MYELOID MALIGNANCIES**
K Naqvi¹ (¹Department of Leukemia, UTMD Anderson Cancer Center, Houston, United States)
- E914 HAPLOIDENTICAL TRANSPLANTATION IS SAFE AND EFFECTIVE FOR OLDER PATIENTS WITH AML/MDS**
S Ciurea¹ (¹Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, United States)
- E915 OPTIMIZATION OF MINIMAL RESIDUAL DISEASE EVALUATION IN ACUTE MYELOID LEUKEMIA TO DRIVE POST REMISSION THERAPY**
P Minetto¹ (¹Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy)

- E916 **THE NUMBER OF CD34+CD38+CD117+HLA-DR+CD13+CD33+ CELLS INDICATES POST-CHEMOTHERAPY NEUTROPHIL RECOVERY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**
 J Wang² (²State Key laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China)
- E917 **MICRORNAS (MIRS) IN HIGH RISK PEDIATRIC ACUTE MYELOID LEUKEMIA (AML) AS PREDICTION TOOLS FOR RELAPSE INCIDENCE**
 PP Leoncini¹ (¹Oncohaematology, Bambino Gesù Children Hospital, Roma, Italy)
- E918 **CYTOKINE RECEPTORS AND SOLUBLE ADHESION MOLECULE LEVELS ARE ASSOCIATED WITH PROGNOSIS OF NEWLY DIAGNOSED AML**
 JM Horacek^{1, 2} (¹ Department of Military Internal Medicine and Hygiene, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic, ² 4th department of Internal Medicine - Hematology, University Hospital and Charles University, Faculty of Medicine, Hradec Kralove, Hradec Kralove, Czech Republic)
- E919 **MRD-DRIVEN CHOICE OF CONSOLIDATION AND MODULATION OF INDUCTION AND CONSOLIDATION INTENSITY RESULTED IN A SIGNIFICANTLY IMPROVED OUTCOME OF YOUNGER AML PATIENTS IN THE LAST THREE YEARS**
 M Clavio¹ (¹Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST, Genova, Italy)
- E920 **EFFECTIVENESS OF TREATMENT ACUTE MYELOID LEUKEMIA IN THE ELDERLY USING CLADRIBINE WITH LOW-DOSE ARAC**
 M Wątek¹ (¹Department of Hematology, Holy Cross Oncology Center of Kielce, Kielce, Poland)
- E921 **SMALL CUSTOMIZABLE NGS BASED TARGET CAPTURE PANELS DETECT VARIANTS IN CLINICAL SPECIMENS AT FREQUENCIES AS LOW AS 0.5%**
 L Chamberlain¹ (¹Inivoscribe, Inc., San Diego, United States)
- E922 **EFFICACY BY OUTPATIENT VS INPATIENT ADMINISTRATION OF CONSOLIDATION: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE MYELOID LEUKEMIA**
 JE Koltitz¹ (¹Monter Cancer Center, Northwell Health System, Lake Success, NY, United States)
- E923 **MOLECULAR GENETIC TESTING PATTERNS FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) ENROLLED IN THE CONNECT® MDS/AML DISEASE REGISTRY**
 D Pollyea¹ (¹University of Colorado Cancer Center, Aurora, United States)
- E924 **PHASE 1, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFECT OF CYTOCHROME P450 (CYP) 3A4 INHIBITION ON THE PHARMACOKINETICS (PK) AND SAFETY OF QUIZARTINIB (Q) AND ITS ACTIVE METABOLITE, AC886**
 J Li¹ (¹Daichi Sankyo, San Diego, CA, United States)
- E925 **SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISON OF GLASDEGIB PLUS LOW DOSE ARA-C VERSUS A HYPOMETHYLATING AGENT FOR ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY**
 A Forsythe¹ (¹Purple Squirrel Economics, New York, United States)
- E926 **CLINICAL OUTCOMES OF CHILDHOOD ACUTE MEGAKARYOBLASTIC LEUKEMIA: THE CHILDREN CANCER HOSPITAL EGYPT 57357 EXPERIENCE**
 N Maarouf¹ (¹Pediatric Oncology, 57357 CCHE, Cairo, Egypt)
- E927 **IDENTIFICATION OF RESISTANCE ASSOCIATED CPG METHYLATION CHANGES IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING INDUCTION CHEMOTHERAPY**
 C Niederwieser¹ (¹Department of Internal Medicine IV, Hematology and Oncology, University Hospital Halle, Halle, Germany)
- E928 **OVER-EXPRESSION OF ZEB2-AS1 LNCRNA PREDICTS POOR OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**
 X Shi^{1, 2} (¹ The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China, ²Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China)
- E929 **INTENSIFICATION OF ANTHRACYCLINE DURING INDUCTION AND CONSOLIDATION IS SAFE AND WELL TOLERATED IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA**
 S Fleming¹ (¹Department of Haematology, Alfred Hospital, Melbourne, Australia)
- E930 **PROGNOSTIC IMPACT OF IDH1 AND IDH2 MUTATIONS IN LOW AND INTERMEDIATE RISK AML: A MULTI-CENTER RETROSPECTIVE STUDY**
 M Riva¹ (¹Department of Medicine, University of Padua, Hematology and Clinical Immunology Unit, Padova, Italy)

- E931 DECITABINE COMBINED WITH HAAG REGIMEN IS AN EFFECTIVE SALVAGE TREATMENT FOR ADVANCED ACUTE MYELOID LEUKEMIA**
X Tang^{1, 2} (¹Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, ²The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China)
- E932 LESS-INTENSIVE TREATMENT LEADS TO DECREASED SURVIVAL IN UNMARRIED ACUTE MYELOID LEUKEMIA PATIENTS AND PATIENTS LIVING ALONE. A DANISH NATIONAL POPULATION-BASED COHORT STUDY**
LSG Østgård^{1, 2} (¹Department of Hematology, Aarhus University Hospital, Aarhus, Denmark, ²Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark)
- E933 TREATMENT OF MOLECULAR RELAPSE IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1 REDUCES TOXICITY OF SALVAGE TREATMENT AND IMPROVES DISEASE CLEARANCE**
F Guolo¹ (¹Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST, Genova, Italy)
- E934 MINIMAL RESIDUAL DISEASE AND LAIP CHANGES BY FLOW CYTOMETRY IN DE NOVO ACUTE MYELOID LEUKEMIA DURING CHEMOTHERAPY AND CLINICAL OUTCOMES**
T Lobanova¹ (¹Hematological Oncology and BMT, National Research Center for Hematology, Moscow, Russian Federation)
- E935 LENALIDOMIDE MAINTENANCE IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKEMIA**
T Kadia¹ (¹Leukemia, MD Anderson Cancer Center, Houston, United States)
- E936 POSTREMISSION THERAPY FOR AML WITH INTERMEDIATE RISK CYTOGENETICS IN FIRST COMPLETE REMISSION**
J Vydra¹ (¹Institute of Hematology and Blood Transfusion, Prague, Czech Republic)
- E937 LONG TERM FOLLOW UP OF PATIENTS OVER 60 YEARS TREATED WITH INTENSIVE CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES**
S Blum¹ (¹Haematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland)
- E938 FLAG-IDA FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA: A SINGLE CENTRE 5-YEAR STUDY**
C Agbuduwe¹ (¹Haematology, CAMBRIDGE UNIVERSITY HOSPITALS NHS TRUST, Cambridge, United Kingdom)
- E939 A MULTICENTER, RETROSPECTIVE ANALYSIS OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO WERE TREATED WITH DECITABINE**
JH Yi¹ (¹Hematology-Oncology, Chung-Ang university Hospital, Seoul, Korea, Republic Of)
- E940 DRUG-DRUG INTERACTION POTENTIAL OF GILTERITINIB IN HEALTHY SUBJECTS AND PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA**
M Levis¹ (¹John Hopkins University, Baltimore, United States)
- E941 A FLUDARABINE-BASED ACUTE MYELOID LEUKEMIA INDUCTION IS WELL TOLERATED UP TO 75Y OF AGE ALLOWS EARLY CONSOLIDATION AND LONG TERM SURVIVAL. A SINGLE CENTRE EXPERIENCE OF 136 CONSECUTIVE PATIENTS**
M Bocchia¹ (¹Hematology Unit, University of Siena, Siena, Italy)
- E942 OVEREXPRESSION OF SOX4 CORRELATEDS WITH POOR PROGNOSIS OF ACUTE MYELOID LEUKEMIA**
CY Hu¹ (¹Clinical Laboratory Sciences And Medical Biotechnology, National Taiwan University, Taipei, Taiwan, Republic of China)
- E943 AN OPEN-LABEL, MULTICENTER, PROSPECTIVE, RANDOMIZED STUDY OF RECOMBINANT HUMAN THROMBOPOIETIN AS AN ADJUNCT AFTER INTENSIVE CONSOLIDATION CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA**
XH Sui¹ (¹Hematology department of Shandong provincial hospital affiliated to Shandong University, Jinan, China)
- E944 TREATMENT-ASSOCIATED SURVIVAL RATES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): A SYSTEMATIC LITERATURE REVIEW**
J Bell¹ (¹Global Outcomes Research, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States)
- E945 SYSTEMATIC REVIEW OF HEALTH STATE UTILITY VALUES FOR ECONOMIC EVALUATION OF ACUTE MYELOID LEUKEMIA**
A Forsythe¹ (¹Purple Squirrel Economics, New York, United States)
- E946 ITALIAN REAL LIFE EXPERIENCE OF DECITABINE IN ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS: INTERIM ANALYSIS OF MULTICENTRIC OBSERVATIONAL DEA65 STUDY.**
L Aprile¹ (¹Hematology Unit, University of Siena, Siena, Italy)

- E947 **ASPARAGINASE ERWINIA CHRYSANTHEMI EFFECTIVELY DEPLETES PLASMA GLUTAMINE, HAS CLINICAL ACTIVITY, AND IS WELL TOLERATED IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA**
A Emadi^{1, 2, 3} (¹ University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, United States, ²Medicine, University of Maryland, Baltimore, United States, ³Pharmacology, University of Maryland, Baltimore, United States)
- E948 **PROGNOSTIC SIGNIFICANCE OF SOX2, SOX3, SOX11, SOX14 AND SOX18 GENE EXPRESSION IN DE NOVO ACUTE MYELOID LEUKEMIA (AML) PATIENTS**
N Totic¹ (¹Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia, Belgrade, Serbia)
- E949 **ACUTE ANTHRACYCLINE INDUCED CARDIOTOXICITY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**
O Pasvolsky¹ (¹beilinson hospital, Petach Tikva, Israel)
- E950 **AN INTEGER WEIGHTED GENOMIC MUTATION SCORING (IWGMS) USING THE TRUSIGHT MYELOID SEQUENCING PANEL SHOWS HIGHER MORTALITY IN PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA- A RETROSPECTIVE STUDY**
Q Qin¹ (¹Internal Medicine, Houston Methodist Hospital, Weill Cornell Medical College, Houston, United States)
- AGGRESSIVE NON-HODGKIN LYMPHOMA - CLINICAL**
- E951 **SUCCESSFUL IDENTIFICATION OF SPECIFIC AMINO ACID-DEPENDENCE IN ADULT T-CELL LEUKEMIA / LYMPHOMA (ATL) AND PRECLINICAL APPLICATION FOR NEW THERAPY**
T Ishigaki^{1, 2} (¹ Division of Stem Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan, ²Department of Laboratory Medicine, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan)
- E952 **VEGF AND VEGFR2 POLYMORPHISMS ARE INVOLVED IN AGGRESSIVENESS AND PROGNOSIS OF DIFFUSE LARGE B-CELL LYMPHOMA**
A Borsarelli Carvalho Brito¹ (¹Department of Internal Medicine, University of Campinas, Campinas, Brazil)
- E953 **BONE MARROW BIOPSY SUPERIORITY OVER PET/CT IN PREDICTING PROGRESSION FREE SURVIVAL IN A HOMOGENOUSLY-TREATED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA**
TH Chen Liang¹ (¹Department of Hematology and Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain)
- E954 **THE PROGNOSTIC SIGNIFICANCE OF CD11B+CX-3CR1+ MONOCYTES IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA**
JY Kwak¹ (¹Internal Medicine, CHONBUK NATIONAL UNIVERSITY HOSPITAL, Jeonju, Korea, Republic Of)
- E955 **RARE NON-HODGKIN LYMPHOMAS (R-NHLS) IN CHILDREN: THE AIEOP EXPERIENCE**
G Biddeci¹ (¹Clinic of Pediatric Hematology-Oncology, Department of Women's and Children's Health, Padova, Italy)
- E956 **PRIMARY ANALYSIS OF THE EFFECT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT OF 110 CASES OF T CELL LYMPHOMA**
C Li^{1, 2} (¹ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China, ²The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China)
- E957 **SHORT COURSE OF R-HYPERCVAD/MTX/ARA-C FOLLOWED BY ASCT AS FIRST-LINE THERAPY IN MANTLE CELL LYMPHOMA PATIENTS PROLONGS PROGRESSION FREE SURVIVAL TO MORE THAN 9 YEARS. SINGLE CENTER EXPERIENCE.**
M Andrade-Campos^{1, 2} (¹ CIBER de Enfermedades Raras, CIBERER, IISCIII, Zaragoza, Spain, ²Department of Hematology, Institut Català d'Oncologia Hospitalet, IDIBELL, Barcelona, Spain)
- E958 **THE FREQUENCY OF INCIDENTAL MALIGNANCIES DETECTED BY PET/CT SCANS IN PATIENTS WITH LYMPHOMA AND THE ASSOCIATED CLINICAL IMPLICATIONS**
J Falconer¹ (¹Haematology, Concord Repatriation General Hospital, Sydney, Australia)
- E959 **CLINICAL IMPACT OF KARYOTYPIC EVOLUTION ON THE PROGNOSIS OF DIFFUSE LARGE B CELL LYMPHOMA**
Y Mizuno¹ (¹Hematology, Kyoto Prefectural University of Medicine, Kyoto, Japan)
- E960 **REGIMEN INTENSIFICATION MAY IMPROVE OUTCOMES IN PATIENTS WITH HIGHER RISK HUMAN IMMUNODEFICIENCY VIRUS (HIV) RELATED AGGRESSIVE B-CELL LYMPHOMAS**
E Wang¹ (¹Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, United States)
- E961 **EPSTEIN-BARR VIRUS LATENT MEMBRANE PROTEIN 1-MEDIATED OVEREXPRESSION OF MYC AND BCL2 CAN PREDICT POOR PROGNOSIS IN PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE**
L Wang¹ (¹Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)

E962 SOLUBLE INTERLEUKIN-2 RECEPTOR AS A PREDICTIVE MARKER FOR SPONTANEOUS REGRESSION OF OTHER IATROGENIC IMMUNODEFICIENCY-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS; A RETROSPECTIVE STUDY

Y Nakajima¹ (¹Department of hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan)

E963 PROGRAMMED DEATH-1 PROTEIN EXPRESSION AND ITS RELATION WITH HISTOLOGIC AND CLINICAL VARIABLES IN MYCOSIS FUNGOIDES.

S Novelli² (² Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

E964 CIRCULATING MICRORNAS AS BIOMARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA: A PILOT PROSPECTIVE LONGITUDINAL CLINICAL STUDY

C Bouvy¹ (¹Department of Pharmacy, University of Namur, Namur, Belgium)

E965 COMBINED CHEMOTHERAPY PLUS RADIATION THERAPY IS MORE EFFECTIVE IN LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA OF THE TONSIL

SN Lim¹ (¹Internal Medicine, Haeundae Paik Hospital, Busan, Korea, Republic Of)

E967 SEQUENTIAL TREATMENT WITH BENDAMUSTINE, RITUXIMAB AND DEXAMETHASONE FOLLOWED BY RITUXIMAB CONSOLIDATION AND LENALIDOMIDE MAINTENANCE FOR FRAIL ELDERLY PATIENTS WITH AGGRESSIVE B-NON HODGKIN LYMPHOMA.

C Selleri¹ (¹Hematology, AUO San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy)

E968 CLINICAL RELEVANCE OF SARCOPENIA IN DIFFUSE LARGE B-CELL LYMPHOMA - TWO ARE BETTER THAN ONE

GW Lee¹ (¹Internal Medicine, Gyeongsang National University School of Medicine, Jinju, Korea, Republic Of)

E969 INTENSIFIED TREATMENT REGIMENS IMPROVE EVENT-FREE AND OVERALL SURVIVAL IN YOUNGER NEWLY DIAGNOSED HIGH-RISK PATIENTS WITH B-LARGE CELL LYMPHOMA; A RETROSPECTIVE OBSERVATIONAL STUDY OF KROHEM

S Basic-Kinda¹ (¹Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia)

E970 HIGH COMORBIDITY INDEX ALONG WITH HIGH NCCN-IPi STRONGLY INFLUENCE SURVIVAL OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS: SERBIAN LYMPHOMA GROUP EXPERIENCE

J Jelcic¹ (¹Clinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia)

E971 SUBSTITUTING DOXORUBICIN WITH ETOPOSIDE IN R-CHOP RESULTS IN A REGIMEN WITH SIMILAR EFFICACY FOR TREATMENT OF NEWLY DIAGNOSED ELDERLY PATIENTS WITH B-LARGE CELL LYMPHOMA (B-LCL)

I Hude¹ (¹Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia)

E972 POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: A SINGLE-CENTER CASE SERIES

C De Miguel¹ (¹Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain)

E973 SURVIVAL OUTCOMES AFTER FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) USING A UNITED STATES (US) ELECTRONIC MEDICAL RECORD (EMR)-BASED COHORT

A Galaznik¹ (¹Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States)

BLEEDING DISORDERS (CONGENITAL AND ACQUIRED)

E974 AN EXPERIENCE WITH LONG ACTING FACTOR VIII PROPHYLAXIS IN PAEDIATRIC AND YOUNG ADULT PATIENTS WITH HAEMOPHILIA A

A Tripathi¹ (¹K. G. Medical University Lucknow, Lucknow, India)

E975 NOVEL MUTATIONS IN THAI CHILDREN WITH CONGENITAL FACTOR VII DEFICIENCY

D Sosothikul¹ (¹Department of Pediatrics, Chulalongkorn University, Bangkok, Thailand)

E976 RETROSPECTIVE EVALUATION OF PHENOTYPE AND MANAGEMENT OF A-HYPO-FIBRINOGENEMIA IN A COHORT OF ITALIAN PATIENTS.

C Santoro¹ (¹Cellular Biotechnology and Hematology, HEMATOLOGY SAPIENZA UNIVERSITY, Rome, Italy)

E977 RETROSPECTIVE REVIEW OF FOUR DAYS OF VON WILLEBRAND'S FACTOR AS SURGICAL PROPHYLAXIS IN VON WILLEBRAND'S DISEASE

S Bal¹ (¹Hematology and Oncology, University of Cincinnati Medical Center, Cincinnati, United States)

E978 AUDIT ON MANAGEMENT OF HIGH INTERNATIONAL NORMALIZED RATIO (INR) IN WARFARINISED INPATIENTS

V Gorur¹ (¹Haematology, Broomfield Hospital, Chelmsford, United Kingdom)

E979 **NOVEL AND RECURRENT F7 MUTATIONS IN KOREAN PATIENTS WITH COAGULATION FACTOR VII DEFICIENCY**
H Kim¹ (¹Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic Of)

BONE MARROW FAILURE SYNDROMES INCL. PNH - CLINICAL

E981 **UTILITY OF CD157 IN A FLAER BASED SINGLE TUBE FIVE COLOR COMBINATION FOR SCREENING OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONE.**
K Rahman¹ (¹Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India)

E982 **IMMUNOPHENOTYPIC DYSPLASTIC FEATURES IN PATIENTS WITH APLASTIC ANEMIA**
Y Davydova¹ (¹Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation)

E983 **SURGICAL MANAGEMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) - DATA FROM THE SPANISH PNH REGISTRY**
S De La Iglesia¹ (¹Hematology, H. Universitario de Gran Canaria Doctor Negrín., Las Palmas de Gran Canaria, Spain)

E984 **EFFICACY OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS WITH OR WITHOUT APLASTIC ANEMIA; PROSPECTIVE STUDY OF KOREAN PNH COHORT**
CW Choi¹ (¹Internal Medicine, Korea University Guro Hospital, Seoul, Korea, Republic Of)

E985 **DIAGNOSIS AND FOLLOW-UP OF THE CLONES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA BY FLOW CYTOMETRY.**
S Oukid¹ (¹Hematology, EHS ELCC CAC, Blida, Algeria)

E986 **ASSOCIATION OF T-, B-, NK AND NKT CELLS WITH THE DURATION, COMPLETENESS AND OTHER CHARACTERISTICS OF REMISSION IN PATIENTS WITH APLASTIC ANEMIA**
O Rozanova¹ (¹laboratory of immunohematology, Russian research institute of hematology and transfusiology, Saint-Petesburg, Russian Federation)

E987 **A NOVEL DUAL-REAGENT SINGLE TUBE FLOW CYTOMETRIC ASSAY TO SCREEN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.**
K Bommanan¹ (¹Hematology, Post Graduate Institute of Medical Education and Research, CHANDIGARH, India)

E988 **TREATMENT OF REFRACTORY APLASTIC ANEMIA WITH ELTROMBOPAG: EXPERIENCE OF A CENTER**
M Gomes¹ (¹ Clinical Hematology , São João Hospital Centre, Porto, Portugal)

CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - BIOLOGY

E989 **DECREASED EXPRESSION OF ADHESION MOLECULES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS OF PATIENTS TREATED WITH IBRUTINIB**
A Guarini¹, ² (¹ Department of Molecular Medicine, Hematology, Sapienza University, Rome, Italy, ²Department of Cellular Biotechnologies and Hematology, Hematology, Sapienza University, Rome, Italy)

E991 **CLL CELLS UNDERGO METABOLIC REPROGRAMMING AND UTILIZE FREE FATTY ACIDS AS THEIR PRIMARY ENERGY SOURCE.**
U Rozovski¹ (¹Hematology, Davidof Cancer Center, Beilinson Campus, Petah Tikva, Israel)

E992 **INHIBITION OF ARGININE UPTAKE VIA HUMAN CATIONIC AMINO ACID TRANSPORTER-1 (CAT-1): A NOVEL APPROACH FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) THERAPY**
M Munder^{2, 3, 4} (² Third Department of Medicine (Hematology, Oncology, and Pneumology), University Medicine Mainz, Mainz, Germany, ³German Cancer Consortium (DKTK), partner site Frankfurt / Mainz, German Cancer Research Center (DKFZ), Heidelberg, Germany, ⁴Research Center for Immunotherapy, University Medicine Mainz, Mainz, Germany)

E993 **FCMR IS A NEGATIVE REGULATOR OF B-CELL RECEPTOR SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS**
S Gobessi¹ (¹Molecular Hematology, International Centre for Genetic Engineering & Biotechnology, Trieste, Italy)

E994 **TRANSCRIPTION FACTORS AND CHECKPOINT INHIBITORS EXPRESSION WITH AGE: MARKERS OF IMMUNOSENESCENCE?**
D Bron¹ (¹Clinical and Experimental Hematology, INSTITUT JULES BORDET, ULB, Brussels, Belgium)

E995 **T-CELL EXHAUSTED PHENOTYPE IS ENHANCED DURING DISEASE PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)**
I Jiménez¹ (¹Experimental Hematology, Vall d'Hebron Institute of Oncology, Barcelona, Spain)

- E996 EARLY SPECIFIC INCREASED EXPRESSION OF SURFACE IGM BUT NOT OF OTHER ASSOCIATED MOLECULES APPEARS TO REFLECT ANTIGEN DISENGAGEMENT IN CLL PATIENTS ON IBRUTINIB THERAPY**
S Drennan¹ (¹Haematology Oncology Group, Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom)
- E997 TRB REPERTOIRE PROFILING OF TCL-1 TRANSGENIC MICE USING NOVEL NGS TECHNOLOGIES REVEALS OLIGOCLONAL EXPANSIONS: SIMILARITIES WITH CHRONIC LYMPHOCYTIC LEUKEMIA**
L Scarfò¹ (¹Strategic Research Program on CLL and B-cell neoplasia Unit, Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, Italy)
- E998 ROLE OF THE COMBINATION MEK1/2 INHIBITOR BINIMETINIB AND AKT INHIBITOR MK2206 IN CLL**
S Sandhu^{1, 2} (¹ Northern Blood Research Centre, Kolling Institute of Medical Research, St Leonards, Australia, ²Acute Medical Unit, Royal Melbourne Hospital, Parkville, Australia)
- E999 TARGETING HIF-1 β AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA**
C Vitale^{1, 2} (¹ Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy, ²Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy)
- E1000 THE ROLE OF GENETIC-BASED PROGNOSTIC FACTORS IN PREDICTING MINIMAL RESIDUAL DISEASE NEGATIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND OFATUMUMAB**
S Raponi¹ (¹Cellular Biotechnologies and Hematology, Sapienza University, Rome, Rome, Italy)
- E1001 ISOCHROMOSOME 17Q, UNBALANCED TRANSLOCATIONS AND 8Q GAIN REPRESENT ADVERSE PROGNOSTIC FACTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION. A GFCH STUDY**
E Chapiro^{1, 2} (¹ UNIVERSITE PIERRE ET MARIE CURIE, Paris, France, ²Service d'Hématologie Biologique, Hôpital Pitie-Salpetriere, AP-HP, Paris, France)
- E1002 THE MICROENVIRONMENT REGULATES THE EXPRESSION OF MIR-21 AND TUMOR SUPPRESSOR GENES PTEN, PIAS3 AND PDCD4 THROUGH ZAP-70 IN CHRONIC LYMPHOCYTIC LEUKEMIA**
J Carabia¹ (¹Experimental Hematology, Vall d'Hebron Institute of Oncology, BARCELONA, Spain)
- E1003 IMPACT OF RECURRENT MUTATIONS ON PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED REGIMENS**
M Hložková¹ (¹University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Brno, Czech Republic)
- E1004 BCR SIGNALLING PROFICIENT CHRONIC LYMPHOCYTIC LEUKAEMIA B CELLS ARE PRONE TO RITUXIMAB MEDIATED ELIMINATION IN VIVO**
G Pavlasová^{1, 2} (¹ Molecular Medicine, CEITEC MU, Brno, Czech Republic, ²Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic)
- E1005 REGULATION OF BCR SIGNALLING IN CHRONIC LYMPHOCYTIC LEUKEMIA: ROLE OF E3 UBIQUITIN LIGASE C-CBL**
L Trentin¹ (¹Department of Medicine, University of Padua, Padua, Italy)
- E1006 ACTIVATION OF SHP-1/PP2A PATHWAYS TRIGGERS APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS**
L Trentin^{1, 2} (¹Department of Medicine, University of Padua, Padova, Italy, ²Venetian Institute of Molecular Medicine (VIMM), Padova, Italy)
- E1007 TARGETING NANOPARTICLES TO CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPLOITING THE PROPERTIES OF CXCR4**
C McCallion¹ (¹School of Chemistry, University of Manchester, Manchester, United Kingdom)
- E1008 THE ROLE OF THROMBOPOIETIN AS A TOOL OF IMMUNE MODULATION IN CHRONIC LYMPHOCYTIC LEUKEMIA**
S Ringelstein-Harlev¹ (¹Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel)
- E1009 TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION IN CLL CELLS**
J Kotasková^{1, 2} (¹ CMBGT, Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic, ²Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic)
- E1010 NORMAL SERUM PROTEIN ELECTROPHORESIS IDENTIFIES AN EXCELLENT PROGNOSIS GROUP AMONG IGHV MUTATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA, WITH A MEDIAN TFS OVER 18 YEARS**
J Chauzeix^{1, 2} (¹ Service d'hématologie biologique, CHU Limoges, Limoges, France, ²UMR7276, Université de Limoges, Limoges, France)

- E1011 HSP70 EXPRESSION IS MODULATED BY ITS MASTER REGULATOR HSF1 VIA MAPKS AND PI3K/AKT/MTOR PATHWAYS IN CHRONIC LYMPHOCYTIC LEUKEMIA**
 L Trentin¹, ² (¹Department of Medicine, University of Padua, Padova, Italy, ²Venetian Institute of Molecular Medicine (VIMM), Padova, Italy)
- E1012 THE INTERPLAY BETWEEN TH17 AND TREGS: A NEW IMMUNOSUPPRESSIVE INSIGHT IN CHRONIC LYMPHOCYTIC LEUKEMIA**
 S De Matteis¹ (¹Bioscience Laboratory, IRCCS Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST), Meldola, Italy)
- E1013 LOW EXPRESSION OF CD25 IN CHRONIC LYMPHOCYTIC LEUKEMIA NOTCH1-MUTATED CASES INDEPENDENT OF CDK4/6 MISREGULATION**
 TH Chen Liang¹ (¹Hematology and Oncology Department, Hospital Morales Meseguer, Centro Regional de Hemodonación. Universidad de Murcia, IMIB, Murcia, Spain)
- E1014 GENE MUTATIONS ANALYZED BY NEXT-GENERATION SEQUENCING ALLOW US TO DEFINE THE PROGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH EARLY-STAGE DISEASE AND 13Q DELETION**
 M Hernández-Sánchez¹ (¹Cancer Research Center/Hospital Universitario de Salamanca, SALAMANCA, Spain)
- E1015 ALTERED COMPLEX C5 IS ASSOCIATED WITH COMPROMISED COMPLEMENT ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA**
 A Braester¹, ² (¹Faculty of Medicine, Bar-Ilan University, Safed, Israel, ²Haematology, Galilee Medical Center, Nahariya, Israel)
- CHRONIC LYMPHOCYTIC LEUKEMIA AND RELATED DISORDERS - CLINICAL**
- E1016 ASSOCIATION OF CPG-STIMULATED KARYOTYPE WITH TIME-TO-FIRST TREATMENT FOR CLL**
 FP Tambaro¹ (¹Bone Marrow Transplantation, OSPEDALE PAUSILIPON, NAPOLI, Italy)
- E1017 COMPARISON OF THE CHRONIC LYMPHOCYTIC LEUKEMIA INTERNATIONAL PROGNOSTIC INDEX (CLL-IPI) WITH THE BARCELONA-BRNO PROGNOSTIC MODEL: ANALYSIS OF 1299 NEWLY DIAGNOSED CASES**
 M Gentile¹ (¹HEMATOLOGY, HOSPITAL ANNUNZIATA, COSENZA, Italy)
- E1018 PRELIMINARY RESULTS OF S55746/BCL201 (A NEW BCL2 INHIBITOR) IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AND EFFECT OF CALIBRATED MODERATE MEAL ON THE PHARMACOKINETICS**
 V Ribrag¹ (¹Institut Gustave Roussy, Villejuif, France)
- E1019 INCREASED VIRUS-SPECIFIC IMMUNE RESPONSES PARALLELED BY A PNEUMOCOCCUS-SPECIFIC-IMMUNODEFICIENCY STATE AND HYPOGAMMAGLOBULINEMIA: ALREADY EMERGE IN HIGH-COUNT MONOCLONAL B LYMPHOCYTOSIS PRIOR TO CLL.**
 I Criado¹ (¹Department of Medicine, Cancer Research Center (IBMCC, CSIC-USAL), Salamanca, Spain)
- E1020 AN EXTENSIVE MOLECULAR CYTOGENETIC CHARACTERIZATION IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA IDENTIFIES KARYOTYPE ABERRATIONS AND TP53 DISRUPTION AS PREDICTORS OF OUTCOME AND CHEMOREFRACTORINESS**
 GM Rigolin¹ (¹Scienze Mediche, Azienda Ospedaliero Universitaria Arcispedale S. Anna, Ferrara, Italy)
- E1021 SHOULD CLL-IPI BE USED TO ASSESS OVERALL SURVIVAL OF EVERY CLL PATIENT? A SYSTEMATIC REVIEW AND META-ANALYSIS.**
 S Molica¹ (¹Hematology-Oncology Department, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy)
- E1022 IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA: IMPACT OF THE CANADIAN YOU&I™ PATIENT SUPPORT PROGRAM ON TREATMENT ADHERENCE**
 A Peters¹ (¹University of Alberta, Edmonton, Canada)
- E1023 TREATMENT AND 17P DELETION TESTING PATTERNS IN COMMUNITY PRACTICE FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE UNITED STATES**
 T Kapustyan¹ (¹AbbVie Inc., North Chicago, United States)
- E1024 SINGLE-AGENT IBRUTINIB VS REAL WORLD TREATMENT FOR PATIENTS WITH TREATMENT-NAÏVE (TN) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): AN ADJUSTED COMPARISON OF RESONATE-2™ WITH THE CLLEAR AND LYON-SUD DATABASES**
 M Doubek¹ (¹Department of Internal Medicine – Hematology and Oncology, University Hospital, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic)
- E1025 CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP**
 O Al-Sawaf¹ (¹Department I of Internal Medicine, German CLL Study Group, University Hospital of Cologne, Köln, Germany)
- E1026 THE ROLE OF CD200 IN THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA**
 A Mora¹, ² (¹Laboratory of Oncology/Hematology and Transplantation, Institute of Biomedical Research, IIB Sant Pau, Barcelona, Spain, ²Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain)

- E1027 COMPARISON OF CHROMOSOME BANDING ANALYSIS AND GENOMIC MICROARRAY TECHNIQUES FOR THE DETECTION OF COMPLEX KARYOTYPES IN CHRONIC LYMPHOCYTIC LEUKEMIA**
A Puiggrós¹, ² (¹Laboratori de Citogenètica Molecular, Hospital del Mar, Barcelona, Spain, ²Grup de Recerca Translacional en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain)
- E1028 ABNORMAL SERUM FREE LIGHT CHAINS RATIO ASSESSMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: A SIMPLE YET POWERFUL TEST CORRELATING WITH CLINICAL OUTCOME AND MINIMAL RESIDUAL DISEASE**
F Durrieu¹ (¹Laboratory of hematology, Institut Bergonie, BORDEAUX, France)
- E1029 PLATELET FUNCTION ASSAYS FOR STRATIFICATION OF BLEEDING RISKS IN CLL PATIENTS ON IBRUTINIB TREATMENT**
E Nikitin¹ (¹Outpatient department for hematology oncology and chemotherapy, S.P.Botkin hospital, Moscow, Russian Federation)
- E1030 HYPOGAMMAGLOBULINEMIA IS A STRONG PREDICTOR OF TIME TO FIRST TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA**
R Cassin¹ (¹Oncohematology Department, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan, Italy, Milan, Italy)
- E1031 CLL: IS LYMPHOCYTE DOUBLING TIME (LDT) A RELEVANT PROGNOSTIC PARAMETER IN THE ERA OF PROGNOSTIC BIOMARKERS?**
T Baumann¹ (¹Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain)
- E1032 INDICATIONS FOR TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICO-BIOLOGICAL CHARACTERISTICS AND PROGNOSTIC IMPACT**
P Mozas¹ (¹Hematology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain)
- E1033 UNCOVERING PRIMARY TP53-DELETED CLONES WITH FISH THROUGH FACS-SUPPORTED PURIFICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA LYMPHOCYTES**
M Pereira², ³ (²Faculty of Medicine, University of Coimbra, Coimbra, Portugal, ³Clinical Hematology Department, Coimbra University Hospital Centre, Coimbra, Portugal)
- E1034 PRIMARY PEGFILGRASTIM PROPHYLAXIS VERSUS FILGRASTIM GIVEN "ON DEMAND" FOR CLADRIBINE - INDUCED NEUTROPENIA IN HAIRY CELL LEUKEMIA**
T Tadmor¹⁴ (¹⁴Hematology Unit, Bnai-Zion Medical Center, Haifa, Israel)
- E1035 REDUCED HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA ACHIEVING COMPLETE REMISSION TO FIRST-LINE THERAPY**
S Heitner Enschede¹ (¹AbbVie, Inc., North Chicago, United States)
- E1036 RITUXIMAB (R) USED AS A SINGLE AGENT FOR AUTO-IMMUNE HEMOLYTIC ANEMIA (AIHA) IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS INDUCES ALSO SIGNIFICANT DISEASE RESPONSE WITHOUT TOXICITY**
S Sachanas¹ (¹Hematologic, Athens Medical Center, Psychiko Branch, Athens, Greece)
- E1037 ATTAINMENT OF COMPLETE REMISSION IS SIGNIFICANTLY ASSOCIATED WITH LONGER SURVIVAL OUTCOMES IN RELAPSED/REFRACTORY (R/R) CLL: A META-ANALYSIS**
VU Ektare¹ (¹Pharmerit International, Bethesda, United States)
- E1038 APPLICATION OF THE CLL-IPI AND THE MDACC PROGNOSTIC INDEXES IN A LOCAL COHORT OF CLL PATIENTS**
I González-Gascón Y Marín¹ (1 Hospital Universitario Infanta Leonor, MADRID, Spain)
- E1039 CHRONIC LYMPHOCYTIC LEUKEMIA: PROGNOSTIC VALUE OF CLINICAL STAGES AND CLASSICAL PROGNOSTIC PARAMETERS DEPENDING ON TREATMENT MODALITY**
T Baumann¹ (¹Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain)
- E1040 AN OBSERVATIONAL STUDY EVALUATING THE USE OF BENDAMUSTINE AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN RUSSIA**
E Stadnik¹ (¹Almazov Federal North-West Medical Research Centre, Saint Petersburg, Russian Federation)

CHRONIC MYELOID LEUKEMIA - BIOLOGY

- E1041 **MUTAGENESIS OF BCR-ABL1 IS REQUIRED FOR RESISTANCE DEVELOPMENT IN DE NOVO CHRONIC MYELOID LEUKEMIA KCL-22 CELLS BUT NOT IN RELAPSED KCL-22 CELLS EXPRESSING BCR-ABL1 INDEPENDENT RESISTANCE.**
K Machova Polakova^{1, 5} (¹Institute of Hematology and Blood Transfusion, Prague, Czech Republic, ⁵Institute of Clinical and Experimental Hematology of the 1st Medicine Faculty, Charles University and Institute of Hematology and Blood Transfusion, Prague, Czech Republic)
- E1042 **FLOW-CYTOMETRY DETECTION OF CD26+ LEUKEMIA STEM CELLS IN PERIPHERAL BLOOD: A SIMPLE AND RAPID NEW DIAGNOSTIC TOOL FOR CHRONIC MYELOID LEUKEMIA**
L Aprile¹ (1 Hematology Unit, University of Siena, Siena, Italy)
- E1043 **LIPID PEROXIDATION AND INFLAMMATORY STATUS DURING TKI TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS: INTERIM ANALYSIS OF A PROSPECTIVE MULTICENTER STUDY**
A Sicuranza¹ (Hematology Unit, University of Siena, Siena, Italy)
- E1044 **TRANSCRIBED ULTRACONSERVED NONCODING RNAs (T-UCRS) IN CHRONIC MYELOID LEUKEMIA: EXPRESSION PROFILES ASSOCIATED WITH MOLECULAR RESPONSE TO THERAPY WITH TYROSINE KINASE INHIBITORS**
P Rodrigues Santos^{1, 2, 3} (¹ Centro de Investigação em Meio Ambiente, Genética e Oncobiologia (CIMAGO), Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal, ²Laboratório de Imunologia e Oncologia, Centro de Neurociências e Biologia Celular, Coimbra, Portugal, ³Instituto de Imunologia, Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal)
- E1045 **MAINTENANCE OF LEUKAEMOGENIC POTENTIAL OF BCR/ABL+ CELLS REQUIRES PAK2 BUT NOT PAK1**
A Hoelbl-Kovacic¹ (¹Institute of Pharmacology and Toxicology, Veterinary University of Vienna, Vienna, Austria)
- E1046 **MIRNA PROFILING OF CIRCULATING EXTRACELLULAR VESICLES IN CML PATIENTS WITH MUSCULOSKELETAL PAIN ASSOCIATED WITH DISCONTINUATION OF TYROSINE KINASE INHIBITORS**
K Ohyashiki¹ (¹Department of Hematology, Tokyo Medical University, Tokyo, Japan)

- E1047 **SOLUBLE AND MEMBRANE-BOUND RECEPTOR-LIGAND IMMUNE CHECKPOINTS AND CHRONIC MYELOID LEUKEMIA: CORRELATIONS WITH MOLECULAR RESPONSE AND TYROSINE KINASE INHIBITOR THERAPY**
P Rodrigues-Santos^{1, 2, 3} (¹ Centro de Investigação em Meio Ambiente, Genética e Oncobiologia (CIMAGO), Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal, ²Laboratório de Imunologia e Oncologia, Centro de Neurociências e Biologia Celular, Coimbra, Portugal, ³Instituto de Imunologia, Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal)
- E1048 **TYROSINE KINASE INHIBITORS SIGNIFICANTLY CHANGE THE EXPRESSION OF POLYCOMB GENES IN CHRONIC MYELOID LEUKEMIA.**
S Grassi¹ (¹Medical Biotechnologies, University of Siena, Siena, Italy)
- E1049 **IDENTIFICATION OF PROGNOSTIC AND SUSCEPTIBILITY MARKERS IN CHRONIC MYELOID LEUKEMIA USING NEXT GENERATION SEQUENCING**
Y Shokeen¹ (¹Department of Medical Oncology, Sir Ganga Ram Hospital, Delhi, India)
- E1050 **FEATURES OF THE A2455G POLYMORPHISM OF GENE CYP 1A1 IN PATIENTS WITH CML**
K Karimov^{1, 1} (¹ institute of hematology and blood transfusion, tashkent, Uzbekistan, ¹institute of hematology and blood transfusion, tashkent, Uzbekistan)

CHRONIC MYELOID LEUKEMIA - CLINICAL

- E1051 **HEMATOLOGIC TOXICITY GRADE III-IV IS ASSOCIATED WITH LOWER SURVIVAL IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS**
LF Casado Montero, MD¹ (¹Hematology, Hospital Virgen de la Salud, Toledo, Spain)
- E1052 **5-YEAR EFFICACY OF DASATINIB AND IMATINIB IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH DOSE MODIFICATIONS FROM DASISION**
A Hochhaus¹ (¹Universitätsklinikum Jena, Jena, Germany)
- E1053 **EFFECT OF PLASMA TROUGH CONCENTRATION OF NILOTINIB AND POLYMORPHISMS OF DRUG TRANSPORTER GENES ON THE FREQUENCY OF ADVERSE EVENTS IN CHRONIC PHASE OF CHRONIC MYELOID LEUKEMIA: STAT1 AND STAT2 TRIALS**
N Takahashi¹ (¹Hematology, AKITA UNIV., Akita, Japan)

- E1054 VERY EARLY MOLECULAR RESPONSE (VEMR) WITH FRONTLINE DASATINIB TREATMENT IS A STRONG PREDICTOR OF LONG-TERM BCR-ABL1 TRANSCRIPT LEVELS IN CHRONIC MYELOID LEUKEMIA PATIENTS: PCR-DEPTH STUDY**
WS Lee¹ (¹Int. Medicine, Hemato-Oncology, INJE UNIVERSITY BUSAN PAIK HOSPITAL, Busan, Korea, Republic Of)
- E1055 SURVIVAL OUTCOMES IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING THIRD- OR SUBSEQUENT LINE (3L) TREATMENT PRIOR TO THE AVAILABILITY OF PONATINIB**
L McGarry² (²ARIAD Pharmaceuticals, Inc., Cambridge, MA, United States)
- E1056 DETECTION AND MONITORING OF BCR-ABL1 KINASE DOMAIN MUTATIONS IN CML AND ALL PATIENTS BY NEXT GENERATION SEQUENCING AND DROPLET DIGITAL PCR, A BELGIAN PROSPECTIVE STUDY.**
C De Rop¹ (¹Molecular Biology, IPG, Gosselies, Belgium)
- E1057 CLINICAL AND IMMUNOLOGICAL EFFECTS OF NILOTINIB IN COMBINATION WITH PEGYLATED INTERFERON- δ 2B IN PATIENTS WITH SUBOPTIMAL MOLECULAR RESPONSE ON IMATINIB (NORDDUTCH-CML009)**
I Geelen¹ (¹Albert Schweitzer Hospital, Dordrecht, the Netherlands)
- E1058 ANALYSIS OF VASCULAR ADVERSE EVENTS IN TKI TREATED JAPANESE CML PATIENTS: RETROSPECTIVE LARGE COHORT STUDY OF CML COOPERATIVE STUDY GROUP**
I Fujioka¹ (¹Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan)
- E1059 UPDATE OF CMREGISTRY: AN OBSERVATIONAL, MULTI CENTER, PROSPECTIVE FOLLOW-UP REGISTRY OF PATIENTS WITH CHRONIC PHASE CML WITH A HIGH PROBABILITY OF OBTAINING A DEEP MOLECULAR RESPONSE \rightarrow CMR4 (IS).**
JM Alonso-Dominguez¹ (¹Hematology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain)
- E1060 ANALYSIS OF DASATINIB AND IMATINIB 5-YEAR EFFICACY AND SAFETY BASED ON BASELINE COMORBIDITY AND AGE IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) IN DASISION**
G Saglio¹ (¹University of Turin, Turin, Italy)
- E1061 ADHERENCE TO SECOND LINE THERAPY WITH NILOTINIB AND QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY**
T Sacha¹ (¹Department of Hematology, Jagiellonian University, Kraków, Poland)
- E1062 RADOTINIB TREATMENT IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO BCR-ABL1 TKIS: 36 MONTHS UPDATE OF RADOTINIB PHASE 2 STUDY**
SH Kim¹ (¹Internal Medicine, Dong-A University College of Medicine, Busan, Korea, Republic Of)
- E1063 100 YEARS OF CHRONIC MYELOID LEUKEMIA PREVALENCE IN FRANCE**
M Delord¹ (¹Biostatistics, Université Paris 7 - INSERM - UMR-S 717, PARIS, France)
- E1064 THE ROLE OF MICRORNAS IN CHRONIC MYELOID LEUKEMIA THERAPEUTIC SELECTION**
AB Sarmento-Ribeiro^{1, 2, 5} (¹CIMAGO, Faculty of Medicine University of Coimbra, Coimbra, Portugal, ²Applied Molecular Biology and University Clinic of Hematology, Faculty of Medicine University of Coimbra, Coimbra, Portugal, ⁵Clinical Hematology Department, Centro Hospital e Universitário de Coimbra (CHUC), Coimbra, Portugal)
- E1065 IMPACT OF ABCB1 AND ABCG2 POLYMORPHISMS ON RESPONSE TO IMATINIB AND 2G-TKIS THERAPY IN PATIENTS WITH CHRONIC PHASE CML**
M Tiribelli¹ (¹Division of Hematology and BMT, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy)
- E1066 THE INTRODUCTION OF SECOND-GENERATION TYROSINE KINASE INHIBITORS MAY REDUCE THE PROGNOSTIC IMPACT OF HIGH-RISK PATIENTS ACCORDING TO EUROPEAN TREATMENT AND OUTCOME STUDY (EUTOS) SCORE**
E Sato¹ (¹Department of Hematology, Juntendo University School of Medicine Nerima Hospital, Tokyo, Japan)
- E1067 CHRONIC MYELOID LEUKEMIA DIAGNOSED DURING PREGNANCY: THERAPY TACTICS AND OUTCOMES**
E Chelysheva¹ (¹National Research Center for Hematology, Moscow, Russian Federation)
- E1068 IMPACT OF KIR3DL1*00501 IN TYROSINE KINASE INHIBITOR-TREATED CML**
H Ureshino¹ (¹Div. Hematology, respiratory medicine and oncology, Japan, Saga University, Saga city, Japan)
- E1069 COMPARISON OF MOLECULAR KINETICS AFTER THE FIRST AND SECOND IMATINIB DISCONTINUATION: RESULTS FROM THE KID STUDY**
SE Lee¹ (¹Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic Of)

- E1070 CLINICAL IMPACT BY 24 MONTHS ACCORDING TO BCR/ABL1 TRANSCRIPT LEVEL AT 3 AND 6 MONTHS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH RADOTINIB 300MG BID OR IMATINIB**
YR Do¹ (¹Keimyung University, Dongsan Medical Center, Daegu, Korea, Republic Of)
- E1071 HYDROXYUREA SUPPRESSES BCR-ABL1 T315I+ CML CLONES IN VIVO AND IN VITRO AND SYNERGIZES WITH PONATINIB IN ELIMINATING TKI-RESISTANT CML CELLS**
M Schneeweiss^{1, 2} (¹ Department of Internal Medicine I/Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria, ²Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria)
- E1072 ASSOCIATION OF BCL2L11 (BIM) DELETION POLYMORPHISM WITH MOLECULAR RELAPSE AFTER TYROSINE KINASE INHIBITOR CESSATION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE**
S Katagiri¹ (¹Department of Hematology, Tokyo Medical University, Tokyo, Japan)
- E1073 XPERT® BCR-ABL ULTRA, A HIGH SENSITIVITY ASSAY WITH A LIMIT OF DETECTION REACHING MR4.5 AND BELOW ON AN INTERNATIONAL REPORTING SCALE**
GJ Day² (² Oncology, R&D, Cepheid, Sunnyvale, United States)
- ENZYMOPATHIES, MEMBRANOPATHIES AND OTHER ANEMIAS**
- E1074 IDENTIFICATION OF INCIDENTS CASES OF GAUCHER DISEASE IN SPLENOMEGALY AND/OR THROMBOCYTOPENIA PATIENTS IN SPECIALIZED MEDICAL SERVICES IN COLOMBIA THROUGH THE USE OF A SELECTION ALGORITHM**
JG Duque³ (³ Antioquia, Clínica Sagrado Corazón, Medellín, Colombia)
- E1075 IMPACT OF PEROXIREDOXIN 2, GLUTATHIONE PEROXIDASE AND CATALASE INHIBITION ON OXIDATIVE STRESS MODIFICATIONS OF RED BLOOD CELL MEMBRANE AND CYTOSOL**
S Rocha² (² UCIBIO, REQUIMTE, Laboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal, Porto, Portugal)
- E1076 MOLECULAR BASIS OF PKLR MUTATIONS IN PATIENTS WITH PYRUVATE KINASE (PK) DEFICIENCY: THE FIRST REPORT FROM SOUTHEAST ASIAN POPULATION**
S Riolueang¹ (¹Siriraj-Thalassemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand)
- E1077 PRELIMINARY RESULTS OF GAU-PED STUDY: PREVALENCE OF GAUCHER DISEASE IN PAEDIATRIC PATIENTS SELECTED BY AN APPROPRIATE DIAGNOSTIC ALGORITHM**
W Morello¹ (¹Pediatric Hematology and Oncology Unit, Sant'Orsola-Malpighi University Hospital, Bologna, Italy)
- E1078 CIRCULATING MICROPARTICLES IN CONGENITAL AND ACQUIRED HAEMOLYTIC ANAEMIA**
W Barcellini¹ (¹UOC Oncoematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy)
- E1079 THE PREVALENCE, ETIOLOGY AND PROGNOSTIC IMPACT OF ANEMIA IN OLDER POPULATION**
L Gil² (² Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland)
- E1080 PIEZO1 MECHANOTRANSDUCTIVE PROTEIN MUTATIONS IN RBCS: WHEN THE PHENOTYPE IS BEYOND HAEMOLYTIC ANAEMIA**
D Mota¹ (¹Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal)
- E1081 MODELLING PYRUVATE KINASE DEFICIENCY IN HUMAN PROGENITORS USING CRISPR/CAS9**
S López-Manzaneda^{1, 2} (¹ Cell Differentiation and Cytometry Unit, Hematopoietic Innovative Therapies Division, CIEMAT/CIBERER, Madrid, Spain, ²Unidad Mixta de Terapias Avanzadas, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain)
- E1082 PHYSIOPATHOLOGY OF HEREDITARY XEROCYTOSIS : PIEZO1 GAIN OF FUNCTION MUTATIONS IMPACT HEMOGLOBIN OXYGEN AFFINITY**
V Picard⁵ (⁵Service d'hématologie biologique, APHP, Hôpital Bicêtre, Le Kremlin Bicêtre, France)
- GENE THERAPY, CELLULAR IMMUNOTHERAPY AND VACCINATION**
- E1083 SAFETY AND EFFICACY OF MULTI-PATHOGEN-SPECIFIC T CELLS IN A HUMANIZED MODEL OF INVASIVE ASPERGILLOSIS : A PROOF OF CONCEPT STUDY**
A Papadopoulou¹ (¹Gene and Cell Therapy Center- Hematology Dpt- BMT Unit, George Papanicolaou Hospital, Thessaloniki, Greece)
- E1084 DONOR LYMPHOCYTE INFUSION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES LEADS TO DIVERSITY OF LEUKEMIA-ASSOCIATED-ANTIGENS-SPECIFIC T CELL RESPONSES AND TO REDUCTION IN REGULATORY T CELL FREQUENCY**
J Greiner^{2, 4} (²Clinic for Internal Medicine III, University of Ulm, Ulm, Germany, ⁴Department of Internal Medicine, Diakonie Klinikum, Stuttgart, Germany)

E1085 GENE-MODIFIED NK-92MI CELLS EXPRESSING A CHIMERIC CD16/CD64-BB- δ RECEPTOR EXHIBIT ENHANCED CANCER-KILLING ABILITY IN COMBINATION WITH THERAPEUTIC ANTIBODY

Y Chen¹ (¹The Cyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu, China)

E1086 A NOVEL IN VITRO METHOD TO QUANTIFY THE PHARMACOLOGY ACTIVITY OF BISPECIFIC ANTIBODIES IN HEMATOLOGICAL SAMPLES.

J Ballesteros¹ (¹ViviaBiotech, Madrid, Spain)

E1087 HUMANIZED CD7 NANOBODY-BASED IMMUNOTOXINS EXHIBIT PROMISING ANTI-T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA POTENTIAL

Y Yu¹ (¹The Cyrus Tang Hematology Center, Soochow University, Suzhou, China)

E1088 STATINS MAY IMPROVE CAR-NK IMMUNOTHERAPY IN MM BY PREVENTING LOSS OF BCMA EXPRESSION ON MM CELLS

G Suñe¹ (¹Hematology, Hospital Clinic/IDIBAPS/Josep Carreras Leukemia Research Institute, Barcelona, Spain)

E1089 DENDRITIC CELL VACCINATION COMBINED WITH LENALIDOMIDE AND PROGRAMMED DEATH-1 (PD-1) BLOCKADE HAS SYNERGISTICALLY INDUCED A MARKED TUMOR REGRESSION IN A MURINE MYELOMA MODEL

SH Jung¹ (¹Department of Hematology-Oncology, CHONNAM NATIONAL UNIVERSITY HWASUN HOSPITAL, Hwasun-Eup, Korea, Republic Of)

E1090 B- AND T-CELL IMMUNE REPERTOIRE PROFILING WITH ANCHORED MULTIPLEX PCR AND NEXT-GENERATION SEQUENCING

D Fugere¹ (¹ArcherDX, Boulder, CO, United States)

E1091 SYNERGISTIC ANTITUMOR IMMUNITY BY DENDRITIC CELLS IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN A MURINE MYELOMA MODEL

SH Jung¹ (¹Department of Hematology-Oncology, CHONNAM NATIONAL UNIVERSITY HWASUN HOSPITAL, Hwasun-Eup, Korea, Republic Of)

E1092 ALTERATIONS IN T-CELL SUBPOPULATIONS AFTER CO-CULTURING WITH MSCS DERIVED FROM DIFFERENT DONORS

N Kapranov¹ (¹Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation)

E1093 GRANULOCYTE COLONY STIMULATING FACTOR AND ERYTHROPOIETIN ENTERALLY GIVEN FOR NEONATES RECOVERING FROM GIT SURGERIES: RANDOMIZED CONTROLLED TRIAL

R El-Farrash¹ (¹Pediatrics Department, Faculty of Medicine-Ain Shams University, Cairo, Egypt)

E1094 GENE EDITING OF HUMAN HEMATOPOIETIC PROGENITORS TO CORRECT PYRUVATE KINASE DEFICIENCY

S Fañanas-Baquero^{1, 2} (¹Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas/Centro de Investigación Biomédica en Red de Enfermedades Raras (CIEMAT/CIBERER), Madrid, Spain, ²Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain)

E1095 BLAST KINETICS AFTER NON-ENGRAFTING HAPLOIDENTICAL MICROTRANSPLANTATION IN PATIENTS WITH REFRACTORY ACUTE MYELOID LEUKEMIA

Z Emarah^{1, 2} (¹Medical Oncology Unit, Oncology Center, Mansoura University, Mansoura, Egypt, ²Medical Oncology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt)

E1096 ALTERATIONS IN T-CELLS SUBPOPULATIONS AFTER CO-CULTIVATION WITH MULTIPOTENT MESENCHYMAL STROMAL CELLS

Y Davydova¹ (¹Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation)

E1097 OPTIMIZATION OF TRANSDUCTION CONDITIONS WITH GMP LIKE LENTIVIRAL VECTORS FOR THE GENE THERAPY OF PYRUVATE KINASE DEFICIENCY

S Navarro^{1, 2} (¹Unidad Mixta de Terapias Avanzadas, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain, ²Hematopoietic Innovative Therapies, CIEMAT/CIBERER, Madrid, Spain)

E1098 INTERACTION OF MULTIPOTENT MESENCHYMAL STROMAL CELLS WITH LYMPHOCYTES REDUCES THEIR IMMUNO PRIVILEGED PROPERTY

N Petinati¹ (¹Physiology of hematopoiesis lab., NATIONAL RESEARCH CENTER FOR HEMATOLOGY, Moscow, Russian Federation)

HEMATOPOIESIS, STEM CELLS AND MICROENVIRONMENT

E1099 SPECIFICATION OF MURINE HEMOGENIC ENDOTHELIAL HEMATOPOIETIC PRECURSORS CEASES ABRUPTLY BY E10.25 AND CONSTITUTES A FUNCTIONALLY HETEROGENEOUS POPULATION.

M Ganuza Fernandez¹ (¹Experimental Hematology, St. Jude Children's Research Hospital, Memphis, United States)

- E1100 C-TYPE LECTIN-LIKE RECEPTOR 2 SPECIFIES A FUNCTIONALLY DISTINCT SUBPOPULATION OF MEGAKARYOCYTE-BIASED LONG-TERM HEMATOPOIETIC STEM CELLS.**
 T Kumode¹ (¹Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan)
- E1101 PRE-TRANSPLANT DEFECTS OF BONE MARROW ENDOTHELIAL CELLS MAY CAUSE THE OCCURRENCE OF POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**
 MM Shi^{1, 2} (¹Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China, ²Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China)
- E1102 EFFICIENT LYMPHOID DIFFERENTIATION OF HEMATOPOIETIC STEM CELLS REQUIRES CXCR4 DESENSITIZATION**
 K Balabanian¹ (¹INSERM U996, Clamart, France)
- E1103 A SUBSET OF ADULT HSC DERIVES FROM GATA4-EXPRESSING PROGENITORS LOCATED IN THE PLACENTA AND LATERAL MESODERM OF MICE**
 A Cañete Sánchez¹ (¹ANIMAL BIOLOGY, SCIENCE FACULTY, UNIVERSITY OF MÁLAGA, MÁLAGA, Spain)
- E1104 EXPLORING THE MECHANISM OF FOG1-DEPENDENT TRANSCRIPTIONAL REGULATION IN ERYTHROID CELLS**
 T Fujiwara¹ (¹Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan)
- E1105 THE STEM CELL ZINC FINGER 1 (SZF1) / ZNF589 PROTEIN INHIBITS TUMOR DEVELOPMENT IN A K562 XENOGRAFT MOUSE MODEL, BLOCKING CELL CYCLING AND INDUCING PREMATURE CELLULAR SENESENCE**
 L Venturini¹ (¹Hematology, Hemostasis, Oncology, Stem Cell Transplantation, Hannover Medical School, Hannover, Germany)
- E1106 THE FUNCTIONAL RELEVANCE OF DNMT3A SPLICE VARIANTS IN HEMATOPOIETIC DIFFERENTIATION**
 W Wagner¹ (¹Stem Cell Biology and Cellular Engineering, Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University Medical School, Aachen, Germany)
- E1107 ERYTHROPOIETIN STIMULATES TRANSDIFFERENTIATION OF BONE MARROW PRO-B CELLS INTO BONE-RESORBING OSTEOCLASTS**
 D Neumann¹ (¹Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel)
- E1109 THE SPINDLE ASSEMBLY CHECKPOINT CONTRIBUTES TO PROPER HEMATOPOIETIC FUNCTION OF HSPCS**
 A Brown¹ (¹Ulm University, Institute for Molecular Medicine, Ulm, Germany)
- E1110 BONE MARROW MYELOPOIESIS INDEPENDENTLY OF CANONICAL NOTCH SIGNALING**
 S Duarte^{1, 2} (¹Clinical Hematology Department, Coimbra Hospital and University Centre, Coimbra, Portugal, ²Haematopoietic Stem Cell Biology Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom)
- E1111 IDENTIFICATION OF NOVEL HUMAN HEMATOPOIETIC STEM CELL SUBPOPULATIONS VIA COMPREHENSIVE SURFACE MARKER ANALYSIS**
 T Jiromaru¹ (¹Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan)
- E1112 DEVELOPMENT OF A 3-DIMENSIONAL CULTURE TO MIMICK THE BONE MARROW MICROENVIRONMENT AND RECAPITULATE DRUG RESISTANCE FOR IN VITRO STUDY**
 M Karimpoor¹ (¹Biomechanical engineering/Pharmacy, University College London, London, United Kingdom)
- E1113 WHOLE EXOME SEQUENCING REVEALED SEQUENTIAL GAIN OF MUTATIONS IN TWO CASES OF DONOR CELL HAEMATOLOGICAL MALIGNANCY AFTER HEMATOPOIETIC TRANSPLANTATION**
 J Suárez González^{1, 2} (¹Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ²Genomic Unit, Instituto de Investigación Sanitaria Gregorio Marañón y Hospital General Universitario Gregorio Marañón, Madrid, Spain)
- E1114 LEUKEMIC STEM CELL-RELATED MRNA EXPRESSION ANALYSIS USING A NOVEL FLOW CYTOMETRY-BASED ASSAY**
 B Depreter^{1, 2} (¹Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium, ²Department of Paediatric Haematology-Oncology and Stem Cell Transplantation, Ghent University, Ghent, Belgium)
- E1115 POTENTIAL PREDISPOSING GERMLINE MUTATIONS IN PATIENTS WITH CONCOMITANT MYELOID AND LYMPHOID MALIGNANCIES**
 F Asmar¹ (¹Department of Hematology, Rigshospitalet, Copenhagen, Denmark)

- E1116 **THE MUTATIONAL LANDSCAPE OF DNMT3A MUTATIONS IN CLONAL HAEMATOPOIESIS OF INDETERMINATE POTENTIAL . CHIPPING AWAY AT THE PROBLEM.**
S Chaudry¹ (¹Brighton and Sussex Medical School, Brighton, United Kingdom)
- E1117 **NEXT-GENERATION REFERENCE INTERVALS FOR PEDIATRIC HEMATOLOGY**
J Zierk¹ (¹Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany)
- E1118 **GROWTH FACTOR INDEPENDENCE 1 (GF11) REGULATES THE AML SUPPORTING FUNCTION OF MESENCHYMAL STROMAL CELLS**
Y Al-Matary¹ (¹University Hospital of Essen/ West centre of tumor, Essen, Germany)

HODGKIN LYMPHOMA - CLINICAL

- E1119 **BASILINE LEUKOCYTE AND EOSINOPHIL COUNTS PREDICT OUTCOME IN RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED WITH PD1 INHIBITION**
I Hude^{1, 2} (¹German Hodgkin Study Group (GHSG), First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany, ²Department of Internal Medicine, Division of Hematology, University Hospital Center Zagreb, Zagreb, Croatia)
- E1120 **THE PROGNOSTIC SIGNIFICANCE OF BETA-2 MICROGLOBULIN (B2M) LEVELS IN PATIENTS WITH HODGKIN LYMPHOMA (HL) TREATED WITH ABVD OR EQUIVALENT (ABVDEQ) CHEMOTHERAPY OR COMBINED MODALITY THERAPY (CT/CMT).**
T Vassilakopoulos¹ (¹Department of Hematology and Bone Marrow Transplantation, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece)
- E1121 **THE PREDICTIVE VALUE OF INTERIM PET-CT IN ELDERLY PATIENTS WITH HODGKIN LYMPHOMA**
OS Bentur¹ (¹Hematology, Tel Aviv Sourasky medical center, Tel Aviv, Israel)
- E1122 **HIGH-DOSE BENDAMUSTINE PLUS BRENTUXIMAB COMBINATION IS EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN THE TREATMENT OF REFRACTORY AND RELAPSED HODGKIN LYMPHOMA**
C Cerchione¹ (¹Hematology, Ematologia e trapianto/au federico ii, Napoli, Italy)
- E1123 **NEED OF HORMONAL THERAPY TO PRESERVE FEMALE FERTILITY IN HODGKIN E NON-HODGKIN LYMPHOMA PATIENTS FOLLOWING CHEMOTHERAPY: A TWO-CENTER SURVEY.**
O Annibaldi¹ (¹UOC Hematology, Stem cell Transplantation, University Campus Biomedico, Rome, Italy)

- E1124 **25(OH)VITAMIN D SERUM LEVELS IN HODGKIN LYMPHOMA**
A Cuccaro¹ (¹Hematology, Catholic University of Sacred Heart, Rome, Italy)
- E1125 **NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: A NEW RISK ADAPTED TREATMENT STRATEGY BASED ON RITUXIMAB**
R Della Pepa¹ (¹Hematology, Federico II University, Naples, Italy)
- E1126 **CASE-BASED LEARNING IN CONTINUING EDUCATION: IMPROVING HEMATOLOGIST/ONCOLOGIST EVIDENCE-BASED DECISIONS FOR PREVENTING HODGKIN LYMPHOMA POST-TRANSPLANT RELAPSE**
P Repetto¹ (¹Oncology, Medscape, Groveville, United States)
- E1127 **QUANTITATIVE PET PARAMETERS PREDICTS OUTCOME IN PATIENTS WITH HODGKIN'S LYMPHOMA**
I Kriachok¹ (¹Oncohematology, National Cancer Institute, Kiev, Ukraine)

INDOLENT NON-HODGKIN LYMPHOMA - CLINICAL

- E1129 **BIOMARKER ANALYSIS OF PATIENTS WITH FOLLICULAR LYMPHOMA TREATED WITH IBRUTINIB IN THE PHASE 2 DAWN STUDY**
G Salles¹ (¹Hospices Civils de Lyon-Université de Lyon, Pierre-Bénite cedex, Lyon, France)
- E1130 **DYNAMO: THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA IN A PHASE 2 STUDY**
PL Zinzani¹ (¹Institute of Hematology Seragnoli, University of Bologna, Bologna, Italy)
- E1132 **WALDENSTROM MACROGLOBULINEMIA: UK REAL WORLD EXPERIENCE**
D El-Sharkawi¹ (¹Cancer Division, University College London Hospital (UCLH), London, United Kingdom)
- E1133 **CLINICAL CHARACTERISTICS AND LONG-TERM RESULTS OF TREATMENT OF INDOLENT NON-HODGKIN'S LYMPHOMA ASSOCIATED WITH HEPATITIS C (IL + C)**
S Lepkov¹ (¹Russian National Research Medical University named after N.I. Pirogov, Moscow, Russian Federation)
- E1134 **90Y-IBRITUMOMAB-TIUXETAN AS FIRST-LINE CONSOLIDATION IN COMPLETE RESPONSE FOLLICULAR LYMPHOMA PATIENTS. SINGLE CENTER ANALYSIS AFTER SIX YEARS MEDIAN FOLLOW-UP.**
M Andrade-Campos¹ (¹Translational Research Unit - Hematology, IIS-Aragon. CIBERER., Zaragoza, Spain)

- E1135 **ASSESSING RISK OVER TIME IN PATIENTS WITH SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA (WM). A STUDY ON 114 PATIENTS (PTS).**
P Morel¹ (¹Service d'Hématologie, CHU d'Amiens, Amiens, France)
- E1136 **TIME TO NEXT TREATMENT ANALYSIS FOR EARLY AND ADVANCED STAGES OF MYCOSIS FUNGOIDES / SEZARY SYNDROME TREATED WITH BEXAROTENE AND PUVA IN COMBINATION**
S Rupoli¹ (¹Clinica di Ematologia, Ospedali Riuniti Umberto I - Salesi-Lancisi di Ancona, ancona, Italy)
- E1137 **PERIPHERAL BLOOD INVOLVEMENT IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA: CLINICAL-BIOLOGICAL CHARACTERISTICS AND PROGNOSTIC IMPACT**
A Rivas-Delgado¹ (¹Hematology department, Hospital Clinic, Barcelona, Spain)
- E1138 **TREATMENT PATTERNS OF PATIENTS WITH FOLLICULAR LYMPHOMA IN A LARGE US-INSURED DATABASE FROM 2010 TO 2014**
M Mehra¹ (¹Janssen Research & Development, LLC, Raritan, NJ, United States, United States)
- E1139 **A PHASE 1 STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS (PK) OF VENETOCLAX (VEN) IN JAPANESE PATIENTS (PTS) WITH NON-HODGKIN LYMPHOMA (NHL) AND MULTIPLE MYELOMA (MM)**
K Yamamoto¹ (¹Department of Clinical Research and Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan, Japan)
- E1140 **A SIMPLIFIED APPROACH IN THE ASSESSMENT OF T-CELL CLONALITY BY FLOW CYTOMETRY**
M Sartor¹ (¹Haematology, Weatmead Hospital, Sydney, Australia)
- E1141 **A HIGHER AMOUNT OF LILOTOMAB PRE-DOSING INCREASES THE ACTIVITY-ADJUSTED AUC AND HAS A PROTECTIVE EFFECT AGAINST MYELOSUPPRESSION OF LUTETIUM (177LU)-LILOTOMAB SATETRAXETAN IN INDOLENT NHL PATIENTS**
A Kolstad MD, PhD¹ (¹Radiumhospitalet, Oslo, Norway)
- E1142 **PHARMACOKINETICS AND TOLERABILITY OF OFATUMUMAB AND BENDAMUSTINE IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN'S LYMPHOMA**
A Forero-Torres¹ (¹Division of Hematology / Clinical Oncology, University of Alabama at Birmingham, Alabama , United States)

INFECTIOUS DISEASES, SUPPORTIVE CARE

- E1143 **ASSESSMENT OF INTERNATIONAL CONSENSUS GROUP FOR HEMATOLOGY (ICGH) SMEAR REVIEW RULES FOR AUTOMATED PLATFORMS IN THE DETECTION OF MALARIA**
J Vaughan^{1, 2} (¹ Haematology, National Health Laboratory Services, Johannesburg, South Africa, ²Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa)
- E1144 **A PROSPECTIVE MULTICENTER STUDY OF CANDIDEMIA IN NEUTROPENIC PATIENTS WITH HEMATOLOGICAL DISEASES: INCIDENCE, RISK FACTOR AND OUTCOMES**
CH Yan¹ (¹Peking University People's Hospital, Beijing, China)
- E1145 **BRONCHOALVEOLAR LAVAGE AS SYSTEMATIC APPROACH FOR EARLY DIAGNOSIS OF LUNG INFILTRATES AND INVASIVE PULMONARY ASPERGILLOSIS IN HEMATOLOGIC PATIENTS: A PROSPECTIVE SINGLE INSTITUTION STUDY**
F Marchesi¹ (¹Hematology and Stem Cell Transplant, Regina Elena National Cancer Institute, Rome, Italy)
- E1146 **ESCAPE DRUG-RESISTANT INFECTIONS IN HEMATOLOGICAL MALIGNANCIES. DARE TO REVIEW!**
C Gentile Sanchez¹ (¹Houston Methodist Cancer Center, Houston Methodist Hospital, Houston, United States)
- E1147 **PROPOSED PEGIFLGRASTIM BIOSIMILAR CHS-1701 DEMONSTRATES PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY TO MARKETED PEGFILGRASTIM IN A RAT NEUTROPENIA MODEL AND IN HEALTHY SUBJECTS**
P O'Connor¹ (¹Coherus BioSciences, Inc., Redwood City, United States)
- E1148 **A RETROSPECTIVE REVIEW IDENTIFYING RESISTANT MICROBIAL STRAINS, ANTIMICROBIAL SENSITIVITIES AND RISK STRATIFICATION OF FIRST LINE ANTIBIOTIC USE IN ADULT CANCER PATIENTS WITH NEUTROPENIC SEPSIS**
A Danga¹ (¹Haematology, North West London NHS Trust, London, United Kingdom)
- E1149 **PRELIMINARY RESULTS FROM A LONG-TERM REPEAT DOSE TOXICITY AND TOXICOKINETIC STUDY OF ANF-RHO, A NOVEL ANTI-NEUTROPENIC FACTOR**
H Misra¹ (¹Prolong Pharmaceuticals, Prolong Pharmaceuticals, South Plainfield, United States)
- E1150 **USE OF MICA FUNGIN IN PROPHYLAXIS IN ONCO-HEMATOLOGY : RESULTS OF AN OBSERVATIONAL, MULTICENTER, PROSPECTIVE FRENCH STUDY (OLYMPE)**
J El-cheikh¹ (¹ American Hospital, Beirut, Lebanon)

E1151 OUTBREAK OF MULTI-DRUG RESISTANT PSEUDOMONAS AERUGINOSA (MPA) IN A HAEMATOLOGY WARD (HW): MANAGEMENT AND INFECTION CONTROL MEASURES

D Armiento¹ (¹Haematology and Stem Cell Transplantation Division, Campus Bio-Medico University Hospital, Rome, Italy)

E1152 MONITORING VORICONAZOLE PHARMACOGENOMICS AND PLASMA CONCENTRATIONS IN THE TREATMENT AND PREVENTION OF INVASIVE FUNGAL DISEASE FOR HEMATOLOGICAL PATIENTS - A SINGLE CENTER EXPERIENCE

X Tang^{1, 2} (¹The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China, ²Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China)

E1153 BACTEREMIA AND SEPSIS FOLLOWING INTENSIVE CHEMOTHERAPY OF ADULT ONCOHEMATOLOGICAL PATIENTS

S Bessmeltsev¹ (¹Haematology, Russian Institute of Haematology and Transfusiology, St. Petersburg, Russian Federation)

IRON METABOLISM, DEFICIENCY AND OVERLOAD

E1154 GLYCOSYLATED FERRITIN MEASURING SIGNIFICANCE FOR SECONDARY HEMOPHAGOCYTTIC SYNDROME DIAGNOSTICS

V Potapenko¹ (¹Municipal clinical hospital №31, Saint-Petersburg, Russian Federation)

E1155 SERUM HEPcidIN QUANTIFICATION IN INFLAMMATORY BOWEL DISEASES

V Manolov¹ (¹Dept. of Clinical laboratory and clinical immunology, Medical University, Sofia, Sofia, Bulgaria)

E1156 MUTATIONS IN YARS2 CAUSE CONGENITAL SIDEROBLASTIC ANEMIA WITHOUT SHOWING EVIDENCES OF MYOPATHY AND LACTIC ACIDOSIS

B Cadenas¹ (¹Iron Metabolism: Regulation and Diseases, Josep Carreras Leukaemia Research Institute (IJC), BADALONA, Spain)

E1157 IRON CHELATION DATA OF CONGENITAL DYSERYTHROPOIETIC ANEMIA PATIENTS: A SINGLE CENTER EXPERIENCE

M Cetin¹ (¹Hacettepe University, Divison Of Pediatric Hematology, Ankara, Turkey)

E1158 ORAL IRON CHELATION FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS IN CHILDREN

M Moraki¹ (¹Thalassemia Unit, First Department of Pediatrics, National and Kapodistrian University of Athens, 'Aghia Sophia' Children's Hospital, Athens, Greece)

E1159 NEUTROPHIL HYPERSEGMENTATION IN ADULTS WITH IRON DEFICIENCY: A CASE-CONTROL STUDY

I Erdogan Ozunal¹ (¹Department of Internal Medicine, Division of Hematology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey)

E1160 M-TOR INHIBITORS-ASSOCIATED MICROCYTTIC ANEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.

R Angel F,¹ (¹Hematology, Hospital de Sant Pau, Barcelona, Spain)

E1161 IRON METABOLISM IN PATIENTS WITH PAROXISMAL NOCTURNAL HEMOGLOBINURIA

E Lukina¹ (¹Department of Orphan Diseases, National Research Center for Hematology, Moscow, Russian Federation)

E1162 ORAL IRON ELEVATES SERUM IRON AND CONSEQUENTLY CHANGES IRON DISTRIBUTION IN LIVER AND ERYTHROCYTES

Y Matsuo-Tezuka¹ (¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan)

E1163 DEFERASIROX FOR SEVERE ANAEMIAS IN YOUNG CHILDREN

A Gunawan^{1, 2} (¹ Haematology, Guy's and St Thomas' NHS Trust, London, United Kingdom, ²Pediatric, Evelina Hospital, Guy's and St Thomas' NHS Trust, London, United Kingdom)

E1164 MONITORING ORAL IRON THERAPY IN CHILDREN WITH IRON DEFICIENCY ANEMIA. AN OBSERVATIONAL, PROSPECTIVE, MULTICENTRIC STUDY

G Russo^{1, 2} (¹ Clinical and Experimental Medicine, University of Catania, Catania, Italy, ²Pediatric Hemato-Oncology Unit, Azienda Policlinico Vittorio Emanuele, Catania, Italy)

E1165 AN INVESTIGATION ABOUT WEIGHT GAIN WITH TREATMENT OF IRON DEFICIENCY ANEMIA: CHANGES OF GHRELIN AND HEPcidIN LEVELS WITH TREATMENT

B Onec² (²Hematology, Duzce University Faculty of Medicine, Duzce, Turkey)

MYELODYSPLASTIC SYNDROMES - BIOLOGY

E1166 SOMATIC MUTATION DYNAMICS IN HIGH-RISK MDS PATIENTS TREATED WITH AZACITIDINE IDENTIFIED VIA SERIAL SAMPLING

T Stopka^{1, 2} (¹ Hematology Clinic, General Hospital, Prague, Czech Republic, ²Biocev, Charles University, Vestec, Czech Republic)

- E1167 WHOLE GENOME MBD-SEQ REVEALS DIFFERENT CPG METHYLATION PATTERNS IN AZACITIDINE-TREATED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) PATIENTS**
PP Leoncini¹ (¹Oncohaematology, Bambino Gesù Children Hospital, Roma, Italy)
- E1168 RESPONSE MONITORING IN MDS WITH DEL(5Q) USING DIFFERENT FLOW CYTOMETRIC (FCM)-SCORES IN COMPARISON TO CYTOGENETICS – AN ELNET IMDS-FLOW EXPERIENCE**
U Oelschlaegel¹ (¹Medical Clinic and Policlinic I, MK1-L06, UNIVERSITY HOSPITAL of TU DRESDEN, Dresden, Germany)
- E1169 EVALUATION OF MUTATIONS AT RELAPSE IN MYELODYSPLASTIC SYNDROME PATIENTS RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION**
M Cabrero¹ (¹Hematology Department, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain)
- E1170 RIGOSERTIB COMBINED WITH AZACITIDINE EPIGENETICALLY MODULATES CHROMATIN AND HEMATOPOIETIC STEM CELL POPULATIONS IN THE MYELODYSPLASTIC SYNDROME (MDS)**
LR Silverman¹ (¹ICAHN SCHOOL OF MEDICINE, MOUNT SINAI, NEW YORK, United States)
- E1171 UNEXPLAINED CYTOPENIAS IN HOSPITAL : INDICATIONS AND BENEFITS OF NEXT-GENERATION SEQUENCING**
D Beauvais¹ (¹Department of Adult Hematology, CHRU University Hospital of Lille, Lille, France)
- E1173 RESISTANCE TO AZACITIDINE IS DETERMINED AT CELLULAR LEVEL BY LOWER EXPRESSION OF NUCLEOSIDE ACTIVATING ENZYMES UCK1 AND UCK2**
E Masala¹ (¹Experimental and Clinical Medicine, University of Florence, Florence, Italy)
- E1174 FAMILIAL TIN2 N-TERMINAL LOSS OF FUNCTION MUTATION IN TELOMERE SYNDROME**
D Di Giacomo¹ (¹Haematology and Bone Marrow Transplantation Unit, University of Perugia, Perugia, Italy)
- E1175 FUNCTIONAL EXPRESSION OF TIM-3 AND CLINICAL SIGNIFICANCE OF PLASMA GALECTIN-9 LEVELS IN MYELODYSPLASTIC SYNDROMES**
T Asayama¹ (¹Division of hematology, Department of medicine, Nippon Medical School, Tokyo, Japan)
- E1176 PROGNOSTIC SIGNIFICANCE OF GENE MUTATIONS IN MDS DEPENDS ON THE LOCI OF GENE VARIANCES**
T Boneva¹ (¹OncoGenomics, HSL Analytics LLP, LONDON, United Kingdom)
- E1177 SUPPRESSION OF DNA METHYLTRANSFERASE ENZYMES BY A NOVEL HYPOMETHYLATING AGENT, SGI-1027, IN AZACITIDINE- AND DECITABINE-RESISTANT CELL LINES**
EH Hur¹ (¹Hematology, Asan Medical Center, University of Ulsan College of Medicine, SEOUL, Korea, Republic Of)
- E1178 MECHANISTIC HIGHLIGHTS OF IMPROVED ERYTHROPOIESIS WITH A LOW DOSE OF DEFERASIROX IN LOW RISK MYELODYSPLASTIC SYNDROMES**
M Mathieu^{1, 2} (¹ Clinique Universitaire d'hématologie, CHU Grenoble Alpes, Grenoble, France, ²Equipe TheReX-laboratoire TIMC, Université Grenoble Alpes, Grenoble, France)
- MYELODYSPLASTIC SYNDROMES – CLINICAL**
- E1179 EVALUATING ERYTHROBLAST PAS POSITIVITY IN THE DIAGNOSTIC APPROACH OF MYELODYSPLASTIC SYNDROME**
R Invernizzi¹ (¹IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy)
- E1180 A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)**
U Platzbecker¹ (¹University Hospital Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany)
- E1181 PRELIMINARY ANALYSIS OF EFFICACY AND SAFETY OF SINTRA-REV CLINICAL TRIAL, LENALIDOMIDE VS PLACEBO PHASE 3 STUDY IN LOW/INT-1 MDS PATIENTS WITH DEL(5Q) AND TRANSFUSION INDEPENDENCY.**
F López Cadenas¹ (¹Department of Hematology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA (SANIDAD CASTILLA Y LEÓN), Salamanca, Spain)
- E1182 MYELODYSPLASIA-RELATED MORTALITY REMAINS THE MAIN CAUSE OF DEATH ALONG DIFFERENT GROUPS OF RISKS: AN ANALYSIS FROM MDS ARGENTINEAN STUDY GROUP**
A Enrico² (² Hospital Italiano de La Plata, La Plata, Argentina)
- E1183 PROSPECTIVE STUDY OF FLOW CYTOMETRY OF BONE MARROW IN 105 CONSECUTIVE PATIENTS WITH CYTOPENIA AND SUSPICION OF MYELODYSPLASTIC SYNDROME: STRONG CORRELATION WITH RISK OF AML-EVOLUTION AND SURVIVAL**
F Marco De Lucas¹ (¹HEMATOLOGÍA, HOSPITAL UNIVERSITARIO BASURTO, BILBAO, Spain)

- E1184 ECONOMIC IMPACT AND HEALTHCARE UTILIZATION IN PATIENTS WITH HIGHER-RISK MYELOYDYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY**
J Bell¹ (¹Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States)
- E1185 INTRAVENOUS IMMUNOGLOBULIN IS AN EFFECTIVE TREATMENT FOR CYTOPENIAS ASSOCIATED TO CIRCULATING T-CELL CLONES IN MYELOYDYSPLASTIC SYNDROMES**
F Schieppati¹ (¹Hematology, ASST Spedali Civili di Brescia, Brescia, Italy)
- E1186 DEVELOPMENT AND EXTERNAL VALIDATION OF A NEW PATIENT-CENTERED PROGNOSTIC INDEX FOR PATIENTS WITH ADVANCED MYELOYDYSPLASTIC SYNDROMES**
F Efficace¹ (¹Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIME-MA), Rome, Italy)
- E1187 PROGNOSTIC AND THERAPEUTIC IMPLICATIONS OF SIGNIFICANT MARROW FIBROSIS IN COMBINATION WITH P53 OVER-EXPRESSION IN PATIENTS WITH MYELOYDYSPLASTIC SYNDROME: A SINGLE CENTRE STUDY**
E Groarke¹ (¹Department of Haematology, Tallaght Hospital, Dublin 24, Ireland)
- E1188 FACS PURIFICATION OF BLAST CELLS IN MDS IMPROVES THE FISH DETECTION RATE FOR DEL(5Q) AND DEL(20Q), BUT NOT FOR DEL(7Q) OR T8**
M Pereira^{1, 2} (¹Clinical Hematology Department, Coimbra University Hospital Centre, Coimbra, Portugal, ² Faculty of Medicine, University of Coimbra, Coimbra, Portugal)
- E1189 COUNTING BONE MARROW BLASTS AS A PERCENTAGE OF NON-ERYTHROID CELLS PROVIDES SUPERIOR RISK STRATIFICATION FOR MDS PATIENTS WITH ERYTHROID PREDOMINANCE**
A Sun^{1, 2} (¹The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China, ²Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China)
- E1190 SUCCESSFUL TREATMENT WITH DANAZOL FOR MYELOYDYSPLASTIC SYNDROMES AND APLASTIC ANEMIA REFRACTORY OR INELIGIBLE TO STANDARD THERAPY**
F Schieppati¹ (¹Hematology, ASST Spedali Civili di Brescia, Brescia, Italy)
- E1191 SURVIVAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELOYDYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY**
J Bell¹ (¹Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, United States)
- E1192 DOSE-CONFIRMATION PK/PD STUDY OF ORAL ASTX727, A COMBINATION OF ORAL DECITABINE WITH A CYTIDINE DEAMINASE INHIBITOR (CDAI) E7727, IN SUBJECTS WITH MYELOYDYSPLASTIC SYNDROMES (MDS)**
G Garcia-Manero¹ (¹UT MD Anderson Cancer Center, Houston, United States)
- E1193 FACTORS PREDICTIVE FOR INFECTION IN PATIENTS WITH HIGHER-RISK MYELOYDYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA AND ACUTE MYELOID LEUKEMIA TREATED WITH AZACITIDINE.**
K Mądry¹ (¹Hematology, Oncology and Internal Diseases, Medical University, Warsaw, Poland)
- E1194 OVERALL SURVIVAL, INITIAL TREATMENT AND TREATMENT DURATION OF PATIENTS WITH MYELOYDYSPLASTIC SYNDROME, A DETAILED POPULATION BASED STUDY**
H Rozema^{1, 2} (¹Pharmacotherapy, -Epidemiology & -Economics, University of Groningen, Groningen, the Netherlands, ²Medical Centre Leeuwarden, Leeuwarden, the Netherlands)
- E1195 DANAZOL TREATMENT FOR THROMBOCYTOPENIA IN LOWER-RISK MYELOYDYSPLASTIC SYNDROMES: A REAL LIFE EXPERIENCE**
E Ravano¹ (¹Hematology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy)
- E1196 TREATMENT PATTERNS IN PATIENTS WITH HIGHER-RISK MYELOYDYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) – A CLAIMS DATABASE STUDY**
J Bell¹ (¹Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, United States)
- E1197 APPRECI8: A PIPELINE FOR PRECISE VARIANT CALLING INTEGRATING 8 TOOLS**
S Sandmann¹ (¹Institute of Medical Informatics, University of Münster, Münster, Germany)
- E1198 COMPARISON OF ADMINISTRATION OF HYPOMETHYLATING AGENTS WITH EFFICIENCY OF ALLOGENEIC SCT IN ELDERLY PATIENTS WITH ADVANCED MDS**
J Cermak¹ (¹Clinical Hematology, Institute of Hematology and Blood Transfusion, Praha, Czech Republic)

- E1199 A MULTICENTER, OPEN-LABEL, PHASE I CLINICAL STUDY: SAFETY, EFFICACY, AND PHARMACOKINETICS OF ORAL RIGOSERTIB IN JAPANESE PATIENTS WITH RECURRENT/RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES**
K Ishizawa^{1, 2} (¹Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, ²Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan)
- MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - BIOLOGY**
- E1200 NON-OVERLAPPING PROMOTER AND SUPERENHANCER DRIVEN PROCESSES SUPPORT MYELOMA CELL GROWTH AND SURVIVAL VIA DISTINCT REGULATORY AXES**
M Fulciniti¹ (¹Dana Farber Cancer Institute, Boston, United States)
- E1201 ANALYSIS OF THE GENOMIC LANDSCAPE OF MULTIPLE MYELOMA HIGHLIGHTS NOVEL CANDIDATE PROGNOSTIC MARKERS AND DISEASE SUBGROUPS**
N Bolli¹ (¹Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy)
- E1202 A NOVEL METHOD FOR GENOME-WIDE COPY NUMBER ASSESSMENT FROM TARGETED SEQUENCING DATA AND CLINICAL APPLICATION IN PATIENTS WITH MULTIPLE MYELOMA**
G Ryland¹ (¹Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia)
- E1203 THE MULTIPLE MYELOMA GENOME PROJECT: DEVELOPMENT OF A MOLECULAR SEGMENTATION STRATEGY FOR RISK STRATIFICATION OF MULTIPLE MYELOMA**
G Morgan² (²Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, United States)
- E1204 ALVOCIDIB SYNERGIZES WITH VENETOCLAX IN PRECLINICAL MODELS OF MULTIPLE MYELOMA**
C Whatcott¹ (¹Discovery Biology, Tolero Pharmaceuticals, Inc., LEHI, United States)
- E1205 NOVEL COMPOUND, OSSL_325096, INDUCES APOPTOSIS IN MULTIPLE MYELOMA CELLS THROUGH VCP INHIBITION**
N Nishimura¹ (¹Department of Hematology, Kumamoto University, Kumamoto, Japan)
- E1206 A NOVEL PREDICTIVE MODEL COMBINING LINCRNAS AND PROTEIN CODING GENES IN MULTIPLE MYELOMA**
M Samur^{1, 2} (¹Harvard Medical School, Boston, United States, ²Dana Farber Cancer Institute, Boston, United States)
- E1207 DYNAMIC IMMUNOHISTOCHEMICAL EVALUATION OF MARROW MICROENVIRONMENT MODIFICATIONS IN PATIENTS WITH SMOLDERING MYELOMA**
A Mussetti¹ (¹Hematology and Adult Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy)
- E1208 IMMUNE CELL PROFILING IN BONE MARROW OF MYELOMA PATIENTS POST AUTOLOGOUS STEM CELL TRANSPLANT SHOWS PRESENCE OF CYTOTOXIC CD4 AND CD8 CELLS, WITH PROMINENT LAG-3 EXPRESSION AND OTHER CHECKPOINT MARKERS**
N Alrasheed¹ (¹UCL Cancer institute, university college london, London, United Kingdom)
- E1209 INHIBITION OF EXTRACELLULAR VESICLE SECRETION INDUCES APOPTOSIS OF BONE MARROW STROMAL CELLS: TOWARDS SOIL-TARGETED THERAPY IN MULTIPLE MYELOMA**
T Umezu¹ (¹Department of Hematology, Tokyo Medical University, Tokyo, Japan)
- E1210 SINGLE-NUCLEOTIDE POLYMORPHISM IN THE PBK GENE IS CLOSELY ASSOCIATED WITH MYELOMA CELL PROLIFERATION.**
I Hanamura¹ (¹Division of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan)
- E1211 THE HISTONE METHYLTRANSFERASES G9A/GLP REPRESENT NEW PROMISING TARGETS FOR THE TREATMENT OF MULTIPLE MYELOMA**
E De Smedt¹ (¹Department of Hematology and Immunology-Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium)
- E1212 CYTOTOXIC LYMPHOCYTES IN NEWLY DIAGNOSED MYELOMA HAVE REVERSIBLE FUNCTIONAL AND PHENOTYPIC ABNORMALITIES THAT MAY OFFER THERAPUTIC OPPORTUNITIES**
F Seymour¹ (¹Haemato-Oncology, Barts Cancer Institute, London, United Kingdom)
- E1213 P53-RESTORING SMALL MOLECULE CP-31398 INDUCES APOPTOSIS VIA INDUCTION OF REACTIVE OXIDATIVE SPECIES IN HUMAN MULTIPLE MYELOMA**
Y Arihara¹ (¹Department of Medical Oncology, Sapporo Medical University, Sapporo, Japan)
- E1214 TUMOR MICROENVIRONMENT TRANSFORMATION FROM MGUS TO MYELOMA IS ASSOCIATED WITH PRO-TUMORAL ACTIVATION OF MESENCHYMAL STROMAL CELLS (MSC)**
C Giallongo¹ (¹Clinical and Molecular Biomedicine, section of Hematology, University of Catania, catania, Italy)

- E1215 LONG TERM CR MULTIPLE MYELOMA PATIENTS STUDIED WITH NEXT GENERATION FLOW SHOW PREDOMINANTLY CURED VS MGUS-LIKE MINIMAL RESIDUAL DISEASE PATTERNS: A STUDY OF THE GTMM-TUSCAN GROUP FOR MULTIPLE MYELOMA**
A Gozzetti¹ (¹Hematology Unit, University of Siena, Siena, Italy)
- E1216 THE NOTCH PATHWAY IN THE INTERPLAY BETWEEN MYELOMA CELLS AND ENDOTHELIUM IN THE BONE MARROW NICHE**
MT Palano¹ (¹Scienze della Salute, Università degli Studi di Milano, Milano, Italy)
- E1217 MIR-101-3P REGULATES BONE MARROW STROMA-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA CELLS BY TARGETING SURVIVIN AND MODULATING CELL-CELL ADHESION**
J Abdi¹ (¹University Health Network, Toronto, Canada)
- E1218 ARQ-197, A SMALL-MOLECULE INHIBITOR OF C-MET, REDUCES TUMOUR BURDEN AND PREVENTS TUMOUR-ASSOCIATED BONE DISEASE IN A MURINE MODEL OF MYELOMA**
A Chantry¹ (¹Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom)
- E1220 THE GENETIC LANDSCAPE OF THE MURINE 5T MODELS FOR MULTIPLE MYELOMA**
K Maes¹ (¹Hematology and Immunology, Vrije Universiteit Brussel, Brussel, Belgium)
- E1221 CHARACTERIZING THE CONTRIBUTION OF BONE MARROW STROMA-DERIVED IL-6 TO MYELOMA GROWTH AND RESISTANCE**
T Csikos¹ (¹Hematology, VU University Medical Center, Amsterdam, the Netherlands)
- E1222 THE PAN-PIM KINASE INHIBITOR, PIM447, POTENTLY SYNERGIZES WITH POMALIDOMIDE PLUS DEXAMETHASONE IN PRECLINICAL IN VITRO AND IN VIVO MODELS OF MULTIPLE MYELOMA**
T Paño^{1, 2} (¹Centro de Investigación del Cáncer (CIC-IBMCC), Salamanca, Spain, ²Complejo Asistencial Universitario de Salamanca-IBSAL, Salamanca, Spain)
- E1223 EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA.**
F Costa¹ (¹Medicine and Surgery, University of Parma, PARMA, Italy)
- E1224 TRIM33 IS A POTENTIAL TUMOR SUPPRESSOR IN MULTIPLE MYELOMA**
CK Johnston¹ (¹Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom)
- E1225 LONG NON-CODING RNAs EXPRESSION HETEROGENEITY AND FUNCTIONAL INVOLVEMENT IN MULTIPLE MYELOMA**
A Carrasco¹ (¹Onco-hematology, Center for Applied Medical Research (CIMA), Pamplona, Spain)
- E1226 ROLE OF EPHA3 IN MULTIPLE MYELOMA: A PERSPECTIVE FOR A NOVEL TARGET THERAPY?**
F La Rocca¹ (¹Laboratory of Clinical Research and Advanced Diagnostics, IRCCS, Referral Cancer Center of Basilicata (CROB), Rionero in Vulture, Italy)
- E1227 PROGNOSTIC SIGNIFICANCE OF AMP1Q21 IN MULTIPLE MYELOMA**
T Abramova¹ (¹Hematology Research Center, Moscow, Russian Federation)
- E1228 ADAPTIVE IMMUNE RESPONSE IN PLASMA CELL DYSCRASIAS: IMMUNE PROFILING AND DETERMINATION OF CIRCULATING B CELL LEVELS AS A SURROGATE ASSAY FOR BONE MARROW TESTING**
S Drain¹ (¹Stratified Medicine, C-tric, Ulster University, Derry, United Kingdom)
- E1229 NOVEL MONOCLONAL ANTIBODY THERAPY TARGETING CD26 IN MULTIPLE MYELOMA**
H Nishida¹ (¹ Pathology, Keio University, School of Medicine, Tokyo, Japan)
- E1230 KYNURENINE INHIBITS T-CELLS THROUGH THE ARYL HYDROCARBON RECEPTOR AT IDO-POSITIVE TUMOR MICROENVIRONMENT**
S Ninomiya¹ (¹Hematology, Gifu University Graduate School Of Medicine, Gifu, Japan)
- E1231 THE ANTI-MYELOMA ACTIVITY OF PERK KINASE INHIBITOR IN TARGETING MORE THAN 50 UPR-RELATED GENES INVOLVED IN THE PROLIFERATION OF MM CELLS**
T Bagratuni¹ (¹National And Kapodistrian University Of Athens, Athens, Greece)
- E1232 ENVIRONMENTAL CONTROL OF PLASMA CELL FITNESS IN MULTIPLE MYELOMA: MALIGNANT CO-OPTION OF ARGININE AS NOVEL IMMUNO-METABOLIC CHECKPOINT**
A Romano^{1, 2} (¹Division of Hematology, Azienda Ospedaliera Policlinico e Vittorio Emanuele di Catania, Catania, Italy, ²Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy)

- E1233 ESTIMATED GLOMERULAR FILTRATION (EGFR) CALCULATED BY CKD-EPI EQUATION COMBINED WITH THE INTERNATIONAL STAGING SYSTEM PROVIDES A POWERFUL PROGNOSTIC MODEL FOR EARLY MORTALITY IN MYELOMA PATIENTS**
 E Katodritou¹ (¹Hematology Department, Theagenion Cancer Hospital, THESSALONIKI, Greece)
- E1234 ACTIVATED AND EXPANDED NATURAL KILLER CELLS FROM MULTIPLE MYELOMA PATIENTS DESTROY TUMOR DRUG RESISTANT CELLS AND CLONOGENIC TUMOR CELLS**
 A Leivas^{1, 2} (¹Hematological Malignancies Clinical Research Unit, Spanish National Cancer Research Center, Madrid, Spain, ²Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain)
- E1235 UNMASKING THE RETROTRANSPOSON-ORCHESTRATED PRODUCTION OF SOLUBLE RANKL IN MULTIPLE MYELOMA CELLS**
 S Papamichos¹ (¹Laboratory of General Biology, Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece)
- E1236 THE RATIO OF PATHOLOGICAL PLASMOCYTES, ASSESSED BY 8-COLOR FLOW CYTOMETRY, PREDICTS OF RISK OF EVOLUTION IN MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE AND SMOULDERING MULTIPLE MYELOMA.**
 C Brouzes¹ (¹Laboratory Onco Hematology, Necker Enfants Malades Hospital and Descartes University, Paris, France)
- E1237 ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION.**
 A Horenstein^{1, 2} (¹CERMS, A.O.U. Citta della Salute e della Scienza, Turin, Italy, ²Medical Sciences, University of Turin, Turin, Italy)
- E1238 TREATMENT OPTIMIZATION FOR MULTIPLE MYELOMA: SCHEDULE-DEPENDENT SYNERGISTIC CYTOTOXICITY OF POMALIDOMIDE AND CARFILZOMIB ON AN IN VITRO AND EX-VIVO MODEL**
 E Borsi¹ (1Fondazione Umberto Veronesi (FUV), Milano, Italy)
- E1240 DARATUMUMAB-BASED COMBINATION THERAPIES IN HEAVILY-PRETREATED PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA**
 P Kapoor¹ (¹Division of Hematology, Mayo Clinic, Rochester, United States)
- E1241 IMPACT OF METFORMIN USE IN THE OUTCOMES OF MULTIPLE MYELOMA PATIENTS POST STEM CELL TRANSPLANT.**
 N Duma¹ (¹Hematology, Mayo Clinic, Rochester, United States)
- E1242 COMPARING WHOLE BODY MRI WITH PET-CT IMAGING AT DIAGNOSIS OF MYELOMA**
 J Vidler¹ (¹Department of Haematological Medicine, King's College Hospital, London, United Kingdom)
- E1243 PERSISTENCE OF MINIMAL RESIDUAL DISEASE BY MULTIPARAMETER FLOW CYTOMETRY CAN HINDER RECOVERY OF ORGAN DAMAGE IN PATIENTS WITH AL AMYLOIDOSIS**
 P Milani¹ (¹Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy)
- E1244 RATES OF PERIPHERAL NEUROPATHY (PN) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH CARFILZOMIB VS COMPARATORS IN PIVOTAL PHASE 3 TRIALS**
 R Niesvizky¹ (¹Center for Myeloma, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, United States)
- E1245 EARLY RELAPSE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT IN MYELOMA IS A POOR PROGNOSTIC MARKER FOR OVERALL SURVIVAL AND IS DIFFICULT TO PREDICT AT DIAGNOSIS OR DURING INDUCTION TREATMENT.**
 I Walker¹ (¹Department of Haematology, King's College Hospital Foundation Trust, London, United Kingdom)
- E1246 PATIENT-REPORTED OUTCOMES (PROS) WITH IBRUTINIB: SUBSTUDY OF INNOVATETM FOR WALDENSTRÖM MACROGLOBULINEMIA (WM)**
 J Trotman¹ (¹Haematology, Concord Repatriation General Hospital, Concord, Australia)
- E1247 INCIDENCE AND RISK FACTORS OF CARDIOVASCULAR ADVERSE EVENTS IN A LARGE POPULATION OF NEWLY-DIAGNOSED, TRANSPLANT INELIGIBLE MYELOMA PATIENTS TREATED WITH CARFILZOMIB.**
 S Bringhen¹ (¹Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy)

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES - CLINICAL

- E1248 POMALIDOMIDE (POM) + LOW-DOSE DEXAMETHASONE (LODEX) AFTER SECOND-LINE LENALIDOMIDE (LEN)-BASED TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PROGRESSION-FREE SURVIVAL ANALYSIS**
DS Siegel¹ (¹John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, United States)
- E1249 "REAL WORLD" DATA ON THE EFFICACY AND SAFETY OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A STUDY OF THE GREEK MYELOMA STUDY GROUP**
E Terpos¹ (¹Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece)
- E1250 EUROPEAN POST-APPROVAL SAFETY STUDY (EU PASS) OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): SAFETY IN A LARGE COHORT OF PATIENTS TREATED WITH LENALIDOMIDE, THALIDOMIDE, AND BORTEZOMIB**
B Gamberi¹ (¹Arcispedale S. Maria Nuova, Reggio Emilia, Italy)
- E1251 NEW CLINICAL PATHWAYS OF THE CENTERS OF EXCELLENCE NETWORK IN GERMANY: A NEW CONCEPT FOR STANDARDIZED CARE OF MULTIPLE MYELOMA PATIENTS**
JP Glossmann¹ (¹CIO Köln Bonn, University Hospital of Cologne, Cologne, Germany)
- E1252 WT1 HETEROCLITIC EPI TOPE IMMUNIZATION FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK MULTIPLE MYELOMA (MM)**
G Koehne¹ (¹MEMORIAL SLOAN KETTERING CANCER CENTER, New York, United States)
- E1253 ANALYSIS OF MULTIPLE MYELOMA PATIENTS WITH PROGRESSIVE DISEASE AT TIME OF FIRST AUTOLOGOUS STEM CELL TRANSPLANTATION: PREDICTORS OF PROGRESSIVE DISEASE AND FACTORS AFFECTING SURVIVAL**
J Blocka¹ (¹University Hospital Heidelberg, Heidelberg, Germany)
- E1254 SEVERE INFECTIONS IMPACTS OVERALL SURVIVAL IN ACTIVE MULTIPLE MYELOMA PATIENTS**
G Barila¹ (¹Dept of Medicine, Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy)
- E1255 EVALUATION OF CARDIOVASCULAR EVENTS ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES OF MULTIPLE MYELOMA IN THE REAL-WORLD SETTING IN THE UNITED STATES**
C Chen³ (³Bristol-Myers Squibb, Lawrenceville, United States)
- E1256 LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW**
K Kupas¹ (¹Bristol-Myers Squibb, Munich, Germany)
- E1257 HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT – A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP**
I Hus¹ (¹Clinical Transplantology, Medical University of Lublin, Lublin, Poland)
- E1258 HIGH CUT OFF HEMODIALYSIS FOR RENAL RECOVERY IN PATIENTS WITH MULTIPLE MYELOMA: FIVE YEARS OF EXPERIENCE**
A Berni Wennekers¹ (¹Nephrology, Hospital Clinico Universitario "Lozano Blesa" Zaragoza, Zaragoza, Spain)
- E1259 IMPACT OF IMMUNOPARESIS IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS**
LG Rodríguez-Lobato¹ (¹Department of Haematology, Hospital Clínic, Barcelona, Spain)
- E1260 TREATMENT PATTERNS AND DURATION OF TREATMENT IN JAPANESE MULTIPLE MYELOMA PATIENTS RECEIVING SECOND LINE THERAPY WITH NOVEL AGENTS**
G Jun^{1, 2} (¹ Department of Public Health, Juntendo University School of Medicine, Tokyo, Japan, ²Japan Medical Affairs, Takeda Pharmaceutical Company Limited, Tokyo, Japan)
- E1261 ROLE OF HEAVY/LIGHT CHAIN RATIO IN MYELOMA PATIENTS ACHIEVING COMPLETE RESPONSE AFTER FIRST LINE THERAPY**
F D'auria¹ (¹IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italy)
- E1262 REAL-WORLD RESULTS OF DARATUMUMAB MONOTHERAPY IN HEAVILY PRETREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN POLAND: A PROSPECTIVE OBSERVATIONAL STUDY OF THE POLISH MYELOMA GROUP.**
K Jamrozik¹ (¹Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland)

- E1263 REAL-WORLD TREATMENT PATTERNS AND PATIENTS CHARACTERISTICS IN MULTIPLE MYELOMA ACROSS EUROPE**
 A Fernandez¹ (¹EUCAN Medical Affairs, Takeda, CH-8152 Glattpark-Opfikon (Zurich), Switzerland)
- E1264 FRAILITY AND MORTALITY IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA**
 N Schutz¹ (¹Medicina Interna - Hematología, Hospital Italiano de Buenos Aires, CABA, Argentina)
- E1265 PROGNOSIS OF AL AMYLOIDOSIS WITH KIDNEY INJURY**
 A Talbot¹ (¹Immunology, hopital Saint Louis, paris, France)
- E1266 REAL-WORLD DATA ON THE TREATMENT OF RELAPSED/REFRACTORY MYELOMA WITH LENALIDOMIDE AND DEXAMETHASONE IN 2ND LINE (LEGEND STUDY): THE PROGNOSTIC SIGNIFICANCE OF BIOCHEMICAL VS. CLINICAL RELAPSE**
 E Katodritou¹ (¹ Department of Hematology, Theaganion Cancer Hospital, THESSALONIKI, Greece)
- E1267 FDG-PET IN MULTIPLE MYELOMA: DUAL TIME POINT FDG UPTAKE IN FOCAL LESIONS CORRELATE TO RESPONSE TO CHEMOTHERAPY.**
 B Oestergaard¹ (¹Hematology, Odense University Hospital, Odense, Denmark)
- E1268 UNDERSTANDING THE CONTRIBUTE OF THE NOTCH PATHWAY IN MULTIPLE MYELOMA BONE MARROW NICHE: A FOCUS ON EXTRACELLULAR VESICLES-MEDIATED COMMUNICATION**
 M Colombo¹ (¹Dept. of Health Sciences, Università degli Studi di Milano, Milano, Italy)
- E1269 THE USE OF CARFILZOMIB AND BORTEZOMIB IN ROUTINE CLINICAL PRACTICE: RESULTS FROM PREAMBLE, AN ONGOING, OBSERVATIONAL COHORT STUDY IN MULTIPLE MYELOMA**
 B Durie¹ (¹Cedars-Sinai Medical Center, Los Angeles, United States)
- E1270 ROLE OF SERUM FREE LIGHT CHAIN VS BENCE JONES MEASUREMENT IN LIGHT CHAIN MULTIPLE MYELOMA (LCMM) AT DIAGNOSIS, DURING TREATMENT AND FOLLOW-UP FOR RESPONSE EVALUATION AND RELAPSE DETECTION**
 M Staderini¹ (¹Hematology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy)
- E1271 SUPPRESSION OF THE NON-MONOCLONAL PAIR AS NEW BIOMARKER OF POOR PROGNOSIS IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS AND AFTER AUTOLOGOUS STEM CELL TRANSPLANT**
 JL Garcia De Veas Silva¹ (¹Department of Laboratory Medicine, Complejo Hospitalario Universitario de Granada, Granada, Spain)
- E1272 SURVIVAL STRATIFICATION OF PATIENTS WITH MULTIPLE MYELOMA (MM) AFTER FIRST RELAPSE: SENSITIVITY ANALYSES OF A NOVEL RISK STRATIFICATION ALGORITHM (RSA)**
 R Hajek¹ (¹Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic)
- E1273 REAL-WORLD DATA ON MULTIPLE MYELOMA: A PROSPECTIVE NATIONAL REGISTRY IN URUGUAY ON 224 NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS FROM 2012-2015**
 E Riva¹ (¹Hematology Department, Hospital de Clínicas, Facultad de Medicina, Montevideo, Uruguay)
- E1274 REPRESENTATION OF MINORITIES, THE ELDERLY AND WOMEN IN MULTIPLE MYELOMA CLINICAL TRIALS**
 N Duma¹ (¹Hematology, Mayo Clinic , Rochester, United States)
- E1275 EVALUATION OF TREATMENT INDUCED NEUROPATHY IN MULTIPLE MYELOMA AND ITS INFLUENCE ON PHYSICAL AND ROLE FUNCTIONING**
 B Sidi Mohamed El Amine¹ (¹Hematology department, University hospital of Sidi Bel Abbés, Sidi Bel Abbes, Algeria)
- E1276 PROGNOSTIC SIGNIFICANCE OF T(11;14) EXPRESSION BY FISH IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE ERA OF NOVEL THERAPIES**
 M Gonzalez Velez¹ (¹Internal Medicine, Rutgers NJMS, Newark, United States)
- E1277 ANALYSIS OF THE CONNECT MM REGISTRY: TREATMENT OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO RECEIVED LENALIDOMIDE MAINTENANCE OR NO MAINTENANCE**
 RM Rifkin¹ (¹US Oncology Research, Rocky Mountain Cancer Centers, Denver, United States)
- E1278 SERUM-FREE LIGHT-CHAINS (SFCL) INSTEAD OF URINE PROTEIN ELECTROPHORESIS (UPEP) FOR MONITORING LIGHT-CHAIN MULTIPLE MYELOMA (LCMM)**
 L Lopez Anglada Fernandez¹ (¹Haematology, Hospital 12 de Octubre, Madrid, Spain)
- E1279 TOPSPIN: A NOVEL ALGORITHM TO PREDICT TREATMENT SPECIFIC SURVIVAL IN CANCER**
 J Ubels^{1, 2, 3} (¹SkylineDx, Rotterdam, the Netherlands, ²Department of Hematology, Erasmus MC Cancer Institute , Rotterdam, the Netherlands, ³Center for Molecular Medicine, UMC Utrecht, Utrecht, the Netherlands)

- E1280 AMYLOIDOSIS RESEARCH CONSORTIUM CARDIAC AMYLOIDOSIS SURVEY: RESULTS FROM PATIENTS WITH AL AMYLOIDOSIS AND THEIR CAREGIVERS**
I Lousada¹ (¹Amyloidosis Research Consortium, Boston, United States)
- E1281 EFFICACY OF DARATUMUMAB-BASED REGIMENS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA – A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS**
MA Dimopoulos¹ (¹National and Kapodistrian University of Athens, Athens, Greece)
- E1282 TRENDS IN TREATMENT PATTERNS AND SEQUENCING IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED 2011-2016 IN THE UNITED STATES USING AN ENHANCED ELECTRONIC HEALTH RECORDS DATABASE**
S Abouzaid¹ (¹Celgene Corporation, Summit, NJ, United States)
- E1283 HLC PAIR SUPPRESSION AS A RISK FACTOR FOR BLOODSTREAM INFECTIONS AND EARLY DEATH IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS**
JL García De Veas Silva¹ (¹Department of Laboratory Medicine, Complejo Hospitalario Universitario de Granada, Granada, Spain)
- E1284 DARATUMUMAB SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA**
D Katalinic¹ (¹Department of Internal Medicine, Faculty of Medicine, J.J. Strossmayer University of Osijek, Osijek, Croatia)
- E1285 COMPARISON BETWEEN IMMUNOFIXATION NEGATIVITY AND NORMAL FREE LIGHT CHAIN RATIO WITH MULTICOLOUR FLOW CYTOMETRY FOR RESPONSE ASSESSMENT IN PATIENTS WITH MULTIPLE MYELOMA WITH VGPR OR BETTER**
K Narita¹ (¹Department of Medicine, Hematology/Oncology Kameda Medical Center, Kamogawa, Japan)
- E1286 DARATUMUMAB IS AN EFFECTIVE AND SAFE SALVAGE THERAPY IN RELAPSED/REFRACTORY PATIENTS WITH MULTIPLE MYELOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.**
E Klyuchnikov¹ (¹Department for Stem Cell Transplantation, UNIVERSITY CANCER CENTER HAMBURG-EPPENDORF, Hamburg, Germany)
- E1287 PROGNOSTIC RELEVANCE OF VEGF AND VEGFR EXPRESSION IN CD138+/CD19- AND CD138+/CD19+ PLASMA CELLS FROM PATIENTS WITH MONOCLONAL GAMMOPATHIES**
C Geraldes¹, ² (¹Applied Molecular Biology and University Clinic of Hematology, Faculty of Medicine University of Coimbra, Coimbra, Portugal, ²Clinical Hematology Department, Centro Hospital e Universitário de Coimbra (CHUC), Coimbra, Portugal)
- E1288 RACIAL DIFFERENCES OF FISH ABNORMALITIES IN MINORITIES WITH MULTIPLE MYELOMA: A SINGLE-CENTER EXPERIENCE**
M Gonzalez Velez¹ (¹Internal Medicine, Rutgers NJMS, Newark, United States)
- E1289 POMALIDOMIDE ALONE OR IN COMBINATION WITH LOW DOSE DEXAMETHASONE AS MAINTENANCE FOLLOWING INDUCTION WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MYELOMA [ALLG MM14]**
A Kaiff¹, ² (¹Alfred Hospital, Melbourne, Australia, ²Monash University, Melbourne, Australia)
- E1290 POMALIDOMID IS MORE EFFECTIVE IN REAL CLINICAL PRACTICE THAN IN RANDOMIZED TRIAL – AN OBSERVATIONAL STUDY OF THE CZECH MYELOMA GROUP**
L Pour¹ (¹department hematology and oncology , University hospital Brno, Brno, Czech Republic)
- E1291 UNDERSTANDING THE REAL-WORLD CLINICAL CHARACTERISTICS OF MULTIPLE MYELOMA PATIENTS IN EUROPE**
T Bacon¹ (¹Janssen Health Economics & Market Access EMEA, Dublin, Ireland)
- E1292 RAD REGIMEN AS INDUCTION BEFORE ASCT: OUTCOMES, SAFETY AND EFFECTS ON BONE METABOLISM AND ANGIOGENESIS; FINAL RESULTS OF A PHASE 2 STUDY OF THE GREEK MYELOMA STUDY GROUP**
E Terpos¹ (¹ Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece)
- E1293 MULTIPLE MYELOMA IN THE REAL WORLD: HOW THERAPEUTIC LANDSCAPE HAS CHANGED IN THE LAST 15 YEARS**
F Cocito¹ (¹Hematology, Policlinico S. Matteo, Pavia, Italy)
- E1294 CUL4A EXPRESSION AS A POTENTIAL PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH IMMUNOMODULATORY DRUGS**
A Malenda¹ (¹Department of Hematology, Insitute of Hematology and Transfusion Medicine, Warsaw, Poland)

- E1295 MAINTENANCE THERAPY WITH BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA (MM) AFTER ASCT AND MINIMAL RESIDUAL DISEASE (MRD)**
 M Solovet¹ (¹Dept. of High-Dose Chemotherapy of Paraproteinemic Hemoblastosis, Research Center for Hematology, Moscow, Russian Federation)
- E1296 LONG-TERM OUTCOME OF MULTIPLE MYELOMA (MM) PATIENTS TREATED UP-FRONT WITH SINGLE OR TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) - SINGLE CENTRE EXPERIENCE WITH 334 PATIENTS**
 J Batinic^{1, 2} (¹Medical School, University of Zagreb, Zagreb, Croatia, ²Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia)
- E1297 EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION: CLINICAL IMPACT IN DIAGNOSIS, TREATMENT AND OUTCOME**
 A Roque^{1, 2} (¹Faculty of Medicine, University of Coimbra, Coimbra, Portugal, ²Clinical Hematology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal)
- E1298 DIFFERENCES IN PATIENT AND DISEASE CHARACTERISTICS OBSERVED AT INITIATION OF FIRST-LINE AND INITIATION OF SECOND-LINE TREATMENT IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA IN THE CZECH REPUBLIC**
 V Maisnar^{1, 2} (¹4th Department of Medicine – Haematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic, ²Faculty of Medicine, Charles University Hospital, Hradec Kralove, Czech Republic)
- E1299 AN EARLY GOOD RESPONSE AFTER BORTEZOMIB-BASED INDUCTION REGIMENS REPRESENTS A SIGNIFICANT PREDICTOR FOR IMPROVED PFS IN NDMM PATIENTS**
 G Rivoli¹ (¹Clinica Ematologica, IRCCS San Martino IST, Genova, Italy)
- E1300 RELATIVE PROGRESSION-FREE SURVIVAL OVER TIME OF NOVEL TRIPLET REGIMENS FOR THE TREATMENT OF RELAPSED/ REFRACTORY MULTIPLE MYELOMA**
 D Makenbaeva² (²Bristol-Myers Squibb, Inc., Plainsboro, NJ, United States)
- E1301 POMALIDOMIDE WITH LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE ANALYSIS IN A POPULATION-BASED REGISTRY**
 R Wester¹ (¹Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands)
- E1302 INVOLVED/UNINVOLVED HEAVY/LIGHT CHAIN INDEX CAN PREDICT PROGRESSION IN MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM TRANSPLANT. PRELIMINARY EXPERIENCE**
 M Espiño Martínez¹ (¹Immunology, UNIVERSITY HOSPITAL RAMON Y CAJAL, Madrid, Spain)
- E1303 MULTIPLE MYELOMA IMMUNOPHENOTYPIC REMISSION IS A SIGNIFICANT PREDICTOR OF PROGRESSION FREE SURVIVAL AFTER FIRST AUTOLOGOUS STEM CELL TRANSPLANTATION - PILOT STUDY**
 K Beranova¹ (¹IV. interni hematologicka klinika, Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czech Republic)
- E1304 REGULATION OF NORMAL AND MONOCLONAL IMMUNOGLOBULIN SECRETION BY CYTOKINES (S- SYNDICAN-1, BLYS & TGF-BETA-1) IN PATIENTS WITH IG-SECRETING B-CELL DISORDERS AT PRESENTATION. PROGNOSTIC IMPLICATIONS.**
 P Papaioannou¹ (¹Hematology Section - 1st Department Of Propaedeutic Internal Medicine, Laikon General Hospital, Athens, Greece)
- E1305 PATIENTS WITH MULTIPLE MYELOMA (MM) IN LONG TERM COMPLETE REMISSION (LTCR) AFTER AUTOLOGOUS TRANSPLANT (APBSCT) EXPRESS A DISTINCTIVE IMMUNE PROFILE WITH POTENTIAL PROGNOSIS VALUE**
 A Artech-Lopez¹ (¹Clinical Analysis, UNIVERSITY HOSPITAL LA PRINCESA, Madrid, Spain)
- E1306 IMPACT OF THE AFFORDABILITY OF NOVEL AGENTS IN PATIENTS WITH MULTIPLE MYELOMA: REAL WORLD DATA ON CURRENT CLINICAL PRACTICE IN MEXICO**
 L Tarin-Arzaga¹ (¹Hematology, Hospital Universitario Dr Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Monterrey, Mexico)

MYELOPROLIFERATIVE NEOPLASMS - BIOLOGY

- E1307 BASAL CALCIUM, AN IMPORTANT ELEMENT IN THE DEVELOPMENT OF CALR MUTANT MPNS**
 M Morlan Mairal¹ (¹Salford University, Manchester, United Kingdom)
- E1308 THE INHIBITION OF JAK/STAT SIGNALING IS COMPENSATED BY ACTIVATION OF MAPK PATHWAY IN MYELOPROLIFERATIVE NEOPLASMS**
 B Beleslin Čokić² (²Clinic for endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Belgrade, Serbia)

E1309 CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB?

L Catani¹ (¹Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. e A. Seragnoli", University of Bologna, Bologna, Italy)

E1310 A COMPARATIVE FUNCTIONAL AND PHENOTYPIC PLATELET ANALYSIS AMONG GENETIC GROUPS OF ESSENTIAL THROMBOCYTHEMIA PATIENTS.

P Papadopoulos^{1, 2} (¹Hematology, IdISCC (HCSC), Madrid, Spain, ²Human Genetics, KU Leuven, Leuven, Belgium)

E1311 ASSOCIATION ANALYSIS OF CYTOGENETIC AND GENETIC ALTERATIONS IN PRIMARY MYELOFIBROSIS

R Norvilas^{1, 2} (¹Department of Innovative Medical Technologies and Health Resort Science, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania, ² Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania)

E1312 FREQUENCY OF CONCURRENT BCR-ABL1, JAK2, CALR AND MPL MUTATIONS IN A COHORT OF 5,545 CASES WITH SUSPECTED MPN BY A DEEP SEQUENCING APPROACH

S Jeromin¹ (¹MLL Munich Leukemia Laboratory, Munich, Germany)

E1313 A COMPREHENSIVE ASSESSMENT OF MOLECULAR AND CYTOGENETIC MARKERS OF PROGNOSIS IN PATIENTS WITH PRIMARY MYELOFIBROSIS

L Polushkina¹ (¹Russian Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russian Federation)

E1314 JAK2 HAPLOTYPE 46/1 (GGCC) HAS NO EFFECT ON THE PRIMARY RISK OF JAK2 V617F MUTATION, BUT IT STRONGLY POTENTIATES THE PROGRESSION OF GROWN ALLELE BURDEN IN MYELOPROLIFERATIVE NEOPLASMS

M Stolyar^{1, 2} (¹Siberian Federal University, Krasnoyarsk, Russian Federation, ²Krasnoyarsk Branch of the Federal State-Funded Institution «National Research Center for Hematology» of the Ministry of Healthcare of the Russian Federation, Krasnoyarsk, Russian Federation)

E1315 MINIMAL RESIDUAL DISEASE MONITORING BY DIGITAL PCR FOR JAK2V617F DETECTION IN PATIENTS WITH MYELOFIBROSIS (MF) OR ACUTE MYELOID LEUKEMIA SECONDARY TO MF AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

S Salmoiraghi¹ (¹Hematology and Bone Marrow Transplant, ASST Papa Giovanni XXIII, Bergamo, Italy)

E1316 S100A8/9 ACTIVATION OF MAPK PATHWAY IS SUPPORTED BY ITS RECEPTORS RAGE AND TLR4 IN POLYCYTHEMIA VERA

M Kovačić¹ (¹Laboratory of neuroendocrinology, Institute for Medical Research, Belgrade, Serbia)

E1317 MUTATIONAL PROFILE STUDY OF DOUBLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA BY HIGH-DEPTH NEXT GENERATION SEQUENCING (NGS)

G Carreno-Tarragona¹ (¹Haematology, Hospital Universitario 12 de Octubre, Madrid, Spain)

E1318 TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES

S Galimberti¹ (¹Clinical and Experimental Medicine, University of Pisa, Hematology, Pisa, Italy)

E1319 PROINFLAMMATORY CYTOKINE IL-6 STIMULATION OF ANGIOGENIC FACTORS AND DNA REPLICATION IS BLOCKED BY JAK-STAT PATHWAY INHIBITION IN MYELOPROLIFERATIVE NEOPLASMS

T Subotički¹ (¹Laboratory of neuroendocrinology, Institute for Medical Research, University of Belgrade, Belgrade, Serbia)

MYELOPROLIFERATIVE NEOPLASMS - CLINICAL

E1320 PERCEPTION OF SYMPTOM BURDEN AND TREATMENT GOALS BETWEEN PHYSICIANS AND PATIENTS WITH MPNS: AN ANALYSIS FROM THE INTERNATIONAL MPN LANDMARK SURVEY

L Foltz¹ (¹St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada)

E1321 BASELINE QUALITY OF LIFE INDEPENDENTLY PREDICTS OVERALL SURVIVAL IN THE MYELOFIBROSIS: KEY INSIGHTS FROM THE COMFORT-I STUDY

R Scherber^{1, 2} (¹Hematology and Oncology, Mayo Clinic, Scottsdale, United States, ²Hematology and Oncology, Oregon Health and Science University, Portland, United States)

E1322 CHARACTERIZATION OF DISEASE AND OUTCOMES OF PATIENTS WITH MYELOFIBROSIS: A POPULATION BASED STUDY

J He¹ (¹Janssen Global Services LLC, Raritan, United States)

E1323 SERUM ALBUMIN IS A STRONG PREDICTOR OF SURVIVAL IN MYELOFIBROSIS, INDEPENDENT OF IPSS, DIPSS, AND DIPSS+ SCORES

AT Kuykendall¹ (¹University of South Florida/Moffitt Cancer Center, Tampa, United States)

E1324 CLINICAL UTILITY OF NEXT-GENERATION SEQUENCING IN THE MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASMS

W Alduaij¹ (¹MPN program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada)

- E1325 **IMPACT OF COMORBIDITIES AND BODY MASS INDEX ON SURVIVAL IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB**
F Palandri¹ (Department of Hematology, University of Bologna, Bologna, Italy)
- E1326 **ANALYSES OF 845 PATIENTS WITH PMF, PET-MF AND PPV-MF TREATED IN 35 GERMAN HEMATOLOGY CENTERS – A RETROSPECTIVE FIELD STUDY**
B Kragl¹ (Department of Internal Medicine 3, Hematology, Oncology, Palliative Care, University of Rostock, Rostock, Germany)
- E1327 **CALR MUTATION TYPE INFLUENCES THE RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTEMIA ACCORDING TO A COOPERATIVE STUDY BETWEEN TWO SPANISH CENTERS**
A Abuin Blanco¹ (Hematology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain)
- E1328 **MONITORING OF LEUKOCYTE-PLATELET AGGREGATES AND SELECTIN LEVELS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS**
D Šefer¹ (Outpatient Clinics and Diagnostic Department, Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia)
- E1329 **HEAT SHOCK PROTEIN 27 EXPRESSION IS INCREASED IN PATIENTS WITH PRIMARY AND SECONDARY MYELOFIBROSIS AND MAY BE AFFECTING THEIR SURVIVAL**
R Kusec² (Clinical Institute of Laboratory Diagnosis, Division of Molecular Diagnosis and Genetics, University Hospital Dubrava, Zagreb, Croatia)
- E1330 **NON-DRIVER MUTATIONS IDENTIFIED BY A 190-GENE NEXT GENERATION SEQUENCING PANEL IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST-POLYCYTHAEMIC/ESSENTIAL THROMBOCYTHAEMIA MYELOFIBROSIS**
B Li¹ (MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China)
- E1331 **DETERMINING MEANINGFUL CHANGE IN THE MYELOFIBROSIS SYMPTOM ASSESSMENT FORM (MFSAF) V2.0 USING A COMBINATION OF DISTRIBUTION- AND ANCHOR-BASED APPROACHES IN THE COMFORT-1 TRIAL**
A Dueck¹ (Mayo Clinic, Scottsdale, AZ, United States)
- E1332 **ERYTHROPOIESIS STIMULATING AGENTS CAN IMPROVE ANEMIA IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB**
E Crisà¹ (Hematology Division, A.O.U. Città della Salute e della Scienza di Torino, University of Turin, Torino, Italy)
- E1333 **COMPARING THE SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH DIPSS LOW/INTERMEDIATE-1-, INTERMEDIATE-2-, AND HIGH-RISK MYELOFIBROSIS (MF) IN JUMP, A PHASE 3B, EXPANDED-ACCESS STUDY**
F Passamonti¹ (University of Insubria, Varese, Italy)
- E1334 **SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) WHO STARTED TREATMENT AT 10 MG BID AND HAD THE DOSE UPTITRATED IN THE PHASE 3B EXPANDED-ACCESS JUMP STUDY**
L Foltz¹ (St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada)
- E1335 **HYDROXYUREA IS ASSOCIATED WITH SKIN TOXICITY IN MYELOPROLIFERATIVE NEOPLASMS: RESULTS FROM A PROSPECTIVE NON-INTERVENTIONAL STUDY**
F Stegelmann¹ (University Hospital of Ulm, Ulm, Germany)
- E1336 **THE NEGATIVE PROGNOSTIC IMPACT OF BASOPHILIA, EOSINOPHILIA AND MONOCYTOSIS AT DIAGNOSIS IN PRIMARY MYELOFIBROSIS**
M Pereira^{1, 2} (Faculty of Medicine, University of Coimbra, Coimbra, Portugal, ²Clinical Hematology Department, Coimbra University Hospital Centre, Coimbra, Portugal)
- E1337 **BLAST PHASE IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS OF 85 PATIENTS**
E Roncoroni¹ (Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy)
- E1338 **TELOMERE LENGTH IS REDUCED IN ESSENTIAL THROMBOCYTHAEMIA PATIENTS COMPARED TO AGE AND GENDER MATCHED HEALTHY CONTROLS**
S Alimam¹ (Haematology, Guys and St Thomas' NHS Foundation Trust, London, United Kingdom)
- E1339 **NUTRITION IN MYELOFIBROSIS: CORRELATES FROM THE COMFORT-1 STUDY**
R Scherber^{1, 2} (Hematology and Oncology, Mayo Clinic, Scottsdale, United States, ²Hematology and Oncology, Oregon Health and Science University, Portland, United States)
- E1340 **IS THE SURVIVAL OF PATIENTS WITH ESSENTIAL THROMBOCYTEMIA BETTER IN THE LAST DECADE? RETROSPECTIVE ANALYSIS OF DATABASE OF LATIAL GROUP FOR THE STUDY OF NMP, PH NEGATIVE.**
A Andriani² (UOSD of Hematology, ASL Roma1, Ospedale Santo Spirito & Nuovo Regina Margherita, Rome, Italy)

E1341 CUTANEOUS INVOLVEMENT IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS-SINGLE-CENTER EXPERIENCE.

JM Sanchez-Raga^{1, 2} (¹Hematology and Hemotherapy, Fundación de Investigación Sanitaria de las Islas Baleares Ramon Llull, Palma de Mallorca, Spain, ²Hematology and Hemotherapy, Hospital Universitari Son Espases, Palma de Mallorca, Spain)

E1342 HEMOGLOBIN AND WHITE CELL COUNT IN PATIENTS CLINICALLY SUSPECTED TO HAVE ESSENTIAL THROMBOCYTHEMIA MAY HELP IN PREDICTING EARLY PRIMARY MYELOFIBROSIS OR UNCLASSIFIABLE MYELOPROLIFERATIVE NEOPLASM

S Sirhan¹ (¹Jewish General Hospital Montreal, Montreal, Canada)

E1343 PK/PD MODELING COMPARING DIVIDED DOSING (200 MG TWICE-DAILY [BID]) VS SINGLE DOSING (400 MG ONCE-DAILY [QD]) OF PACRITINIB (PAC) IN PATIENTS WITH MYELOFIBROSIS (MF) ON THE PERSIST-2 PHASE 3 TRIAL

S Al-Fayoumi¹ (¹CTI BioPharma Corp., Seattle, WA, United States)

E1344 ZMYM2-FLT3 IS A RARE, RECURRENT, CYTOGENETICALLY CRYPTIC FUSION IN MYELOID/LYMPHOID NEOPLASMS WITH EOSINOPHILIA THAT IS RESPONSIVE TO FLT3 INHIBITION

M Jawhar¹ (¹Department of Hematology and Oncology, Medical Faculty Mannheim of University of Heidelberg, Mannheim, Germany)

E1345 COMPLETE HEMATOLOGIC AND CYTOGENETIC RESPONSE IN A PATIENT WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 ACTIVATED MYELOPROLIFERATIVE NEOPLASM RECEIVING INCB054828

N Daver¹ (¹MD Anderson Cancer Center, Houston, TX, United States)

E1346 THE GRADE OF STROMAL CHANGES IMPACTS ON PROGNOSIS IN PATIENTS WITH PRIMARY MYELOFIBROSIS

U Gianelli¹ (¹Division of Pathology, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation and University of Milan, Milano, Italy)

E1347 INCREASED RISK OF INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH PHILADELPHIA NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS

M Bak¹ (¹Department of Haematology, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark)

E1348 ESSENTIAL THROMBOCYTHEMIA WITH AQUAGENIC PRURITUS: AN ENTITY WITH MORE AGGRESSIVE CLINICAL AND BIOLOGICAL PROFILE AT THE DIAGNOSIS AND A HIGH MORBIDITY DURING THE FOLLOW-UP.

C Le Gall-Ianotto^{1, 2} (¹Service dermatologie, CHU Brest - Hôpital Augustin Morvan, Brest, France, ²laboratory of interactions epitheliums-neurones, university of Brest, Brest, France)

E1349 ANAGRELIDE RESPONSE ACCORDING TO THE MOLECULAR PROFILE: SOMETHING TO CONCLUDE ON THE MECHANISM OF ACTION OF THE DRUG IN MYELOPROLIFERATIVE NEOPLASMS (MPN)?

M Montero¹ (¹Haematology and haemotherapy Service, Hospital Universitario Virgen del Rocío, Sevilla, Spain)

E1350 THE DELAYED DIAGNOSIS OF PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN) IS COMMON AND RESULTS IN A HIGH INCIDENCE OF POTENTIALLY PREVENTABLE THROMBOTIC COMPLICATIONS.

C Forsyth¹ (¹Medicine, Wyong Hospital, Kanwal, Australia)

E1351 LONG-TERM AND LOW-DOSE BUSULFAN IS SAFE AND EFFECTIVE IN ELDERLY PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

R Renso¹ (¹Hematology Division, San Gerardo Hospital, Monza, Italy)

E1352 DIFFERENCES IN JAK2V617F POSITIVE PATIENTS WITH AND WITHOUT THROMBOSIS ACCORDING TO DIAGNOSIS, AGE, SEX AND V617F ALLELE BURDEN

I Horvat¹ (¹Department of Laboratory Diagnostics, University Hospital Center Zagreb, Zagreb, Croatia)

NON-HODGKIN & HODGKIN LYMPHOMA - BIOLOGY

E1353 PROTECTION AGAINST DEVELOPMENT OF B CELL LYMPHOMA BY TETRASPANIN CD37

A Van Sriel¹ (¹Radboud University Medical Center, Nijmegen, the Netherlands)

E1354 CONCOMITANT DUAL ABLATION OF BLIMP1 AND P53 IN B-CELLS AS A NOVEL IN VIVO MODEL FOR HIGH-GRADE B-CELL LYMPHOMA

A Roccaro¹ (¹ASST Spedali Civili di Brescia, Brescia, Italy)

E1355 IDENTIFICATION AND CHARACTERISATION OF THE LYMPHOMA INITIATING CELL (LIC) POPULATION IN AN ALCL MOUSE MODEL

S Kreutmair¹ (¹Hematology, Oncology and Stem Cell Transplantation, University medical center Freiburg, Freiburg, Germany)

- E1356 **HSP110 SUSTAINS MYD88-DEPENDENT NFKB SIGNALING IN ACTIVATED B CELL DIFFUSE LARGE B CELL LYMPHOMA**
G Jego¹ (¹University of Burgundy, Dijon, France)
- E1357 **STAT3 ACTIVATION MEDIATES CD8+/CD16+/CD56-T-LGLL NEUTROPENIA THROUGH FAS LIGAND SECRETION**
G Barila¹, ² (¹Dept of Medicine, Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy, ²Venetian Institute of Molecular Medicine, Padua, Italy)
- E1358 **CYCLIN D2 OVEREXPRESSION RECAPITULATES MANTLE CELL LYMPHOMA IN MICE**
T Pieters¹ (¹Ghent University, Ghent, Belgium)
- E1359 **HDAC6 INHIBITION INCREASES CD20 LEVEL BY STIMULATING TRANSLATION OF CD20 MRNA**
A Graczyk-Jarzynka¹ (¹Department of Immunology, Medical University of Warsaw, Warsaw, Poland)
- E1360 **CARD11 DUPLICATION AT DIAGNOSIS IDENTIFIES VERY LOW-RISK MANTLE CELL LYMPHOMA PATIENTS: RESULTS OF THE LYMA-GENOMIC PROJECT CONDUCTED ON BEHALF OF THE LYSA GROUP.**
Y Le Bris¹, ² (¹Hematology biology, Nantes University Hospital, Nantes, France, ²CRCINA, INSERM UMR1232, Nantes, France)
- E1361 **CLINICOBIOLOGICAL FEATURES OF B-CELL NEOPLASMS WITH CDK6 TRANSLOCATIONS: FREQUENT ASSOCIATION WITH MARGINAL-ZONE LYMPHOMA, CONTINGENT OF PROLYMPHOCYTIC CELLS AND TP53 ABNORMALITIES. A GFCH STUDY.**
E Chapiro², ⁴ (²Service d'Hématologie biologique, Hôpital Pitié-Salpêtrière, AP-HP, PARIS, France, ⁴UNIVERSITE PIERRE ET MARIE CURIE, Paris, France)
- E1362 **PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE, EXPRESS STEREOTYPED B-CELL RECEPTORS WITH UNIQUE NONSYNONYMOUSLY MUTATED CONSTANT REGIONS**
MT Koning¹ (¹Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands)
- E1363 **LOSS OF NR4A1 ACCELERATES MYC-DRIVEN LYMPHOMAGENESIS ACCOMPANIED BY OVEREXPRESSION OF GENES INVOLVED IN IMMUNOREGULATION**
K Fechter¹ (¹Department of Hematology/ University Clinic for Internal Medicine, Medical University of Graz, Graz, Austria)
- E1364 **DISSECTING THE PI3K PATHWAY IN A CYCLIN D1-DRIVEN MODEL OF MCL**
S Ehrenfeld¹, ², ³, ⁴ (¹Department of Medicine I: Hematology, Oncology, and Stem-Cell Transplantation, Medical Center, University Freiburg, Freiburg, Germany, ²German Cancer Consortium (DKTK) Partnersite Freiburg, Freiburg, Germany, ³German Cancer Research Center (DKFZ), Heidelberg, Germany, ⁴Faculty of Biology, University Freiburg, Freiburg, Germany)
- E1365 **MUTATIONAL PROFILING OF HODGKIN- AND REED-STERNBERG CELLS (HRSC) OF CLASSICAL HODGKIN LYMPHOMA (CHL) ENRICHED FROM ARCHIVAL FORMALIN-FIXED AND PARAFFIN-EMBEDDED TISSUE SAMPLES**
D Juskevicius¹ (¹Institute of Pathology, University Hospital Basel, Basel, Switzerland)
- E1366 **LACK OF STAT1 PREDISPOSES TO A DIFFUSE LARGE B-CELL LYMPHOMA-LIKE DISEASE**
S Tripolt¹ (¹Institute of Pharmacology and Toxicology, Veterinary University of Vienna, Vienna, Austria)
- E1367 **MOLECULAR HETEROGENEITY OF MANTLE CELL LYMPHOMA**
O Cédile¹ (¹Haematology-Pathology Research Laboratory, Department of Haematology, Odense University Hospital, Odense C, Denmark)
- E1368 **NOVEL TARGET GENES OF Deregulated MIRNAS IN DLBCL REVEALED BY ENDOGENOUS AGO2 PAR-CLIP**
M Fernandez-Mercado¹, ² (¹Oncology, Bionostia HRI, San Sebastian, Spain, ²Biomedical Engineering, School of Engineering, University of Navarra, San Sebastian, Spain)
- E1369 **DARATUMUMAB, A NOVEL HUMAN CD38 MONOCLONAL ANTIBODY FOR THE TREATMENT OF B-CELL NON-HODGKIN LYMPHOMA**
A Matas-Céspedes¹ (¹Hematology-Oncology, IDIBAPS, Barcelona, Spain)
- E1370 **ECTONUCLEOTIDASES CD39/CD73 ARE HIGHLY EXPRESSED ON ATLL CELLS AND RESPONSIBLE FOR GENERATING AMP/ADENOSINE.**
Y Nagate¹ (¹Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan)
- E1372 **ACTIVATION OF SYK TYROSINE KINASE PLAYS A ROLE IN RESISTANCE AGAINST THE SELECTIVE BTK INHIBITOR ONO/GS-4059 IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL).**
K Tsukamoto¹ (¹Cancer studies, University of Leicester, Leicester, United Kingdom)

- E1373 **STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC) FOR TREATMENT OF B-CELL NON-HODGKIN'S LYMPHOMA (NHL)**
A Molina¹ (¹Sutro Biopharma, South San Francisco, United States)
- E1374 **DETECTING MALIGNANT B-CELLS IN CEREBROSPINAL FLUID: DOES THE IDEAL METHOD EXIST?**
M Le Garff-Tavernier¹ (¹Biological Haematology Department, Pitie-Salpetriere Hospital, Paris, France)
- E1375 **THE SYK INHIBITOR R406 DRAMATICALLY INCREASES THE SENSITIVITY OF GCB AND ABC DLBCL CELL LINES TO THE BCL-2 INHIBITOR VENETOCLAX**
B Sasi¹ (¹Molecular Hematology, International Centre for Genetic Engineering & Biotechnology, Trieste, Italy)
- E1376 **V β EXPRESSION ASSESSMENT AND CLONALITY DETECTION IN T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) BY FLOW CYTOMETRY (FCM) AND NEXT GENERATION SEQUENCING (NGS): A COMPARISON OF BOTH METHODS**
M Kotrová^{1, 2} (¹Medical Department II, Unit for Hematological Diagnostics, University Hospital Schleswig-Holstein, Kiel, Germany, ²contributed equally, Kiel, Germany)
- E1377 **IRF4 EXPRESSION IS ASSOCIATED WITH RESPONSE OF MANTLE CELL LYMPHOMA TO BRUTON'S TYROSINE KINASE INHIBITORS**
HP Thompson¹ (¹Institute of Translational and Stratified Medicine, Plymouth University, Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom)
- E1378 **LOSS OF TPL2 KINASE ACCELERATES MYC-INDUCED LYMPHOMAGENESIS**
E Stagakis^{1, 2} (¹Laboratory of Molecular and Cellular Biology, Medical School, University of Crete, Heraklion, Greece, ²Department of Hematology, University Hospital of Heraklion, Heraklion, Greece)
- E1379 **LIQUID BIOPSY: DECIPHERING A SIGNATURE OF CIRCULATING MICRORNAs AS NOVEL NON-INVASIVE BIOMARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA**
F Marchesi¹ (¹Hematology and Stem Cell Transplant, Regina Elena National Cancer Institute, Rome, Italy)
- E1380 **INTRACELLULAR CALCIUM AND METABOLISM HAVE CRITICAL ROLES IN DETERMINING ANTI-CD20 ANTIBODY EFFICACY IN DLBCL**
E Vilvethraraja¹ (¹Centre for Haemato-Oncology, Barts Cancer Institute, London, United Kingdom)
- E1381 **CYCLIN D1 ONCOGENIC OVEREXPRESSION LEADS TO A GLOBAL TRANSCRIPTIONAL DOWNREGULATION IN MALIGNANT LYMPHOID CELLS**
R Albero¹ (¹IDIBAPS, Barcelona, Spain)
- E1382 **MICROENVIRONMENTAL EXPRESSION OF IMMUNOREGULATORY MOLECULES AND CYTOKINES IN CLASSICAL HODGKIN LYMPHOMA PROGNOSIS**
O Novosad¹ (¹Oncohematology, National Cancer Institute, Kiev, Ukraine)
- E1383 **AN IN VIVO TRACEABLE AND MULTIPLEXING CRISPR/CAS9 GENOME EDITING SYSTEM**
L Cheng¹ (¹Department of Hematology and Research Laboratory of Hematology, West China Hospital Sichuan University, Chengdu, China)
- E1385 **HDAC6 INHIBITION SENSITIZES TUMOR CELLS TO ANTI-CD20 IMMUNOTHERAPY IN VIVO**
M Bobowicz¹ (¹Department of Immunology, MEDICAL UNIVERSITY OF WARSAW, Warsaw, Poland)
- E1386 **NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A CELAC NETWORK STUDY.**
M Cheminant^{1, 2} (¹Hematology Unit, Necker Hospital - Paris Descartes - Sorbonne Paris Cité University, Paris, France, ²U1163, IMAGINE Institute, Paris, France)
- E1387 **HIGH EXPRESSION LEVELS OF MIR23A CLUSTER IN DLBCL ANTAGONIZE INDUCTION OF APOPTOSIS**
S Eberth¹ (¹Junior Research Group Molecular Cancer Research, Leibniz-Institute DSMZ - German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany)
- E1388 **PLASMA CELLS ARISE FROM DIFFERENTIATION OF CLONAL LYMPHOCYTES AND SECRETE IGM IN WALDENSTRÖM MACROGLOBULINEMIA**
D Talaulikar^{1, 2} (¹Haematology, Canberra Hospital, Canberra, Australia, ²Australian National University, Australian National University, Canberra, Australia)
- E1389 **LMP-1 MEDIATED UPREGULATION OF IL-2R β PROMOTES LYMPHOMAGENESIS AND CHEMOTHERAPY RESISTANCE IN NATURAL KILLER/T-CELL LYMPHOMA AND COULD BE A POTENTIAL THERAPY TARGET**
L Wang² (²Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
- E1390 **LENALIDOMIDE (LEN) DRIVES PROGRAMMED DEATH-1 (PD1) PATHWAY UPREGULATION IN A TUMOR MICROENVIRONMENT (TME) MODEL OF ACTIVATED LOW-GRADE LYMPHOMA CELLS**
F Morabito^{1, 20} (¹Unita di Ricerca Biotecnologica, Azienda Sanitaria Provinciale di Cosenza, Aprigliano (CS), Italy, ²⁰Hematology Department, Annunziata Hospital of Cosenza, Cosenza, Italy)

- E1391 IDENTIFICATION AND DIAGNOSTIC APPLICATION OF GENOMIC NPM-ALK FUSION SEQUENCES IN ANAPLASTIC LARGE CELL LYMPHOMAS**
M Krumbholz¹ (¹Department of Pediatrics, University Hospital Erlangen, Erlangen, Germany)
- E1392 ARSENIC TRIOXIDE TARGETS BCL6 FOR DEGRADATION AND INHIBITS THE PROLIFERATION OF BCL6-DEPENDENT DIFFUSE LARGE B-CELL LYMPHOMA**
E Tse¹ (¹Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong)
- E1393 PROTEOMIC PHOSPHOSITE ANALYSIS IDENTIFIED CRUCIAL NIPA SERINE RESIDUES FOR NPM-ALK-MEDIATED TRANSFORMATION**
A Gengenbacher¹ (¹Dept. of Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany)
- E1394 APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B CELL LYMPHOMAS**
MJ Baptista¹ (¹Department of Hematology, ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain)
- E1395 CXCR4 AND CXCL12 ARE IMPLICATED IN BONE MARROW INFILTRATION PROCESS OF AGGRESSIVE B CELL LYMPHOMAS AND THEIR INHIBITION SUPPRESSES LYMPHOMA CELL GROWTH IN VITRO**
A Deutsch¹ (¹Hematology, Internal Medicine, Graz, Austria)
- E1396 EPSTEIN-BARR VIRUS LOAD IN PLASMA IS AN EARLY BIOMARKER OF HIV-RELATED LYMPHOMA**
J Muncunill¹ (¹Department of Hematology, ICO-Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain)
- E1397 CLONOTYPE AND MUTATIONAL PATTERN IN TCRGD LARGE GRANULAR LYMPHOCYTE LEUKEMIA**
A Teramo^{1, 2} (¹Department of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Padua, Italy, ²Venetian Institute of Molecular Medicine (VIMM), Padua, Italy)
- E1398 INCREASED EXPRESSION OF IRF8 IN TUMOR CELLS INHIBITS THE GENERATION OF TH17 CELLS AND PREDICTS UNFAVORABLE SURVIVAL OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS**
Q Li¹ (¹Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China, Guangzhou, China)
- E1399 GENOMIC PROFILING OF BCL2 AND MYC DOUBLE EXPRESSOR DIFFUSE LARGE B CELL LYMPHOMA**
V Dirse^{1, 2} (¹Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania, ²Department of Internal, Family Medicine and Oncology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania)
- E1400 ARQ 531, A REVERSIBLE BTK INHIBITOR, DEMONSTRATES POTENT ANTI-TUMOR ACTIVITY IN ABC-DLBCL AND GCB-DLBCL**
S Eathiraj¹ (¹Clinical Development, ArQule Inc., Burlington, United States)
- E1401 ROLE OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY**
L Rigacci¹ (¹Haematology, AOU Careggi and University of Florence, Florence, Italy)
- E1402 CDK4/6-INHIBITION BY ABEMACICLIB INDUCES POTENT EARLY G1-ARREST IN MCL CELL LINES AND SHOWS SEQUENCE-SPECIFIC INTERACTIONS WITH CYTARABINE AND IBRUTINIB**
L Fischer¹ (¹Dept. of Medicine III, Univ. Hospital Grosshadern/LMU; Experimental Leukemia and Lymphoma Research (ELLF), Munich, Germany)
- E1403 CD8+ T-CELL CLONES PERSISTENT IN BONE MARROW AND PERIPHERAL BLOOD DURING COURSE OF CD4+ ANGIOIMMUNOBLASTIC LYMPHOMA**
S Smirnova¹ (¹Department of Molecular Hematology, National Research Center for Hematology, Moscow, Russian Federation)
- E1404 CD5 POSITIVE DIFFUSE LARGE B CELL LYMPHOMA SHOWED FREQUENT MYC EXPRESSION AND AGGRESSIVE CLINICAL BEHAVIOR**
JE Kim⁸ (⁸Pathology, Seoul National University Boramae Hospital, Seoul, Korea, Republic Of)
- E1405 REACTIVE FLORID B-LINEAGE LYMPHOID PROLIFERATIONS IN HIV INFECTION MAY MIMIC LYMPHOMA**
T Wiggill¹ (¹Molecular Medicine and Haematology, National Health Laboratory Service and University of the Witwatersrand, Johannesburg, South Africa)
- E1406 MICROVESSEL DENSITY IN CD30 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMAS.**
F Gaudio¹ (¹Hematology, Bari, Italy)
- E1407 ANTIGEN SELECTION PROMOTES CLONAL CYTOTOXIC T-CELL RESPONSES: HIGH-THROUGHPUT IMMUNOGENETIC EVIDENCE**
E Stalika¹ (¹Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece)

E1408 MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN LYMPHOMAS WITHIN THE FIL (FONDAZIONE ITALIANA LINFOMI) MRD NETWORK: INTER-LABORATORY REPRODUCIBILITY ON BORDERLINE SAMPLES

I Della Starza¹ (¹Department of Cellular Biotechnologies and Hematology, Hematology, Sapienza University, Rome, Italy)

E1409 RHOA GLY17VAL MUTATION AND T-CELL CLONALITY ANALYSIS IN PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA

Y Sidorova¹ (¹Department of Molecular Hematology, National Research Center for Hematology, Moscow, Russian Federation)

OTHER NON-MALIGNANT HEMATOPOIETIC DISORDERS

E1410 USEFULNESS OF CHITOTRIOSIDASE ACTIVITY, CCL18/PARC, 7-KETOCHOLESTEROL AND GLUCOSYLSPHINGOSINE CONCENTRATIONS FOR SCREENING OF LYSOSOMAL STORAGE DISORDERS.

P Irún¹, ² (¹Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Zaragoza, Spain, ²Unidad Investigación Traslacional. Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain)

E1411 THE VALUE OF SOLUBLE IL-2R ALPHA SUBUNIT MEASUREMENT IN CSF OF CHILDREN WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH): PRELIMINARY OBSERVATIONS

Y El Chazli¹ (¹Department of Pediatrics, Hematology/Oncology unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt)

E1412 GAUCHER DISEASE PATIENTS EXHIBIT A HIGH EXPRESSION OF LIPOCALINE (LCN2) AS POSSIBLE BIOMARKER OF RESIDUAL DISEASE ACTIVITY. EXPLORATORY STUDY AND CORRELATION WITH OTHER CYTOKINES.

M Andrade-Campos¹ (¹Translational Research Unit, IIS-Aragon. CIBERER. IISCIII, Zaragoza, Spain)

E1413 COMPARISON OF TREATMENT AND OUTCOMES BETWEEN ACQUIRED PRIMARY AND SECONDARY THROMBOTIC THROMBOCYTOPENIC PURPURA

SH Wai¹, ² (¹Monash University, Melbourne, Australia, ² Singapore General Hospital, Singapore, Singapore)

E1414 EVANS SYNDROME IN CHILDHOOD: LONG TERM SINGLE CENTER EXPERIENCE

M Economou¹ (¹Aristotle University of Thessaloniki, Thessaloniki, Greece)

E1415 LOW DOSE RITUXIMAB IS A USEFUL ADDITION TO CORTICOSTEROIDS FOR NEWLY DIAGNOSED PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA

A Gomez-De Leon¹ (¹Hematology, Hospital Universitario Dr Jose Eleuterio Gonzalez Universidad Autonoma de Nuevo Leon, Monterrey, Mexico)

E1416 INFECTIOUS COMPLICATIONS IN PRIMARY AUTOIMMUNE NEUTROPENIA OF CHILDHOOD

A Makis¹ (¹Department Of Pediatrics, University Hospital Of Ioannina, Ioannina, Greece)

E1417 NEW EPO-RECEPTOR MUTATION IN A -17 YEAR OLD WOMAN WITH ERYTHROCYTOSIS

B Robredo¹ (¹Hematology, Hospital Universitario Son Espases, Palma De Mallorca, Spain)

E1418 FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN CHILDREN

Z Salcioglu¹ (¹Pediatric Hematology and Oncology Clinic, İstanbul Kanuni Sultan Süleyman Education and Research Hospital, İstanbul, Turkey)

E1419 ABNORMAL MONOCYTE POPULATIONS IN THE PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA

M Velegraiki¹ (¹Department of Haematology, University of Crete School of Medicine, Heraklion, Greece)

E1420 DIAGNOSTIC VALUE OF CELL BOUND AND CIRCULATING ANTI-NEUTROPHIL ANTIBODY DETECTION IN PEDIATRIC NEUTROPENIA

L Porretti¹ (¹Flow Cytometry Service, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy)

E1421 INAPPROPRIATE TREATMENT COULD MASK COBALAMIN DEFICIENCY: ROLE OF METHYLMALONIC ACID EVALUATION.

R Angel F.¹ (¹Hematology, Hospital de Sant Pau, Barcelona, Spain)

E1422 ACTIVATED PI3K-D SYNDROME IN A PEDIATRIC PATIENT WITH RECURRENT EBV ASSOCIATED LYMPHOPROLIFERATION

FB Belen¹ (¹Department of Pediatric Hematology and Oncology, Izmir Katip Celebi University Medical Faculty, Izmir, Turkey)

E1423 RITUXIMAB IN AUTOIMMUNE HEMOLYTIC ANEMIA OF INFANCY

M Economou¹ (¹Aristotle University of Thessaloniki, Thessaloniki, Greece)

- E1424 **EARLY LESSONS FROM WHOLE-GENOME SEQUENCING IN THE CLINICAL DIAGNOSIS OF RARE INHERITED ANAEMIAS**
N Roy^{1, 2} (¹Molecular Haematology Unit, OXFORD UNIVERSITY HOSPITALS NHS TRUST, Oxford, United Kingdom, ²BRC Molecular Diagnostic Centre, OXFORD UNIVERSITY HOSPITALS NHS TRUST, Oxford, United Kingdom)
- E1425 **CONGENITAL ERYTHROCYTOSIS: DISCOVER OF A NEW MUTATION**
J Barradas¹ (¹Serviço de Hematologia Clínica, Centro Hospitalar Tondela-Viseu, Viseu, Portugal)
- E1426 **A RETROSPECTIVE STUDY OF THE THROMBOTIC MICROANGIOPATHIES DIAGNOSED IN THE LAST 17 YEARS IN ONE SINGLE CENTRE**
A Esteban Figuerola¹ (¹Hospital Joan XXIII Tarragona, Tarragona, Spain)
- E1427 **CHILDREN WITH CHRONIC-REFRACTORY AUTOIMMUNE CYTOPENIAS: A SINGLE CENTER EXPERIENCE**
TH Karapinar¹ (¹Pediatric Hematology and Oncology, Dr. Behcet Uz Children Training and Research Hospital, Izmir, Turkey)
- E1428 **INHERITED PROTHROMBOTIC RISK FACTORS IN TURKISH CHILDREN WITH HEREDITARY ANGIOEDEMA. SINGLE CENTER**
T Patiroglu¹ (¹Pediatric Hematology, Erciyes University Medical Faculty, Kayseri, Turkey)
- E1429 **FLOW CYTOMETRIC ANALYSIS OF TISSUE SAMPLES IN 42 ADULT PATIENTS WITH MALIGNANCY-ASSOCIATED HEMOPHAGOCYTTIC LYMPHOHISTIOCYTOSIS**
M Klimkowska¹ (¹Department of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden)
- PLATELETS DISORDERS**
- E1430 **BLEEDING IN PRIMARY IMMUNE THROMBOCYTOPENIA: WHO ARE MOST AT RISK?**
U Doobaree¹ (¹Haematology, Barts and The London School of Medicine and Dentistry, London, United Kingdom)
- E1431 **A MULTICENTRE, SINGLE ARM, OPEN LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF ELTROMBOPAG IN PATIENTS WITH SEVERE PERSISTENT IMMUNE THROMBOCYTOPENIC PURPURA (ITP) WITHIN SIX MONTHS OF DIAGNOSIS**
H Tran^{1, 2} (¹Clinical Haematology, Monash University, Melbourne, Australia, ²Clinical Haematology, The Alfred Hospital, Melbourne, Australia)
- E1432 **A NOVEL RUNX1 MUTATION IN FAMILY WITH FAMILIAL PLATELET DISORDER WITH PREDISPOSITION TO ACUTE MYELOGENOUS LEUKEMIA**
L Krupkova¹ (¹Department of Hemato-oncology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic)
- E1434 **PROFILING CIRCULATING MICRORNAs IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) TO EXPLORE THE ROLE OF MICRORNAs AND POSSIBLE BIOLOGICAL PATHWAYS INVOLVED IN THE PATHOGENESIS OF ITP**
L Garabet^{1, 2, 3} (¹Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ²Akershus University Hospital, Lorenskog, Norway, ³Østfold Hospital Trust, Grålum, Norway)
- E1435 **NORDIC COUNTRY PATIENT REGISTRY FOR IMMUNE THROMBOCYTOPENIA (NCPRITP): A COHORT OF PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA IN DENMARK, SWEDEN, AND NORWAY**
W Ghanima³ (³Department of Medicine, Østfold Hospital Trust, Fredrikstad, Norway)
- E1436 **EPIDEMIOLOGY OF PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ADULTS IN RUSSIAN FEDERATION (RESULTS OF REGISTRY OF NATIONAL HEMATOLOGIC ASSOCIATION)**
A Melikyan¹ (¹Standardisation of methods of therapy, National Research Center for Hematology, Moscow, Russian Federation)
- E1437 **ELTROMBOPAG (EPAG) FOR THE TREATMENT OF PATIENTS AGED ≥65 YEARS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP): SAFETY AND EFFICACY RESULTS FROM THE EXTEND STUDY**
A Salama¹ (¹Charite-Universitätsmedizin, Berlin, Germany)
- E1438 **SAFETY AND EFFICACY OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC IMMUNE THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS**
Y Yamada¹ (¹Medicine, Mount Sinai Beth Israel, New York, United States)
- E1439 **CHILDHOOD IMMUNE THROMBOCYTOPENIA: A NATIONWIDE COHORT STUDY ON CONDITION MANAGEMENT AND OUTCOMES**
C Nordon² (²LASER, PARIS, France)
- E1440 **SIROLIMUS FOR THE TREATMENT OF CHILDREN WITH IMMUNE THROMBOCYTOPENIA AND EVANS SYNDROME. A SINGLE CENTRE EXPERIENCE**
M Miano¹ (¹Haematology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy)

- E1441 **ASSESSMENT OF ROMIPLOSTIM SELF-ADMINISTRATION BY PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA AND CAREGIVERS FOLLOWING RECEIPT OF HOME ADMINISTRATION TRAINING (HAT) MATERIALS: A CROSS-SECTIONAL STUDY**
M Schipperus¹ (¹Department of Haematology, Haga Teaching Hospital, The Hague, the Netherlands)
- E1442 **FCBIIA 131 H/R (A→G) RECEPTOR GENE POLYMORPHISM IN PATIENTS OF PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)**
A Tripathi¹ (¹Clinical Hematology, K.G. Medical University Lucknow India, Lucknow, India)
- E1443 **SHORT- AND LONG-TERM RESULTS OF FIRST LINE THERAPY WITH PULSED HIGH-DOSE DEXAMETHASONE IN ADULT IMMUNE THROMBOCYTOPENIA PATIENTS: A RETROSPECTIVE SINGLE-CENTER REPORT.**
L Crucitti¹ (¹Hematology and Oncology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, MILANO, Italy)
- E1444 **EFFECT OF OSELTAMIVIR TREATMENT ON PLATELET COUNTS**
N Revilla¹ (¹Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain)
- E1445 **CLINICAL UTILITY OF CARDIAC MRI IN IMMUNE MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA**
F Alwan¹ (¹ Haematology Department, University College London Hospital, London, United Kingdom)
- E1446 **THE FREQUENCY AND CLINICAL SIGNIFICANCE OF MEJV GENE MUTATIONS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**
I Kaygusuz Atagunduz¹ (¹Hematology, Marmara University Hospital, Istanbul, Turkey)
- E1447 **PD-1 AND CTLA-4 POLYMORPHISMS AFFECT THE SUSCEPTIBILITY AND CLINICAL FEATURES OF CHRONIC IMMUNE THROMBOCYTOPENIA.**
R Ino¹ (¹ Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Gunma, Japan)
- E1448 **IS THE SPLENECTOMY OUTCOME PREDICTABLE IN PATIENTS WITH ITP?**
M Mitrovic^{1, 2} (¹Clinic of Hematology, CCS, Belgrade, Serbia, ²Faculty of Medicine, University of Belgrade, Belgrade, Serbia)
- E1449 **FINAL RESULTS FROM AN OBSERVATIONAL STUDY (PLATEAU) OF ADULT PATIENTS TREATED WITH ROMIPLOSTIM FOR PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ROUTINE CLINICAL PRACTICE IN GERMANY**
M Reiser¹ (¹PIOH Koeln, Koeln, Germany)
- E1450 **THE CLINICAL UTILITY OF NEUROPSYCHOLOGY TESTING IN IMMUNE MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA**
F Alwan¹ (¹Haematology Department, University College London Hospital, London, United Kingdom)
- E1451 **FIVE NEW CASES OF HERMANSKY-PUDLAK SYNDROME: IDENTIFICATION OF NOVEL GENETIC VARIANTS IN HPS4 AND HPS3 ASSOCIATED TO RELEVANT CLINICAL COMPLICATIONS**
J Bastida¹ (¹Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain)
- E1452 **CHARACTERIZATION OF PLATELET ACTIVATION MARKERS IN EARLY ONSET PREECLAMPSIA**
D Angelov^{1, 2} (¹ School of Medicine, University College Dublin, Dublin, Ireland, ² UCD Conway SPHERE Research Group, University College Dublin, Dublin, Ireland)
- E1453 **PRIMARY ITP IN ADULTS TREATED WITH ELTROMBOPAG: A RETROSPECTIVE STUDY USING DATA FROM THE UNITED KINGDOM ADULT IMMUNE THROMBOCYTOPENIA REGISTRY.**
D Provan¹ (¹Haematology, Barts and The London School of Medicine and Dentistry, London, United Kingdom)
- E1454 **EFFICACY OF TPO-MIMETICS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**
F Bacchiarri¹ (¹Hematology, AOU Careggi, Firenze, Italy)
- E1455 **PREVALENCE AND RISK FACTORS FOR THROMBOSIS IN ADULT ITP PATIENTS**
A Rovó³ (³University Hospital of Bern, Bern, Switzerland)
- E1456 **OSELTAMIVIR FOR THE TREATMENT OF ITP PATIENTS NOT RESPONDING TO CONVENTIONAL TREATMENT: BIOLOGICAL CHARACTERIZATION AND CLINICAL RESPONSES**
N Revilla¹ (¹Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain)

QUALITY OF LIFE, PALLIATIVE CARE, ETHICS AND HEALTH ECONOMICS

- E1457 **BORTEZOMIB THERAPY IS ASSOCIATED WITH SIGNIFICANT RESOURCE IMPLICATIONS FOR BOTH PATIENTS AND PROVIDERS: RESULTS OF A TIME-IN-MOTION STUDY**
A Peniket¹ (¹Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom)
- E1458 **HOSPITAL CARE AT HOME ADMINISTRATION OF SUBCUTANEOUS AZACITIDINE IS FEASIBLE AND PREFERRED BY PATIENTS COMPARED TO HOSPITAL ADMINISTRATION: A FRENCH REGIONAL HEMATOLOGY NETWORK EXPERIENCE**
M Touati^{1, 2} (¹Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire, Limoges, France, ²Réseau Hématolim, Centre Hospitalier Universitaire, Limoges, France)
- E1459 **USE OF COMBINED ORAL FENTANYL CITRATE (ACTIQ®) AND MIDAZOLAM AS PREMEDICATION FOR BONE MARROW BIOPSY IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RANDOMIZED CONTROLLED PATIENT BLINDED CLINICAL TRIAL**
C Cerchione¹ (¹Hematology, Ematologia e trapianto/au federico ii, Napoli, Italy)
- E1460 **ASSESSMENT OF THE ECONOMIC IMPACT OF HORSE-ATG IN SWEDEN FOR APLASTIC ANAEMIA**
V Katkade⁶ (⁶Pfizer, Philadelphia, United States)
- E1461 **NEUROPSYCHOLOGICAL ANALYSIS OF LONG-TERM CONSEQUENCES OF ANTINEOPLASTIC TREATMENT**
S Khrushchev² (²National Research Institute for Hematology, Moscow, Russian Federation)
- E1462 **A CLINICAL AUDIT OF NUTRITIONAL SCREENING AND SUPPORT OF HOSPITALIZED PATIENTS WITH HEMATOLOGIC DISEASES.**
P Diamantopoulos¹ (¹1st Department of Internal Medicine, Hematology Unit, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece)
- E1463 **ASSESSING REAL-WORLD TREATMENT PATTERNS, OUTCOMES AND RESOURCE USE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) POST AUTOLOGOUS STEM CELL TRANSPLANT ACROSS EUROPE**
D Judge² (²Adelphi Real World, Bollington, United Kingdom)
- E1464 **NUMBER-NEEDED-TO-TREAT (NNT) AND COST OF RESPONSES ACHIEVED IN TYROSINE KINASE INHIBITOR (TKI) TREATMENT OF REFRACTORY CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN THE UNITED STATES (US)**
MY Levy¹ (¹Baylor University Medical Center, Dallas, TX, United States)
- E1465 **THE COST-EFFECTIVENESS OF PEGASPARGASE FOR FIRST-LINE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A COST-UTILITY ANALYSIS**
C Rowntree³ (³University Hospital of Wales, Cardiff, United Kingdom)
- E1466 **IMPACT OF VENETOCLAX ON THE QUALITY OF LIFE OF PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PHASE 2, OPEN-LABEL STUDY OF VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY**
W Wierda¹ (¹The University of Texas MD Anderson Cancer Center, Houston, United States)
- E1467 **WHICH HAEMATOLOGICAL CONDITIONS CAN THIRD YEAR MEDICAL STUDENTS RECOGNISE INTERPRETING FULL BLOOD COUNT RESULTS?**
S Lovato^{1, 2} (¹Postgraduate, London North West Healthcare NHS Trust, London, United Kingdom, ²Undergraduate, Imperial College London, London, United Kingdom)
- E1468 **LONGITUDINAL ASSOCIATIONS BETWEEN HEALTH-RELATED QUALITY OF LIFE AND HEALTH-CARE UTILIZATION IN AL AMYLOIDOSIS**
KL McCausland¹ (¹Optum, Lincoln, United States)
- E1469 **SAFETY, FEASIBILITY AND EFFECTIVENESS OF ELECTRICAL MUSCLE STIMULATION IN HOSPITALIZED PATIENTS UNDERGOING AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANTATION AND INTENSIVE CHEMOTHERAPY**
A Klostermann¹ (¹Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg, Germany)
- E1470 **MYELOMA PATIENT VALUE MAPPING: A DISCRETE CHOICE EXPERIMENT**
J Galinsky¹ (¹Research, Myeloma UK, Edinburgh, United Kingdom)
- E1471 **COST-MINIMIZATION ANALYSIS OF RITUXIMAB SUBCUTANEOUS FORMULATION VERSUS INTRAVENOUS ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMA IN THE REPUBLIC OF MACEDONIA**
O Nikolov¹ (¹Roche Macedonia DOOEL Skopje, Skopje, Macedonia, The Former Yugoslav Republic Of)
- E1472 **QUALITY OF LIFE AND ABILITY TO WORK OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH THYROSINE KINASE INHIBITORS**
B Sidi Mohamed El Amine¹ (¹Hematology department, University hospital of Sidi Bel Abbes, Sidi Bel Abbes, Algeria)

- E1473 **QUALITY OF LIFE AND EMPLOYMENT AFTER AN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN A MEXICAN POPULATION.**
S Rivas-Vera² (²Hematology, National Cancer Institute, Mexico, Mexico City, Mexico)
- E1474 **ANTHRACYCLINE INCREASES THE RISK OF DEVELOPING DIABETES IN B CELL LYMPHOMA**
HC Lin¹ (¹Division of Hematology/Medical Oncology, VTaichung Veterans General Hospital, Taichung, Taiwan, Republic of China)
- E1475 **THE COST-EFFECTIVENESS OF LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN CHINA**
J Lu¹ (¹Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China)
- E1476 **DEVELOPMENT OF A NEW HAEMATOLOGICAL MALIGNANT PATIENT-REPORTED OUTCOME MEASURE FOR USE IN CLINICAL PRACTICE: HM-PRO**
P Goswami¹ (¹School of Life and Medical Sciences, University Of Hertfordshire, Hatfield, United Kingdom)
- E1477 **OVARIAN TISSUE CRYOPRESERVATION IN PEDIATRIC AND ADOLESCENT PATIENTS UNDERGOING CANCER CHEMOTHERAPY AND/OR HEMATOPOIETIC STEM CELL TRANSPLANTATION**
A Kinoshita¹ (¹Pediatric hematology/oncology, St. Marianna University School of Medicine, Kawasaki, Japan)
- E1478 **A MULTI-DISCIPLINARY APPROACH TO CHEMOTHERAPY PRESCRIBING AT NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST**
S Gabriel¹ (¹Northern Centre for Cancer Care- Pharmacy, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom)
- E1479 **FINANCIAL TOXICITY OF THE MANAGEMENT OF MULTIPLE MYELOMA**
B Sidi Mohamed El Amine¹ (¹Hematology department, University hospital of Sidi Bel Abbés, Sidi Bel Abbes, Algeria)
- E1480 **THE IMPLICATIONS OF NON-PROPORTIONAL HAZARDS FOR THE MEASUREMENT OF SURVIVAL BENEFIT IN HEALTH TECHNOLOGY ASSESSMENT: CURRENT APPROACHES AND THE ROLE OF RESTRICTED MEAN SURVIVAL TIME**
G Monnickendam¹ (¹PRMA Consulting, Fleet, United Kingdom)

SICKLE CELL DISEASE

- E1481 **DISEASE SEVERITY AND SLOWER PSYCHOMOTOR SPEED IN ADULTS WITH SICKLE CELL DISEASE**
E Novelli¹ (¹Medicine, Vascular Medicine Institute, University of Pittsburgh, BST E1240, 200 Lothrop St., Pittsburgh, United States)
- E1482 **MONITORING OF CHRONIC HEPATIC DAMAGE IN SICKLE CELL DISEASE: LONGITUDINAL OBSERVATION OF A COHORT OF ADULT PATIENTS**
GL Forni¹ (¹Haematology-Centro Microcitemia Anemie Congenite, Ospedale Galliera Genova, Genova, Italy)
- E1483 **MICROSTRUCTURAL ANALYSIS OF RETINO-CHOROID LAYERS USING OPTICAL COHERENCE TOMOGRAPHY IN ADULT PATIENTS WITH SICKLE CELL DISEASE**
G Graziadei¹ (¹Rare Diseases Center, Internal Medicine Unit, Department of Medicine and Medical Specialties, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy)
- E1484 **NONABLATIVE TRANSPLANT CONDITIONING WITH TREOSULFAN IS CURATIVE IN A MURINE MODEL OF SICKLE CELL DISEASE**
D Devadasan¹ (¹Pathobiology and Molecular Medicine theme, Department of Graduate Biomedical Sciences, University of Alabama at Birmingham, Birmingham, United States)
- E1485 **SILENT CEREBRAL ISCHEMIA AND THROMBOEMBOLIC EVENTS IN SICKLE CELL DISEASE: ANALYSIS OF COAGULATION PARAMETERS AND THROMBOELASTOGRAPHY**
M Dimopoulou¹ (¹Thalassemia and Sickle Cell Disease Center, Laikon General Hospital, Athens, Greece)
- E1486 **ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE POLYMORPHISMS AND RISK OF VASCULOPATHY IN SICKLE CELL DISEASE**
H Ellithy¹ (¹Internal medicine- Clinical hematology dep., Kasr Al-ainy school of medicine- Cairo university, Cairo, Egypt)
- E1487 **INVASIVE BACTERIAL INFECTIONS IN GAMBIAN PATIENTS WITH SICKLE CELL ANEMIA IN AN ERA OF WIDESPREAD PNEUMOCOCCAL AND HAEMOPHILUS INFLUENZA TYPE B VACCINATION**
G Soothill¹ (¹Royal Free Hospital, London, United Kingdom)
- E1488 **THE ASSOCIATION OF IGF-1 AND IGFBP-3 SERUM LEVELS AND GENE EXPRESSION WITH THE PATHOGENESIS OF INFLAMMATION IN SICKLE CELL DISEASE**
S Ünal¹ (¹mersin üiversity pediatic hematology department, mersin, Turkey)

- E1489 UNIVERSAL NEWBORN SCREENING FOR SICKLE CELL DISEASE: PRELIMINARY RESULTS OF THE FIRST YEAR OF A MULTICENTRIC ITALIAN PILOT PROJECT**
R Colombatti¹ (¹Clinic of Pediatric Hematology Oncology, Department of Child and Maternal Health, Azienda Ospedaliera-Università di Padova, Padova, Italy, Padova, Italy)
- E1490 EXTENDING ACCESS TO CARE FOR CHILDREN WITH SICKLE CELL DISEASE THROUGH TELEHEALTH**
J Kanter¹ (¹Pediatrics, Medical University of South Carolina, Charleston, United States)
- E1491 EMERGING NEED FOR SICKLE CELL DISEASE NEWBORN SCREENING PROGRAM IN ITALY, A EUROPEAN COUNTRY WITH INTENSE MIGRATION FLUXES**
D Venturelli¹ (¹Servizio Immunotrasfusionale, Azienda Ospedaliero Universitaria Policlinico, Modena, Italy)
- E1492 GENETIC HEMOLYTIC MARKER IN SICKLE CELL ANAEMIA**
P Pereira Nascimento¹ (¹Departamento de Biologia, Instituto de Biociências, Letras e Ciências Exatas - Ibilce/UNESP - São José do Rio Preto, São José do Rio Preto, Brazil)
- E1493 ASSESSMENT OF INTERNATIONAL DAY HOSPITALS/ INFUSION UNITS FOR THE EVALUATION AND TREATMENT OF SICKLE CELL DISEASE**
L De Castro¹ (¹Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, United States)
- E1494 REDUCED SERUM HAEMOPEXIN LEVELS IN HAEMOGLOBIN SC DISEASE OCCUR INDEPENDENTLY FROM THE DEGREE OF HAEMOLYSIS**
F Vendrame¹ (¹Hematology and Hemotherapy Center, Unicamp, Campinas, Brazil)
- E1495 ASSOCIATION OF TOLL-LIKE RECEPTOR 2 GENE POLYMORPHISM WITH THE INCIDENCE OF BACTERIAL INFECTIONS IN SICKLE CELL DISEASE.**
K Tozatto-Maio^{1, 2, 3} (¹Eurocord, Université Paris 7, Paris, France, ²Monacord, International Observatory on Sickle Cell Disease, Centre Scientifique de Monaco, Monaco, Monaco, ³Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil)
- STEM CELL TRANSPLANTATION - CLINICAL**
- E1496 HIGH PROGNOSTIC VALUE OF PRE-SCT MOLECULAR MINIMAL RESIDUAL DISEASE ASSESSMENT BY WT1 GENE EXPRESSION IN AML TRANSPLANTED IN CYTOLOGIC COMPLETE REMISSION.**
A Candoni¹ (¹Division of Hematology and SCT, University Hospital, Udine, Udine, Italy)
- E1497 GOOD IMMUNOLOGICAL RECONSTITUTION IN ADULTS WITH ACUTE LEUKEMIA AFTER Δ LFA-BETA TCR/CD19+ DEPLETED HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).**
L Prezioso¹ (¹Hematology and BMT Unit, Parma, Italy)
- E1498 UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION CONDITIONING WITH BUSULFAN, CYCLOPHOSPHAMIDE AND ANTI-THYMOGLOBULIN FOR ADULT SEVERE APLASTIC ANEMIA: GOOD OUTCOME AND PROGNOSIS ANALYSIS**
L Xu¹ (¹ Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China, Beijing, China)
- E1499 PLERIXAFOR EFFICIENTLY AND SAFELY MOBILIZES PERIPHERAL BLOOD STEM CELLS: HOVON-107 RESULTS IN HLA-IDENTICAL SIBLING DONORS AND TRANSPLANTED RECIPIENTS.**
G De Greef¹ (¹Hematology, Erasmus Cancer Institute Rotterdam , Rotterdam, the Netherlands)
- E1500 A FEASIBILITY STUDY OF THE FULL OUTPATIENT CONDUCT OF HEMATOPOIETIC TRANSPLANTS IN PERSONS WITH MULTIPLE SCLEROSIS EMPLOYING AUTOLOGOUS NON-CRYOPRESERVED PERIPHERAL BLOOD STEM CELLS**
GJ Ruiz Argüelles¹ (¹Hematología, Centro de Hematología y Medicina Interna, Puebla, Mexico)
- E1501 VEDOLIZUMAB IN STEROID REFRACTORY INTESTINAL GRAFT-VERSUS-HOST DISEASE**
AE Myhre¹ (¹Hematology, Oslo University Hospital, Oslo, Norway)
- E1502 RISK FACTORS, OUTCOMES AND CHARACTERIZATION OF 'AUTOLOGOUS GRAFT VERSUS HOST DISEASE': THE MAYO CLINIC EXPERIENCE.**
T Anagnostou¹ (¹Hematology/Medical Oncology, Mayo Clinic, Rochester, United States)
- E1503 CNS DEMYELINATION AFTER HAPLO-HSCT AND ITS ASSOCIATION WITH THE IGG INTRATHECAL SYNTHESIS INDEX AND ANTI-MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY IN CEREBROSPINAL FLUID**
X Zhang¹ (¹Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China)
- E1504 BASELINE CREATININE CLEARANCE AND ALBUMIN ARE POWERFUL RISK FACTORS FOR ALLOGENEIC TRANSPLANTATION RELATED MORTALITY**
R Shouval¹ (¹Hematology Division, Chaim Sheba Medical Center, Tel-HaShomer, Ramat- Gan, Israel)

- E1505 CYTOGENETIC AND MOLECULAR RISK FACTORS AT DIAGNOSIS ARE OVERCOME BY WT1 AND FLOW CYTOMETRY-BASED PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS**
F Guolo¹, ¹ (Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST, Genova, Italy, ¹ Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU San Martino-IST, Genova, Italy)
- E1506 IMPACT OF ALLELE SPECIFIC PATIENT:DONOR HLA DISPARITY ON OUTCOME OF REDUCED INTENSITY TRANSPLANTS PERFORMED USING HLA MISMATCHED UNRELATED DONORS: ON BEHALF OF THE ALWP OF THE EBMT**
C Craddock¹ (Department of Haematology, University of Birmingham, Birmingham, United Kingdom)
- E1507 PRE-EMPTIVE THERAPY WITH IFN- γ -2B FOR ACUTE LEUKEMIA PATIENTS WITH HIGH RISK OF RELAPSE TENDENCY POST ALLO-HSCT**
X Tang^{1, 2} (The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China, ² Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China)
- E1508 PREDICTING SURVIVAL AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. THE GATMO SCORE**
M Berro¹ (Hematology, Transplant Unit, Hospital Universitario Austral, Derqui, Argentina)
- E1509 A RETROSPECTIVE ANALYSIS OF PATIENT CHARACTERISTICS AND RISK FACTORS FOR ADMISSION TO THE INTENSIVE CARE UNIT (ICU) FOLLOWING HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT (HDC-ASCT)**
L Jeyaraj Nallathambi¹ (Haematology, Kings college hospital, London, United Kingdom)
- E1510 AUTOLOGOUS STEM CELL TRANSPLANTATION WITH BENDA-EAM (BENDAMUSTINE, ETOPOSIDE, CYTARABINE, MELPHALAN) IN AGGRESSIVE NON HODGKIN AND HODGKIN'S LYMPHOMA**
R Simanek¹ (Hematology and Oncology, Hanusch Krankenhaus, Vienna, Austria)
- E1511 THROMBOTIC MICROANGIOPATHY WITH CONCOMITANT AGVHD AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: RISK FACTORS, SEVERE OUTCOME AND TREATMENT EXPERIENCE**
X Zhang¹ (Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China)
- E1512 CANCE OF MINIMAL RESIDUAL DISEASE MONITORING BY QUANTITATIVE RT-PCR IN CORE BINDING FACTOR AML ON TRANSPLANTATION OUTCOMES**
B Oran¹ (Stem Cell Transplantation and Cellular Therapy, The University of Texas MDACC, Houston, United States)
- E1513 LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN ADULT SEVERE APLASTIC ANEMIA WITH ABNORMAL CYTOGENETICS AT DIAGNOSIS**
SE Lee¹ (Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic Of)
- E1514 PROGNOSTIC VALUE OF PET/CT PRIOR TO AUTOLOGOUS HCT IN RELAPSED / REFRACTORY LYMPHOMA**
M Damla^{1, 2} (Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia, ²King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia)
- E1515 COMPARISON OF OUTCOMES AFTER DONOR LYMPHOCYTE INFUSION WITH OR WITHOUT PRIOR CHEMOTHERAPY FOR MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.**
XD Mo¹ (Peking University People's Hospital, Institute of Hematology, Beijing, China)
- E1516 DIFFERENTIAL PROGNOSTIC IMPACT OF HEMATOPOIETIC CELL TRANSPLANTATION SPECIFIC COMORBIDITY INDEX (HCT-CI) ON TRANSPLANT OUTCOMES BY STEM CELL SOURCES**
Y Adachi¹ (Department of Hematology and Oncology, Konan Kosei Hospital, Konan, Japan)
- E1517 LOW DOSE POSTTRANSPLANTATION CYCLOPHOSPHAMIDE CAN ENHANCE THE PROTECTIVE EFFECT OF ATG /G-CSF ON GVHD: RESULTS OF A PHASE II PROSPECTIVE TRIAL**
Y Wang¹ (Peking university people's hospital, beijing, China)
- E1518 HEPATITIS B REACTIVATION IN HEMATOPOIETIC STEM CELL TRANSPLANTED PATIENTS: 22 YEARS EXPERIENCE OF A SINGLE CENTRE**
T Soysal² (Hematology, Cerrahpasa Medical Faculty, Istanbul, Turkey)
- E1519 ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION FROM HAPLOIDENTICAL DONOR WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE WAS RELATED TO LESS INPATIENT COST COMPARED TO CORD BLOOD TRANSPLANTATION**
N Kurita¹ (Department of Hematology, University of Tsukuba, Tsukuba, Japan)

- E1520 THE ROLE OF PPAR δ EXPRESSION IN PATIENTS WITH AGVHD FOLLOWING ALLO-HSCT**
X Wu^{1, 2} (¹The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China, ² Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China)
- E1521 HAPLOIDENTICAL TRANSPLANTATION WITH MYELOABLATIVE CONDITIONING REGIMEN COULD SERVE AS AN OPTIONAL SALVAGE THERAPY FOR YOUNGER PATIENTS WITH REFRACTORY OR RELAPSED NON-HODGKIN LYMPHOMA**
H Huang¹ (¹Soochow University, Suzhou, China)
- E1522 OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA HARBORING INV(3)/(Q21;Q26.2)/T(3;3)(Q21;Q26.2)**
J Aoki¹ (¹Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan)
- E1523 PHARMACOKINETICS (PK) OF PROPYLENE GLYCOL-FREE MELPHALAN HCL (PG-FREE MEL) IN MULTIPLE MYELOMA (MM) PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION (AHCT)**
P Hari¹ (¹Medical College of Wisconsin, Milwaukee, United States)
- E1524 IMPAIRED LYMPHOCYTE RECONSTITUTION AFTER AUTOLOGOUS TRANSPLANT IS ASSOCIATED WITH APOPTOSIS OF CD8+ T CELLS AND PREDICTS ADVERSE CLINICAL OUTCOME**
U Rozovski^{1, 2} (¹Hematology, Davidof Cancer Center, Beilinson Campus, Petah Tikva, Tel Aviv, Israel, ²Tel Aviv University, Tel Aviv, Israel)
- E1525 COMPARISON OF TECAM AND BEAM HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LYMPHOMA: EFFICACY AND TOXICITY**
F Sahin¹ (¹Hematology, Ege University Hospital Internal Medicine, Bornova, Turkey)
- E1526 GENETIC MARKERS OF THE NEUTROPENIA DURATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA**
E Nazarova¹ (¹Laboratory of Immunology of Leukemia, Kirov Research Institute of Hematology and Blood Transfusion, Kirov, Russian Federation)
- E1527 SUCCESSFUL TREATMENT WITH GRANULOCYTE TRANSFUSION AND EARLY NEUTROPHIL ENGRAFTMENT IN ALLOGENEIC TRANSPLANT PATIENTS WITH FEBRILE NEUTROPENIA;**
A Ünal¹ (¹Erciyes University Medical School, Kayseri, Turkey)
- E1528 DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION; A SINGLE CENTER EXPERIENCE**
B Antmen¹ (¹Pediatric Bone Marrow Transplantation Unit, Department of Pediatric Hematology, ADANA ACIBADEM HOSPITAL, Adana, Turkey)
- E1529 ACUTE RENAL IMPAIRMENT IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS, A PREDICTOR OF MORTALITY**
AJ Mahdi¹ (¹Department of Haematology, University hospital of Wales, Cardiff, United Kingdom)
- E1530 PREDICTIVE INDEXES FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, A SINGLE-CENTER EXPERIENCE**
J Zanabali Al-Sibai¹ (¹Hematology, HUCA, Oviedo, Spain)
- E1531 ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR HIGH-RISK PERIPHERAL T-CELL LYMPHOMAS**
H Huang^{1, 1} (¹Soochow University, Suzhou, China, ¹Soochow University, Suzhou, China)
- E1532 IMPACT OF BASELINE BILIRUBIN ON SURVIVAL IN PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME RECEIVING DEFIBROTIDE: POST-HOC ANALYSIS OF EXPANDED-ACCESS PROTOCOL FINAL DATA**
P Richardson¹ (¹Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States)
- E1533 LONG-TERM FOLLOW-UP OF A PROSPECTIVE TRIAL OF INTENSIFIED CHEMO-IMMUNOTHERAPY WITH AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS AFFECTED BY PERIPHERAL T-CELL LYMPHOMA**
P Corradini¹ (¹Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy)
- E1534 UNRELATED DONOR ATTRITION AT A LATE STAGE: THE BRITISH BONE MARROW REGISTRY EXPERIENCE**
K Balassa^{1, 2} (¹Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ² British Bone Marrow Registry, NHS Blood and Transplant, Filton, United Kingdom)
- E1535 POLIMORPHISM IN TGFB1 GENE PREDISPOSES TO RELAPSE AND DEVELOPMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE GRADES III-IV.**
N Meggyesi¹ (¹Laboratory of Molecular Diagnostics, Hungarian National Blood Transfusion Service, Budapest, Hungary)

- E1536 EARLY AND LATE LOST OF PROTECTIVE ANTIBODY LEVELS AGAINST MEASLES, MUMPS AND RUBELLA IN PATIENTS GIVEN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION**
J Bögeholz¹ (¹Hematology, University Hospital Zurich, Zurich, Switzerland)
- E1537 MICA AND NKG2D POLYMORPHISMS HAVE A SIGNIFICANT IMPACT ON GRAFT VERSUS HOST DISEASE AFTER HLA-MATCHED HEMATOPOIETIC STEM CELL TRANSPLANTATION.**
MJ Apithy¹ (¹Hematology and Histocompatibility, University Medical Center, AMIENS, France)
- E1538 STEM CELL TRANSPLANTATION WITH MYELOABLATIVE CONDITIONING USING TIMED SEQUENTIAL BUSULFAN IMPROVES OUTCOMES IN OLDER AML AND MDS PATIENTS**
B Oran¹ (¹Stem Cell Transplantation and Cellular Therapy, The University of Texas MDACC, Houston, United States)
- E1539 HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH DEPLETION OF TCR $\delta\delta$ (+) IN CHILDREN: ERCIYES PEDIATRIC BMT CENTER**
T Patiroglu¹ (¹Department of Pediatrics, Division of Pediatric Hematology Oncology, Erciyes University, Faculty of Medicine, Kayseri, Turkey)
- E1540 SECONDARY MYELODYSPLASTIC SYNDROME AND/OR ACUTE LEUKEMIA INCIDENCE AFTER AUTOLOGOUS TRANSPLANTATION FOR LYMPHOMA PATIENTS IS CONNECTED WITH DECREASE OF HEMATOPOIETIC RESERVE.**
M Trněný¹ (¹Charles University General Hospital, Prague, Czech Republic)
- E1541 USE OF DEFIBROTIDE TO TREAT TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY**
M Martínez-Muñoz¹ (¹Hospital Universitario Puerta de Hierro Majadahonda (Madrid), Majadahonda, Spain)
- E1542 PRE-TRANSPLANT COMORBIDITY AS AN OUTCOME PREDICTOR IN HEMATOPOIETIC CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA**
SN Lim¹ (¹Internal Medicine, Haeundae Paik Hospital, Busan, Korea, Republic Of)
- E1543 EFFICACY AND SAFETY OF FILGRASTIM BIOSIMILAR COMPARED TO FILGRASTIM ORIGINATOR IN THE STEM CELL MOBILIZATION AND HEMATOPOIETIC ENGRAFTMENT IN PATIENTS UNDERGOING STEM CELL TRANSPLANTATION**
M López-Parra¹ (¹Hematology, University Hospital of Salamanca, Salamanca, Spain)
- E1544 PERIPHERAL BLOOD STEM CELL DONATION IN OLDER SIBLING DONORS: IS IT SAFE?**
K Balassa¹ (¹Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom)
- E1545 LONG-TERM RESULTS OF DONOR LYMPHOCYTE INFUSIONS IN RELAPSED AND MIXED CHIMERISM PATIENTS AFTER ALLOGENEIC STEM CELLS TRANSPLANTATION.**
O Koroleva¹ (¹BMT, National Research Center for Hematology, Moscow, Russian Federation)
- E1546 MEMORY T CELLS DONOR LYMPHOCYTE INFUSIONS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION AS A SAFE PROCEDURE TO IMPROVE T-CELL RECONSTITUTION**
S Cortez¹ (¹Hematology, Hospital Universitario La Paz, Madrid, Spain)
- E1547 FLAG REGIMEN WITH IDARUBICINE AS CYTOREDUCTION THERAPY BEFORE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH REFRACTORY ACUTE MYELOID LEUKEMIA**
L Wang¹ (¹Blood and marrow transplantation center, Department of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China)
- E1548 STUTTER PCR PRODUCTS MAY NOT INTERFERE WITH STR BASED CHIMERISM MONITORING AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION**
N Kostritsa¹ (¹School of Medicine, Lomonosov Moscow State University, Moscow, Russian Federation)
- E1549 INTRODUCING PLERIXAFOR TO IMPROVE MOBILIZATION IN MULTIPLE MYELOMA PATIENTS WHO BEHAVE AS POOR-MOBILIZERS IS COST-EFFECTIVE CONSIDERING THE WHOLE MOBILIZATION AND TRANSPLANT PROCEDURE**
C CHABANNON¹ (¹Centre de Therapie Cellulaire. Département de Biologie du Cancer, Institut Paoli-Calmettes, Marseille, France)
- E1550 PERIPHERAL BLOOD STEM CELL (PBSC) HAPLOIDENTICAL TRANSPLANTATION VERSUS MISMATCHED UNRELATED DONOR TRANSPLANTATION: A SINGLE UK CENTRE EXPERIENCE**
J O'Sullivan¹ (¹Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom)
- E1551 IMPACT OF ABO BLOOD GROUP INCOMPATIBILITY ON THE OUTCOME OF RECIPIENTS UNDERGOING ALLOGENIC TRANSPLANTATION: EXPERIENCE IN OUR CENTER BETWEEN 2013 AND 2016.**
GA Méndez Navarro¹ (¹Servicio de Hematología y Hemoterapia, Hospital Universitario Ramón y Cajal. Madrid, Madrid, Spain)

- E1552 LOW BLOOD CONCENTRATION OF TACROLIMUS CAN BE A RISK OF GRAFT FAILURE AFTER CORD BLOOD TRANSPLANTATION.**
 A Fujimoto¹ (¹Hematology, KOBE CITY MEDICAL CENTER GENERAL HOSPITAL, Kobe, Japan)
- E1553 THE EXPRESSION OF TOLL-LIKE RECEPTORS GENES IN PATIENTS WITH LYMPHOID MALIGNANCIES AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.**
 J Rybka¹ (¹Hematology, Wroclaw Medical University, Wroclaw, Poland)
- E1554 TIMING OF DEFIBROTIDE INITIATION POST-DIAGNOSIS OF HEPATIC VENO-OCCLUSIVE DISEASE/SINU-SOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPANDED ACCESS PROGRAM FINAL DATA**
 P Richardson² (²Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States)
- E1555 RED BLOOD CELL DISTRIBUTION WIDTH (RDW) AS AN ACUTE GRAFT VERSUS HOST DISEASE PREDICTOR MARKER IN ALLOGENIC STEM CELL TRANSPLANTATION.**
 B Lopez Andrade¹ (¹Hematology, Hospital Universitario Son Espases, Palma Mallorca, Spain)
- E1556 COMPARISON OF THE BEEAM CONDITIONING REGIMEN AND THE BEAM CONDITIONING REGIMEN IN THE AUTOLOGOUS TRANSPLANTATION FOR HL AND NHL.**
 S Lozenov¹ (¹INSHATHD, Sofia, Bulgaria)
- E1557 DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION IN ADULTS: CORRELATION OF ALLELE-LEVEL HLA MATCHING WITH OUTCOME AND WHICH CORD BLOOD UNIT WILL BECOME DOMINANT**
 M Westendorp¹ (¹Leukemia/BMT Program of BC, Vancouver General Hospital, Vancouver, Canada)
- E1558 CLINICAL ANALYSIS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR 46 ACTIVE RELAPSED AND REFRACTORY ACUTE PEDIATRIC LEUKEMIA**
 J Wang¹ (¹Department of Hematology, Aerospace Center Hospital, Beijing, China)
- E1559 POST-TRANSPLANT HIGH-DOSE CYCLOPHOSPHAMIDE AFFECT T-CELL RECONSTITUTION IN BONE MARROW, BUT NOT IN PERIPHERAL BLOOD STEM CELLS RECIPIENTS**
 E Mikhaltsova¹ (¹BMT department, National Research Center for Hematology, Moscow, Russian Federation)
- E1560 OUTCOMES OF PATIENTS RELAPING FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION FOR AML IN FIRST CR: SINGLE CENTER EXPERIENCE**
 D Pastore¹ (¹Hematology with Transplantation-University Policlinico, Bari, Italy)
- E1561 ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH CHEMOREFRACTORY HODGKIN LYMPHOMAS: A RETROSPECTIVE MULTICENTER EXPERIENCE OF THE RETE EMATOLOGICA PUGLIESE (REP).**
 V Pavone¹ (¹Haematology, Panico Hospital, Tricase, Italy)
- E1562 RESULTS OF THE IMPLEMENTATION OF CRYOTHERAPY IN PROTOCOLS OF ORAL MUCOSITIS PROPHYLAXIS IN PATIENTS SUBJECT TO A TRANSPLANT OF HEMATOPOIETIC PROGENITORS. EXPERIENCE OF ONE CENTER.**
 E Fernández Poveda¹ (¹Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Spain)
- E1563 REDUCED INCIDENCE OF PRIMARY GRAFT FAILURE IN PATIENTS UNDERGOING HAPLOIDENTICAL STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE.**
 A Martínez-Velandia¹ (¹Hematology and Hemotherapy, Hospital Universitario La Paz, Madrid, Spain)
- E1564 RESULTS OF HAPLOIDENTIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH LYMPHOMA: A SINGLE CENTER EXPERIENCE**
 Z Gulbas^{1, 1} (¹Bone Marrow Transplantation Department, Anadolu Medical Center, Kocaeli, Turkey, ¹Bone Marrow Transplantation Department, Anadolu Medical Center, Kocaeli, Turkey)
- E1565 COLLECTION OF PERIPHERAL BLOOD HEMATOPOIETIC PROGENITOR CELLS (PBPC) FROM HEALTHY DONORS: 15 YEARS SINGLE CENTER EXPERIENCE.**
 B Aguado¹ (¹Hematology, H.U. LA PRINCESA, MADRID, Spain)

STEM CELL TRANSPLANTATION - EXPERIMENTAL

- E1566 ALLORESPONSES OF HUMAN T-CELLS FROM ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD ARE DIFFERENTIALLY IMPACTED BY LENALIDOMIDE - IMPLICATIONS FOR AHSCT**
 C Besley¹ (¹Centre for Haemato-Oncology, BARTS CANCER INSTITUTE, London, United Kingdom)

E1567 USING MARKER GENES ANALYSIS INSTEAD OF MLR ASSAY FOR IDENTIFICATION OF FUNCTIONAL CD4+FOXP3+ REGULATORY T CELLS IN GVHD PROPHYLAXIS

TJ Chiou¹ (¹Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan, Republic of China)

E1568 OXIDANT-ANTIOXIDANT SYSTEM IN PATIENTS WITH MULTIPLE MYELOMA

L Aleksanian¹ (¹Biochemistry laboratory, Russian Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russian Federation)

E1569 SURFACE RECEPTOR EXPRESSION PROFILE DEFINES ALLOREACTIVE DONOR CD8+ T-CELLS AFTER MURINE ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION

M Qureischi¹ (¹Medical Department II, University Clinics Wuerzburg, Wuerzburg, Germany)

THALASSEMIAS

E1570 SOLUBLE FORM OF TRANSFERRIN RECEPTOR IS ASSOCIATED WITH AGE AT DIAGNOSIS AND RISK OF THERAPEUTICAL INTERVENTION AND IRON OVERLOAD IN PATIENTS WITH NON-TRANSFUSION-DEPENDENT THALASSAEMIA.

P Ricchi¹ (¹AORN A. Cardarelli, Naples, Italy)

E1571 LOW SERUM FERRITIN LEVELS DO NOT PROTECT FROM CARDIAC AND HEPATIC IRON IN PATIENTS WITH THALASSEMIA MAJOR

A Meloni¹ (¹Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy)

E1572 ISCHEMIA MODIFIED ALBUMIN AS A MARKER OF OXIDATIVE STRESS IN CHILDREN AND ADOLESCENTS WITH δ -THALASSEMIA: RELATION TO LIPID PEROXIDATION, IRON OVERLOAD AND VASCULAR DYSFUNCTION

AAM Adly¹ (¹Pediatric Hematology&oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt)

E1573 SERUM N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE LEVEL AND ECHOCARDIOGRAPHIC TISSUE DOPPLER ABNORMALITIES IN PATIENTS WITH BETA THALASSEMIA MAJOR

M El-Ghamrawy¹ (¹Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt)

E1574 PRENATAL DIAGNOSIS OF HEMOGLOBINOPATHIES IN NORTHERN GREECE. 15 YEARS REPORT

S Theodoridou¹ (¹Thalassemia Unit, Hippokraton General Hospital, Thessaloniki, Greece)

E1575 THE IMPACT OF LIVER STEATOSIS ON THE ABILITY OF SERUM FERRITIN LEVELS TO PREDICT LIVER IRON CONCENTRATION AMONG NON-TRANSFUSION-DEPENDENT THALASSAEMIA PATIENTS: A CROSS-SECTIONAL EVALUATION.

P Ricchi¹ (¹AORN A. Cardarelli, Naples, Italy)

E1576 CIRCULATING CELL-FREE DNA (CFDNA) AND INEFFECTIVE ERYTHROPOIESIS IN BETA-THALASSEMIA INTERMEDIA

MD Cappellini¹ (¹Dip. Scienze Cliniche e di Comunità, Università degli Studi di Milano, MILANO, Italy)

E1577 LEFT VENTRICULAR HYPERTRABECULATION BY CARDIAC MAGNETIC RESONANCE IN THALASSEMIA INTERMEDIA PATIENTS: FREQUENCY AND PROGNOSTIC ROLE

A Meloni¹ (¹Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy)

E1578 NITRIC OXIDE DYSREGULATION IN BETA-THALASSEMIA MAJOR: RELATION TO PULMONARY HYPERTENSION

M Elshinawy^{1, 2} (¹Pediatric Hematology, SULTAN QABOOS UNIVERSITY HOSPITAL, Muscat, Oman, ² Pediatric Hematology, Faculty of Medicine, Alexandria, Egypt)

E1580 SPECKLE-TRACKING ECHOCARDIOGRAPHY FOR DIAGNOSIS OF EARLY MYOCARDIAL DISEASE IN EGYPTIAN BETA THALASSEMIA MAJOR PATIENTS

AAG Tantawy¹ (¹Pediatric Hematology&oncology, faculty of medicine, Ain Shams University, Cairo, Egypt)

E1581 EFFICACY, SAFETY AND GENETIC BASIS OF VARIABILITY OF RESPONSE TO HYDROXYUREA THERAPY IN BETA THALASSEMIA: A SYSTEMATIC REVIEW

S Khaliq^{1, 2} (¹Pathology, fauji foundation hospital/Foundation University Medical college Rawalpindi, rawalpindi, Pakistan, ²Hematology, hemophilia Centre, Rawalpindi, Pakistan)

E1582 EVALUATION OF CONTINUOUS BLOOD GLUCOSE MONITORING METHOD FOR DETECTION OF ALTERATIONS IN GLUCOSE HOMEOSTASIS IN BETA-THALASSEMIA PATIENTS

A Tantawy¹ (¹AinShams university, Cairo, Egypt)

E1583 LEFT VENTRICULAR REGIONAL FUNCTION IN CHILDREN WITH BETA THALASSEMIA WITH NO CARDIAC MANIFESTATIONS (FOUR-DIMENSIONAL ECHOCARDIOGRAPHIC STUDY)

M El-Shanshory¹ (¹Pediatrics, Faculty of Medicine, Tanta University, Tanta, Egypt)

- E1584 **THE IMPORTANCE OF SERUM GDF-15 LEVELS TO ASSESS IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR**
U Caliskan² (²Pediatric Hematology and Oncology, NECMETTIN ERBAKAN UNIVERSITY MERAM MEDICAL FACULTY, Konya, Turkey)
- E1585 **ASSOCIATION OF SP1 POLYMORPHISM IN THE COLLAGEN TYPE I ALPHA -1 (COL1A1) GENE WITH OSTEOPOROSIS IN CHILDREN WITH BETA-THALASSEMIA**
M Hesham¹ (¹Pediatric, Zagazig University Hospital, Zagazig, Egypt, Zagazig, Egypt)
- E1586 **UNUSUAL MOLECULAR MECHANISMS IN THE ORIGIN OF ALPHA-THALASSEMIA**
P Faustino^{1,11} (¹Departamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA), Lisboa, Portugal, ¹¹ ISAMB, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal)
- E1588 **VALUE OF HBA2 IN THE DIAGNOSIS OF BETA-THALASSEMIA MINOR - "ATTENTION TO THE GRAY ZONE"**
L Relvas¹ (¹Serviço de Hematologia Clínica, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal)
- E1589 **DIAGNOSIS OF HEMOGLOBINOPATHIES BY CAPILLARY ZONE ELECTROPHORESIS: EXPERIENCE WITH 925 CASES**
P Tripathi¹ (¹dept of hematology, All India Institute of Medical Sciences, New Delhi, India)
- THROMBOSIS AND VASCULAR BIOLOGY**
- E1590 **RELEVANT ROLE OF VON WILLEBRAND FACTOR-ADAMTS13 AXIS IN HEPATIC ISCHEMIA- REPERFUSION INJURY**
Y Urisono¹ (¹Emergency and Critical Care Medicine, Nara Medical University, Kashihara, Japan)
- E1591 **THE IMPORTANCE OF THE FULL BLOOD COUNT, JAK II AND ADAMTS 13 TESTING IN STROKE EVALUATION: A REVIEW OF 619 CONSECUTIVE YOUNG STROKE AND TIA PATIENTS**
A Taylor¹ (¹Haematology, University College London Hospital, London, United Kingdom)
- E1592 **PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) RELATED THROMBOSIS IN 230 PATIENTS WITH HEMATOLOGICAL MALIGNANCIES. A 6 YEARS SINGLE EXPERIENCE CENTER.**
JM Bastida¹ (¹Hematology, Hospital Universitario de Salamanca, Salamanca, Spain)
- E1593 **A STUDY OF VENOUS THROMBOEMBOLISM SUSCEPTIBILITY LOCUS FACTOR XI, ABO AND FIBRINOGEN IN A PORTUGUESE POPULATION SAMPLE**
L Manco¹ (¹Research Center for Anthropology and Health (CIAS), University of Coimbra, Coimbra, Portugal)
- E1594 **PEDIATRIC VENOUS THROMBOEMBOLISM: INCIDENCE, RISK FACTORS AND MANAGEMENT OF HOSPITALIZED PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL**
P Raheja¹ (¹Hematology Department, Vall d'Hebron University Hospital, Barcelona, Spain)
- E1595 **CELL-BASED EVALUATION OF CHANGES IN COAGULATION ACTIVITY INDUCED BY ANTINEOPLASTIC DRUGS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA**
H Shinki¹ (¹Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan)
- E1596 **DESCRIPTION OF THROMBOTIC EVENTS AND/OR PREGNANCY LOSSES IN A COHORT OF HOMOZYGOUS CARRIERS FOR THE C46T POLYMORPHISM OF THE F12 GENE**
S Martín Herrero¹ (¹Hematology, Fundación Jiménez Díaz, Madrid, Spain)
- E1597 **ANALYSIS OF CHARACTERISTICS OF HOSPITAL ASSOCIATED THROMBOSES**
N Smith¹ (¹Haematology, Heart of England NHS Foundation Trust, Birmingham, United Kingdom)
- E1598 **THROMBOSIS DURING INFANCY AND NEWBORN PERIOD: AN UNRESOLVED ISSUE**
F Gumruk¹ (¹Pediatric Hematology, Hacettepe University, Ankara, Turkey)
- E1599 **THE QUALITY COMPOSITION OF SOLUBLE FIBRIN MONOMER COMPLEX FRACTION FOR ACUTE AND POST ACUTE ISCHEMIC STROKE PATIENTS**
T Katrii¹ (¹Biochemistry, Educational and Scientific Centre "Institute Of biology and medicine", Kyiv, Ukraine)
- E1600 **EVALUATION OF A RAPID NANOPARTICLE-BASED LATERAL FLOW IMMUNOASSAY (STIC EXPERT HIT) FOR THE DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA IN A CARDIOTHORACIC HOSPITAL.**
G Soufla¹ (¹Department of Haematology, Blood Transfusion Unit and Coagulation and Haemostasis, Onassis Cardiac Surgery Center, Athens, Greece)
- E1601 **AUDIT OF 'DOOR TO NEEDLE' TIME IN ADMINISTRATION OF PROTHROMBIN COMPLEX CONCENTRATE TO PATIENTS REQUIRING URGENT REVERSAL OF ANTICOAGULATION**
S Elshafie¹ (¹Haematology, HEART OF ENGLAND NHS FOUNDATION TRUST, Birmingham, United Kingdom)



E1602 **THE IMPORTANCE OF PLATELET MEMBRANE FLUIDITY AND OXIDATIVE STRESS IN THROMBOTIC COMPLICATIONS ACQUIRED BY CHRONIC MYELO-PROLIFERATIVE NEOPLASMS PATIENTS**
VM POPOV¹ (¹Hematology, COLENTINA CLINICAL HOSPITAL, Bucharest, Romania)

E1603 **USE OF ROTATIONAL THROMBOELASTOGRAPHY TO PREDICT CENTRAL VENOUS CATHETER RELATED VENOUS THROMBOSIS IN CHILDREN: PRELIMINARY RESULTS**
T Bayhan¹ (¹Division of Pediatric Hematology, Hacettepe University, Ankara, Turkey)

E1604 **THE POTENCIAL ROLE OF ANTINEOPLASTIC DRUGS IN THE PREDICTION OF THROMBOTIC RISK IN ONCOLOGIC PATIENTS IN ADDITION TO THE KHORANA SCORE**
E Gómez¹ (¹Hematology, Complejo Hospitalario de Navarra, Pamplona, Spain)

TRANSFUSION MEDICINE

E1605 **CLINICAL OUTCOMES AND UTILIZATION OF BLOOD BANK RESOURCES OF PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP), HEMOLYTIC UREMIC SYNDROME (HUS), AND OTHER MICROANGIOPATHY- A 14 YEARS' EXPERIENCE**
CT Lee^{1, 2} (¹Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore, ²Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore)

E1606 **HEPATITIS E VIRUS: INVESTIGATION IN NORTH ITALIAN BLOOD DONORS**
L Raffaele¹ (¹Transfusion Medicine and Hematology, ASST-Lecco, Lecco, Italy)

E1607 **SHORT-TERM ADMINISTRATION OF RECOMBINANT HUMAN ERYTHROPOIETIN DECREASES B CELL IN HUMAN PERIPHERAL BLOOD**
T Nagashima¹ (¹Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Gunma, Japan)

E1608 **BLOODLESS TREATMENT OF HEMATOLOGIC MALIGNANCIES AND APLASTIC ANEMIA - JEHOVAH'S WITNESSES (JW)**
K Kim¹ (¹Internal Medicine, Soonchunhyang University Hospital, Seoul, Seoul, Korea, Republic Of)

E1609 **PREOPERATIVE ANEMIA: A SINGLE INSTITUTION EXPERIENCE IN SPAIN**
G Pinto¹ (¹Hematology, HOSPITAL RAMON Y CAJAL, Madrid, Spain)

E1610 **RED BLOOD CELLS (RBC) AND PLATELET (PLT) TRANSFUSIONS IN TRANSPLANTED AND NOT-TRANSPLANTED PATIENTS WITH HEMATOLOGICAL MALIGNANCIES**
D Sotiropoulos¹ (¹Haematology Department & BMT Unit, George Papanicolaou Hospital, Thessaloniki, Greece)

INDEX

Please find below the indexes of the congress and the special indications of the travel grant winners.

SPEAKER & DISCLOSURE INDEX →

Page 235

ABSTRACT AUTHORS INDEX →

Page 247

TRAVEL GRANT WINNERS → **RED**

GUISEPPE BIGI GRANT WINNER → **GREEN**



STOCKHOLM
23RD CONGRESS
JUNE 14-17 | 2018
European Hematology Association

Don't forget
to apply for a travel grant
for next year's Congress in Stockholm!

APPLICATION CRITERIA
Authors wishing to be considered
for a grant should be:
- a member of EHA
- the first and presenting author
of a submitted abstract
- 36 years or younger of age

SPEAKER & DISCLOSURE INDEX

SPEAKER & DISCLOSURE INDEX (as of May 16)

EHA would like to thank the following persons for their contribution to the congress as speakers and chairs in the invited speaker program.

Abdel-Wahab O <i>Molecular Hemopoiesis Workshop,</i> <i>Poster Walk</i> Disclosures: <i>No Affiliations</i>	<i>Squibb (Advisory Board); Gilead (Advisory Board); C4 Therapeutics (Scientific Founder); Oncopep (Scientific Founder)</i>	<i>Amgen (Advisory Board, Research Support)</i>
Adamson P <i>Hematology-in-Focus</i> Disclosures: <i>No Affiliations</i>	Andolfo I <i>Scientific Working Groups</i> Disclosures: <i>No Affiliations</i>	Bacon P <i>EU Projects in Hematology</i> Disclosures: <i>Affiliations Unknown</i>
Adès L <i>Simultaneous Session</i> Disclosures: <i>Affiliations Unknown</i>	Angelucci E <i>Education Session</i> Disclosures: <i>Novartis Oncology (Chair Steering Committee, Telesto Protocol, Advisory Board); Celgene (Chair DMC)</i>	Balduini CL <i>Scientific Working Groups</i> Disclosures: <i>No Affiliations</i>
Agno W <i>Education Session, Clinical Debate, EHA-ISTH Joint Symposium</i> Disclosures: <i>Bayer (Advisory Board, Research Support, Honoraria); Boehringer Ingelheim (Advisory Board, Honoraria); Daiichi Sankyo (Advisory Board, Honoraria); BMS/Pfizer (Honoraria); Aspen (Honoraria)</i>	Ann Sutton L <i>EU Projects in Hematology</i> Disclosures: <i>Affiliations Unknown</i>	Baldus C <i>Poster Walk</i> Disclosures: <i>Affiliations Unknown</i>
Aguado Bueno B <i>Poster Walk</i> Disclosures: <i>Affiliations Unknown</i>	Ansell S <i>Scientific Working Groups</i> Disclosures: <i>Bristol Myers Squibb (Research Funding); Merck (Research Funding); Affimed (Research Funding); Seattle Genetics (Research Funding); Celldex (Research Funding)</i>	Barata J <i>Basic-Science-in-Focus</i> Disclosures: <i>No Affiliations</i>
Akashi K <i>EHA-JSH Joint Symposium</i> Disclosures: <i>No Affiliations</i>	Apperley J <i>Patient Advocacy Session 2</i> Disclosures: <i>Ariad (Advisory Board, Satellite Symposia Speaker, Research Support); Bristol Myers Squibb (Advisory Board, Satellite Symposia Speaker); Incyte (Advisory Board, Satellite Symposia Speaker); Novartis (Advisory Board, Satellite Symposia Speaker, Research Support); Pfizer (Advisory Board, Satellite Symposia Speaker, Research Support)</i>	Barcellini W <i>Poster Walk</i> Disclosures: <i>Affiliations Unknown</i>
Alegre A <i>Education Session, Simultaneous Session</i> Disclosures: <i>Celgene (Advisory Board, Research Support); Janssen (Advisory Board, Research Support); Amgen (Advisory Board); Takeda (Advisory Board)</i>	Asmar F <i>Poster Walk</i> Disclosures: <i>Affiliations Unknown</i>	Bartels M <i>Poster Walk</i> Disclosures: <i>Affiliations Unknown</i>
Almeida A <i>Poster Walk</i> Disclosures: <i>Affiliations Unknown</i>	Aurer I <i>Simultaneous Session</i> Disclosures: <i>Affiliations Unknown</i>	Baruchel A <i>Hematology-in-Focus</i> Disclosures: <i>Affiliations Unknown</i>
Almeida JM <i>Simultaneous Session</i> Disclosures: <i>Affiliations Unknown</i>	Avet-Loiseau H <i>Education Session, Simultaneous Session</i> Disclosures: <i>Celgene (Advisory Board, Research Support); Janssen (Advisory Board, Research Support); Sanofi (Advisory Board, Research Support); Takeda (Advisory Board);</i>	Basso G <i>Scientific Working Groups</i> Disclosures: <i>No Affiliations</i>
Altamura S <i>Early Career Session</i> Disclosures: <i>No Affiliations</i>		Becker H <i>Early Career Session</i> Disclosures: <i>BMS (Honoraria); Novartis (Honoraria)</i>
Amorim CA <i>Education Session</i> Disclosures: <i>No Affiliations</i>		Bene MC <i>Laboratory Diagnosis Workshop, Scientific Working Groups</i> Disclosures: <i>Beckman Coulter (Research Support)</i>
Anderson K <i>EHA-ASH Joint Symposium</i> Disclosures: <i>Millennium Takeda (Advisory Board); Bristol Myers</i>		Berneman Z <i>Simultaneous Session, Poster Walk</i> Disclosures: <i>Affiliations Unknown</i>

SPEAKER & DISCLOSURE INDEX

- Disclosures: *Affiliations Unknown*
Bondanza A
Hematology-in-Focus, Poster Walk
Disclosures: *Affiliations Unknown*
Bonini C
Simultaneous Session
Disclosures: *Affiliations Unknown*
Bonnet D
Basic-Science-in-Focus, Scientific Working Groups
Disclosures: *No Affiliations*
Borkhardt A
Basic-Science-in-Focus
Disclosures: *No Affiliations*
Bornhauser B
Simultaneous Session
Disclosures: *Affiliations Unknown*
Bosman G
Scientific Working Groups
Disclosures: *No Affiliations*
Bourquin JP
Simultaneous Session
Disclosures: *No Affiliations*
Brand A
Education Session
Disclosures: *No Affiliations*
Braun T
Poster Walk
Disclosures: *Affiliations Unknown*
Breems D
Poster Walk
Disclosures: *Affiliations Unknown*
Brice P
Education Session
Disclosures: *Takeda (Advisory Board); BMS (Advisory Board); Millenium (Research Support); Takeda (Research Support); Amgen (Research Support)*
Bron D
Scientific Working Groups
Disclosures: *Amgen (Advisory Board, Educational Grant); Gilead (Advisory Board); Janssen (Advisory Board); Novartis (Educational Grant); Roche (Advisory Board, Educational Grant); Takeda (Advisory Board, Educational Grant); Teva (Advisory Board)*
Brousse V
Simultaneous Session
Disclosures: *Affiliations Unknown*
Brugnara C
Scientific Working Groups
Disclosures: *Pfizer Inc. (Consulting Agreement)*
Bullinger L
Education Session, EU Projects in Hematology
Disclosures: *BMS (Advisory Board, Speaker's Bureau); BI (Advisory Board, Speaker's Bureau); MSD (Advisory Board, Speaker's Bureau); Merck (Advisory Board, Speaker's Bureau); Celgene (Advisory Board, Speaker's Bureau)*
Burnouf T
Education Session
Disclosures: *No Affiliations*
Caballero D
Simultaneous Session
Disclosures: *Affiliations Unknown*
Cabeçadas J
Laboratory Diagnosis Workshop
Disclosures: *Roche (Institutional Reserch Support, Travel Grant); Takeda (Travel Grants); MSD (Advisory Board)*
Caligaris-Cappio F
Education Session
Disclosures: *No Affiliations*
Camaschella C
Simultaneous Session
Disclosures: *Affiliations Unknown*
Campbell P
EHA-JSH Joint Symposium
Disclosures: *AACR (Member)*
Campo E
Education Session
Disclosures: *Gilead (Scientific Boards, Consultancy, Expert Testimony, Grant Support); Celgene (Educational Support, Patent on DLBCL cell or rigin gene expression assay)*
Canaani J
Simultaneous Session
Disclosures: *Affiliations Unknown*
Cappellini MD
Education Session,
Disclosures: *Sanofi/Genzyme (Advisory Board); Novartis Pharma (Advisory Board); Vifor Pharma (Advisory Board)*
Carlomagno F
Basic-Science-in-Focus
Disclosures: *No Affiliations*
Castaman G
Meet-the-Expert
Disclosures: *CSL Behring (Advisory Board); Bayer (Advisory Board); Baxalta (Advisory Board); Kedrion (Advisory Board); Pfizer (Advisory Board); Sobi (Advisory Board); Novo Nordisk (Advisory Board)*
Cazzola M
Hematology-in-Focus, Simultaneous Session
Disclosures: *No Affiliations*
Chamuleau ME
Hematology-in-Focus
Disclosures: *No Affiliations*
Chevrou-Severac H
EU Projects in Hematology
Disclosures: *Affiliations Unknown*
Chiaretti S
Scientific Working Groups, Poster Walk
Disclosures: *No Affiliations*
Chng WJ
Poster Walk
Disclosures: *Affiliations Unknown*
Chomienne C
EHA-HST Joint Symposium
Disclosures: *No Affiliations*
Clappier E
Simultaneous Session
Disclosures: *Affiliations Unknown*
Clark B
Hematology-in-Focus
Disclosures: *No Affiliations*
Colombatti R
Clinical Debate, Simultaneous Session
Disclosures: *Eli Lilly (Research Support)*
Colomer D
Poster Walk
Disclosures: *Affiliations Unknown*
Copland M
Education Session
Disclosures: *Novartis (Advisory Board, Speaker's Bureau, Travel Grant); Bristol-Myers Squibb (Advisory Board, Speaker's Bureau, Research Support, Travel Grant); Ariad (Advisory Board, Speaker's Bureau, Research Support); Pfizer (Advisory Board, Speaker's Bureau); Shire Pharmaceuticals (Speaker's Bureau); Cyclacel (Research Support); Amgen (Advisory Board)*
Corn J
EHA-ASH Joint Symposium
Disclosures: *Mission Therapeutics (Scientific Advisory Board)*
Craddock C
Simultaneous Session
Disclosures: *Affiliations Unknown*
Cross N
Education Session
Disclosures: *Novartis (Advisory*

- Board, Speaker, Research Support); Qiagen (Advisory Board)*
- Da Costa L
Education Session
Disclosures: *Affiliations Unknown*
- Davies A
Poster Walk
Disclosures: *Affiliations Unknown*
- De Carvalho D
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- de la Rubia J
Poster Walk
Disclosures: *Affiliations Unknown*
- de Montalembert M
Clinical Debate, Poster Walk
Disclosures: *Novartis (Advisory Board, Speaker's Bureau); Addmedica (Advisory Board)*
- de Vooght KMK
Education Session
Disclosures: *No Affiliations*
- Delforge M
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Della Porta MG
Education Session
Disclosures: *No Affiliations*
- Delwel R
Scientific Working Groups
Disclosures: *No Affiliations*
- Devereux S
Scientific Working Groups
Disclosures: *Gilead (Advisory Board, Speaker's Bureau, Travel Sponsorship); Roche (Advisory Board, Speaker's Bureau); Janssen (Advisory Board, Speaker's Bureau, Travel Sponsorship); Abbvie (Advisory Board); GSK (Advisory Board, Speaker's Bureau); BMS (Advisory Board)*
- Devos T
Poster Walk
Disclosures: *Affiliations Unknown*
- Di Michele D
Plenary Session 2, Clinical Debate
Disclosures: *No Affiliations*
- Dolmans MM
Education Session
Disclosures: *No Affiliations*
- Dolstra H
Basic-Science-in-Focus, Simultaneous Session
Disclosures: *No Affiliations*
- Dombret H
Meet-the-Expert, Scientific Working
- Groups*
- Disclosures: *Roche/Genentech (Grants, Fees); Amgen (Grants, Fees); Pfizer (Fees); Ariad (Incyte) (Grants, Fees); Novartis (Fees); Celgene (Fees); Jazz Pharma. (Grants, Fees); Agios (Fees); Sunesis (Fees); Ambit (Daiichi Sankyo) (Fees); Karyopharm (Fees); Kite Pharma. (Grants, Fees); Menarini (Fees); Astellas (Fees); Janssen (Fees); Servier (Fees); Seattle Genetics (Fees); Cellectis (Fees)*
- Donadieu J
Scientific Working Groups
Disclosures: *Roche (Research Support); Prolong (Research Support)*
- Doubek M
Scientific Working Groups
Disclosures: *Gilead Sciences (Grant, Advisory Board); Janssen Cilag (Grant, Advisory Board); AbbVie (Research Support, Advisory Board); Roche (Advisory Board)*
- Dreyling M
Scientific Working Groups, Simultaneous Session
Disclosures: *No Affiliations*
- Dufour C
Scientific Working Groups
Disclosures: *No Affiliations*
- Durie B
Laboratory Diagnosis Workshop
Disclosures: *No Affiliations*
- Eichhorst B
Education Session
Disclosures: *Roche (Advisory Boards, Honoraria, Research); Abbvie (Advisory Boards, Honoraria, Research); Janssen (Advisory Boards, Honoraria, Research); Gilead (Advisory Boards, Honoraria, Research); Celgene (Advisory Boards, Honoraria); Novartis (Advisory Boards, Honoraria)*
- Eichinger S
EHA-ISTH Joint Symposium, Simultaneous Session
Disclosures: *Bayer (Speaker Fees); Boehringer-Ingelheim (Speaker Fees); Daiichi-Sankyo (Speaker Fees); Pfizer (Speaker Fees); BMS (Speaker Fees)*
- Einsele H
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Eisfeld AK
Early Career Session
Disclosures: *No Affiliations*
- El-Galaly TC
Scientific Working Groups
Disclosures: *Takeda (Travel Funding); Roche (Advisory Board, Travel Funding)*
- Engert A
Education Session, Hematology-in-Focus, Simultaneous Session
Disclosures: *Takeda (Advisory Board, Research Support); Bristol Myers Squibb (Honorarium, Research Support); Amgen (Honorarium, Research Support); Affimed (Advisory Board, Research Support)*
- Enver T
Plenary Session 1
Disclosures: *Affiliations Unknown*
- Essers M
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- Esteve J
Poster Walk
Disclosures: *Affiliations Unknown*
- Estey EH
Patient Advocacy Session 1
Disclosures: *No Affiliations*
- Fain O
Scientific Working Groups
Disclosures: *No affiliations*
- Falkenburg JHF
Education Session
Disclosures: *No Affiliations*
- Fenaux P
Education Session, Clinical Debate, EU Projects in Hematology
Disclosures: *No Affiliations*
- Falanga A
Scientific Working Groups
Disclosures: *Pfizer (Speaker's Bureau); Janssen (Advisory Board); Aspen (Speaker's Bureau); Rovi (Speaker's Bureau)*
- Fibbe W
Scientific Working Groups, Simultaneous Session
Disclosures: *No Affiliations*
- Fielding A
Scientific Working Groups, Simultaneous Session
Disclosures: *Amgen (Advisory Board); Pfizer (Advisory Board)*
- Fioredda F
Scientific Working Groups
Disclosures: *No Affiliations*
- Flores-Montero JA
Scientific Working Groups
Disclosures: *No Affiliations*



SPEAKER & DISCLOSURE INDEX

- Forni GL
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Freeman S
Poster Walk
Disclosures: *Affiliations Unknown*
- Fry T
Education Session, Hematology-in-Focus
Disclosures: *No Affiliations*
- Fulop T
Scientific Working Groups
Disclosures: *Pfizer (Consultation Fee)*
- Gaidano G
Hematology-in-Focus
Disclosures: *Roche (Advisory Board; Speaker's Bureau); Janssen (Advisory Board; Speaker's Bureau); Gilead (Advisory Board); Novartis (Advisory Board); Amgen (Advisory Board); Abbvie (Advisory Board)*
- Gaidzik V
Early Career Session
Disclosures: *No Affiliations*
- Ganser A
Scientific Working Groups, Simultaneous Session
Disclosures: *Boehringer-Ingelheim (Consultancy); TEVA (Consultancy); Celgene (Consultancy); JAZZ Pharmaceuticals (Consultancy); Seattle Genetics (Consultancy)*
- Garcia-Marco JA
Poster Walk
Disclosures: *Affiliations Unknown*
- Gaulard P
Laboratory Diagnosis Workshop
Disclosures: *Takeda (Honoraria); Celgene (Research Funding)*
- Geissler J
Patient Advocacy Session 2, EU Projects in Hematology
Disclosures: *Novartis (Advisory Board, Consultancy, Speaker's Bureau); Amgen (Advisory Board); Gilead (Speaker's Bureau); Roche (Speaker's Bureau); Pfizer (Speaker's Bureau)*
- George T
Laboratory Diagnosis Workshop
Disclosures: *No Affiliations*
- Gjertsen B
Poster Walk
Disclosures: *Affiliations Unknown*
- Ginzburg Y
Education Session
Disclosures: *CSL Behring (Research Support); ApoPharma (Research Support)*
- Giralt S
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Gluckman E
EHA-EBMT Joint Symposium
Disclosures: *No Affiliations*
- Gökbuğet N
Scientific Working Groups
Disclosures: *Amgen (Honoraria, Advisory Board, Research Support); Pfizer (Honoraria, Advisory Board, Research Support); Baxalta/Shire (Advisory Board)*
- Goldschmidt H
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Gomez Perdiguerro E
Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*
- Goodell P
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- Goodlad J
Laboratory Diagnosis Workshop
Disclosures: *No Affiliations*
- Gotlib JR
Meet-the-Expert
Disclosures: *Affiliations Unknown*
- Gottlieb E
Basic-Science-in-Focus, Simultaneous Session
Disclosures: *Metabomed LTD Israel (Shareholder, Executive Board Member)*
- Gratwohl A
Scientific Working Groups
Disclosures: *No Affiliations*
- Grebien F
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Green AR
Opening Ceremony, Plenary Session 2, EHA-ASH Joint Symposium, EHA-ISEH Joint Symposium, Presidential Symposium, EHA-EBMT Joint Symposium
Disclosures: *No Affiliations*
- Gribben J
Early Career Session
Disclosures: *Janssen (Research Support, Principal Investigator, Honoraria); Genentech (Scientific Advisory Board); Roche/Genentech (Honoraria, Principal Investigator); Takeda (Principal Investigator); Celgene (Principal Investigator, Consultant, Honoraria); TG Therapeutics (Consultant, Honoraria); Unum (Scientific Advisory Board, Consultant); Cellectis (Scientific Advisory Board, Consultant); Pharmacyclics (Principal Investigator, Honoraria); Gilead (Principal Investigator); Abbvie (Scientific Advisory Board, Principal Investigator, Honoraria); Epizyme (Principal Investigator); Medimmune (Principal Investigator); Merck (Principal Investigator); AZ (Research Support)*
- Griesshammer M
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Gronbaek K
Basic-Science-in-Focus, Scientific Working Groups, Simultaneous Session
Disclosures: *Celgene (Advisory Board); Janssen (Advisory Board)*
- Gröschel S
Poster Walk
Disclosures: *Affiliations Unknown*
- Gruber M
Early Career Session
Disclosures: *No Affiliations*
- Guillén A
Patient Advocacy Session 2
Disclosures: *No Affiliations*
- Haas T
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Hagenbeek A
Simultaneous Session, EHA Advocacy Session
Disclosures: *Affiliations Unknown*
- Hallek M
Molecular Hemopoiesis Workshop
Disclosures: *Affiliations Unknown*
- Hansen JB
Poster Walk
Disclosures: *Affiliations Unknown*
- Harrison C
Education Session
Disclosures: *Novartis (Grant, Advisory Board, Speaker's Bureau); Shire (Speaker's Bureau); Gilead (Grant, Advisory Board, Speaker's Bureau); Baxalta (Advisory Board, Speaker's Bureau); Sanofi (Advisory Board, Speaker's Bureau); CTI (Advisory Board, Speaker's Bureau)*
- Harrousseau JL
Simultaneous Session

- Disclosures: *Affiliations Unknown*
 Hasle H
Simultaneous Session
 Disclosures: *Affiliations Unknown*
 Hasselbalch H
Simultaneous Session
 Disclosures: *Affiliations Unknown*
 Hehlmann R
Scientific Working Groups, EU Projects in Hematology
 Disclosures: *BMS (Consultation); Novartis (Research Support)*
 Hellström Lindberg E
EHA-ESH Joint Symposium
 Disclosures: *Celgene (Grant)*
 Hermouet S
Simultaneous Session
 Disclosures: *Affiliations Unknown*
 Hernández JM
EU Projects in Hematology
 Disclosures: *Affiliations Unknown*
 Hills R
Early Career Session
 Disclosures: *Celgene (Speaker); Janssen (Advisory Board); Pfizer (Advisory Board); Sunesis (Consultancy); CTI (Consultancy)*
 Hochhaus A
Education Session
 Disclosures: *Novartis (Research Support); BMS (Research Support); Pfizer (Research Support); Incyte (Research Support)*
 Hrusak O
Hematology-in-Focus
 Disclosures: *No Affiliations*
 Huang X
EHA-CSH Joint Symposium
 Disclosures: *No Affiliations*
 Hübel K
Education Session
 Disclosures: *Roche (Advisory Board, Speaker's Bureau); Sanofi (Advisory Board, Speaker's Bureau); Cell Therapeutics (Speaker's Bureau); Servier (Advisory Board, Speaker's Bureau); Gilead (Speaker's Bureau); Teva (Advisory Board); Hexal (Advisory Board), Amgen (Travel Grants, Speaker's Bureau)*
 Huisman M
Education Session
 Disclosures: *No Affiliations*
 Hultcrantz M
Scientific Working Groups
 Disclosures: *No Affiliations*
 Hutchings M
Early Career Session, Simultaneous Session
 Disclosures: *Affiliations Unknown*
 Inaba H
Hematology-in-Focus
 Disclosures: *No Affiliations*
 Iolascon A
Hematology-in-Focus, Scientific Working Groups, Simultaneous Session
 Disclosures: *No Affiliations*
 Ionova T
Scientific Working Groups
 Disclosures: *BMS (Research Grant); MSD (Lecturer)*
 Itkin T
Poster Walk
 Disclosures: *Affiliations Unknown*
 Izraeli S
Opening Ceremony, Plenary Session 1, EHA-CSH Joint Symposium, Presidential Symposium
 Disclosures: *prIMEOncology (Direct/ Indirect); Jazz Pharmaceutical (Indirect)*
 Jäger U
Hematology-in-Focus
 Disclosures: *No Affiliations*
 Jain N
Hematology-in-Focus
 Disclosures: *BMS (Research Support); Pharmacyclics (Research Support, Advisory Board); Abbvie (Research Support); Genentech (Research Support); Pfizer (Research Support, Advisory Board); Incyte (Research Support); Infinity (Research Support); ADC Therapeutics (Research Support, Advisory Board); Seattle Genetics (Research Support); Celgene (Research Support); Servier (Research Support, Advisory Board); Novimmune (Advisory Board); Adaptive Biotechnologies (Advisory Board); Novartis (Advisory Board)*
 Jansen J
Education Session
 Disclosures: *No Affiliations*
 Janssen J
Simultaneous Session
 Disclosures: *Affiliations Unknown*
 Jares P
Laboratory Diagnosis Workshop
 Disclosures: *No Affiliations*
 Johnson S
EHA-ESH Joint Symposium
 Disclosures: *No Affiliations*
 Jones JA
Scientific Working Groups
 Disclosures: *Abbvie (Advisory Board, Research Support); Pharmacyclics (Advisory Board, Research Support); Janssen (Advisory Board, Research Support); Acerta (Research Support); Genentech (Research Support); Gilead (Advisory Board, Research Support)*
 Jost P
Molecular Hemopoiesis Workshop
 Disclosures: *Novartis (Advisory Board, Travel Support); Pfizer (Advisory Board, Travel Support); Ariad (Advisory Board, Travel Support); Abbvie (Research Support); Böhringer Ingelheim (Research Support)*
 Jourdain P
Scientific Working Groups
 Disclosures: *Affiliations Unknown*
 Juffermans NP
Scientific Working Groups
 Disclosures: *No Affiliations*
 Kaiser M
Scientific Working Groups
 Disclosures: *Amgen (Advisory Board, Honoraria); BMS (Advisory Board, Travel Support); Celgene (Advisory Board, Research Support); Chugai (Advisory Board); Janssen (Advisory Board); Takeda (Advisory Board, Travel Support)*
 Kamphuisen PW
EHA-ISTH Joint Symposium
 Disclosures: *Boehringer Ingelheim (Research Funding, Steering Board Committee); Daiichi Sankyo (Research Funding, Advisory Board); Pfizer (Research Funding)*
 Kapitein P
EHA Advocacy Session
 Disclosures: *No Affiliations*
 Karlsson S
Simultaneous Session
 Disclosures: *Affiliations Unknown*
 Kastritis E
Hematology-in-Focus
 Disclosures: *Janssen (Honoraria); Takeda (Honoraria); Amgen (Honoraria); Genesis Pharma (Honoraria)*
 Kater A
Simultaneous Session
 Disclosures: *Affiliations Unknown*
 Kattamis A

- Poster Walk
Disclosures: *Affiliations Unknown*
- Kenet G
Education Session
Disclosures: *BPL (Research Support); Bayer (Research Support, Speaker's Bureau, Advisory Board); Pfizer (Research Support, Speaker's Bureau); Opko Biologics (Research Support, Consultant); Alnylam (Research Support); Baxalta (Research Support, Consultant, Advisory Board)*
- Kennedy B
EHA-ESH Joint Symposium
Disclosures: *Janssen (Speaker's Bureau, Advisory Board); Roche (Speaker's Bureau); Abbvie (Speaker's Bureau, Advisory Board)*
- Kersten MJ
Scientific Working Groups
Disclosures: *Celgene (Research Support, Advisory Board); Millennium/Takeda (Research Support, Speaker's Fee, Advisory Board); Roche (Research Support, Speaker's Fee, Advisory Board); Mundipharma (Advisory Board); Janssen (Advisory Board)*
- Kiladjian JJ
Scientific Working Groups
Disclosures: *Novartis (Advisory Board, Insitutional Research Support); AOP Orphan (Advisory Board, Insitutional Research Support); Shire (Advisory Board)*
- Kilpivaara O
Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*
- Kirkham F
Education Session
Disclosures: *Shire (Speaker's Bureau)*
- Knapper S
EHA-HST Joint Symposium
Disclosures: *Novartis (Advisory Board, Honoraria, Funding for Conference Attendance); MSD (Honoraria); Celgene (Funding for Conference Attendance); Teva (Advisory Board)*
- Koehl U
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- Kolb HJ
EHA-EBMT Joint Symposium
Disclosures: *Sandoz (Advisory Board); Apceth (Advisory Board), medac (Advisory Board)*
- Kortüm KM
Scientific Working Groups
Disclosures: *No Affiliations*
- Kratz C
Education Session
Disclosures: *No Affiliations*
- Krause D
Scientific Working Groups, Simultaneous Session
Disclosures: *No Affiliations*
- Kremer Hovinga JA
Scientific Working Groups
Disclosures: *Ablynx (Advisory Board); Baxalta (Advisory Board, Research Grant); Bayer (Research Grant); CSL Behring (Research Grant); NovoNordisk (Research Grant)*
- Krishnamurti L
Clinical Debate
Disclosures: *No Affiliations*
- Kristinsson S
Clinical Debate, Poster Walk
Disclosures: *No Affiliations*
- Kröger N
Education Session, Clinical Debate, Simultaneous Session
Disclosures: *No Affiliations*
- Kuball J
Hematology-in-Focus
Disclosures: *Novartis (Grants); Pierre Fabre (Grants); Miltenyi Biotech (Grants); Gadeta (Scientific Co-founder, CSO); Inventor on multiple patents on gdTCR receptors and isolation strategies for engineered immune cells*
- Kühn M
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Kyrle PA
Clinical Debate
Disclosures: *Boehringer Ingelheim (Advisory Board, Speaker's Bureau); Bayer (Advisory Board, Speaker's Bureau); Daiichi Sankyo (Advisory Board, Speaker's Bureau)*
- la Fuente Burguera A
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Landau D
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- Laurenti E
Early Career Session
Disclosures: *No Affiliations*
- Leleu X
Scientific Working Groups
Disclosures: *Janssen (Honorarium, Advisory Board); Celgene (Honorarium, Advisory Board); Amgen (Honorarium, Advisory Board); Takeda (Honorarium, Advisory Board); Pierre Fabre (Honorarium); Novartis (Honorarium, Advisory Board); BMS (Honorarium, Advisory Board); Abbvie (Honorarium); Mercq (Honorarium, Advisory Board); Sanofi (Honorarium, Advisory Board)*
- Lenz G
Education Session
Disclosures: *Janssen (Advisory Board, Research Funding); Celgene (Advisory Board, Research Funding, Lectures); Gilead (Advisory Board); Roche (Advisory Board); Astra Zeneca (Research Funding)*
- Levi M
Clinical Debate
Disclosures: *No Affiliations*
- Levis M
Education Session
Disclosures: *Astellas (Advisory Board, Research Support); Novartis (Advisory Board, Research Support); Daiichi-Sankyo (Advisory Board, Consultant); FujiFilm (Advisory Board); Arog (Advisory Board); Takeda (Research Support); Agios (Advisory Board, Consultant)*
- Lhermitte L
Scientific Working Groups
Disclosures: *Affiliations Unknown*
- Lin DT
EHA-HST Joint Symposium
Disclosures: *No Affiliations*
- Lion T
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- Liptrott S
Patient Advocacy Session 1
Disclosures: *No Affiliations*
- Lobry C
Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*
- Loefgren C
EU Projects in Hematology
Disclosures: *Affiliations Unknown*
- Longstaff C
Scientific Working Groups
Disclosures: *No Affiliations*
- Lowenberg B
Early Career Session
Disclosures: *No Affiliations*

- Lozano M
Education Session
Disclosures: *Grifols (Advisory Board); Terumo BCT (Research Support)*
- Ludwig H
Clinical Debate, Simultaneous Session
Disclosures: *Celgene (Advisory Board, Speaker's Bureau); Takeda (Advisory Board, Research Funding), Amgen (Advisory Board, Speaker's Bureau, Research Funding); Janssen (Advisory Board, Speaker's Bureau); AbbVie (Advisory Board), BMS (Advisory Board, Speaker's Bureau)*
- Macintyre E
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Mahon FX
Scientific Working Groups
Disclosures: *Affiliations Unknown*
- Makris M
Hematology-in-Focus
Disclosures: *NovoNordisk (Consultancy); CSL Behring (Consultancy); Grifols (Consultancy)*
- Malcovati L
Laboratory Diagnosis Workshop
Disclosures: *No Affiliations*
- Malmberg K
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- Maloney D
Basic-Science-in-Focus
Disclosures: *Juno Therapeutics (Institutional Research Support); Celgene (Advisory Board, Honoraria); F. Hoffmann La Roche (Advisory Board); Gilead (Advisory Board)*
- Mannucci PM
Clinical Debate
Disclosures: *Alexion (Lecture Fee); Baxalta/Shire (Lecture Fee); Bayer (Lecture Fee, Advisory Board Membership); CSL Behring (Lecture Fee); Grifols (Lecture Fee); Kedrion (Lecture Fee, Advisory Board Membership); LFB (Lecture Fee); Novo Nordisk (Lecture Fee)*
- Martinez-Lopez J
Hematology-in-Focus
Disclosures: *No Affiliations*
- Martin-Subero JI
Basic-Science-in-Focus, Simultaneous Session
Disclosures: *No Affiliations*
- Mateos MV
Hematology-in-Focus, Clinical Debate
Disclosures: *Janssen (Advisory Board, Lectures); Celgene (Advisory Board, Lectures); Takeda (Advisory Board, Lectures); Amgen (Advisory Board, Lectures); BMS (Advisory Board, Lectures)*
- Mayer J
Poster Walk
Disclosures: *Affiliations Unknown*
- McMahon C
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Meirow D
Education Session
Disclosures: *No Affiliations*
- Menzel S
Education Session
Disclosures: *Shire Plc (Research Grant)*
- Mercher T
Poster Walk
Disclosures: *Affiliations Unknown*
- Merlini GP
Meet-the-Expert
Disclosures: *Millennium Takeda (Advisory Board); Janssen (Advisory Board)*
- Mesa R
Scientific Working Groups
Disclosures: *Novartis (Advisor); Shire (Advisor); AOP (Advisor); Galena (Advisor); Ariad (Advisor); Incyte (Research Support); Celgene (Research Support); Gilead (Research Support); CTI (Research Support); Promedior (Research Support)*
- Metzeler K
Early Career Session
Disclosures: *Celgene (Research Support)*
- Milsom M
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- Mitchell R
Education Session
Disclosures: *No Affiliations*
- Mohty M
EHA-EBMT Joint Symposium
Disclosures: *Amgen (Advisory Board, Speaker's Bureau, Research Support); Sanofi (Advisory Board, Speaker's Bureau, Research Support); Jazz (Advisory Board, Speaker's Bureau, Research Support); Janssen (Advisory Board, Speaker's Bureau, Research Support); Molmed (Advisory Board, Speaker's Bureau, Research Support); Celgene (Honoraria); Takeda (Honoraria); BMS (Honoraria, Research Support); Novartis (Honoraria); Pfizer (Honoraria); Keocyt (Honoraria); Keocyt (Research Support); EBMT (President)*
- Moreau P
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Moreno C
Hematology-in-Focus, Meet-the-Expert
Disclosures: *Janssen (Advisory Board, Speaker's Bureau); Gilead (Advisory Board, Grant)*
- Muckenthaler M
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- Mufti G
Education Session
Disclosures: *Celgene (Advisory Board, Research Funding); Novartis (Research Funding)*
- Mullally A
Education Session, Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*
- Muller-Tidow C
Poster Walk
Disclosures: *No Affiliations*
- Mulligan S
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Munshi N
Education Session
Disclosures: *Celgene (Consulting Agreement); Merck (Consulting Agreement); Pfizer (Consulting Agreement); Takeda (Consulting Agreement); Oncopep (Consulting Agreement, Ownership Interest); Janssen (Consulting Agreement)*
- Müschen M
Basic-Science-in-Focus
Disclosures: *Pfizer (Center of Therapeutic Innovation, Research Support); AbbVie (Research Support, Grant); ADC Therapeutics (Research Support, Grant)*
- Mutch N
Education Session
Disclosures: *No Affiliations*
- Nagler A
EHA-CSH Joint Symposium
Disclosures: *No Affiliations*

- Nai A
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- Naldini L
EHA-ASH Joint Symposium
Disclosures: *GSK (Collaboration Agreement); Bioverativ (Research Support); Sangamo (Advisory Board); Editas (Research Support); Magenta (Advisory Board); OncoRus (Advisory Board); Genenta (Advisory Board, Research Support)*
- Neuberg D
Early Career Session
Disclosures: *Madriral Pharmaceuticals (Stock Ownership); Patent: Signatures for predicting the survivability of myelodysplastic syndrome subjects; Patent: Methods for determining response to a hypomethylating agent*
- Nicolini FE
Poster Walk
Disclosures: *Affiliations Unknown*
- Niemeyer C
Hematology-in-Focus
Disclosures: *No Affiliations*
- Nowak D
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Ntziachristos P
Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*
- Ogawa S
EHA-JSH Joint Symposium
Disclosures: *Takeda Pharmaceutical, Inc. (Advisory board); Kan Research Laboratory, Inc. (Advisory board); RegCell Corporation Inc. (Stockholder); Asashi Genomics Inc. (Stockholder); Qiagen Corporation (Royalties); Daiippon-Sumitomo Pharmaceutical, Inc. (Research Grant)*
- Olavarria E
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Oliva E
Scientific Working Groups
Disclosures: *Novartis (Advisory Board, Speaker's Bureau); Celgene (Advisory Board, Speaker's Bureau, Consultancy); Amgen (Advisory Board); La Jolla (Advisory Board, Consultancy)*
- Onida F
Hematology-in-Focus
Disclosures: *No Affiliations*
- Orazi A
Laboratory Diagnosis Workshop
Disclosures: *No Affiliations*
- Orfao A
Laboratory Diagnosis Workshop, Scientific Working Groups
Disclosures: *Alexion (Speaker's Bureau); Becton/Dickinson (Speaker's Bureau, Patent Licensing); Cytognos (Research Support, Patent Licesing); Immunostep (Patent Licensing, Research Support); International Myeloma Foundation (Research Support); Mundipharma (Speaker's Bureau, Research Support); Janssen (Speaker's Bureau)*
- Ossenkoppelle G
Education Session, Scientific Working Groups, Simultaneous Session
Disclosures: *Novartis (Advisory Board, Research Support); Pfizer (Advisory Board); BMS (Advisory Board); J&J (Advisory Board, Research Support, Consultant); Sunesis (Advisory Board); Celgene (Advisory Board, Research Support); Karyopharm (Advisory Board); Immunogen (Research Support); Amgen (Advisory Board); BD (Research Support); Seattle Genetics (Advisory Board)*
- Ostrand-Rosenberg S
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- Ouwehand WH
Education Session
Disclosures: *Bristol Myers Squibb (Educational Grant)*
- Padron E
Hematology-in-Focus
Disclosures: *Incyte (Advisory Board, Research Funding); CTI (Advisory Board, Research Funding); KaloBios (Research Funding)*
- Palladini G
Scientific Working Groups
Disclosures: *Celgene (Travel Expenses); Janssen-Cilag (Advisory Board); Prothena (Honoraria, Travel Expenses)*
- Pawelec G
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- Pecci A
Scientific Working Groups
Disclosures: *Novartis Farma S.p.A (Research Support)*
- Pellagatti A
Poster Walk
Disclosures: *Affiliations Unknown*
- Pendry K
Meet-the-Expert
Disclosures: *No Affiliations*
- Pérez Simón JA
Clinical Debate
Disclosures: *Jazz (Advisory Board, Speaker's Bureau); Janssen (Research Support Grant); Roche (Research Support Grant); Celgene (Research Support Grant)*
- Peyvandi F
Education Session, Hematology-in-Focus
Disclosures: *Bayer (Honoraria); Biotest (Honoraria); CSL Behring (Honoraria); Grifols (Honoraria); Novo Nordisk (Honoraria); Sobi (Honoraria); Ablynx (Scientific Advisory Board); Alexion (Institutional Research Funding); Biokit (Institutional Research Funding); Kedrion Biopharma (Consulting Fees); LFB (Consulting Fees); Octapharma (Consulting Fees)*
- Pfreundschuh M
Education Session
Disclosures: *Celgene (Advisory Board); Roche (Advisory Board, Research Support, Honoraria); Novartis (Advisory Board); Sandoz (Advisory Board); Spectrum (Advisory Board, Research Support); Takeda (Honoraria)*
- Pieters R
Education Session
Disclosures: *No Affiliations*
- Pignatti F
Clinical Debate, Patient Advocacy Session 1
Disclosures: *No Affiliations*
- Pileri S
Education Session, Laboratory Diagnosis Workshop
Disclosures: *Takeda (Advisory Board)*
- Plate A
Patient Advocacy Session 2, Education Session
Disclosures: *Celgene (Advisory Board, Speaker Agreement); Amgen (Advisory Board), Janssen (Advisory Board); BMS (Advisory Board); Takeda (Advisory Board, Speaker Agreement)*
- Platzbecker U

- Scientific Working Groups*
Disclosures: *No Affiliations*
- Pleyer L
Poster Walk
Disclosures: *Affiliations Unknown*
- Pluchino S
Scientific Working Groups
Disclosures: *No Affiliations*
- Porkka K
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Pospisilova S
Education Session
Disclosures: *No Affiliations*
- Prati D
Poster Walk
Disclosures: *Affiliations Unknown*
- Puissant A
Poster Walk
Disclosures: *Affiliations Unknown*
- Rachmilewitz E
Meet-the-Expert
Disclosures: *No Affiliations*
- Raderer M
Education Session
Disclosures: *No Affiliations*
- Radich J
Scientific Working Groups
Disclosures: *Novartis (Advisory Board, Lab Contract); BMS (Advisory Board); Ariad (Advisory Board)*
- Ravandi F
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Reiter A
Meet-the-Expert
Disclosures: *Novartis Pharma (Advisory Board, Honoraria, Travel Expenses)*
- Renné T
Education Session
Disclosures: *No Affiliations*
- Rezvani K
Basic-Science-in-Focus
Disclosures: *No Affiliations*
- Ribera JM
Education Session, Meet-the-Expert
Disclosures: *No Affiliations*
- Rodeghiero F
Clinical Debate, EHA-ISTH Joint Symposium
Disclosures: *No Affiliations*
- Roschewski M
Scientific Working Groups
Disclosures: *No Affiliations*
- Rossi D
Basic-Science-in-Focus
Disclosures: *Gilead (Unrestricted Research Grant, Honoraria); AbbVie (Honoraria); Janssen (Honoraria)*
- Rule S
Education Session, Scientific Working Groups
Disclosures: *Janssen (Advisory Board, Research Funding); Roche (Advisory Board); Astra Zeneca (Advisory Board); Celgene (Advisory Board)*
- Ruutu T
Meet-the-Expert, Simultaneous Session
Disclosures: *No Affiliations*
- Salek S
Scientific Working Groups
Disclosures: *No Affiliations*
- Salles G
Education Session
Disclosures: *Amgen (Advisory Board); BMS (Honoraria); Celgene (Advisory Board, Honoraria); Gilead (Advisory Board, Honoraria); Janssen (Advisory Board); Novartis (Advisory Board); Roche (Advisory Board, Research Support); Servier (Honoraria); Merck (Advisory Board, Research Support)*
- Samuelsson J
Education Session
Disclosures: *Novartis (Advisory Board)*
- Sanders M
Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*
- Sankaran V
Hematology-in-Focus
Disclosures: *No Affiliations*
- San-Miguel JF
Education Session, Simultaneous Session
Disclosures: *Millennium (Advisory Board); Celgene (Advisory Board); Novartis (Advisory Board); Onyx (Advisory Board); Janssen (Advisory Board); BMS (Advisory Board); MSD (Advisory Board); Amgen (Advisory Board)*
- Sanz G
EU Projects in Hematology
Disclosures: *Affiliations Unknown*
- Santini V
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Scadden D
Plenary Session 1
Disclosures: *Fate Therapeutics (Consultant, Stockholder); Magenta Therapeutics (Consultant, Stockholder, Director); Bone Therapeutics (Consultant); Bayer Therapeutics (Sponsored Research); Novartis (Sponsored Research)*
- Scharenberg C
Early Career Session
Disclosures: *No Affiliations*
- Schellong S
Education Session
Disclosures: *Bayer (Advisory Board, Speaker Fees); BMS (Speaker Fees); Boehringer (Advisory Board, Speaker Fees); Daiichi (Advisory Board, Speaker Fees); Pfizer (Speaker Fees)*
- Schneider R
Molecular Hemopoiesis Workshop, Simultaneous Session
Disclosures: *No Affiliations*
- Schroeder T
Molecular Hemopoiesis Workshop, EHA-ISEH Joint Symposium
Disclosures: *No Affiliations*
- Schuurhuis GJ
Scientific Working Groups
Disclosures: *Becton Dickinson (Research Support)*
- Schwaller J
Basic-Science-in-Focus, Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*
- Sevilla J
Education Session
Disclosures: *Novartis (Advisory Board, Speaker's Bureau); Terumo BCT (Speaker's Bureau)*
- Sexl V
Basic-Science-in-Focus, Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*
- Shimamura A
Education Session, Hematology-in-Focus
Disclosures: *No Affiliations*
- Shlush L
Basic-Science-in-Focus
Disclosures: *Affiliations Unknown*
- Sierra J
Plenary Session 1, Simultaneous Session
Disclosures: *Pfizer (Honoraria, Speaker's Bureau); Amgen (Grant); Celgene (Grant, Honoraria, Speaker's Bureau); Janssen (Honoraria, Speaker's Bureau); Seattle Genetics (Honoraria, Speaker's Bureau);*



- Novartis (Honoraria, Speaker's Bureau)
Skoda R
Plenary Session 2
Disclosures: Novartis (Advisory Board, Speaker's Bureau); Shire (Speaker's Bureau); Baxalta (Speaker's Bureau)
Snoeck HW
Scientific Working Groups
Disclosures: No Affiliations
Solana R
Scientific Working Groups
Disclosures: No Affiliations
Solano C
Poster Walk
Disclosures: Affiliations Unknown
Solary E
Hematology-in-Focus
Disclosures: Servier (Research Support); CIT Pharma (Research Support)
Sonneveld P
Plenary Session 2, Simultaneous Session
Disclosures: Celgene (Institutional Research Support, Advisory board, Honoraria); Janssen-Cilag (Institutional Research Support, Advisory board, Honoraria); Amgen (Institutional Research Support, Advisory board, Honoraria); Karyopharm (Institutional Research Support, Advisory board, Honoraria); SkylineDx (Institutional Research Support, Advisory board); Takeda (Institutional Research Support, Advisory board, Honoraria)
Soulier J
Poster Walk
Disclosures: Affiliations Unknown
Soverini S
Education Session
Disclosures: Incyte (Consultancy); Bristol-Myers Squibb (Consultancy); Novartis (Consultancy)
Spurrier-Bernard G
Patient Advocacy Session 1
Disclosures: No Affiliations
Squizzato A
Education Session
Disclosures: No Affiliations
Steedmann JL
Meet-the-Expert
Disclosures: BMS (Speaker Honoraria); Incyte (Speaker Honoraria, Advisory Board, Research Grant to Study Group); Novartis (Speaker Honoraria, Advisory Board, Research Grant to Study Group); Pfizer (Speaker Honoraria, Advisory Board, Research Grant to Study Group)
Stanworth S
Poster Walk
Disclosures: Affiliations Unknown
Steele A
Simultaneous Session
Disclosures: Affiliations Unknown
Stilgenbauer S
Plenary Session 2
Disclosures: AbbVie (Advisory Board, Research Support, Travel Support); Amgen (Advisory Board, Research Support, Travel Support); Boehringer-Ingelheim (Advisory Board, Research Support, Travel Support); Celgene (Advisory Board, Research Support, Travel Support); Genentech (Advisory Board, Research Support, Travel Support); Genzyme (Advisory Board, Research Support, Travel Support); Gilead (Advisory Board, Research Support, Travel Support); GSK (Advisory Board, Research Support, Travel Support); Janssen (Advisory Board, Research Support, Travel Support); Mundipharma (Advisory Board, Research Support, Travel Support); Novartis (Advisory Board, Research Support, Travel Support); Pharmacyclics (Advisory Board, Research Support, Travel Support); Hoffmann La-Roche (Advisory Board, Research Support, Travel Support); Sanofi (Advisory Board, Research Support, Travel Support)
Storb R
EHA-EBMT Joint Symposium
Disclosures: No Affiliations
Subklewe M
Basic-Science-in-Focus, Scientific Working Groups
Disclosures: Pfizer (Advisory Board); Amgen (Advisory Board; Research Support); Seattle Genetics (Advisory Board); Gilead (Advisory Board); Oxford Biotherapeutics (Research Support); Roche (Advisory Board); Celgene (Travel Support)
Sullivan R
EHA Advocacy Session
Disclosures: No Affiliations
Sureda A
Education Session, Poster Walk
Disclosures: Takeda (Advisory Boards, Honoraria Consultancy); BMS (Advisory Boards, Honoraria Consultancy)
Suttorp M
Simultaneous Session
Disclosures: Affiliations Unknown
Swerdlow SH
Hematology-in-Focus
Disclosures: No Affiliations
Taher A
Poster Walk
Disclosures: Affiliations Unknown
Takubo K
Scientific Working Groups
Disclosures: No Affiliations
Tamary H
Poster Walk
Disclosures: Affiliations Unknown
Taylor N
Basic-Science-in-Focus, Scientific Working Groups
Disclosures: Metafora Biosystems (Scientific Advisory Board)
Teachey D
Hematology-in-Focus
Disclosures: No Affiliations
Tedeschi A
Scientific Working Groups, Simultaneous Session
Disclosures: Gilead (Speaker's Bureau); Janssen spa (Advisory Board)
ten Cate H
Scientific Working Groups
Disclosures: Stago (Consultant, Research Support); Bayer (Research Support, Advisory Board); Boehringer (Research Support); Aspen (Research Support); Pfizer (Research Support, Advisory Board); Leo (Advisory Board); Dutch Federation of Anticoagulation Clinics (Chair, Unpaid)
Theurl I
Basic-Science-in-Focus
Disclosures: Gilead Sciences (Research Support, Grant); Novartis (Advisory Board); Kymab (Consultant)
Thompson A
Simultaneous Session
Disclosures: Affiliations Unknown
Tichelli A
Scientific Working Groups
Disclosures: No Affiliations
Tien HF

- EHA-HST Joint Symposium*
Disclosures: *Celgene (Research Support, Grant)*
- Toh CH
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Traver D
EHA-ISEH Joint Symposium
Disclosures: *No Affiliations*
- Treon S
Hematology-in-Focus
Disclosures: *Pharmacyclics Inc. Consultant (Research Funding); Janssen Pharmaceuticals (Consultant, Speaker, Research Funding)*
- Trka J
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Turner D
Patient Advocacy Session 2
Disclosures: *No Affiliations*
- Vago L
Poster Walk
Disclosures: *Affiliations Unknown*
- van de Loosdrecht AA
Basic-Science-in-Focus
Disclosures: *Celgene (Advisory Board, Research Support); Novartis (Advisory Board); Amgen (Advisory Board); Janssen (Advisory Board); Alexion (Research Support)*
- van den Brink M
Education Session, Basic-Science-in-Focus
Disclosures: *Seres (Research Support); Evelo (Consultant); Novartis (Consultant); Regeneron (Consultant); Flagship Ventures (Consultant); Boehringer Ingelheim (Consultant); Merck (Consultant)*
- van den Heuvel-Eibrink MM
Meet-the-Expert, Simultaneous Session
Disclosures: *No Affiliations*
- van Dijk P
EU Projects in Hematology
Disclosures: *Affiliations Unknown*
- van Dongen JJM
Laboratory Diagnosis Workshop, Scientific Working Groups
Disclosures: *InVivoScribe (Patent Royalties; Royalties for the EuroClonality Consortium); Cytognos (Patent Royalties; Royalties for the EuroFlow Consortium); BD Biosciences (Patent Royalties; Royalties for the EuroFlow Consortium); BD Biosciences (Educational Services; Institutional Fee)*
- Vannucchi AM
Education Session
Disclosures: *Novartis (Lectures, Advisory Board, Institutional Research Funding); Gilead (Lectures); Shire (Lectures)*
- Vasconcelos A
EU Projects in Hematology
Disclosures: *Affiliations Unknown*
- Vassiliou G
Basic-Science-in-Focus
Disclosures: *Kymab (Consultant); Celgene (Research Grant)*
- Venditti A
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Vey N
Education Session
Disclosures: *Novartis (Advisory Board, Honoraria); Amgen (Advisory Board); Seattle Genetics (Advisory Board); Sunesis (Advisory Board); Roche (Advisory Board); Bioknesis (Consultant); Boehringer (Advisory Board)*
- Viprakasit V
Education Session
Disclosures: *Novartis Pharmaceuticals (Research Support, Honoraria); Genzyme-Sanofi (Research Support, Honoraria); Sebia (Research Support, Honoraria); Roche Diagnostics (Research Support, Honoraria); Shire (Research Support); Sideris (Research Support); Siriraj Hospital (Research Support)*
- Visco C
Scientific Working Groups
Disclosures: *Mundipharma Italy (Research Funding); Janssen (Research Funding); Lundbeck Canada Inc. (Advisory Board, Advisor); Celgene (Advisory Board, Advisor); Mundipharma International (Advisory Board, Advisor); Gilead (Advisory Board, Advisor)*
- von Lilienfeld-Toal M
Simultaneous Session
Disclosures: *Affiliations Unknown*
- Vora A
Education Session
Disclosures: *Jazz (Advisory Board, Meeting Support); Pfizer (Advisory Board); Amgen (Advisory Board); Medac (Advisory Board, Meeting Support)*
- Vyas P
Molecular Hemopoiesis Workshop
Disclosures: *No Affiliations*
- Waldmann A
Scientific Working Groups
Disclosures: *Affiliations Unknown*
- Wallace WH
Education Session
Disclosures: *No Affiliations*
- Wang J
EHA-CSH Joint Symposium
Disclosures: *No Affiliations*
- Weisel K
Poster Walk
Disclosures: *Affiliations Unknown*
- Weiss M
Education Session
Disclosures: *Glaxo SmithKline (Consultant); Biogen (Research Support); Rubius (Advisory Board); CRISPR therapeutics (Consultant); Editas (Consultant)*
- Welte K
Scientific Working Groups
Disclosures: *No Affiliations*
- Wendtner C
Education Session
Disclosures: *Hoffmann-La Roche (Research Support, Advisory Boards, Consultant); Celgene (Research Support, Advisory Boards, Consultant); Mundipharma (Research Support, Advisory Boards, Consultant); Janssen (Research Support, Advisory Boards, Consultant); Gilead (Research Support, Advisory Boards, Consultant); Morphosys (Research Support, Advisory Boards, Consultant); Abbvie (Research Support, Advisory Boards, Consultant)*
- Windyga J
Hematology-in-Focus
Disclosures: *No Affiliations*
- Wintrich S
Patient Advocacy Session 1
Disclosures: *Celgene (Grant); Novartis (Advisory Board, Grant); Janssen (Grant)*
- Woermann B
Patient Advocacy Session 1
Disclosures: *No Affiliations*
- Xu Y
Scientific Working Groups



Disclosures: *No Affiliations*

Younes A

Education Session

Disclosures: *Bayer (Honoraria); Celgene (Honoraria); Incyte (Honoraria); Janssen (Honoraria); Sanofi (Honoraria); Seattle Genetics (Honoraria); Takeda Millenium (Honoraria); Genentech (Honoraria); Merck (Honoraria); Novartis (Research Support); J&J (Research Support); Curis (Research Support); Roche (Research Support); BMS (Honoraria, Research Support)*

Zamagni E

Scientific Working Groups

Disclosures: *No Affiliations*

Zeiser R

Education Session

Disclosures: *No Affiliations*

Zijlstra J

Scientific Working Groups

Disclosures: *Takeda (Advisory Board); BMS (Advisory Board); Roche (Advisory Board); Roche (Research Support); Gilead (Grant)*

Zini G

Laboratory Diagnosis Workshop

Disclosures: *No Affiliations*

Zuber J

Molecular Hemopoiesis Workshop

Disclosures: *Mirimus Inc. (Advisory Board, Share Holder); Boehringer Ingelheim GmbH & Co KG (Research Support)*

Zwaan CM

Hematology-in-Focus

Disclosures: *Pzifer (Research Support/Grant); Karyopharm (Research Support); Novartis (Speaker's Bureau); Jazz pharmaceuticals (Travel Support)*

ABSTRACT AUTHORS INDEX

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Abad, L, P510
Abad, M, E985
Abáigar, M, P318, P655, E1169
Abali, H, P281
Abarrategi, A, P264, P657
Abaskharoun, M, E1060
Abaza, Y, P207
Abbadessa, G, E1400
Abbenante, M, E882
Abboud, C, P319
Abd El-Maksoud, M, E1411
Abdelaziz, R, E926
Abdelhameed, A, E1580
Abdelkader, H, E1093
AbdElmonem, D, E1585
Abdi, J, E1217
Abdul-Aziz, A, E873, E874
Abdurahmanova, N, E1050
Abe, Y, E1285
Abecassis, L, P370
Abel, G, E1186
Abella, E, E1027, E1394
Abeykoon, J, E1240
Abildgaard, N, S501, E1267, E1367
Abonour, R, P349, E1239, E1277
Abou Mourad, Y, P581, E1557
Abou Zahr, A, P550
Aboukhalil, Z, S140
Abouzaid, S, E1277, E1282
Abraham, M, P269
Abrahams, C, P328, E1373
Abramova, T, E1227, E1295
Abranches, P, E1044
Abreu, M, P157
Abrisqueta, P, S461, P298, E995,
E1002, E1027, E1394
Abruzzese, E, S485, P256, P604, P705,
E1042, E1043, E1067
Abuelgasim, K, E1514
Abuín Blanco, A, E1327
Abumiya, M, E1053
Accardi, F, E1223
Accordi, B, E1011
Acharya, S, P257
Achenbach, H, P704
Acosta Maldonado, B, E1473
Acquavella, J, E1435
Adachi, S, P531
Adachi, Y, E1516
Adami, R, E1268
Adamidou, D, E1414, E1423, E1574
Adamo, A, E821
Adamopoulos, I, E1266
Adams, J, E1007
Adams, R, E875
Adams, S, P526
Adedayo, T, P669
Ades, L, P657
Adjalle, R, E1286
Adjei, A, E1274
Adly, A, P398, E1572, E1582
Adrienne, D, P174
Advani, A, S793, P201, P203, P519,
P525, P547
Advani, R, P571
Advani, V, S417
Afanasyev, B, E1154, E1506
Agajanian, R, E1248
Agami, R, P153
Agarwal, A, S460, P349, E1239, E1282
Agarwal, A, P194
Agarwal, S, P675, E1139
Agathangelidis, A, E997
Agbuduwe, C, E938
Aggarwal, S, P333
Aggarwal, S, E1049
Agha, H, E1573
Agirre, X, P300, P325, E1225
Aglietta, M, P322
Agnelo, H, E1374
Agostinelli, C, E1408
Agostini, C, E1254
Agouti, I, S131
Agrawal, M, P535, E864, E868
Agrawal, T, P552
Agresta, S, S471
Agrippino, R, P166
Aguadé-Gorgorió, J, S437
Aguado, B, E1305, E1565
Aguilar, R, S126
Aguilar, C, P655, E1014
Aguilar-Guisado, M, S804
Aguilar Martinez, P, S453, P289
Aguilar Ponce, J, E1473
Aguilera Gomez, C, E957
Aguinaco Culebras, R, E1426
Aguirre, X, P679
Aguzzi, C, P667
Ahlstrand, E, P697
Ahlwalia, J, E987
Ahmed, A, E1582
Ahmed, S, S450, S792, P739, E914,
E1512, E1538
Ahn, I, P588
Ahn, J-S, S491
Ahn, S-Y, S491
Aichler, M, S809
Aid, Z, S427
Aifantis, I, P297
Ailawadhi, S, P257
Airaud, F, P712
Airoldi, I, E1226
Aiuti, A, S128
Ak, E, E1488
Akad Soyev, N, E1525
Akalestos, A, P337
Akard, L, P633
Akasaka, H, P263
Akashi, K, E1111
Akbar, H, S149
Akhmerzaeva, Z, E836
Akici, F, E1418
Akin, C, S788
Akinduro, O, E875
Akiyama, M, S799
Akiyoshi, K, S452
Akria, L, P548
Aktas Samur, A, E1206
Aktypi, A, E1266
Akylzhanova, G, P585
Al-Ali, H, P555, P702, E1333, E1334
Al Ali, N, P352
Al Assaf, C, E1310
Al-Atrash, G, S792
Al-Fayoumi, S, P699, P701, E1343
Al Hinai, A, P538
Al-Ismaïl, S, E1476
Al-Kali, A, P165
Al-Matary, Y, P534, E1118
Al-Oqaily, Q, P233
Al Sawaf, O, S464, P251, E1025
Al-Zahrani, M, E1514
Aladjidi, N, S131, P716, E1439
Alakbarzade, V, E1591
Alamelu, J, E1163
Alarcón, A, E972
Alashkar, F, P582
Alaskar, A, E1514
Alavi, A, E1267
Albano, F, S485, P351, P598, E1000,
E1560
Alberich-Jorda, M, P273
Albero, R, E1381
Alberquilla, O, E1081
Albers, C, S127
Alblooshi, R, P708
Alcoceba, M, S115, E887, E1019,
E1394
Alduaij, W, E1324
Alegre, A, E1565
Alegre Amor, A, E1302, E1305
Aleinikova, O, P161

- Aleksandr, C, P311
Aleksanian, L, E1568
Aleksanyan, L, P308
Aleksenko, M, E1409
Alex, J, P364
Alexander, D, E1228
Alexis, M, P572
Alfonso, A, S444, S489, P200, P315, P652
Alfonso, G, E1182
Alfonso Pierola, A, P665
Algarín, E, E1222
Algarotti, A, E1315
Algeri, M, S146, P381, S495
Alhammer, A, P512
Ali, H, S794
Aliberti, S, P214
Alignami, D, P329
Alignani, D, E1225
Alikian, M, P233
Alimam, S, E1338
Alimohamed, M, E897
Alizadeh, S, P309
Aljurf, M, S797
Alkadi, N, E1349
Alkhateeb, H, P165
Allen, M, S147
Allepuz, A, P720
Alli, N, E1143
Allione, B, P214, P667
Allsup, D, P252
Almeida, A, S426, E1064
Almeida, J, E1044, E1047
Almeida, J, P584, E1019
Alonso, A, P205
Alonso, A, P554
Alonso, J, P510
Alonso, J, P329
Alonso, J-M, E1014
Alonso, R, E834
Alonso Álvarez, S, P747
Alonso Caballero, C, E1183
Alonso-Domínguez, J, E1059, E1596
Alonso-Lopez, D, P361
Alonso-Saladrigues, A, P168
Alonso Vence, N, E1327
Alousi, A, S450, S792, P739, E914, E1512, E1538
Alpár, D, E820
Alrasheed, N, E1208
Altamura, S, S809
Altan, I, E855
Alten, J, E849
Alter, D, P564
Alterini, R, E1136
Altman, J, S110, S471, P560, E940
Altmann, B, P216, P222
Alunni, G, E946
Alvanou, M, E1083
Alvarado, Y, S487, P170, P315, P317, E913
Alvarellos, M, E1604
Alvarez, A, E1310
Alvarez, I, P543
Alvarez, L, P623
Álvarez, S, P696
Alvarez-Fernández, C, S816
Álvarez-Laderas, I, P213, P756
Álvarez-Larrán, A, P694, P703
Alvarez Lipe, R, E1258
Alvarez-Twose, I, P713
Alves, R, E1064, E1287
Alves, V, E1044, E1047
Alwan, F, E1445, E1450
Alzate, S, P675
Amador, M, P554
Amador, V, P296
Amadori, S, S111
Amam, J, P222
Amann, E, P627
Amano, M, E1205
Amar, H, P587
Amaravadi, R, S481
Amatangelo, M, E1203
Ambaglio, I, E1179
Ambarkhane, S, S470, E839
Ambesi-Impiombato, A, S135
Ambrosetti, A, P355
Ame, S, P316
Amendola, G, P393
Amigo, M, P660, E1181
Amin, H, S459
Amiot, M, P675
Amir, A, P567
Amitai, I, E949
Amler, S, P546
Ammirati, L, E1254
Amorim, S, P572
Amrein, P, E947, E1192
Amzai, G, E1471
An, G, E1085
Anagnostopoulos, A, S461, P242, P280, E1083, E1233, E1266, E1407, E1610
Anagnostopoulos, N, P280
Anagnostou, T, P254, E1241, E1502
Anargyrou, K, P280
Anastasiou, T, E862
Ancelet, S, E1178
Ancliff, P, P668
Andersen, C, P697
Andersen, M, S109, S486
Anderson, K, S456, S457, E1200, E1201, E1203, E1206
Anderson, M, P247
Anderson, S, E1487
Andersson, B, P743, E1538
Andersson, P-O, S805
Andjelic, B, S443, E970
Ando, K, E1046, E1072
Ando, K, E1199
Ando, S, P263
Ando, T, E962
Andolfo, I, S811
Andorsky, D, P634
Andrade-Campos, M, E957, E1134, E1412
Andre, M, S470
Andreasson, B, P697, E1250
Andreeff, M, P192, P200, P315, P550
Andrescu, M, E1602
Andreu-Vieyra, C, P562
Andrews, T, E1276
Andriani, A, E1325, E1340
Andrieux, G, P243, E1355
Andrikovics, H, E1535
Anelli, L, P598
Anfuso, C, E1214
Ang, A, P646
Ang, H, E875
Angelillo-Scherrer, A, E1455
Angelini, S, P394
Angelopoulou, M, S416, P280, P639, E1036, E1120, E1304
Angelov, D, E1452
Angelucci, E, S796, P341, P667, E1247
Angmo, S, S810
Anguille, S, S141
Ankarali, H, E1165
Annibali, O, P736, E1123, E1151, E1243
Annunziata, M, S485, P604
Annunziata, S, E1124
Annunziata, S, E967
Anota, A, E1186
Ansell, S, S412
Antelo, M, E1604
Antic, D, S443, E970, E1448
Antin, J, S808, P650, P740, P748, E1532, E1554
Antmen, B, E1528
Antoniades, M, S420
Antonini, E, P544
Antonio, S, E829
Antonio de Souza, C, E952
Antonioli, E, E1270
Anthony-Debre, I, S135
Antunes, E, P627
Anurathapan, U, P743
Anze, G, E972
Aoki, J, P389, E1522
Aoki, K, P389

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Aoki, S, P302
Aoki, Y, P642
Aotsuka, N, E1522
Apithy, M-J, E1537
Apostolou, F, P337
Apostolidis, I, P280
Apostolou, P, E895
Appelmann, I, E819
Apperley, J, S423, S817, P603
Appolloni, V, P358
Aprile, L, E941, E946, E1042, E1043
Aquino, S, S410, S796, E1299
Aquino, V, S146
Ar, M, E1159, E1518
Araguás Arasanz, C, E1426
Arai, A, P302
Arakaev, O, P161
Arakawa, Y, S799
Araki, M, P691
Aralica, G, E1329
Arana-Yi, C, P562
Aranda Lopez, P, P643, P651
Arapaki, M, E1120
Arat, M, P281
Arauzo-Bravo, M, E1368
Aravin, A, S429
Arbe-Barnes, S, P317
Arbelbide, J, E1182, E1508
Arbones, M, E1412
Arboscello, E, P283, E854
Arbushites, M, S794
Arcangeli, S, P630
Arcese, W, S111, S493, P384, E908
Ardeshna, K, S777
Ardila-Novoa, J, E1074
Arellano, M, S472, P204, P207
Arenas, A, P695, E900, E1317
Arenillas, L, E1417
Arias Fernández, T, E1530
Aricò, M, S480, P714
Arihara, Y, E1213
Ariza, L, E1103
Ariza-McNaughton, L, P264
Arizaga Berber, J, E1500
Arlinde, C, E1429
Armand, M, E1374
Armand, P, S412
Armiento, D, E1151
Armstrong, R, S122
Armytage, T, E1350
Arnán, M, S790, P202, P376
Arnaud, J, E1178
Arnaudov, G, E1556
Arndt, G, P154
Arnold, J, E1467
Arnold, L, P369
Arock, M, P693
Aroldi, A, E1351
Arondekar, B, E925
Arora, B, E837
Arora, M, S492
Aróstegui, J, E1259
Arras, M, P256
Arratibel, N, P747, E1543, E1592
Arredondo-Campos, D, E1306
Arriazu, E, P205, P536
Arriba, F, E1278
Arribas Arranz, J, E1387
Arriero, A, E1302, E1305, E1565
Arrigoni, E, E1048
Arrizabalaga Amunchastegui, B, E983, E1181
Arruda, A, P708, E1324
Arteche-Lopez, A, E1302, E1305
Artoni, A, P722, E1078
Arzideh, F, E1117
Arzt, J, S771
Asahi, M, P642
Asano, M, E1046
Asatiani, E, E1345
Asaulenko, Z, E1313
Asayama, T, P327, P659, E1175
Asenjo, S, S445
Asensio Matas, A, E1258
Ashby, C, E1203
Ashcroft, J, P669, E1463
Asma, H, E1275, E1472, E1479
Asmal, M, S814, P631
Asmar, F, P324, E1115
Asmussen, J, E1267
Asnafi, V, S440, E1236, E1386
Asou, N, P314, E1058, E1066
Assem, H, E1411
Assenov, Y, P350, P663
Assimakopoulos, J, E1120
Assouline, S, S468, S777
Astolfi, M, P341
Astori, C, P357, E1337
Atabay, B, E1422
Ataga, K, S454
Atallah, E, P207, E1060
Ataseven, E, E1422
Atelda, R, P604
Athanasiadis, A, E1574
Athanasiadou, A, S461
Athnasiou, E, E1083
Athineos, D, S419
Atkinson, D, E1110
Atkinson, S, P723
Atsuta, Y, P389, E1522
Attal, M, P345, P348
Attar, E, P215
Attie, K, S129, P666
Auber, B, P226
Auclair, D, P322
Audisio, E, P163, P214, P520
Auer, F, S148
Auger, N, E1001
Augeul-Meunier, K, P217, P572
August, K, S477
Augustson, B, P674
Aul, C, E937
Aurer, I, E969, E971, E1296
Austgen, K, P188, E884
Auvinen, A, P734
Avenoso, D, P283, E1299
Aversa, F, E1223, E1325, E1497
Avery, S, E929
Avet-Loiseau, H, S101, P348, E1200, E1201, E1203, E1206
Avigad, S, S436
Avigan, D, S783, P344
Avigdor, A, S413
Avila Arreguin, E, P719
Ávila Idrovo, L, E1530
Aviv, A, E1034
Avivi, I, S107, E1121
Avni, B, P744
Avvisati, G, E1151
Awad, H, P398
Awad, S, P593
Awan, F, S788
Awasthi, R, S477
Awata, M, E1607
Awogbade, M, P619
Axelrod, M, P158
Ay, Y, E1427
Ayala, R, P609, P661, P679, P695, P696, E891, E899, E900, E1317
Ayala Diaz, R, E1059
Ayana, K, S120
Ayçiçek, A, E1418
Aycock, J, S466, P523, E840
Aydin, S, P214
Aydin, Y, E1159
Aydin Köker, S, E1427
Aydogan, E, E1202
Aydoğan, G, E1418
Ayed, A, P588
Ayllón, V, E893
Aymerich, M, S115, S117, E1031, E1032, E1039

- Aytac, S, E855, E1598
Ayuda-Durán, P, E866
Ayuk, F, P231, E1286
Ayuso, C, P623
Azab, M, E1192
Azad, R, P683
Azar, N, P345
Aziz, A, E1307
Aznar, M, E1604
Azzena, S, E1489
Baak, M, P187
Babaeva, T, E1436
Babbs, C, E1424
Babu, S, P249
Baccarani, M, S485, P603, P605, P607
Bacchiari, F, E1454
Baccianti, F, E1216, E1268
Bachelier, F, E1102
Bachy, E, E1024
Bacigalupo, A, S796, P232, E915, E1505
Bacigalupo, L, P400
Bacon, C, S478
Bacon, P, P343, E1250
Bacon, T, P687, E1291
Badell Serra, I, S452, P580
Bader, P, S476, P382, P517
Badoux, X, S465
Badre, S, E1180
Badrinath, Y, E837
Badros, A, S779
Badshah, C, S807
Badugama, B, P761
Bae, S, E1608
Bae, Y, P635
Baecke, V, E1256
Baer, C, S121
Baer, M, E912, E947
Baerlocher, G, S424
Bagnato, A, E1340
Bago-Horvath, Z, E1045
Bagratuni, T, E1201, E1231
Bah, G, E1487
Bahceci, E, S110, P560, E940
Bahl, S, P236
Bahlis, N, S100, P334, P335, E1248
Bahlo, J, S464, P236, P251, P585, E1025
Bahmanyar, S, E1435
Bai, J, S103
Baile, M, E953, E1543, E1592
Bainazar, M, E883
Baird, S, P668
Bairey, O, E1034
Bajel, A, E907
Baji, P, P730
Bajin, I, E1603
Bak, M, E1347
Baka, M, E862
Bakala, J, E1135
Bakchoul, T, P364
Baker, D, E1109
Baker, K, E950
Bakhtiar, S, P382
Bakshinskayte, M, E1098
Bal, S, E977
Bal, V, E945
Balabanian, K, E1102
Balague, O, E1137
Balanzategui, A, E887
Balaratnam, G, P620
Balas, A, E1113
Balasco, D, P714
Balassa, K, E1534, E1535, E1544
Balassopoulou, A, E1574
Balasubramanian, S, E1129, E1369
Balbarin, K, P247
Baldacci, E, P306, P722, E976
Baldazzi, C, E882
Baldini, C, E1318
Baldoumi, E, E1610
Balducci, E, E1361
Balducci, M, E1124
Balduini, C, S432
Baliakas, P, S461, S462
Ballanti, S, S410, E1174, E1247
Ballari, E, P658, P667
Balleisen, L, S424
Ballerini, F, P283, E854, E915, E919, E933, E1505
Ballerini, P, S427
Ballester, C, E1417
Ballester, E, P300
Ballester, I, E953
Ballester, M, E1341
Ballesteros, J, P554, E1086
Ballina, B, P737
Balocco, M, P400, E1482
Balsalobre, P, E1113
Balsas, P, P296
Bamezai, S, S429
Ban, S, P707
Banawali, S, E837
Banerjee, A, E912
Bangerter, M, P700
Bannister, A, S430
Banno, F, P651
Bannon, S, S496
Banos, A, P217
Banquet, S, E907
Bao, G, S147
Bao, Y, E1087
Bao Pérez, L, E1327
Baptista, M, E1394, E1396
Baquero, P, S481
Barachini, S, E1048
Baraldi, E, E1489
Barankiewicz, J, E1294
Baranova, O, E836
Baranwal, A, P763
Barata, J, P157, E822
Baratè, C, S485, P599, P640, E1048
Barba, G, E1174
Barba, P, S804, P745
Barbado, M, P543
Barbado, V, P756
Barbaric, D, E849
Barbero, D, P304
Barbier, A, S451
Barbieri, I, S430
Barbosa de Carvalho, N, E1283
Barbui, A, S775, S778
Barbui, T, P351
Barcellini, W, S451, P616, P722, E1030, E1078
Barcia Duran, J, S137
Bardi, A, E1020
Bardy-Bouxin, N, S425
Bareau, B, P649
Barete, S, P709
Bárez, A, E887
Bargay, J, S790, P202
Bargay, J, S409, P316, P688, E1181
Bargay, J, E1278
Bargou, R, P320
Bargues, N, E1010
Barhoum, M, E1015
Barilà, G, E1254, E1357, E1397
Barin, C, E1001, E1361
Baringo, T, E1134
Barison, A, E1577
Barista, I, P281
Barker, D, P368
Barker, S, E1022
Barnett, M, P581, E1557
Barone, A, P715, P717
Barone, M, E1309
Barozzi, S, S432
Barr, P, S769
Barra, M, E1460
Barradas, J, E1425
Barragán, E, P696, E891, E899
Barreña, B, E1183
Barrenetxea, C, E1183
Barrientos, J, S769
Barrington, S, S774
Barrio, S, P320, P329, P679
Barro, C, S453
Barta, A, E1535
Bartalucci, G, E941, E946
Bartels, M, P187, P579, E901

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Barteselli, G, E1483
 Barth-Miesala, K, P206
 Bartholdy, B, S135
 Bartizal, K, P645
 Bartlett, N, S106, S466
 Bartolovic, K, P270
 Bartolucci, P, P631
 Bartram, C, S480
 Bartram, J, S801
 Bartzi, V, E1304
 Barua, A, P761
 Basak, G, S795
 Baseggio, L, E1024
 Bashir, Q, S792, E914, E1512, E1538
 Basic-Kinda, S, E969, E971, E1296
 Basile, U, E1124
 Baskhaeva, G, E836
 Baslar, Z, E1159, E1518
 Basquiera, A, E1182, E1508
 Bassan, R, P163, P520
 Bassett, M, P337, P684, E1243
 Bassi, C, E1020
 Basso, G, S480, P738, E844, E917, E1011, E1489
 Bastard, C, E1001
 Bastia, R, E1179
 Bastida, J, P361, P721, E1451, E1592
 Bastie, J-N, P514
 Basu, O, P382
 Basu, S, S474
 Basu, S, E1465
 Basu, S, P347
 Basut, N, E1488
 Batai, A, E1535
 Batalha Reis, A, E1586
 Bates, M, E1073
 Batinic, J, E1296
 Batlle, A, E1027
 Batlle, M, E831
 Batsis, I, E1233, E1407
 Battail, C, P274
 Battipaglia, G, S493
 Battisti, L, P715
 Batyuk, L, E1127
 Bauckneht, M, P283
 Bauer, M, P159, E1203
 Bäuerlein, C, E1569
 Baues, C, S150
 Baumann, T, S115, E1031, E1032, E1039, E1137
 Baumeister, S, S146
 Bautista, MD, G, P554, E1051, E1059, E1541
 Bavaro, L, S485, P600
 Bay, J-O, P572
 Bayer, E, P588
 Bayer, V, S487
 Bayhan, T, E1157, E1603
 Bayley, R, S119
 Bayliss, M, P373, E1468
 Baylor Curtis, L, E1141
 Bayram, C, E1418
 Baz, R, S780
 Beà, S, S115, S117, P300, E1381
 Beach, C, P208
 Beam, D, P727
 Bearss, D, E881, E902, E1204
 Beata, P, E1385
 Beauvais, D, E1171
 Becht, R, E1061
 Bechter, O, P565
 Becilli, M, P736, E1123, E1151
 Becker, A, P266
 Becker, H, P656
 Becker, I, S812
 Becker, P, S472, P203, P547
 Beckert, H, P651
 Becquart, M, E1018
 Bedoucha, V, P601
Beekman, R, S117, P300, P325
 Beelen, D, P388, P516
 Beggiano, E, E1332
 Begna, K, P165
 Beham-Schmid, C, E1363, E1395
 Behre, G, P380
 Beider, K, P269
 Beier, F, P231, P593
 Beier, R, S480
 Beilhack, A, E1569
 Beinicke, S, P380
 Bekadja, M, P640
 Bekker, O, E1436
 Bekoz, H, P281
 Beksac, M, S100, S456
 Belada, D, S774, P218
 Belch, A, S456
 Belcher, J, P284
 Belen, F, E1422
 Beléndez, C, P580
 Belenfant, X, E1265
 Beleslin-Cokić, B, E1308, E1316, E1319
 Belhocine, M, S440
 Belhoul, K, P286
 Belini Junior, É, E1492
 Bell, J, E944, E973, E1184, E1191, E1196
 Bellas, C, E972
 Bellesi, S, E1124
 Bellet-Fraysse, E, E1458
 Belli, C, E1182
 Bellini, M, P357, E1337
 Bello, C, E960
 Bello López, J, E1327
 Bellodi, A, P283, E854
 Belloni, M, E844
 Bellosillo, B, P694, P696, E1310, E1417
 Belotti, A, S410, P322
 Belotti, C, E1315
 Belton, L, P521
 Ben-Califa, N, E1107
 Ben-Yehuda, D, E1244
 Ben Yakar, R, P548
 Benabed, K, P649
 Benade, E, E1143
 Benard, A, E820
 Benboubker, L, P335, P675
 Bendaña López, Á, E1327
 Bendelac, L, E1082
 Béné, M-C, S105, E1360
 Benedetti, D, P588
 Benedetti, E, P671
 Benedetti, F, S778, E1533
 Beneduce, E, P392
 Benelli, G, E1401
 Benesova, K, P218
 Benet, C, E953
 Bénéteau, C, S453
 Benevolo, G, S784, P351, P705, E1247
 Bengoechea, E, P688
 Benito, R, P655, E1014, E1169, E1451
 Benjamin, R, P669, E1242, E1245, E1509
 Benjet, C, E1473
 Bennabi, M, E1495
 Bennett, J, E1441
 Bennett, K, S133
 Benni, M, E1577
 Bensasson, C, S784
 Bensinger, W, S457
 Bento, C, E1080, E1425, E1588
 Bentolila, G, E1508
 Benton, C, S489, S496, P200
 Bentur, O, E1121
 Bentz, M, S150
 Bentzen, H, E1367
 Bentzen, S, E947
 Benvenuti, P, P357, E1337
 Benyamini, N, P257
 Bera, R, P653, E872
 Beranova, K, E1303
 Bérard, E, P557
 Berardi, M, E1270



- Berdeja, J, S142, S408, S780, P680
Berdel, C, P216
Berdel, W, S424, P546, E885, E927
Berdoukas, V, P398
Berenguer-Piqueras, M, E1562
Berenschot, H, S107, P567
Berentsen, S, P613
Berg, D, S408, S780, P735
Berg, J, S419
Bergamaschi, M, P283, P705, E1186, E1325
Berger, A, E1045
Berger, C, S131, S453
Berger, D, P693
Berger, M, S426
Bergeron, J, E1192
Bergesio, F, S413
Bergin, K, P674
Bergon, A, S440
Bergua, J, P554
Bergua, J, E1086
Beris, P, S453
Berk, S, E1159
Berkowitz, N, S788
Berlin, A, E894
Bermejo, N, P721, E1451
Bermudo Guitarte, C, E1271, E1283
Bernal, M, P696
Bernal, T, E1181
Bernal-Ruiz, R, P213
Bernard, L, E847
Bernard, O, S427
Bernardeschi, P, E946, E1401
Bernardi, M, S806, P544
Bernardi, S, P607
Bernardini, A, S410
Bernardo, P, E1080
Berneman, Z, S141
Berni Wennekers, A, E1258
Bernink, J, S448
Berno, T, E1254
Bernstein, B, S428
Bernstein, I, E1099
Berro, M, E1508
Berruoco, R, P168
Bertaina, A, S146, S495, P381, P738, E917, E1167
Bertamini, L, E882
Berthel, E, E1359
Berthon, C, P316, E1171
Berthou, C, E1250
Berti, P, P736, E1243
Bertolami, W, P671
Bertoli, E, E1496
Bertoli, S, P557, E906
Bertoni, E, E1164
Bertoni, F, P282
Bertorelle, R, E930
Bertrand, Y, S131, S422
Bertucci, F, P183
Berox, G, S438, E1358
Besalduch, J, E1278
Besley, C, E1566
Besses, C, P694, P704, E1310
Bessette, M, E894
Bessmeltsev, S, E1153, E1313, E1568
Besson, H, E1024
Best, G, E998
Best, S, P657
Bestach, Y, E1182
Bet, L, E1508
Bethancourt, C, P554
Bethge, W, P516
Bettacchi, A, P636
Bettelheim, P, P559
Better, M, P522
Betts, K, E1300
Beverloo, H, P677
Bewarder, M, E1469
Beyne-Rauzy, O, P316
Bézieau, S, P712
Bezombes, C, E1369
Bhathena, A, S771, P682
Bhatia, S, S148
Bhatnagar, N, P668
Bhatta, S, S782
Bhaw, L, P264
Bhoi, S, P244
Bhutani, D, S779
Bhutani, M, S779
Bi, X-W, E961, E1389
Biagi, E, P628, P630
Biagiotti, C, E946, E1454
Bialas, K, P741
Bialopiotrowicz, E, E886
Bianchi, P, S452
Bianco, R, E967
Biancolini, D, P544
Biancon, G, E1201
Biavasco, F, P544
Bibeau, J, P371
Bibi, S, P693
Biddeci, G, P715, E844, E955
Bidet, A, E1001
Bielczyk-Maczynska, E, P227
Biemond, B, S112, S455
Bierhoff, H, P663
Bierings, M, S452, P579
Bierman, P, P563
Bihin, B, P230
Bijou, F, E1028
Bila, J, S443, E970
Bilbao, C, P696
Bilbao Sieyro, C, E1327
Bildat, S, S424
Bilger, K, E856
Bilgin, S, E1159
Bilinski, J, S795
Bill, M, P380
Billio, A, S413
Bilotti, E, P672, E1246
Binder, M, P559
Binder, M, P331
Binotto, G, P604, P705, E1325
Binsaleh, N, P368
Biondi, A, S436, S480, P628, P630, E1489
Biran, N, E1276, E1288
Bird, R, E1431
Birekul, A, E1527
Birgegård, G, P704
Birgens, H, P613
Birger, Y, S436
Birgisdóttir, A, S442
Birnbaum, D, P354
Birrell, M, S773
Birtolo, S, E1401
Bischoff, M, E1251
Biscocho, J, P182
Bishop, M, P523
Bishop, R, P245, P589
Bisso, N, E854, E1299
Bitetti, C, E1261
Bitner, H, P269
Bitran, J, P634
Bitsani, K, E1304
Bittenbring, J, E1469
Bittencourt, H, S476, P517
Bittolo, T, P583
Bixby, D, P201, P203, P210, P547
Bižić-Radulović, S, E1328
Bjelica, S, E1308
Bjerrum, O, P697
Björkholm, M, S442, P330, P678
Bjourson, T, E1228
Blachnio, K, P162
Blackburn, S, P278
Blacklock, H, P674
Bladé, J, S409, P339, P679, P688, E1259, E1278
Blaette, T, E868
Blahovcova, P, E1540, P218
Blain, J, S500
Blair, H, P512
Blaise, D, S493, S798, P384, P388, E1506, E1547
Blakey, S, E1478
Blakkisrud, J, E1141
Blanc, J, S117
Blanc-Brude, O, P617
Blanchard Rodríguez, M, E1302

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Blanche, S, P631
Blanchette, V, P367, P727
Blanchi, J, E1028
Blanco, A, E1183
Blanco, L, E1026, E1027
Blanco-Vaca, F, P765
Blandchard, B, E1278
Blandino, G, E1379
Blanquer-Blanquer, M, E1562
Blas, C, E1596
Blatný, J, P711
Blatt, K, P693
Blätte, T, P182, P248, P535, E864
Blau, W, P231
Blazar, B, S492
Blazer, M, E1184, E1191, E1196
Blázquez, B, E1183
Bleckmann, K, S480, E849
Bleul, S, P656
Blijlevens, N, E1057, E1301
Blinder, M, P285
Blitzer, M, E947
Blocka, J, E1253
Bloehdorn, J, P585
Blom, B, S448
Blombery, P, E1202
Blonska, D, E1257
Bloomfield, C, P174, E883
Bloor, A, S770, S797, S817, P245, P252, P589
Blum, A, E1349
Blum, P, P342
Blum, S, P664, E937
Blum, W, P191, P562
Blumberg, E, S807
Blumel, S, P563
Blunt, M, P587
Blyth, K, S419
Boaz, N, P744
Bob, R, E847
Bobbili, P, P285, P286
Bober, G, E1061
Bobillo, S, P298, E995
Boboev, K, E1050
Bobrowicz, M, S125, E1359, E1385
Boccardo, M, S102, S410, P322, E999, E1247, E1332
Bocchia, M, P163, P604, E941, E946, E1042, E1043, E1215
Boccomini, C, S778
Bochicchio, M, P599, P607
Bociek, G, P563
Bodden, K, P315
Bodí Saera, A, E1426
Bodmer, N, E849
Bodor, C, E820
Bodrozic, J, E1448
Boeckh, M, S807
Boeckx, B, E1220
Boeckx, N, P151
Boenig, H, P382
Boerries, M, P350, E1355
Böettcher, S, S771
Bogdanović, A, E1328
Bögeholz, J, E1536
Boghaert, E, P189
Bogner, J, P568
Bogova, V, E1436
Bohannan, Z, P321
Bohdan, N, P573
Bohlander, S, E885
Bohlius, J, S812
Boissel, N, S440, E907
Bojanic, I, E1296
Bojarczuk, K, S125
Bolarinde, L, E1487
Bolettieri, A, P736
Bolis, S, S413
Bołkun, L, E1193
Bollati, V, E1268
Bollì, N, E1201
Bolton, K, S503
Bolzoni, M, E1223
Bomben, R, P583, P588
Bommannan, K, E987
Bonadonna, P, P355
Bonafonte Arruga, E, E1258
Bonanad, S, P376
Bonanomi, S, P717
Bond, J, S440
Bondanza, A, S806
Bondarenko, S, E836, E860
Boneva, T, E905, E1176
Bonfiglio, S, E997
Bonifacio, M, S485, P355, P705, E821, E1325
Bonnafous, C, E1386
Bonnemye, P, E1374
Bonnet, A, P217
Bonnet, D, P264, P657
Bonnetain, F, E1186
Bono, E, P355
Bonomini, S, E1223, E1497
Booth, A, E1007
Booth, C, S421
Boothroyd, R, P706, E1320
Boque, C, P609
Boquimpani, C, P257
Borate, U, P194
Borchmann, P, S150, P275
Borchmann, S, E1119
Bordessoule, D, P217, P316, E1458
Bordin, G, E844
Bordin, L, E1006
Borg, K, P594
Bories, P, P641
Borin, L, P570, E1186
Borisovskaya, S, P220, E1133
Borkhardt, A, S148, S429, S436, P515
Borland, T, S147
Borlenghi, E, P163, E1190
Bornhauser, B, S437
Bornhäuser, M, P326, P516, E1168
Bornkamm, G, S809
Bornschein, S, S439
Borrajo, J, P751
Börries, M, P243
Bors, A, E1535
Borsarelli Carvalho Brito, A, E952
Borsi, E, E1238
Borsky, M, E1003, E1004
Borthakur, G, S463, S487, S489, P170, P200, P209, P315, P665, E913
Bortoli, S, E829
Boruchov, A, S779
Bos, G, S411, S501
Boscarol, G, E1164
Bosch, F, S468, P298, E995, E1002, E1027, E1594
Bosch, R, E1026
Bose, P, E987
Bose, P, S463, S487, P315, P352, E913
Bosga, A, E897
Boshier, A, E1441
Bosi, A, E946, E1043, E1215, E1270, E1401, E1454
Bosi, C, P705, E1325
Bosmann, M, P651
Boss, A, P266
Bossard, C, P217
Bossi, A, E1346
Bossio, S, P586, E1017, E1390
Bossler, A, E1073
Bot, A, S466
Botet, J, P696
Botezatu, L, P534, E1118
Bottega, R, P365
Botthof, J, P227
Bottomly, D, P194
Bouabdallah, K, S105
Bouabdallah, R, S467, P217, E1549
Bouard, C, P702, E1333, E1334

- Boudesco, C, E1356
 Boudova, L, P218
 Bouhoutou, D, E862
Bouillon, A-S, P231, P593
 Boukarabila, H, E1110
 Boulanger, C, P617
 Boulanger, V, P649
 Boulos, S, P287
 Boulwood, J, S122, S123
 Boumendil, A, P379
 Bounaix, L, P217
 Bourget, P, P631
 Bourhis, J-H, S493, P345
 Bouriez-Jones, T, E1110
 Bourquin, J-P, S437, P159
 Bousiou, Z, P280
 Boutalbi, Z, E1458
 Boutou, E, E1574
 Bouvy, C, P230, E964
 Bouwmeester, W, E1272, E1298
 Bove, V, E1273
 Boveri, E, P357, E1179
 Bowen, D, P254
 Bowers, M, E1228
 Bowles, K, E873, E874
 Boxer, M, P249
 Boyer, M, S476, S477, P517
 Boyer, T, E876
 Boykin, D, S135
 Bozic, T, E1106
 Bozzi, V, S432
 Bozzola, M, P684
 Braakman, E, E1499, E1504
 Brabbs, S, P753
 Bradbury, C, P228
 Bradner, J, E1200
 Bradshaw, A, S817
 Braess, J, P546, E885
 Braester, A, E1015, E1034
 Braganca, N, P669
 Braggio, E, P320
 Brambilla, S, E1606
 Branca, A, E1254
 Brander, D, P247
 Brandozzi, G, E1136
 Brandt, M, S474, P209, P211, E935
 Brandt, P, P375
 Branford, S, S484
 Braun, A, P585, E1380
 Braunschweig, I, S466, P522
 Brazma, D, E905, E1176
 Bréal, C, P217
 Breccia, M, S485, P604, P605, P705,
 E1043, E1186, E1325, E1340
 Brede, C, E1569
 Breems, D, S113
 Bregante, S, S796
 Brentjens, R, S143, S479
 Bresolin, S, E823, E1011
 Brethon, B, P521
 Brezinova, J, E1041
 Briasoulis, E, P280
 Bridoux, F, P343
 Briggs, J, S417
 Brighton, T, E1431
 Brillat, C, E1458
 Bringhen, S, E1247
 Brink, M, P686
 Brioli, A, P647
 Briones, J, S816, E963, E1394
 Brionne-François, M, P370
 Broady, R, P581, E1557
 Brocco, F, P190
 Brock, K, S770, P245, P589
 Bröckelmann, P, S414
 Brocks, D, P350, P663
 Broderick, P, P295
 Brodzky, V, P730
Broeckelmann, P, E1119
 Broers, A, E1504
 Broers, R, P567
 Brogi, A, E1173
 Broijl, A, S411, P677, E1279, E1301
 Bromberg, J, P219
 Bron, D, E994
 Brooks, C, P191
 Brooks, H, P634
 Brors, B, P663
 Brossart, P, S424, P533, P535
 Brosteanu, O, P555
 Brousse, N, E1386
 Brousse, V, P631
 Brouwer, R, S501
 Brouzes, C, E1236
 Brown, A, E1109
 Brown, D, E1140
 Brown, J, S769, P236, P237, P253
 Brown, P, E840
 Brown, P, S109
 Brown, S, P375
 Brozova, L, E1290
 Bruederle, A, S454, P286, P288
 Brüggemann, M, S801, S803, E1376
 Brugia, M, E1401
 Brugnara, C, P392
 Bruins, L, P320
 Brümmendorf, T, S424, S425, S482,
 P231, P255, P593, E819
 Brun, A, E1300
 Bruna, R, S778
 Brunati, A, E1006
 Bruneau, J, E1386
 Brunelli, C, P283
 Brunet, S, S790, P202, E1160
 Brunetti, C, P598
 Brunetti, L, P173
 Bruno, A, E967
 Bruno, B, S493, P384, E1533
 Brusca, A, P282, P304
 Bruserud, Ø, E903
 Brustad Melhus, K, E1141
 Brychtova, Y, P238, E1003, E1004
 Bryja, V, E1009
 Bscheider, M, S446
 Bu, L, S468
 Buadi, F, P331, P673, E1240, E1241,
 E1502
 Bubnova, L, E986
 Bucci, G, P544
 Buccisano, F, S111, E908
 Bucelli, C, P729, E1346
 Buck, G, P270, P668
 Buda, G, P671, E1215
 Budziszewska, K, E920
 Buechner, J, S476, P517
 Buecker, A, P216
 Bueno, D, E1563
 Bueno, J, E1541
 Bueno, R, P361
 Bueren, J, S144, P229, P580, P623,
 P755, E1081, E1094, E1097
 Bueso-Ramos, C, S487, S489, P192,
 P200, P315, P352, P550, P665,
 P690, E830
 Buezard, Y, P631
 Buffardi, S, E955
Buffière, A, P514
 Bug, G, P382
 Bugatti, L, E1136
 Bui, D, P563
 Bulder, I, S455
 Buldini, B, E844
 Bulian, P, P583, P588
 Bullinger, L, P172, P182, P248, P533,
 P535, E864, E868, E870, E888
 Bumbea, H, E1602
 Bundschuh, R, P174, E883
 Bunjes, D, E1084
 Buño, I, P696, E1113
 Bunworasate, U, E1070
 Burakov, V, P308
 Buratti, J, E1368
 Burchert, A, S424, P255
 Burciu, A, S775
 Burda, P, S483
 Burgaleta, C, P554
 Burger, J, S463, S769, S772, P240,
 P241, P588, E991, E1016
 Burger, P, S132
 Burgstaller, S, P195, P558, P707
 Burke, J, P634

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Burkhardt, D, S147
 Burmeister, T, P516
 Burnelli, R, P715
 Burnett, A, S114, S475
Burney, C, P228
 Burrows, F, P571, E834
 Burthem, J, E1007
 Burylev, V, E1153
 Busca, A, P214
 Busch, H, P243, P350, E1355
 Büschel, G, P255
 Buske, C, S429, S809, P635, E1246
 Bussel, J, S435, P367, P723, P727, E1434, E1437
 Bussolari, J, E1322
 Bustoros, M, S779
 Butler, A, E1201
 Butters, M, E1481
 Büttner, C, P527
 Buxhofer-Ausch, V, P707
 Bygrave, C, P374, E1245
 Byrd, J, S769
 Byrgazov, K, P596, E1071
 Byrne, C, P338, P339
 Byrne, J, S423
 Byrne, K, P278
 Bystry, V, S801, S803
Cabal-Hierro, L, S428
 Caballero, A, E963
 Caballero, D, P746, E1129, E1169
 Caballero, J, E1169, E1543
 Caballero, M, P747, E1543
 Caballero, T, P543
 Caballero Berrocal, J, P318
 Caballero-Velázquez, T, P213, P756
 Cabanas-Perianes, V, E1562
 Cabezón, M, P696, E831
 Cabras, A, E1207
 Cabrelle, A, E1357, E1397
 Cabrera, C, S409, P688
 Cabrera, J, E972, E1541
 Cabrero, M, P318, P655, E1169, E1592
 Caccavelli, L, P631
 Cacciagiù, S, E1123
 Cacciola, E, P358
 Cacciola, R, P358
 Cadenas, B, E1156
 Cadievski, L, E1471
 Caeiro, G, E1508
 Caers, J, E1250
 Caguioa, D, P197, E921
 Caguioa, P, E1070
 Cahn, J, E1178
 Caiado, F, E889
 Caillot, D, P345, P572
 Caimi, L, P607
 Caimi, P, S469, P633
 Cairns, D, S407, S781
 Cairoli, R, S111, P722, E1195, E1443
 Caivano, A, E1226
 Calabrese, C, P658
 Calabretto, G, E1357, E1397
 Calabria, A, S128
 Calabuig, M, S790
 Calado, D, S125
 Calafiore, V, S111
 Calasanz, M, S461, P198, P205, P696, E1027
 Calbi, V, S128
 Caldas, C, P713
 Calderon-Cabrera, C, S804, P318
 Caldini, A, E1270
 Caldora, M, P393
 Caliskan, E, E1165
 Çalıkan, Ü, E1584
 Calistri, D, E904
 Calistri, E, S485, P604
 Call, J, P633
 Call, T, P254
 Callahan, J, P699, P701, E1343
 Callanan, M, E1360
 Calle, MD, C, E1051
 Callet-Bauchu, E, E1024
 Callum, J, S784
 Calmels, B, P183, E1549
 Calpadaki, C, P280
 Calpe, E, E1002
 Calvaruso, G, P290
 Calvillo, M, P234, P575, E1440
 Calvo, J, S140
 Calzamilgia, T, P667
 Camacho, L, P694
 Cametti, G, P667
 Camiolo, G, E1214
 Camos, M, P168
 Campagna, G, P277
 Campanati, A, E1136
 Campanini, N, E1223
 Campbell, H, P668
 Campbell, P, E1201
 Campillo, N, P543
 Campion, L, E1360
 Campiotti, L, P163
 Campo, E, S115, S117, P244, P296, P300, P325, E1137, E1369, E1381
 Campos, R, P721, E1456
 Campr, V, P218
 Camps, C, E1424
 Canafoglia, L, P636, E1136
 Canales, M, S469, E1563
 Canales Albendea, M, S775
 Canals, T, E1594
 Cancado, R, S454
 Cancelas, J, S149
 Cancelli, V, P607
 Cancian, L, S119
 Candi, V, E941, E1215
 Candoni, A, S111, E1496
 Canepa, L, S410, P322, E1299
 Cañete Sánchez, A, E1103
 Cangini, D, E1012
 Caniglia, M, P738
 Canioni, D, S105, P709, E1360
 Cañizo, C, P316
 Canli, O, S809
 Cannell, P, S775
 Cano, I, E856
 Cansever, M, E1428
 Cantero-Fortiz, Y, E1500
 Cantone, L, E1268
 Cantonetti, M, S413
 Cantoni, S, P616, P722, E1443
 Cantu-Rodriguez, O, E1306, E1415
 Canzian, F, P295
 Canziani, L, E1232
 Cao, J, E931
 Cao, X-N, S449, P507, P725, E833
 Cao, X, S103
 Caocci, G, P256, P358, P610, E1042, E1186
 Caola, A, S779
 Caparrós, E, P660
 Capdevila, C, E1381
 Capel, I, E1183
 Capelli, D, S111
 Capochiani, E, E946
 Capodanno, I, S485, P604
 Caporale, R, E1215
 Caporarello, N, E1214
 Cappellari, A, E1489
 Cappelli, B, E1495
 Cappelli, E, P234, E1440
 Cappellini, M, S128, P396, E1483, E1576
 Cappuccio, I, P277
 Cappuccio, J, S779
 Cappuzzello, C, P630
 Capria, S, P166
 Carabia, J, P298, E995, E1002
 Caracciolo, F, P671
Caraffini, V, S419, E879
 Caramazza, D, P351, P722

- Caramella, D, P671
Caramella, M, P351
Caravita di Toritto, T, E1247
Carbaat-Ham, J, S113
Carbone, C, P722
Carbonell, F, E1027
Carcassi, C, P256
Carda, J, E1336
Cardenas, P, P211
Cardenas Cardos, R, S422
Cardeza, A, E1273
Carella, A, P605
Carillo, S, S499
Carini, E, E1483
Cario, G, S436, S437, S480
Carlin, L, E875
Carlioni, S, E904
Carlo-Stella, C, P282
Carluccio, P, E1560
Carluccio, V, E1406, E1560
Carmichael, C, S427
Carminati, E, E915
Carmona, R, E1103
Carniti, C, E1201
Carnuccio, F, S485
Carollo, A, P399
Carpenedo, M, P722
Carpenter, N, P367
Carpio, C, P298, E1002
Carrà, A, E1571
Carrabba, M, S806, P544
Carrai, V, P722, E1454
Carrara, P, E1482
Carraro, E, E955
Carraro, S, E1357
Carrasco, A, P325, E1225
Carrasco, R, E1354
Carrascoso, C, P229
Carraway, H, S120
Carreno-Tarragona, G, E1317
Carrillo Cruz, E, P696, E1349
Carrió, A, E1031, E1039
Carroll, A, E883
Carson, A, S108, P197, E921
Carter-Cooper, B, E947
Cartia, C, E1293
Caruso, N, P586, E1390
Caruso, V, S129
Carusone, R, E821
Carvajal, L, S135
Casadevall, N, P712
Casado, F, P609
Casado, J, S144
Casado-Izquierdo, P, P532
Casado Montero, MD, L, E1051, E1059
Casale, M, P399
Casalone, R, P351
Casasnovas, O, S105
Casasnovas, R-O, S469
Cascavilla, N, P520, E1561
Case, M, P512
Caselli, D, E1164
Casetti, I, P357, E1337
Cashen, A, P319
Casieri, P, P598
Casiraghi, M, S128
Casneuf, T, S459, P334
Casoria, A, E1459
Cassarà, F, P290
Cassibba, V, P163
Cassiman, D, P152, P153
Cassin, R, E1030
Cassinat, B, S787
Castagnetti, F, S485, P600, P604, P605, P607
Castaldi, B, E844
Castaman, G, P306, E976
Castañón Fernández, C, E1530
Castella, B, E999
Castellano, G, S117, P244, P300, E1381
Castellino, C, S778
Castellvi, J, P298
Castex, M-P, S131
Castiglioni, C, P288
Castillo, A, P510
Castillo, A, E1074
Castillo, J, E1246
Castillo, M, E1013
Castro, J, P523
Castro, M, E1508
Castro, N, E900
Castro-Dager, A, E1074
Caswell, M, P668
Català, A, S144, P168, P350, P580
Catalano, J, S785
Catalano, L, E1459
Catalano, M, E1293
Cataldi, I, P636
Catani, L, E1309
Cattaneo, C, P163, P644
Cattaneo, D, E1043, E1346
Cattaneo, L, E1489
Cattina, F, P607
Causse, S, E1356
Cavaliere, M, P667
Cavallari, M, E1020
Cavalli, F, P282
Cavalli, M, E1000, E1408
Cavalloni, C, P357, E1337
Cavazzana, M, P631
Cavazzini, F, P604, P705, E1020, E1325
Cavenagh, J, S791, P669, E1212
Cavo, M, S101, S102, S410, S485, P322, P335, P600, P605, P705, E1238, E1247, E1309, E1325
Cazzaniga, G, S436, S801, P628
Cazzola, M, S122, S123, P351, P355, P357, E1179, E1293, E1337
Cea, M, E1299
Ceballos, M, P756
Ceballos, P, E1150
Ceberio, I, P303, E1368
Cebolla, J, E1410
Ceccarelli, M, P667
Ceccherini, I, P234, P575, E1440
Ceccon, M, P570
Cecconi, N, P671
Cedeña, M-T, S409, P316, P661, P688, E891, E899
Cedena Romero, M, E983
Cédile, O, E1367
Cedrone, M, P604, P605, E1340
Cefalo, M, E1167
Cekdemir, D, E1564
Celesti, F, P604
Cellier, C, E1386
Cellini, A, P636
Cenci, S, E1232
Cencini, E, E1401
Cerchiara, E, E1151
Cerchione, C, S504, P277, E1122, E1125, E1459
Cerdá, S, P737
Cerf-Bensussan, N, E1386
Cermak, J, E1198
Cerna, K, E1004
Cerqui, E, P520, E1190, E1325
Cerrano, M, E1332
Cerrato, C, P322
Ceri, E, S771
Cervantes, F, S785, S786, P351, P703
Cervera, J, P318
Cervera Calvo, M, S790, P202, E1426
Cerveró, C, P554
Cervetti, G, P671
Cervinek, L, S435
César Razquin, A, S133
Cesaro, S, P715
Cetin, K, E1435
Çetin, M, E855, E1157, E1598, E1603
Çetin, M, E1527
Cetkovský, P, E936, E1198
Cevreska, L, E1471
Cha, H, E1404
Chabaeva, Y, E1067
Chabannon, C, P183, E1549
Chabot, A, P271, E1099
Chaffee, K, P254, P588
Chaganti, S, S797
Chakraborty, A, S477

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Chakraborty, T, S147
Chakravarty, P, P264
Chalabi, S, P274
Chaliasos, N, E1416
Chamberlain, L, P197, E921
Champlin, R, S450, S792, P739, E914, E1512, E1538
Chan, E, S147
Chan, G, P204, E925
Chan, K, P167
Chan, R, P530
Chan, S, P708, E1324
Chanan-Khan, A, S460
Chander, C, P197
Chandesris, M-O, E1236
Chandler, J, E1142
Chandra, D, P761
Chandratheva, A, E1591
Chang, H, P224, E1217
Chang, M, E1069
Chang, Y, P506, P577
Chang, Y-J, P725, E1517
Chang, Y, P363, E1503, E1511
Chantray, A, E1218
Chapaprieta, V, S117
Chapiro, E, E1001, E1361
Charbonneau, C, E1460
Charbonnier, A, E1537
Charbonnier, A, P354
Chari, A, S780, P334, P676
Charlinski, G, E1257
Charue, D, P617
Chase, A, E1344
Chatburn, E, P566
Chatelain, C, E964
Chatterjee, G, E837, E843
Chau, D, E1392
Chaudhry, G, P294
Chaudhuri, J, P297
Chaudry, S, E1116
Chaurasia, P, E1170
Chauzeix, J, E1010
Chavez, J, P608, E960
Chebotkevich, V, E1153
Chechetkin, A, P308, E1313
Checuz, L, E1254
Chelala, C, E1566
Chelysheva, E, E1067
Chemaly, R, S807
Cheminant, M, E1386
Chen, A, S106
Chen, B-A, E863
Chen, C-Y, E942
Chen, C, P339
Chen, C, E1255, E1300
Chen, F, P390, E1507
Chen, H, E1503, E1511
Chen, H, P387, E1515
Chen, J-J, P392
Chen, J, P191
Chen, J, P390, E956
Chen, J, S135
Chen, J, S452
Chen, J, S450, E914, E1512
Chen, L, P356
Chen, Q, S434
Chen, S, S436
Chen, S-H, E825
Chen, S, E928, E1189
Chen, T, P660
Chen, X, E956, E1531
Chen, Y, E1503, E1511
Chen, Y, E1217
Chen, Y, E1503, E1511
Chen, Y-B, S794
Chen, Y, E1085
Chen, Y, S103
Chen, Y-S, S147
Chen, Y, E1498
Chen, Y-H, S449, P387, P752, E1101, E1515
Chen, Z, P297
Chen, Z, S436
Chen Liang, T, E953, E1013
Cheng, F, P167
Cheng, L, E1383
Cheng, W, P285
Cheok, M, E876
Cheong, J-W, E892
Cherel, B, P217
Cherif, H, S805
Chernookaya, N, E1154
Chernova, N, E1403, E1409
Chervenick, P, E960
Cheson, B, E1129
Cheung, G, P624
Chevalier, C, P183
Chevallier, P, E856
Chevassut, T, E1116
Chevet, E, E819
Chevret, S, E910
Chhabra, S, E1523
Chi, J, S420
Chiappella, A, S467
Chiara, E, P355, P729
Chiaromonte, R, E1216, E1268
Chiarella, M, P210, P556, E922
Chiarenza, A, P588
Chiaretti, S, S800, P166
Chiba, K, S120, S123, S124, S799, P299, P314, P537
Chiba, S, P301, P314, E1519
Chien, K-H, E1567
Chigae, A, P588
Chikalova, H, E1127
Childs, B, S776
Chillemi, A, E1223, E1237
Chillón, C, P318, E1169
Chillón, M, P696, E887
Chin, D, E1110
Chin, M, E1202, E1208
Chinen, Y, E959
Chiodin, G, E996
Chiou, T-J, E1567
Chiroli, S, E1464
Chiron, D, E1360
Chitre, S, P326, P541
Chiu, C, S100, S101, S459, P334, P335, E1369
Chiu, M-C, P653
Chiurazzi, F, P616
Chng, W-J, S458
Cho, B-S, P551, P561, P742, E1513
Cho, C, P745
Cho, D, E1062
Cho, S-G, P638, P742, E1513
Cho, Y-U, E857, E909
Chocarro, S, P536
Choe, J, E1404
Choi, C, P223, E984, E1070
Choi, D, E1177
Choi, E, S499
Choi, E, P310, E850
Choi, E-J, E1177
Choi, I, P385
Choi, I, P659
Choi, J, S794
Choi, J, P569
Choi, M, P247
Choi, M-Y, E1054, E1069
Choi, S, S491
Choi, S-Y, P259, E1054, E1069
Choi, Y, P569
Chojnowski, K, S435
Chomienne, C, P657
Chopra, M, E1569
Choquet, S, S469, E1374
Chou, S, S147
Chou, W-C, P212
Chouvarda, I, E1407
Chretien, S, P631
Chrétien, M-L, P345

- Christensen, J, P324
Christiansen, C, E1435
Christofyllakis, K, P216
Christopeit, M, E1286
Christopoulou, G, E1292
Christoulas, D, S130, S415, E1292
Chromik, J, P666
Chu, S-T, E1567
Chuah, C, S425, P603
Chubukov, V, P614
Chung, D, E1252
Chung, J, E984, E1070
Chung, K, P372, E922
Chung, N-G, S422
Chung, W, E1248
Chunilal, S, E1431
Chupryna, M, E1127
Chyla, B, S771, P682
Ciabatti, E, E1048, E1318, E1397, E1408
Ciancia, G, E1459
Cibeira, M, E1259
Cibien, F, P715
Ciboddo, M, P357, E1337
Cibulskis, C, P236
Cicalese, M, S128
Ciccarone, M, E1123
Cicccone, G, P214, E1247
Cicconi, L, E908
Ciceri, F, S128, S485, S493, S778, S806, P163, P384, P544, E1232
Cid, M, P296
Cieri, N, E1207
Ciesielka, M, E888
Cigalini, E, S433, P365
Cilloni, D, P658, P667, E1226, E1332
Ciminello, A, P722
Cimino, G, E1325, E1340
Cimminiello, M, S413
Cimmino, L, P297
Cinetto, F, E1254
Cinque, P, E1570
Ciofini, S, E941, E946
Ciotti, F, S128
Cipolotti, L, E1450
Circhetta, E, E1151
Ciroto, M, P399
Cisneros-Herreros, J, S804
Ciurea, S, S792, P739, E914, E1512, E1538
Civoli, F, E1147
Clackson, T, P603
Claessen, M-J, S132
Clara, J, E960
Clark, R, S423, P258
Clark, S-A, E1110
Clark, S, P403
Clarke, L, S117
Claudio, J, P708
Claus, R, P243, P350, P656
Claus Marcher, C, S486
Clavio, M, P667, E854, E915, E919, E933, E1505
Clementino, N, P257
Cleyrat, C, S499
Clifton-Hadley, L, S802, P160, P164, P669
Climent, F, E957
Clise-Dwyer, K, P321, P652
Cloos, J, S113
Closs, E, E992
Clot, G, S115, S117, P300
Cluzeau, T, E910
Coady, A, E1245
Coccaro, N, P598
Cocciardi, S, P172, P535, E864, E868
Coccioli, M, P365
Cocito, F, E1293
Codarin, E, P607
Coe, A, P285
Coelho, A, E1033, E1188, E1586
Coenen, J, S501
Coffey, G, S773, P587
Cogle, C, E923
Cohen, J, S412, S772
Cohen, M, S451
Coiiffier, B, P635
Cokić, V, P692, E1308, E1316, E1319, E1328
Colado, E, S115
Colaiuta, E, P763
Cole, C, P680
Coleman, M, P634
Coll, R, E1181
Colla, S, S487, P321, P652
Collado, R, S461, E1027
Collett, C, S407, S781
Collett, L, P252
Collins, A, P276, E874
Collins, G, S412, S775, E1476
Collins, R, S471, P552
Collins, S, P343
Collonge-Rame, M-A, E1361
Collord, G, S420
Colom, B, P609
Colombatti, R, E1164, E1489
Colombo, M, E1216, E1268
Colombo, N, E854, E915, E933, E1505
Colomer, D, S115, P696, E1369
Colorado, M, P554
Colunga Pedraza, P, E1306, E1415
Combeau, V, E1010
Comenzo, R, S104, P676
Comia, N, E1070
Comuzzi, C, E1496
Conconi, A, P667
Condoluci, A, P282
Conesa Garcia, V, E1059
Coniglio, M, P714
Conley, P, P587
Conneally, E, P601
Connor, P, P668
Conrad, M, S809
Consoli, U, P722
Consonni, D, P616
Constanço, C, E1425
Conte, M, P254
Contentin, N, P572
Conter, V, S480
Conti, C, E908
Conticello, C, E1214, E1232, E1247
Contreras, T, E1019
Cook, G, S101, S407, S781, P335, P669, E1269
Cook, M, P669
Cooke, R, P295
Cools, J, S439, P151, P152
Cools, N, S141
Cooper, M, P332
Cooper, N, P367
Copland, M, S423, P591
Coppola, M, S128
Corbacioglu, A, P533
Corbacioglu, S, P231
Corbineau, S, P712
Corchete, L, P329, P751
Corcoran, S, S147
Cordero, J, S460
Cordoba, R, P733
Córdoba, C, E1273
Core, L, P237
Cornago, J, E1565
Cornelissen, A, S448
Cornelissen, J, S112, S798, P262, P388, E1499, E1504, E1506
Cornillet-Lefebvre, P, E1361
Cornillon, J, P572
Corradini, P, S413, S778, P341, E1201, E1207, E1247, E1533
Corral, J, S445, P721, E1444, E1456
Corral, R, E887
Correa, J-G, P703
Corrente, F, E1124
Corso, A, E1293
Cortelazzo, S, P304
Cortelezzi, A, P163, P355, P616, P729, E1030, E1078
Cortes, J, S110, S474, S487, S489, P170, P192, P200, P204, P209, P211, P315, P518, P550, P556, P560, P562, P603, P665, E914,

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- E922, E935, E1052, E1060
 Cortes, J, S425
 Cortes, M, S147
 Cortesão, E, E1287, E1297, E1336
 Cortez, S, E1546, E1563
 Corti, C, S806
 Cortinovic, I, E1346
 Corton, M, P623
 Coscia, M, E999
 Cosh, H, P374
 Cosmi, C, E1571
 Costa, A, S136
 Costa, D, E1031, E1032, E1039
 Costa, F, E1223, E1237
 Costa, F, E1494
 Costa, L, P293
 Costantini, S, P393, E1570
 Costanzi, M, E867
 Costeas, P, S420
 Costello, J, P353
 Costopoulos, M, E1374
 Cottone, F, E1186
 Couceiro, P, E1044, E1047, E1064
 Counsell, N, P669
 Couronné, L, S124
 Courtier, F, P354
 Coutinho, J, P293
 Coutinho, M, P293
 Coutre, S, S769, S771
 Couzens, S, S114
 Coviello, E, E919, E933, E1505
 Cowan, C, S147
 Cowell, E, S503
 Cox, C, E1478
 Coyle, M, P550
 Craddock, C, S791, E1506
 Cradick, T, S147
 Cragg, M, P585
 Craig, J, E938
 Craig, M, P339
 Cramer, P, S464, E1025
 Craviotto, L, E1497
 Crawford, L, E1224
 Crawley, C, P669, E938
 Cremasco, F, E1232
 Crespo, M, P298, E995, E1002
 Creighton, M, P187
 Criado, I, P584, E1019
 Crisà, E, P604, E1332
 Criscuolo, C, E1016
 Crisp, R, E1182
 Crispino, J, S427
 Cromwell, C, E1438
 Cronin, A, E1186
 Cross, M, P261, P555
 Cross, N, E1344
 Crotty, G, E1250
 Crowe, J, P669
 Crucitti, L, E1443
 Crugnola, M, P604, P658, P705, E1325
 Cruz-Jentoft, A, P376
 Csikos, T, P265, E1221
 Cuccaro, A, P282, E1124
 Cuccia, L, P394
 Cuellar, C, E1026
 Cuéllar-García, C, S462
 Cuenca, I, P320, P329, P679
 Cuervo-Sierra, J, E1074
 Cueto-Felqueroso, C, E1278
 Cuevas, B, P703
 Cui, W, E931
 Culver, B, E1090
 Cumbo, C, P598
 Cunat, S, P289
 Cuneo, A, S111, E904, E1000, E1012, E1020, E1325
 Cunha, E, E1080, E1588
 Cunningham, A, E1487
 Cupelli, E, P282
 Cupit, L, S776
 Curík, N, S483, E1041
 Curnutte, J, S773
 Cusano, R, P256
 Cushion, M, P645
 Custódia, C, P157
 Cuthill, K, P326, E1242, E1245, E1509
 Cutica, I, P729
 Cutillas, P, P532, E869
 Cutler, C, S492
 Cutrona, G, P586, E1017, E1390
 Cutter, K, P563
 Cvejic, A, P227
 Cybakova, N, E1313
 D'Adda, M, S485, P605, P705, E1190, E1325
 D'Addosio, A, P604
 D'Agostino, M, P322
 D'Agostino, S, E1406, E1560
 D'Alò, F, E1124
 D'Ambrosio, R, E1263
 D'Amico, M, E1016
 D'Amore, E, E955
 D'Anca, M, P321
 D'Angelo, E, S128
 D'Angelo, P, P738
 D'Ardia, S, P214
 D'Arena, G, P583, E1261
 D'Auria, F, E1226, E1261
 D'Avola, A, E996
 D'Incan, E, P354
 D'Odorico, C, E1496
 D'Rozario, J, E1289
 D'Sa, S, P669, E1132
 D'Souza, A, E1523
 Da Col, A, P283
 Da Silva, F, E832
 Da Silva, M, P304
 Da Silva Filho, M, P295
 Da-Via, M, P320
 Daal, B, P404
 Dados, A, E1591
 Daglis, T, E1574
 Daher-Reyes, G, P708
 Dahl, C, S109
 Dahle, J, E1141
 Dai, S, S769
 Dail, M, P662
 Dal Bo, M, P583, P588
 Dal Collo, G, E821
 Dalal, B, P581
 Dalal, M, P637
 Dalal, S, P245, P589
 Dalgaard, J, P613
 Dalia, S, E960
 Dalla-Venezia, N, E1359
 Dalle, J-H, E1150
 Dally, N, E1121
 Dalmau, J, E1396
 Daly, R, P699, P701, E1343
 Damaj, G, S105
 Damianaki, A, E1419
 Damiani, D, E1065
 Damlaj, M, E1514
 Damle, R, E1129
 Damm-Welk, C, E1391
 Dana, H, E862
 Danby, R, E1544
 Dang, L, P614
 Dang, L, E994
 Dang, P, P268
 Dang, P, S484
 Danga, A, E1148
 Danhof, S, P681
 Daniel, C, P566
 Daniels, S, P368
 Danilina, A, E1227
 Danilov, A, S118, P249
 Danilova, O, S118
 Danise, P, P667
 Dantas Rodrigues, C, E1425
 Danylesko, I, E1504
 Daraki, A, E895

- Darboe, S, E1487
Darden, D, S473
Darren, L, E1218
Darzentas, N, S801, S803
Dasgupta, A, E1255
Dasilva-Freire, N, P713
Daskalakis, M, P663
Datta, A, S117
Dauba, J, P649
Daulange, A, E1458
Daver, N, S474, S487, S489, S496,
P170, P192, P200, P209, P211,
P315, P317, P352, P518, P665,
E913, E914, E935, E1345
Davi, F, S801, P244, E1374
Davidova, J, E861
Davidovic, S, E948
Davids, M, S771, P564
David-Tarud, G, E1074
Davies, A, S502, S774
Davies, D, E1529
Davies, F, S407, S781
Davies, J, E1566
Davies, S, P517
Dávila, B, E1183
Dávila, J, E1543
Davis, C, E1269
Davis, J, P750
Davis, K, S476
Davis, Z, P244
Davydova, J, E1295, E1559
Davydova, Y, E934, E982, E1092,
E1096, E1098
Day, G-J, E1073
Dazzi, F, S817
De Arriba, F, P402, P688, E1013
De Bellis, E, E908
De Benedittis, C, S485
De Best, L, P677
De Bie, J, P151
De Boer, E, E897
De Boer, J, S412, P567
De Botton, S, S471, P215, P316
De Braekeleer, E, S430
De Bruijn, J, P265
De Bruyne, E, E1211, E1220
De Candia, M, E1560
De Castro, L, E1493
De Cuyper, I, P404, E1310
De Dios Soler, M, E1182
De Fabritiis, P, S111, P616
De Filippo, K, E875
De Franceschi, L, P392, E1491
De Graaf, A, E1197
De Greef, G, E1499
De Gregoris, C, E1340
De Groen, R, P567
De Groot, K, E820
De Groot, M, P576
De Haro Muñoz, T, E1271, E1283
De Haro-del Moral, F, P685
De Jaureguiberry, J-P, S453
De Jong, N, E1504
De Jong-Korlaar, R, P265
De Keersmaecker, K, S417, S439, P152,
P153
De Keyser, F, P565
De Klerk, W, S447
De Koning, E, S500
De Korte, D, P404
De la Banda, E, E957
De la Camara, R, E1565
De la Chapelle, A, E883
De La Cruz Vicente, F, S469, E953
De la Cruz-De la Cruz, C, E1306
De la Fuente, A, P554
De la Fuente, I, E1014
De la Fuente, J, P233
De La Iglesia, S, E983
De La Morena-Barrio, B, S445
**De La Morena-Barrio, M, S445, E1444,
E1456**
De la Rubia, J, S409, P343, P376
De la Serna, J, E1086
De Laiglesia, A, E1541
De las Heras, N, P737
De Lavallade, H, S423, E1550
De Luca, L, E1226
De March, E, E1254
De Marchi, F, E1065, E1496
De Matteis, S, E904, E1012
De Miguel, C, P685, E972
De Moerloose, B, S476, P350, P517,
E1114
De Montalembert, M, P631
De Muro, M, E1340
De Novi, L, E1000, E1408
De Paepe, K, P565
De Paoli, L, E1247
De Paz, MD, R, P257, P609, E1051,
E1181, E1546, E1563
De Paz Arias, R, E1059
De Philippis, C, E1201
De Pooter, N, P370
De Propriis, M, P166, E989, E1000
De Renzis, B, P712
De Ridder, J, E1279
De Rocco, D, S432, S433, P365
De Rop, C, E1056
De Rosa, G, S811
De Santis, R, E955
De Santis, S, P600
De-Silva, D, P669, P731, E1208
De Smedt, E, E1211
De Smedt, R, P156
De Souza, C, S422
De Stefano, L, P586, E1390
De Stefano, V, P351, P722
De Tute, R, P245, P589, P669
De Veirman, K, E1211, E1220
De Vos Klootwijk, L, P190
De Vries, J, P683
De Waal, E, P340
De Winde, C, E1353
De Wreede, L, P567, P576
DeAlmeida, V, P328, E1373
Deambrogi, C, P282
Dean, M, E1350
DeAngelo, D, S788, P201, P203, P204,
P519, P525, P547, P562
Dearden, L, E1281
Debals-Gontier, M, E1549
Debatin, K-M, P508, P754, E838
Declercq, H, E1135
Deconinck, E, S453, S493, P345, P572
DeCosta, L, E1298
Deenik, W, S501, P340, P567
Defasque, S, E1361
Defina, M, E941, E946
Degan, M, P583
Dego, A, E1299
Deguchi, T, S799
Deighan, I, E1228
Deiningner, M, S425, P603, E1071
Deiteren, K, S141
Dejoie, T, P348
Del Cañizo, M, P318, P655, P660,
P751, E1169
Del Cañizo Fernández Roldán, M,
E1181
Del Giudice, I, E989, E1000, E1408
Del Poeta, G, P583, P588, E908
Del Principe, M, S111, E908
Del Rey, M, P318, E1169, E1451
Del Rey, Ó, E1592
Del Vecchio, L, E1226
Delabesse, E, P557
Delaite, P, S794
Delaki, B, E1574
Delaporta, P, P397, E1158
Delarue, R, E1236, E1386
Delaunay, J, P217, P316
Delea, T, P372, E1055
Delette, C, E1135
Deleuze, J-F, P274
Delfau-Larue, M-H, E1360
Delforge, M, E1180, E1272
Delgado, J, S115, S117, S461, S465,
E1031, E1032, E1039, E1137
Delgado, R, P720
Delgado-Beltrán, M-P, E1014

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Delia, M, E1560
Delifer, C, E907
Delimpasi, S, E1266
Dell'Arti, L, E1483
Della Corte, G, P288
Della Pepa, R, S504, P277, E1122, E1125, E1459
Della Porta, M, E1179
Della Starza, I, E1000, E1408
Dellacasa, C, P214
Delord, M, E1063
Delva, L, S139, P514
Demajo, S, E1381
Demakos, E, S488, E1170, E1185
DeMarco, S, S500
DeMarini, D, P633
Demeter, J, S502, S776
Demeyer, S, P151
Demir, S, P508
Demirkaya, M, P281
Dem'janova, V, E1526
Dempsey-Hibbert, N, P368
Demurtas, A, P214
Deng, W, S785
Deng, W, P601
Dengler, J, S424, P255, P257, E1326
Denkers, F, P190
Dennis, M, S791
Dennis, M, S503, P382
Denys, B, E1114
Deo, S, E1140
Depaoli, L, P163
DePinho, R, P321
Deplano, S, S817
Depreter, B, E1114
DeRome, M, P322
Derreal, A, E1018
Deschamps, M, E1073
Deshet-Unger, N, E1107
Deshpande, N, E837, E843
Desmond, R, E1460, E1187
Desnica, L, S795
Desoutter, J, E1537
Despas, F, P641
Desphande, S, E1129
Despotovic, J, P367, P727
Dessen, P, S427
Deutsch, A, E1363, E1395
Deutsch, E, P268
Devadasan, D, E1484
Devalet, B, P230
Devereux, S, P245, P589, E1509
Deveza, M, E1010
Deviller, R, E1547
Devin, J, E1211
Devizzi, L, S778
Devlin, M, S469
Devlin, R, P708, E1324
Devlin, S, P553, P745, E1252
Devos, H, E1056
Devos, T, S784, S785, P351, E1310
Devre, P, E837
Dhakal, B, E1523
Dhaliwal, D, E843
Dhanasiri, S, E1463
Di Bartolomeo, P, P394, P738
Di Bella, N, P249
Di Benedetto, A, E1379
Di Bona, E, S485, P163
Di Carlo, E, E1226
Di Felice, N, E854, E1299
Di Florio, F, E1167
Di Genua, C, S421
Di Giacomo, D, E1174
Di Giusto, S, E1065
Di Grazia, C, S796, E915, E1505
Di Ianni, M, P394
Di Marcantonio, D, P528
Di Marco, F, P717
Di Matola, T, E1570
Di Micco, A, P343, E1250
Di Noi, M, E1406
Di Palma, F, E873
Di Paolo, A, E1048
Di Perna, M, S504, E1122
Di Raimondo, F, S778, P583, E1043, E1214, E1232
Di Rocco, A, P304
Di Rocco, M, E1077
Di Serio, C, S806
Di Tomaso, E, P188, E884
Di Trani, M, P282
Di Tucci, A, P667, E1186
Di Tullio, A, P264, P657
Di Veroli, A, E908, E1340
Di Vita, A, P599, E1048
Diagne, I, E1495
Diamantopoulos, P, E1120, E1462
Diamond, J, S426
Diana, G, P264
Dias, J, S420
Díaz, L, E1273
Díaz-Beyá, M, S790, P202
Díaz de Heredia, C, S144, P580, P623
Díaz Varela, N, E1327
Dickinson, M, E1202
Dickman, P, P330
Diehl, V, S150, P275
Diels, J, P687, E1024
Dierickx, D, P565
Dierlamm, J, S150
Dietlein, M, S150
Dietsche, T, E1365
Dietz, A, E840
Dietzfelbinger, H, E1449
Diez, B, P623
Díez, J, E1113
Díez-Campelo, M, P316, P318, P655, P660, P751, E1169, E1181
Díez Gallarreta, Z, E1183
Dijk, A, P340
Diklić, M, E1316, E1319
Dimitrakopoulou, A, S416, P639
Dimopoulos, K, P324
Dimopoulos, M-A, S100, S101, S415, S456, S458, P334, P335, P337, P338, P343, E1201, E1231, E1233, E1246, E1249, E1250, E1281, E1292, E1304
Dimopoulou, M, S130, E1120, E1485
Dimou, M, P255, E1120
Dimovski, A, E1471
DiNardo, C, S471, S472, S487, S489, S496, P192, P200, P209, P215, P315, P317, P352, P518, P550, P665, E913
Ding, W, P254
Dingli, D, P673, E1240, E1241
Dinman, J, S417, S439
Dinmohamed, A, P219, P250, P686, E1301
Diong, C, S776
Diop, F, P282
Diop, M, S427
DiPersio, J, S794, P319
Dirnhofer, S, E1365
Dirse, V, E1311, E1399
Dispenzieri, A, P331, P673, E1240, E1241
Diviskova, E, P238, E1003
Divoka, M, E1432
Divona, M, E908
Dixon, S, S441
Djikić, D, E1308, E1316
Djurasinovic, V, S443, E970
Djurdjevic, P, S443
Dlouhy, I, E1137
Dmitrieva, E, E1029
Dmoszynska, A, E1257
Dmytruk, N, E1010
Do, K-A, P241
Do, T, E1263

- Do, Y, P259, P569, E871, E1054, E1069, E1070
Do Nascimento, J, E1426
Dobashi, A, S124
Dobashi, N, P314
Dobay, M, S437
Dobbernack, V, S494
Dobrenic, M, E971
Dobson, R, P587
Docherty, S, P276
Dodero, A, E1533
Doehner, H, P248
Doganis, D, E862
Dogné, J-M, P230, E964
Dogu, M, P281
Döhner, H, P182, P208, P533, P535, P700, E864, E868, E870, E1084, E1335
Döhner, K, P182, P533, P535, P700, E864, E868, E870, E1335
Dokal, A, E869
Dolatshad, H, S122
Dolnik, A, P182, P248, P535, E864, E868, E888
Dolph, M, E945
Doma, E, P749
Domanska-Czyz, K, P162
Dombret, H, S478, P208, E856, E910
Domenichini, C, P599, E1048
Domingo Domenech, E, E957
Domingo-Reinés, J, E893
Dominguez, D, E831
Dominguez, P, P297
Dominguez, A, P205
Dominguez, M, E1349
Dominietto, A, S796
Dominoni, F, E1207
Donadieu, J, E1102
Donato, B, P369
Dondi, A, S778
Dong, H, S786
Dong, T, P224
Donnellan, W, S793, P662
Donzelli, S, E1379
Doobaree, U, E1430, E1453
Doondeea, J, S140
Doorduijn, J, S467, P219, P250
Dorff, M, P602
Dorgalaleh, A, P309
Dorsey, C, P566
Dorvaux, V, P572
Doshi, P, P676, E1369
Dosquet, C, P657
Dotlic, S, E971
Doubek, M, S461, P238, E841, E1003, E1004, E1009, E1024
Douka, V, E1266
Douna, V, E862
Dourdil Sahun, M, E1258
Doyle, K, P189
Draber, P, P273
Draberova, L, P273
Drachneris, J, E1399
Dragan, C, E1602
Dragani, A, P358
Dragosky, M, P719
Drain, S, E1228
Drakos, E, E1378
Drandi, D, E1408
Drayson, M, S407, S781
Dreau, H, P228, P246, P668, E1424
Dreger, P, P516
Drennan, S, E996
Drent, E, E1221
Dreta, B, E1296
Drexler, H, E1387
Dreyling, M, S470, S776, P216, P222, E1402
Drize, N, E1092, E1096, E1098
Droin, N, S427, P268
Drokov, M, E1545, E1559
Drozd-Soko_owska, J, E1193, E1257
Drummond, M, P699, P701, E1343
Druzd-Sitek, A, E1257
Duan, M, P356
Duarte, D, E875
Duarte, R, S807, E1541
Duarte, S, E1110
Dubnyak, D, E1545, E1559
Dubois, O, P624
Dubovsky, J, S492
Dubowy, R, S465, S785
Dubravcic, K, E1296
Dubreuil, P, P709
Duca, L, E1483, E1576
Ducastelle-Leprêtre, S, E906, E1150
Ducou Le Pointe, H, P716
Dudakov, J, S446
Dueck, A, P359, P377, E1321, E1331, E1339
Duell, J, S470
Duffy, K, E875
Duffour, A, E885
Duffour, C, P232, P234, P575, P717, E1440
Dugas, M, E1197
Duh, M, P285, P286
Duhamel, A, E1135
Dührsen, U, P534, P582, E1118
Dujmovic, D, E971
Dukovski, D, E1471
Dulery, R, P217
Duliege, A, S435
Duma, N, E1241, E1274, E1276, E1288, E1502
Duma, V, E1127
Dumee, B, P677
Dumesnil, C, S131
Dumit, V, E1393
Dummer, R, P637
Dumon, S, S119
Dumond Wibaux, E, E1458
Dumont, S, P712
Dunbar, M, S473, P675
Dunn, R, E905, E1176
Dunning, A, P295
Duong, D, E847
Duong, V, E912, E947
Duprez, E, P183
Dupuy, C, P268
Duque, J, E1074
Durakovic, N, S795
Durán, M-A, P703, E1341, E1417, E1555
Duran-Ferrer, M, S117, P300
Durand, J-M, P716
Durbini, E, P279
Durcan, E, E1159
Durechova, K, S461, P238
Durgun, E, E1427
Durian, M, S501
Durie, B, S782, P349, P687, E1239, E1269, E1277
Dürig, J, S775
Durot, E, E1001
Durrant, S, S478
Durrieu, F, E1028
Durusoy, R, E1525
Dušátková, L, P711
Dusilkova, N, E1166
Dutka, M, E1193
Duval, V, E1142
Duverger Munch-Petersen, H, P324
Duvic, M, P191, P637
Duvillier, H, E994
Duyster, J, P243, P656, E1355, E1393
Dvorak, N, S472
Dwilewicz-Trojaczek, J, E1193
Dwojak, M, S125, E1359, E1385
Dworzak, M, P350
Dyer, M, E1372
Dytfeld, D, E1262
Dzierzak-Mietla, M, P741
Eaddy, M, E973, E1191, E1196, E1184
Earnshaw, I, P767
Easton, D, P295
Eathiraj, S, E1400
Eaton, M, E884
Ebbesen, L, E1367
Eberlein, J, E1090
Eberth, S, E1387

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Ebner, J, S133
 Ebner, K, P651
 Echaniz, O, E1368
 Echchannaoui, H, P627, E992
 Echeveste Gutierrez, M, P339
 Eckert, C, S436, S437, P155
 Eckert, R, P255
 Eckert, R, S505
 Eckstein, V, P179, P206
 Eclache, V, E1001
 Economou, M, E1414, E1423, E1574
 Edahiro, Y, P691
 Edelmann, B, E865
 Edelmann, J, P585
 Edenfield, J, P633
 Eder, T, S133, S134
 Edirisinghe, M, E1112
 Edlinger, L, E1045
 Edwards, D, E874
 Eeles, R, P295
 Eeltink, C, P340
 Ernstman, J, S132
 Efficace, F, E1186
 Efremov, D, E993, E1375
 Egan, D, E901
 Egan, K, E1452
 Egan, P, E1228
 Eggermann, T, P231
 Egle, A, P707
 Egorova, E, E1436
 Eguileor, Á, P296
 Egyed, M, S784, S785
 Ehall, B, E1395
 Ehninger, G, P172, P384, P388, E880, E927, E1168
 Ehrencrona, H, S426
 Ehrenfeld, S, E1364
 Eich, H, S150
 Eichenauer, D, S150, P275
 Eichhorst, B, S464, S771, P251, E1025
 Eidukaitė, A, E828
 Eijkelenboom, A, P239
 Einsele, H, S145, S807, S816, P320, P341, P681, E1251, E1569
 Eisen, M, P367, P727
 Eisenkolb, G, S446
 Eisfeld, A-K, E883
 Eiwen, K, E1109
 Ejerblad, E, P697
 Ek, S, S109, P244
 Ekdahl, L, E826
 Ektare, V, E1037
 Ekwattanakit, S, S452, E1076
 El-Ayoubi, A, E1388
 El-Benna, J, P268
 El Chaer, F, E912
 El Chazli, Y, E1411
 El-Cheikh, J, E1150
 El Demery, M, P649
 El-Farrash, R, P291, E1093
 El Fassi, D, E1115
 El-Galaly, T, E1115
 El-Ghamrawy, M, E1573
 El-Hamri, M, E906
 El-Najjar, I, E1245
 El-Nemer, W, P631
 El Samahy, M, E1582
 El-Shanshory, M, E1583
 El-Sharkawi, D, E1132
 El-Shehaby, W, E1583
 El-Tagui, M, E1573
 El-Zaafarany, M, E1095
 Elalfy, M, P291, P398
 Elbaz, N, E1585
 Eldad, D, E1121
 Elder, P, E1228
 Eldosoky, E, E1583
 Elefante, E, E1318
 Elemento, O, P297
 Elezovic, I, E1448
 Elfrink, S, E1353
 Elhaddad, A, E926
 Elia, L, S800, P166
 Elias, M, S466
 Eliopoulos, A, E1378
 ElKholy, A, E1583
 Elli, E, E1332, E1351
 Elliott, M, P165
 Elliott, N, P270
 Ellithy, H, E1486
 Elmetwally, S, E1572
 Elming, M, P221
 Elnaggar, A, E1578
 Else, R, E1476
 Elshafie, S, E1601
 Elshamia, A, E1583
 Elsharkawy, A, E1411
 Elsherif, N, E1572, E1580
 Elshinawy, M, E1578
 Elverdi, T, E1518
 Emadi, A, E912, E947
 Emarah, Z, E1095
 Embry, M, P328, E1373
 Emruli, V, P244
 Enami, T, P301
 Encinas, C, P376, P688
 Endo, H, P691
 Endo, S, E1205
 Endo, T, E859
 Engelhardt, M, P341, E1251
 Engelke, A, S464
 Engert, A, S150, S412, S414, P275, P295, E1119
 Enjeti, A, S473
 Enjuanes, A, S115, E1381
 Ennishi, D, P297
 Enrico, A, E1182
 Enright, H, E1187
 Enserink, J, E866
 Ensoli, F, E1145
 Entrena, A, P513
 Eom, H-S, E984
 Eom, K-S, P551, P561, P638
 Eom, K-S, P742, E1513
 Er, E, E1564
 Eradat, H, P253
 Erba, H, S793, P201, P210, P556, P562, E923
 Erba, P, P671
 Ercolani, C, E1379
 Ercolano, G, E1048
 Ercolin, C, E1397
 Erdogan Ozunal, I, E1159
 Erlanson, M, E1141
 Ernst, T, P647
 Errichiello, S, S485, P599
 Escalante, F, P329
 Escamilla, V, E1349
 Escherich, G, P515
 Escoda, L, S790, P202, E831
 Escoda Teigell, L, E1426
Escribà-Garcia, L, S816
 Escribano, L, P713
 Escudero, A, P509
 Escudero-Góngora, M, E1341
 Eser, B, E1527
 Eşkazan, A, E1159, E1518
Eske Lund, C, S109
 Esma, F, E1247
 Espadana, A, E1297
 Espéli, M, E1102
 Espigado, I, S804, E1349
 Espín, J, P573
 Espín, S, P573
 Espinet, B, S461, E1027
 Espiño Martínez, M, E1302, E1305
 Espinosa Lara, N, E1134
 Esquirol, A, P746, E1160
 Essa, N, E1095
 Esser, S, P568
 Essers, M, P663
 Esteban Figuerola, A, E1426

- Estell, J, E1289
Estella, C, P168
Esterfelder, S, S116, P248, P585
Estepp, J, P620
Esteve, J, S790, S798, P202, E831
Estrada, N, P703
Estrov, Z, S463, P209, P518, P690,
E935, E991, E1016
Estupiñan-Perico, D, E1074
Etienne, G, E1028
Eto, K, P691
Ettinger, O, P220, E1133
Eustace, B, S147
Evangelista, A, P214, P304, P322
Ewins, K, E1187
Ezine, S, P274
Ezoe, S, E1370
Ezponda, T, P325, E1225
Fabarius, A, S424, P255, E1344
Fabbiano, F, S111, P520
Fabbri, A, E1401
Fabris, S, E1000
Facchini, E, E1164
Facciolo, F, E1145
Facco, M, E1005, E1006, E1011, E1357
Facon, T, S460, P675
Fadda, P, E917
Faderl, S, S793, P201, E1192
Fagioli, F, S422, P738, E1491
Fahmy, S, E1093
Fahmy, S, E926
Fahrbach, K, E1281
Failes, T, P154
Fais, F, P586, E1390
Fakouhi, K, S473
Falanga, A, P760, P766
Falantes, J, S804, E1349
Falco, G, E1226
Falcone, M, P172
Falconer, J, E958
Faldum, A, P546
Falge, C, S424
Falini, B, S111, P173
Falkenburg, F, P576
Falkenburg, J, S447
Faller, D, E944, E1184, E1191, E1196
Falzetti, F, P604
Fama, A, E1325
Fan, F, S103
Fan, X, E1547
Fanadka, M, E1008
Fanale, M, S412
Fañanas-Baquero, S, E1094
Fancello, L, S439, P153
Fanciullo, L, P234
Fanin, R, E1065, E1325, E1496
Fanning, M, P566
Fanning, S, P634
Fantl, D, E1264
Farahat, A, S135
Faraone, S, E989
Farber, C, S773
Faria, R, E889
Farina, F, P570
Farmaki, E, E1414, E1423
Farooqui, M, P344
Farrelly, E, E1184, E1191, E1196
Farruggia, P, P717, E955, E1420
Farsaci, B, S412
Fasan, A, P199, E1312
Fasoli, S, E1164
Fathi, A, S471, S793, P201, P215, E947
Fätkenheuer, G, P568
Fattizzo, B, P616, E1030
Faul, C, P516
Faure, P, E1178
Faustino, P, E1586
Fava, C, P604
Favre, C, P714, P738
Fayed, A, E1583
Fazi, P, S111
Fazio, G, S801, P628
Fearn, A, P160
Fechina, L, P161
Fechter, K, E1363, E1395
Fedeli, F, E1077
Federici, I, P636, E1136
Federico, V, E946
Federti, E, P392
Fedorova, N, E1436
Fedotov, A, E1029
Fedullo, A, S800
Fegan, C, P245, P589
Fein, J, E1504
Feldman, E, S793
Feldman, G, E1073
Felici, S, E1340
Feliciano, J, P637
Feliu, E, E831, E1396
Fellague-Chebra, R, P257
Fenaux, P, S488, P316, P657, E1181
Feneant-Thibault, M, E1082
Fenerich, B, E832
Feng, F-E, S431
Feng, Q, P366
Feng, R, S431
Feng, S, S458
Feng, Y, S138
Feng, Y, E1475
Fenoglio, D, P586, E1390
Fenske, T, S773
Fenu, S, P658
Ferguson, P, S791
Ferhanoglu, B, P281
Ferini, G, E1508
Fernandes, H, P716
Fernandes, J, E832
Fernandes, S, P697
Fernandes, S, P236, P237
Fernandez, A, E1263
Fernández, L, P509, E1234
Fernandez, M, P554
Fernandez, P, P554
Fernández, P, P376
Fernandez-Avilés, F, P746
Fernández de Larrea, C, E1259
Fernandez de Sevilla, A, E957
Fernandez Escobar, N, E1508
Fernandez-García, M, P755
Fernández-González, M, E953
Fernandez-Mercado, M, P198, P303,
E1368
Fernández-Navarro, P, P584, E1019
Fernández-Ordoño, R, P376
Fernández Poveda, E, E1562
Fernandez Ramos, A, E829
Fernández-Rodríguez, C, P694, P696
Fernández-Sevilla, L, P513
Fernando, E, P737
Ferrajoli, A, S463, P240, P241, P588,
E935, E991, E1016
Ferrand, C, E1073
Ferrando, A, S135
Ferrão, J, E1586
Ferrara, F, P722
Ferrara, G, P306, E976
Ferrarazzo, G, P283
Ferrari, A, E882, E898
Ferrari, A, P616
Ferrari, G, S128
Ferrarini, M, P586, E1017, E1390
Ferrario, A, P644
Ferraro, F, P528
Ferraro, S, P736, E1151
Ferré, Ó, P747
Ferreira, F, E988
Ferreira, L, P227
Ferrer, R, P721
Ferrer-Garrido, G, E1014
Ferrer-Marin, F, P660, P703, E1059
Ferreri, A, S413, P304
Ferrero, D, P604, E1332
Ferrero, S, P304, E1408
Ferretti, A, E976
Ferretti, V, P357, E1293, E1337
Ferri, V, E1078
Ferrigno, I, E1042
Ferro, F, E1318
Ferry, H, E1110
Fert-Ferrer, S, E1001
Fertrin, K, E1494

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Fest, T, E1356
 Feugier, P, S105
 Feuillard, J, E1010
 Feuring-Buske, M, S150, S429
 Fianchi, L, E1186
 Fibach, E, P284
 Fidalgo, T, E1593
 Fidarova, Z, E982
 Fidy, K, E827
 Fiedler, W, S473, P533, P535, E868, E870
 Fielding, A, S802, P160, P164, E1476
 Fifer, S, E1470
 Figdor, C, E1353
 Figuera, A, E891, E1113, E1565
 Figueroa, M, E1173
Figueroa, R, S444
 Filaci, G, P586, E1390
 Fili, C, E1496
 Filocamo, M, E1077
 Filonenko, K, E1127
 Filosa, A, P290, P393, P399, E1570, E1575
 Finazzi, G, P760, P766, E1315
 Finazzi, M, E1315
 Finck, B, E1147
 Finelli, C, P658, P667
 Fineman, R, E1034
 Finetti, P, P183
 Fingerle-Rowson, G, S774, S775
 Fink, A, E1025
 Fink, A-M, S464, P251
 Finke, J, S797, S798, P388
 Finkelstein, D, P271
 Finocchi, A, P717
 Fiore, C, P188, E884
 Fioredda, F, P234, P575, P717, E1440
 Fioretti, G, P393
 Fiori, S, E1346
 Fiorini, E, P321
 Fiorino, D, P290
 Firatli Tu_Jular, T, P281, E1446
 Firczuk, M, E827
 Firsova, M, E1227, E1295
 Fischer, A, P350
 Fischer, J, S446, P272
 Fischer, K, S464, P236, P251, P585, E1025
 Fischer, L, E1402
 Fischer, M, P648
 Fischer, T, P535, E865
 Fischer, U, S436
 Fischer von Weikersthal, L, S464
 Fisher, M, E1218
 Fita, J, E1156
 Fitoussi, O, P217
 Fitzgibbon, J, P303, P532
 Fiz, F, P283
 Flachs, E, E1347
 Flaherty, L, P526
 Flaishon, L, P548
Flasinski, M, S789
 Fleischman, A, P377, E1321, E1339
 Fleischman, R, P279
 Fleming, J, E1453
 Fleming, S, E848, E929
 Fletcher, T, P319
 Fleury, I, S468
 Flevari, P, E1485
 Flicek, P, S117
 Flick, E, P349
 Flickinger, Z, S439
 Flindt, T, P706, E1320
 Flinn, I, S471, S777, E1130
 Flintrop, M, S494
 Fløisand, Y, E866, E1501
 Flörcken, A, P172
 Florensa, L, E1417
 Flores, G, E1182
 Flores, W, S474
 Florido Ortega, Y, E1327
 Florschütz, A, S502
 Flotho, C, P350, P353
 Flowers, C, S468, S772
 Flowers, M, S492
 Flynt, E, E1203
 Foà, R, P322, P520
 Foà, R, S111, S800, P166, P306, E976, E989, E1000, E1017, E1408
 Fodor, W, S147
 Fogli, M, P607
 Foglieni, B, E1606
 Foglietta, M, E999
 Folber, F, E841
 Foli, A, P684, E1243
 Folkvaljon, Y, P704
 Follmann, M, E1251
 Follo, M, E1355
 Follows, G, S469, S776, P276, E938
 Foltz, L, P702, P706, E1320, E1333, E1334
 Fominykh, M, E1313
 Foncillas, M, E1038
 Foncuberta, C, E1508
 Fonder, A, P673, E1240, E1241
 Fong, E, P620
 Font, L, S790
 Fontana, D, P570
 Fontana, M, E882, E898
 Fontana, R, E967
 Fontanelli, G, E946
 Fontcuberta, J, P759, P765
 Foon, K, P634
 Forcade, E, S798
 Forcella, D, E1145
 Forcina, A, S806
 Forconi, F, S770, P587, E996
 Forde, E, E873
 Fordham, N, P270
 Forero-Torres, A, P633, E1142
 Forés, R, E972
 Forestieri, G, P282
 Forman, S, P186
 Formigaro, L, E1020
 Fornecker, L-M, S105, P217
 Forni, G, P288, P400, E1482, E1491
 Foroni, L, S423
 Forrest, D, P581, E1557
 Forslund, A, P158
 Försti, A, P295
 Forstpointner, R, S775
 Forsyth, C, E1350
 Forsythe, A, E925, E945
 Forte, D, E1309
 Forthun, R, E903
 Foster, K, P264
 Foster, R, E1035
 Foster, T, P258
 Fotiou, D, P337, E1266
 Fotzi, I, P714
 Foucar, K, E923
 Fouzia, O, E1275, E1479
 Fowler, A, P276
 Fowler, N, S772, E1129
 Fox, C, S770, P245, P589, E1037
 Fox, M-L, P703
 Foxwell, D, E1529
 Fraboni, D, E908
 Fracchiolla, N, S111, P644
 Fragoso, R, E822
 Frairia, C, P214, E1332
 Fram, R, E944, E1184, E1191, E1196
 Franceschini, L, P607
 Franchini, E, E882, E898
 Francia di Celle, P, P214
 Francomm, S, E1483
 Frange, P, S131
 Frank, S, E1524
 Franke, G-N, P261, P380
 Frankfurt, O, S472
 Franklin, J, E1180
 Fraquelli, M, P396

- Fraser, P, S117
Frassoni, F, P658, E1226
Frederiksen, H, E1347
Freedman, A, P237
Freedman, M, P237
Freeman, S, S114
Freeman, T, E1509
Freiberger, T, P711
Freiburghaus, C, S109
Freilone, R, P667
Freise, K, E1139
Freitas, C, E1102
Freitas-Tavares, P, E1044, E1047, E1064
Frenzel, L, E1236, E1386
Frey, S, E865
Freysoeldt, B, E1402
Freytag, N, E1387
Frezza, C, S136
Frezza, F, E1005, E1006, E1011
Fridrik, M, P336
Friis, L, P193, E932
Frismantas, V, P159
Fritz, C, P188, E884
Frobel, J, E1106
Fröhling, S, P528
Froňková, E, S801, P711
Frost Andersen, N, E1250
Fruchtman, S, S488
Fu, C, E1520
Fu, J-F, E872
Fu, R, P724
Fuchs, D, P595
Fuchs, M, S150, P275
Fuchs, R, S424
Fuentes, I, P721, E1456
Fuertes, M, P737
Fugazza, E, E1293
Fugazza, G, E915
Fugere, D, E894, E1090
Fuji, S, P385
Fujii, T, E1438
Fujii, Y, S799
Fujimoto, A, E1552
Fujimoto, K, P301
Fujioka, I, E1058, E1066
Fujisawa, M, P301
Fujisawa, S, E962
Fujisawa, Y, P642
Fujishima, Y, P642
Fujita, H, E1058, E1066
Fujita, J, E1370
Fujiwara, H, P753
Fujiwara, R, E1100
Fujiwara, T, P612, E1104
Fukuda, T, P385, P389, E1522
Fukuhara, N, P612, E1104, E1139
Fukumoto, K, P301
Fukushima, N, E1516
Fulciniti, M, P321, E1200, E1206
Fumagalli, M, P163, P520
Fumagalli, S, E1606
Furlan, F, E1077
Furman, R, S769
Furness, A, E1208
Furuhata, K, P401
Futreal, A, S489, S496, P192, P207, P241, P550, E830
Gaballa, S, E914
Gabdoulline, R, S494
Gabelier, L, P217
Gabelli, M, P738
Gabet, Y, E1107
Gabillaud, C, E1001, E1361
Gabriel, S, P236
Gabriel, S, E1478
Gabrielli, S, S434
Gachard, N, E1010
Gad, G, E1093
Gadisseur, A, S141
Gaemers, S, P719
Gagliardi, V, E1560
Gaidano, G, P244, P282, P304, P358, P583, P616, P667, E1017, E1186
Gaidano, V, P658, P667
Gaidzik, V, P533, P535, E864, E868, E870
Gaillard, J-B, E1001, E1361
Gaillard, B, E1001, E1361
Gainaru, G, E1120
Gajewski, M, P710
Gaken, J, P541
Galactéros, F, S451, E1082
Galamburn, C, S131
Galas-Filipowicz, D, E1208
Galaverna, F, S146, S495, P381, E1505
Galazka, A, E1257
Galaznik, A, E944, E973, E1184, E1191, E1196
Gale, R, P511
Gale, R, P597
Galende, J, E1014
Galera, A, P580
Galletto, R, E1094
Galicia, T, E1604
Galieni, P, E946, E1247, E1561
Galigalidou, C, E1407
Galimberti, S, S485, P256, P599, P604, P671, E1042, E1043, E1048, E1318, E1397, E1408
Galindo Vázquez, O, E1473
Galinsky, J, P731, E1470
Gallagher, D, P761
Gallagher, M, E1550
Gallamini, A, S413, P163, E1533
Gallardo, D, S790, P202
Gallardo, M, P329, P590, P695, E891, E899
Galleu, A, S817
Galli, A, S123
Galli, E, E1124
Galli, M, S102, S410
Gallipoli, P, S136
Galteland, E, P613
Galtseva, I, E861, E934, E982, E1092, E1096, E1098, E1295, E1559
Galullo, V, S500
Galunic-Bilic, L, E971
Galvez, E, S144, P580
Galvez, K, E1074
Galy, A, S144
Gamage, O, P347
Gamba, S, P760, P766
Gambacorti-Passerini, C, S425, P570, E1351
Gambale, A, S811
Gambella, M, S102, P322
Gambella, M, E854
Gamberi, B, S410, P343, E1250
Gamberini, R, S129
Gammon, G, S475, E924
Gañán-Gómez, I, S489, P321, P652
Gandhi, V, S463, P209
Ganeva, P, E1556
Gangat, N, P165
Ganser, A, S494, S798, P388, P533, P535, P537, E864, E868, E870, E1105, E1506
Ganuza Fernandez, M, P271, E1099
Ganzetti, M, E1293
Gao, L, S457
Garabet, L, E1434
Garate, L, E1225
Garaud, S, E994
Garavelli, S, E1216, E1268
Garaventa, A, E955
Garayoa, M, E1222
Garbarino, L, S796
Garcia, A, S790, P202
Garcia, B, P528
Garcia, E, P756
Garcia, J, E1508
Garcia, N, E1381
Garcia, O, E1396
Garcia, P, E1508
Garcia, P, S119
Garcia, R, P554
García-Álvarez, M, E887
García Arroba, J, E1426
García-Ballesteros, C, E1394
García-Barberá, N, P573
Garcia-Cadenas, I, S145, P746, E1160

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Garcia-Cuellar, M, P527
Garcia de Andoin, N, S144
García de Coca, A, P329, E1014
García de Veas Silva, J, E1271, E1283
García-Guerrero, E, P681
García-Gutiérrez, V, P601, P609, P703, E1051
García Iglesias, L, P376
García-Lozano, J, P696
Garcia-Malo, M, P402, E1013
García-Manero, G, S474, S487, S488, S489, S496, P170, P192, P200, P207, P209, P315, P317, P321, P352, P518, P550, P652, P665, E830, E913, E1192
Garcia Manteiga, J, E1232
García-Martín, L, E1543
García-Montero, A, P713
García-Mouriz, A, S444
Garcia Muret, P, E963
Garcia-Ormeña, N, E1051
García-Pavía, P, P685
García-Ramírez, I, S148
García-Ramírez, P, P205, E1604
García Raso, A, E1596
García Ruiz, M, P768
García-Sanz, R, S801, S782, P679, E887, E1246, E1278, E1543
Garcia Sobreviela, M, E1412
García-Torralba, A, E1081
Garcia-Vargas, J, S776
Garcia Vela, J, E891
Garciaz, S, P183
Garçon, L, S453, E1082
Garderet, L, P345
Gardie, B, P712
Gardner, H, S469
Gardner, K, P619
Garg, A, S441
Garg, M, S407, S781
Garitano-Trojaola, A, P320
Garmo, H, P704
Garrec, C, P712
Garrel, C, E1178
Garrido, A, S790, P202
Garrido, C, E1356
Garris, R, P170, P518, P739
Garside, J, E1024
Garzon, R, P174, P528
Garzon, S, S804
Garzone, G, E1207
Gasal, E, E1180
Gascoyne, R, P297
Gasior, M, E1546, E1563
Gasior, Y, S487
Gasova, Z, E1540
Gasparetto, C, P349, P675, E1239, E1277
Gassner, F, P195, P558
Gastineau, D, P254, E1502
Gastl, G, P595, P707
Gattei, V, P583, P588
Gattermann, N, P601, E937
Gatti, A, E821
Gattillo, S, S128
Gaudig, M, E1281, E1291
Gaudio, F, E1406, E1561
Gaulard, P, P301
Gaumann, A, E1326
Gautam, A, P637
Gauthier, G, E1035
Gavarotti, P, S413
Gavathiotis, E, S135
Gavin, A-C, S122
Gavriatopoulou, M, S415, P337, E1249, E1292
Gavriliina, O, E836, E860
Gay, F, S410, P322, P341
Gaya Valls, A, E983
Gayoso, J, E1113
Gazzola, A, E1408
Gbandi, E, S791
Gdovin, J, P728, E1466
Ge, Z, E863
Gecek, I, E1329
Geçgel, F, E1446
Gedde-Dahl, T, E866, E1057, E1501
Geelen, I, P262, E1057
Geer, T, S424
Geerdens, E, S439, P151, P152
Geeta, G, P570
Geffers, R, S494, E878
Geffroy, S, E876
Gehrs, L, S794
Geiger, H, E1109
Geiger, O, S419
Geirnaert, M, P732
Geisler, C, S109
Geisler, S, P595
Geissler, K, S419
Gemdzian, E, E1295
Gemenetzi, K, P242
Genadieva-Stavrik, S, E1471
Genel, F, E1427
Genesca, E, E831
Geneste, O, P175
Geng, H, P353
Geng, S-Y, P726
Gengenbacher, A, E1393
Gengrinovitch, S, P548
Gentile, M, P586, E1017, E1390
Gentili, S, P341
Gentille Sanchez, C, E950, E1146
Gentner, B, P544
Genuardi, E, E1408
Genuardi, M, E1247
Genutis, L, E883
Geoffroy, V, P354
Georgantis, S, E1600
George, T, S788, E923
Georgiev, O, E1155
Georgievski, B, E1471
Georgin-Lavialle, S, P709
Geraldès, C, E1287, E1297
Geranio, G, P715, E844
Gerardi, C, P290
Gerasimou, P, S420
Gerbino, E, E847
Gerds, A, P662, P699, P701, E1343
Gerecitano, J, P564
Gerhäuser, C, P663
Germing, U, S494, P533, P664, P666, E868, E870, E937
Gerofotis, A, E1233, E1292
Geron, I, S436
Gerrie, A, P581, E1557
Gershon, P, P301
Gerstung, M, E1201
Gertz, M, S104, P331, P673, E1240, E1241
Gervas Arruga, J, E1412
Geskin, L, P637
Getz, G, P236
Geyer, H, P359, P377, E1321, E1339
Ghanem, A, E1578
Ghanima, W, E1434, E1435
Ghavamzadeh, A, S493
Ghazal, K, E1082
Ghazaly, E, E1566
Ghazi, S, E1514
Ghazzawi, M, E1344
Gheysens, O, P565
Ghia, P, S461, S462, P244, P378, E997, E1086
Ghilardi, R, P717, E1420
Ghione, P, P297, P304
Ghiurau, C, P175
Ghizzinardi, M, E1232
Ghobadi, A, P522
Ghobrial, I, S779, P323, E1354
Ghogale, S, E837, E843
Ghori, R, S783

- Ghoti, H, P284
 Ghysdael, J, S440
 Giaccherini, C, P760
 Giacchetti, A, P636
 Giagounidis, A, S122, P666, E937, E1181
 Giai Via, V, P658
 Giaimo, M, E1440
 Giallongo, C, E1214, E1232
 Giammarco, S, P232
 Gianelli, U, E1346
 Giancesin, B, P400, E1482
 Gianfelici, V, S800, P166
 Giangregorio, T, S433
 Giannakoulas, N, S415
 Giannakoulas, N, E1266
 Giannarelli, D, E1021, E1030
 Gianni, A, S413, S778
Giannoni, L, S796
 Giannopoulos, K, E888, E1262
 Giannopoulou, E, E1233, E1266
 Giannotta, J, P616, E1078
 Giannouli, S, S415
 Giannoullia, P, P280
 Giansily Blaizot, M, P289
 Giantomassi, F, P636, E1136
 Giardino, S, P234
 Giatra, C, E895
 Gibson, B, P668
 Gibson, C, P332
 Giebel, S, S797
 Giglio, F, S128
 Giglio, G, P604
 Gil, L, E1079, E1193
 Gil-Bazo, I, S444
 Gilboa, D, E1107
 Giles, F, P601
 Giles, F, P595
 Gilestro, M, S102
 Gilkes, A, S114
 Gill, J, P566
 Gillor, D, P568
 Giménez Pérez, T, E1426
 Gimeno, E, E1027
 Gimondi, S, E1201
 Gimsing, P, S501, P324
 Giné, E, E1137, E1369
 Gineikiene, E, E1311
 Gini, G, S413, S778, E1123
 Gioia, D, P667
 Giona, F, P234, E1164
 Gionfriddo, I, P173
 Giordano, C, P277, E1125
 Giordano, P, P365
 Giorgino, T, P351
 Giotopoulos, G, S136
 Giraldo, MD, P, P702, E1051, E1134, E1333, E1334, E1410, E1412
 Giralt, S, P740, P745, P748, E1252, E1532, E1554
 Girard, R, S499
 Girardi, K, E1167
 Girardi, T, S439, P152, P153
 Giraud, C, P345
 Giraud, M, S801
 Girmenia, C, E1145
 Girnius, S, E977
 Girodon, F, P712
 Gironella, M, S409, P376, P688
 Girot, R, E1495
 Girschikofsky, M, P559
 Gisslinger, B, P707
 Gisslinger, H, S787, P707
 Giuliani, N, S410, P321, E1223, E1237, E1247
 Giuliano, M, P393
 Giustacchini, A, S421
 Gjadrov-Kuvezdic, K, E1296
 Gjertsen, B, P181, E866, E903, E1057
 Gkirkas, K, P280
 Gkoutasias, A, E1416
 Glader, B, S451
 Glaser, N, P243
 Glazanova, T, E986
 Gleixner, K, P693, E1071
 Glembotsky, A, P365
 Glinshchikova, O, E1403, E1409
 Glossmann, J-P, E1251
 Gluckman, E, E1495
 Gmati, G, E1514
 Gnan, C, P365
 Gniot, M, P602, P611
 Go, R, P331, P673, E1240, E1274
 Go, S-I, E968
 Go, W, S466, P522
 Goardon, N, S140
 Gobbi, G, P528
 Gobbi, M, P283, E854, E915, E919, E933, E1299, E1505
 Gobessi, S, E993
 Godeau, B, S453
 Godfrey, L, P540
 Godon, C, E1001
 Godoy, A, E887
 Goebeler, M, S424, P255
 Goecke, T, E1106
 Goede, J, E1180
 Goede, V, P251, E1025
 Goekbuget, N, P516
 Goergen, H, S150
 Goerlich, D, P546
 Gogishvili, T, P681
 Gogos, D, E1266
 Göhring, G, S494, P533
 Goicoechea, I, E1368
 Gökbüget, N, P519, P525
 Göksel, O, P266
 Gołąb, J, S125, E827, E1359, E1385
 Goldberg, S, E922
 Golding, J, S503
 Goldman, F, E1484
 Goldschmidt, H, S458, P334, E1251, E1253, E1269
 Goldschmidt, N, E1034
 Göllner, S, E927
 Golobokov, A, P307
 Goma, W, S440
 Gomáriz, Á, P266
 Gombert, M, S436
 Gomes, M, E988
 Gomes, S, E1586
 Gomez, C, P554, E1086
 Gómez, E, E1604
 Gómez, M, P703
 Gómez, P, E831
 Gomez, V, E1565
 Gomez-Almaguer, D, E1306, E1415
 Gómez Casares, M, P601, P696, P703, E1327
 Gómez-Castañeda, E, P591
 Gomez-De Leon, A, E1306, E1415
 Gómez-Espuch, J, E953
 Gómez-Llonín, A, E1027
 Gómez Morales, M, P768
 Gómez Roncero, M, E983
 Gonçalves, A, E1064, E1287
 Gonçalves, J, E1586
 Gonçalves, L, E1586
 Gong, B, E911, E916
 Gong, X, E911, E916
 Gong, X, P182
 Gong, Y, P224
 Gonsalves, W, P331, P673, E1240
 Gonzales, F, E876
 Gonzalez, A, P554
 González, B, P376, P554
 Gonzalez, J, S790, E1182, E1349
 González, M, S115, E1169, E1014, E1019
 Gonzalez, M, E1274
 González, N, P721
 González, Y, P688, E1278
 González Barca, E, S470, E957, E1394
 Gonzalez-Campos, J, S804, P213
 González-Díaz, M, E887
 González-Espinosa, M, P696
 Gonzalez-Farre, B, E1394
 Gonzalez Garcia, M-E, P329
 González-Gascón y Marín, I, E1038
 González Huerta, A, E1530
 González-López, E, P685

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- González-López, T, P329, P720
 González Martín, J, E1327
 González Martínez, T, E1327
 Gonzalez-McQuire, S, E1272, E1298
 González-Méndez, L, E1222
 González Muñoz, S, E1530
 Gonzalez-Murillo, A, P510, P513
 González Pérez, M, E1327
 González-Porras, J, P361, E1451, E1592
 González-Pozas, F, E893
 González Rodríguez, A, E1530
 Gonzalez Velez, M, E1276, E1288
 Goo, B-K, E1177
 Goodell, M, P173
 Gooriah, M, E1269
 Goossens, S, S438, P156, E1358
 Gopal, A, E1129
 Gopalakrishna, P, P601
 Gopcsa, L, P382, E1535
 Göransson-Kultima, H, P244
 Gora-Tybor, J, P594, E1061
 Gorbach, O, E1382
 Gorbenko, A, E1314
 Gordon, T, S474
 Gore, L, S422
 Goretti, R, P667
 Górka, M, E1193
 Gorniak, M, E848
 Gorniak, P, E886
 Gorrochategui, J, P554, E1086
 Gorur, V, E978
 Goswami, P, E1476
 Goswami, R, P682
 Goteri, G, P636, E1136
 Göthert, J, E1118
 Gotić, M, E1316, E1319, E1328
 Gotlib, J, S785, S788, P351, P699, P701, E1343
 Goto, H, E859
 Gotoh, M, E1046, E1072
 Gotoh, N, E1447, E1607
 Gottardi, D, S413
 Gottardi, E, P599
 Gottardi, M, E930
 Gottgens, B, S140
 Gottlieb, D, E1140
 Gottlieb, E, S481
 Götz, M, E1084
 Götze, K, P533, P666
 Gouble, A, E1094
 Goudevenou, K, P624
 Goulard, M, P657
 Gounis, M, E1083
 Gourin, M, E1458
 Gowin, K, S505
 Goyal, G, E1502
 Goyert, N, P375
 Goynes, J, S484
 Gó_d_, S, E920
 Gözmen, S, E1427
 Gozzetti, A, E1215
 Gozzini, A, P604, P605, E1042, E1043
 Grace, C, E905, E1176
 Grace, R, S451
 Grachev, A, E1227
 Gracia-Aznarez, F, P198
 Graczyk-Jarzynka, A, E827, E1359
 Graef, T, E1246
 Graf, C, E1569
 Graham, C, P326
 Grainger, J, P367
 Gramatzki, M, P341, E1506
 Grammatico, S, S102
 Granada, I, E831
 Granata, A, E1549
 Granell, M, E1278
 Granston, T, P699, P701
 Grasedieck, S, P182
 Grassetonio, E, P399
 Grassi, S, P599, E1048, E1318, E1408
 Grasso, M, S410, P322
 Grattan, C, P709
 Gratwohl, A, S424
 Graux, C, S112
 Gravetti, A, E1459
 Gray, N, S421, E1110
 Graziadei, G, S128, P396, E1483, E1576
 Grebenyuk, L, E1227
 Grebien, F, S133, S134
 Greco, M, P256
 Greco, R, S806
 Green, A, S421
 Green, C, P662
 Green, D, P344
 Greenbaum, U, E1034
 Greenberg, P, P662
 Greenwood, M, E950
 Gregora, E, E1272, E1290, E1298
 Gregory, W, S407, S781
 Greil, J, P382
 Greil, R, S150, P195, P336, P558, P707
 Greinacher, A, P364
 Greiner, J, E1084
 Greinix, H, E1363, E1395
 Greisshammer, M, S784
 Grembecka, J, S134
 Grentzelias, D, P280
 Gressick, L, P564
 Gressin, R, S105
 Greten, F, S809
 Grevent, D, P631
 Gribabi, D, P280
 Gribanova, E, E836, E1227
 Gribben, J, S770, P264, P532, P585, E869, E1212, E1380, E1566
 Griesshammer, M, P700, P704, E1333, E1334, E1335
 Griffin, L, E894, E1090
 Griffith, K, P680
 Griffiths, A, E1534
 Griffiths, E, E1192
 Grifoni, F, P355
 Grigg, A, E1431
 Griggio, V, E999
 Grigoriadis, G, E848
 Grigoropoulos, N, P646
 Grigoropoulos, N, P276
 Griguolo, D, E1065
 Grima, D, P375
 Grimaldi-Bensouda, L, E1439
 Grimm, J, P380
 Grimwade, D, S114, P176
 Grioni, A, S801
 Grisariu, S, P744
 Gri_kevi_ius, L, E828, E1311, E1399
 Gritsaev, S, E1568
 Groarke, E, E1187
 Grob, T, P538
 Groen, R, P265, E1221
 Groenen, P, S801, P239
 Grogan, M, E1280
 Grohmann-Izay, B, S787, P707
 Gromek, T, E888, E920
 Grønbaek, K, S109, S486, P324, E1115
 Grootes, M, E1499
 Grosicki, S, S456, P248, P338
 Grossbard, E, S435
 Grossi, A, P234, P575, E1440
 Grossi, R, E1318, E1397
 Grosso, M, P393
 Grozdanova, A, E1471
 Gruber, A, S501, P338
 Grundschober, E, E1045
 Grunig Humberto da Silva, D, E1492
 Grupp, S, S476, S477, S808, P517, P650, P740, P748, E1532, E1554
 Grzasko, N, P338, E888, E1257
 Gu, C, E956
 Gu, L, S103
 Gu, R, E911, E916

- Gu, Y, E863
 Gu, Z, P350
 Gu-Trantien, C, E994
 Gualandi, F, S796
 Gualberto, A, P571, E834
 Guan, Y, P362
 Guardabasso, V, E1164
 Guardalben, E, E1020
 Guardia, R, S790, P202, E831
 Guardo, D, E854, E915, E919, E933, E1505
 Guariglia, R, E967
 Guarini, A, S800, P166, E989, E1000, E1408
 Guarneri, I, E1606
 Gudiol, C, S804
 Guegan, N, E1386
 Gueli, A, S778
 Guenechea, G, S144, P229
 Guerin, A, E1035
 Guérin, E, E1010
 Guerra Assunção, J, P303
 Guerrero, P, E1349
 Guerrini, F, P599, E1048, E1318
 Guglielmelli, P, S784, P351, P702, P706, E1320, E1334
Gugliotta, G, S485, P358, P600, P604, P605
 Gugliotta, L, P358, P704
 Guidez, S, P345, E1135
 Guieze, R, P316
 Guigó, R, S117
 Guihard, S, E876
 Guilherme, R, E1336
 Guilhot, F, P603, E1052
 Guilhot, J, S426, P255
 Guillaume, N, E1537
 Guillot, O, P289
 Guimarães, J, E988
 Guinot, M, E953
 Guitton, C, S453, E1082
 Gujar, J, S119
 Gujral, S, P169, E837, E843
 Gulácsi, L, P730
 Gulbas, Z, P281, E1564
 Gulbis, A, E914
 Guldberg, P, S109
 Gülez, N, E1427
 Gulino, A, P586, E1390
 Gulla, A, E1206
 Gullberg, U, E826
 Gumbs, C, P192, P207, P241, P550, E830
 Gumenyuk, S, E1145
 Gumruk, F, E855, E1157, E1598, E1603
 Gunawan, A, E1163
 Gunay, Y, E1159
 Gundry, M, P173
 Gunes, A, E1603
 Gungor, T, S452
 Gunji, M, P171
 Gunsilius, E, P336
 Günther, A, P341
 Guo, D, E931, E1152
 Guo, D, E1152
 Guo, Y, P224
 Guolo, F, E854, E915, E919, E933, E1505
 Gupta, D, P553
 Gupta, I, P215
 Gupta, N, P339
 Gupta, P, P761
 Gupta, R, E981
 Gupta, T, E981
 Gupta, V, S786, P699, P701, P702, P708, E1324, E1333, E1334, E1343
 Gurung, S, P347
 Gustovic, P, P369
 Gut, I, S117, P300
 Gut, M, S117
 Guthrie, S, S104, P373, E1280, E1468
 Gutierrez, A, E1555
 Gutiérrez, E, P720
 Gutierrez, L, P404, P584, E1310
 Gutierrez, M, P633
 Gutierrez, N, P329, P688, E887, E1543
 Gutierrez-Aguirre, C, E1415
 Gutjahr, J, P588
 Gutman, J, P386
 Gutwein, O, E1121
 Guzicka-Kazimierzczak, R, E1193
 Guzman, A, P173
 Gyan, E, S105, P217, P316, P572
 Gygi, S, S428
 Györfy, B, S133
 Ha, J-S, E850, E871
 Haaber, J, E1367
 Haack, K, P342
 Haas, R, P664, E937
 Haas, S, P663
 Haas, T, S446, S818, P272
 Haase, D, P226, P533
 Habeeb, N, E1580
 Haber, M, P154
 Habermeier, A, E992
 Hacein-Bey-Abina, S, P631
 Hadfield, A, E1291
 Hadi, M, P532
 Hadland, B, E1099
 Hadzidimitriou, A, P242, E997, E1407
 Hadzijušufovic, E, P693
 Haeckel, R, E1117
 Haenel, M, P216, P555
 Haferlach, C, S121, S424, S461, P199, P549, E1312
 Haferlach, T, S121, P199, P549, E1312
 Hagihara, M, E962
 Hagiwara, M, P372
 Hah, J, E850
 Haigh, J, S438, E1358
 Haimes, J, E894
 Haioun, C, S105, S106
 Hájek, R, S101, S102, P333, P336, P339, P672, E1250, E1272, E1290, E1298
 Hale, M, S500
 Halfmeyer, I, P231
 Halkes, C, S447
 Halkes, S, P576
 Hall, G, P668
 Hall, R, E1431
 Hall, T, E1400
 Hall, T, P271
 Hallam, T, P328, E1373
 Hallek, M, S464, S771, P216, P222, P236, P251, P585, E1025, E1344
 Hallworth, P, P278
 Halova, I, P273
 Haltalli, M, E875
 Haltrich, I, E820
 Hama, A, P171
 Hamada, M, P171
 Hamadani, M, S408, E1523
 Hamaguchi, I, P401
 Hamblin, A, S122, P668
 Hameiri-Grossman, M, S436
 Hamey, F, S140
 Hamidou, M, P716
 Hamilton, J, S477
 Hamilton, L, E973
 Hamlin, P, S773
 Hamman, A, E1356
 Hammarlund, Y, S805
 Hamsten, A, P759, P765
 Han, B, E939
 Han, J, P286, P288
 Han, J, E1404
 Han, N, S430
 Han, P, P366
 Han, Q, E863
 Han, T, E1498
 Han, T-T, E1101
 Han, W, E1503, E1511
 Han, W, P387, P752, E1498, E1515
 Han, Y, P569
 Han, Y, P390, E1520
 Hanada, R, S799
 Hanamura, I, P642, E1210
 Hanash, A, S446
 Hancock, J, S801
 Handa, H, P327, E1447, E1607

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Handgretinger, R, P521, E840
Hänel, M, S424, S502, P222
Hänenberg, H, E878
Hangaishi, A, P537
Hanna, M, P237
Hanousek, J, E1303
Hansen, J, S109, S486
Hansen, M, P184
Hansen, M, E1367
Hansen, M, S132
Hansson, J, P172
Hansson, M, S501, P338, P677
Hantschel, O, P596
Häntschel, J, P380
Hanzel, S, P255
Hao, Y, P285
Hara, T, E1230
Haralambieva, E, E1536
Harankhedkar, S, E981
Harbi, S, E1547
Hardin, J, P349, E1239, E1277
Harding, S, E1304
Harhalakis, N, P280
Hari, P, S408, P735, E1523
Harigae, H, P612, E1104
Harmeier, A, P392
Harrington, Y, P233
Harris, D, E991
Harrison, C, S439, P152
Harrison, C, S786, P697, P699, P701, P704, P706, E1320, E1338, E1343
Harrison, S, S460
Harrison, T, E1090
Hartmann, K, S788
Hartmann, T, P195, P558, P588
Hartwig, U, P626, P629
Harvey, L, P526
Härzschel, A, P588
Hasan, E, E1580
Hasbak, P, P221
Hasegawa, Y, E1519
Hasford, J, S424
Hashii, Y, S799
Hashimoto, D, E859
Hashimoto, H, P196
Hashimoto, M, P689
Hashmi, S, E1502
Hasibeder, A, P643, P651
Hasle, H, P350
Hassanain, O, E926
Hasselbalch, H, P602, P697, E1347
Hassoun, H, E1252
Hastings, S, E1055
Hata, H, E1205
Hatake, K, E1139
Hatjiharissi, E, S415
Hatta, S, E1104
Hatta, Y, E1058, E1066
Hatzimichael, E, P280, E1266
Hatzl, S, S419
Hauer, J, S148
Haukås, E, S501, P613
Havariyoun, G, E1242
Haverkos, B, P386
Havyarimana, S, E1143
Hawkins, E, E875
Hawrylecka, D, E1262
Haws, H, E881, E902, E1204
Hayasaka, K, P360
Hayasaka, N, E1213
Hayashi, M, E1229
Hayashi, Y, S799
Hayman, S, P331, P673, E1240, E1241
Hayslip, J, S473
Hazenberg, B, S411
Hazenberg, M, S448
He, A, S103
He, C, P224
He, J, E1322
He, S, E1431
He, X, P390
He, Y, P363, E1503, E1511
Healey, M, P406
Healy, N, E1024
Hearn, K, S488, P317
Heath, S, S117, P300
Heather, S, E1557
Hebart, H, S464, P700
Hebraud, B, P345
Heckl, D, P177
Heckman, C, P181
Heeg, B, E842
Heemskerk, J, P760
Heffner, L, E1246
Hegde, S, S149
Hege, K, S142, S467
Hegenbart, U, S411, P342
Heger, A, P246
Hehlmann, R, S424
Heidegger, S, S818
Heidel, F, P700
Heideveld, E, S132
Heilmann-Heimbach, S, E1106
Heim, D, S424
Hein, N, E1388
Heinrich, M, P731
Heintges, T, P216, P222
Hejazi, A, E1514
Helal, B, P398
Helbling, P, P266
Held, G, P216, P222, P533, E864
Helevaut, N, E876
Helf, M, P663
Helgason, G, S481
Heller, G, E1366
Heller, P, P365
Hellman, A, S785, P235
Hellmann, A, S435
Hellmann, A, P601, E1061
Hellström-Lindberg, E, S122, S486, E1197
Hellwig, D, P216
Hemmelder, M, P683
Hemminki, K, P295
Henderson, M, P154
Henderson, S, P228
Hendra, H, E978
Hendrickson, S, S474
Henig, I, P548, P753
Hennenfent, K, E973
Henrick, P, S779
Henriques, A, P713
Henry, J, E1208
Hentrich, M, P568
Hentze, M, P284
Heras, C, E1038
Heras, I, S790, P402, E1444
Herbrecht, R, E1150
Herbst, R, P255, P555
Herich-Terhürne, D, P582
Herishanu, Y, E1034, E1121
Herling, C, E1025
Herling, M, E1376
Herman, S, P588
Hermetet, F, S139
Hermida, J, S444
Hermine, O, S105, S124, S788, P268, P631, P709, P716, E1236, E1360, E1386
Hermouet, S, S499
Hernandez, D, S790
Hernández, J, E1038
Hernandez, J, E1278
Hernández, M, S409, E1250
Hernández, M, P688, E1278
Hernandez, P, P554, E1086
Hernández-Boluda, J, P703, E1310
Hernández-Díaz, P, P213
Hernández-García, S, E1222
Hernandez-Marques, C, P510
Hernández-Rivas, J, P316, P318, P361, P655, E1014, E1038, E1169, E1451

- Hernández Rivas, J, P554, P635,
E1014, E1051, E1181
Hernandez-Rodriguez, A, E1396
Hernández Sánchez, J, P318, P361,
P655, E1169, E1451
Hernández-Sánchez, M, P655, E1014,
E1038
Hernando-Rodríguez, M, P755
Herndlhofer, S, P693, E1071
Herold, M, S775
Herold, T, P546, E885
Herr, W, S145
Herraez, I, E1341
Herráez, S, E1183
Herraez, V, P584
Herrera, A, S468
Herrera, P, P554
Herrmann, C, P172
Herrmann, D, S801, S803
Herrmann, O, S482
Hertenstein, B, S424
Hertzberg, M, S775
Hervey, V, P225
Herzig, R, P279
Hesham, M, E1585
Heshusius, S, S132
Hess, G, E1129
Hesson, L, P654
Hetzner, K, P527
Heukelom, S, P190
Heumüller, A, P243, P656
Heuser, M, S494, P533, P535, P537,
E864, E868, E870, E1105
Hexner, E, S788
Heyes, E, S134
Hidaka, M, P385, E1522
Hidalgo, F, P543
Hiddemann, W, S774, S775, P546,
E867, E877, E885, E1402
Hielscher, T, E1253
Hiemeyer, F, S776
Higby, K, S428
Hijiyá, N, S422
Hild, S, P243
Hildebrandt, B, P664, E937
Hildebrandt, G, P279
Hilden, P, P745
Hilgendorf, I, P647
Hill, A, P235, P369
Hill, B, S469
Hill, J, S110, P560
Hillengass, J, E1253
Hillmen, P, S465, S498, S769, S770,
S771, P245, P252, P589
Hills, R, S114, S475, P176
Himberlin, C, P572
Hino, M, P263
Hiradate, Y, P401
Hiram-Bab, S, E1107
Hiramatsu, H, S476
Hiramoto, N, P196
Hirase, C, P314
Hirata, J, S106, P253
Hirata, M, E1162
Hiroaki, M, S124
Hironaka, Y, P691
Hirschmann, J, E1117
Hivert, B, E1135
Hixon, J, P614
Hjorth-Hansen, H, S426, P593, E1057
Hlozkova, M, E1003
Hlusi, A, E1432
Ho, A, S122, S424, P172, P179, P206,
P342
Ho, J, P708
Ho, P, P674, E1244, E1289
Ho, P, P201
Ho Yew Leng, A, P646
Hoang, K, P236
Hoang-Xuan, K, E1374
Hoarty, M, S500
Hobbs, M, P673, E1240
Hochepped, T, S438, E1358
Hochhaus, A, S424, S425, S426, P595,
P601, P603, P647, P648, P700,
E1052, E1060
Höchsmann, B, S498, P369
Hockaday, A, P252
Hodges, S, E1430
Hodson, A, P276
Hoehstetter, M, E1025
Hoefler, G, S419, E879
Hoelbl-Kovacic, A, E1045, E1366
Hoell, J, S429
Hoellein, A, P199
Hoelzer, D, P516
Hoermann, G, E1045, E1071
Hoever, P, E1142
Hof, J, P155
Hofferek, C, S450
Hoffman, R, P548
Hoffman, R, P699, P701, E1343
Hoffman, S, P300
Hoffmann, C, P568
Hoffmann, P, P295
Hofmann, S, E1084
Hofmann, W, P226
Hofmann, W-K, P255
Hofmeister, C, S780
Hofste op Bruinink, D, S102
Hogan, W, P165, P254, E1502
Hogge, D, P210, P581, E922, E1557
Hohaus, S, P282, E1124
Høilund-Carlsen, P, E1267
Hölbl, A, P749
Holdgaard, P, E1267
Holly, E, E1218
Holly, G, E1331
Holm, M, S486
Holmberg, L, P704
Holojda, J, E1262
Holroyd, A, P295
Holstein, S, P332
Holte, H, E1141
Holtzman, N, E912
Holyoake, T, S481
Holzerova, M, E1432
Homenda, W, S435
Hönes, J, P534
Hong, D, E1608
Hong, W-J, S468
Hong, X, S502
Hongeng, S, S814, P743
Honma, K, E1447, E1607
Hoogendoorn, M, P262, P683, E1194
Hopcroft, L, P591
Hoppe, P, S809
Horacek, J, E841, E858, E918
Horenstein, A, E1223, E1237
Horibe, K, S799
Horiike, S, E959
Horio, T, E1210
Horiuchi, T, P689
Hörl, R, P508
Hormigo, A, P733
Horn, P, S122
Hornbaker, M, P590
Horne, G, P591
Horny, H-P, S788
Horobryh, M, E1526
Horowitz, M, P745
Horowitz, N, P548, E1008
Horst, H-A, P533, E864
Horvat, I, E1352
Horvath, N, P674, E1289
Horwitz, S, P637
Hosing, C, E914, E1538
Hosokawa, Y, E1210
Hosono, N, S120
Hossfeld, D, S424
Hou, H-A, P212, E942
Hou, J-Y, E825
Hou, J-Z, S473, E1129
Hou, M, S431, P366, P726, E1144
Houillier, C, E1374
Houlston, R, P295
Houlton, A, S791
House, M, P287, P292
Howard, D, P252
Hoyos, M, S790, P182, P202
Hrabovsky, S, E841

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Hrusak, O, E823
 Hsu, K, E1280
 Htut, M, S780
Hu, B, P241
 Hu, C-Y, E942
 Hu, G, P356
 Hu, J-D, E1144
 Hu, J, E1547
 Hu, S, E1475
 Hu, Y, E1144
 Hua, L, S451
 Huang, X-J, P507
 Huang, D, P175
 Huang, H, E1521, E1531
 Huang, H, E1144
 Huang, H, E1055, E1464
 Huang, H-Q, E961, E1389
 Huang, J, P224
 Huang, J-Y, S436
 Huang, K, S135
 Huang, L, P726
 Huang, M, P390
 Huang, T-Y, E825
 Huang, V, P285, P286
 Huang, W, P197, E921
 Huang, X, S452
 Huang, X, P506, P577, P606, E1498
 Huang, X, P363, E1503, E1511
 Huang, X-J, S431, S449, P384, P387, P511, P725, P752, E833, E1101, E1144, E1515, E1517
 Huang, X, P180
 Huang, X, S487, S489, P209, P315
 Huang, Y, E846, E847
 Huang, Y-J, P653, E825, E872
 Huang, Y, E1087
 Hubbard, D, P197, E921
 Huber, M, S482
 Huber, W, P179, P206
 Hubert, K, P555
 Huberty, J, S505
 Hude, I, E969, E971, E1119, E1296
 Hudecek, M, S145, S816, P681
 Huelin, R, E944
 Hughes, D, E1132
 Hughes, M, P566
 Hughes, T, S484, P257, P603, E1052
 Huguët, F, P557, E856
 Hui, Y, E1148
 Hulin, C, P345
 Hultcrantz, M, P330, P678
 Hültner, L, S809
 Hume, R, S808, P650, P740, P748, E1532, E1554
 Humerickhouse, R, S472, P728, E1466
 Hummel, M, S801
 Hummel, S, P593
 Humphrey, C, P767
 Hunault, M, E856
 Hundarova, K, E1336
 Hung, S-Y, P212
 Hungria, V, S101, S459, P333, E1244
 Hunter, H, S817
 Huntington, N, S815, P750
 Huntly, B, S136
 Huntsman Labeled, A, S788
 Hur, E-H, E1177
 Hurtado, A, P318, E1013
 Hurtado López, A, P660
 Hus, I, E1257
 Hus, M, E920, E888, E1257
 Hussaini, M, E894
 Hutchaleelaha, A, P620
 Hutchings, M, P221
 Hutchinson, C, E1377
 Hutt, K, E846, E847
 Hutter, G, E1402
 Hüttmann, A, S150
 Huynh, A, S493, P572
 Huynh, D, P323, E1354
 Huynh, V, E840
 Hwa, Y, E1240
 Hwa, Y, P331, P673
 Hwang, W-L, E1474
 Hwang, W, P646
 Hylkema, T, P184
 Hypolite, G, S440
 Hyun, S, E892, E984
 Iakobishvili, Z, E949
 Iannazzo, S, E1464
 Iannicello, A, S481
 Iannotti, T, E1174
 Iannotto, J-C, E1348
 Iastrebner, M, E1182
 Ibatici, A, S796, P705
 Ibrahim, Y, E1572
 Ibrahim, I, E950, E1146
 Ibrahim, S, E926
 Ichii, M, P592, E1370
 Ichikawa, D, P171
 Ichikawa, S, E1104
 Ichinohe, T, E1522
 Idrobo-Quintero, H, E1074
 Ielo, D, P610
 Igea, A, P536
 Ignacimoutou, C, S427
 Ignatova, A, E1029
 Iida, H, E1199
 Iida, S, P335
 Illangakoon, E, E1112
 Ikeda, H, E1213
 Ikeno, S, P383
 Ilari, C, E1000
 Ilhan, O, S107
 Iliakis, T, E1120
 Iliasov, R, E1436
 Ilic, I, E1296
 Illert, A, S127, E1355, E1393
 Illidge, T, E1141
 Illig, T, P226
 Illmer, T, P255
 Ilveskero, S, P670
 Im, H, E857, E909
 Imadome, K-I, P302
 Imagawa, J, P263
 Imai, C, P625
 Imai, K, P314
 Imai, M, P691
 Imai, Y, P327
 Imamura, M, E859
 Imamura, M, P625
 Imamura, T, S799
 Imanishi, S, E1209
 Imbergamo, S, E1011
 Imberti, L, E1354
 Imbusch, C, P663
 Impera, L, P598
 Improgo, M, P236, P237
 Imran, D, E1564
 Imran, M, E912, E947
 Inamoto, Y, P385
 Inati, A, P620
 Inbar, M, E1034
 Infante, M, E1038
 Ingham, C, E873
 Inghirami, G, P297
 Ingram, W, P374, E1245, E1529
 Ingravallo, G, E1406
 Iniesta, P, P402, E1444
 Innocenti, I, E993, E1017
 Ino, R, E1447, E1607
 Inocencio, T, E1037
 Inokuchi, K, P327, P659, E1175
 Inoue, Y, P385
 Intermesoli, T, P163
 Intoppa, S, E989
 Inusa, B, E1163
 Invernizzi, A, E1483
 Invernizzi, R, E1179, E1186
 Ioannidou, A, E895
 Iole, D, P736
 Iolascon, A, S811, P392

- Ionova, T, E1476
Iori, A, P166, P738
Iovino, L, P671, E1401
Iraqi, W, E1024
Iredale, R, P374
Irger, M, E1402
Irina, Z, P311
Iriyama, N, E1058, E1066
Irno Consalvo, M, E908
Irún, P, E1410, E1412
Irvine, A, E1224
Irving, J, P512
Isaac, K, P566
Isaksson, A, P244
Isenalumhe, L, P608, P632
Isfort, S, P231
Ishibashi, M, P327, P659, E1175
Ishida, Y, P263, P642
Ishigaki, T, E951
Ishihara, Y, P621
Ishii, Y, E962
Ishikawa, M, E1058, E1066
Ishikawa, T, P196, E1552
Ishiyama, K, P389, P537, E1522
Ishizawa, K, E1199
Isidori, A, P604, P705, E1325
Isii, M, P313
Iskander, D, P233
Iskander, K, E1244
Iskas, M, S461
Islam, S, P663
Ismail, E, P291, E1572, E1582
Isnard, F, P316, E910
Isobe, T, S799
Isringhausen, S, P266
Issa, G, P192
Issing, P, P226
Isusi, P, E1183
Ito, M, P171
Ito, S, P327, P642
Ito, T, E1291
Ito, Y, E1072
Ittel, A, E1361
Ittiwut, R, E975
Itzykson, R, P316
Iurlo, A, S485, P358, P604, P729,
E1042, E1043, E1346
Ivanov, M, E1314
Ivanova, M, E1313
Ivanova, V, P220, E1133
Ivashenko, R, P220, E1133
Iwabuchi, H, P625
Iwafuchi, H, P171
Iwama, A, S799
Iwasaki, H, E1111
Iwasaki, K, E1260
Iwato, K, P389

Iyama, S, E1213
Iyer, S, E950, E1142, E1146
Izquierdo, M, E1142
Izraeli, S, S436
Izumi, T, P689
Izumida, W, P642
Izutsu, K, S124, P301
Izzo, B, P599
Izzo, P, P393
Jaafar, S, P305
Jabbour, E, S474, S487, S489, P170,
P192, P200, P209, P211, P315,
P518, P519, P550, P665, P739,
E830, E839, E913, E935, E1052
Jablonska, E, E886
Jaccard, A, P345, E1458
Jackson, G, S407, S781, E1203
Jacob, J, P170
Jacobsen, A, E847
Jacobsen, E, P571
Jacobsen, S, S421, E1110
Jacobsohn, D, S146
Jacobson, C, S466, P522
Jacoby, M, P319
Jacquet, M, E1458
Jaeger, U, S769
Jaekel, N, P555
Jagannath, S, S142, P349, E1239,
E1277
Jagasia, M, S492, S794
Jagowski, S, S492
Jahn, N, P535, E864, E868
Jaime-Perez, J, E1415
Jaimovich, G, E1508
Jain, D, P578
Jain, N, S463, P170, P209, P240, P241,
P518, E830, E991, E1016
Jain, P, P240, E991
Jain, R, P523, E840
Jaing, T-H, E825
Jakob, C, P555
Jakubowiak, A, S779, P676, P680
James, A, E940
James, D, S492, S769
Jamieson, C, P699, P701, E1343
Jamieson, L, S421
Jamroziak, K, E1262
Jandial, A, E851
Jang, H, P663
Jang, J, E939, E984
Jang, S, E857, E909
Janik, D, S809
Janikova, A, P218
Janke, H, P546
Jankowska-Lecka, O, E888
Jansen, J, E1197
Jansko, B, P195, P558

Janßen, C, P255
Janssen, J, S112, S426, P190, P262,
P595, E1057, E1499
Janssens, A, P565
Jantunen, E, P670
Janusz, K, P318, E1451
Janzen, V, P255
Jara-Acevedo, M, P713
Jaramillo Restrepo, V, E1288
Jarana, M, P733
Jardin, F, E1356
Jares, P, S115, E1381
Jarisch, A, P382
Jarque, I, P376
Jarrett, R, P295
Järvstråt, L, E826
Jassem, E, P709
Jauhri, M, E1049
Javarappa, K, P181
Javierre, B, S117
Jawhar, M, S788, P693, E1344
Jawniak, D, E1257
Jaye, A, P176
Jaźwiec, B, E1553
Jeanis, V, P518
Jeannet, L, E1458
Jebavy, L, E858, E918
Jedema, I, S447
Jędrzejczak, W, P338
Jeffers, M, E1187
Jefferson, Y, S770
Jego, G, E1356
Jelicic, J, S443, E970, E1448
Jelinek, T, E1290
Jelinkova, H, E841
Jeng, L, E947
Jenner, M, S407, S781
Jennings, D, E1476
Jenny, D, E1218
Jenq, R, S446
Jensen, B, P568
Jensen, M, P697
Jentsch-Ullrich, K, E1326
Jentzsch, M, P380
Jeon, D-S, E871
Jeon, Y-W, P638, P742, E1513
Jerez, A, P402, P660, E953, E1013
Jerkeman, M, S109
Jeromin, S, S424, S461, E1312
Jess, T, E1347
Jetani, H, S145
Jeyaraj Nallathambi, L, E1509
Jeynes-Ellis, A, S425
Jeziorski, É, S499
Ji, J, P224
Ji, Y, E1520
Jia, J, S460

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Jia, Y, P224
Jian, J-Y, E1567
Jiang, B, P511
Jiang, D, S126
Jiang, D, E1023
Jiang, H, S431, P507, P511, E833
Jiang, M, E1144
Jiang, Q, S431, P356, P507, P511, P606, E833
Jiang, W-Q, E961, E1389
Jiang, Y, P682
Jiang, Y, E1531
Jiang, Y, S466, P523, E840
Jiao, Y, P750
Jie, J, E1338
Jillella, A, P201
Jimenez, C, S801, E887
Jiménez, I, P298, E995, E1002
Jimenez, S, P554
Jimenez Barral, E, E1565
Jimenez-Castillo, Y, E1074
Jiménez Martín, A, E1551
Jiménez-Velasco, A, P696
Jin, S, E1110
Jin, Y, P257
Jin, Z, E931, E1507, E1521, E1531
Jindra, P, E1506
Jing, H, P356
Jiromaru, T, E1111
Jo, D-Y, E984
Joaquin, M-L, P688
Jöckel, K-H, P295
Johansson, E, E1594
Johansson, L, E897
Johansson, U, E1168
Johnsen, H, E1115
Johnson, J, S149
Johnson, K, P614
Johnson, L, E894, E1090
Johnson, P, E996
Johnsson, E, E826
Johnston, C, P377
Johnston, C, E1224
Jonas, B, S472, P203, P547
Jonasova, A, E1166
Jonassaint, J, E1493
Jones, G, E1478
Jones, J, S769
Jones, J, S407, S417, S781
Jones, K, E1202
Jones, S, P368
Jongen-Lavrencic, M, S112
Jootar, S, E1062, E1070
Jordán Garrote, A-L, E1569
Jorge, L, E1033, E1188
Jorgensen, D, E1481
Joris, M, E1135
Joshua, D, S458
Jost, E, E1106
Jost, P, P255
Josten, K, E1449
Jouni, R, P364
Joussain, I, E1458
Ju, H, E852
Juarez Garcia, A, P278
Jucker, D, E1365
Judge, D, E1463
Juel, K, E1347
Jumaa, H, E1362
Jun, G, E1260
Juncà, J, E831
June, C, S477, P517
Jung, C, E1070
Jung, C, E939
Jung, S-H, P332
Jung, S Y, P259
Jung, S-H, S491, E1089, E1091
Junghanss, C, P208, E1326
Jungova, A, E1290
Jurado Chacón, M, P768, E1271, E1283
Jurczak, W, S470, S771, P635, E1129
Jurczyszyn, A, E1257
Jurk, K, P651
Juskevicius, D, E1365
Justus, D, S127
Juszczynski, P, E886, E1294
Jutzi, J, S418
Jyotsana, N, E1105
Kabukcu Hacioglu, S, P281
Kacprzyk, P, E1193
Kaddu-Mulindwa, D, E1469
Kadia, T, S489, S496, P192, P200, P209, P211, P315, P518, P665, E830, E913, E935
Kadlecova, P, P707
Kadnikova, T, E1127
Kadokura, T, E940
Kafassi, N, E1304
Kafourou, A, P397
Kagaya, Y, P383
Kahl, C, P555
Kaiafa, G, E1441
Kairisto, V, S426
Kaiser, M, S407, S781
Kakihara, T, E1139
Kakiuchi, N, P299
Kako, S, P621
Kakosaïou, K, E895
Kalaitzidou, V, E1610
Kalakonda, N, S470
Kalf, A, E1289
Kaliafentaki, V, E1419
Kalin, B, S112
Kalina, T, P711, E1041
Kalinina, M, E1436
Kalkan, F, E1603
Kalkan, N, E1157
Kállay, K, P382
Kaloyiannidis, P, P280, E1083
Kalpadaki, C, E1120
Kalpadakis, C, S416, P639, E1036
Kalvala, A, P186
Kamalakar, R, P728, E1466
Kamburov, A, P236
Kamdar, M, S468, P386
Kamel-Reid, S, P708, E1324
Kamihara, Y, E1213
Kamikubo, Y, P531
Kampen, K, S439, P152, P153
Kanaeva, M, E1227
Kanagavel, D, S457
Kanai, Y, E1607
Kanakamedala, H, E1255
Kanakura, Y, P592, E1370
Kanasugi, J, E1210
Kanate, A, E1142
Kanda, Y, P389, P621
Kanderová, V, P711, E1041
Kane, E, P295
Kanellopoulou, T, E1600
Kanellou, P, E1419
Kanfer, E, S817
Kang, G, P271, E1099
Kang, K-W, P223
Kanhai, K, E1040
Kanioura, E, E1462
Kankam, M, E924
Kanno, H, S452, E1076
Kantarjian, H, S463, S471, S474, S478, S487, S489, S496, P170, P191, P192, P200, P209, P211, P315, P317, P352, P518, P519, P525, P550, P603, P665, P690, P739, E830, E913, E914, E935, E1016, E1052, E1192
Kanter, J, S454, E1490
Kanz, L, S424, P216, P222
Kao, H-W, E872
Kapedanovska-Nestorovska, A, E1471
Kapetaniou, K, E862
Kaplan, J, S469
Kapoor, N, S146

- Kapoor, P, P331, P673, E1240
 Kaporskaya, T, E1436
 Kapranov, N, E861, E934, E982, E1092,
 E1096, E1098, E1559
 Kapur, R, P530
 Kapustin, S, P308, E1568
 Kapustyan, T, E1023
 Kara, O, E1446
 Karadimitris, A, P233, P270, P624
 Karadogan, I, P281
 Karadurmus, N, P281
 Karagun, B, E1528
 Karahan, F, E1488
 Karakantza, M, E1476
 Karakasidou, O, E1574
 Karakasis, D, P280
 Karakükçü, M, E1539
 Karamanidou, C, P378
 Karamatic Crew, V, P391
Karamitros, D, S140
 Karampatzakis, N, E1233
 Karanfilski, O, E1471
 Karanth, M, P276
 Karapinar, T, E1427
Kardosova, M, P273
 Karev, E, E1154
 Kargin, V, P308
 Kari, C, E1017
 Karimi, M, S123, S486, E1197
 Karimov, K, E1050
 Karimpoor, M, E1112
Karjalainen, R, P181
 Karkukak, M, E1451
 Karlin, L, P345
 Karnan, S, E1210
 Karnebogen, M, P226
 Karpov, E, P307
 Karpova, I, E1161
 Karpova, O, E1127
 Karrasch, C, S137
Karsa, M, P154
 Kartsios, C, E1597
 Kartsonis, N, S807
 Karube, K, E1381
 Karunanithi, K, S407, S781
 Karyagina, E, E1154
 Kasahara, S, E1230
 Kasahara, Y, P625
 Kasamatsu, T, E1447, E1607
 Kasar, S, P236
 Kashanikhatib, Z, P309
 Kashishian, A, E896
 Kashiwakura, J-I, P592
 Kashofer, K, S419, E879
 Kaspar, I, E1256
 Kassam, S, E1509
 Kastritis, E, S415, P337, E1201, E1231,
 E1246, E1249, E1292, E1304
 Katafygioti, M, E1600
 Katagiri, S, E1046, E1072
 Katalinic, D, E1284
 Kataoka, K, S120, S124, S799, P299,
 P314, P537
 Kataoka, S, P171
 Kater, A, S461
 Katkade, V, E1460
 Kato, J, E1213
 Kato, K, S412
 Kato, M, S124, S799
 Kato, S, P171
 Kato, S, P689
 Kato, T, E1519
 Katodritou, E, S415, E1233, E1249,
 E1266, E1292
 Katoh, D, P196
 Katrui, T, E1599
 Kattamis, A, P397, E1158
 Kättström, M, S805
 Katus, H, P342
 Katz, T, E1008
 Kauffman, M, S469
 Kaufman, J, S408, P675, E1281
 Kauppinen, S, P174
 Kavelaars, F, P538
 Kawaguchi, A, E1068
 Kawaguchi, T, E1058, E1066
 Kawamura, K, P621
 Kawamura, T, P689
 Kawano, Y, E1354
 Kawano, Y, E1213
 Kawashima, J, S786
 Kawashima, N, P171
 Kawata, E, E959
 Kay, N, P254
 Kaya, A, P281
 Kaya, H, E1248
 Kaygusuz Atagunduz, I, E1446
 Kaynar, L, P281, E1527
 Kayserová, J, P711
 Kaytandzhan, E, E1153
 Kazakbaeva, K, E1067
 Kazmi, M, E1245, E1550
 Kearney, T, P317
 Kearns, P, S422
 Keating, M, S463, P240, P241, E991,
 E1016
 Kebriaei, P, S792, P525, P739, E914,
 E1538
 Kedia, S, E843
 Keegan, K, E896
 Keenan, F, P225
 Kees, U, P154
 Keil, F, E1510
 Keim, H, E1023
 Keino, D, E1477
 Keklikkiran, C, E1446
 Kelder, A, S113
 Kell, J, P374, E1476
 Keller, A, E1355
 Kelly, A-M, S503
 Kemal Samur, M, P321
 Kemizh, Y, P220, E1133
 Kenderian, S, P254, E1502
 Keni, N, E1527
 Kennard, K, P566
 Kennedy, E, E912
 Kennedy, J, P708, E1324
 Kennedy, K, E953
 Kennedy, N, E1289
 Kenvin, L, P215
 Keogh, B, P317
 Keramidioti, K, E1233
 Kerguelen, A, P703
 Kerkhoffs, J, P312
 Kern, W, S121, P199, P549, E1312
 Kernan, N, S808, P650, P740, P748,
 E1532, E1554
 Kernytsky, A, S147
 Kerry, J, P540
 Kersten, M, S467, P567
 Kerver, E, P567
 Keskin, D, E1159
 Ketterling, R, P331
 Khadwal, A, E851
 Khalaf, M, E1095
 Khaled, M, S427
 Khaled, S, P207
 Khalifa, N, E1585
 Khaliq, S, E1581
 Khan, M, S784
 Khan, N, S114
 Khan, S, P626, P629
 Khan, Y, S417, S439
 Khandanpour, C, P534, E1118
 Kharabi, B, E819
 Kharfan-Dabaja, M, E960
 Khatcheressian, J, S773
 Khelif, A, P723, E1437
 Khoi Viet, N, P287
 Khokhar, N, P676
 Khorashad, J, E1112
 Khorshed, R, E875
 Khouri, I, S450, E914, E1538
 Khoury, J, S794, P603
 Khranovska, N, E1382
 Khrushchev, S, E1461
 Khwaja, O, P392
 Ki, C-S, E871
 Kiani, A, P255
 Kibbelaar, R, P683, E1194
 Kidson-Gerber, G, E958

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

Kielbasa, S, E1362
Kiewe, P, P666
Kiezun, A, P236
Kiger, L, P617, E1082
Kiguchi, T, P314, E1199
Kikuchi, S, E1213
Kiladjian, J-J, S785, S786, S787, P351, P704
Kile, B, S427
Kılınc, H, E1165
Kiliszek, P, E886
Killick, S, S122
Kim, B, P223
Kim, C-K, E1608
Kim, D, P223, P569
Kim, D-Y, E1069, E1070
Kim, D, S491
Kim, D-H, E871
Kim, D-W, S425, P257, P259, P742, E1054, E1062, E1067, E1069, E1070, E1513
Kim, E, P241
Kim, E, E850
Kim, H, E939
Kim, H, P236
Kim, H, E1608
Kim, H, P259, E984, E1054, E1062, E1069, E1070
Kim, H, P742
Kim, H, E1404
Kim, H-J, P551, P561, P638, E1513
Kim, H-J, E979
Kim, H, P310, E850
Kim, H, E979
Kim, H, S135
Kim, H-J, P259, E1054
Kim, H-J, S491, E1062, E1069, E1070, E1089, E1091
Kim, H-J, E1404
Kim, I, P764
Kim, J-A, P259, E954, E984, E1054, E1069, E1070
Kim, J, E1404
Kim, J, P223
Kim, J, P635, E984
Kim, J-C, P346
Kim, J, E939
Kim, K, E1608
Kim, M, P569, E984
Kim, S, E1608
Kim, S, P223
Kim, S-H, P259, E1054, E1069
Kim, S, E857
Kim, S, E1466

Kim, S, S771, P247, P564
Kim, S, S491
Kim, S-H, P259, E984, E1054, E1062, E1069, E1070
Kim, S-H, E979
Kim, T, S468
Kim, T, S491
Kim, W, S468, S776, P635
Kim, W, E881, E902, E1204
Kim, Y-K, S491, E984
Kim, Y, S465
Kim, Y-J, P551, P561, P638, P742, E1513
Kim, Y, P637
Kim, Y, E852
Kim, Y, E850
Kimball, A, S458
Kimby, E, S805
Kimmich, C, P342
Kimura, F, P689
Kimura, S, P263, E1068
Kimura, S, S799
Kindler, T, P533, P700
Kindrakevych, O, E1127
Kinet, J-P, P709
King, T, P674
Kinglesey, C, P253
Kinney, G, S104
Kinoshita, A, E1477
Kinoshita, T, S502
Kioumi, A, E1266
Kipps, T, S769, P247, P253
Király, P, E820
Kiryama, T, E1139
Kirkwood, A, S802, P160, P164
Kirsanova, T, P718
Kirschner, M, P231
Kirschner-Schwabe, R, P155
Kiryu, M, P301
Kischel, R, E867, E877
Kiselev, P, E923
Kiseleva, E, E1153
Kishore, B, S407, S781, S817
Kitagawa, J, E1230
Kitai, Y, P592
Kitali, A, P349, E1239, E1277
Kitamura, Y, E1447, E1607
Kittivorapart, J, P391
Kiya, O, P197, E921
Kiyoi, H, P314
Kiyokawa, N, S799
Kiyose, H, P531
Kizaki, M, E1058, E1066
Kjaer, L, P602

Kjollerstrom, P, E1586
Klade, C, S787, P707
Klamová, H, S483, E1041
Klanova, M, S775
Klasen-Sansone, J, P515
Klaus, M, P647
Klausmann, M, P255
Klee, D, P515
Kleijer, M, S448
Klein, L, S147
Klein, S, S501, P340
Klener, P, P218
Kliasova, G, E836
Klimenchenko, N, P718
Klimiankou, M, S497
Klimkowska, M, P710, E1429
Klimova, O, E1314
Klimovich, A, E1154
Kline, I, P215
Kline, T, P328, E1373
Klingeberg, C, S127, E1355
Klingeblat, T, P382
Klink, A, P647
Klisovic, R, E839
Klitgaard, J, P237
Kloetgen, A, S429
Kloos, I, E907, E1018
Klostermann, A, E1469
Klous, P, E897
Kluin-Nelemans, H, S788
Klusmann, J-H, S789, P177
Klymenko, T, P585
Klyuchnikov, E, E1286
Kmetyuk, Y, E1127
Knapper, S, P697
Kneba, M, S424, S464
Knecht, H, S801, S803, E1376
Kneisel, N, P172
Knežević, V, E1328
Knight, K, P258
Knight, R, S471
Knight, S, E1424
Knight, T, E1349
Knop, S, P336
Knöpfel, N, E1341
Knopińska-Postuszny, A, E1262
Knopińska-Postuszny, W, E1193
Knöb, S, P177
Knut, M, E1344
Ko, S-H, E954
Kobayashi, A, P689
Kobayashi, C, E1046
Kobayashi, H, P389
Kobayashi, M, E1104

- Kobayashi, N, E859, E1522
 Kobayashi, R, S799
 Kobayashi, S, P621
 Kobayashi, S, P689
 Kobayashi, T, E959
 Kobayashi, Y, E1139
 Kobbe, G, S494, E937
 Kobe, C, S150
 Koblíhová, J, S483
 Kobune, M, E1213
 Koc, Y, P384
 Koch, J, P226
 Kochenderfer, J, S142
 Kockova, H, E1009
 Koclega, A, P741
 Koehler, M, P706, E1320
 Koehne, G, E1252
 Koelbel, C, P216, P222
 Koenders, J, P677
 Koene, H, S411, P576
 Koenecke, C, S494
 Koenig, M, P596
 Koester, R, P534
 Kogan, S, P176
 Kogure, Y, S124
 Koh, K, S799
 Koh, K-N, E857
 Koh, M, P669
 Koh, Y, P764
 Köhlbrenner, K, S424
 Köhler, N, S812
 Kohlschmidt, J, E883
 Köhne, C-H, S424, P533
 Köhnke, T, E867, E877
 Kohno, A, E1516
 Kohno, A, E982
 Köhrer, S, P508
 Kojima, D, P171
 Kojima, H, E1068
 Kojima, S, P171
 Koka, M, E912
 Kokosadze, N, P220, E1133
 Kokoviadou, K, E1233, E1266
 Kolb, H-J, S424
 Kolch, W, S419
 Koldej, R, P750
 Kolibaba, K, P634
 Kollitz, J, P556, E883, E922
 Koller, E, E1510
 Koller, M, S104
 Kolomansky, A, E1107
 Kolomejtsev, O, P220, E1133
 Kolosheina, T, E1436
 Kolstad MD, PhD, A, S109, E1141
 Komarnicki, M, P611
 Komarov, I, P220, E1133
 Komatsu, N, P691, P706, E1058,
 E1066, E1320
 Kommers, I, S484
 Komori, D, P301
 Komrokji, R, P351, P352, E960, E1323
 Komvilaisak, P, E975
 Kong, J, P259, E1054, E1070
 Kong, Y, P363
 Kong, Y, S449, P507, P725, P752,
 E833, E1101
 Kongsgaard Nielsen, L, S501
Koning, M, P267, E1362
 Konishi, H, E1210
 Konopleva, M, S474, S489, P170, P191,
 P192, P200, P209, P211, P317,
 P518, P550, P665, E830, E914
 Konova, Z, E1545, E1559
 Konstandin, N, E885
 Konstantinidou, P, E1233, E1292
 Konstantopoulos, K, P280, E1462
 Konstantopoulos, K, E1120
 Kontievskiy, I, E1436
 Kontopidou, F, S416, P639, E1120
 Kontro, M, P181
 Konuma, T, P389
 Koo, H, E845
 Kook, H, S491
 Kopi_ska, A, E1193, E1257
 Koppes, M, E1057
 Korchuenjit, J, P395
 Korchuenjit, W, P395
 Korde, N, E1252
 Korenev, S, E1163
 Koren-Michowitz, M, P548
 Korkolopoulou, P, S416, P639
 Kormany, W, P524
 Kornblau, S, S474, S487, P200, P315,
 P550
 Korner, A, P392
 Kornowski, R, E949
 Koroleva, A, P307
 Koroleva, O, E1545, E1559
 Kors, W, S452
 Kortüm, K, P320
 Koschmieder, S, S482, P231, P700,
 P706, E1320
 Kose, S, E1539
 Koseoglu, F, P281
 Kosinska, J, P594
 Kosinski, P, S451, P614
 Kosior, K, P710, E1429
 Kosiorek, H, S505, P359, E1321,
 E1331, E1339
 Koskenvesa, P, S426
 Kosmidis, H, E862
 Kostadima, M, S117
 Kostelidou, T, E1600
 Köster, R, E1118
 Kostritsa, N, E1548
 Kota, V, E1052
 Kotaskova, J, S461, P238, E1009
 Kote-Jarai, Z, P295
 Kotlyarchuk, K, E1067
 Koto, Y, E1477
 Kotowska, A, E1061
 Kotrová, M, S801, S803, E823, E1376
 Kotsanti, S, E1304
 Kotsianidis, I, P280
 Kotsiou, E, E1566
 Kotsopoulou, M, E1249, E1266
 Koudouna, A, E1304
 Koukoulis, K, E1083
 Koulieris, E, S416, P639, E1036, E1304
 Kourakli, A, E1292
 Kouraklis, A, P286
 Kourelis, T, E1240
 Koutala, H, E1419
 Koutkias, V, P378
 Koutsouri, D, E1485
 Kouzarides, T, S430
 Kovacevic Grujicic, N, E948
 Kovačić, M, E1316, E1319
 Kovacs, E, E1602
 Kovacsovics, T, P201
 Kovalchuk, S, E1401
 Kovrigina, A, P220, P307, E1133,
 E1403, E1409
 Kovtun, Y, P526
 Kovy, P, E1535
 Kowata, S, P642
 Koyama, T, P302, E1595
 Kozlov, I, E1127
 Kozlov, V, E1127
 Kraan, W, P567
 Kraemer, D, P533
 Kragl, B, E1326
 Kraguljac-Kurtović, N, E1328
 Krahel, R, P555
 Kralik, M, E971
 Kralovics, R, P707
 Krampira, M, P355, E821
 Kraus-Berthier, L, P175, E1018
 Krause, S, S424
 Krauter, J, P533
 Krauth, M, P707
 Kreimeyer, H, S494
 Kreipe, H-H, S494
 Krejci, A, S801, S803
 Kreuger, A, P312
 Kreutmair, S, S127, E1355, E1393
 Kreutzman, A, P609
 Kreutzmann, A, E1305
 Kreuzbauer, G, E1441
 Kreuzer, K-A, S464, E1344
 Kriachok, I, E1127

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Krijgsveld, J, P172
Krimm, S, P328
Krishnamoorthy, R, E1495
Krishnamurthy, P, E938
Krishnamurti, L, S146
Krishnan, K, P662
Kristen, A, P342
Kristensen, N, E1435
Kristensen, T, E1367
Kristiansen, J, E1501
Kristinsson, S, S442, P330, P678
Krivolapov, I, E1313
Krochmalczyk, D, E1193
Kroeger, N, S494, E1286
Kroeze, L, P239
Krsnik, I, P685
Krstic-Demonacos, M, E1307
Krueger, S, P328
Krug, U, P546
Krull, K, P515
Krumbholz, M, E1391
Krunic, N, P257, P601
Krupka, C, E867, E877
Krupkova, L, E1432
Kruse, T, E1367
Kryachok, I, E1382
Krzymieniewska, B, E886
Ksienzyk, B, E885
Kuang, P, P224
Kube, D, E1387
Kubo, N, P625
Kucerova, J, E1432
Kuci, S, P382
Kuci, Z, P382
Kücüksarioglan, E, S414
Kudlow, B, E894, E1090
Kueenburg, E, P343, E1250
Kuendgen, A, E937
Kufer, P, E867, E877
Kugler, S, S116
Kuhlen, M, P515
Kuhn, A, E1449
Kuhnert, G, S150
Kühnhardt, D, S150
Kuhr, K, S812
Kuiper, R, P677
Kuipers, J, E1504
Kuklik-Roos, C, S809
Kukreti, V, P680
Kulagin, A, S498, P718
Kulasekararaj, A, P657, E1550
Kulibaba, T, E1154
Kuliczkowski, K, E1553
Kulikov, S, E836, E853, E860, E1067, E1227, E1436
Kulikovskiy, A, E853
Kulis, M, S117, P300, P325, E1225
Kulvait, V, E1166
Kumagai, T, P263
Kumar, A, E974
Kumar, A, S135
Kumar, A, E843
Kumar, A, E1442
Kumar, B, P186
Kumar, N, E974
Kumar, P, E974
Kumar, S, S101, S408, S460, P331, P338, P673, P675, P687, E1240, E1241
Kumode, T, E1100
Kunar, B, S137
Kündgen, A, E864
Kung, C, S451, P614
Kunishima, S, P360
Kunkl, A, E915
Kunstreich, M, P515
Kuntz, E, S481
Kuo, K, S451
Kupas, K, E1256
Kupryshina, N, P220, E1133
Kupsa, T, E858, E918
Kurasawa, M, E1162
Kuribayashi, W, P401
Kuribayashi-hamada, Y, P327, P659, E1175
Kurita, N, E1519
Kuroda, J, E959
Kurosawa, S, P385
Kurt Yuksel, M, P281
Kuruvilla, J, S412, S469
Kusec, R, E1329
Kushchevyy, E, E1127
Kushwaha, R, E974
Kuskonmaz, B, E855, E1598
Kusminsky, G, E1508
Kustanovich, A, P161
Kusumoto, S, E1139
Kusunoki, Y, E1068
Kuter, D, E1269
Kutlar, A, S454
Kuykendall, A, P608, E1323
Kuzmina, L, E836, E860, E861, E982, E1092, E1096, E1098, E1545, E1559
Kvikstad, E, E1424
Kwak, C, P764
Kwak, D-H, P551, P561
Kwak, J-Y, P259, E954, E1054, E1062, E1069, E1070
Kwak, L, P635
Kwei, L, P672
Kwiatkowski, J, S451, S814
Kwon, J, E1069
Kwon, M, E1113
Kwong, Y-L, E1392
Kyle, R A, P331, P673, E1240
Kyrz-Krzemie, S, P741, E1061
Kyriakaki, S, S416
Kyriakopoulou, D, P397, E1158
Kyriakou, D, E1266
Kyrtsolis, M, S415, S416, P639, E1120, E1266
Kyrtsolis, M-C, E1304
La Cava, P, E1214, E1232
La Nasa, G, S413, P256
La Rocca, F, E1226, E1261
La Sala, E, S111
Laadem, A, S129, P666
Labate, C, P610
Labopin, M, S493, S797, S798, P379, P384, P388, E1506
Labotka, R, P338
Labourey, J-L, P649
Labreuche, J, E1135
Lacerda, J, E1586
Lachaine, J, P371
Lachance, S, P371
Lackmann, M, E1226
Lacout, C, P268
Lacroix, R, P766
Lacy, M, P331, P673, E1240, E1241
Lad, D, E851
Laddaga, F, E1406
Ladetto, M, S778, P304, E1408
Ladinig, C, S809
Ladjemil, N, P371
Ladogana, S, P717
Laetsch, T, S476, S477, P517
Lafage, M, E1361
Laforêt, M-P, E1010
Laganà, C, P610
Laharanne, E, E1001
Lahary, A, S453
Lahuerta, J-J, S409, P329, P679, P688, E1234, E1278
Lai, K, P526
Lai, S, P256
Lai, Y-Y, P507, P511, P725, E833
Lake, A, P295
Lakshmi, T, E1089, E1091
Lakshman, A, E1240
Lal, I, S492



- Lalayanni, C, E1610
Lam, A, P687, E1281
Lam, L, S142
Lamagna, M, P400
Lamana, M, S144, P755
Lambilliotte, A, S131
Lambrechts, D, E1220
Lammens*, T, P156, E1114
Lamparelli, T, S796
Lampropoulou, P, E1249
Lamy, T, S106
Lamy De La Chapelle, T, S105
Lan, P, P175
Lancaster, D, S422
Lancet, J, P191, P201, P210, P556, E922, E1323
Lanciotti, M, P234, P575
Land, J, P731
Landau, D-A, P236
Landau, D, E923
Landau, H, S104, E1252
Lander, E, P236
Landgren, O, S442, P330, P678, E1252
Landini, B, E1293
Landini, I, E1401
Landman-Parker, J, S422, P716
Landsburg, D, P566
Landthaler, M, E1368
Lane, A, S428, P191
Lang, F, P516
Lang, P, P382
Lange, E, P516
Lange, T, P261, P380
Langella, M, P358
Langemeijer, S, P369, P576
Langer, S, S482
Langerak, A, S801, P244
Langerbeins, P, S464, E1025
Langlais, B, S505, P359, P377, E1321, E1331, E1339
Langton, C, E1476
Lanino, E, P738
Lannon, M, E1478
Lansigan, F, P634
Lanza, F, S111
Lanza, T, P234, P575, P717, E1440
Lanzarone, G, E1332
Lapidus, R, E947
Lapin, S, E1154
Lapin, V, E860
LaPlaca, D, S500
Lapunzina, P, P580
Larcher, M-V, P557
Laribi, K, P217
Lario, A, E1541
Larocca, A, P322
Larocca, L, P282
Larrayoz, M, P198, P696, E1027
Larrea, E, P303, E1368
Larripa, I, E1182
Larsen, H, P697
Larson, M, P254
Larson, R, S110, P524, P560, E868, E870
Lasa, M, P329
Lasater, E, P189
Lash, L, P247
Lashgari, N, P309
Lassailly, F, P264
Latagliata, R, P604, P705, E1325, E1340
Latasha, L, E830
Latorre, M, E1318
Latorre, T, P566
Latour, S, E1422
Lattanzi, A, S147
Lau, E, E1140
Lau, H, P719
Lau, I-J, P540
Laubach, J, S408, S779, P335
Laudato, S, P663
Laurent, G, P641
Laurent-Puig, P, E829
Laurenti, L, E993, E1017
Laurenzana, I, E1226
Lauretti, A, S800
Laursen, A, P221
Lauseker, M, S424
Lavabre-Bertrand, T, S499
Lavi, N, P548
Lavie, D, S786, E1121
Lavilla, E, P554
Lavilla Rubira, E, E983
Lavinha, J, E1586
Lavorgna, S, P607, E908
Law, J, E912
Law, P, P295
Lawes, M, E873
Lawless, M, P293
Lawrie, C, P303, E1368
Lawrie, E, S802, P160
Lawson, L, E1218
Lawson, S, S817
Layton, D, S451
Lazarev, I, P220, E1133
Lazarevic, D, P544
Lazarus, K, E1148
Lazo-Langner, A, S441
Lazzaro, A, E1325
Lazzarotto, D, E1496
Le Bouar, M, E1028
Le Bris, Y, E1360
Le Calloch, R, E1348
Le Corroller-Soriano, A-G, E1549
Le Coutre, P, P601, P603
Le Coz, M-F, S453
Le Du, K, S105
Le Gall-Ianotto, C, E1348
Le Garff-Tavernier, M, E1374
Le Guill, S, S105, P217, E1018, E1360
Le Jeune, S, P617
Le Mouël, L, S427
Lea, N, P532
Leal, I, E1183
Leavitt, R, S807
Leblanc, T, P716, E1439
Leblond, V, S465, E1246
Leboulch, P, P631
Lebovic, D, S780
Lech-Maranda, E, P524, E827, E886, E1294
Lechner, D, P336
Lecoq-Lafon, C, E1361
Lecumberri, R, S444
Ledda, A, S410, P322
Ledesma, C, P739
LeDieu, R, E1566
Lee, C, S106
Lee, C, E871
Lee, C-T, E1605
Lee, C-W, E1105
Lee, C, S147
Lee, D, E840
Lee, D, E852
Lee, E, P188, E884
Lee, G, E1062
Lee, G-W, E968
Lee, H, P590
Lee, H, E852
Lee, H-J, E1089, E1091
Lee, J, P333, E984
Lee, J, P310, E850
Lee, J, P259
Lee, J-Y, S491
Lee, J-H, E909, E984, E1177
Lee, J-J, S459, S491, E1089, E1091
Lee, J, P569
Lee, J, P292
Lee, J, E1373
Lee, J I, E892
Lee, J, S498, P742, E984, E1513
Lee, J-W, P551, P561, P638
Lee, J-H, E1177
Lee, K-O, E979
Lee, K-H, E909, E1177
Lee, K, E1608
Lee, L, E1208
Lee, M, S422
Lee, M, S147
Lee, M-Y, E1608
Lee, M, P346

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Lee, M, E947
Lee, N, E852
Lee, N-S, E1608
Lee, S, P635
Lee, S-C, E1608
Lee, S, P223
Lee, S, P551, P561, P638, P742, E1513
Lee, S, E912
Lee, S-S, S491
Lee, S, E1605
Lee, S, P347
Lee, S-E, P259, P551, P561, P638, P742, P757, E1054, E1069, E1513
Lee, S, P635
Lee, W-S, P259, P569, E1054, E1069, E1070
Lee, W-M, E871
Leeds, J, S773
Leeksa, A, S461
Lees, M, P278
Lefebvre, C, S427
Lefebvre, C, E1001, E1178, E1361
Lefebvre, T, S453, P631
Lefort, S, E1458
Lefrere, F, P631
Legdeur, M-C, S112
Legrand, A, P274
Legros, L, E856
Leguay, T, E856
Lehal, R, P159
Lehman, J, E1502
Lehmann, L, P740, P748, E926, E1532, E1554
Lehrer-Graiwer, J, P620
Lei, B, S103
Leiba, M, S101, P334
Leip, E, S425
Leite, J, S135
Leivas, A, P509, E1234
Lekakis, L, S466, P522
Leković, D, E1316, E1319, E1328
Leleu, X, P323, P345
Lelieveld, D, E901
Lemaire, P, E1361
Lemarie, C, E1549
Lemeire, K, S438, E1358
Lemme, G, P636
Lemoli, R, P283, E854, E915, E919, E933, E1043, E1299, E1505
Lenain, P, P345
Lendahl, U, E1110
Lendvai, N, E1252
Leneus, A, S129
Lengyel, L, E1535
Lenihan, D, E1255
Lenive, O, P295
Lennard, A, P225
Lennard, J, P225
Lentzsch, S, S101, S459
Lenz, G, S776
Leon, E, P536
Leon Gonzalez, M, E1500
Leon Peña, A, E1500
Leoncin, M, E1254, E1357, E1397
Leoncini, P P, E917, E1167
Leonetti Crescenzi, S, E1340
Leoni, P, P636, E1136
Lepkov, S, P220, E1133
Leporace, A, P616
Leppa, S, S776
Lepretre, S, E856
Lesokhin, A, E1252
Lessene, G, P175
Lessi, F, E930
Lesty, C, E1001, E1361
Letai, A, S472, P508
Leuchtner, N, E992
Leung, A, P167
Leung, K, P167
Leung, M, S477, P517
Leung, N, P331, P673, E1240
Leung, T, P167
Leung, W, P509
Leux, C, P217
Levati, G, E1030
Levato, L, P605, E1021
Leverger, G, S427, P716, E1439
Leverson, J, S460, P189, P675
Levin, M-D, S501, P340, P677
Levine, B, S477
Levine, J, S477, P517
levis, A, P667
Levis, M, S110, P560, E940
Levitas, A, E1073
Levy, M, S793, P201, E1464
Lewandowski, K, P611
Ley, R, S501
Lheritier, V, E856
Lhermitte, L, E1236, E1386
Lhospice, F, E1386
Li, A, P405
Li, B, E1330
Li, C, E956
Li, C, P167
Li, C, P662
Li, D, P663
Li, H, E947
Li, H, P362, P724
Li, J, P249
Li, J, P634
Li, J, E1085, E1087
Li, J, P224
Li, J, E924
Li, J, E1246
Li, J, P356
Li, J, P356
Li, J-Y, E863
Li, J, E928
Li, J, P663
Li, J, E1144
Li, K, P167
Li, L, E1052, E1060
Li, M-F, P726
Li, M, P356
Li, P, E991
Li, Q, E1398
Li, S, S482
Li, W, P526
Li, W, P356
Li, X, P328, E1373
Li, X-L, P726
Li, X, P726
Li, Y, E911, E916
Li, Y, P724
Li, Y, E1201
Li, Y, E943, E1534
Li, Y, S492
Li, Z, E1152
Li Pira, G, S146, S495, P381
Liacos, C, E1231
Lian, Y, P224
Liang, D-C, P653, E825, E872
Liang, G, P324
Liang, W, S808, P650, P748, E1532, E1554
Liang White, J, P519
Liao, E, S408, S780
Liaskas, A, E1462
Liberati, A, S470, S778, E946, E1247
Liberato-Ramon, C, E1074
Liço, A, E1254, E1357
Lidonizzi, M, S128
Liedtke, M, S104, S142, S780, P519
Lierman, E, E1310
Liesveld, J, P203, P547
Lievano Segundo, P, E1134
Lievonen, J, P670
Lifermann, F, S453
Lightfoot, T, P295
Liles, D, S454
Lill, M, E1129
Lim, C, S419



- Lim, D, E939
Lim, J-Y, P757
Lim, J, P346
Lim, J, E1388
Lim, K, E1605
Lim, S, E1018
Lim, S-N, E965, E1542
Lim, S, E1605
Lim, Y, E850
Lima, J, E1033, E1188
Limat, S, P345
Lin, A-P, S126
Lin, C, E1200
Lin, C-C, P212
Lin, D, E911, E916
Lin, F, P356
Lin, H-C, E1474
Lin, H-H, E1567
Lin, H, P735
Lin, H-M, P637
Lin, L-I, E942
Lin, L, S799
Lin, M, S147
Lin, P, E1465
Lin, T, S473, P210
Lin, T-H, E825
Lin, X, E1507
Lin, Y, S142, S466, P522, E1240
Lin, Z, P224
Linares, M, E900
Linde, P, S129, P666
Lindemann, H-W, S424
Lindemans, C, S446
Linder, O, P697
Lindroth, A, P663
Lindsay, J, S407, S781
Linhartova, J, E1041
Link, C, E912
Linn, Y, P646
Lintermans, B, S438, E1358
Lion, E, S141
Lion, T, P596, E1071
Lipka, D, P350, P353, P663
Lippert, L, S127
Lipton, J, P257
Liron, T, E1107
Lis, K, E1193
Lis, R, S137
List, A, E1323
Lista, E, E1020
Littera, R, P256
Little, L, P241, P550
Little, M, P637
Litzow, M, S110, P165, P254, P560, E940, E1502
Liu, B, P270
Liu, B, E911, E916
Liu, C, S110, P560, E940
Liu, C, P753
Liu, C-J, S779
Liu, D, E1189
Liu, E, S104
Liu, H-C, E825
Liu, H, S431, E1211
Liu, J, S103
Liu, J, E1330
Liu, K, E911, E916
Liu, K, S138, P506
Liu, K-Y, S431, P387, P511, E1515
Liu, K, P363, E1503, E1511
Liu, L, P506
Liu, L-Y, P726
Liu, M, P181
Liu, P, P531
Liu, T, P224, E1144
Liu, W, P224
Liu, W-J, E1389
Liu, X, E1511
Liu, X, P724
Liu, X, P356
Liu, X, P366
Liu, Y, P366
Liu, Y-R, P511
Liu, Y, P637
Liu, Y, E1383
Liu, Y, E916
Liu, Z, P224
Liu, Z, E991
Livingston, M, E881, E1204
Livun, A, E1329
Ljungman, P, S807, E1506
Llamas, P, P733, E1596
Llaudet Planas, E, P615
Llops, M, E891, E899
Llorente, L, P685
Llorente, M, P634
Lluch, R, P376
Lo, P, P194
Lo Celso, C, E875
Lo Coco, F, S111, E908
Lo Monaco, S, E882, E898
Lo Nigro, L, E955
Lo Riso, L, E1417, E1555
Lo Valvo, L, P717, E1164
Loayza Puch, F, P153
Lobanova, T, E861, E934
Loberiza, F, P525, E835, E842
Lobry, C, S427
Locatelli, F, S146, S480, S495, S814, P350, P381, P521, P738, E1167
Locatelli, S, P282
Lock, R, P154
Locke, F, S466, P522
Lockstone, H, S122
Lockwood, C, E1073
Lodewyckx, J-N, E994
Lodick, A, E1022
Lodie, T, P188, E884
Loeffeld, P, S494
Loffredo, G, S433, P715
Loftus, J, P158
Logan, A, S492
Logan, B, P745
Loh, J, E929
Loh, M, P353
Lohi, O, P734
Lohri, A, S150
Loken, M, E912
Lombardi, A, P715
Lonial, S, S408, S456, P339, P676
Loose, K, P243
Lopes, I, P157
Lopes de Castro Lobo, C, E1492
Lopez, A, P554
Lopez, B, E1341, E1417
Lopez, C, S427
Lopez, J, P554, P685
Lopez, L, P618
Lopez, L, E1134
Lopez, O, P543
López, R, S144
Lopez, S, P645
Lopez, S, P759, P765
Lopez, W, S463
Lopez Andrade, B, E1555
Lopez Anglada Fernandez, L, E1278
López-Bigas, N, P655
López Cadenas, F, P316, P318, P747, E1169, E1181, E1543
Lopez-Corral, L, P746, P747, E1169
Lopez de Frutos, L, E1410
Lopez de la Guia, A, E1278
Lopez-Godino, O, P402, P746, P747
López González, S, E1551
López-Guerra, M, P696
López-Guillermo, A, S115, S117, P300, E1137, E1369, E1394
López Jaime, F, E1327
López Jiménez, F, E1302, E1551
López-Jiménez, J, E953
López-Manzaneda, S, E1081, E1097
López-Otín, C, S115, S117
Lopez-Parra, M, P361, P751, E1543, E1592
López Picazo, J, S444
López Velez, M, E1271, E1283
López-Villar, O, E1543
Lorenzatti, R, P599
Lorenzo, J, P316
Loriot, M-A, E829
Lortholary, O, P709

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Louache, F, E1102
 Louie, A, P210, P556, E922
 Louka, E, P270, P668
 Loureiro, P, E1586
 Loury-Larivière, I, P217
 Lousada, I, E1280
 Louzada, M, S441
 Lovato, S, E1467
 Lowder, J, E1192
 Lowenberg, B, S112, S113
 Lowy, E, S117
 Lozano, M, P229
 Lozano, M, P402, P721, E1444, E1451, E1456
 Lozenov, S, E1556
 Lozic, D, E969
 Lu, J, S431, E1475
 Lu, V, P339
 Lu, W, S138
 Lu, Y, E1389
 Lu, Z, E940
 Lübbert, M, P350, P533, P535, P656, P663, E868, E870
 Luca, B, E930
 Lucchesi, A, E904, E1012
 Lucchini, G, P382
 Luciana, C, E1000
 Luciano, L, P605, E1043
 Luciano, L, P604
 Lucijanec, M, E969, E1329
 Lucini, C, P596
 Ludikova, B, E1432
 Ludwig, H, P336
 Luengo-Gil, G, P573, P660
 Luft, T, S122
 Lugtenburg, P, S107
 Luís, T, E1110
 Luken, B, S455
 Luker, S, E1022
 Lukina, E, P719, E1161
 Lukjanec, E, E1127
 Lukyanova, I, E861
 Lumberras, E, P318, P361, P655, P660, E1181
 Lund, S, P678
 Lundan, T, P670
 Lundberg, A, S147
 Lundin, K, E1501
 Lunghi, F, S485
 Lunghi, M, P616
 Lunin, S, S777, E1130
 Lunn, M, E1132
 Lunning, M, S772, P563
 Luño, E, P316
 Luo, Y, E1368
 Luoma, S, P670
 Lupascò, D, E1123
 Lupher, M, P328, E1373
 Lupini, L, E1020
 Lupo Stanghellini, M, S806
 Luppi, M, S111, E1186
 Lust, J, P331, P673
 Lustgarten, S, P603
 Lutz, C, P172, P179, P206
 Luu, V, E1140
 Lv, M, P363
 Lykke, C, E1073
 Lyons, S, P225
 Lyons-Lewis, J, P669
 Lyu, M, P724
 Ma, D, E880
 Ma, H, P224
 Ma, H, P590
 Ma, L, E928
 Ma, S, E1520
 Ma, S, P247
 Ma, W, P204
 Ma, X, P390, E1507
 Ma, X, S103
 Ma, Z, P632
 Maagnoli, M, S776
 Maalouf-Soukupova, J, E1198
 Maarouf, N, E926
 Mabry, M, S472, S473
 Macaione, F, E1577
 Maccari, G, E1065
 MacDonagh, B, E1187
 MacDonald, D, P245
 MacEwan, R, S774
 Machaczka, M, P710, E1429
 Machado-Neto, J, E832
 Machalkova, K, E1303
 Machherndl-Spandl, S, P559
 Machnicki, M, S125, P594
 Machová Poláková, K, S426, S483, E1041
 Machowicz, R, E1193
 Maciag, P, S460, P675, P682, E1139
 Macias-Garcia, A, P392
 Maciejewski, J, S120, P352, P578, P660, E1013
 MacInnes, A, P579
 Macintyre, E, S440, S801, P156, E1236, E1360, E1386
 Macro, M, P345
 MacWhannell, A, P208, P347
 Madan, S, E1142
 Maddocks, K, S470
 Madero, L, P510, P580
 M_dry, K, E1193
 Madsbu, U, E1141
 Maeda, S, P531
 Maeda, T, E1111
 Maegawa, R, S779
 Maekawa, T, P689
 Maerevoet, M, S469
 Maertens, J, S113, S798, S807, E1506
 Maes, A, E1211
 Maes, K, E1211, E1220
 Maes, M-B, S141
 Maffioli, M, P351, E1333
 Magalhães Maia, T, E1080, E1588
 Magen, H, S456, P269
 Maggio, A, P290
 Maglaveras, N, E1407
 Magnani, A, P631
 Magnani, C, P628, P630
 Magnani, J, P203, P547
 Magnano, L, E1137
 Magrangeas, F, E1206, E1360
 Magrin, E, P631
 Mah, J, E1605
 Mahadeo, K, S146, P381
 Mahajan, S, S147
 Mahdi, A, E1529
 Mahdi, D, E1445, E1450
 Maher, J, P624
 Maher, J, E1037
 Maher, O, S450
 Mahler, M, E1022
 Mahmoud, I, E1573
 Mahmoud, S, E926
 Mahon, F-X, S426, P255, P257
 Maia, R, E1586
 Maia-Silva, D, E889
 Maier, J, P261
 Mailankody, S, E1252
 Maillan, G, E1458
 Maisnar, V, P672, E1272, E1290, E1298, E1303
 Maisonneuve, H, S105
 Majdan, M, E888
 Majeti, R, S140
 Major, S, P680
 Majowicz, D, E920
 Makenbaeva, D, E1300
 Makis, A, E1416
 Makishima, H, S120, S123, P314, P537
 Malagola, M, P607
 Malamut, G, E1386
 Malaspina, F, P306
 Malatesta, R, P168

- Malavasi, F, E1223, E1237
Malbora, B, E1422
Malcikova, J, P238, E1003, E1009
Malcovati, L, S122, S123, P355, E1179
Malecka, A, P613
Malek, E, E1248
Malenda, A, E1294
Malfait, R, S141
Malfitano, A, E1247
Malhotra, P, E851
Mali, R, P189
Malikhova, O, P220, E1133
Malinge, S, S427
Malinverni, R, E831
Malla, R, P189
Mallm, J-P, P663
Mallo, M, E831
Mallouri, D, E1610
Maloisel, F, P649
Maloum, K, E1361
Maloy, M, P745
Maltezas, D, E1304
Maltzman, J, S785, S786
Mammi, C, P610
Mamta, P, E1146
Manabe, A, S799
Mancini, C, E1223
Mancini, F, P166, E1000
Mancini, M, P600
Mancini, V, P644
Manco, L, E1593
Mandelli, F, E1186
Mandelli, G, S128
Manfra, I, E1497
Mangelson, R, E881, E902, E1204
Mangiavacalli, S, E1293
Manier, S, S779, P323, E1354
Manko, J, E1257
Mann, G, S480
Manna, F, S811
Mannelli, F, P355
Mannelli, L, E1401
Mannion, N, P180
Mannu, C, E1408
Mano, H, S799
Mano, S, P691
Manoj, N, E894
Manola, K, E895
Manolov, V, E1155
Mansfield, C, P709
Manshour, T, P690
Mansouri, L, P244
Mansueto, G, P604, E1261
Manta, L, P179, P206
Mantoan, B, S778, E1408
Mantzaris, I, S135
Mañu, A, P198
- Mañu Pereira, M, P615
Manz, K, P255
Manz, M, S112, S113, P231, P266, E1536
Manzoni, M, P586, E1390
Maragno, A, P175
Marani, L, E1494
Marantz, J, S498
Marasco, V, S806
Marçais, A, E1386
Marcatti, M, S806
Marcé, S, E831
Marcelli Graziosi, B, E967
Marcher, C, P193, E932
Marchesi, F, P760
Marchesi, F, E1145, E1379
Marchesini, M, P321
Marchetti, M, P760, P766
Marchetti, M, E1332
Marchetti-Laurent, C, E829
Marchica, V, E1223
Marco De Lucas, F, E1183
Marcon, A, P396, E1576
Marconi, C, S433, P365
Marconi, G, E882, E898
Marcos Jubilar, M, S444
Marcotegui, N, P536
Marcucci, G, P186
Marcus, R, S774, S775
Mardiros, A, P523, E840
Marekovic, I, S795
Marfa, S, P532
Margaritis, D, P280
Mariana, A, P154
Mariaselvam, C, E1495
Mariglia, P, E989, E1000
Marimpietro, D, E1237
Marin, D, S792, P739, E914, E1512, E1538
Marín, L, E887
Marinakos, T, E895
Marinello, P, S783, P344
Marini, I, P364
Marini, S, E1080
Marino, M, E1379
Mariotti, V, E1048, E1274
Maris, M, S793
Marit, G, P345
Mark Toye, A, P391
Markevärn, B, E1057
Markham, J, E1202
Markiewicz, M, P741
Markova, J, S150
Markova-Štastna, M, E1198
Markovic, O, E970
Marković, D, E1328
Marks, D, S802, S817, P164, P525
- Markt, S, S128
Marlein, C, E874
Marlton, P, P203, P547
Marmont, F, P214
Marocolo, D, E1190
Marolleau, J, S107, E1135, E1537
Marotta, P, E1226
Marques, G, E1033, E1188
Márquez, F, E1349
Márquez, J A, E1183
Marquez-Malaver, F, P746
Márquez-Matito, A, P213
Marra, N, P717
Marra, R, S811
Marrero, C, P376
Marsh, J, E1550
Martella, E, E1223
Martella, M, E1489
Martelli, M, S485, P600
Martelli, M, P173
Martello, M, E1238
Martens, J, S117, P325
Martí, E, P554
Martí-Renom, M, S117
Marti-Tutusaus, J, S790, P202
Martin, L, E1356
Martin, P, S476, P517
Martin, P, E1129
Martín, A, E953
Martín, A-Á, E1014, E1592
Martín, J, E972
Martín, J, S409, P688
Martín, P, E972
Martín-Antonio, B, E1088
Martin Azara, M, E1258
Martín-Calvo, N, P688
Martín-Clavero, E, P661
Martín-García, D, S115
Martín Herrero, S, E1596
Martín-Izquierdo, M, P655, E1169
Martín-Lorenzo, A, S148
Martín-Núñez, G, E1014
Martín-Peña, A, S804
Martín-Sánchez, M, E1222
Martin-Santiago, A, E1341
Martín-Santos, T, E953
Martin-Subero, I, E1381
Martin-Subero, I, S117
Martín-Subero, J-I, P244, P300, P325, E1225
Martinat, A, P758
Martinelli, G, S110, S111, S473, S478, S485, P344, P355, P519, P560, P599, P600, P605, P607, E882, E898, E904, E1086
Martinelli, S, E1020
Martinelli, V, P358, E1459

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Martinello, L, E1005, E1006, E1011
 Martínez, A, E1546
 Martínez, A, E1137, E1394
 Martínez, C, P746
 Martínez, C, P573, E1434
 Martínez, E, P528
 Martínez, I, P573
 Martínez, J, P509, E1086
 Martínez, N, E1113
 Martínez, R, S409, P688, E1278
 Martínez Bea, A, E1426
 Martínez-Cuadron, D, P554, E1086
 Martínez-Laperche, C, P513, P696, E1113
 Martínez-López, MD, J, S409, P320, P329, P554, P609, P661, P679, P695, P696, P703, E831, E891, E899, E900, E1051, E1234, E1278, E1317
 Martínez-Marín, A, E1562
 Martínez-Martínez, I, E1456
 Martínez-Millán, C, E953
 Martínez-Muñoz, M, E1541
 Martínez-Pacheco, V, E1306
 Martínez-Picado, J, E1396
 Martínez-Robles, V, P737
 Martínez Roca, A, E1426
 Martínez Rolon, J, E1508
 Martínez-Trillos, A, E1137
 Martínez-Velandia, A, E1563
 Martinho, P, E1593
 Martini, M, P282
 Martini, V, E1005, E1006, E1011
 Martino, B, P256, P358, P601, P605, P610, P702, P705, E1333, E1334
 Martino, M, S804, E1349
 Martino, R, P746, E1026, E1160
 Martinou, J-C, P268
 Martire, B, P717, E1420
 Martorelli, C, E967
 Marty, F, S807
 Martynenko, L, E1313
 Martynkevich, I, E1313
 Marun Chagin, J, E1074
 Maruzzi, M, E1164
 Marwood, E, P164
 Masala, E, E1173
 Mascarenhas, J, P699, P701, E1343
 Maschan, A, P367
 Mascheroni, M, E1315
 Maschio, N, P358, P616
 Maschmeyer, G, P555
 Masciulli, A, P163
 Masera, N, S128, E1489
 Masetti, R, P350
 Maslah, N, S787
 Massa, M, E1243
 Massaia, M, E999
 Massano, D, E955
 Massaro, F, P306, E976, E1325
 Masselli, E, P528
 Masszi, T, P601, E1535
 Masternak, A, E1193
 Masubuchi, N, P691
 Mata-Vázquez, M-I, P703
 Matarese, C, P393
 Matarese, S, E915
 Matas-Céspedes, A, E1369
 Matasar, M, S468
 Mate, J-L, E1394, E1396
 Mateos, M, P205
 Mateos, M-V, S409, S456, S459, S783, P329, P335, P339, P679, P688, E1222, E1278
 Mateos, R, P679
 Matheny, S, P328, E1373
 Matheson, E, P512
 Mathian, A, P716
 Mathias, J, P706, E1320
 Matic, S, E1448
 Matito, A, P713
 Mato, A, S465, P566
 Matos Silva, H, E1425
 Matous, J, S779, E1246
 Matsuda, T, P592
 Matsue, K, P301, E1285
 Matsui, H, E1590
 Matsumoto, C, P401
 Matsumoto, K, E962
 Matsumura, A, E962
 Matsumura, I, E1100
 Matsuo, A, P531
 Matsuo-Tezuka, Y, E1162
 Matsuoka, M, E1205
 Matsuoka, S, P401
 Matsuoka, Y, E1477
 Matsushita, A, P196
 Matte', A, P392
 Mattei, D, P163
 Mattenheimer, K, E1569
 Matteucci, C, E1174
 Matthews, J, S474
 Matthijssens, F, S438, E1358
 Mattiello, F, S774
 Mattiello, V, E1030
 Mattijssen, V, S501
 Mattsson, M, S462
 Matutes, E, E1137
 Maude, S, S476, S477, P517
 Maung, S, E1187
 Maung, Z, P225
 Maura, F, E1201
 Maurer, A, P231
 Maurer, M, E1280
 Maurillo, L, S111, E908
 Mauro, E, P604
 Mauro, F, E989, E1000, E1017
 Mauro, M, S425, S788, E1060
 Maus, M, S142
 Mavilio, F, S144, S147
 Mavrianou, N, E1231
 Mavrommatis, K, E1203
 Mavroudi, I, E1419
 Maw, K, P276
 Mayado, A, P713
 Mayer, A, E1402
 Mayer, J, S426, S435, E936, E1003, E1004, E1180
 Mayer, K, P666
 Mayer, P, E1376
 Mayne, E, E1405
 Maza-Villadiego, A, E1074
 Maze, D, P708, E1324
 Mazis, C, E1431
 Mazor, T, P353
 Mazza, P, S111, E1561
 Mazziotta, F, P671
 Mazzucconi, M, P306, P358, P722, E976, E1340
 Mba, C, E1051, E1059
 Mc Cormack, E, E866, E903
 Mc Guckin, S, E1445
 McBean, M, E848
 Mccallion, C, E1007
 McCallum, M, S441
 McCarthy, P, P332
 McCausland, K, P373, E1468
 McClain, V, S108, P197, E921
 McComb, S, S437
 McConnell, S, E1476
 McCormack, E, P181
 McCourt, P, P697
 Mcdermott, S, P761
 McDonald, D, P589
 McDonald, P, P191
 McDonnell, K, P680
 Mcelligott, J, E1490
 McGarry, L, E1055, E1464
 McGuirk, P, P317
 McHugh, J, E1187
 McKendrick, J, E1480
 McKenna, M, E1288



- McKeown, A, P248
Mckeown, M, P188, E884
Mckerrell, T, S420
McKinney-Freeman, S, P271, P758,
E1099
McKittrick, I, E1090
McLornan, D, S785, E1338, E1550
McMullin, M, P697
McNamara, C, P708, E1324
McNeil, J, P674
McNicholl, F, E1228
McParland, L, P252
McPherson, S, P697
McQuilten, Z, P674
McWeeney, S, P194
Mead, A, S421, P270, P668, E1110
Meade, J, S469
Mecacci, B, E1042, E1215
Mecucci, C, E1174
Meddeb, B, P640, P723, E1437
Medeiros, B, S471, P193, P207, P210,
E922, E932
Medeot, M, E1065
Medina Ceballos, E, E1500
Medrano, M, P543, P756
Medrano Engay, B, E1412
Mędraś, E, E1061
Medvedeva, N, E1154
Megalakaki, A, S415, E1266
Megalakaki, E, P280
Meggendorfer, M, P199, P549, E1312
Meggyesi, N, E1535
Megido, M, P655
Mehra, M, E1138, E1322
Mehta, A, S468
Mehta, A, P731
Mehta, B, P367, P727, E1180
Mehta, T, E873
Meier, O, P640
Meignan, M, S774
Meijer, A, P404
Meijer, E, P576
Meijer, R, S113
Meijerink, J, S439, P152
Meissner, B, E1023, E1035
Meissner, J, S150
Mejstříková, E, P711
Mekan, S, S456
Melandri, A, E1020
Melanthiou, K, S420
Melazzini, F, P365, S432, S433
Melchardt, T, P707
Melear, J, P634
Melen, G, P513
Meliksetyan, K, E1067
Melikyan, A, E1436
Melillo, L, S111
Mellor-Heineke, S, S497
Mellqvist, U-H, S501
Melnick, A, P297, P325, E1225
Melo, D, E1075
Meloni, A, P394, P399, E1570, E1571,
E1575, E1577
Meloni, G, P520
Melosi, A, E1401
Melpignano, A, S129
Melville, K, E1350
Melvin, C, P571
Mendek-Czajkowska, E, P741
Mendeleva, L, E1227, E1295, E1545
Méndez Navarro, G, E1551
Mendoza, M, P550
Menezes, R, P190
Meng, H, E1085
Meng, L, P356
Mengarelli, A, E1145, E1379
Menna, G, P715
Menon, H, E1062
Menon, K, E904
Menu, E, E1211, E1220
Menzl, I, E1045
Merati, G, E1078
Mercadal, S, E831, E957
Merchant, A, P204, P525
Mercher, T, S427
Mercier, M, P572
Mercier Blas, A, P649
Meresse, B, E1386
Meritet, J-F, P631
Merkel, A, S117, P300
Merkhoffer, Y, E1387
Merli, M, P351
Merli, P, S146, S495, P381
Merlini, G, P337, P684, E1243
Merritt, B, E950
Mershina, E, E1161
Mertens, D, S116, P248
Mesa, R, S505, S785, P359, P377,
P699, P701, P706, E1320, E1321,
E1331, E1339, E1343
Mesegue, M, P168
Meshinchi, S, P184
Messina, C, P738
Messina, M, S800
Messinger, Y, S808
Mestice, A, E1560
Metais, J-Y, P509
Metelli, M, P599, E1048, E1318
Metti, A, E1481
Mettivier, L, E967
Metzeler, K, P546, P656, E885
Metzler, M, E1117, E1391
Metzner, M, S791
Meunier, M, E1178
Meydan, C, P325, E1225
Meyer, L-H, P508, E838
Meyer, M, E838
Meyer-Pannwitz, V, S116
Meziani, L, P268
Mezzabotta, M, P667, E1332
Mezzasoma, F, P173
Mezzatesta, C, S437
Mi, Y, E911, E916
Mian, S, P657
Miano, M, P234, P575, E1440
Mianulli, A, E946
Miao, L, E1152
Miao, M, E931
Miazek, N, S125, E1359, E1385
Micalizzi, C, P234, P575, E1440
Miccio, A, S147
Miceli, R, E1533
Michaels, V, P274
Michaelis, L, E1192
Michalak, S, E1079
Michalis, E, P280
Michalis, M, S415
Michallet, M, S131, S797, S798, P557
Michalski, W, P162
Michaud, L, E1001
Michal, G, P716
Michelis, R, E1015
Michot, J-M, S467, E1018
Mickeviciute, O, E1311
Mickys, U, E1399
Micò, M, E1315
Micò, C, P520
Micucci, G, P636, E1136
Middelburg, R, P312
Midolo, M, E821
Miesel, L, P645
Miething, C, S127, E1355, E1364
Migling, M, S413, P283, P667, E854,
E915, E919, E933, E1505
Migliori, V, S430
Migone De Amicis, M, P396
Mihai, F, E1602
Mihaljevic, B, S443, E970
Mihaylov, G, E1556
Mikhael, J, S457, P675
Mikhael, N, E1411
Mikhalcova, E, E1545
Mikhaltsova, E, E1559
Mikhaylova, E, E982
Miklos, D, S466, S492, P522
Milan, E, E1232
Milani, M, E989
Milani, P, P337, P684, E1243
Milani, R, S128
Milani, S, E1420
Milano, F, P173

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Milenkovski, R, P732
 Milic, N, S443
 Miljić, P, E1328
 Millacoy, D, E1604
 Miller, C, S773, S777, E1130
 Miller, C, P233
 Miller, J, S108, P197, E846, E847, E921
Miller, K, P165
 Miller, M, P526
 Miller, R, P317
 Mills, K, P539, P697
 Mills, K, E1224
 Millstine, D, S505
 Milne, T, P540
 Milojkovic, D, S423, S817
 Milovic, V, E1508
 Milsom, M, P528
 Mims, A, E1073
 Min, C-K, P638, P742, P757, E1513
 Min, W-S, P551, P561, P638, P742, E1513
 Mina, R, E1247
 Minaeva, N, E1526
 Minami, Y, P263
 Miñano, A, S445, P721, E1456
 Minarik, J, P333, E1272, E1290, E1298
 Minarik, L, E1166
 Minauchi, K, E859
 Minden, M, P708
 Minderman, M, P567
 Mine, T, P642
 Mineno, J, P621
 Minervini, A, P598
 Minervini, C, P598
 Minetto, P, E854, E915, E919, E933, E1505
 Minga, E, P242
 Mingot-Castellano, M E, P720
 Minh Thong, P, P287
 Minhas, S, E1049
 Mini, E, E1401
 Minnema, M, S411, P340, P686, E1250
 Minotti, C, P166
 Minotto, C, E930
 Minvielle, S, E1201, E1206, E1360
 Mir, B, P629
 Mirabelli, R, E1021
 Miraki-Moud, F, P532
 Miralles, P, E1394
 Miranda, A, E1586
 Mirandola, P, P528
 Mirás, F, P661
 Mironova, O, E1154
 Mirra, N, S128, E1420
 Misery, L, E1348
 Mishima, Y, E1354
 Mishin, G, P307
 Mishiro, I, E1260
 Mishra, B, S147
 Mishra, K, E851
 Mishra, V, P571
 Misiewicz-Krzeminska, I, P751
 Miskin, H, S772, P563
 Misra, H, P618, E1149
 Missere, M, P399
 Mistretta, L, P290
 Mitchell, K, S135
Mitchell, R, S802, P160
 Mitchell, R, S481
 Mitev, V, E1155
 Mitrovic, M, E1448
 Mitrovic, Z, E969
 Mitrović-Ajtić, O, E1316, E1319
 Mitscheunig, L, P283
 Mitschke, J, E1364
 Mitsuda, Y, P531
 Mittelman, M, E1107
 Miura, M, E1053
 Miura, O, P302
 Miyamura, K, P383
 Miyanishi, K, E1213
 Miyano, S, S120, S123, S124, S799, P299, P314, P537
 Miyashita, K, E962
 Miyashita, N, P360
 Miyawaki, K, E1111
 Miyawaki, S, P537
 Miyazaki, T, E962
 Miyazaki, Y, P314
 Miyazaki, Y, E1068
 Miyoshi, H, P299, P301
 Mizukami, T, P401
 Mizukami, Y, P691
 Mizuno, S, E1210
 Mizuno, Y, E959
 Mladov, V, E1040
 Mlak, R, E888
 Mo, X, E1498
 Mo, X-D, P387, E1503, E1511, E1515
 Moarii, M, E1201
 Moccia, A, P282
 Mocikova, H, P218
 Moehle, B, E1109
 Moericke, A, P515
 Moestl, M, E1510
 Mogg, R, S783
 Mohamed, S, E1573
 Mohamedali, A, P657
 Möhle, R, P700
 Mohmoud, F, S149
 Mohr, B, E1168
 Mohty, B, P354
 Mohty, M, S493, S797, S798, P345, P379, P384, P388, E1506
 Moiraghi, B, P257
 Moiseeva, T, E982
 Moisesescu, M, E1602
 Mojsilović, S, E1308, E1319
 Moka, H, P591
 Mokhtar, N, P291
 Moles, M-P, P217
 Molfetta, R, E1005
 Molica, M, E1325
 Molica, S, E1017, E1021
 Molina, A, P328, E1373
 Molina, T, E1386
 Molina-de-Salazar, D, E1074
 Molinari, A, P304
 Moll, R, P403, P405
 Mollard, L-M, E1348
 Mollee, P, P674, E1289
 Møller, M, E1367
 Mollica, L, S776
 Molloy, T, E880
 Mologni, L, P570
 Molteni, A, E1195
 Momčilović, S, E1316
 Momotow, J, E1119
 Monagheddu, C, P667
 Monaldi, C, P600
 Monceyron Jonassen, C, E1434
 Monchecourt, F, P649
 Mondejar, R, P571, E834
 Mondet, J, P692
 Mondini, M, P268
 Monfray, J, P557
 Monga, N, E1138
 Monitillo, L, P304, E1408
 Monnickendam, G, E1480
 Monohan, G, P279
 Monsef, I, S812
 Montalban-Bravo, G, S487, S489, P200, P315, P317, P652, P665
 Montali, M, E1048
 Montanaro, M, E1340
 Montano, C, S109
 Montaña, A, E1014
 Montefusco, E, P604, E1340
 Montefusco, V, S410, P341, E1207
 Monteiro, E, E1586
 Monter, A, E1160
 Montero, I, S804, P609

- Montero, M, E1349
Montes, R, E893
Montesdeoca, S, E1156
Monteserin Monteserin, C, E983
Montesinos, P, P554, E1086
Monti, A, E1497
Montillo, M, S465, S769
Montini, E, S128
Montoto, S, E1394
Montoya, M, E1604
Montserrat, E, E1259
Montserrat, E, E1031, E1032, E1039
Moon, J, E1445
Moon, J-H, P569
Moon, J, E1177
Moore, E, P674
Moorman, A, P152, P160, P164
Mopett, J, S801
Mora, A, E1026
Mora, B, P351
Mora, E, P703
Mora Casado, M, P554
Morabito, F, P586, E1017, E1390
Morais Bras, L, E1530
Moraki, M, P397, E1158
Moraleta, J-M, E1394
Moraleta-Jiménez, J, E1562
Morales, M, E900
Morales Hernandez, A, P758
Morales-Cacho, L, E893
Morales-Camacho, R, P213
Morandi, F, E1237
Moravcsik, E, P176
Morbelli, S, P283
Mordak-Domagala, M, E1262
Moreau, A, S105, E1360
Moreau, P, S456, S458, S460, S783,
P334, P345, P348, P675, P735,
E1201
Moreau, S, E1458
Moreaux, J, E1211
Moreira, C, P293
Morel, P, E1135, E1537
Morel-Kopp, M-C, S434
Morelli, O, E949
Morello, W, E1077
Moreno, C, S462, S769, E1026, E1027
Moreno, C, S461
Moreno, G, E1609
Moreno, M, E1396
Moreno, T, S420
Moreno Jiménez, G, E1551
Moreno-Martinez, D, P368
Morente Constantin, E, P768
Moret, C, E1455
Morgades, M, E831
Morgan, E, E1354
Morgan, G, S407, S781, E1203
Morgan, R, S142
Morgan, S, E848
Morganti, R, P599
Mori, M, E1273
Mori, N, P313
Mori, S, P570
Mori, T, E1477
Mori, Y, E1111
Möricke, A, S480, E849
Morishita, S, P691
Morishita, T, P383
Morita, K, P531
Morita, K, P550
Morita, M, P612
Morita, S, P263
Moritake, H, S799
Moriuchi, Y, P385
Moriya, K, P327, P659, E1175
Morlan Mairal, M, E1307
Morley, N, S802, P164
Morlino, G, S125
Morresi, L, P636
Morris, C, E1228
Morrison, H, P591
Morschhauser, F, S106, E1018
Morscio, J, S438, P156, E1358
Morton, D, S451
Morton, J, E1129
Mosa, C, P717
Mosca, M, E1318
Moscardó, F, P554
Moschetta, M, E1354
Moschini, A, E1268
Moschogiannis, M, S416, P639, E1036,
E1120
Moschoyianni, M, P280
Moseley, A, S146, S495, P381
Moshous, D, P631
Moskowitz, C, E1126
Mosna, F, E930
Mosquera Orgeira, A, E1327
Mossuz, P, P692
Mosulen, S, S467
Mota, D, E1080
Motohashi, K, E962
Mottok, A, E1569
Motwani, J, P668
Motyko, E, E1313
Moujalled, D, P175
Moulis, G, P289
Moulis, J, E1178
Mounter, P, P225
Mountford, J, E1081
Mourits-Andersen, T, P697
Mouro, J, E1248
Moussy, A, P709
Mowery, C, S428
Moya, M, E953
Moya-Arna, M, E1562
Mozas, P, E1031, E1032, E1039, E1137
Mozo, Y, E1546
Mozos, A, E963
Mozzicafreddo, G, E1136
Mozziconacci, M-J, P354
Mpanti, A, P280
Mpatsis, I, P280
Mraz, M, E1003, E1004
Mrozek, K, E883
Mrray, A, P761
Muche, S, P754
Muchowicz, A, E1385
Muckenthaler, M, S809, S813, P284,
P293
Mudie, L, E1201
Mufti, G, P326, P532, P541, P657,
E1245, E1338, E1550
Muftuler Londalen, A, E1141
Mügge, L, P647
Muhar, M, S133
Muiña, B, E953
Muir, K, P295
Mulas, O, P256
Mulaw, M, S429
Mulder, A, E897
Mulholland, N, E1242
Müller, A, E1536
Müller, H, S414
Müller, L, E927
Müller, M, P568
Müller, M, S424, S426, P603
Müller-Tidow, C, S429, E927
Mullier, F, P230
Mulligan, S, S769, S771, E998
Mumford, A, P228
Mun, Y-C, P259, E1054, E1069, E1070
Mun, Y, P249
Munasinghe, W, S460
Muncunill, J, E1394, E1396
Munder, M, S459, E992
Mundle, S, E1322
Mundy, H, E1163
Munir, T, S770, S771, P245, P252, P589
Munje, C, P591
Munk Johansen, M, E1115
Munn, D, E912
Munneke, J, S448
Munoz, J, S106, S773
Muñoz, C, P609
Muñoz, J, P316
Muñoz-Ballester, J, E1013
Muñoz-Calleja, C, E1302, E1305
Muñoz-Chápuli, R, E1103
Muñoz-Criado, S, E1019

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Muñoz-González, J, P713
 Muñoz-Mármol, A-M, E1394
 Muñoz Novas, C, E1038
 Muñoz-Vicente, S, S770, P245, P589
 Munshi, N, S142, S779, S783, P321, E1200, E1201, E1203, E1206
 Munteanu, M, P562
 Muntion, S, P751
 Mura, R, E955
 Murai, K, P263, P642
 Murakami, H, E1447, E1607
 Murakami, N, P171
 Murakami, S, E1210
 Muramatsu, H, P171
 Murase, K, E1213
 Murata, K, E1607
 Murata, T, P385
 Muratani, M, P301
 Murati, A, P354
 Murawski, N, P216, P222
 Muromoto, R, P592
 Murone, M, P159
 Murphy, C, E884
 Murray, J, P589
 Murray, M, S797
 Murt, A, E1518
 Musilova, K, E1004
 Musolino, C, E1247
 Mussetti, A, E1207
 Musso, M, S778
 Mussolin, L, P156, E955
 Mustjoki, S, S426, P593, P595, E1057
 Musto, P, S410, P322, P667, E1226, E1232, E1247, E1261
 Musuraca, G, E904, E1012
 Mutis, T, E1221
 Mutvei, A, E1110
 Muus, P, P369
 Mya, H, E1413
 Myakova, N, P161
 Myers, G, S476, P517
 Myhre, A, E1501
 Mykhalska, L, E1127
 Mysliwicz, J, S809
 Na, E, E892
 Na, H-Y, E1404
 Nachbaur, D, P533
 Nacheva, E, E905, E1176
 Nachmias, B, E1121
 Nadal, N, E1001, E1361
 Nadali, G, E1120
 Nadarajah, N, P549
 Nadeem, O, S779
 Nader, N, E926
Nadeu, F, S115
 Nagai, H, E1139
 Nagao, S, P689
 Nagarajan, C, P646
 Nagarkar, R, P635
 Nagasawa, T, P266
 Nagase, I, E940
 Nagashima, T, E1447, E1607
 Nagata, Y, P537
 Nagate, Y, E1370
 Nagi, W, E978
 Nagler, A, S107, S493, S776, S797, S798, P269, P379, P384, P388, E1504, E1506
 Nagy, Z, S470, S777
 Nahi, H, P334, P338
 Naik, S, S146
 Naima, M, E1472
 Najet, S, E1275, E1479
 Najib, D, E1034
 Nakagawa, M, S120
 Nakagawa, Y, P263
 Nakajima, H, E962
 Nakajima, Y, E962
 Nakamae, H, P263
 Nakamura, H, E1213
 Nakamura, N, P301
 Nakamura, N, E1230
 Nakamura, R, S492
 Nakamura, S, P691
 Nakamura, Y, P612
 Nakao, S, P314
 Nakashima, M, P383
 Nakasone, H, P621
 Nakastoev, I, E1227
 Nakatochi, M, P171
 Nakauchi, H, E951
 Nakazato, T, E1058, E1066
 Nakazawa, H, S120
 Nakazawa, Y, P171
 Nakry, T, P649
 Naldini, L, S128
 Nam, J, P680
 Nam, J, P732
 Naman, H, P217
 Nan, X, E950
 Nandigam, R, E1430
 Nanni, J, E882
 Nanni, M, E1000
 Nannya, Y, S120, P314
 Nantel, S, P581, E1557
 Naoe, T, P314
 Naparstek, E, E1524
 Napoli, C, E1401
 Napolitano, R, E904, E1012
 Nappi, D, E1459
 Naqvi, K, S487, E913, E935
 Narang, M, P349, E1239, E1277
 Narayanagari, S-R, S135
 Narayanan, S, P581, E1557
 Nardacci, M, E1000
 Nareyko, M, E1227, E1295
 Narita, A, P171
 Narita, K, E1285
 Narni, F, S778
 Narula, G, E837
 Nascimento, T, E1080
 Nascimento Costa, J, E1287
 Nassar, K, S777
 Nasserinejad, K, S411, P340
Nasso, D, P384
 Nasta, S, P566
 Nastoupil, L, S772
 Natale, A, P394
 Natalija, B-V, E1110
 Natalya, M, P311
 Nathwani, A, P252
 Nattamai, K, E1109
 Naughton, T, S802, P160
 Naumann, N, E1344
 Naumovska, Z, E1471
 Nava, I, E1576
 Navada, S, S488, E1170, E1185
 Navale, L, S466, P522, P523, E840
 Navarro, A, S115, E1032
 Navarro, B, E1541
 Navarro, B, E972
 Navarro, B, S115
 Navarro, J-T, E1394, E1396
 Navarro, S, S144, E1097
 Navas, B, P554
 Nazarova, E, E1526
 Nazha, A, P352
 Nebreda, Á, P536
 Nee, J, P279
 Neelapu, S, S466, P522
 Neff, F, S809
 Negrin, R, E1569
 Negrini, M, E1020
 Nemecek, E, S146, S476
 Nemet, D, E969, E1296
 Nemra, M, E1472
 Nerea, M, P205
 Neri, A, P586, E1000, E1017, E1216, E1226, E1268, E1390
 Nerich, V, P345
 Nerl, C, S424
 Nerlov, C, P540, E1110

- Nerreter, T, S145
 Nesterova, A, E1461
 Nestheide, S, S149
 Neubauer, A, S110, S424, P216, P222, P560
 Neuberg, D, P237
 Neumann, D, E1107
 Neumeister, P, E1363, E1395
 Neureiter, D, P195, P558
 Neven, B, P716
 Nevill, E, P581
 Nevill, T, P581
 Newberry, K, P690
 Newell, L, P210, P556
 Newland, A, E1430, E1453
 Newmark, J, E1149
 Nezi, L, P321
 Ng, H, E1413
 Ngoc Quynh, A, P654
 Nguyen, A, P287
 Nguyen, C-H, P514
 Nguyen, J, E1102
 Nguyen, L, P186
 Nguyen, N, P287
 Nguyen-Khac, F, E1001, E1361
 Nguyen-Quoc, S, E910
 Ni, Q, E1282
 Ní Ainle, F, E1452
 Niazi, G, E1572
 Nibourel, O, E1171
 Nickel, A, S497
 Nicolás, M, S444
 Nicolas-Virelizer, E, P572
 Nicolini, F, P257, P603
 Nicolini, M, P636
 Nicolino, B, P214
 Nicolo', C, E1254
 Nie, K, S478, P524
 Nie, Y, S490
 Niederwieser, C, E927
 Niederwieser, D, P388
 Niederwieser, D, P261, P380, P555, E1506
 Nidoszytko, M, P709
 Nielsen, A, E1267
 Nielsen, T, S774, S775
 Niemann, C, S109
 Niemeyer, C, P350, E1167
 Niemöller, C, P656
 Niesiobedzka-Krezel, J, P594
 Niesvizky, R, S408, S458, E1244
 Nieters, A, P656
 Nieto, J, E1444
 Nieto, W, P584, E1019
 Nieto, Y, E1538
 Nifenecker, M, E923
 Nigauri, C, E962
 Niggli, F, S480
 Nigita, G, E917
 Niioka, T, E1053
 Nijland, M, P567
 Nijls, G, S141
 Nikita, M, E862
 Nikitin, E, E1029
 Nikitin, I, P220, E1133
 Nikkilä, A, P734
 Nikolaou, E, E1266, E1304
 Nikolic, V, E970
 Nikolov, O, E1471
 Nikolova, Z, S467
 Nikolovski, S, S443
 Nikulina, E, E1409
 Nikulina, O, E1161
 Nilsson, B, E826
 Nilsson, I, S805
 Nimmagadda, S, E865
 Ninomiya, S, E1230
 Niolat, J, S788
 Nippgen, C, S469
 Niscola, P, P658, E1186
 Nishida, H, E1229
 Nishida, K, S124, P299
 Nishikawa, E, P171
 Nishikii, H, E1519
 Nishimura, J-I, P578
 Nishimura, N, E1205
 Nishimura, S, P621
 Nishio, K, E1590
 Nishio, N, P171
 Nishizawa, S, P301
 Nityanand, S, E981
 Niu, T, P224, E1383
 Nizzero, M, E955
 Nloga, A-M, P657
 Nobili, S, E1401
 Noe, L, P728, E1466
 Noens, L, S411
 Noesslinger, T, E1510
 Nofrini, V, E1174
 Noguchi-sasaki, M, E1162
 Noguera-Gonzalez, G, S487, S489, P315
 Noh, H, P259
 Nojima, K, P401
 Nollet, F, E1056
 Nöllke, P, P350
 Nombela Arrieta, C, P266
 Nomdedeu, B, E1181
 Nomdedeu, J, S790, P202
 Nomdedeu, J, P759, P765, E831, E1026
 Nooka, A, S459, P335
 Noonan, K, S779
 Nordon, C, E1439
 Norell, H, E889
Norfo, R, S421
 Nørgaard, J, P193, E932
 Nørgaard, M, P193, E932, E1435
 Noria, A, E1273
 Noris, P, S432, S433, P365
 Noroozi-Aghideh, A, P309
 Nørrellykke, S, P266
 Norris, B, P194
 Norris, M, P154
 Norton, A, P668
 Norvilas, R, E1311
 Nosari, A, P644
 Nota, B, P404
 Notarangelo, L, P717, E1420
 Notario McDonell, C, E983
 Nöthen, M, P295
 Novák, J, E936
 Novak, R, S147
 Novak, U, S150
 Nováková, M, E1376
 Novella, E, S485
 Novelli, E, E1481
 Novelli, S, E963
 Novo, S, E1577
 Novoa, V, E1182
 Novosad, O, E1382, E1127
 Noyszewska-Kania, M, E886
 Nozzoli, C, E1215, E1270
 Ntanasis-Stathopoulos, I, E1249
 Ntoufa, S, P244
 Nucifora, E, E1182
 Nudejima, M, P691
 Nudelman, O, P548
 Nunez, A, P654
 Nuñez Cortés, A, E1500
 Nunn, M, P235
 Nur, E, S455
 Nyvold, C, E1367
 O'Brien, M, P521
 O'Brien, S, S423, P591
 O'Brien, S, S463, S769, S772, P170, P209, P240, P253, P518, P519, E991, E1016
O'Byrne, S, P270
 O'Connell, A, P204
 O'Connor, D, P668
 O'Connor, P, E1147
 O'Dwyer, M, P203, P547
 O'Meara, M, P201
 O'Meara, S, E1201
 O'Reilly, R, P745
 O'Rourke, L, P334
 O'Sullivan, J, E1550
 Oakes, C, P663
 Oakes, R, P225
 Obara, M, E859

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Obara, N, E1519
Oberbeck, S, E1376
Obéric, L, S105, P217, P641
Obregón-Martínez, M, E1074
Obreja, M, P333
Obukhova, T, E860, E1227
Obukhova, T, E836
Ocak, O, P723
Ocak Arıkan, O, E1437
Occhini, U, E1043
Ocio, E, S409, S783, P688, E1222
Odchimar-Reissig, R, S488, E1170, E1185
Oddolo, D, P322
Odenike, O, E1192
Odero, M, P205, P536
Oehler, V, P204
Oehme, I, P663
Oelmüller, M, P582
Oelschlaegel, U, E1168
Oestergaard, B, E1267
Offidani, A, P636
Offidani, M, S102, S410, P322, P341, P343, E1247
Ofran, Y, P548
Oganesian, A, E1192
Ogasawara, M, P263
Ogata, M, P385
Ogawa, S, S120, S123, S124, S799, P299, P301, P314, P537
Ogbonnaya, A, E973, E1184, E1191, E1196
Ogoti, Y, P321, P652
Ogura, M, P635
Ogusa, E, E962
Oguz, B, E1603
Oh, S, P259, E1054, E1069
Oh, S-J, E1062, E1070
Ohanian, M, S487, P315, E913
Ohara, A, S799
Ohashi, K, P263, P389, E1522
Ohbiki, M, P383
Ohki, K, S799
Ohkuma, K, P401
Ohmori, T, P621
Ohsaka, A, P691
Ohshima, K, S124, P299
Ohwashi, M, P313
Ohyashiki, J, E1046, E1072, E1209
Ohyashiki, K, P314, E1046, E1072, E1209
Oka, A, S799
Okabe, S, E1046, E1072
Okada, M, P263
Okada, Y, P689
Okamoto, S, P621
Okamoto, Y, E1205
Okano, Y, P642
Okasha, D, S802
Okitsu, Y, P612, E1104
Okosun, J, P303
Oksman, M, P613
Okuchi, K, E1590
Okumura, H, E1522
Okuno, Y, P171, P314
Okuno, Y, E1205
Olaso, R, P274
Olavarria, E, E1059
Olave, T, P554
Oldani, E, P163
Olde Weghuis, D, P239
Oliva, E, P290, E1180, E1476
Oliva, S, S102, P322
Olivares-Gazca, J, E1500
Oliveira, A, E1080
Oliveira, A, E1588
Oliveira, M, E822
Oliveira Ramos, A, E957
Olivera, P, E1594
Olivier, C, P376, P655
Olivier, E, E1081
Olkhovskiy, I, E1314
Olmedo-Pelayo, J, E893
Olona Cabases, M, E1426
Olsen, R, E950
Olshanskaya, Y, P161
Olshen, A, P353
Olson, A, S792, E1538
Olson, E, P188, E884
Olsson-Strömberg, U, S426, E1057
Oltova, A, P238
Oluwole, O, S466, P522
Omar, S, S448
Omedè, P, S102, S410
Omer, M, E1602
Onder Sıvıs, Z, E1422
Onec, B, E1165
Onec, K, E1165
Onecha De La Fuente, E, E891, E899
Ong, V, P645
Ongoren, S, E1159
Ongoren Aydin, S, E1518
Onishi, Y, P612, E1104, E1199
Öniz, H, E1422
Ono, Y, P196
Onodera, A, P327
Onodera-Kondo, A, E1175
Onofrillo, D, P717
Onozawa, E, P302
Onozawa, M, P360
Oortgiesen, B, P683
Ooyama, R, E1477
Op de Beeck, J, S439, P152, P153
Opalka, B, P534, E1118
Opatrna, V, P248
Opelz, G, P597
Or, R, P744
Oran, B, S450, S792, P739, E914, E1512, E1538
Oravec-Wilson, K, P753
Orazi, A, E1342
Orchard, K, S797, S817
Orciuolo, E, P671
Ordoñez, R, P325, E1225
Orero, M, E953
Orfao, A, P329, P584, P713, E1019
Origa, R, S128, P286, P288
Oriol, A, S409, S458, P333, P334, P672, P688, E1278
Oriol, A, P329
Oritani, K, P592, E1370
Orlandi, E, P604, P729
Orlando, G, P295
Orlowski, R, S458, S783, P334
Orlowsky, R, P321
Orman, I, E1094
Orofino, N, S485, E1346
Orr, N, P295
Orru, S, P256
Orsini, P, P598
Ørskov, A, S486
Ortega, M, E1027
Ortega, R, P751
Ortiz, M, E1203
Ortiz-Maldonado, V, E1031, E1032, E1039
Ortuño, F, P402, P660, E953, E1013
Osaki, M, P383
Osawa, Y, P689
Osborne, S, S107
Oscier, D, P244
Oshima, K, P301
Osickova, J, E1004
Osman, J, E1374
Osmanov, D, P635, E1129
Osnes, L, E1501
Osorio, MD, S, E1051
Osowiecki, M, E1262
Ossenkoppele, G, S112, S113, P190, P265
Østengen, Å, E1141
Oster, H, E1107

- Østgård, L, P193, E932
 Ostojic, A, E971, E1296
 Ostrovsky, O, P269
 Ostrowska, B, P162
 Ota, A, E1210
 Ota, S, E859
 Ota, Y, S124
 Otero, V, E1264
 Otsuka, M, E1205
 Ottaiano, M, P393
 Ottaviani, E, E882, E898, E1309
 Otten, V, P272
 Ottmann, O, P516
 Otto, G, S140
 Ottone, T, E908
 Oughton, J, P252
 Oukid, S, E985
 Oussoren-Brockhoff, Y, S113
 Overman, B, S450
 Owen, C, S774
 Owen, E, P258
 Owen, R, S407, S781, P669
 Oyake, T, P642
 Oyen, R, P565
 Oymak, Y, E1427
 Ozawa, Y, P383, P389
 Ozbalak, M, P281
 Ozcan, A, E1428, E1539
 Ozcan, M, P281
 Özcan, M, P672
 Özdemir, G, E1418
 Ozeki, K, E1516
 Özgümü_, T, E1446
 Özgür Yurtas, N, E1159
 Ozkocaman, V, P281
 Özkul, Y, E1428
 Ozlem, O, P720
 Ozmen, D, E1159
 Paba-Prada, C, S779
 Pabst, T, S112, S113
 Pacault, M, P712
 Paccagnella, M, P519
 Pachzelt, L, E877
 Paciello, M, P661
 Pacini, S, E1048
 Packham, G, P587, E996
 Padayatty, J, P276
 Padella, A, E882, E898
 Padgett, R, S120
 Padilla, J, S445
 Padrnos, L, P359, P377, E1321, E1331, E1339
 Padron, E, E1323
 Pagani, C, P607, P644
 Pagani, I, S484
 Pagano, A, E1151
 Pagano, M, E1006
 Page, I, E1609
 Pagel, J, S769, P253, E923
 Paglia, M, E1145
 Pagliara, D, S146, S495, P381
 Pagliuca, A, S817, E1245
 Pagliuca, T, E1550
 Pagoni, M, P255, E895
 Pahl, H, S418
 Paik, E, S147
 Paillard, C, S131
 Paíno, T, E1222
 Pais de Barros, J-P, S139
 Paiva, A, E1033, E1188
 Paiva, B, S409, P325, P329, P688, E1225
 Paiva, C, S118
 Pakakasama, S, P743
 Pakstyte, S, E1311
 Palacio, C, P298, E995, E1002
 Palanca-Wessels, M, P637
 Palandri, F, S784, P351, P705, E1309, E1325
 Palano, M, E1216, E1268
 Palascak, J, E977
 Palascak, M, E1288
 Palaska, V, E1233
 Palatonova, N, E1216
 Paley, C, P285
 Palgrave, C, P176
 Palianopoulos, T, E1416
 Palladini, G, P337, P684, E1243
 Pallaud, C, P248, P681
 Pallet, N, E829
 Pallisgaard, N, P602
 Palm, A, E826
 Palma-Barquero, V, E1451
 Palmas, A, S410
 Palmer, J, P359, P377, E1321, E1331, E1339
 Palmer, S, E1508
 Palmesino, E, P207
 Palmi, C, S436
 Palmisani, E, P234, P575, E1440
 Paloma, M, E1604
 Palombi, F, E1145, E1379
 Palombo, F, P365
 Palomera, MD, L, P329, P688, E1051, E1278
 Palomera Bernal, L, E1258
 Palomero, J, P296
 Palomo, L, P660
 Palomo Moraleda, M, E1530
 Pals, S, P567
 Paludo, J, E1241, E1274, E1502
 Palumbo, A, S102, S410, P322, P341, E1247
 Palumbo, E, S117
 Palumbo, G, P705, E1186, E1325
 Palumbo, S, E1048
 Palumbo, A, P586, E1390
 Pamboucas, C, P337
 Pan, L, P224, P356
 Pan, Z, P356
 Panagiota, V, S494
 Panagiotidis, P, S415, P639
 Panagiotidis, P, P255
 Panayiotidis, P, S426, P280, E1120, E1304
 Pandey, A, S773, P587
 Pandey, R, P530
 Pandolfini, L, S430
 Pane, F, S485, S504, P277, P599, P605, P667, P722, E1122, E1125, E1459
 Pang, W, P287
 Pangalis, G, S416, P280, P639, E1036, E1120, E1304
 Panganiban, J, E847
 Panitsas, F, E895, E1457
 Panizo, C, P640
 Pankratz, M, S494
 Pannetier, M, E1361
 Panny, M, E1510
 Panovska, A, P238, E1003
 Panse, J, P231
 Pansy, K, E1363
 Pantani, L, S102, E1238
 Panteleev, M, E1029
 Panzarella, T, P708
 Panzer-Grümayer, R, S480
 Paolini, R, E1005
 Paolini, S, P520, E882, E898
 Paoloni, F, P166, P520
 Papa, E, E1145
 Papadaki, H, S416, P280, P639, E1266, E1378, E1419
 Papadaki, S, E1233, E1249
 Papadopoulos, P, E1307, E1310
 Papadopoulos, V, E1610
 Papadopoulou, A, E1083
 Papadopoulou, E, P337
 Papaefstathiou, A, S130
 Papaemmanuil, E, S122, E1201
Papaioannou, D, P174
 Papaioannou, G, S461
 Papaioannou, M, E1407
 Papaioannou, P, E1304
 Papajik, T, S470, E1432
 Papakonstantinou, N, P244
 Papakostas, E, E1263
 Papalexandri, A, E1407
 Papamichos, S, E1235
 Papassotiriou, I, P337
 Papathanasiou, M, E1249, E1610
 Papatheodorou, A, S130

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Papayannidis, C, S485, P355, E882, E898
 Papenfuss, T, E1202
 Papini, G, E941, E1042, E1043, E1215
 Pappa, V, P280, E895, E1266
 Paquette, R, P603
 Páramo, J, S444
 Paramonov, I, E1526
 Paran, E, E1121
 Pardal, E, P329
 Paredes Henao, V, E957
 Parikh, K, E1277, E1282
 Parikh, S, P254, E1017
 Parisi, L, E1138
 Park, B-K, E852
 Park, C-J, E857, E909
 Park, G, E1404
 Park, G, P757
 Park, H-S, E1177
 Park, H, E1062
 Park, H, E852
 Park, H, P764
 Park, J, S143, S479
 Park, J, P350
 Park, J, S779, P323, E1354
 Park, J, E1069, E1070
 Park, J, E1062, E1069, E1070
 Park, K, E852
 Park, M, E968
 Park, N, S420
 Park, S, E1062
 Park, S, P764
 Park, S, E939
 Park, S, P316, E1178
 Park, S, E850
 Park, S, E1608
 Park, S, P742, E1513
 Park, S-K, S491
 Park, S-S, P551, P561, P638
 Park, Y, P223, P569
 Park, Y, E954
 Parmesar, K, E1550
 Parmigiani, G, E1206
 Parody, R, S804, P746
 Parody Porras, R, E957
 Parovichnikova, E, E836, E853, E860, E861, E934, E982, E1092, E1096, E1098, E1545, E1548, E1559
 Parrinello, L, E1232
 Parrinello, N, E1214
 Parrondo, R, E1274, E1276
 Parsons, A, P181
 Parvis, G, S413, S778
 Pasalic, L, E1140
 Pasca, S, P306, E976
 Paschka, P, P533, P535, E864, E868, E870
 Pasciolla, C, E1560
 Pashayan, N, P295
 Pasiarski, M, E920
 Pasquale, R, E1017
 Pasquet, M, P716
 Pasquini, M, E1523
 Passamonti, F, S777, S784, S786, P351, E1333
 Passamonti, F, E1130
Passaro, D, P264
 Passera, R, S778
 Passweg, J, S112, S797, P232
 Pasterkamp, G, P614
 Pasternak, A, E1257, E1262
 Pastorczak, A, E827
 Pastore, A, S432
 Pastore, D, E1560
 Pastore, F, E885
 Pastori, G, E854
 Pastushenko, I, E1127
 Pasvolsky, O, E949
 Patay, B, S108, P197, E921
 Patel, A, E913
 Patel, K, S489, S496, S792, P192, P200, P241, P352, P550, E830, E1512
 Patel, M, S471, S773
 Patel, S, E945
 Paterson, K, S770
 Pati, H, E1589
 Patil, S, E929
 Patir, P, E1525
 Paticroglu, T, E1428, E1539
 Patkar, N, P169, E837, E843
 Patkowska, E, E827
 Patnaik, M, P165, P207, E1502
 Patnaik, M, P254
 Patnana, P, P534
 Patriarca, A, E1261
 Patriarca, F, S410, P341, E1533
 Patrick, K, P668
 Patrick, P, S802, P160, P164
 Patrinoiu, O, E1602
 Patten, P, E1509
 Patterson, J, E819
 Patti, C, S778
 Patti, K, S413
 Paubelle, E, E906
 Paul, A, S135
 Paul, C, P709
 Paul, G, P266
 Pauli, E, P563
 Paulino, G, P618
 Paulson, K, P732
 Pautasso, C, S410
 Pavan, V, E1006
 Pavesi, F, P644
 Pavkovic, M, E1471
 Pavlasova, G, E1004
 Pavlicek, P, E1290
 Pavlova, S, P238, E1009
 Pavlovic, S, E948
 Pavlu, J, S797
 Pavluchenko, E, E1154
 Pavone, V, E946, E1561
 Pavoni, C, S413, P163
 Pawłowicz, E, P710
Pawlyn, C, S407, S781
 Pawsan, R, E1534, E1544
 Payan, S, E1160, E1421
 Paydas, S, P281
 Payen, E, P631
 Payer, A, P703
 Payne, G, P526
 Payton, J, E1073
 Paz, Y, E1565
 Peccatori, J, S806
 Pecci, A, S432, S433, P365
 Pecherková, P, S483
 Pedersen, A, S109
 Pedersen, L, S109
 Pedote, P, E1406
 Pedreira, C, P584
 Pedreiro, S, E1033, E1188
 Pedri, R, P599
 Pedro, C, S790, P202
 Pedro, C, E1156
 Peffault De Latour, R, S131, P232, P572, E1460
 Pegourie, B, P675
Pei, X, P577
 Peirs, S, P156
 Pejsa, V, E969, E1329
 Peled, A, P269
 Pelidis, M, E1163
 Pelizzari, A, P658, E1190
 Pellagatti, A, S122, S123
 Pellanera, F, E1174
 Pellegrinelli, A, E1207
 Pellegrini, S, E1048
 Pelletier, S, E935
 Pelliniemi, T-T, P670
 Peltier, D, P753
 Pemmaraju, N, S474, S487, S489, S496, P170, P191, P200, P209,

- P518, P665, E914, E935
Pena, G, E1037
Peñalver, F, E891
Peñarrubia, MD, M, E1051
Peng, J, S431, P726
Peniket, A, E1457, E1544
Penna, D, E1065
Pennaforste, S, E1018
Pennisi, M, P396, E1207
Péntek, M, P730
Penther, D, E1001
Pentony, M, E1424
Penuel, E, S106
Pepe, A, P394, P399, E1570, E1571,
E1575, E1577
Pepedil Tanrikulu, F, P281
Peppa, M, S130
Peragine, N, E989
Perales, M-A, S794, P745
Pereira, A, P703
Pereira, J, E1588
Pereira, M, E1033, E1188, E1336
Pereira Nascimento, P, E1492
Perel, Y, P716
Perez, A, E1417
Pérez, A, E1546
Perez, C, E834
Perez, M, P733
Perez-Amill, L, E1088
Pérez-Ceballos, E, E953
Pérez de Oteyza, J, S409, P554, P688,
E1086
Perez-Encinas, MD, M, P703, E1051,
E1059
Pérez Encinas, M, E1327
Pérez-Galán, P, E1369
Pérez López, E, P747, E1169
Pérez-López, O, P213
Perez-Martinez, A, P759, P765
Pérez-Martínez, A, P509, E1234, E1563
Pérez-Oteiza, J, P316
Perez Oteyza, J, E891
Pérez-Persona, E, P376
Perez Romasanta, L, P751
Perez Ronco, J, S784, P702, P706,
E1320, E1333, E1334
Pérez-Simón, J, S804, P213, P543,
P554, P681, P746, P756, E1349
Perfetti, P, P520
Perfler, B, S419
Perglerová, K, S121
Peric, Z, S795
Peritore, G, E1577
Perl, A, S110, P560, E940
Perona, R, P229, P580
Peroni, E, P712
Perrin, J, S453
Perrina, V, E1365
Perrone, G, E1401
Perrone, T, E1406
Perrotta, S, P286
Perrotti, D, S483
Perry, C, E1121
Persky, D, P633
Pertesi, M, E826
Perucca, S, P607
Pervakova, M, E1154
Peschel, C, S446
Pession, A, E1077
Petečuková, V, E936
Peter, B, P693
Petermann, E, S119
Peters, A, E1007
Peters, A, E1022
Peters, C, S476, P521
Peters, D, E977
Peters, S, E1250
Peterschmitt, M, P719
Petersen, E, E1499
Peterson, P, E881, E902, E1204
Petevi, K, P624
Petinati, N, E1092, E1096, E1098
Petit, A, S427
Petkovic, I, E970
Peto, J, P295
Petarca, M, S467
Petri, A, P174
Petriani, I, E1318, E1397
Petriani, M, P599, P671, E946, E1043,
E1048, E1215, E1318, E1401
Petroni, M, S488
Petrov, Y, E1556
Petrova, N, E1154
Petrovic, I, E948
Petrovskii, D, P307
Petrucci, M, S410, E1247
Petrungaro, A, P586, E1390
Petrusich, A, S814
Petruskevicius, P, E1273
Petruzzello, F, P715
Petsa, P, E1304
Pettengell, R, S502
Pettiglio, M, S147
Pettinato, G, E1459
Pettine, L, E1078
Pettitt, A, S777, P245, P589
Petty, R, E1566
Petullà, M, P644
Petzer, A, P336
Peyrouze, P, E876
Peyvandi, F, P306, E976
Pezet, M, E1178
Pezzullo, L, E967
Pfeifer, D, P656, E1355
Pfeifer, H, P516
Pfirrmann, M, S424, S426, P255
Pflumio, F, S140, P514
Pfreundschuh, M, S107, S424, P216,
P222, E1469
Pfumio, F, S427
Pham, A, S450
Pharoah, P, P295
Philippé, J, E1114
Phillips, D, P252
Phillips, E, P669
Phillips, T, P633
Phuong, P, P662
Piazza, F, E1011, E1254, E1357
Piazza, R, P570, E1174
Picard, C, E1422
Picard, V, S453, E1082
Picardi, M, S413, S504, P277, E1122,
E1125, E1459
Piccaluga, P, E1408
Piccin, A, P304
Piciocchi, A, S111, S800, E1000
Pickford, R, P654
Pidcock, R, E874
Piechaczyk, L, E866
Piechna, K, E886
Pienkowska-Grela, B, P594
Pierce, S, S474, S487, P200, P315,
P352, P665
Pieri, L, P355
Pierrri, F, P234, P575, E1440
Pieters, R, E840
Pieters, T, S438, E1358
Pietra, D, P351, P357, E1337
Pietrangelo, A, S129
Pietrantuono, G, E1261
Piga, A, S129, P288
Pigazzi, M, E917
Piglione, M, E955
Pigneux, A, S472, E910
Piguet, C, S131
Pike, R, P532
Piko, H, E820
Pileri, S, E847, E1533
Pilkington, L, P368
Pillai, S, S791
Pilling, D, P690
Pillon, M, P717, E844, E955
Pimanda, J, P654
Pimpinelli, F, E1145
Pimpinelli, N, E1136
Pina, F, E1586
Piñán, M, E1027
Piñana, J, P746
Pincez, T, P716
Pingali, S, E950, E1146
Pinilla-Ibarz, J, P603, P608

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Pintado-Berninches, L, P229
Pinto, A, E1297
Pinto, F, P668
Pinto, G, E1609
Pinto, I, E822
Pinto, V, P400, E1482
Pinto Simões, B, E1495
Pinyol, M, S115, S117, E1381
Piolletti, P, E1351
Pippa, R, P536
Pippucci, T, S433
Pirillo, C, E875
Piris, M, P571
Piris, M, E834, E1113
Pirmohamed, M, P258
Piruat, J, P543, P756
Pisani, F, E1145
Pisanti, N, E1318, E1397
Piskunova, I, E836
Pistoia, L, P394, P399, E1570, E1571, E1575, E1577
Pitisci, A, E1167
Pitrolo, L, P290
Pivkova-Veljanovska, A, E1471
Pizzato, C, E1164
Pizzolo, G, E1120
Place, A, S422
Planas-Rigol, E, P296
Plass, C, S429, P350, P353, P663
Plata, E, E1120
Platonova, N, E1268
Platt, M, P406
Platzbecker, U, S494, S786, S813, P231, P666, E1168, E1180, E1181, E1186
Plaza, C, P733
Plaza, D, P580
Plebani, S, P358
Plesner, T, S501, P334, E1267
Plevova, K, S461, P238, P244, E1009
Pleyer, L, P195, P558
Plo, I, P692
Ploch, P, P626
Ploski, R, P594
Pluen, A, E1007
Plunkett, W, S463, P209
Pluta, A, E920
Pluta, A, S465, E1257
Plütschow, A, P275
Pochet, N, P237
Pocock, C, S423
Poddighe, P, E1221
Podestà, M, P658
Podoltsev, N, P210
Poeck, H, S446, S818, P272
Poensch, W, P336, P341
Poeschel, V, P216, P222
Poggio, T, E1393
Pogodek, B, E1257
Pogodzinski, M, P155
Poh, W, P236
Pohlreich, D, E1540
Poindessous, V, E829
Poiré, X, S798
Poiree, M, S131
Poirot, C, P631
Poirot, L, E1094
Poisa Beiro, L, P206
Pokrovskaya, O, E1227, E1295
Pol, R, P382
Polack, B, E1178
Polak, A, E886
Poletaev, A, E1029
Polgarova, K, E1166
Polge, E, S798
Pollitis, D, E1462
Politou, M, E1485
Polivkova, V, E1041
Pollack, A, P182
Pollack, J, P182
Pollard, J, P184
Polliack, A, E1034
Pollyea, D, S471, S472, P204, P386, E923
Polokhov, D, E1029
Poloni, A, P658, P667
Polprasert, C, S120
Polushkina, E, E1067
Polushkina, L, E1313
Polverelli, N, P607, P705, E1325
Polyanskaya, T, P307
Polydoros, F, S423
Polzer, H, E877
Pomares, H, S790, P202
Pomilio, G, P175
Pommerenke, C, E1387
Pondarré, C, S131
Pönisch, W, P380
Pons, V, E1594
Ponstingl, H, S420, S430
Pontikoglou, C, P639, E1419
Pooliam, J, P395
Poon, G, S135
Popa, M, P181, E866
Popat, R, P669
Popat, U, S792, P739, E914, E1512, E1538
Poplawska, L, P162
Popov, A, P161
Popov, S, E1269
Popov, V, E1602
Popova, N, E1545, E1559
Popovic, R, S771
Poppis, E, E1036
Poppova, L, P238, E1009
Porcher, C, S140
Poręba, R, E1553
Porkka, K, P181, P670
Porrata, L, E1502
Porrizzo, M, E1017
Porretti, L, P717, E1420
Porrini, R, E1340
Porta, F, P738
Porter, J, E1130
Porter, J, S814
Porter, J, P286
Porteus, M, S147
Portilla, C, E1074
Porto, G, P284, P293
Posada, J, P344
Positano, V, P399, E1571, E1575, E1577
Pospiech, J, E1109
Pospíšilová, D, P711, E1432
Pospíšilová, Š, S461, P238, P244, E1003, E1004, E1009
Post, S, P590, P690
Posthuma, W, P250
Postorino, M, P588
Postorino, M, P610
Potapenko, V, E1154
Poteracki, M, S771
Potikhonova, N, E1154
Potluri, J, S472, P728
Potluri, R, E1138, E1255
Pott, C, S801
Potter, V, E1509, E1550
Potuckova, L, P273
Poulakidas, E, P280
Pouli, A, S415
Poulia, L, E1462
Pour, L, P335, P672, E1272, E1290, E1298
Pourdehnad, M, S467
Poursidis, A, E862
Povinelli, B, S421, P270
Powell, B, P210, E883
Power, M, P581, E1557
Poza, M, E1038
Pozzato, G, P583, E993
Pozzo, F, P583
Pozzorini, C, E878

- Prado, M, S428
 Prados, S, E1130
 Prakash, G, E851
 Prange-Krex, G, P255
 Prapas, N, E1574
 Prassek, V, P546
 Pratcorona, M, P202, P696, E831
 Prati, D, E1606
 Prats-Martin, C, P213
 Pratt, G, P347, P669
 Pratz, K, S472
 Pravettoni, G, P729
 Preciado Pérez, S, P751
 Prego, P, P604, E1042
 Prete, A, P738
 Preudhomme, C, E876, E1171
 Preudhomme, J, E876
 Preuner, S, E1071
 Preziosi, P, E1575
 Prezioso, L, E1497
 Priesca Marin, M, E1500
 Prieto, M, P696
 Prieto-Conde, M, E887
 Prignano, G, E1145
 Prijic, S, P690
 Prime, J, S484
 Primo, D, E1086
 Prince, H, P637
 Prince, M, E1202
 Prine, B, P247
 Prins, H-J, P265, E1221
 Printz, D, P596
 Priolo, M, P610
 Pristupa, A, P699, P701, E1343
 Pritsch, M, E1253
 Prka, Z, E969
 Prochazka, K, E1363, E1395
 Prochazka, V, P218
 Procházková, D, P711
 Prochorec-Sobieszek, M, E1294
 Proetel, U, S424
 Proietti, R, P736
 Prokharau, A, P635
 Prokopiou, C, S420
 Prokosch, H-U, E1117
 Prósper, F, P198, P300, P325, P329, E1225
 Prosperini, G, S413
 Protin, C, P641
 Proulle, V, S453, E1082
 Provan, D, E1430, E1453
 Proven, M, P228
 Provencio, M, S776, E1394
 Prüfer, S, P651
 Průhová, Š, P711
 Pruszczyk, K, P594
 Prychodzen, B, S120, P660, E1013
 Pshonkin, A, E1029
 Psimenou, E, P337
 Psomopoulos, F, P242
 Psyllaki, M, S416
 Ptáčnik, V, S774
 Ptushkin, V, E1029
 Puccetti, L, E1043
 Puccini, B, E1401
 Puccio, G, P717
 Puente, X, S115, S117
 Puerta, P, E1278
 Pugh, R, P374
 Pugliese, N, S504, P277, E1122, E1125, E1459
 Puig, N, S409, P329, P679, P688
 Puiggros, A, S461, E1027
 Puiggros, M, S117, P300
 Pujol-Moix, N, P759, P765
 Pule, M, P624, E1208
 Pulini, S, E1577
 Pullarkat, V, S472, P186
 Pulsipher, M, S476, S477, P517, E840
 Pulsoni, A, S778
 Punnoose, E, P682
 Purdom, M, S772, P563
 Purdon, T, S479
 Purev, E, P386
 Purroy, N, E1002
 Pursche, B, E1363, E1395
 Purton, L, E875
 Pushpakom, S, P258
 Pusic, I, S492
 Pusongchai, T, E975
 Pustovaya, E, E1436
 Putti, M, P715, E844, E955
 Puvvada, S, S771, P564
 Puy, H, P631
 Puy Vicente, E, S462
 Puzone, S, P393
 Puzzolo, M, E989
 Pyatkova, O, E1436
 Pyl, P, P179, P206
 Pylypenko, G, E1127
 Pyszynska, B, S125, E1359
 Pytlik, R, P218, E1540
 Qasim, W, S146
 Qayed, M, S476, P517
 Qazilbash, M, E914
 Qi, J, P390
 Qi, M, S459, S101
 Qian, M, E1248
 Qian, Q, E1146
 Qin, Q, E950
 Qin, T, E1330
 Qin, X, S101, S459, P334, P335
 Qin, X, P356
 Qin, Y-Z, P507, P511, E833
 Qiu, H, E931, E1507
 Qiu, S, E911, E916
 Quach, H, S101, S459, S502, P674, E1289
 Quaglia, F, E1179
 Quaglia, F, E1020
 Quaglino, P, P637
 Quarona, V, E1223, E1237
 Quarta, A, P399
 Quebe-Fehling, E, P720, P723, E1437
 Queipo de Llano, M, S790, P202
 Queirós, A, P244
 Queizán, J-A, E1014
 Quek, J, E1413
 Quek, L, S140, S791
 Quentmeier, H, E1387
 Queralto, J, E1421
 Quéré, R, S139, P514
 Queríos, A, P300
 Quesnel, B, E876
 Quezada, S, E1208
 Quigley, M, S142
 Quijada, M, E1014
 Quillinan, C, S503
 Quiniou, J-B, E1150
 Quinlan, M, E1142
 Quinn, M, P669
 Quintana-Bustamante, O, E1094, E1097
 Quinteiro García, C, E1327
 Quintela-Fandino, M, E900
 Quintero-de-Charry, M, E1074
 Quintini, M, E1174
 Quintino, S, P400
 Quoc Khanh, B, P287
 Quock, T, P373, E1468
 Quota, A, P290
 Qureischi, M, E1569
 Raab, M, P320, E1253, E1272
 Raaijmakers, M, P576
 Raake, P, P342
 Raanani, P, P702, E949, E1333, E1334
 Rabassi, N, E1496
 Rabbolini, D, S434
 Rabian, F, E910
 Rabin, K, S422
 Rabin, N, P334, P669, P731
 Rabuñal Martínez, M, E1327
 Rabusin, M, P738
 Rachmilewitz, E, P284
 Ráčil, Z, E936
 Radek, S, P698
 Rademaker, R, P267
 Radford, J, S468, S775, E1129
 Radford-Weiss, I, E1361
 Radia, D, E1338
 Radic Antolic, M, E1352
 Radich, J, P601

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Radić-Krišto, D, E969
 Radivoyevitch, T, S120
 Radlwimmer, B, P172
 Radman, I, E969, E971
 Radocha, J, E1290, E1303
 Radsak, M, P643, P651, P666
 Radtke, F, P159
 Radujkovic, A, S122
 Radwan, M, E1205
 Raffaele, L, E1606
 Raffel, S, P172, P179
 Raffoux, E, E856, E910
 Rafii, S, S137
 Raggi, F, E1005, E1006, E1011
 Rago, A, P358, E1340
 Rahal, I, S131
 Raheja, P, E1594
 Rahman, K, E981
 Rai, L, E905, E1176
 Rai, S, E1100
 Raić, A, E1106
 Raine, K, E1201
 Raiola, A, S796, E915, E1505
 Raitanen, J, P734
 Raj, A, P727
 Raj, K, E1245, E1550
 Rajalingam, K, E992
 Raje, N, S142, S457, S780, S782
 Rajeeve, V, P532
 Rajkumar, V, S408, P331, P673, E1240
 Rajnic, P, P333
 Raju, A, E973, E1184, E1191, E1196
 Ram, R, P548
 Ramanna, J, P708
 Ramasamy, K, P343, E1457
 Ramasamy, S, E875
 Rambaldi, A, S413, S778, P163, P351, P760, P766, E1315, E1533
 Rambaldi, B, P607
 Ramchandren, R, S412
 Ramchandren, R, P633
 Ramdas, B, P530
 Rameau, P, S427
 Ramenghi, U, P717, E1164
 Ramirez, J, E1097
 Ramirez, M, P510, P513
 Ramírez, J, E1081
 Ramírez, M-J, P703
 Ramírez Payer, Á, P376
 Ramírez-Plazas, N, E1074
 Ramiro Infate, L, E1426
 Ramlal, R, P279
 Ramos, F, P554, P655, E887
 Ramos, S, E1027
 Ramos, T, P751
 Ramos-Aviles, A, E1421
 Ramos-Mejía, V, E893
 Rancoita, P, S806
 Randen, U, P613
 Randi, M, P358, P712, P715
 Rangberg, A, E1434
 Ranghetti, P, E1086
 Ransdorfova, S, E1041
 Rao, A, P668
 Rapado, I, P329, E891, E899, E900, E1234, E1317
 Rapezzi, D, S413
 Raponi, S, E1000
 Rapoport, A, E912
 Raslova, H, S427
 Raspadori, D, E1042, E1215
 Rasras, R, P284
 Rastgoo, N, E1217
 Rathkolb, B, S809
 Rätty, R, S109
 Ratzon, R, E949
 Rauch, E, P336
 Rauh, M, E1117
 Ravandi, F, S474, S489, S793, P170, P192, P200, P201, P209, P211, P315, P518, P550, P665, P739, E830, E913, E914, E935
 Ravano, E, E1195
 Ravera, S, P658
 Ravindranath, Y, S451
 Rawat, V, S429
 Rawstron, A, P245, P589
 Rawstron, A, S770, P252
 Raya, J-M, P703, E953
 Raymakers, R, S452, P250, P576
 Raynor, W, E1267
 Rayon, C, P554
 Razny, M, E1257
 Read, L, S423
 Reagan, M, E1354
 Reagan, P, S466, P522
 Rebullá, P, E1420
 Recchia, A, P586, E1017, E1390
 Recher, C, S472, P183, P557, E906, E910
 Recio, I, P655
 Reda, G, E1030
 Reddy, N, S769
 Reddy, P, P753
 Reddy, P, E1170
 Redmond, D, P297
 Redondo, A, P751, E1169, E1181
 Redondo, A, E1604
 Redondo-Guijo, A, P318, P655
 Reece, D, S456, S783, P680
 Rees-Unwin, K, E1007
 Reforço, C, E889
 Regazzo, G, E1379
 Rege Cambrin, G, P604, P605
 Regina Bonini-Domingos, C, E1492
 Rego, E, E832
 Reichenzeller, M, S116
 Reid, A, E1112
 Reid, C, P674
 Reiff, S, E1400
 Reigl, T, S803
 Reilly, L, S425
 Reilly, M, P317
 Reim, R, P700
 Rein, A, S436
 Reinhardt, D, S789, E878
 Reinhardt, K, S789
 Reinisch, A, S140
 Reis, R, E1033, E1188
 Reis Andrade, M, E1425
 Reiser, M, E1449
 Reisser, T, P754
 Reiter, A, S788, P693, P700, E1344
 Rekab, N, E985
 Reksodiputro, A, E1070
 Relvas, L, E1080, E1588
 Remacha, A, P759, P765, E1160, E1421
 Remacha, J, P759, P765, E1160, E1421
 Remak, E, E1460
 Reményi, P, P382
 Remenyi, P, S797, E1535
 Remington, N, S503
 Ren, X, P606
 Renard, J, P274
 Renat, V, E1010
Rencz, F, P730
 Renne, S, E1571
 Renshaw, H, E1132
 Renso, R, E1351
 Renz, N, P656
 Renzi, D, E1145
 Repa, K, S130
 Repapi, E, S122, S140, S421, E1110
 Repetto, P, E1126
 Repousi, E, P397, E1158
 Repousis, P, S415, P280, E1249, E1266
 Requejo, A, E1508
 Requena, MD, M, E1051
 Resci, F, P355
 Ressenrova, A, P663
 Reu, F, E1248
 Reunes, L, S438, E1358

- Reuter, S, P651
Revilla, N, P402, P721, E1444, E1456
Rey, J, S787, P354
Reyal, Y, P731
Reyes, J, P756
Reyes, K, S779
Reyes-Castellanos, J, E1074
Reynolds, J, E1289, E1431
Rezo Vranjes, V, S795
Rezvani, K, E914
Rezvani, K, S792, P739, E1512, E1538
Rhein, K, S794
Rheinbay, E, P236
Ria, R, E1216, E1247
Riaz, M, E977
Riba, J, P656
Ribakovsky, E, P269
Ribaldo, G, E1006
Ribeil, J-A, P631
Ribeiro, D, P157
Ribeiro, J, E1080
Ribeiro, L, E1033, E1064, E1188,
E1287, E1297, E1336
Ribeiro, M, E1080, E1588, E1593
Ribeiro, S, E1075
Ribera, J, S790, P202
Ribera, J, E831
Ribera, J, E1086
Ribera, J-M, E831, E1394, E1396
Ribolla, R, S102
Ribrag, V, S105, S467, P344, E1018
Ricardo, A, S500
Ricchi, P, S129, E1570, E1571, E1575
Ricci, F, E1048
Ricci, F, E1309
Ricco, A, P598, E1560
Rice, L, E950, E1146
Richard, S, E1470
Richard Espiga, C, S798
Richardson, D, S817
Richardson, P, S408, S456, S457, S779,
S780, S808, P332, P334, P650,
P735, P740, P748, E1532, E1554
Richebourg, S, E1361
Richter, J, S426, P593, E1057
Richter, J, E1276, E1288
Ricker, J, P634
Rico, A, P751
Ricordeau, I, P712
Rider, A, E1291
Ridley, A, E832
Riedel, S, E1569
Riegl, T, S801
Rienhoff, H, S418
Riera, L, P214
Ries, F, P643
Ries, R, P184
Rieux-Laucat, F, P716
Rifkin, R, P349, E1239, E1277
Rifón, J, P205
Rigacci, L, E1401
Riganti, C, E999
Riger, T, P161
Righi, R, E1571
Rigolin, G, E1012, E1020
Rigoni, M, E999
Ríhová, L, S102
Rijal, S, P175
Rijneveld, A, P164
Rinaldetti, S, S424, P255
Ringdén, O, P379
Ringelstein-Harlev, S, E1008
Ringhoffer, M, P533
Rio, P, S144, P623
Rio-Machin, A, P532
Riolueang, S, P395, E1076
Rios Tamayo, R, E1271, E1283
Ripa, R, P221
Ripaldi, M, P738, E1016
Rippe, K, P663
Ripperger, T, P226
Risinskaya, N, E1548
Risitano, A, S796, E1460
Rismani, A, E1132
Risueño, C, P623
Ritchey, J, S794
Ritchie, D, P750
Ritchie, E, S110, P560
Ritgen, M, S464
Ritz, M, E1569
Riva, E, E1273
Riva, L, E1483
Riva, M, E930
Riva, M, E1195
Riva, S, P729
Rivas, M, E1508
Rivas-Delgado, A, E1032, E1137
Rivas-Vera, S, E1473
Rivera, J, E1451, E1456
Rivera, V, P603
Rivera-Fong, L, E1473
Riveros Rosas, A, E1473
Rives, S, S476, P168, P517
Riviere, I, S143, S479
Rivière, J, S427
Rivoli, G, E1299
Rivotto, B, S779
Riwes, M, P753
Rizo, A, E1322
Rizvi, S, E1248
Rizzieri, D, P191, P556
Rizzo, D, E1010
Rizzo, J, P745
Rizzo, M, E1281
Rizzo, M, E1379
Rizzuto, V, P615
Robak, P, E1262
Robak, T, P235, P248
Roberts, A, S460, S771, P175, P247,
P564, E1139
Roberts, C, S791
Roberts, I, P233, P270, P668
Robertson, J, E866
Roberts-Rapp, L, P682
Robinson, S, S502, E874
Robledo, C, P318, P510, P655, E1014,
E1169
Robles, A, P554
Robles Garcia, R, E1473
Roboz, G, S471, S473, E923, E1192
Robrecht, S, S464, P236, P251, P585
Robredo, B, E1417, E1555
Robson, S, S430
Roccamo, G, P290
Rocco, A, E1354
Rocchi, S, E1238
Rocha, P, E1425
Rocha, S, E1075
Rocha, V, E1534
Roddie, C, P669
Rodi, S, P610
Rodig, S, S412
Rodon, P, P649
Rodrigues, F, E1033, E1188
Rodrigues, P, E843
Rodrigues Alves, A, E832
Rodrigues-Santos, P, E1044, E1047,
E1064
Rodríguez, A, P361, E1014
Rodríguez, B, E1592
Rodríguez, C, P751
Rodríguez, J, E1183
Rodríguez, J-N, E1014
Rodríguez, M, P296
Rodríguez, N, E1349
Rodríguez, V, E1369
Rodríguez-Caballero, A, P584, E1019
Rodríguez-García, G, E953
Rodríguez-García, J, P737
Rodríguez Hernández, G, S148
Rodríguez-Lobato, L, E1259
Rodríguez-Macias, G, P554, E1113
Rodríguez-Otero, P, S409, S783, P688
Rodríguez-Real, G, E893
Rodríguez-Torres, N, S804
Rodríguez-Vicente, A, E1038
Rodzaj, M, E1193, E1257
Roels, J, P156
Roemer, M, P190
Rögnvaldsson, S, P678
Rohde, C, S429, E927

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Rohmer, J, P217
 Rohrllich, P-S, P572
 Rojas, A, E1103
 Rojas, J, P554
 Rojas, S, P316
 Rokito, A, E1035
 Roland, V, P217
 Rolink, A, P628
 Roman, E, P295
 Roman-Rodriguez, F, P623
 Romani, C, P163
 Romano, A, S413, E1214, E1232
 Romano, A, E1145
 Romano, M, E1309
 Rombo, L, S805
 Romejko-Jarosinska, J, P162
 Romero-Furones, A, P584, E1019
 Romero Garcia, P, P768
 Roncevic, P, E971, E1296, E1352
 Ronci, B, S111
 Ronco, F, S111, P520, P610
 Roncoroni, E, P357, E1337
 Rondeau, V, E1102
 Rondon, G, S792, P739, E914
 Rondoni, M, P355, E946
 Rontogianni, D, S416, P639
 Roodman, G, S782
 Roque, A, E1297
 Rosamilio, R, E967
 Rosano, C, E1481
 Rosato, B, S811
 Rose, C, S451, S453, P712
 Rosenbaum, C, S780, P680
 Rosenbaum, H, P719
 Rosenberg, E, P269
 Rosenberger, A, S419
 Rosenblatt, J, S779
 Rosengarten, B, P674
 Rosenquist, R, S462, P244
 Rosenwald, A, P320
 Rosettani, B, P343, E1250
 Rosich, B, E1546
 Rosiñol, L, S409, P679, P688, E1244, E1259, E1278
 Ross, C, E1342
 Ross, D, S484, P601
 Ross, J, S460, P675, P682
 Rossi, A, S413
 Rossi, C, E1369
 Rossi, C, S128
 Rossi, C, P753
 Rossi, D, P244, P282, P304, P583, E1017
 Rossi, E, P722
 Rossi, F, P583, P588
 Rossi, G, P607, P616, P644, E1190, E1354, E1533
 Rossi, J, S466, P522, P523, E840
 Rossi, V, P628, E908
 Rossig, C, P521
 Rossini, F, S778
 Rosso, R, P290, E1571
 Rosta, A, S774
 Rosti, G, S485, P600, P605, P607
 Rota, R, E917
 Rota Scalabrini, D, S410, S778
 Rotarski, M, P649
 Roth, D, S805
 Roth, M, S133
 Röth, A, P231, P578, P582
 Rothenberg-Thurley, M, P546, P656, E885
 Rotiroti, M, P630
Rotolo, A, P624
 Rotulo, A, E1440
 Rotunno, G, P351
 Rouault-Pierre, K, P264, P657
 Roué, G, E1369
 Roumelioti, M, P639
 Roumenina, L, P617
 Roumier, C, E876
 Rounioja, S, P670
 Rousseau, M, P671
 Roussel, M, P345
 Roussou, M, P337
 Roussou, P, P280
 Routbort, M, S496
 Rouvio, O, E1034
 Rovelli, A, P738
 Roviada, A, E997
 Rovira, J, E1137
 Rovira, M, S804, P746
 Rovó, A, E1455
 Rowe, A, E866
 Rowe, J, P548
 Rowland, T, S118
 Rowntree, C, P164, E1465
 Roy, A, P270
 Roy, J, P727
 Roy, L, S787
 Roy, N, P228, E1424
 Roy, S, S122
 Roy, V, S408
 Royaert, J, S439
 Royer, B, E1135
 Royo, R, S117, P300
 Rozanova, O, E986
 Rozema, H, E1194
 Rozman, M, S115, E1031, E1039
 Rozovski, U, E949, E991, E1524
 Ruan, C, P390, E928
 Ruan, G-R, P511
 Ruano, D, P510
 Rubio, A, E1074
 Ruchlemer, R, E1034
 Rucker, F, P182
 Rudolf, A, E1393
 Ruebe, C, P216
 Rueda, A, S107
 Rufibach, K, S502
 Rufini, V, E1124
 Ruggeri, A, S493, P384, E1495
 Ruggeri, G, P607
 Ruggeri, M, P351, P722
 Ruggieri, S, E1406
 Ruhparwar, A, P342
 Ruiter, R, P265
 Ruivard, M, S453
 Ruivo, N, E875
 Ruiz, C, E1365
 Ruiz, F, E1609
 Ruiz, P, S144
 Ruiz, R, E831
 Ruiz Arguelles, A, E1500
 Ruiz Arguelles, M, E1500
 Ruiz Argüelles, G, E1500
 Ruiz-Cabello, F, P696
 Ruiz Delgado, G, E1500
 Ruiz Delgado, R, E1500
 Ruiz-Heredia, Y, P679, E891, E899
 Ruiz-Llobet, A, P168
 Ruiz Reyes, G, E1500
 Ruiz-Xiville, N, S461
 Ruland, J, S818
 Rule, S, E1377
 Rumi, E, P351, P357, E1337
 Rummelt, C, E1393
 Rupa-Matysek, J, E1079
 Rupoli, S, P636, E1136
 Rupp, J, E992
 Rushworth, S, E873, E874
 Rusinov, M, E853, E860
 Rusinov, M, E836, E1227
 Russell, J, P276
 Russell, N, S114, S407, S781
 Russell, S, P331, P673, E1240
 Russiñol, N, S117, P325
 Russo, D, P607, P705, E1325
 Russo, F, P337, P684, E1243
 Russo, G, P715, P717, E1077, E1164, E1491
 Russo, L, P760, P766

- Russo, M, E1263
 Russo, R, S811
 Russo, S, P604
 Russo Rossi, A, S485, P598, P604, E1560
 Rutten, A, P190
 Ružičková, L, E1044, E1047
 Ryabukhina, Y, P220, E1133
 Ryan, J, P508
 Ryan, K, S481
 Ryan, R, S808, P210, P556, P740, E922
 Ryan, R, E894
 Rybakova, L, P308, E1568
 Rybicka-Ramos, M, P741
 Rybka, J, E11553
 Rydzek, J, S816
 Ryland, G, E1202
 Rymkiewicz, G, P162
 Ryoo, N-H, E871
 Ryu, D-B, P757
 Ryzhak, O, E1127
 Ryzhikova, N, E1403, E1409
 Saad, S, E1494
 Saadoun, H, P649
 Sabater-LLeal, M, P759, P765
 Sabatini, F, P658
 Sabatino, M, P523
 Saccà, V, P644
 Saccenti, E, E1020
 Sacchi, M, S422
 Sacchi, N, S796
 Sacco, A, E1354
 Sacconi, A, E1379
 Sacha, T, P257, P594, E1061
 Sachanas, S, S416, P639, E1036, E1120, E1304
 Sachdeva, M, E851, E987
 Sadak, K, P292
 Sadeghi, B, P379
 Sadelain, M, S143, S479
 Sadiq, S, P258
 Sadjadian, P, P702
 Sadoudi, S, P617
 Sadri, S, E1159
 Sadullah, S, S502, P276
 Sadykova, N, P307
 Saeed, B, P179, P206
 Saeed, H, P279
 Saes, I, P567
 Sáez Salinas, A, E1327
 Saft, L, S486
 Saga, R, P689
 Saglio, G, S485, P599, P601, P605, E1060
 Sagou, K, E1516
 Saha, C, P276
 Saha, V, E1465
 Sahin, D, S774
 Sahin, F, E1525
 Said, Q, P285
 Saif, M, S817
 Saikia, T, S422, E1062
 Sail, K, P728, E1466
 Saillard, C, P354
 Sainati, L, E1489, E1491
 Saint-Martin, J-R, S469
 Saito, H, P592
 Saito, K, P612, E1104
 Saito, K, E1230
 Saitoh, A, P625
 Saitoh, K, P592
 Saitoh, T, E1447, E1607
 Saji, H, E1068
 Sakai, H, S120
 Sakamaki, H, P263
 Sakamoto, J, P263
 Sakamoto, M, E1229
 Sakata, S, S124
 Sakata-Yanagimoto, M, P301, E1519
 Sakellari, I, P280, E1233, E1407, E1610
 Sakk, V, E1109
 Sakura, T, E1522
 Sala, A, E955
 Sala, E, P544
 Salama, A, P720, P723, E1437
 Salama, H, E1514
 Salamero, O, S790, P202, P554
 Salanoubat, C, P316
 Salaroglio, I, E999
 Salaverria, I, S115
 Salazar, R, E1074
 Salcioglu, Z, E1418
 Saleh, M, P723, E1437
 Salehzadeh, S, E1048
 Salek, C, E841
 Salek, D, P218
 Salek, S, E1476
 Šálek, C, E936
 Salem, A H, S460, E1139
 Salem, K, S779, P323
 Saliba, R, S450, S792, P739, E914, E1538
 Saliev, S, E1067
 Salih, H, P533, E868, E870
 Salihoglu, A, E1159, E1518
 Salimi, A, E819
 Salinero, M, E1543
 Salles, G, S105, S106, S470, P572, E906, E1018, E1024, E1129
 Sallman, D, E1323
 Salman, Z, P672
 Salmoiraghi, S, E1315
 Salmon, J, P175
 Salomo, M, S501
 Salomoni, P, P176
 Salomon-Perzy_ski, A, E1262
 Salson, M, S801
 Saltarella, I, E1216
 Salunkhe, V, P404
 Salutari, P, S111
 Salvatore, C, P277
 Salvatore, D, S493
 Salvetti, C, E999
 Salvi, A, E1315
 Salvi, F, P658, E1533
 Salvucci, M, P605
 Salzmann, E, P382
 Samali, A, E819
 Sambani, C, E895
 Sambuceti, G, P283
 Sameena, I, P532
 Samitsch, M, S140
 Sammarelli, G, E1497
 Sammartano, V, E946
 Samp, J, E1035
 Sampaolo, M, E1123
 Sampath, D, P189
 Samperi, P, E1164
 Sampietro, M, E1576
 Sampiev, M, P307
 Sampol, A, S790, P202, E1341, E1417, E1555
 Samuelsson, J, P697
 Samur, M, E1200, E1203, E1206
 San Miguel, J, S101, S409, S456, S783, P325, P329, P339, P334, P679, P688, E1225, E1278
 San-Segundo, L, E1222
 Sanada, M, S120, S124, S799, P299, P314, P537
 Sancetta, R, S485
 Sanchez, J, E831, E1181
 Sánchez, M, E1103
 Sanchez, M-L, P329
 Sanchez, M, E1156
 Sanchez, R, S144
 Sanchez Abarca, L, P751, P756
 Sánchez Barba, M, P318, E1592
 Sánchez-Blanco, J, E953
 Sánchez-Domínguez, R, P755, E1081
 Sanchez-Fuentes, A, P402
 Sánchez-Gallego, J, P713
 Sánchez-García, I, S148
 Sanchez-Guijo, F, P609, P751
 Sánchez-Muñoz, L, P713
 Sánchez-Raga, J, E1341, E1555
 Sánchez-Salinas, A, E1562
 Sánchez-Valdepeñas, C, P510, P513
 Sánchez-Vega, B, P329, P679
 Sancho, J-M, S502, P635, E1394, E1396

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.** Abstract author marked in **green** has won the Guiseppe Bigi grant award.

- Sanchorawala, V, S104
 Sanders, M, P538
 Sandhu, S, E998
 Sandler, L, P631
 Sandmann, S, E1197
 Sandrine, J, E1372
 Sandset, P, E1434
 Sanford, D, P581, E1557
 Sangaralingam, A, E1566
 Sanginario, A, S147
 Sanna, A, E1173
 Sano, K, E1100
 Santacroce, B, E1238
 Santacruz, R, E1031, E1039
 Santamaria, A, E1594
 Santamaria, V, E1577
 Santana-Hernandez, P, E1306, E1415
 Santana Santana, G, E1327
 Santarone, S, S493, P384, P394
 Santibanez, J, E1308
 Santillana, S, P603
 Santilli, R, E1136
 Santinelli, E, P588
 Santini, S, E1401
 Santini, V, P658, P667, E1173
 Santoleri, L, S128
 Santomasso, B, S143
 Santopietro, M, P234
 Santoro, A, S412, S776, P304
 Santoro, C, P306, P358, E976, E1340
 Santoro, N, E955
 Santoro, R, P306, E976
 Santoro, U, P358
 Santos-Rosa, M, E1044, E1047
 Santos-Silva, A, E1075
 Santucci, M, P600
 Sanyal, I, E837
 Sanz, G, P316, P318, E1181
 Sanz, M, P554
 Sanz, P, E1305
 Saraci, E, E1247
 Sarappa, A, P393
 Sarasquete, M, E887
 Sarda, P, P759, P765, E1421
 Sardella, L, E1577
 Sargent, B, E940
 Sarid, N, E1121
 Sarkar, M, E981
 Sarkozy, C, P217
 Sarlo, C, P736
 Sarmiento, A, E1593
 Sarmiento-Ribeiro, A, E1064, E1287, E1297, E1336
 Sarmiento, R, S467
 Sarocchi, M, P283
 Sarrà Escarre, J, E1426
 Sarris, A, E1120
 Sarris, K, E1304
 Sarry, A, P557
 Sarry, J-E
 Sartor, M, E1140
 Sartori, F, E1341, E1555
 Sasaki, E, P401
 Sasaki, K, E11194
 Sasaki, K, P170, P209, P518
 Sasaki, M, P327
 Sasaki, R, P642
 Sasi, B, E993, E1375
 Sasmaz, I, E1528
 Sasse, S, E1119
 Sassi, M, E1497
 Sastre, A, E1546, E1563
 Sastre, L, P229
 Sastre, M, E1592
 Satake, M, P401
 Sathiaselvan, V, E1201
 Sato, A, S799
 Sato, E, E1058, E1066
 Sato, K, P689
 Sato, S, P263
 Sato, T, P383
 Sato, T, P263, E1213
 Sato, Y, S124, P299
 Sato, Y, P401
 Sato, Y, S123
 Sato-Otsubo, A, S123
 Sauer, M, S814
 Sauerland, C, E885
 Sauerland, M, P546
 Saunders, V, S484
 Saussele, S, S424, S426, P255, P601
 Sausville, E, E912, E947
 Savage, K, S412
 Savage, K, P539
 Savani, B, P379, P384, P388, E1506
 Savchenko, V, E861, E1295
 Savchenko, V, E836, E860, E982, E1092, E1096, E1098, E1227, E1545, E1559
 Savchuk, O, E1599
 Saveliev, L, P161
 Savell, A, S779
 Savic, R, P620
 Savino, A, S436
 Savoia, A, S432, S433, P365
 Savola, S, E820
 Savona, M, P352, E1192
 Savopol, T, E1602
 Savvopoulos, N, E1083
 Savvulidi, F, S483, E1041
 Sawa, M, P389
 Sawicki, M, E1257
 Sawicki, W, P594
 Saxena, R, E1589
 Saydam, G, S784, E1525
 Sayer, H, P555, P647
 Scaccetti, A, E1571
 Scaffidi, L, P355, E1325
 Scalzulli, P, P358
 Scappini, B, E946
 Scaramucci, L, P616
 Scaramuzza, S, S128
 Scardocci, A, E1151
 Scarfo, L, S462, E997, E1086
 Scarisbrick, J, P637
 Scattolin, A, P163, P520
 Scerbo, G, P736
 Schäfer, D, S148
 Schaffer, M, S100, E1129
 Schafhausen, P, P255
 Schaible, B, P632
 Schalling, M, P707
 Schanz, U, E1536
 Scharrer, I, P651
 Schauer, S, E879
 Schauer, S, E1335
 Schecter, J, S101, S100, S459, P335
 Scheffold, A, P508
 Scheibke, K, S789
 Scheid, C, S424, P700, E1251
 Scheijen, B, E1353
 Schemionek, M, S482, P593
 Schenk, D, S104
 Schenk, M, S424
 Schenkel, B, E1138
 Scherber, R, P359, P377, E1321, E1331, E1339
 Scherr, M, E1105
 Schetelig, J, S771
 Scheucher, P, E832
 Scheurer, J, P754
 Schey, S, P669, E1245
 Schiattone, L, E946, E1042
 Schiavotto, C, S413
 Schieppati, F, E1185, E1190
 Schifano, C, E1223, E1497
 Schiffer, C, E1073
 Schild, H, P643, P651
 Schiller, G, S794, P523, P556, E1248

- Schilling, K, P647
Schimmel, M, S455
Schimmer, A, P708, E1324
Schipperus, M, E1441
Schlegel, P, E1569
Schlegelberger, B, S424, S494, P226, P533
Schleicher, A, P568
Schlenk, R, P533, P535, E864, E870, E868
Schlesner, M, P350
Schlis, K, S476, P517
Schloegl, E, P707
Schlossman, R, S779
Schmalbrock, L, P535, E864, E868, E870
Schmemionek, M, P231
Schmidt, C, P663
Schmidt, G, P226
Schmidt, L, S134
Schmitt, A, E1028
Schmitt, M, E1084
Schmitz, N, P216, P222
Schmöllerl, J, S133
Schmugge, M, P350
Schneckenleithner, C, E1366
Schneeweiss, M, P693, E1071
Schneider, B, E1344
Schneider, D, E1364
Schneider, D, P177
Schneider, M, S809
Schneider, S, P546, E885
Schneidewind, G, E1263
Schnetzke, U, P648
Scholl, C, P528
Scholl, S, P647, P648
Schöllkopf, C, P193, E932
Scholten, W, S113
Scholz, C, P571, E834
Schommers, P, P568
Schonland, S, S411, P342
Schott, J, P663
Schouten, J, E820
Schrader, A, E1376
Schramm, F, P515
Schrappe, M, S436, S437, S480, P515, E849
Schreder, M, P320, P336, P681
Schreeder, M, S772, P563
Schrezenmeier, H, S498, P231
Schroeder, M, S794, P204
Schroeder, T, S494
Schroeder, T, S809
Schroyens, W, S141
Schub, N, P341
Schubert, K, P380
Schuh, A, S478, P208, P524, P708, E1324
Schuh, A, S122, S770, P228, P246, E1424
Schuler, E, P664, E937
Schulz, A, P382
Schulz, J, P380
Schulze, S, P555
Schuster, S, P566, E1129
Schütte, J, P534, E1118
Schutz, N, E1264
Schuurhuis, G, S112, S113, P190
Schwaab, J, S788
Schwab, C, S439, P160
Schwaller, J, S427
Schwartz, B, E1400
Schwartzman, O, S436
Schwarz, J, E936
Schwarz, M, S801, S803
Schwarzer, A, P177
Schwind, S, P380
Sciumbata, V, E1078
Sciumè, M, P355
Scomazzon, E, E1011, E1005
Scopim-Ribeiro, R, E832
Score, J, E1344
Scortechini, A, P605
Scott, B, P662
Scott, C, E1424
Scott, D, P297
Scott, E, S459
Scott, G, E1529
Scully, M, E1445, E1450, E1591
Sebag, M, E1248
Sebastian, E, S144, P580
Seda, V, E1004
Sedej, M, E1395
Šedivá, A, P711
Seesaghur, A, E1441
Šefer, D, E1308, E1328
Seferynska, I, P594
Seftel, M, P732
Segal, D, P175
Segovia, J, P685
Segovia, J, S144, S452, E1081, E1094, E1097
Segura, V, E1225
Sehn, L, S468
Seifarh, W, P255
Seifried, E, P382
Seiler, T, S464
Seiter, K, E923
Sekeres, M, S120, S471, P352
Sekhar, M, P403
Seki, M, S799
Sekiya, Y, P171
Selleri, C, P667, E967
Sellink, E, S132
Semenova, A, P220, E1133
Semenzato, G, S778, E930, E1005, E1006, E1011, E1254, E1357, E1397
Semeraro, M, P631
Seneca, E, E1261
Senechal, B, S143, S479
Senent, L, E953
Sengeloev, H, P388
Senín, A, P694
Seo, J, S422, E857, E909
Seoane, J, P298
Serafinelli, J, P717
Serbest, M, E1528
Serdaro_lu, E, E1427
Seregina, E, E1029
Sergey, G, P311
Sergey, K, P311
Seri, M, S433, P365
Serio, B, E967
Serizawa, K, E1100
Serra, A, S485
Serra, F, S117
Serra, M, E1421
Serrano, D, E1113
Serrano, J, P554, E1086
Serresi, S, E1136
Sertic, D, E1296
Serve, H, E927
Serventi-Seiwerth, R, S795, E1296, E1352
Servitzoglou, M, E862
Sesques, P, E906
Sessa, R, P393
Seuanes, F, E1586
Seung-Tae, L, P300
Sevcikova, S, E1290
Severin, F, E1005, E1006, E1011
Severinsen, M, P193, E932
Severson, E, P680
Sevilla, J, S144, S452, P580, P623
Sewastianik, T, E886
Sewell, D, E947
Sexl, V, P542, P749, E1045, E1366
Seyb, K, S500
Seyfried, F, P508
Seymour, F, E1212
Seymour, J, S472, S771, P208, P247, P564
Sezgin, A, E1446
Sfikakis, P, E1304
Sgherza, N, P705, E1043, E1325
Shaaban, K, E926
Shacham, S, S469
Shafat, M, E874
Shafeek, S, P347
Shah, B, P523, P608, E960

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Shah, J, P349, E1239, E1277
 Shah, M, E914
 Shah, N, P603, E1060
 Shah, P, P526
 Shah, P, E846
 Shaheen, G, E1486
 Shahlaee, A, E912
 Shaik, M, P204
 Shakhovich, R, P297
 Shamaa, S, E1095
 Shamas, M, E1206
 Shams, S, P608
 Shanafelt, T D, P254, P588, E1017
 Shankara, P, P252
 Shao, Z, E1144
 Shapira, I, E1438
 Shapira, M, P744
 Shardakov, V, E1526
 Sharif, J, P767
 Sharma, A, P372
 Sharma, E, S122
 Sharma, N, E1049
 Sharma, P, S474
 Sharma, P, P386
 Sharman, J, S106, P249, P634
 Sharpe, C, P619
 Shaswar, R, S494
 Shaulov, A, E1034
 Shaver, A, P352
 Shaw, B, E1508
 Sheehy, O, P245, P589
 Shelat, S, E1052
 Shelton, D, P261
 Shem-Tov, N, E1504
 Shemesh, S, P191
 Shen, J-L, S431
 Shen, J, S138
 Sherbenou, D, P386
 Sherman, M, S129, P666
 Shestopalova, I, E1436
 Sheth, S, S451
 Sheth, V, P744
 Shi, J, S430
 Shi, M, S454
 Shi, M-M, P507, P725, E1101
 Shi, X, E928
 Shibayama, H, P302
 Shigematsu, A, E859
 Shih, H-C, E1184, E1191, E1196
 Shih, L-Y, P537, P653, E825, E872
 Shikhbabaeva, D, E1313
 Shiku, H, P621
 Shilova, E, E986
 Shim, Y, P310, E850
 Shimamura, T, S799
 Shimizu, K, S782
 Shimizu, M, E1230
 Shimizu, R, P612
 Shimoda, K, S785
 Shimomura, Y, P196
 Shimonaka, Y, E1162
 Shimoni, A, P269, P388, E1504
 Shimura, Y, E959
 Shin, C, P625
 Shin, D-Y, P764
 Shin, H-J, P569, E1070
 Shin, J, E1062
 Shin, M-G, S491
 Shin, S, P742
 Shindo, T, E1068
 Shinki, H, E1595
 Shintani, M, E1139
 Shinzo, H, E1260
 Shiozawa, Y, S120, S123, S124, S799, P299, P314, P537
 Shipp, M, S412, E1354
 Shiraishi, Y, S120, S123, S124, S799, P299, P314, P537
 Shirneshan, K, P226
 Shiseki, M, P313
 Shlyakhto, V, S127
 Shmakov, R, P718, E1067
 Sho, M, E1590
 Shokeen, Y, E1049
 Shoman, W, E1411
 Shorikov, E, P161
Short, N, P170, P209, P518, E830
 Shou, Y, E973
 Shoumariyeh, K, E1364
 Shouval, R, E1504
 Shpall, E, S450, S792, P739, E914, E1512, E1538
 Shpilberg, O, S456
 Shrestha, R, P279
 Shridhar, K, E1073
 Shustik, C, E1246
 Shuttleworth, P, E1431
 Shuvaev, V, P257, E1313
 Shvidel, L, E1034
 Shyamsundar, V, P276
 Siakantaris, M, S416, E1120
 Sibai, H, P708, E1324
 Sibille, C, E994
 Sibon, D, E1386
 Sica, S, S485
 Siciliano, A, P392
 Sickert, D, S477
 Sicre de Fontbrune, F, S498
 Sicuranza, A, E1042, E1043
 Sidana, S, P673
 Siddiq, N, P708, E1324
 Siddiqi, T, S466, S772, P522, P563
 Siddique, S, S791
 Siddiqui-Jain, A, E881, E902, E1204
 Sidi Mohamed El Amine, B, E1275, E1472, E1479
 Sidoli, S, P528
 Sidorova, Y, E1403, E1409
 Siebert, R, P300
 Siegel, D, S142, S783, P333, P344, E1248, E1276, E1288
 Sieni, E, P714
 Sieniawski, M, P225
 Sierlecka, E, E920
 Siernicka, M, E1385, E1359
 Sierra, J, S790, P202
 Sierra, J, S145, P554, E1160
 Sierra, J, S816, E963, E1026
 Signes, B, E1604
 Signorovitch, J, E1300
 Sijmons, R, E897
 Sikka, S, P526
 Sikkema-Raddatz, B, E897
 Sill, H, S419, E879
 Silva, A, P284
 Silva, C, E1593
 Silva, J, P157
 Silva, M, E1586
 Silva-Santos, B, E889
 Silvennoinen, R, P670
 Silver, B, S451
 Silver, R, P351
 Silver, S, P652
 Silverman, L, S488, E1170, E1185
 Silvestri, G, S483
 Silvia Passos Lima, C, E952
 Silzle, T, P664
 Simanek, R, E1510
 Simeon, V, E1226, E1232, E1261
 Simeone, E, E1496
 Simeone, L, P277
 Simiele, A, P554
 Simister, R, E1591
 Simkovic, M, S465
 Simões, B, E832
 Simon, P, S131
 Simona, S, P232
 Simonacci, M, E1136
 Simonetti, G, E882, E898, E904, E1086
 Simplício, J, E1044, E1047
 Sims, D, P246
 Sims, J, E1090

- Sindaco, P, E1406
Singer, J, P699, P701, E1343
Singer, T, P392
Singh, G, P174
Singh, J, S120
Singh, J, E848
Singh, S, P763
Singh, Z, E912, E947
Singhal, A, S456
Singhal, N, S810
Sinicina, M, E1403
Siniscalchi, A, S410
Sinitzyn, V, E1161
Sinitzyna, M, E1409
Sinke, R, E897
Sinnige, H, S501
Siotou, E, E1083
Siret, A, S427
Sirhan, S, E1342
Sirianni, S, E1042, E1215
Siritanaratkul, N, P391
Sivakumaran, M, P406
Sivaprakasam, P, S817
Sive, J, E1202
Sivgin, S, S784, E1527
Siwiec, A, E888
Six, E, S140
Sjö, L, S486, P324
Sjøholt, G, E903
Skacel, T, E1260
Skachkova, O, E1382
Skatharoudi, E, E1574
Skettino, S, P249
Sklar, L, P588
Skoetz, N, S812, E1251
Skokowa, J, S497
Skorobogatova, N, E1154
Skorski, T, P528, P594
Skov, V, P602
Skrypets, T, E1127
Skucha, A, S133
Slama, B, E1180, E1181
Slany, R, P527
Slatter, M, S146
Slavcev, M, E1281
Slee-Valentijn, M, P340
Sleight, B, P519, P525
Sloan, J, E1321, E1331
Slomp, J, S113
Sloss, C, P526
Smahi, M, P370
Srnardova, J, P238
Smedby, K, P244
Smias, C, E1610
Smiers, F, S452
Smietniansky, M, E1264
Smiljanic, M, S443, E970, E1448
Smirnova, S, E1403, E1409
Smíšek, P, P711
Smit, L, P190
Smit, M, P190
Smit, W, E1057
Smith, A, P657, E842
Smith, A, P292, P740, P748, E1532, E1554
Smith, B, P204
Smith, C, S110, P560, E940
Smith, C, S122
Smith, C, P386
Smith, D, P188, E884
Smith, G, S423
Smith, J, P539
Smith, N, E1597, E1601
Smith, O, P350
Smith, P, P669
Smith, P, P763
Smith, R, S107, P640
Smith, S, S793
Smith, S, S773
Smith, S, S780
Smith, T, P246
Smits, E, S141
Smits, S, E1310
Smolej, L, E1024
Snedecor, S, E1037
Snel, S, S113
Snijders, T, P576
Snowden, J, S817, P164
Snydman, D, S807
Sobata, R, P401
Sochacki, A, P352
Sociè, G, S493, S797, P232
Socoro Yuste, N, P692
Soeda, J, E1260
Soerensen, J, P382
Søgaard Helbo, A, P324
Soiffer, R, S808, P650, P740, P748, E1532, E1554
Soilleux, E, S421
Sokol, L, P571, P632, E960
Sokolov, A, E836, E860, E861
Sokolova, I, E1436
Sokolowska, B, E888
Sola, M, P402
Solà Fernández, M, E1426
Solanes, N, E831
Solano, C, P746
Solarska, I, P594
Solary, E, P268
Soldatenkov, V, P308
Solé, F, P660, E831
Solé Magdalena, A, E1530
Soler, E, S427
Soler, J, P376
Soli, M, E1497
Solier, S, P268
Solinas, C, E994
Sollazzo, D, E1309
Solli, V, E1238
Solodovnikov, A, P161
Solomon, E, P176
Solomon, S, P210, P556
Solovev, M, E1227, E1295
Søltøft, F, P687
Somers, K, P154
Song, C, E863
Song, H-Y, P259, E1069
Song, H, S450
Song, K, P333, P339, P581, E1248, E1557
Song, X, P192, P241, P550, E830
Song, Y, S449, P507, P752, E833, E1101
Songer, S, P208
Songia, S, S801
Sonmez, M, P281
Sonneveld, P, S101, S102, S411, S459, S501, P320, P340, P341, P343, P677, P686, E1247, E1279, E1281, E1301
Soong, D, S101, S100, P335
Soothill, G, E1487
Sopper, S, P595
Sorà, F, S485, P604
Sørensen, H, E1435
Sorenson, R, E896
Soret-Dulphy, J, S787
Soria, J, P759, P765
Soroka-Wojtaszko, M, E888
Sorrentino, F, P399
Sosothikul, D, E975
Sotiriadis, A, E1574
Sotiropoulos, D, E1610
Sotirova, T, E1471
Soto, C, P609
Soto, M, P536
Sotomayor, E, E960
Sotomayor-Duque, G, E1306, E1415
Soucek, O, E1303
Souers, A, P189
Soufla, G, E1600
Souto, J, P759, P765
Souza Torres, L, E1492
Soverini, S, S485, P600, P605, P607
Sovová, Ž, S483
Soysal, T, E1159, E1518
Spaargaren, M, P567
Spacek, M, E1024
Spada, S, S102, P322
Spadano, A, S410
Spadea, A, E1145, E1340

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Spadola, V, P290
Spagnuolo, M, E1379
Spallarossa, P, P283
Spanoudakis, E, S415, E1266
Sparla, R, S813, P284
Spasiano, A, P394, E1570, E1571, E1575
Spassov, B, E1556
Specchia, G, S111, P358, P520, P598, P722, E1000, E1043, E1406, E1560, E1561
Spencer, A, S459, P335, P674, E929, E1129, E1289
Sperli, D, E1077
Sperr, W, P693, E1071
Špička, I, S100, S456, P339, P672, E1290, E1272
Spicuglia, S, S440
Spiegel, J, E1324
Spiekermann, K, S424, P546, E867, E877, E885
Spierer, A, P706, E1320
Spiess, B, P255
Spina, V, P282, P304
Spinelli, O, P163, E1315
Spinner, C, P568
Spinosa, G, S485
Spinsanti, M, P705, E1309, E1325
Spirito, F, E1340
Splinter, E, E897
Spoerl, S, P272
Spolzino, A, E1497
Sportelli, P, S772, P563
Sprangers, M, E1186
Spreafico, F, E955
Spreafico, M, E1606
Springer, G, E1326
Spruit, M, S448
Spyridonidis, A, P280
_rámková, L, P711
Sreekantham, B, S118
Sretenovic, A, S443, E970
Sretenovic, S, E970
Srinivasan, S, P349, E1239, E1248, E1277
Šrūtová, K, S483, E1041
St Pierre, T, P287, P292
Stacchini, A, P214
Stachura, J, E1359, E1385
Staderini, M, E1215, E1270
Stadler, M, S494, P516, E1105
Stadnik, E, E1040
Stadtmauer, E, P332
Stafford, R, P328, E1373
Stagakis, E, E1378
Stagno, F, S485, P604, P605, E1043
Staib, P, S424
Stalika, E, S461, P242, E1407
Stamatopoulos, B, P246, E994
Stamatopoulos, K, S461, P242, P244, P378, E997, E1407
Stamatoullas, A, P316
Stamou, A, E1462
Stamouli, M, P280
Stanislav, B, P311
Stanulla, M, S436, S437
Starbatty, B, E1251
Starý, J, P350, P711, E823
Staser, K, S794
Stassen, M, P651
Stathis, A, P282
Statuto, T, E1261
Stauder, R, E1186
Stavroula, K, E1485
Stavroyianni, N, S461, E1407
Stawinski, P, P594
Steegmann, MD, J, P609, E1051, E1059
Steele, A, P587, E996
Steensma, D, E1192
Steeple, V, S122
Stefanova-Petrova, D, E1155
Stefanski, H, S476
Stefanzl, G, P693
Stefoni, V, P304
Stege, C, S501, P340
Stegelmann, F, S424, P700, E1335
Stehlikova, O, E841, E1009
Steidl, U, S135
Stein, A, S471, S793, P191, P201, P524
Stein, B, S141
Stein, B, P701, P699, E1343
Stein, E, S471, P201, P215, P553
Stein, H, S150
Steinbauer, E, E1395
Steinemann, D, P226
Steinmetz, H, E1326
Stelitano, C, S778
Stella, S, S485
Stellato, D, E1055
Stellitano, C, E1390
Stelljes, M, P516, P519, P525
Stengel, A, P549
Stenson, L, E1110
Stentoft, J, P601
Stenzel, T, E846, E847
Stenzel, T, S108, P197, E921
Stepanishyna, Y, E1127
Stephens, K, E884
Stephens, L, P680
Sterjev, Z, E1471
Sternberg, D, S788
Steschenko, D, S131
Stevanovic, M, E948
Stevens, D, S773, S776
Stevens-Kroef, M, S501, P239, P677
Stevenson, F, P587, E996
Stevenson, W, S434, P524
Stewart, A, S408, P320
Stewart, G, S119
Stieglitz, E, P353
Stiehl, T, P206
Stilgenbauer, S, S116, S464, S771, P236, P248, P251, P508, P585, E1018, E1025, E1466
Stizhak, N, E1153
Stock, W, P519
Stockerl-Goldstein, K, P319, E1248
Stockley, T, P708, E1324
Stoecklin, G, P663
Stoiber, M, P799
Stoilova, B, S140
Stojanovic, A, E1471
Stokes, M, E944
Stokke, C, E1141
Stoklosa, T, P594
Stolyar, M, E1314
Stölzel, F, P326, E880
Stoma, S, P266
Stone, R, S471, P552, E868, E870, E883
Stoos-Veic, T, E1329
Stopka, T, S483, E1166
Stoppa, A-M, E1549
Storino, F, P586, E1390
Storino, M, P393
Stork, L, S422
Štork, M, E1290
Storti, G, S111
Storti, P, P321
Storti, S, P604
Stosch, J, P656
Stoškus, M, E828, E1311, E1399
Stoumbos, D, E1249
Stout, S, P523, E840
Strahm, B, P350
Stratford, E, P176
Strati, P, P241
Strauss, G, P754
Streetly, M, P326, P343, P669, E1242, E1245, E1550
Strefford, J, P587
Strefford, J, P585

- Streichert, T, E1117
 Strembitska, N, E1127
 Strenea, O, P161
 Strickland, S, S110, S473, P210, P560, E922
 Striha, A, S407, S781
 Stringer, J, S500
 Strobl, H, S419
 Stroppiano, M, E1077
 Strovel, E, E947
 Strub, H, E1374
 Struski, S, E1001, E1361
 Stryker, S, E1435
 Stuart, R, P556, E922
 Stuchly, J, P711, E823
 Stuhler, G, S797
 Stühmer, T, P320
 Stukalov, A, S133
 Stunnenberg, H, P325
 Stunnenberg, H, S117
 Sturniolo, M, E1239
 Stüssi, G, P282
 Styles, L, S492
 Su, Y, E835, E842, E925, E1480
 Suarez, F, P631, E910, E1236, E1386
 Suárez González, J, E1113
 Suárez-Cisneros, H, S115, E1381
 Subbiah, V, E1345
 Subirá, D, E1168
 Subklewe, M, P546, E867, E877
 Subocz, E, E1193
 Subortseva, I, P220, E1133
 Subotički, T, E1308, E1316, E1319
 Subramanian, P, P169, E837, E843
 Such, E, P316, P318, P696
 Sud, A, P295
 Sudarikov, A, E860, E1403, E1409, E1548
 Suessbier, U, P266
 Sugai, T, E1148
 Sugawara, N, P642
 Sugimoto, K-J, E1058, E1066
 Sugimoto, M, E1590
 Sugita, J, E859
 Sugiyama, H, P531
 Sugrue, M, E923
 Sui, X-H, E943
 Suito, M, E1349
 Sukhai, M, P708, E1324
 Suková, M, P711
 Suksangpleng, T, P395
 Sulen, A, E903
 Sulima, S, S417, S439
 Sultanova, M, E1457
 Sumbul, A, S412
 Sun, A, E931, E1189, E1507
 Sun, C-W, E1484
 Sun, H, P155
 Sun, J, P356
 Sun, K, E1146
 Sun, Y, P682
 Sun, Y, P753
 Sun, Y, P366
 Sun, Y, E1498
 Sun, Y-Q, S449, P725, E1101
 Suñe, G, E1088
 Sung, H, P223
 Superti-Furga, G, S133
 Suphapeetiporn, K, E975
 Surano, M, P736
 Sureda, A, E957
 Suri, G, E974
 Surkis, W, P566
 Surralles, J, S144, P580
 Sutherland, H, P581
 Sutter, U, P700
 Sutton, D, P761
 Sutton, K, E1460
 Sutton, L, E1001
 Sutton, L-A, P242, P244
 Sutton, R, P154, E848
 Suturkova, L, E1471
 Suvajdzic, N, E1448
 Suvajdzic Vukovic, N, E948
 Suvorov, A, E1244
 Suzu, S, P689
 Suzuki, H, S123, S799
 Suzuki, H, E1229
 Suzuki, K, S101, P334
 Suzuki, K, P531
 Suzuki, K, P171
 Suzuki, N, E1477
 Suzuki, S, E1210
 Suzuki, T, E962
 Suzuki, Y, P171
 Suzuki, Y, P642
 Svatoň, M, P711
 Svenkrtova, A, S801
 Svensson, M, S805
 Svensson, T, S805
 Svergun, N, E1382
 Sverrisdóttir, I, S442, P678
 Svetlana, G, P311
 Svitina, S, P308
 Svoboda, J, P566
 Svobodova, V, E1004
 Swanink, R, S422
 Sweat, R, P184
 Sweet, K, P191, P608, E1323
 Swerdlow, A, P295
 Swern, A, E923
 Swiderska, A, E1257
 Swieringa, F, P760
 Swinkles, D, P293
 Swoboda, J, P182
 Swords, R, S471
 Sy, O, S456
 Sychevskaya, K, E1403
 Syed, G, E1514
 Sykes, D, S428
 Sykes, S, P528
 Sykora, K-W, P382
 Sykorova, A, P218
 Symeonidis, A, S415, E1180, E1266, E1292
 Syrigou, A, E1610
 Syssoeva, E, E1161
 Szabo, Z, E1298
 Szalat, R, E1206
 Szarc vel Szic, K, P243, P656
 Szatkowski, D, S501
 Szczygiel, K, E827
 Szelagoswki, M, E1508
 Szer, J, P369
 Szeremet, A, E1262
 Szmigielska-Kaplon, A, P235
 Szoke, A, P699, P701, E1343
 Sztokowski, T, E1432
 Szudy-Szczyrek, A, E888
 Szumera-Cie_kiewicz, A, E1294
 Szydlo, R, S817
 Szydowski, M, E886
 Szymanski, G, E1178
 T'Sas, S, S438, E1358
 Tabrizi, R, P388
 Tacchetti, P, S410, E1238
 Tachavanich, K, E1076
 Tachi, N, P689
 Tadele, D, E866
 Tadmor, T, E1034
 Tadokoro, K, E1072
 Tafuri, A, S111
 Tafuri, M, P736, E1123, E1151
 Tafuro, G, P736
 Taghvaei, R, E1267
 Taha, H, P291
 Tahan, F, E1428
 Taher, A, P286
 Takachi, T, P625
 Takada, K, E1213
 Takada-Okuyama, N, E1175
 Takae, S, E1477
 Takagi, M, S799
 Takagi, S, E1354
 Takahashi, H, E962
 Takahashi, K, S489, S496, P192, P200, P207, P241, P315, P550, P665, E830, E913
 Takahashi, N, P257, E1053
 Takahashi, N, E1447
 Takahashi, S, E1053

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Takahashi, Y, P171
 Takaku, T, E1058, E1066
 Takam Kamga, P, E821
 Takamatsu, H, E1285
 Takami, A, E1210
 Takanashi, M, P389
 Takano, K, P689
 Takaori-Kondo, A, P537
 Takeda, J, S120, P314, P537
 Takei, H, P691
 Takeoka, T, P263
 Takeuchi, K, S124, P301
 Takeuchi, M, E1285
 Takita, J, S799
 Takizawa, M, E1447
 Talamo, G, E1248
 Talarn Forcadell, C, E1426
Talati, C, P608, E1323
 Talaulikar, D, E1388
 Talbot, A, E1265
 Tallman, M, S471, P552, P553
 Talpaz, M, P603, P699, P701, E1343
 Tam, C, S769
 Tamaki, H, P753
 Tambaro, F, E1016
 Tamborero, D, P655
 Tamma, R, E1406
 Tammiso, E, E1020
 Tamouza, R, E1495
 Tamura, H, P327, P659, E1175
 Tan, B, P646
 Tan, L, E1605
 Tan, S, S147
 Tan, T, P646
 Tan, Y, P646
 Tanaka, H, E1068
 Tanaka, H, P263
 Tanaka, H, E1100
 Tanaka, H, S124, S799, P299, P314, P537
 Tanaka, J, P313, P327, E1522
 Tanaka, Y, P621
 Tanaka, Y, E1072
 Tanay, A, S436
 Tandilova, K, E1161
 Tandon, N, P673
 Taneja, V, E1049
 Tang, F, E1498
 Tang, F-F, P752
 Tang, G-Q, S500
 Tang, H, E1147
 Tang, W, E1547
 Tang, X, E931, E1085, E1087, E1152, E1507, E1520
 Tang, Y, P390
 Tang, Y, P224
 Tani, M, S107
 Taniguchi, R, P171
 Taniguchi, Y, E1100
 Tanis, B, S501, P340
 Tannheimer, S, P158, E896
 Tanosaki, S, P327
 Tanphaichitr, V, E1076
 Tantawy, A, E1580, E1582
 Tanzima, S, P301
 Taoussi, S, E985
 Taparkou, A, E1414, E1423
 Tapia, G, E1394, E1396
 Tappe, W, S808, P650, P740, P748, E1532, E1554
 Tapper, W, E1344
 Taran, T, S476, S477, P517
 Tarantino, M, P367, P727
 Tarella, C, S413, S778, E1533
 Tarfi, S, E1374
 Tarif, M, P398
 Tarin-Arzaga, L, E1306, E1415
 Tarlock, K, P184
 Tarrini, G, E1048, E1318, E1397
 Tartaglione, I, S129, P288
 Tartakovsky, B, E1524
 Tartari, C, P766
 Tasian, S, P158
 Tassi, R, E1401
 Tassielli, D, P736
 Tassone, P, P586, E1390
 Tastemir, N, P281
 Tata, N, P698
 Tatarczuch, M, E1457
 Tatetsu, H, E1205
 Tatli Gunes, B, E1422
 Tauchi, T, E1046, E1072
 Tausch, E, S116, P236, P248
 Tavares, R, P702, E1333, E1334
 Tavazzi, D, E1576
 Taverna, P, E1192
 Tavitian, S, P557, E856
 Taya, Y, E951
 Tayabali, S, E1450
 Taylor, A, E1591
 Taylor, J, E1424
 Taylor, K, E1289
 Taylor, L, E1441
 Taylor, R, E1037
 Taylor, S, S122, S140, E1110
 Taylor-Stokes, G, P706, E1320, E1463
 Taylor-Weiner, A, P236
 Tazzari, P, E1309
 Te Kronnie, G, S436, E823
 Teague, J, E1201
 Teal, V, S807
 Teater, M, P297
 Tedeschi, A, E1246
 Teegavarapu, P, E1146
 Tegg, E, E1140
 Teh, T-C, P175
 Tekgunduz, E, P281
 Teleanu, M-V, E870
 Telek, V, E1535
 Teles, M, E988
 Teli, A, E1414, E1423, E1574
 Tellez-Gabriel, M, S816
 Tembhare, P, P169, E837, E843
 Ten Cate, H, P760
 Ten Hacken, E, P588
 Teng, C-L, E1474
 Teng, Z, P338
 Tensen, C, E1362
 Tenti, E, S485
 Teodosio, C, P584, P713
 Teramo, A, E1357, E1397
 Teramoto, M, P689
 Terán, C, P733
 Terebelo, H, P349, E1239, E1277
 Termini, R, E1238
 Terol, M, S115, E995, E1394
 Terpos, E, S130, S415, S782, P337, E1231, E1233, E1249, E1266, E1292, E1304
 Terragna, C, E1238
 Terranova, P, P234, P575, E1440
 Terre, C, E1001
 Terreri, S, P174
 Tertreault, S, S777, E1130
 Teruel, A, E953
 Teruel, A-I, P688, E1278
 Teruel, R, S445
 Teruel-Montoya, R, P573, E1434
 Tesar, B, P237
 Teschner, D, P643
 Tesé, L, P290
 Teshima, T, P301, P360, E859
 Tessarolo, S, P760
 Testoni, N, E882
 Tettamanti, S, P630
 Thachil, J, P767
 Thackray, H, P203, P547
 Thai Ton, D, P287
 Thakurta, A, E1203, E1248
 Thaler, J, P195, P558, P707
Theis, F, P533, E868, E870
 Theobald, M, P626, P627, P629, P643,

- E992
Theodoridis, T, E1574
Theodoridou, S, E1574
Thepot, S, E1181
Thieblemont, C, S105, S469
Thiede, C, S494, P172
Thiel, M, S132
Thielen, N, P262
Thiollier, C, S427
Thirant, C, S427
Thirman, M, S472
Thivakaran, A, P534, E1118
Thiyagarajah, P, S459
Thol, F, S494, P231, P533, P535, P537, E864, E868, E870
Tholouli, E, S817, E1250
Thomas, A, P540
Thomas, C, S131
Thomas, D, P170, P518
Thomas, I, S114
Thomas, M, E1445, E1450
Thomas, M, P708, E1324
Thomas, N, E1557
Thomas, S, S145
Thomas, X, P557, E856, E906, E907
Thomassen, M, E1367
Thompson, A, S814
Thompson, C, P237
Thompson, H, E1377
Thompson, M, E923
Thompson, P, S463, P170, P240, P241, E991, E1016
Thompson, R, E1523
Thomsen, H, P295
Thongjuea, S, E1110
Thornes, J, P197, E921
Thornton, P, S769
Thornton, R, P550
Thorsteinsdottir, S, P330
Thow, C, E1605
Thrasher, A, S814
Thruue, C, P174
Thu Ha, N, P287
Thudium Mueller, K, S476, S477
Thune, J, P221
Thuret, I, S131, S814
Thusek, S, E1569
Thuss, N, S411, E1499
Tiab, M, P217
Tian, X, E1152
Tiao, G, P236
Tibaldi, E, E1006
Tibes, R, P320
Tibullo, D, E1214, E1232
Tichelli, A, E1455
Tick, L, S411
Tieghi, A, S111, P358, P705, E1325
Tien, H-F, P212, E942
Tikhe, J, S500
Tiley, C, E1350
Tilly, H, S105, S106
Timbol, Z, E1140
Timlin, C, P566
Timmerman, J, S412, S466, P522
Tinquaut, F, P572
Tippen, S, P241, P550, E830
Tiribelli, M, P604, P605, P607, P705, E1065, E1325
Tirindelli, M, E1151
Tischer, J, P384
Tisi Baña, M, E1508
Tissino, E, P583, P588
Titov, A, P308
Titov, S, E1314
Tiwari, R, P702, E1333, E1334
Tjon, J, P576
Tjønnefjord, G, P369, P613, E1501
Tkhostov, A, E1461
Tobinai, K, S775, E1139
Tobu, M, E1525
Tocco, V, E917, E1167
Toda, J, P592, E1370
Todaro, M, E999
Toddendoro, D, E1117
Todeschini, G, E1533
Todesco, A, E844
Todisco, E, P644
Todoerti, K, E1226
Todorovic, M, S443
Todorovic-Balint, M, E970
Todorovic-Tirnanic, M, E1448
Toes, R, P267
Toffalori, C, P544
Toffoletti, E, E1065, E1496
Togami, K, S428
Tojo, A, E951
Tokgoz, H, E1584
Tokuhira, M, E1058, E1066
Tokushige, C, P531
Tolba, O, E1583
Tolosano, E, S813
Tom, N, E1003
Toman, O, E1041
Tomarchio, V, P736, E1123
Tomassian, L, S477
Tombuloglu, M, E1525
Tomer, T, S459
Tomin, D, E1448
Tomkinson, K, S147
Tomlins, J, S503
Tonda, M, P620
Tondo, A, E955
Tonon, G, P544
Toofan, P, P591
Toomey, K, P349, E1239, E1277
Topp, M, S478, P524
Toprak, S, P281
Toptas, T, P281, E1446
Torbagyi, E, E1535
Tordai, A, E1535
Töret, E, E1427
Tormo, M, S790, P554, E831
Torrebadell, M, P168
Torrens, D, P300
Torrents, D, S117
Torres, M, E1341
Torres, P, S790
Torres, R, E1081
Torres Martin, M, E1173
Torres Miñana, L, E1327
Torres Priego, M, E1500
Torres-Ruiz, R, P623
Torresan Delamain, M, E952
Toscani, D, E1223, E1237
Tosi, M, P163
Tosic, N, E948
Tota, G, P598
Toth, R, P350
Touati, M, E1458
Toubai, T, P753
Toulon, P, P370
Tournilhac, O, S105, S777, E1001
Toutain, F, S453
Touzani, R, E1549
Touzart, A, P156
Touzeau, C, S460, P675
Touzot, F, P631
Tovar, N, E1259
Towfic, F, E1203
Townes, T, E1484
Tozatto-Maio, K, E1495
Toze, C, P581, E1557
Trabacchi, E, P605
Trabazo, M, P168
Traeger, L, E1473
Traer, E, P562
Traficante, A, E1261
Traina, F, E832
Traivaree, C, E975
Trajanoski, Z, P595
Trajkova, S, E1471
Tran, D, S450
Tran, D, P375
Tran, H, E1431
Tran, N, S421
Trang-Quang, C, S440
Trapero, M, E1451
Trask, P, S502
Travaglino, E, E1179
Traverse-Glehen, A, P217
Trawinska, M, P604, E1067

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Trbusek, M, E1003
Tremblay, G, E925, E945
Trentin, L, S413, P722, E996, E1005,
E1006, E1011, E1357
Tresoldi, C, P544
Trestman, S, E1524
Trevarthen, D, S776
Tricta, F, P398
Trifa, A, E1602
Trifilo, K, E894
Trigueros, C, E1097
Trimarco, V, E1005, E1006, E1011,
E1357
Trimoreau, F, E1010
Trino, S, E1226
Trinquand, A, E1386
Tripathi, A, E974
Tripathi, A, E1442
Tripathi, P, E1589
Tripepi, G, P610, E1017
Triplett, B, P650, P740, P748, E1532
Tripodo, C, P586, E1390
Tripolt, S, E1366
Trizzino, A, P717
Trka, J, S801, P711, E823
Trnĕný, M, S412, P218, E1540
Trnkova, M, E1540
Troadec, E, P186
Troconiz, I, P554
Troia, R, S102, E1247
Troitskaya, V, E836, E860, E861, E934,
E982
Trollmann, I, P267
Trombetta, E, E1078
Trone, D, S475, E924
Tronik-Le Roux, D, P274
Trotman, J, S774, E1129, E1246
Trotter, M, E1203
Trpkovska-Terzieva, S, E1471
Trucas, M, P256
Trucco, J, E1508
Truemper, L, P216, P222
Truman, M, P640
Trumpp, A, P172, P179
Trunzo, V, E1420
Tsafaridis, P, E1120
Tsalimalma, K, E1304
Tsaur, G, P161
Tschuri, S, E885
Tse, E, E1392
Tsioutsias, P, E1485
Tsirigotis, P, S415, P280
Tsirkinidis, P, S416, P639, E1036
Tsoi, Y, E1110
Tsourouflis, G, E1120
Tsui, H, E1324
Tsui, M-L, P190
Tsukamoto, K, E1372
Tsukushi, Y, P642
Tsunaka, M, E1595
Tsuneda, S, P691
Tsurumi, H, E1230
Tsuzuki, S, E1210
Tsuzura, A, P302
Tsvetaeva, N, E1161
Tsvirenko, S, P161
Tu, N, P208
Tucci, A, S778
Tucci, F, P717, E1164
Tucci, G, P636
Tucker, D, E1377
Tummino, M, E1214
Tumyan, G, P220, E1133
Tung, M, E1605
Tupek, K, E1329
Tupoleva, T, P307
Turak, E, E1527
Turazzi, N, P628
Turchiano, A, P182
Turesson, I, P330, P678
Turgut, M, S107, P281, P672
Turka, A, S142
Turkalj, S, E1375
Turker, A, P281
Türker, M, E1422
Turkina, A, P257, E1067
Turlure, P, P208
Turner, D, P252
Turner, S, E1141
Turowski, A, P680
Tvedt, T, P613
Tyndel, M, S491
Tyner, J, P194
Tytorenko, I, E1127
Tzankov, A, E1365
Tzanninis, I-G, E1462
Tzatchev, K, E1155
Tzelepis, K, S136, S430
Tzeng, W-F, E1567
Tzenou, T, S416, E1304
Tzonev, S, P261
Tzrantcheva, R, E1155
Ubeda, J, E1026
Übelhart, R, E1362
Ubels, J, E1279
Ucan, G, E1539
Uccello, G, P586, E1017, E1390
Uchida, N, P389, E1522
Uchimaru, K, P385, P621, E951
Uchino, K, E1210
Uchiyama, H, E959
Uckan, D, E855
Ucman, M, E1584
Udby, L, P602
Udvardy, M, S502
Ueda, R, E1210
Ueda, Y, E1199
Ueno, H, S120, S799, P299
Ueno, N, E1205
Ueno, S, E1205
Uhm, J, E939
Uike, N, P263, E1199
Ulianchenko, K, E1127
Ulillarrena Redondo, C, E1327
Ullrich, S, S117
Umez, T, E1046, E1072, E1209
Ünal, A, E1527
Ünal, E, E1539
Ünal, S, E1488
Unal, S, E855, E1157, E1598, E1603
Ung, B, E1282
Unnikrishnan, A, P654
Unterhalt, M, S502
Uoshima, N, P263, E959
Uras, I, P542
Urbano-Ispizua, A, E1088
Urbanova, R, E1024
Ureshino, H, E1068
Uriarte, J, E1183
Urisono, Y, E1590
Urity, V, P552
Urrego, M, E1074
Urso, A, E1020
Urucuqui, L, E1074
Usala, E, P605
Usikova, E, E861
Usmani, S, S457, S779, P334, P335,
P676
Usnarska-Zubkiewicz, L, E1257, E1262
Ussowicz, M, P350
Usui, Y, E1285
Usukhbayar, B, S140
Usuki, K, P263, P537, E1199
Utsumi, T, P263
Utsunomiya, A, P385
Uttenenthal, B, P276, E938
Uy, G, P319, P556, E1073
Uyttbroeck, A, P151, P152, P156
Uzan, B, P514
Vackova, B, E1540
Vadaketh, J, P528
Vadysirisack, D, S500

- Vago, L, P544
 Vahanian, N, E912
 Vainchenker, W, S427
 Vaitkevicienė, G, E828
 Vakoc, C, S430
 Valcárcel, D, P318
 Valdez, B, E1538
 Valencia, A, E1173
 Valent, P, S133, S788, P542, P596,
 P693, E1071
 Valentín, J, P509, E1546
 Valentino, J, P618, E1149
 Valera-Ágamez, A, E1074
 Valeri, A, E1278
 Valero Saldaña, L, E1473
 Valk, P, S113, P538
 Valkovic, T, E969
 Vall-Llovera, F, E831, E1394
 Vallance, G, E1457
 Vallansot, R, E1426
 Vallejo, F, P573
 Vallespin, E, P580
 Vallet, N, P572
 Valli, V, E1078
 Vallisa, D, P658
 Vallone, R, P586
 Valsecchi, M, S480
 Valtola, J, P670
 Van Alphen, F, P404
 Van Avondt, K, S455
 Van Balen, P, S447
 Van Beers, E, S451, S452
 Van Beers, E, P677, E1279
 Van Bruggen, R, S455
 Van de Donk, N, S501, P340, P343
 Van de Loosdrecht, A, E1168
 Van de Meent, M, S447
 Van de Velde, A, S141
 Van de Velde, H, P339
 Van De Wyngaert, Z, P345
 Van den Akker, E, S132
 Van den Berg, T, P404
 Van Den Berg-De Ruiter, E, E897
 Van den Bergh, M, P632
 Van den Brand, M, E1353
 Van den Brink, M, S446
 Van den Heuvel-Eibrink, M, P350
 Van Den Neste, E, S105, S469
 Van der Bom, J, P312
 Van der Hem, K, S501
 Van der Holt, B, S102, S501, P340,
 P677, E1499
 Van der Meer, P, P404
 Van der Meijden, P, P760
 Van Der Merwe, I, E947
 Van der Meulen, M, P219
 Van der Reijden, B, E1197
 Van der Schaaf, A, E1353
 Van der Velden, A, S501, P677
 Van der Velden, V, S102, S113
 Van der Zeeuw, S, E1362
 Van der Zwaan, C, P404
 Van Deventer, S, E1353
 Van Dongen, J, S801
 Van Dooijeweert, B, P579
 Van Driessche, A, S141
 Van Duin, M, P677
 Van Galen, P, S428
 Van Gils, N, P190
 Van Hoeven, V, S448
 Van Keerberghen, C-A, P565
 Van Krieken, H, E1353
 Van Lint, M, S493, S796, P384
 Van Marwijk Kooy, M, S112
 Van Mierlo, G, S455
 Van Min, M, E897
 Van Oirschot, B, P614
 Van Oostrum, I, E835, E842
 Van Randenbourgh, A, E1286
 Van Rensburg, M, P368
 Van Rhenen, A, P190
 Van Roon, E, P683, E1194
 Van Roy, N, P156
 Van Solinge, W, S452
 Van Spriël, A, E1353
 Van Straaten, S, S452, P614
 Van Swelm, R, P293
 Van Tendeloo, V, S141
 Van Veen, S, P265
 Van Vlierbergh, P, S438, P156, E1358
 Van Vliet, M, P677, E1279
 Van Wijk, R, S452, P614
 Vandecaveye, V, P565
 Vandenaabeele, P, P268
 Vandenberghe, P, P156, E1310
 Vandenberg, I, S141
 Vandendries, E, P519, P525, E835
 Vandepoele, K, E1114
 Vanderkerken, K, E1211, E1220
 Vanek, J, E858
 Vangeli, M, E1048
 Vannucchi, A, S786, P351, P355, E1333
 Vannuffel, P, E1056
 Varaldo, R, S796
 Varas, A, P513
 Vardi, A, P242, E1407
 Varela, I, S420
 Varga, E, S132
 Varga, L, E1535
 Vargas-de los Monteros, M, P213
 Vargas Espinosa, J, E1500
 Vargova, K, E1166
 Variami, E, E1120
 Varma, N, E851, E987
 Varma, S, E851
 Varotto, E, P715, E844
 Varvoutsis, M, E862
 Vasilatou, D, E895
 Vasilev, V, E1155
 Vasilica, M, P635
 Vasiliiev, D, P307
 Vasilyeva, V, E1545, E1559
 Vaskova, M, E823
 Vasquez, C, E963
 Vassallo, J, E952
 Vassilakopoulos, T, S416, P280, P639,
 E1036, E1120
 Vassiliou, G, S136, S420, S430
 Vassilopoulos, G, P280
 Vassilopoulos, G, E1266
 Vasu, S, S793, P191
 Vaturi, M, E949
 Vaughan, J, E1143, E1405
 Vaxman, I, E949
 Vázquez, I, P205, P198
 Vázquez, J, P685
 Vazquez, L, S804, P747
 Veeger, N, P683, E1194
 Veelken, H, P267, P567, E1362
 Veenbergen, S, E1353
 Vega-Garcia, N, P168
 Végi, N, S429, S809
 Vegliante, M, P296
 Veiga, Á, P361, E1543, E1592
 Vekemans, M-C, S112
 Vela, M, P509
 Velasco, F, P721, E1456
 Velasco-Rodríguez, D, E1596
 Veldhuizen, D, S113
 Velegraki, M, E1419
 Velez, P, P703
 Vellenga, E, E897
 Venditti, A, S111, E908
 Vendrame, F, E1494
 Vendramini, E, P583
 Vener, C, E1420
 Veneziano, D, E917
 Venn, N, E848
 Ventura, G, E1496
 Ventura Ferreira, M, P231, P593
 Venturelli, D, E1491
 Venturi, C, P607
 Venturini, L, E1105
 Venuso, A, P541
 Vera, J, P554
 Vera-Aguilera, J, E1241, E1274
 Veratti, P, E1364
 Verbeeck, J, S417, S439, P152, P153
 Vercellotti, G, P284
 Verdaguer-Dot, N, S117, P325
 Verdugo, M, S460, S771, P247, P564,

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- P675, P682, P728, E1466
Verecke, S, S417, S439
Verga, L, P570, P644
Verger, E, S787
Vergez, F, P557
Vergin, C, E1427
Verhagen, H, P190
Verhoef, G, P565
Verhoeyen, E, E1356
Verlay, M, E1135
Verlinden, A, S141
Verma, A, S135, P662
Verma, S, E974
Vermaat, J, P567
Vermeer, M, E1362
Vermeersch, P, P152, P153
Vermeulen, J, E1129
Vermeulen, K, S141
Vermeulen, M, P677
Vermue, E, P190
Vernerey, J, P183
Verneris, M, S476, P517
Veronese, L, E1001
Verrou, E, E1233
Versluis, J, S112
Verstovsek, S, S786, P352, P359, P690,
P699, P701, P709, E1321, E1331,
E1339, E1343, E1345
Vervessou, E, S415
Very, C, S453
Verzegnassi, F, P717
Verzeroli, C, P760
Verzhbitskaya, T, P161
Vescio, R, S408
Vescovini, R, E1223
Vesole, D, S780, E1276, E1288
Vestergaard, H, P697
Vetter, K, P700
Vexler, V, E1147
Vey, N, P183, P316, P354, E907, E1547
Veizan, R, S769
Viallard, J-F, P720
Vianelli, N, P358, P705, P722, E1309,
E1325
Viardot, A, P216, P222
Viarengo, G, S128
Vicari, L, P393
Vicario, J, E1113
Vicente, A, P513
Vicente, C, S439, P205, P536
Vicente, E, E1026
Vicente, M, E1086
Vicente, V, S445, P402, P573, P660,
P721, E1013, E1444, E1451, E1456
Vicente-Dueña, C, S148
Vicenzetto, C, E1357, E1397
Vicuña, I, E1565
Vidal, R, E1596
Vidal-Crespo, A, E1369
Vidal-Manceñido, M-J, E1014
Vidler, J, E1242
Vidriales, M-B, P329, P554
Vieri, M, E819
Viero, P, S413
Vieth, S, E849
Vigna, E, P586, E1017, E1390
Vignal, C, P253
Vigneri, P, S485
Vignetti, M, P520, E1000, E1186
Vignoli, A, P760, P766
Vij, R, P344, P675, E1269
Vilalta, N, P759, P765
Vilanova, D, P376
Vilarrasa-Blasi, R, S117, P300
Villalobos, L, P737
Villalobos-Ortiz, M, P508
Villamor, N, S115, E1031, E1032,
E1039, E1137
Villani, O, E1226, E1261
Villano, F, E1273
Villanueva, M, E1097
Villanueva-Luna, J, E1074
Villar, L, E1302, E1305
Villar, S, S444
Villarese, P, S801
Villegas, C, E953
Villegas Martinez, A, E983
Villemagne, B, P217
Villivà, N, E1340
Villoria, J, P554
Vilvenhtharaja, E, E1380
Vinas, L, P714
Vincelli, I, P586
Vinchi, F, S813, P284
Viniou, N-A, E1120, E1462
Vinogradova, M, P718
Viola, F, E1483
Viola, G, E1489
Viprakit, V, P395, E1076
Virchis, A, P669
Virgo, P, S114
Virijevec, M, E948
Virlojeux, A, E856
Visanica, S, P316
Visconti, F, E1124
Visentin, A, E1005, E1006, E1011
Visser, H, P677
Visser, O, P219, P250, P262, P686
Visser-Wisselaar, H, S501, P340
Viswanathan, G, P169
Vitale, A, S800, P166, P520
Vitale, C, E999
Vitale, M, P528
Vitek, A, E1198
Vitolo, U, S467, P163, P214, E1129,
E1533
Vitrano, A, P290
Vitriu, A, E1508
Vittori, S, S133
Vitullo, P, E917, E1167
Vives, S, S790, P202, P554, E831,
E1086
Vives Corrons, J, P615
Vivian, G, E1242
Viviane Okumura, J, E1492
Viviani, S, S413
Vizcarra-Reyes, M, E1074
Vlachadami, I, E895
Vlachonikola, E, E997
Vladareanu, A, E1602
Vlasova, A, S117, P161
Vlčková, M, P711
Vo, M-C, E1089, E1091
Vockenhuber, T, P559
Vodanovic, M, E971
Voellinger, J, S793
Voermans, C, S448
Voevoda, V, P269
Vogel-Gonzalez, M, E893
Vohra, S, S136
Voisset, E, P176
Volin, L, S797, S798, P388
Volinia, S, P174
Volkert, A, E884
Volodicheva, E, E1436
Voloshin, S, E1313
Volpe, G, S119
Volta, E, E1012, E1020
Von Bubnoff, N, P700
Von Lilienfeld-Toal, M, P647
Von Lindern, M, S132
Von Luettichau, I, P382
Von Neuhoff, C, S789
Von Neuhoff, N, E878
Von Pein, U-M, E1286
Von Stackelberg, A, S436, S437
Von Strandmann, E, P295
Von Tresckow, B, S414, P275, E1119
Von Tresckow, J, S464, E1025
Vora, A, S817, P521, P668
Vormoor, J, P512
Vose, J, S772, P563



- Voskanyan, A, S424
Voskaridou, E, S129, S130, E1485, E1574
Voso, M, P607, P658, E908
Votyakova, O, E1227
Vovk, T, E1599
Vredenburgh, J, S779
Vrhovac, R, S795
Vu, T, E880
Vucinic, V, P380, P516
Vucinic, V, E1499
Vukovic, V, S443, E970
Vulcano, A, E1145
Vural, F, E1525
Vyasa, P, S122, S140, S791, P540
Vyasamneni, R, S500
Vybornykh, D, E1461
Vydra, J, E936
Vyrla, D, E1378
Vyzantiadis, T-A, E1083, E1574
Waage, A, S501, P677, E1250
Wabbels, C, P516
Wąclaw, J, E1061
Wagdy, M, E1578
Wagner, B, S436
Wagner, L, P349, E1239, E1277
Wagner, W, E1106
Wagner-Johnston, N, S777, E1130
Wahiduzzaman, M, E1210
Wai, S, E1413
Wakita, H, P263
Walch, A, S809
Waldron, E, S477
Walewski, J, P162, E1018
Walker, B, E1203
Walker, C, E883
Walker, I, E1242, E1245, E1550
Walker, P, P674, E929
Waller, C, S424, P255
Waller, E, S492
Waller, J, P706, E1320
Walling, J, S104
Wallis, W, P739, E914
Walter, C, E878
Walter, H, E1372
Walter, M, P319
Walter, R, S473, S793, P201
Walter-Croneck, A, S456, E1262
Walters, M, S814
Wan, H, S807
Wang, A, E1507
Wang, B, S103
Wang, C, S799
Wang, C, E1144
Wang, E, P632, E960
Wang, E, S110, P191, P204, P552, P560, P562, E883
Wang, F, S103
Wang, F, S489, P192, P207, P241, P550, E830
Wang, F, E1498
Wang, F-R, P387, E1515
Wang, F, E1503, E1511
Wang, H, E894
Wang, J, E1388
Wang, J, S103
Wang, J, P676
Wang, J, E911, E916
Wang, J, S103
Wang, J, E1558
Wang, J-H, E961
Wang, J-W, S431
Wang, J, E1498
Wang, J-Z, P387, E1503, E1511, E1515
Wang, J, P585
Wang, K, E880
Wang, L, E961, E1389
Wang, L, P258
Wang, L, S106
Wang, L, E1547
Wang, L, P366
Wang, L, S126
Wang, M, S431
Wang, P-Z, P511
Wang, Q, E1531
Wang, Q, E928, E1189
Wang, Q, P363, E1503, E1511
Wang, S, S490, P362
Wang, S-J, P511
Wang, S-Y, P555
Wang, T, P519, P525
Wang, T, P663
Wang, T, E956
Wang, W, P172
Wang, W, P179
Wang, X, E943
Wang, X, S143, S479
Wang, X, P727
Wang, X, S103
Wang, Y, E1503, E1511
Wang, Y, S773
Wang, Y, E1178
Wang, Y, P390, E911, E916
Wang, Y, P637
Wang, Y, S143, S479
Wang, Y, S449, P387, P506, P725, P752, E1101, E1498, E1515, E1517
Wang, Y, E1241, E1274
Wang, Y, P362
Wang, Y-T, S449
Wannez, A, P230, E964
Warcel, D, P403, P405
Ward, C, S119
Ward, C, S434
Wardell, C, E1203
Wardley, C, S503
Ware, P, P668
Warner, S, E881, E902, E1204
Warren, D, E1501
Warsame, R, E1240, E1274
Warzocha, K, E886, E1262, E1294
Wąsac-Szulowska, E, E1061
Washington, C, P620
Wasmuth, J-C, P568
Wass, M, P555
Wassenberg, C, E1326
Waszczuk-Gajda, A, E1193, E1257
Watanabe, J, P689
Watanabe, K, P171
Watatani, Y, S124, P299
Wątek, M, E920
Waterhouse, A, S407, S781
Watkins, K, P526
Watman, N, P719
Wattad, M, P533, P535, E864
Wayne, A, E840
Webb, S, E1007
Weber, A, E1356
Weber, D, P533, E864, E870
Weber, D, P159
Weber, L, P631
Weber, T, E875
Wedler, H, P195, P558
Wegman, J, P567
Wegner, E, E958
Wegner, J, S816
Wehrle, J, P656
Wei, H, E916
Wei, A, S472, S473, S478, P175, E907, E929
Wei, H, E911
Wei, H, E1073
Wei, L, S103
Wei, S, E911, E916
Wei, Y, P317
Weichenhan, D, P663
Weigl, A, S812
Weinberg, J, S146, S495, P381
Weinstein, M, S147
Weirather, J, S470
Weisel, K, S101, S456, S459, P335, P336, P343, E1256, E1281
Weiss, B, S104, P676
Weiss, L, P269
Weiss, M, S772, P563
Weitman, S, E881, E902, E1204
Weitz, J, P578
Welch, V, E835
Wellendorf, A, S149
Wells, R, E1192
Welslau, M, E1449

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Welte, K, S497
 Weltermann, A, P559
 Wemmer, M, E1090
 Wen, L, E928
 Wen, T, E1413
 Wendelin, K, P516
 Wendtner, C, E1025
 Wendtner, C-M, S464, S771, P251
 Wennerberg, K, P181
 Wenzl, K, E1363
 Wermke, M, E1018
 Werner, A, E992
 Werner, L, P237
 Wertheim, M, P633
 Wessling, C, S482
 West, J, S147
 Westendorp, M, E1557
 Wester, R, E1301
 Westerman, D, E848, E1202
 Westerman, M, S501, P340
 Westermann, J, P172
 Westers, T, E1168
 Westervelt, P, P319
 Westerweel, P, P262, E1057
 Westin, J, S469
 Westman, M, S109, S486
 Westmose Yde, C, E1115
 Weston-Davies, W, P235
 Westwood, J, E1445, E1450
 Wetten, S, E1441
 Whatcott, C, E881, E902, E1204
 Wheadon, H, P591
 Wheatley, K, S791
 White, D, S456, E1244
 White, D, S484
 White, M, P373, E1468
 Whitehead, K, P368
 Whittaker, S, P637
 Wicherska-Pawłowska, K, E1553
 Wichmann, C, S427
 Wichmann, M, S494
 Wieland-Greguare-Sander, A, E1455
 Wiemels, J, P300
 Wierda, W, S463, S771, S772, P209, P240, P241, P518, P523, P564, P728, E991, E1016, E1466
 Wiernikowski, J, E1022
 Wierzbowska, A, E920
 Wiesenfarth, M, P350
 Wiesneth, M, E1084
 Wiestner, A, P588, E1369
 Wiezorek, J, S466, P522, P523, E840
Wiggers, C, P187, E901
 Wiggill, T, E1405
- Wigley, C, P368
 Wihlborg, A-K, E826
 Wildenberger, K, P261
 Wilhelm, A, P526
 Wilke, T, E842
 Wilkes, E, P532
 Will, B, S135
 Will, R, P663
 Willard-Gallo, K, E994
 Wille, K, E1335
 Willemze, R, E1362
 Willenbacher, E, P707
 Willenbacher, W, S782
 Williams, C, S407, S781
 Williams, S, E1509
 Wilmot, B, P194
 Wilop, S, P231
 Wilson, A, S498, P369
 Wilson, B, S499
 Wilson, D, S129, P666
 Wilson, K, E1245, E1529
 Wilson, W, S135
 Wimperis, J, P276
 Winderlich, M, E839
 Windyga, J, S435, P235
 Wingett, S, S117
 Winiarska, M, S125, E1359, E1385
 Winograd, B, P332
 Winstone, D, E1534
 Winter, M, P392
 Wintges, A, S446
 Winton, E, S785, S786
 Wise-Draper, T, P344
 Witt, O, P663
 Witte, B, S501
 Witte, T, P350
 Wittner, M, E1102
 Witzens-Harig, M, S502
 Witzig, T, P571
 Wlodarski, M, P350
 Wnek, R, S783
 Woermann, B, P546
 Woessmann, W, E1391
 Wojciechowska, M, E1262
 Wojdacz, T, P585
 Wójtowicz, M, E1262
 Wolach, O, E949
 Wolan, M, P710
 Wolbers, M, S775
 Wolf, D, P595, P707
 Wolf, T, P568
 Wolfe, B, P680
 Wolff, T, P666
 Wolfgang Blau, I, E1250
- Wölfler, A, S419, E879
 Woll, P, E1110
 Wolleschak, D, P700
 Wolschke, C, E1286
 Wolter, P, P565, P637
 Wolz, O, E1356
 Won, J-H, E984, E1608
 Won, Y-W, P259, E939, E1054
 Wong, G, P646
 Wong, K, E1354
 Wong, N, E847
 Wong, R, P723, E1437
 Wong, S, E1146
 Wong, S, E1140
 Wong, W, E1073
 Woo, A, S147
 Wood, B, S793
 Wood, E, P674
 Wood, M, S147
 Wood, P, S476, S477, P517
 Woods, G, P620
 Woolfrey, A, S146, P381
 Woolworth, J, E1073
 Wörmann, B, E885
 Woyach, J, E1400
 Wozniak, J, E886
 Wray, K, P228, E1424
 Wrench, B, S802, P160, P164
 Wright, L, P295
 Wrigley, B, S469
 Wróbel, T, E1553
 Wrodnigg, T, E1395
 Wu, C, P236
 Wu, C-J, P550
 Wu, D, P390, E928, E931, E956, E1152, E1189, E1507, E1520, E1521, E1531
 Wu, D-P, E1144
 Wu, J, S138
 Wu, J, P704
 Wu, J, P753
 Wu, K, S101, P334, P335, P676
 Wu, N, E1073
 Wu, W-H, E1567
 Wu, X, P390, E1520
 Wu, Y, P719
 Wu, Y-L, P507
 Wu, Y, P224
 Wuchter, P, P172
 Wulf, G, P226, E868, E870
 Wust, T, S132
 Wyen, C, P568
 Wylie, B, E1350
 Wynn, R, S817, P668



- Wypasek, E, S445
Xia, Z-J, E961, E1389
Xiang, B, P224
Xiao, L, P209
Xiao, V, E1073
Xiao, X, E1521
Xiao, Y, P285
Xiao, Z, P356, E1330
Xicoy, B, P609, E1181
Xie, L, P224
Xie, Y, E1520
Xie, Z, S108, P197, E921
Ximeri, M, P639, E1419
Xing, Y, E950
Xingzhi, S, S489, P207
Xiong, B, S490
Xochelli, A, S461, P378
Xu, F, P224
Xu, J, E1520
Xu, L, P506
Xu, L, E1498
Xu, L-P, S431, S449, P387, P511, P725, P752, E1101, E1515
Xu, L, P363, E1503, E1511
Xu, L, P363, E1503, E1511
Xu, P, E1475
Xu, T, E1152, E1531
Xu, T, S472, S473, P675
Xu, Y, E1152
Xu, Y, E1281
Xu, Z, E1330
Xu, Z, E1498
Xu, Z, E878
Xue, A, P522
Xue, F, P724
Xue, J, P363
Xue, S, E1507
Xue, S, E1558
Yabushita, T, P196
Yacoub, A, P634, E1129
Yadav, D, E1442
Yagüe, J, E1259
Yahiaoui, A, P158
Yahng, S, P742
Yaish, H, S451
Yajamanam, B, E843
Yakoub-Agha, I, S797, S798
Yakutik, I, E1409
Yaldiran, A, E1159
Yalla, K, P591
Yallop, D, E1509
Yam, A, P328, E1373
Yamada, T, E1229
Yamada, Y, P531
Yamada, Y, E1438
Yamaga, Y, E1516
Yamaguchi, T, P385
Yamamoto, K, E1139
Yamamura, T, P689
Yaman Bajin, I, E855, E1598
Yamasaki, S, P385
Yamazaki, E, E962
Yamazaki, S, E951
Yan, C, E1144
Yan, C, E1498
Yan, C-H, P387, P752, E1515
Yan, M, P662
Yan, P, P174
Yan, Y, S794
Yanamadala, A, P763
Yanez, L, S452
Yañez, R, S144, P755
Yang, C-P, E825
Yang, D, E956
Yang, D-H, S491, P569
Yang, F, P155
Yang, H, S451
Yang, H, S487, P317, P652
Yang, H, P338
Yang, J, S793
Yang, J, P350
Yang, L, E1085, E1087
Yang, L, P356
Yang, N, S103
Yang, R, P362, P724
Yang, S, E1089, E1091
Yang, S, P259
Yang, Y, S103
Yang, Z, S467
Yannaki, E, S814, E1083
Yano, A, P531
Yano, S, E1522
Yantorno, S, E1508
Yao, H, E928
Yao, H-W, E825
Yaspo, M-L, S117
Yates, F, P245, P589
Yee, A, S779
Yee, K, P708, E1192, E1324
Yee, T, P305
Yeganeh, S, P548
Yeh, T-C, E825
Yeleswaram, S, P633
Yen, A, S147
Yerushalmi, R, E1504
Yeshurun, M, E949, E1524
Yesil, J, P322
Yfanti, E, E1574
Yhim, H-Y, P569, E954
Yi, H, P346
Yi, J, E939
Yiakoumis, X, S416, P639, E1036
Yiakoumis, X, E1120
Yiangou, M, E1083
Yigit, S, E1598
Yildirim, R, P281
Yilmaz, E, E1539
Yilmaz, M, P518
Yimer, H, P249
Yin, J, E1152
Yin, S, S776
Yiu Cheung, R, P646
Yokohama, A, E1447, E1607
Yokose, N, E1175
Yokota, M, P373
Yokoyama, Y, E1519
Yomade, O, P647
Yonetani, N, P196
Yong, K, P669, P731, E1202, E1208
Yoo, K-Y, E979
Yoon, C, E857, E909
Yoon, J-H, P551, P561, P638, P742, E1513
Yoon, J, E1608
Yoon, S-S, P335, P764
Yorozu, K, E1162
Yoshida, K, S120, S123, S124, S799, P299, P301, P314, P537
Yoshida, S, P625
Yoshimi, A, P350
Yoshinaga, K, P313
Yoshino, M, P383
Yoshino, T, S124, P299
Yoshioka, S, P196
Yoshizato, T, S120, S123, P299, P537
Yoshizawa, S, E1209
You, E, E857, E909
You, F, E1085
Younes, A, S412
Young, E, P244
Young, K, E1353
Yousef, N, E1582
Yousri, S, E1486
Youssoufian, H, E1130
Ypma, P, S411, P340
Ysebaert, L, P641
Yu, A, P328, E1373
Yu, A, P652
Yu, E, P223
Yu, J, P167
Yu, L, P356
Yu, S, E947
Yu, Y, E1189
Yu, Y, E1400
Yu, Y, E1087
Yu, Z, E1203
Yu-Tzu, T, E1201
Yuan, H, P265
Yuan, L, E1085, E1087, E1558
Yuan, X, P356
Yuanqing, Y, P241

Only presenting authors are included in the program pages of this book. For the full abstract details including all authors we refer to the Abstract Book and the EHA website. **Abstract Authors marked in red have been awarded with an EHA Travel Grant.**

- Yucel, Y, E1451
 Yue, K, E1392
 Yue, P, E896
 Yuen, G, E940
 Yuklea, M, E1034
 Yumi, G, E1609
 Yunger, S, P732
 Yurakok, M, E1598
 Yuste, J, P573
 Zabalza, A, E1604
 Zach, O, P559
 Zacheo, I, P277, E1125
 Zadro, R, E1352
 Zafar, F, P349, E1239, E1277
 Zagadailov, E, P637
 Zagaria, A, P598
 Zagorac, I, E900
 Zagotto, G, E1006
 Zagouri, F, E1292
 Zahia, Z, E1275, E1472, E1479
 Zaja, F, P583, P588, P722
 Zajac, C, P753
 Zajac, M, E888
 Zak, P, E858, E918, E936, E1303
 Zakaria, M, E1585
 Zaleska, J, E888
 Žaliová, M, P711, E823
 Zallio, F, S778
 Zambagni, E, E1238, E1250
 Zambello, R, S410, E1247, E1254, E1357, E1397
 Zamora, L, P660, P696, E831
 Zanabili Al-Sibai, J, E1530
 Zanaglio, C, P607
 Zang, D, P259, E1054, E1062, E1069, E1070
 Zang, X, S103
 Zangrilli, I, E1124
Zaninetti, C, S432
 Zaninoni, A, P616, E1078
 Zankovich, R, S424
 Zannier, M, E1496
 Zanotti, L, P544
 Zanotti, R, S413, P355
 Zapala, P, S125, E1359, E1385
 Zapico, E, E1421
 Zapotocka, E, E849
 Zappasodi, P, P644, E1337
 Zappone, E, E941
 Zaratzian, C, E1236
 Zarfati, G, S436
 Zaritksey, A, P702, E1040, E1333, E1334
 Zarubina, K, E860, E861
 Zaucha, J, E1262
 Zavidij, O, E1354
 Zaw, M, P347
 Zawada, M, P594
 Zbyszewski, P, S488
 Zebisch, A, S419, E879
 Zecca, M, P738
 Zeerleder, S, S455, P576
 Zeev, E, P240
 Zeidler, C, S497
 Zeijlemaker, W, S112, S113
 Zejnalova, P, P220, E1133
 Zeldenrust, S, P331
 Zemanova, Z, E1166
 Zéphir, H, P716
 Zeppa, P, P277
 Zerazhi, H, S105
 Zeremski, M, P204
 Zerres, K, P231
 Zerrouqi, A, S125
 Zeuner, H, S502
 Zhang, J, S138
 Zhang, B, E866
 Zhang, B, P663
 Zhang, C, P167
 Zhang, G, E911, E916
 Zhang, H, E1186
 Zhang, J-M, S431, P363, E1503, E1511
 Zhang, J, P192, P241, P550, E830
 Zhang, J, S103
 Zhang, J, E1520
 Zhang, K, P234
 Zhang, L, E1023
 Zhang, L, P724
 Zhang, L, P321
 Zhang, L, P632
 Zhang, N, E1605
 Zhang, P, S103
 Zhang, R, S103
 Zhang, S-J, P356
 Zhang, T, E1189
 Zhang, W, S103
 Zhang, X, E1511
 Zhang, X, P522
 Zhang, X, P363, P506, E1498, E1503
 Zhang, X-H, S431, S449, P387, P511, P725, P752, E1101, E1515
 Zhang, X, S780
 Zhang, X, P590, P690
 Zhang, X, S129, P666
 Zhang, Y, S103
 Zhang, Y, S147, P690
 Zhang, Y, S476, P517
 Zhang, Y, S138
 Zhang, Y, E1498
 Zhang, Y, E1330
 Zhang, Y, E1503, E1511
 Zhang, Z, S491
 Zhao, X, E916
 Zhao, H-Y, P507, P752, E833
 Zhao, M, P356
 Zhao, W, S103
 Zhao, X, P577
 Zhao, X, E1503
 Zhao, X, P363
 Zhao, X, P363
 Zhao, Y, P366
 Zhao, Y, P390
 Zhavrid, E, P635
 Zheng, S, P197
 Zheng, Y, S149
 Zhernyakova, A, E1313
 Zhong, W, E1398
 Zhou, B-B, P155
 Zhou, C, E911, E916
 Zhou, F, S429
 Zhou, H, E1343
 Zhou, L, S771, P247, P564
 Zhou, L, P633
 Zhou, L, E1244
 Zhou, X-L, E863
 Zhou, Z, E874
 Zhu, H, P224
 Zhu, L, S782
 Zhu, M, E1480
 Zhu, R, S138
 Zhu, X, E1152, E1507
 Zhu, X, P363, E1503, E1511
 Zhu, X, E1087
 Zhu, Y, P637, P735
 Zhu, Y, P344
 Zhu, Z, S454
 Zhuang, Q, S103
 Zia, M, P279
 Zichlin, M, E1300
 Zielińska, P, E1262
 Ziepert, M, P216, P222
 Zierk, J, E1117
 Zieske, A, E950
 Zigman-Hofman, E, E1524
 Zijlstra, J, S150, S469
 Zikos, P, E1266
 Zimmerman, T, P680
 Zimmerman, Z, S478, P524
 Zimmermann, M, S480, S789, E849
 Zimmermann, S, P656
 Zimmermann, Y, E1402
 Zinngrebe, J, P508, E838



ABSTRACT AUTHORS INDEX

Zinzani, P, S412, S467, S470, S776,
S777, P637, E1130

Ziogas, D, P337

Zirakchian, M, E1267

Zirn, B, P226

Ziti-Ijjajic, S, S457

Zittersteijn, H, P229

Ziyatdinov, A, P759, P765

Zizzari, A, E908

Zjablovskaja, P, P273

Zkékely, G, P266

Zoerer, M, P707

Zoidl, M, E1395

Zojer, N, P336

Zoli, V, S413, S778

Zomas, A, E1263

Zonder, J, S104, P680

Zonta, F, E1006

Zorenko, V, P307

Zorina, N, E1526

Zorloni, C, E1489

Zotina, E, E1436

Zotova, I, E1436

Zou, Q, E956

Zreid, H, P284

Zuanelli Brambilla, C, E941, E1215

Zuber, J, S133

Zuborne Alapi, K, S802, P160

Zucca, E, P282

Zucchetto, A, P583, P588

Zuckerman, K, E1323

Zuckerman, T, P548

Zudaire, M, P376

Zugmaier, G, P521

Zuna, J, E823

Zunica, F, P717

Zuo, L, P606

Zuo, X, S490

Zurawska, J, E1193

Zvonkov, E, E1403, E1409

Zwaan, C, S422

Zweegman, S, S411, S501, P190, P340,
P677, P686, P697, E1221

Zweidler-McKay, P, P562



Zwisler, A-D, E1347

Zyczynski, T, E1269

FLOOR PLANS

FLOOR PLAN CONGRESS CENTER

North
Entrance








Ground floor

- Information Desk
- Internet Corner
- First Aid
- Cloakroom
- Charging Point
- Restaurant
- Coffee

FLOOR PLAN EXHIBITION

Hall 7 - Exhibition



-  Internet Corner
-  Information Desk
-  Charging point
-  Diagnostic Area



FLOOR PLAN EXHIBITION

An extensive exhibition of pharmaceutical, technical and research products, equipment and services is organized in conjunction with the 22nd Congress of EHA. The scientific program will allow participants ample opportunity to visit the exhibits.

The exhibition will be open during the following hours:

Thursday, June 22	09:00-16:30
Friday, June 23	09:00-16:30
Saturday, June 24	09:00-16:30
Sunday, June 25	09:00-13:30

Company	Booth number	
Abbvie	440	International Society for Laboratory Hematology
Adaptive Biotechnologies Corporation	660	ITP Support Association
Agios Pharmaceuticals	920	Janssen Pharmaceutica
Alexion Pharma GmbH	910	Japanese Society of Hematology
American Society of Hematology	514	Jazz Pharmaceuticals
Amgen	430	Karyopharm Therapeutics
ArcherDX	806	Leukemia Patient Advocates Foundation
Argentinean Society of Hematology	210	Lipomed AG
AROG Pharmaceuticals	726	Lymphoma Coalition
BD	770	Maco Pharma
Binding Site	860	MDS Alliance
Bio-Rad	664	MDS Foundation, Inc
Biotype Diagnostic GmbH	762	MediCom Oncology
Bristol-Myers Squibb	930	MorphoSys AG
Celgene	140	MPN Advocates Network
Celltrion Healthcare	250	MSD
Cepheid	764	Myeloma Patients Europe
CLL Advocates Network	560	NeoGenomics
CML Advocates Network	560	Nordmedica
Cytognos SL	872	Novartis
Daiichi Sankyo Europe GmbH	520	Omeros Corporation
Erytech Pharma	100	Otsuka Pharmaceutical Europe Ltd.
ESLHO Foundation	560	Oxford Gene Technology
EuroBloodNet	800	Pfizer Oncology
European School of Haematology	310	Pharmacoclycs, an AbbVie Company
EWMn European Waldenström Network	560	PIVOTAL
F. Hoffmann-La Roche Ltd	230	PROFILE
Gilead Sciences	240	Prothena Corporation
Harmony Alliance	800	QIAGEN
Hematology Specialist Association	314	Resonance Health
Illumina	214	Sandoz
Incyte Biosciences International Sàrl	640	Sanofi Genzyme
Invivoscribe® Technologies, Inc.	720	Seattle Genetics
		SEI Healthcare
		SERVIER INTERNATIONAL
		Shire
		SkylineDx B.V.
		Sunesis Pharmaceuticals, Inc.
		Takeda Oncology
		Turkish Society of Hematology
		Verastem, Inc.
		VIVIA BIOTECH
		Wisepress Medical Bookshop
		37th World Congress of the
		International Society of Hematology (ISH 2018)



EUROPEAN
HEMATOLOGY
ASSOCIATION



STOCKHOLM
23RD CONGRESS
JUNE 14-17 | 2018

European Hematology Association

January 1, 2018

Start abstract submission
and congress registration

March 1, 2018

Deadline abstract submission

May 10, 2018

Deadline early registration fee



RAISING THE BAR

A Jazz Satellite Symposium

Thursday 22nd June 2017

10:45 – 12:45

Room N103

**NEW MANAGEMENT
AND TREATMENT
IN ACUTE LEUKAEMIAS**

AGENDA:

- 10:45–10:50 **Welcome**
Prof Hartmut Döhner, University Hospital Ulm, Germany
- 10:50–11:20 **The latest movement: What's new in the management and treatment of Acute Lymphoblastic Leukaemia?**
Prof Nicolas Boissel, Assistance Publique – Hôpitaux de Paris, France
- 11:20–11:50 **New players in the treatment of Acute Myeloid Leukaemia: Are we improving treatment?**
Prof Nigel Russell, University of Nottingham, UK
- 11:50–12:40 **Setting the tone: Managing challenging patients with Acute Myeloid Leukaemia – case study overview**
Prof Gail Roboz, Weill Medical College of Cornell University, USA, and Prof Hartmut Döhner, University Hospital Ulm, Germany
- 12:40–12:45 **Close**

A medical education symposium organised and funded by Jazz Pharmaceuticals

This symposium may contain information relating to drugs which do not have marketing authorisation



Jazz Pharmaceuticals

Date of preparation: April 2017
Job code: VYX-INT-015-0417-01

Introducing the first and only approved BCL-2 inhibitor^{1,2}

AIM HIGH with VENCLYXTO™

VENCLYXTO demonstrated an ORR of 79% (95% CI: 70.5, 86.6, N=107, IRC assessed) or 77% (95% CI: 69.9, 83.5, N=158, investigator assessed) in a phase 2, single-arm, open-label, multicentre study (M13-982) in relapsed/refractory CLL harbouring del(17p).^{1,3}

In a second, ongoing, phase 2, open-label, multicentre, non-randomised study (M14-032) evaluating CLL patients who had been previously treated with and failed ibrutinib or idelalisib therapy, VENCLYXTO demonstrated a combined ORR of 64% (95% CI: 51.1, 75.7, N=64, investigator assessed) at the time of data cut-off or 67% as determined after further evaluation by an IRC.¹

Overall response rate (CR, CRi, PR, and nPR) was assessed using the 2008 International Workshop for Chronic Lymphocytic Leukemia updated National Cancer Institute-sponsored Working Group (iwCLL NCI-WG) guidelines.¹

Select Safety Information

The most commonly occurring adverse reactions (≥20%) of any grade were neutropaenia/neutrophil count decreased, diarrhoea, nausea, anaemia, upper respiratory tract infection, fatigue, hyperphosphataemia, vomiting and constipation.

The most frequently occurring adverse reactions (≥2%) were pneumonia, febrile neutropaenia and TLS.

VENCLYXTO monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or *TP53* mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.

Study M13-982 description: A phase 2, single-arm, open-label, multicentre study evaluating the efficacy and safety of VENCLYXTO in relapsed or refractory subjects with CLL harbouring del(17p). Patients followed a dose-titration schedule starting at 20 mg and increasing up to 400 mg once daily and continued on 400 mg until disease progression or unacceptable toxicity; N=107 patients were enrolled in the main cohort with the data cut-off date of 30 April 2015. ORR, the primary efficacy endpoint, was evaluated by an Independent Review Committee (IRC) according to the iwCLL NCI-WG guidelines (2008). Secondary endpoints included CR, CRi, PR, nPR, DOR, PFS, and TTR. MRD was an exploratory endpoint. Fifty-one additional patients were enrolled in a safety expansion cohort. Investigator-

assessed efficacy endpoints are presented for 158 patients (main + safety expansion cohorts) with a later data cut-off date of 10 June 2016.^{1,3}

ORR=overall response rate; IRC=independent review committee; CLL=chronic lymphocytic leukaemia; CR=complete remission; CRi=complete remission without complete marrow recovery; PR=partial remission; nPR=nodular partial remission; DOR=duration of response; MRD=minimal residual disease; PFS=progression-free survival; TTR=time to first response.

Study M14-032 description: An ongoing phase 2, 2-arm, open-label, non-randomised study evaluating the efficacy and safety of VENCLYXTO in CLL patients who had been previously treated with and failed ibrutinib (n=43) or idelalisib (n=21) treatment. Patients followed a dose-titration schedule starting at 20 mg and increasing up to 400 mg once daily and continued on 400 mg until disease progression or unacceptable toxicity. Primary efficacy endpoint includes ORR. Secondary endpoints included PFS and DOR. MRD was an exploratory endpoint.^{1,4}

References: 1. VENCLYXTO [Summary of Product Characteristics]. AbbVie Ltd; Dec. 2016. 2. European Medicines Agency. Assessment Report EMA/725631/2016: Venclyxto. London, UK: Committee for Medicinal Products for Human Use; 2017:1-132. Procedure No. EMEA/H/C/004106/0000. 3. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. *Lancet Oncol*. 2016. [http://dx.doi.org/10.1016/S1470-2045\(16\)30019-5](http://dx.doi.org/10.1016/S1470-2045(16)30019-5). Accessed October 10, 2016. 4. US National Institutes of Health. A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy. <https://clinicaltrials.gov/ct2/show/NCT02141282?term=M14-032&rank=1>. Accessed December 27, 2016.

SmPC included in the congress bag.

VENCLYXTO (venetoclax) may not be marketed in all EU countries.
VENCLYXTO (venetoclax) no se encuentra aún comercializado en España.
Está pendiente de la decisión de Precio y Reembolso.

▼ This product is subject to additional monitoring.
The report of the adverse events related to this medicine is a priority.

abbvie

©2017 AbbVie Inc. GBL/ONC/1016/1209(2)
ES/VEN/0417/0526 April 2017

 **VENCLYXTO™**
venetoclax tablets